<SEC-DOCUMENT>0001737287-20-000027.txt : 20200506
<SEC-HEADER>0001737287-20-000027.hdr.sgml : 20200506
<ACCEPTANCE-DATETIME>20200506161827
ACCESSION NUMBER:		0001737287-20-000027
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200506
DATE AS OF CHANGE:		20200506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		20852857

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>allo-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:57bc89fc-7004-4307-9757-f5809462a759,g:be24e03f-ee2b-47ea-87e1-15803658ae8d,d:39d9204faee04259b4794495e3dfeace--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:allo="http://allogene.com/20200331" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl81LTEtMS0xLTA_3c5c847b-3cfb-4ff2-ab02-671baa06a620">12-31</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl81LTEtMS0xLTA_ff357e67-b11c-42d7-9d34-2ee335cd5301">12-31</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl83LTEtMS0xLTA_5313a180-6cf6-46f0-b510-2df5d705ff4c">false</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl83LTEtMS0xLTA_ce146290-2394-4be8-8f50-1c6f058964aa">false</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl84LTEtMS0xLTA_54e49ed3-7e9c-4cc5-a258-131a40ce43f0">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl84LTEtMS0xLTA_bac79e7b-789f-4b4f-a782-46454d424771">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl8xMS0xLTEtMS0w_657400ac-93d9-4f96-888a-2ec2c9499535">2020</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl8xMS0xLTEtMS0w_923ae766-b3f2-4acc-9bd0-b18becbbf3e6">2020</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl8xMi0xLTEtMS0w_2d738991-2fa3-402e-99b5-439601b547bb">Q1</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl8xMi0xLTEtMS0w_77f5a9d0-c899-4798-8c3d-49f5be0e3c24">Q1</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMi0xLTEtMS0w_df6e510e-895a-457d-8673-26432ff56386">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMi0yLTEtMS0w_4c56aa4d-4a0a-4cd0-8387-bbf21335215d">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMy0xLTEtMS0w_b822c5b2-0013-4238-bde4-e13a086ae724">10,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMy0yLTEtMS0w_7c4b733c-107d-466d-9499-2a422a9051df">10,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNC0xLTEtMS0w_943bea65-0cac-41aa-8615-39674b00d555">0</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNC0yLTEtMS0w_78e2437d-6111-4bc8-8371-ae102aef8553">0</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNS0xLTEtMS0w_d517d755-a48d-4dd8-876f-ee39c70d0a67">0</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNS0yLTEtMS0w_32440c3f-6777-4a3f-9ed8-0504c439aabc">0</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNy0xLTEtMS0w_ac9e6bd2-5d6b-4fed-9d1c-73bde6a20c95">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNy0yLTEtMS0w_a3baa691-2f00-4431-a245-f010e311c4f8">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfOC0xLTEtMS0w_97b5245c-88fb-4f84-bd1b-37438b855262">200,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfOC0yLTEtMS0w_2cfda621-8ddb-4002-b4fb-2a1f3804cdd2">200,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfOS0xLTEtMS0w_288c4ad4-ed0e-4fdd-beb7-635cb64353ed">125,262,537</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfOS0yLTEtMS0w_e6b3a84e-8444-4a76-9a32-6ada028d28cd">124,267,358</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMTAtMS0xLTEtMA_ca55e953-f0a3-49b0-b318-6daf953ed5ae">125,262,537</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMTAtMi0xLTEtMA_7191bdf6-4ca7-4bf0-8187-26cc8630bdcd">124,267,358</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yOC9mcmFnOmFjMGRjYmJmNTBlMzQ2NWI4NDJlZDA3MzBkYmJkODc0L3RhYmxlOjVlZmZiNWQ1MjY3MjRjYmM5ZDY0MGQ3YzQ4N2M2YWUyL3RhYmxlcmFuZ2U6NWVmZmI1ZDUyNjcyNGNiYzlkNjQwZDdjNDg3YzZhZTJfMS0yLTEtMS0w_f2bdcdc9-637b-4b48-be76-df3f7964f14b">0.3</ix:nonFraction><ix:nonNumeric contextRef="i1d5b8ad9f2214bb9a3c41b2eb10f54f2_I20190228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY3Ng_1448f1a5-3854-48ed-9be5-baf156294104">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTE4Mg_4fe0cc3d-a369-4851-b84c-7f351e9ac8c3">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i8ef7c7c1fbbb4a6d8c7680dee4a924e5_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfMi0yLTEtMS00MzA3_76d239eb-abb8-4d27-aa98-0ac40ebdce44">6.07</ix:nonNumeric><ix:nonNumeric contextRef="ic1365263cdfd4531ba6410ef52ae2d7c_D20190101-20190331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfMi00LTEtMS00MzA3_557281b8-1ce8-47d5-9d36-d342927f0861">5.99</ix:nonNumeric><ix:nonNumeric contextRef="i533d042f0e4b4aa0835939c4b7b40375_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfMy0yLTEtMS00MzA3_d665a2ab-1c36-46db-bb38-05809ebd9836">6.08</ix:nonNumeric><ix:nonNumeric contextRef="i65deebc5365d4675bec1b4bf6d5257f9_D20190101-20190331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfMy00LTEtMS00MzA3_8a097832-7d9f-446c-a5b8-72126d629bf1">6.25</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfNC0yLTEtMS00Mjk5_09e78b19-e800-49c9-bc7b-a6279261c339">0.080</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfNS0yLTEtMS00Mjk5_50ab2878-7ef6-4396-8955-e29547dadffe">1.65</ix:nonFraction><ix:nonNumeric contextRef="i01f52e60f0bd4993a35a31633444b2b1_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RleHRyZWdpb246ZmE1Y2VkNmZmMWM3NDVmMmEyZmEyMzZlYjcwM2MzNzFfNA_f01bbb1b-a4f2-471b-96f8-b73d62230db1">4</ix:nonNumeric><ix:nonNumeric contextRef="i69081a2c4b1044628425bb0109c6e671_I20181231" name="us-gaap:LessorOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0MzgzMg_3cee6d69-25e1-4997-bf53-faf3f51e1036">P3Y</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i6952a438f572450bb5403156594291a9_D20190101-20190331" decimals="-5" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84NS9mcmFnOmJlMjVlYmM4MWQ1NTQ2ZWJiMTA5N2Q4MGYxNjRmMWRkL3RleHRyZWdpb246YmUyNWViYzgxZDU1NDZlYmIxMDk3ZDgwZjE2NGYxZGRfMzA_663b68d8-2a04-40de-b357-2e93f49d0008">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="allo-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic5bdd569810d4befa6a36d1e4004d538_I20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i42aa16303efb4bc6861242f37d3e85a3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3daf6576012d44c8b3f0de79aadb808c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b243d5d14ca428a81206fb743a2faa3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24719ab8a31244cdb4cba2ecccb072dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87661f5bec634fb2b877c2938198f6a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i749043ca65e44bea947b65e2c95571ac_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i767920b98e2f4003b8475671f78d9345_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9497157f0a8641b5a4e3470cb9b6fd0c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69502d27e52e465e989f7e07ee489c5f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a2956e8ab954ea0b941e529700743f1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6173f0f328164026a81e07620570a7af_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ce85bfa375439480cf635174a723ff_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d2750238b547a5986767e128f298e1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i817b1dd844554db0a5646a5dd9119801_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98374caa36d418b8ca406c7fd775cf0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05344e9e256b4ef59dbf389eedbe08a6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40cd434f10fa4889b2c48316c97c4704_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if197a8d8554d43febd171636f2d48955_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200487f1142e4fa4b0efb617a113945d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7f172d70c2466aba3c80b6dbcb2add_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b220cfada114841ac5d4351643cf0a7_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6459e8c9e94fe7835b12bb81b8b9c9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f4f44335274501a6f0ba4b9f3d78e0_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d8ec996eb94984af0eecc13ed46271_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8710054b59684a4391833aea00414337_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e2b42df48e469fab49a7cae3c52280_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib5acde4df4b6477ebafbbb5d30553ac7_D20200106-20200117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-06</xbrli:startDate><xbrli:endDate>2020-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacebb076771044bc98c51c446b109263_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f16cc2983b042dfb0cb862ba0b07d6a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a112586aa5424895bcba47c2513994_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d6b66797f34f81b5840fec178a1bc8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853b0c71982b4d179054c90adbd2cc10_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1260b9ca85a04e0bae3d00635ba471c8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4837ec01c954862a0cbeef2ee46566d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if130ef65efeb433abd2824aa7335e2d2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b7527e5965c407c93e541d90cc5482a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2777e669ef784ebc95aca7676abd3f3f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f5a98d93ba478caf983096343142d2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6c4c7c5daf45f4babd1352a4271518_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc7562bce744e5ea5f471db41840a69_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i363eee17eaa248bbbcb21c694cf72a07_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e236ed56584d6a81223bb2f2ab2d5f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba7a439b13144ebb18a81a73851f2bb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90490ce088944c1d8583aa65de02a75d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49cf82683efa4c01a1df81a844831a04_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7720fa13a9c5481da95a3fb62d3f993d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74207d979464bf4853a5a3515777c63_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93e27bd09a004d319f93b738f2239aa5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafa17b9dd5da493ebcc56be63f41e109_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1f6c595d5743cc81b052ef7f75068e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df7b51138624b92826dfe6b7fea694a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a451c6e18e41cd9cdd174e7f67d1d4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic600adb00bc948368ce4b74fbe96ddb6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee733965a28948da8136b97f1eddbd10_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c4ef25a178d487e8f1f527c4f4c862b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0641a17bd2409fa5a15a2678a01bf3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief0866696c6849e992758e967b5a3373_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa95fa7e31a642ad9cd96a1b3fcf9c53_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de41313418040828be43e5a80c4efe2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a094d14f3345cf98071f778c000dee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f3f7be17bc46db883ba607846df111_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf394f5d90a047168042ea66bcdd28a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37dbdde627f041b198d1ebf46adee969_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id01aefa120cb41b1a07c570b285b6778_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c461309afd84ba1ba2d93c6c1318f70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2c3f56a38964674b3be5794ce01fbe8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d3828189e540c3b1a53ffca0d571b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8580644452b94e12ab9e3485cfc60784_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i792bbadca48943bfaf71a2bb11414136_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d9949e90384e369f45910b88cec3f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id601068b37f04845aafc46fd43f5e853_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d8b29ad214b4978b3bc65dd87a1284c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f0d72dfa6c42f5bba2b89d78731ebf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04aad2f3e4fe42c98e0232d3eae8a9d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcd82b2e8101404ab7f516da762fb5d1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10fb1c7bf324168ab0a2db735f79147_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c15b3ab1e74889b26989029ae6d673_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i364cd7afc1844168ad816a8621088d26_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d8447678cb4fc0b136d8049103aa1b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c64460a47e84af39d4f40bacaa2fd75_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8466b8753547e7a17d250705529eae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c611e2c37aa4636b1d74f643ed27edd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i639bc019200d423cac9e1f1b8acfbaa7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab02fe568304455a85402d84dbb39c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0de266e8b9e4b318c1b6289ecb6ce00_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff732cfa26a242859b76df19609edf5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77059c64b65f479fb071a0e986cf7b09_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80325903deab4700b1323494502a9120_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1f1460cc8942cf818d575042f8c4f0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10f2b6782cf247b5a11b92d52590baed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie075cc2a67084ac1b3eb62f94228b0ef_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca85fe9deb54d98b46c30a75fb18924_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i790b82aa47544194a8a63de2efdb8636_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7a98f96eeb4c94afb207c3aad9d5b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e45882827dc473d9cccdddf46d4bc37_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb902fc0cbf494384e4080a72eb2561_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia733fa51ba7647a6aba865395e1556a1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789c0228925e4672b7ac566e5e3afc54_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i600ae8e97f094c078004eb149339e911_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c687c20085e4f9daaa84f4f372fadd1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:DevelopmentAndSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98399c769a4a488aaa46d0a7c26a9054_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib28fed9c91714dbea81ced010fd4dff8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e12e6daa2c4fb5b8ad43e1cd9547e8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73435ce9243740bd8574ccf58e1a1558_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c737287cec94ddba5b57cbf684bfb99_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5d5e7c43ae443da8eacbed133ea82c3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25eec7c7b62e480a8a24e1d2fc01cb00_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf058e9146a44db8d47e1921229a153_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="iec4bd58ba39b42698636440287c1b64f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e0de113752c4ee3912070b56b2b88e7_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6403cfdee14280a2a1c6dc64afba04_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d07d0342c54b11b26f9a2900615150_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a48ecd5e6aa4995bcfa8af46e4b858e_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a11830e93d74ad8a671b309eacfb9e7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia387f6863fef4d76b7a4661c9545f04d_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb5da102c704b2ab704e75453c50364_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6012c21655b348b4b23bf36d66ffd9cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cad33ed23754ac189892f31dc1b6c1a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ClinicalRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c634926bf9d49b1a097075a247d38eb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i5ac8b68de98741d19e6456e14a0805cf_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b47b163f76a4417a683c3539110e2f9_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeeba5c202074b8680a92945d8d5cdcb_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5b8ad9f2214bb9a3c41b2eb10f54f2_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewal"><xbrli:measure>allo:renewal</xbrli:measure></xbrli:unit><xbrli:context id="ib223d885c64d4b53a8881033526b8151_D20191101-20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53599948fe6c4ca5b584914643acddbc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic19af5f089974c2497122fe4a4e2e3dd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bb738593bb4a4aa0333b29c524327a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf428979ee4648a58838e99d47fc80b6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie582f6e76ada438881e8098bffd2c1d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bbdece93a42441ab703824c19120916_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936160ad8bb942058d8f222ec9ddc536_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic177a9557377487499e270097c358bf7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521694cbaa114dddb6a6dff0b4c9abb9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb31faa7f5644ea697201adc41fddd67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i945dc20d171348f08a92572145268721_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1565ebe58524c9791944236e646ac49_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2a6d6310eb4804acffb0d4e70789c4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c4dd589aec54659af36f7495218487c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16de5530e6d44bc99f02f418df776b94_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef7c7c1fbbb4a6d8c7680dee4a924e5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1365263cdfd4531ba6410ef52ae2d7c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i533d042f0e4b4aa0835939c4b7b40375_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65deebc5365d4675bec1b4bf6d5257f9_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f52e60f0bd4993a35a31633444b2b1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a437f63084d4bd18d9edeff003da5ff_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id52499d716214a2699bbb179be7d9b7c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ff5875cc6044a67885d7490df6c5659_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied67c130b61d4499b7927fceb186af36_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c84a8b6258472092c7917980204432_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eea165234764f838579662624ec9d90_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56aaf1b58d7b4ec7b18900c8eb264775_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic321d0b1fd1c4b0f95aed3cd5340beae_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69081a2c4b1044628425bb0109c6e671_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c3fcf903a048f7b77fd696a381f82e_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="board_member"><xbrli:measure>allo:board_member</xbrli:measure></xbrli:unit><xbrli:context id="i5f17f2b211344d3f82185666cdfd8064_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae2200f0f404af2a52ee56081d823e3_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30246310ab084bc99257f27e94986e6b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e9df642ead424798c3bcd699e0d11f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ed49038db9439d99e49ced4b34596f_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05acd1d072c943d799c0703a556368b1_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2664c61460fd4fa8ac2b86b83a9aaef9_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6da9f07f2d4b2cb4f36dece4d79776_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a074fef5cf4808a3421b475b2b6e1f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6952a438f572450bb5403156594291a9_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445474810986457d86157ac99ce513eb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6ed85ff10640e0a2e3c27c4de1f868_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab11e5afc21498ca4e40dc435770e6f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5c7873bcbb436f9297d5dc64e8c936_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea9ba03c9b646619b56dd93138eaddd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164061d208364d798deb08ac4045936a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i493f3fa88aa246efb2e80fa6c3b6d7d7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90aa7f4abe04f2383035e03129a402e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ae26fbb0794fceb415878169f539c2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72a829b0930b4e63aaf7cd159033b693_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOS0zLTEtMS0w_267729df-178c-4f99-9da9-08c858d420e1 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjktMy0xLTEtMA_16c931b2-01bb-4c23-9851-4a88affb89ca id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTktMy0xLTEtMA_87a46259-4c6c-4db3-b6f9-c82bb6d3e074 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjUtMy0xLTEtMA_09558e9b-3c8f-445b-9177-a021bc68441f id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOC0zLTEtMS0w_c2fb4451-14a9-493a-bc41-f0aac362dd76 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNy0zLTEtMS0w_75b3f085-32a3-42ca-ac9c-2a466790768e id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTEtMy0xLTEtMA_65611136-94ce-4f40-b42a-634c2ec07a01 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjAtMy0xLTEtMA_1394a926-75d4-427f-a343-84f5ae0e6eff id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMzAtMy0xLTEtMA_25c2142d-611d-401e-b3b3-bc2affec8f73 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTgtMy0xLTEtMA_81b602ae-51d9-4c69-b1c9-c803ec52daad id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTAtMy0xLTEtMA_6fdca938-4822-4f97-902b-5eaedc185973 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjYtMy0xLTEtMA_3344a037-4917-4d6f-8623-c66f16b6fdfc id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjEtMy0xLTEtMA_13d32409-3d89-4e8f-ad03-a1d493d78e05 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNS0zLTEtMS0w_7204c4ce-4dfd-4201-a4a5-485fb92a1764 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtMA_3b8f6973-beef-4821-be9f-842b90aa6f3d id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjctMy0xLTEtMA_64c8cf6c-0199-4bb8-9d42-b7039e300df2 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNC0zLTEtMS0w_4190bc71-19e9-46da-8b2b-b8bf1692e9f2 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTctMy0xLTEtMA_16ee153e-c141-48c9-98ce-f7206b3a4d50 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMy0zLTEtMS0w_19730378-fffb-446a-a6ce-58998e797b13 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjItMy0xLTEtMA_8b82c55b-7a84-40c6-8c00-231a48d41b4d id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTItMy0xLTEtMA_fd6b51e2-07a6-4019-bc10-3ebf9006a359 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNi0zLTEtMS0w_3e2c1b39-dcfd-41c9-9ad2-aea84a1d357c id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjQtMy0xLTEtMA_5443e109-d7f3-458b-9032-8f06e3e3c545 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTYtMy0xLTEtMA_a5219db8-6479-4e10-b6c3-6b8ba31424c3 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjgtMy0xLTEtMA_52a0de29-628f-48a4-9b43-a03917898152 id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtODM_3a8f62bf-21ae-4179-ad0f-b5632893bbb7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i39d9204faee04259b4794495e3dfeace_1"></div><div style="height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON, DC 20549</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">________________________________________________________</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF8xMzk_267f65d1-6e05-4681-bb33-db3663077929">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">________________________________________________________</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.219%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6MGRiMDdmM2FjZDYzNGQ3YTkzMzBlMDA1MGZiMDZkMDcvdGFibGVyYW5nZTowZGIwN2YzYWNkNjM0ZDdhOTMzMGUwMDUwZmIwNmQwN18wLTAtMS0xLTY0Mw_1f041a89-19c1-4af6-a1de-69321ed355bb">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF83MTQ2ODI1NTgyODE2_cffc8aef-41d5-4ff1-b38d-f9d4bcf8eaa5">March 31, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.219%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6YzQ3NjBmZWM1MTcyNGRmN2FlNTk1NGE1NDgyNGRmNjgvdGFibGVyYW5nZTpjNDc2MGZlYzUxNzI0ZGY3YWU1OTU0YTU0ODI0ZGY2OF8wLTAtMS0xLTY0NQ_4b841b77-d887-4595-adeb-660652ca2403">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;to&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF8zNTM_0533fc89-4f08-43c1-87b3-2b8ddfc7e5dc">001-38693</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">________________________________________________________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF80MTQ_2c3aa228-0a4a-403a-8fe0-e4bec091ff75">Allogene Therapeutics, Inc.</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">________________________________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:30.404%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:33.190%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.406%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6MmNjNThlZDA4ZmI5NGZkNGFlZjFhNWQ0MTNjYWM1NzgvdGFibGVyYW5nZToyY2M1OGVkMDhmYjk0ZmQ0YWVmMWE1ZDQxM2NhYzU3OF8wLTAtMS0xLTY0OQ_e83c2deb-2371-40cb-8761-9d292a785df9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6MmNjNThlZDA4ZmI5NGZkNGFlZjFhNWQ0MTNjYWM1NzgvdGFibGVyYW5nZToyY2M1OGVkMDhmYjk0ZmQ0YWVmMWE1ZDQxM2NhYzU3OF8wLTItMS0xLTY1MQ_0e97de4e-fc24-4c82-8115-b86f9123e015">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(State or other jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">incorporation or organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF85ODk1NjA0NjUyNDYw_07d0bc89-8f98-42a9-8caf-7d64645cddd8">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF85ODk1NjA0NjUyNDYx_edf2ee57-4a65-45e9-82f0-8338d1b8c7b9">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF83MTQ2ODI1NTgzMDQ5_604e91e4-80e7-4b10-a6f7-51c2b2a75798">California</ix:nonNumeric> <ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF85ODk1NjA0NjUyNDY1_6ae10715-87ff-4311-9ca7-b15e9af1fe67">94080</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Address of principal executive offices including zip code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDE4_55464353-1a0b-4f53-8368-8fd1cbeb37c1">650</ix:nonNumeric>) <ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDIy_c264f609-9243-4d91-b104-68c46cb9ab5b">457-2700</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:29.231%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.536%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:29.233%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Former name, former address and former fiscal year, if changed since last report)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:29.432%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:28.994%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:34.406%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6OTgyNWY2ZjJkY2E2NGI0MGIxMjU5ZmE1YzY1MWNmNmQvdGFibGVyYW5nZTo5ODI1ZjZmMmRjYTY0YjQwYjEyNTlmYTVjNjUxY2Y2ZF8xLTAtMS0xLTY2Ng_bde0e6c6-9db7-4797-acab-02ed248af57e">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6OTgyNWY2ZjJkY2E2NGI0MGIxMjU5ZmE1YzY1MWNmNmQvdGFibGVyYW5nZTo5ODI1ZjZmMmRjYTY0YjQwYjEyNTlmYTVjNjUxY2Y2ZF8xLTEtMS0xLTY2OA_b370397c-7d74-464a-874c-c574fb242d50">ALLO</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6OTgyNWY2ZjJkY2E2NGI0MGIxMjU5ZmE1YzY1MWNmNmQvdGFibGVyYW5nZTo5ODI1ZjZmMmRjYTY0YjQwYjEyNTlmYTVjNjUxY2Y2ZF8xLTItMS0xLTY3MA_6ca53bc1-8b14-404f-bca8-365017cf0267">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDIz_b099272e-3f12-4d49-b008-bdde011863b8">Yes</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDI1_7ec81648-ce49-4c62-a129-cf22160bc78a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:19.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.083%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.486%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.673%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6NmNlZTY5ZWRmYTc0NGY1YWE4YmFjMWZkZTRiYzdkNDgvdGFibGVyYW5nZTo2Y2VlNjllZGZhNzQ0ZjVhYThiYWMxZmRlNGJjN2Q0OF8wLTAtMS0xLTY4NQ_d9d8e6f0-4d2c-4df3-8c63-5b2e8036e698">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6NmNlZTY5ZWRmYTc0NGY1YWE4YmFjMWZkZTRiYzdkNDgvdGFibGVyYW5nZTo2Y2VlNjllZGZhNzQ0ZjVhYThiYWMxZmRlNGJjN2Q0OF8xLTQtMS0xLTY4OQ_3442d7a1-b4f0-473f-9ef7-dd6b61c1b293">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6NmNlZTY5ZWRmYTc0NGY1YWE4YmFjMWZkZTRiYzdkNDgvdGFibGVyYW5nZTo2Y2VlNjllZGZhNzQ0ZjVhYThiYWMxZmRlNGJjN2Q0OF8yLTEtMS0xLTY4Nw_b132cc97-cc65-41f6-84f7-632d58b1fd4a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;&#9744;</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF83MTQ2ODI1NTgyODQ1_4b2538b0-735e-4fde-8fe6-a347ec99afdf">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9746;</span></div><div><span><br/></span></div><div style="text-indent:27pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">As of May&#160;4, 2020, the registrant had <ix:nonFraction unitRef="shares" contextRef="ic5bdd569810d4befa6a36d1e4004d538_I20200504" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDI3_fdd61473-367b-4176-8e86-2dd7cdc6857f">125,331,495</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_7"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Table of Contents</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.532%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:79.021%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.447%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page no.</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_10">PART I:</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_13">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_13">Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_16">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_22">Condensed Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_22">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_25">Condensed Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_25">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_31">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_31">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_34">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_97">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_97">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_97">18</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_130">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_130">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_130">25</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_133">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_133">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_133">26</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_136">PART II:</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_136">OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_139">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_139">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_139">27</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_142">Item 1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_142">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_142">27</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_145">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_145">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_145">67</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_148">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_148">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_148">68</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_151">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_151">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_151">68</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_154">Item 5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_154">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_154">68</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_157">Item 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_157">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_157">69</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_160">Signatures</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i39d9204faee04259b4794495e3dfeace_160">70</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_10"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I: FINANCIAL INFORMATION</span></div><div id="i39d9204faee04259b4794495e3dfeace_13"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Financial Statements</span></div><div id="i39d9204faee04259b4794495e3dfeace_16"></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:73.806%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMy0xLTEtMS0w_88331008-e33a-4db5-b8a5-bf926f561465">135,897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMy0zLTEtMS0w_19730378-fffb-446a-a6ce-58998e797b13">175,126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNC0xLTEtMS0w_cb9888b1-1a19-4cb2-ac4d-73f30f356d43">357,026</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNC0zLTEtMS0w_4190bc71-19e9-46da-8b2b-b8bf1692e9f2">355,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNS0xLTEtMS0w_ee26067c-fea2-45bd-88ad-5e3eed056b43">11,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNS0zLTEtMS0w_7204c4ce-4dfd-4201-a4a5-485fb92a1764">14,043</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNi0xLTEtMS0w_fe7b49f7-4c14-4c71-bc9b-f06fa6e8a3c7">504,414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNi0zLTEtMS0w_3e2c1b39-dcfd-41c9-9ad2-aea84a1d357c">544,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNy0xLTEtMS0w_d5e1a8bb-94b9-4236-b63a-633684b7e40d">60,121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNy0zLTEtMS0w_75b3f085-32a3-42ca-ac9c-2a466790768e">58,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOC0xLTEtMS0w_a7e3bc24-b588-48c7-992b-866dbff794dd">43,836</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOC0zLTEtMS0w_c2fb4451-14a9-493a-bc41-f0aac362dd76">44,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOS0xLTEtMS0w_df5c5674-025e-49ce-a50f-bbfb4225d53f">66,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOS0zLTEtMS0w_267729df-178c-4f99-9da9-08c858d420e1">56,449</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTAtMS0xLTEtMA_44303252-f501-4afd-92ea-3389a39d8d10">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTAtMy0xLTEtMA_6fdca938-4822-4f97-902b-5eaedc185973">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTEtMS0xLTEtMA_8a2668d3-dadf-4d2a-aac6-ad8c593c78df">4,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTEtMy0xLTEtMA_65611136-94ce-4f40-b42a-634c2ec07a01">4,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTItMS0xLTEtMA_f3f7507e-0f74-4700-ace9-3336f402dfe9">4,675</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTItMy0xLTEtMA_fd6b51e2-07a6-4019-bc10-3ebf9006a359">4,618</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity method investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMS0xLTEtNzE4_7c701b96-72bd-45fa-90ab-14a4dff530de">4,829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtODM_3a8f62bf-21ae-4179-ad0f-b5632893bbb7">4,892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMS0xLTEtMA_e2383eb9-e3a5-4b9c-8f4b-2d761e2d443f">688,523</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtMA_3b8f6973-beef-4821-be9f-842b90aa6f3d">717,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTYtMS0xLTEtMA_283a0e4a-94db-47ba-a047-325c2c7f96e1">7,199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTYtMy0xLTEtMA_a5219db8-6479-4e10-b6c3-6b8ba31424c3">9,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTctMS0xLTEtMA_f9ee452a-81e6-495f-b174-1c18e998547c">19,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTctMy0xLTEtMA_16ee153e-c141-48c9-98ce-f7206b3a4d50">23,829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTgtMS0xLTEtMA_cf5eab1e-24b0-480c-9ccb-8c258a249627">26,818</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTgtMy0xLTEtMA_81b602ae-51d9-4c69-b1c9-c803ec52daad">33,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability, noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTktMS0xLTEtMA_1fb5b932-ec8e-4b5e-b4a8-97e519c05cfc">51,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTktMy0xLTEtMA_87a46259-4c6c-4db3-b6f9-c82bb6d3e074">51,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjAtMS0xLTEtMA_9b5b7ff2-194a-4522-a7ba-ede9d2eea951">3,650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjAtMy0xLTEtMA_1394a926-75d4-427f-a343-84f5ae0e6eff">4,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjEtMS0xLTEtMA_2a8c0aee-96c2-41ff-883c-ba870e7ce605">82,004</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjEtMy0xLTEtMA_13d32409-3d89-4e8f-ad03-a1d493d78e05">88,779</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and Contingencies (Notes 6 and 7)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjItMS0xLTEtMA_02a38a36-820e-4ec4-9d9a-558e978c0212"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjItMy0xLTEtMA_8b82c55b-7a84-40c6-8c00-231a48d41b4d"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares were issued and outstanding as of March 31, 2020 and December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjQtMS0xLTEtMA_38d1b268-ccd8-41bb-8320-36de1e4dadc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjQtMy0xLTEtMA_5443e109-d7f3-458b-9032-8f06e3e3c545">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 125,262,537 and 124,267,358 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjUtMS0xLTEtMA_a47725d3-eb01-4814-8c3c-e234e2a0fb2c">125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjUtMy0xLTEtMA_09558e9b-3c8f-445b-9177-a021bc68441f">124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjYtMS0xLTEtMA_77086fb3-df58-4765-bdd3-ee560d285aa6">1,055,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjYtMy0xLTEtMA_3344a037-4917-4d6f-8623-c66f16b6fdfc">1,023,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjctMS0xLTEtMA_7b8eb25f-4e43-421b-9d83-2e2631fc0a71">450,602</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjctMy0xLTEtMA_64c8cf6c-0199-4bb8-9d42-b7039e300df2">396,122</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjgtMS0xLTEtMA_c3a14aa5-d569-4785-bc8f-a11041024463">1,610</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjgtMy0xLTEtMA_52a0de29-628f-48a4-9b43-a03917898152">1,145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjktMS0xLTEtMA_ba3971df-9573-4039-9151-a8d031dba88b">606,519</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjktMy0xLTEtMA_16c931b2-01bb-4c23-9851-4a88affb89ca">629,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMzAtMS0xLTEtMA_4c6ee7bc-6be1-4cb6-8616-8712758b56c3">688,523</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMzAtMy0xLTEtMA_25c2142d-611d-401e-b3b3-bc2affec8f73">717,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="text-indent:-36pt;padding-left:67.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801" xml:lang="en-US" footnoteRole="http://www.xbrl.org/2003/role/footnote">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</ix:footnote></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_22"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:74.315%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.260%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMy0xLTEtMS0w_0dfcb0af-dd7b-496c-9c2a-b07e6b5e50c9">42,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMy0zLTEtMS0w_301824ce-2039-400d-b06f-960e6253517d">23,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNC0xLTEtMS0w_7d590733-fde8-4fb4-8755-3216cf2851cc">15,641</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNC0zLTEtMS0w_8b63eb3e-0938-4030-8d3d-f011efbf7752">13,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNS0xLTEtMS0w_fac78693-906a-45a3-9b02-7fb9144caf97">57,683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNS0zLTEtMS0w_6138e1d5-11d0-445b-8b4e-f472e0ceeeef">36,461</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNi0xLTEtMS0w_3d3e5abc-1e56-4db6-9709-a286e9844da0">57,683</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNi0zLTEtMS0w_827adc92-6f32-49de-875c-1a29db61728d">36,461</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMS0xLTEtMA_e4d4dde6-583c-499b-ac6f-7682a5f0f5b1">3,261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMy0xLTEtMA_03340b92-282c-44db-b3a9-fc3a9491b89c">4,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMS0xLTEtMTE0_da804c14-5507-4b24-b24c-feb2355b7ae8">58</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMy0xLTEtMTE0_535f6952-becd-452f-b177-d50d32bbc811">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMS0xLTEtMzU2Mw_d7495ea3-8152-4e30-9c02-e0279cc65f46">3,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMy0xLTEtMzU2Mw_cbde23d3-62ed-4843-8588-43f788e9200d">4,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTEtMS0xLTEtMA_9fe1c62b-3fc4-4551-b8b7-4aa3814be630">54,480</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTEtMy0xLTEtMA_0f499474-3e78-4324-96b6-91accf0a2f9e">31,636</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTItMS0xLTEtMA_0198ec80-26d5-4540-93a5-b9fcb02bd423">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTItMy0xLTEtMA_ad4ceb59-13f0-488d-bc04-4fbc30360edd">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTMtMS0xLTEtMA_23eaf08f-5c16-4291-b6b6-26f6a68ce7e6">54,480</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTMtMy0xLTEtMA_ba786467-6c64-4dba-9ed2-b5308f635f60">31,586</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net unrealized gain on available-for-sale investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTUtMS0xLTEtMA_a45d031e-b1c8-4ec7-94d2-33679c2a369f">465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTUtMy0xLTEtMA_db2870a0-c7e3-4f85-886d-ca20fdefbf1f">1,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTYtMS0xLTEtMA_f2aecc98-5319-4f97-aa26-b7b04ceba9c3">54,015</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTYtMy0xLTEtMA_799396ef-4be5-4eb3-818d-392801272cf1">30,487</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTctMS0xLTEtMA_b1d5801e-8a40-4887-806d-02a9ff898565">0.50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTctMy0xLTEtMA_4509b67d-d396-4156-a6e5-a047bfdf011a">0.32</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average number of shares used in computing net loss per share, basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTgtMS0xLTEtMA_e0ea7d84-068c-4e52-b1c8-1de2e46310a6">108,963,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTgtMy0xLTEtMA_5a9d2f95-dc74-42ea-a63a-02376798e52e">97,315,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_25"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(In thousands, except share amounts)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:28.991%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.881%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.126%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.917%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.432%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.223%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.990%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance - December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3daf6576012d44c8b3f0de79aadb808c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi04LTEtMS0w_a463a3d8-e939-4c64-8ead-98eb109a22da">124,267,358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3daf6576012d44c8b3f0de79aadb808c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0xMC0xLTEtMA_8be4e9e9-4591-4c5b-b900-b5ffb7c537f5">124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b243d5d14ca428a81206fb743a2faa3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0xNC0xLTEtMA_3c7b894a-c9ab-44fb-979b-c3dddf10af69">1,023,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i24719ab8a31244cdb4cba2ecccb072dc_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0xNi0xLTEtMA_f97490a5-5f5a-4116-a3a6-230b6f5230fe">396,122</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87661f5bec634fb2b877c2938198f6a7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0xOC0xLTEtMA_efa714fe-68fa-438d-bbd4-83a0ce571417">1,145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0yMC0xLTEtMA_eba98ffa-cbcd-4fe8-b036-b0a8bde5dfe5">629,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options and vesting of RSU's</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMy04LTEtMS0w_483b6acf-10ec-48a1-93ef-c00c1c90fe2a">339,775</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMy0xMC0xLTEtMA_1c88b84a-75bd-4a99-bacd-559cdb3e4e8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMy0xNC0xLTEtMA_7d0fa841-0267-46f9-a7ff-15de2b564f96">303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMy0yMC0xLTEtMA_b79aac40-babe-4a38-8ad7-9bd27e9b1e58">303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Vesting of early exercised common stock</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNC0xNC0xLTEtMA_b59b4bba-77c8-4046-97e7-4408d33cfd8d">710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNC0yMC0xLTEtMA_641d93c4-aaad-4335-859b-a57083f94a0a">710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNS0xNC0xLTEtMA_508d260b-4468-4d1c-8643-78b63789bc8c">14,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNS0yMC0xLTEtMA_11fb4eac-2f10-4807-880e-cf385e1da8d9">14,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNi04LTEtMS0w_d7ddfa14-a11e-4b38-bcf9-6a3d04981507">84,565</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNi0xNC0xLTEtMA_67f8cc5d-b55b-481f-a97e-252e0b5657c5">1,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNi0yMC0xLTEtMA_9c7cef7a-d2b6-44d1-9d3f-90ba5d5f49ae">1,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Issuance of common stock from public offering, net of commissions and offering costs of $0.3 million</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0xLTEtMS0xMzU_9f7c96ec-f9b2-41d0-aa29-9f7b20f4a6d3">570,839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0zLTEtMS0xMzU_73ad705a-e501-478c-abdd-6769bd25434b">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy01LTEtMS0xMzU_3e8f6255-09b7-4834-abd4-7cc0d2194089">14,844</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0xMS0xLTEtMTM1_f8f54242-eab7-4c09-9533-496ea41da3eb">14,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i749043ca65e44bea947b65e2c95571ac_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0xNi0xLTEtMA_6fb33f5e-2c58-4065-9827-8eeee6f0ba7a">54,480</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0yMC0xLTEtMA_df4df3d6-87ad-494d-a47e-f9aad7e54e0d">54,480</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net unrealized gain on available-for-sale investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i767920b98e2f4003b8475671f78d9345_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOC0xOC0xLTEtMA_e61c18bb-8d2f-4b5f-a98c-1eeae42d6410">465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOC0yMC0xLTEtMA_d34edc9d-ff9f-4c82-b266-54e6b6ce064d">465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance - March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9497157f0a8641b5a4e3470cb9b6fd0c_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS04LTEtMS0w_33bc1274-ee65-466e-acc8-2e2195f9eadd">125,262,537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9497157f0a8641b5a4e3470cb9b6fd0c_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0xMC0xLTEtMA_a74a0832-e163-4e9d-9b7b-af3a821cfdb3">125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69502d27e52e465e989f7e07ee489c5f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0xNC0xLTEtMA_bf608c28-9fbb-45fe-bbe2-0edbdd900cb2">1,055,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7a2956e8ab954ea0b941e529700743f1_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0xNi0xLTEtMA_7d051b95-fef4-44a1-917f-8bbb7090f512">450,602</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6173f0f328164026a81e07620570a7af_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0xOC0xLTEtMA_3bc154a9-3ca6-4920-b2a5-99082a27593b">1,610</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0yMC0xLTEtMA_b7c07cb6-fc4d-4991-a7cc-26d60f2141ef">606,519</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:28.991%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.881%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.126%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.917%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.432%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.223%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.990%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance - December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i66ce85bfa375439480cf635174a723ff_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi04LTEtMS0w_70eda19a-6b9d-42fb-92de-77127298e143">121,482,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66ce85bfa375439480cf635174a723ff_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0xMC0xLTEtMA_8a7449f7-2945-4888-9e68-46b08522b2f3">121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01d2750238b547a5986767e128f298e1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0xNC0xLTEtMA_31d6d9aa-948b-4c95-ab49-672f5ee12056">914,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i817b1dd844554db0a5646a5dd9119801_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0xNi0xLTEtMA_114c62d5-e30d-4283-9677-3998b56b6ab5">211,528</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie98374caa36d418b8ca406c7fd775cf0_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0xOC0xLTEtMA_231d26e4-7f90-4300-b914-7026fbe5e520">306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05344e9e256b4ef59dbf389eedbe08a6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0yMC0xLTEtMA_3b43c4b5-cb50-4aa9-9246-df6557860617">703,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40cd434f10fa4889b2c48316c97c4704_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMy0xNC0xLTEtMA_e2f58b37-ffa7-48fa-99d2-0244af8e5334">7,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMy0yMC0xLTEtMA_4f3b6094-2c00-46cd-9573-ea28094c2d9c">7,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if197a8d8554d43febd171636f2d48955_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNC04LTEtMS0w_f8e5fd1a-9f98-44eb-9eb6-becf80995f56">44,649</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40cd434f10fa4889b2c48316c97c4704_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNC0xNC0xLTEtMA_354358c2-9102-43c9-bd91-8983fd2b6070">684</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNC0yMC0xLTEtMA_0f56f973-4ec0-4424-a05f-9cb2531d3478">684</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i200487f1142e4fa4b0efb617a113945d_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNS0xNi0xLTEtMA_3d741618-9345-46aa-a9ba-5f2f0f2b10aa">31,586</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNS0yMC0xLTEtMA_403bd614-448d-4e4c-9a57-8720439f76ad">31,586</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net unrealized gain on available-for-sale investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a7f172d70c2466aba3c80b6dbcb2add_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNy0xOC0xLTEtMA_a98f3ffe-3cde-4cb9-a8c7-0685c09656f8">1,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNy0yMC0xLTEtMA_c0a79016-2425-4513-9a0b-a6e2f575f9a4">1,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance - March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9b220cfada114841ac5d4351643cf0a7_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC04LTEtMS0w_ff75ef0c-36c8-485c-a34a-ca251b9f789b">121,527,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b220cfada114841ac5d4351643cf0a7_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0xMC0xLTEtMA_d3fdba38-b24d-44d1-85a6-6dcdbaf86d01">121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc6459e8c9e94fe7835b12bb81b8b9c9_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0xNC0xLTEtMA_cba48bf8-88f3-4563-b763-9a732ba120d7">922,816</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia3f4f44335274501a6f0ba4b9f3d78e0_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0xNi0xLTEtMA_364db832-4742-4283-868e-1813a0815d22">243,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2d8ec996eb94984af0eecc13ed46271_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0xOC0xLTEtMA_d19d825b-1112-4029-8c59-ea4838427c8c">1,405</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8710054b59684a4391833aea00414337_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0yMC0xLTEtMA_9c16fddd-9811-4eb9-89d2-9f1a2beb97d2">681,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_31"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(In thousands)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.830%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMy0xLTEtMS0w_8e4a067c-a268-4f26-b5be-afdeb20e8c2a">54,480</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMy0zLTEtMS0w_d6912687-4491-4dea-a13a-50e302102237">31,586</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNi0xLTEtMS0w_18e30120-fce5-4271-8a5c-7d33c60aa797">14,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNi0zLTEtMS0w_c9a9d032-ea7e-4c8d-894a-d460fa058c64">7,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of other intangible assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNy0xLTEtMS0w_97b66e30-f0b3-4b93-85d8-be1b0ed54a8c">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNy0zLTEtMS0w_2dd6a66a-46d0-4b2c-84f4-e0a320b1c62d">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfOC0xLTEtMS0w_01662e9f-190e-48ab-99bd-3e357eaf6250">1,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfOC0zLTEtMS0w_76037e07-25a9-41f9-8242-5ca358a4dc58">544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net amortization/accretion on investment securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfOS0xLTEtMS0w_e7f80da9-e2e9-4610-805c-6d9d5c11f366">207</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfOS0zLTEtMS0w_0013026d-b29d-4653-882a-7893bf43bbba">1,223</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash rent expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:LeaseAndRentalExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTAtMS0xLTEtMA_0e81f06c-e71f-448e-9227-8195aaf18f9c">718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTAtMy0xLTEtMA_262ef924-69bf-49d2-b7f8-cdfc95190891">1,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTMtMS0xLTEtMA_567c81ea-ccc4-4358-ba05-5bfd14777d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTMtMy0xLTEtMA_a16a86db-9e27-4f84-b8cb-f30ac0b9e5fc">50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share of losses from equity method investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" name="allo:IncomeLossFromCostMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTEtMS0xLTEtMjgz_a77b8e14-3547-4ffe-aa9e-4056aaba813a">64</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="allo:IncomeLossFromCostMethodInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTEtMy0xLTEtMjgz_cae1fb57-4aab-4e03-899f-da5241a43d06">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTUtMS0xLTEtMA_187dbedf-86dc-42b2-8176-eec1d7e640bf">2,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTUtMy0xLTEtMA_f1ca72ec-7eed-426f-b33b-e3c32f2c8313">1,892</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTYtMS0xLTEtMA_f444aa26-911c-4dc6-9486-955866276a2b">57</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTYtMy0xLTEtMA_48ed48e6-c84d-454b-93ea-d76b4345507f">188</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTctMS0xLTEtMA_c9b24969-a66d-4e2f-b633-6934149448de">1,044</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTctMy0xLTEtMA_f617efc2-ef14-49fe-8644-0b03df753c1e">348</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTgtMS0xLTEtMA_d5ffc30c-63b5-4d51-aa64-a399858c3c09">3,913</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTgtMy0xLTEtMA_52dab935-3104-4106-a394-02979eddad10">4,095</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTktMS0xLTEtMA_6b7b07c9-992d-4f47-9abe-eb2c51db903b">701</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTktMy0xLTEtMA_02e25543-088e-44f4-9036-9d080cb86a26">711</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjAtMS0xLTEtMA_0c3b4cbd-a1ee-43f3-a63a-b2f7c4d5d9f7">40,809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjAtMy0xLTEtMA_2c2395a8-df9d-4b0a-8211-a4579b294fad">30,256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjItMS0xLTEtMA_07ba44e7-8027-47bd-bf9b-5e00ab8656b5">12,253</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjItMy0xLTEtMA_93870386-08cd-4aae-8142-64b1c43f2793">10,423</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturities of investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjQtMS0xLTEtMA_791ae932-ccae-4c1a-8d13-018430ff5de2">120,261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjQtMy0xLTEtMA_45f8f15c-4fb8-4523-9f4b-e894225af34c">95,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjUtMS0xLTEtMA_49176044-16b1-4de4-9ec6-3ae070c3a6c7">123,015</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjUtMy0xLTEtMA_61fb8405-9dea-4379-a6cf-828e789bb30f">52,397</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjYtMS0xLTEtMA_5e1d1648-4907-4e9e-b6df-d807dd7ee1a5">15,007</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjYtMy0xLTEtMA_ebc8bd63-13f0-42b3-b2c3-31377c828bdf">32,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock, net of commissions and issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzItMS0xLTEtMA_4bf1f115-053a-450f-9451-b6151260b9ea">14,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzItMy0xLTEtMA_32bd4b8f-56cc-48db-9385-0faf7628747e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock and upon exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjYtMS0xLTEtNzYz_01039699-8978-4a7d-be6c-5599130c6896">303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjYtMy0xLTEtNzYz_f8a0f241-3463-4099-b566-d58f391e8dae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock under the employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzMtMS0xLTEtMA_dc145671-9f15-436a-aefb-ccee21181b4e">1,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzMtMy0xLTEtMA_22c082d2-4049-442f-8fb5-a80ecdcba6c8">684</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzQtMS0xLTEtMA_2510fb85-c6e2-46fc-a3e7-ea701460080a">16,586</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzQtMy0xLTEtMA_b6059ae6-77d7-47dd-b53e-6e9e41fa43b4">684</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzUtMS0xLTEtMA_123e83ce-49a3-4c1a-948e-d215dc8f20e1">39,230</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzUtMy0xLTEtMA_77717191-4304-43e0-8f84-b5dd47397b5b">3,316</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash &#8212; beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzYtMS0xLTEtMA_b9726b67-82e8-4304-9621-692ab9aec9f8">179,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05344e9e256b4ef59dbf389eedbe08a6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzYtMy0xLTEtMA_807c2983-b39d-4672-a6db-09dd83c68971">93,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash &#8212; end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzctMS0xLTEtMA_c212ddfe-f633-436f-8de8-ac36dc129d54">140,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8710054b59684a4391833aea00414337_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzctMy0xLTEtMA_ba358622-a153-4bbb-8565-5aea6ded77bd">97,047</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment purchases in accounts payable and accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzktMS0xLTEtMA_3b48f00e-09d0-4d51-8103-2dae949b027f">4,208</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzktMy0xLTEtMA_d322418d-b169-46e0-9c76-9c128ef08bd0">5,134</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNDQtMS0xLTEtMA_2af661d0-3971-4a0c-ae10-3770186a6c9a">1,396</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNDQtMy0xLTEtMA_c4f5e49c-872c-4a25-a66a-da0f2dda0082">391</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash received for amounts related to tenant improvement allowances</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNDUtMS0xLTEtMA_c70ef285-3c01-448e-8c4d-f7a0d2a193c6">532</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNDUtMy0xLTEtMA_60ee4e24-eda2-4caf-a961-e81165f4068b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_34"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div id="i39d9204faee04259b4794495e3dfeace_37"></div><div style="text-indent:-31.5pt;padding-left:31.5pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfNzE0NjgyNTU5NDg4NA_738ef1e2-38fc-4836-8d72-3dcbab67487a" continuedAt="i6e7b4ad715684177ba224243f1bb0175" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i6e7b4ad715684177ba224243f1bb0175" continuedAt="ie119a063fd274b17932b4dabdcbd6925"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offerings </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i95e2b42df48e469fab49a7cae3c52280_I20191130" decimals="-5" format="ixt:numdotdecimal" name="allo:StockIssuanceMaximumValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfOTg5NTYwNDY2MjE3NQ_221ddd31-be77-4057-a025-b7e79c30bc74">250.0</ix:nonFraction>&#160;million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to <ix:nonFraction unitRef="number" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="3" name="allo:StockIssuanceMaximumCompensationDueToThirdPartyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfOTg5NTYwNDY2MjE5MQ_e452fbc7-5d7e-4f23-8700-de60c5eb68ad">3.0</ix:nonFraction>% of the gross sales price of the shares sold through it pursuant to the sales agreement. In January 2020, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib5acde4df4b6477ebafbbb5d30553ac7_D20200106-20200117" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfOTg5NTYwNDY2MjIzNw_dcdbd92c-b4e6-4e48-95fd-24f8b71f4f7c">570,839</ix:nonFraction> shares of common stock in ATM offerings resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib5acde4df4b6477ebafbbb5d30553ac7_D20200106-20200117" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfOTg5NTYwNDY2MjI0Ng_0f2fbcd3-7b59-4edf-a13e-442d9a094339">14.8</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Need for Additional Capital</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of $<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfMTc3MA_cd8badf0-eb5b-4cc8-b68f-6e4c9ab26984">553.0</ix:nonFraction> million as of March&#160;31, 2020. Since inception through March&#160;31, 2020, the Company has incurred cumulative net losses of $<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfMTg2MQ_dccede9e-df62-411e-95c9-0de08522b64d">450.6</ix:nonFraction> million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed financial statements are filed with the Securities and Exchange Commission (SEC). </span></div></ix:continuation><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie119a063fd274b17932b4dabdcbd6925">In March 2020, the World Health Organization declared the global novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 outbreak on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.</ix:continuation></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div id="i39d9204faee04259b4794495e3dfeace_43"></div><div style="text-indent:-31.5pt;padding-left:31.5pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzYzNg_a83dc3a5-bddc-4687-9dbe-90712c89bb90" continuedAt="id2f6c45797e84f798ea700f280185215" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="id2f6c45797e84f798ea700f280185215" continuedAt="i30caec07562549c3ae8e926004361e59"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNDUxNw_a783282a-b20c-4912-9932-a0aefcd63777" continuedAt="i2e8e0dc93d5a409e9f2e4be50b4a93d7" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed balance sheet as of March&#160;31, 2020, the condensed statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed statements of stockholders&#8217; equity as of March&#160;31, 2020 and 2019, the condensed statements of cash flows for the three months ended March&#160;31, 2020 and 2019, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="i30caec07562549c3ae8e926004361e59" continuedAt="id0fb5ea5dd4a4cc59685f7c41d0fb1dc"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2e8e0dc93d5a409e9f2e4be50b4a93d7">December&#160;31, 2020, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2019, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 27, 2020.</ix:continuation></span></div><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNDUyMQ_011b5377-7470-47ba-a97d-990e751884ae" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="allo:ChangesInSignificantAccountingPoliciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNDUyMg_69620c0c-5e73-4e08-a746-0d314bd8e190" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Accounting Policies</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2020, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report, with the exception of the recently adopted accounting pronouncements in the section below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="allo:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzYzNw_ccf6c2e8-0f48-4c0e-aa7a-12e22cf5a543" continuedAt="i041907344c5544aaa363602b588d3e95" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. This standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted beginning the first quarter of 2019. The Company&#8217;s financial instruments that are in the scope of ASU 2016-13 include, but are not limited to, other receivables and available-for-sale debt securities. The Company adopted this standard on January 1, 2020 and applied the modified retrospective approach. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles &#8211; Goodwill and other &#8211; Internal-Use Software (Subtopic 350-40)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard on January 1, 2020, on a prospective basis for applicable implementation costs. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard on January 1, 2020. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued Accounting Standards Update No. 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company early adopted this standard</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">as of January 1, 2020 on a prospective basis in accordance with ASC 250, Accounting Changes and Error Corrections. The adoption resulted in the Company no longer needing to determine the tax effect from unrealized gains on available for sale securities, which previously had been disclosed in the condensed statement of operations as a benefit from income taxes. The impact of the adoption in the three months ended March 31, 2020 is that the </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="id0fb5ea5dd4a4cc59685f7c41d0fb1dc"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i041907344c5544aaa363602b588d3e95">benefit from income taxes in the condensed statement of operations and comprehensive loss is <ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzY0NQ_7930a47f-5cbe-4291-a29a-06fdcfdcdf09">zero</ix:nonFraction> compared to recognition of a $<ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzY0OQ_72dbd0d6-292c-4120-9155-fb3bbcb8212a">0.1</ix:nonFraction>&#160;million tax benefit for the three months ended March 31, 2019.</ix:continuation> </span></div><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="allo:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzYzOA_b2c3171c-f412-448a-884f-047b8b67cdc4" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the FASB issued Accounting Standard Update No. 2020-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which clarifies the interactions between topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance will be effective for the Company in the first quarter of 2021, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i39d9204faee04259b4794495e3dfeace_46"></div><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfODky_99d20754-48c3-4c57-9820-c066de0c1dd4" escape="true"><div style="text-indent:-31.5pt;padding-left:31.5pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs except for investments in U.S treasury securities which are classified as Level 1.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were <ix:nonFraction unitRef="usd" contextRef="iacebb076771044bc98c51c446b109263_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfNDI3_4235526a-cecb-4ee5-a845-eb8ab9738bc5"><ix:nonFraction unitRef="usd" contextRef="i2f16cc2983b042dfb0cb862ba0b07d6a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfNDI3_6112e11e-7acf-4a36-a9fe-d8f77a995777"><ix:nonFraction unitRef="usd" contextRef="i2f16cc2983b042dfb0cb862ba0b07d6a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfNDI3_7b7bcca1-d81d-40fb-9587-91d9daafb0ea"><ix:nonFraction unitRef="usd" contextRef="iacebb076771044bc98c51c446b109263_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfNDI3_98269e50-dba1-474b-9a39-5077cd0d53eb">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> Level 3 assets or liabilities as of March&#160;31, 2020 and as of December&#160;31, 2019.</span></div><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfODkz_6a93a9e0-b9ed-40d3-81bd-fce2640401aa" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a112586aa5424895bcba47c2513994_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNC0xLTEtMS0w_eed140a8-d562-4fdb-90a4-f080ac590f85">113,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40d6b66797f34f81b5840fec178a1bc8_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNC0zLTEtMS0w_ba210004-8678-4c53-8e93-753180aaf073">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i853b0c71982b4d179054c90adbd2cc10_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNC01LTEtMS0w_449ca65d-aa67-4792-a763-de18e54ccc86">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1260b9ca85a04e0bae3d00635ba471c8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNC03LTEtMS0w_4fd4431d-d4db-43d9-adc4-58b2d29260b4">113,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if4837ec01c954862a0cbeef2ee46566d_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNS0xLTEtMS0w_2bb2afd5-4da5-41ab-a208-c7cb40ec4c57">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if130ef65efeb433abd2824aa7335e2d2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNS0zLTEtMS0w_dd441467-4ef4-4a6d-bbfa-bcf58f88d537">25,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b7527e5965c407c93e541d90cc5482a_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNS01LTEtMS0w_45f99793-3bd8-444b-b44a-990ff4e1f442">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2777e669ef784ebc95aca7676abd3f3f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNS03LTEtMS0w_9758cfc4-3783-4f0d-894e-b7db7223b940">25,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i81f5a98d93ba478caf983096343142d2_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNi0xLTEtMS0w_88cd1cb6-8d2d-4234-be26-dada1c4f8902">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b6c4c7c5daf45f4babd1352a4271518_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNi0zLTEtMS0w_31be5c00-4ed1-4883-ae19-1ca81ab4b3b7">190,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bc7562bce744e5ea5f471db41840a69_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNi01LTEtMS0w_50d08e53-751e-4587-8e08-0978547b2f49">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363eee17eaa248bbbcb21c694cf72a07_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNi03LTEtMS0w_1d45c345-be1c-40f1-ad36-f72b7a8f21b7">190,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3e236ed56584d6a81223bb2f2ab2d5f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNy0xLTEtMS0w_b4542b4c-f5a5-46c0-9efb-e1e4e4648582">180,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibba7a439b13144ebb18a81a73851f2bb_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNy0zLTEtMS0w_ea940f8a-9e40-4e51-959e-a432b7b12c5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90490ce088944c1d8583aa65de02a75d_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNy01LTEtMS0w_c9227a3c-c495-4f6a-8176-a1a36fcec573">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49cf82683efa4c01a1df81a844831a04_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNy03LTEtMS0w_c9939df2-0fbd-4a38-ac2c-e7d56497bad7">180,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7720fa13a9c5481da95a3fb62d3f993d_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOC0xLTEtMS0w_0dc390b9-eac9-43b6-a91f-a1642a80b971">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id74207d979464bf4853a5a3515777c63_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOC0zLTEtMS0w_853941a6-ed55-4f1e-85b5-54a6f33f7e24">29,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93e27bd09a004d319f93b738f2239aa5_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOC01LTEtMS0w_778aa1cd-9999-46b3-a048-72381459d010">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafa17b9dd5da493ebcc56be63f41e109_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOC03LTEtMS0w_901b5d47-dd87-42a0-a10b-a9e70639930d">29,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b1f6c595d5743cc81b052ef7f75068e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOS0xLTEtMS0w_43ea9b52-014e-4616-8547-2b5c8da36db5">293,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1df7b51138624b92826dfe6b7fea694a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOS0zLTEtMS0w_3f47da6c-490d-4e46-865a-76bdbe0e343e">245,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iacebb076771044bc98c51c446b109263_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOS01LTEtMS0w_8346f361-5667-4104-bd3c-1fe22b173da4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31a451c6e18e41cd9cdd174e7f67d1d4_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOS03LTEtMS0w_f4548671-2691-4e0e-9a8e-2827828ec139">539,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:48.662%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.784%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic600adb00bc948368ce4b74fbe96ddb6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNC0xLTEtMS0w_2148bfa3-1358-4342-9b0c-cc868f164e5b">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee733965a28948da8136b97f1eddbd10_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNC0zLTEtMS0w_3c18596a-3a5a-4b32-a3f4-9a5e1abccce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c4ef25a178d487e8f1f527c4f4c862b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNC01LTEtMS0w_a05318e3-d217-4a95-916f-c72496808486">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf0641a17bd2409fa5a15a2678a01bf3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNC03LTEtMS0w_ef775494-4da6-4971-9570-a47d075f397d">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief0866696c6849e992758e967b5a3373_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNS0xLTEtMS0w_b9fd16b8-a73c-42eb-a63f-3c2dc748c52e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa95fa7e31a642ad9cd96a1b3fcf9c53_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNS0zLTEtMS0w_23d9b4c1-def5-40ba-8cf0-d555b279ab6b">205,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4de41313418040828be43e5a80c4efe2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNS01LTEtMS0w_5867ce89-2e17-4fb7-91a3-2d709ff0ca51">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64a094d14f3345cf98071f778c000dee_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNS03LTEtMS0w_ca7eb338-303d-4dc5-bf73-a6d87c5e8307">205,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79f3f7be17bc46db883ba607846df111_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNi0xLTEtMS0w_316ea2eb-edb0-4f19-89b4-d9abfe4ca199">181,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf394f5d90a047168042ea66bcdd28a8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNi0zLTEtMS0w_2f35afc7-2714-4e92-965c-0af21027a5ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37dbdde627f041b198d1ebf46adee969_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNi01LTEtMS0w_28342acd-3cf6-4855-ab90-a5c2fb89dae7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id01aefa120cb41b1a07c570b285b6778_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNi03LTEtMS0w_a676e897-7a8d-4e2a-ab7d-abbba951fc96">181,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c461309afd84ba1ba2d93c6c1318f70_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNy0xLTEtMS0w_cfb4be9c-fe7d-4d91-a44a-81100cdfea4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2c3f56a38964674b3be5794ce01fbe8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNy0zLTEtMS0w_22ae3b73-2cac-4f5a-9002-0570ad708f66">25,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i26d3828189e540c3b1a53ffca0d571b8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNy01LTEtMS0w_c124ce0a-c1b3-4cb2-a5df-5e9145d01cb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8580644452b94e12ab9e3485cfc60784_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNy03LTEtMS0w_86388af0-28fe-4ef1-b7c5-357021c25bee">25,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i792bbadca48943bfaf71a2bb11414136_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOC0xLTEtMS0w_04a5c3c2-b414-41be-ba96-c79a80b79130">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17d9949e90384e369f45910b88cec3f9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOC0zLTEtMS0w_47c42dd4-6ea6-4542-9549-bce63825afcc">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id601068b37f04845aafc46fd43f5e853_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOC01LTEtMS0w_e7cacc27-bd7d-4192-b292-505e5218698d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8b29ad214b4978b3bc65dd87a1284c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOC03LTEtMS0w_33489b54-25b2-4aa4-a9ca-1c2e6085eceb">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55f0d72dfa6c42f5bba2b89d78731ebf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOS0xLTEtMS0w_d121b2f3-2750-4e7d-a9de-fd8fd13f5b00">304,794</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04aad2f3e4fe42c98e0232d3eae8a9d9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOS0zLTEtMS0w_9e57577c-c223-4dfe-898b-0f520ef5f367">231,835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f16cc2983b042dfb0cb862ba0b07d6a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOS01LTEtMS0w_fcfd0e10-0bd1-4476-94a8-66c917507b73">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifcd82b2e8101404ab7f516da762fb5d1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOS03LTEtMS0w_fedb172e-8363-4d74-8f17-8288c899f8dd">536,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Included within cash and cash equivalents on the Company&#8217;s balance sheets</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;"><span><br/></span></div><div id="i39d9204faee04259b4794495e3dfeace_52"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RleHRyZWdpb246ZTQ3NzFlNTY5YmZkNDBlMWI3Y2JhYjcwN2ZjYzI4ZTlfODgy_6ce85372-7cd2-402f-a90a-4120499f09b7" continuedAt="i3f9ce57451bb4081a53417085ba05a00" escape="true">Financial Instruments</ix:nonNumeric></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3f9ce57451bb4081a53417085ba05a00" continuedAt="icf9fcc4e05594db7b6dab9ce86195e95"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RleHRyZWdpb246ZTQ3NzFlNTY5YmZkNDBlMWI3Y2JhYjcwN2ZjYzI4ZTlfODgz_4f1033e2-734f-4b19-8716-de7ec7ebbe52" continuedAt="if9dbed61949144d38b0d9778ac8187c0" escape="true">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:</ix:nonNumeric></ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="icf9fcc4e05594db7b6dab9ce86195e95"><ix:continuation id="if9dbed61949144d38b0d9778ac8187c0"><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia10fb1c7bf324168ab0a2db735f79147_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMy0xLTEtMS0w_2b5c6f78-dd4a-4a8b-9761-a3c10494b5e4">113,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia10fb1c7bf324168ab0a2db735f79147_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMy0zLTEtMS0w_ef953e39-0d6a-429b-827f-a22eaaba5ed2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia10fb1c7bf324168ab0a2db735f79147_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMy01LTEtMS0w_4313c5ae-f27a-43af-a6e2-3fdbbc3c5ebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia10fb1c7bf324168ab0a2db735f79147_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMy03LTEtMS0w_74bd2804-8cf5-4d9a-b67a-72f09619582a">113,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c15b3ab1e74889b26989029ae6d673_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNC0xLTEtMS0w_350591be-fbf7-435a-9518-1b79d31f603c">25,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c15b3ab1e74889b26989029ae6d673_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNC0zLTEtMS0w_44d56867-fb6f-49a9-ad1e-a9ccf1fccb43">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c15b3ab1e74889b26989029ae6d673_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNC01LTEtMS0w_5c99cbdb-add8-465e-a7ff-0b7012790f63">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c15b3ab1e74889b26989029ae6d673_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNC03LTEtMS0w_cad5ee97-ba20-4bcf-96ea-ac8b12b73f83">25,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i364cd7afc1844168ad816a8621088d26_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNS0xLTEtMS0w_2b1b6ac1-fc67-4fab-bff1-f0d5b389e885">190,625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i364cd7afc1844168ad816a8621088d26_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNS0zLTEtMS0w_7a4a0111-d9dd-4740-b2db-f4b133c237c7">505</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i364cd7afc1844168ad816a8621088d26_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNS01LTEtMS0w_f2e4b3e5-854d-41ae-9aa5-800de6257de5">276</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i364cd7afc1844168ad816a8621088d26_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNS03LTEtMS0w_ce95ca19-6d47-4882-a9aa-cb90328bdbd9">190,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01d8447678cb4fc0b136d8049103aa1b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNi0xLTEtMS0w_03a7a5e9-c7db-425d-8967-bf606daf00a9">178,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01d8447678cb4fc0b136d8049103aa1b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNi0zLTEtMS0w_7f024cf2-537e-4b0f-9d23-8173b25b9748">1,618</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01d8447678cb4fc0b136d8049103aa1b_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNi01LTEtMS0w_a6020029-d094-4eec-b61e-8ec7ffff7135">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01d8447678cb4fc0b136d8049103aa1b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNi03LTEtMS0w_a2514043-ddb1-4b3c-90d0-94218b4ea83b">180,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c64460a47e84af39d4f40bacaa2fd75_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNy0xLTEtMS0w_f374b51f-813f-46ee-8551-2392b355aeea">28,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c64460a47e84af39d4f40bacaa2fd75_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNy0zLTEtMS0w_c60019ae-f40f-4c5c-af8a-ed7a5befd48b">207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c64460a47e84af39d4f40bacaa2fd75_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNy01LTEtMS0w_8ac0b7bf-7d65-4777-8e5b-e31ab6753ad5">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c64460a47e84af39d4f40bacaa2fd75_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNy03LTEtMS0w_40266466-fb73-42e1-a13e-467cfb8503b2">29,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfOC0xLTEtMS0w_380c4645-7243-4f5a-8352-ee790ad173ed">537,235</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfOC0zLTEtMS0w_1085552d-f2bf-4f61-ad31-6db8d954f4db">2,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfOC01LTEtMS0w_e10ca7d1-147b-4784-810c-f28490262c80">277</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfOC03LTEtMS0w_5cddaf98-2295-4055-9413-65f790cc03f3">539,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMTEtNy0xLTEtMA_fccf9bb4-f5fa-48fa-9ab5-4eee606c02e9">122,141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMTItNy0xLTEtMA_13aceb1f-be09-4e82-9b99-d640537a064e">357,026</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMTMtNy0xLTEtMA_f2e7df67-c327-4066-b9c7-8dc1c71b9269">60,121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMTQtNy0xLTEtMA_2a5e3fb5-cbc5-4eb8-bb94-93ab5b23c0fa">539,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b8466b8753547e7a17d250705529eae_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMy0xLTEtMS0w_1491c01a-3b9a-4510-9bba-9ba679e2f2f4">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b8466b8753547e7a17d250705529eae_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMy0zLTEtMS0w_6ea33fbc-2fb0-4c70-904c-a5c95b476fbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b8466b8753547e7a17d250705529eae_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMy01LTEtMS0w_d93482fd-13f9-4808-98bc-897c7c68d5e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b8466b8753547e7a17d250705529eae_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMy03LTEtMS0w_d6357fd1-6df8-4eac-9095-4cbb8cd645c0">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNC0xLTEtMS0w_92cf601f-b6a8-40ed-b842-3b9134b03ba8">204,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNC0zLTEtMS0w_cdff2e6b-89e5-42f5-b41a-a2decc51756b">871</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNC01LTEtMS0w_f4751714-8aa8-4599-a57f-5206edf2a4c0">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNC03LTEtMS0w_38e30d5a-0cb9-410b-bcdb-4b0abcd12770">205,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c611e2c37aa4636b1d74f643ed27edd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNS0xLTEtMS0w_5c5978ac-89a2-4b4d-adbd-a537f3f120a2">181,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c611e2c37aa4636b1d74f643ed27edd_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNS0zLTEtMS0w_e1ea41d2-b380-4d66-b106-99cffdca26e9">557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5c611e2c37aa4636b1d74f643ed27edd_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNS01LTEtMS0w_192eeeed-a552-4763-8ad5-543547df5c97">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c611e2c37aa4636b1d74f643ed27edd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNS03LTEtMS0w_ab75c9c7-c7a8-49c9-8e1c-9e18c7c6cecc">181,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i639bc019200d423cac9e1f1b8acfbaa7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNi0xLTEtMS0w_22b65429-f36b-42d4-80c9-dba94f115e5e">25,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i639bc019200d423cac9e1f1b8acfbaa7_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNi0zLTEtMS0w_068b7a00-66c4-4335-b942-4a3fd4e6b898">167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i639bc019200d423cac9e1f1b8acfbaa7_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNi01LTEtMS0w_a2721f8c-54e6-4c1f-b900-c9b8b642a3af">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i639bc019200d423cac9e1f1b8acfbaa7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNi03LTEtMS0w_bc57ab4c-b11e-49f9-bfb6-10913faf5be2">25,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ab02fe568304455a85402d84dbb39c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNy0xLTEtMS0w_540fad64-9a6f-45c3-8d4a-f2f7b874b2e4">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ab02fe568304455a85402d84dbb39c4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNy0zLTEtMS0w_9940ce1c-27f8-494e-bcb4-c03a378af318">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ab02fe568304455a85402d84dbb39c4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNy01LTEtMS0w_fe920f87-229e-4150-a020-16b1581d49b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ab02fe568304455a85402d84dbb39c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNy03LTEtMS0w_d0e452b0-5fe4-4b84-9fd7-94f8461774c1">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfOC0xLTEtMS0w_cdc64684-ea25-4fcd-963e-6826fd7587e3">535,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfOC0zLTEtMS0w_b32287f6-10dc-4708-9259-f3e6390f3071">1,595</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfOC01LTEtMS0w_386bff25-517c-4aef-ab5d-516524a31b7f">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfOC03LTEtMS0w_c4ce2e9c-60a1-4315-9589-1d547c28daa4">536,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMTEtNy0xLTEtMA_4ee6ed83-3c50-43b2-9c62-36c5ee12c432">122,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMTItNy0xLTEtMA_cb0872f5-1a30-4c18-8651-19606cf4cdcd">355,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMTMtNy0xLTEtMA_46c0c5f3-67bc-426d-a56c-ab7ab2e04a1b">58,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMTQtNy0xLTEtMA_b3f9f700-d262-4252-b705-b5fa5e80dce1">536,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020,&#160;the remaining contractual maturities of available-for-sale securities were less than <ix:nonNumeric contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" format="ixt-sec:duryear" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RleHRyZWdpb246ZTQ3NzFlNTY5YmZkNDBlMWI3Y2JhYjcwN2ZjYzI4ZTlfMzE3_753efe3b-e4e3-45ad-ab93-2f1703c7c4ce">3</ix:nonNumeric> years. There have been no significant realized losses on available-for-sale securities for the period presented. As of March 31, 2020, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#8217;s marketable securities are due to market factors. To date, the Company has not recorded any impairment charges on marketable securities.</span></div></ix:continuation><div id="i39d9204faee04259b4794495e3dfeace_55"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RleHRyZWdpb246OTViY2FjMzYyNDY1NGMzODhhMjczNTYwNmVjMDZhNmZfMjk0_77914a15-a3c5-422a-a74c-9a23e87c1fcd" continuedAt="ia6fd25e02c4f417ba31363d465b43fe5" escape="true">Balance Sheets Components</ix:nonNumeric></span></div><ix:continuation id="ia6fd25e02c4f417ba31363d465b43fe5" continuedAt="i9291ede6cdd942fd94f417496e130701"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RleHRyZWdpb246OTViY2FjMzYyNDY1NGMzODhhMjczNTYwNmVjMDZhNmZfMjg5_bb5f30f3-c81b-4e63-976b-ec079b1a969f" continuedAt="i80c6fa9e04be4c2e995ca61d6f4a6a4e" escape="true">Property and Equipment consist of the following:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><ix:continuation id="i9291ede6cdd942fd94f417496e130701"><ix:continuation id="i80c6fa9e04be4c2e995ca61d6f4a6a4e"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.114%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.077%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib0de266e8b9e4b318c1b6289ecb6ce00_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfMi0xLTEtMS0w_a12cc1f4-8df6-4875-b7c4-a5636cad0a76">31,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff732cfa26a242859b76df19609edf5d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfMi0zLTEtMS0w_7abc8fdf-8fa4-4a33-bfb3-963010fadcfd">29,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77059c64b65f479fb071a0e986cf7b09_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfMy0xLTEtMS0w_fc3d808f-0642-4a55-9eb7-f184db011a09">21,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80325903deab4700b1323494502a9120_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfMy0zLTEtMS0w_6d0379c5-0e5f-4507-8f9f-ce2e157a7967">12,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c1f1460cc8942cf818d575042f8c4f0_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNC0xLTEtMS0zMzI_d2069822-f469-4361-8a39-92db02f3bf23">13,967</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10f2b6782cf247b5a11b92d52590baed_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNC0zLTEtMS0zMzI_468174f0-e1ad-4356-86e0-ae445a8c2903">13,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers equipment and purchased software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie075cc2a67084ac1b3eb62f94228b0ef_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNC0xLTEtMS0w_23a26e18-a5bc-49b6-8015-cb0e325d3873">3,774</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ca85fe9deb54d98b46c30a75fb18924_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNC0zLTEtMS0w_41b2b724-b5a0-4767-8acf-e2aff4974acf">3,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i790b82aa47544194a8a63de2efdb8636_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNS0xLTEtMS0w_a4b2cf10-4d34-4d83-8dc4-d66d98b97be1">2,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d7a98f96eeb4c94afb207c3aad9d5b1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNS0zLTEtMS0w_0258645a-f6f4-4077-a21a-a1397ff20908">2,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNy0xLTEtMS0w_2b6929a4-1c6f-4dee-88cd-76520d7f1065">73,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNy0zLTEtMS0w_efe86942-d99d-4a10-812a-d4dd23ea085a">61,921</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfOC0xLTEtMS0w_50a0283f-fa97-48c1-ae67-f21c925d7806">7,365</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfOC0zLTEtMS0w_61f11eae-ba66-451f-83e5-b5ff9f0583b0">5,472</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfOS0xLTEtMS0w_829a06aa-bbdd-4fa7-98c6-9cb54dfa6827">66,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfOS0zLTEtMS0w_b4cf81d7-5406-4de3-8f25-020f2fe4be5c">56,449</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:6pt;"><span><br/></span></div><div id="i39d9204faee04259b4794495e3dfeace_58"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="allo:LicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNzE0NjgyNTYwMTM0OA_5d0a13af-10c7-4360-9409-7f175f3c9e11" continuedAt="i69a00d07240f42a6905bf5af36333f0e" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="i69a00d07240f42a6905bf5af36333f0e" continuedAt="ie68e5d8b490b489da56e146c71dc0521"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Contribution Agreement with Pfizer</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $<ix:nonFraction unitRef="usd" contextRef="i3e45882827dc473d9cccdddf46d4bc37_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNzg5_05b957fd-9738-49a4-9516-2d5415893dbd">30.0</ix:nonFraction> million or $<ix:nonFraction unitRef="usd" contextRef="iccb902fc0cbf494384e4080a72eb2561_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNzk1_cc91b008-2d06-460b-9c5c-3ac6d699efb0">60.0</ix:nonFraction> million, depending on the target, with aggregate potential regulatory and development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iccb902fc0cbf494384e4080a72eb2561_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialRegulatoryAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODk2_018773c3-8bce-438a-b4e8-d0b4e1280b4e">840.0</ix:nonFraction> million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $<ix:nonFraction unitRef="usd" contextRef="ia733fa51ba7647a6aba865395e1556a1_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTM1MA_5195b2a2-447d-4b1c-bb30-c532da5beaf3">325.0</ix:nonFraction> million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three months ended March&#160;31, 2020 and 2019 respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) <ix:nonNumeric contextRef="i789c0228925e4672b7ac566e5e3afc54_D20200101-20200331" format="ixt-sec:duryear" name="allo:RoyaltyObligationPeriodFromDateOfFirstSale" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMjMzNQ_8a778ac1-93ec-41ca-abb0-8f15a7deb8fe">12</ix:nonNumeric> years from the first sale of such product in such country.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Cellectis</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="ie68e5d8b490b489da56e146c71dc0521" continuedAt="i54131c6e6cd14333bbe13f25699e7dee"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $<ix:nonFraction unitRef="usd" contextRef="i600ae8e97f094c078004eb149339e911_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNDYwNA_18ad2141-bba4-4d51-aa63-bb48b2f493c5">185.0</ix:nonFraction> million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i8c687c20085e4f9daaa84f4f372fadd1_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNDc0NQ_360bce44-698f-4de9-9fa3-b89d013d332c">2.8</ix:nonFraction> billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All costs the Company incurred in connection with this agreement were recognized as research and development expenses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March&#160;31, 2020 and 2019,  <ix:nonFraction unitRef="usd" contextRef="i98399c769a4a488aaa46d0a7c26a9054_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNzI5MA_4562c0da-6619-4373-8374-6732237c9cb3"><ix:nonFraction unitRef="usd" contextRef="ib28fed9c91714dbea81ced010fd4dff8_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNzI5MA_4d2613b1-82b8-4fa6-ae0b-a7518822572b">zero</ix:nonFraction></ix:nonFraction> costs were incurred related to the achievement of a clinical development milestone under this agreement. For the three months ended March&#160;31, 2020 and 2019, <ix:nonFraction unitRef="usd" contextRef="i64e12e6daa2c4fb5b8ad43e1cd9547e8_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNzMxMQ_0c36eef0-76ce-4474-86a3-4c653d6c399d"><ix:nonFraction unitRef="usd" contextRef="i73435ce9243740bd8574ccf58e1a1558_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNzMxMQ_c6f5c573-1e9a-4aeb-8e53-05c5bfb018f1">zero</ix:nonFraction></ix:nonFraction> costs were incurred associated with research services performed by Cellectis under this agreement. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License and Collaboration Agreement with Servier</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="i54131c6e6cd14333bbe13f25699e7dee" continuedAt="ic9a5867df7fe4d299c665f0e5ce5ba9b"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for <ix:nonFraction unitRef="number" contextRef="i7c737287cec94ddba5b57cbf684bfb99_D20200101-20200331" decimals="2" name="allo:PercentageOfDevelopmentCostPayableByTheCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTEyMTI_60ed3cf7-80c9-47d1-9a0e-fc8f40dc828f">60</ix:nonFraction>% of the specified development costs and Servier is responsible for the remaining <ix:nonFraction unitRef="number" contextRef="i7c737287cec94ddba5b57cbf684bfb99_D20200101-20200331" decimals="2" name="allo:PercentageOfDevelopmentCostPayableByCollaborationPartner" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTEyOTU_e3edd897-a6d8-44c4-a52f-73a76ec6ab86">40</ix:nonFraction>% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $<ix:nonFraction unitRef="usd" contextRef="ia5d5e7c43ae443da8eacbed133ea82c3_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTE5MzY_db26b1cc-1530-4b9a-b823-9b02d500e729">137.5</ix:nonFraction> million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $<ix:nonFraction unitRef="usd" contextRef="i25eec7c7b62e480a8a24e1d2fc01cb00_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTIwNjg_250cef34-e96b-452e-8872-ecbeb762fe31">78.0</ix:nonFraction> million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $<ix:nonFraction unitRef="usd" contextRef="i4bf058e9146a44db8d47e1921229a153_I20200331" decimals="-6" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTI1Mjg_fb2cf80d-e329-4155-baa2-d4c5c87c87f7">42</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="iec4bd58ba39b42698636440287c1b64f_I20200331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTI1MzU_dc2b3d5d-0b60-4b31-8540-999bf6541f93">70.5</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="iec4bd58ba39b42698636440287c1b64f_I20200331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTI1Mzk_2bc0ba12-a60e-4f06-9ba3-9e2f12e00597">77.4</ix:nonFraction> million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March&#160;31, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i7c737287cec94ddba5b57cbf684bfb99_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="allo:RecoveryOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTM4NzI_733bcee0-298f-4c87-a7b1-4759a82b7e0e">1.0</ix:nonFraction> million&#160;of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. For the three months ended March 31, 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i3e0de113752c4ee3912070b56b2b88e7_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNjk2MQ_09c6dc59-4bb3-4da1-bd95-ae332706f328">0.7</ix:nonFraction> million of costs as research and development expenses. As of March&#160;31, 2020, amounts due from Servier of $<ix:nonFraction unitRef="usd" contextRef="i2f6403cfdee14280a2a1c6dc64afba04_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTQxNjI_12c29ca7-201a-4ab1-b21e-9a4148d2cc9f">0.2</ix:nonFraction> million were recorded in other current assets in the accompanying condensed balance sheet. As of December&#160;31, 2019, amounts due to Servier of $<ix:nonFraction unitRef="usd" contextRef="i53d07d0342c54b11b26f9a2900615150_I20191231" decimals="-5" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzI5ODUzNDkwMzY1OA_6e7c9e9e-4b90-4304-a0c8-41537d126cbf">2.2</ix:nonFraction> million were recorded in accrued and other current liabilities in the accompanying balance sheets. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Notch</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="ic9a5867df7fe4d299c665f0e5ce5ba9b" continuedAt="i1929453dd41f4b1cb571757d787d9358"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $<ix:nonFraction unitRef="usd" contextRef="i8a48ecd5e6aa4995bcfa8af46e4b858e_I20191101" decimals="-5" format="ixt:numdotdecimal" name="allo:CollaborationAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTIxMg_a9198527-3425-452e-b846-db9c1e55cb04">10.0</ix:nonFraction>&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i3a11830e93d74ad8a671b309eacfb9e7_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTIyNw_19f8e97c-a6e3-47a3-a29a-27ccf193c379">10</ix:nonFraction>&#160;million during the year to December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $<ix:nonFraction unitRef="usd" contextRef="ia387f6863fef4d76b7a4661c9545f04d_I20191101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI0MA_d5add150-cd39-4c87-879a-59f935044d2e">5.0</ix:nonFraction>&#160;million investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a <ix:nonFraction unitRef="number" contextRef="ia387f6863fef4d76b7a4661c9545f04d_I20191101" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI1NA_977050bb-9110-4513-9874-ec0589bdc194">25</ix:nonFraction>% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#8217;s board of directors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Notch Agreement, Notch will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ifdb5da102c704b2ab704e75453c50364_I20200331" decimals="-4" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI1OQ_054aac9d-286a-4233-9aeb-cad4c1b780d2">7.25</ix:nonFraction>&#160;million upon achieving certain agreed research milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i6012c21655b348b4b23bf36d66ffd9cf_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI3NA_591bab66-42e5-4f46-b637-253543ba3647">4.0</ix:nonFraction>&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i4cad33ed23754ac189892f31dc1b6c1a_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI4OA_9b1a4bc1-c8b8-4843-86ee-f95189b43589">283.0</ix:nonFraction>&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has determined that Notch continues to be a variable interest entity as of March&#160;31, 2020. The Company does not have the power to direct the activities which most significantly affect Notch's economic performance. Accordingly, for the three months ended March&#160;31, 2020, the Company did not consolidate Notch because the Company determined that it was not the primary beneficiary. </span></div></ix:continuation><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i1929453dd41f4b1cb571757d787d9358">For the three months ended March&#160;31, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i5c634926bf9d49b1a097075a247d38eb_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="allo:CollaborationArrangementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzI5ODUzNDkwNDEyMg_630c0ec7-c34b-4dcc-944b-ce8fcb23c101">0.3</ix:nonFraction> million in collaboration costs as research and development expenses.</ix:continuation>  </span></div><div id="i39d9204faee04259b4794495e3dfeace_64"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzE0NjgyNTU5MTkzNA_90cc7977-f502-4ebe-9d85-e6c78bc6dc9c" continuedAt="i34059aaf7b354568a23dd9fc3d4497df" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i34059aaf7b354568a23dd9fc3d4497df" continuedAt="i7564fc9c246040239a9e862ca506ca40"><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately <ix:nonFraction unitRef="sqft" contextRef="i5ac8b68de98741d19e6456e14a0805cf_I20180831" decimals="-3" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTUz_3e09f38d-ae5c-4036-b541-0eb813bf0e84">68,000</ix:nonFraction> square feet located in South San Francisco, California. The lease term is <ix:nonNumeric contextRef="i5ac8b68de98741d19e6456e14a0805cf_I20180831" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMjMw_6afc2b7c-c8cd-4469-8561-b4f862328b10">127</ix:nonNumeric> months beginning August 2018 through February 2029 with an option to extend the term for another <ix:nonNumeric contextRef="i5ac8b68de98741d19e6456e14a0805cf_I20180831" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY1Mg_63f2d84c-5fee-41d3-9c30-152331d85b14">seven years</ix:nonNumeric> which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $<ix:nonFraction unitRef="usd" contextRef="i5ac8b68de98741d19e6456e14a0805cf_I20180831" decimals="-5" format="ixt:numdotdecimal" name="allo:AllowanceForTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNTE1_1ada7f99-dc86-4a79-b31c-5cccbf4f4764">4.5</ix:nonFraction> million of tenant improvement allowances up to March 31, 2020. The rent payments began on March 1, 2019 after an abatement period. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of <ix:nonFraction unitRef="sqft" contextRef="i9b47b163f76a4417a683c3539110e2f9_I20181031" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTE1MQ_1e3b8303-0ab0-4603-96ea-cd72b5d58f7b">14,943</ix:nonFraction> square feet located in South San Francisco, California. The lease term is <ix:nonNumeric contextRef="i9b47b163f76a4417a683c3539110e2f9_I20181031" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTIyOA_c766418b-691e-45b9-ad8d-aa98f7befc74">124</ix:nonNumeric> months beginning November 2018 through </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="i7564fc9c246040239a9e862ca506ca40" continuedAt="ia59f676aed50447ba348fbb57db30e84"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February 2029, with an option to extend the term for another <ix:nonNumeric contextRef="i9b47b163f76a4417a683c3539110e2f9_I20181031" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTMyNA_63083420-f51a-40f4-9d38-3dbf5a94bc60">seven years</ix:nonNumeric> which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $<ix:nonFraction unitRef="usd" contextRef="i9b47b163f76a4417a683c3539110e2f9_I20181031" decimals="-5" name="allo:AllowanceForTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTUyNg_50470d01-f9f5-40e5-8768-781bfeb1cb82">0.8</ix:nonFraction> million. Rent payments began in November 2018. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company entered into a lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="ieeeba5c202074b8680a92945d8d5cdcb_D20190201-20190228" decimals="-3" format="ixt:numdotdecimal" name="allo:AreaOfOperatingLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMjk2NQ_5ed64a05-ca6d-4aa1-8e59-1b062920d422">118,000</ix:nonFraction> square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of <ix:nonNumeric contextRef="i1d5b8ad9f2214bb9a3c41b2eb10f54f2_I20190228" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMzA4NQ_84095c6d-60e4-48a4-97c5-2b95de7cd33e">188</ix:nonNumeric> months and is expected to commence in April 2020. Upon certain conditions, the Company has <ix:nonFraction unitRef="renewal" contextRef="ieeeba5c202074b8680a92945d8d5cdcb_D20190201-20190228" decimals="INF" format="ixt-sec:numwordsen" name="allo:NumberOfOptionsToExtendLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY2Mg_833803c1-0172-458d-b108-d9cd24ddb78f">two</ix:nonFraction> <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY3Ng_1448f1a5-3854-48ed-9be5-baf156294104">ten</span>-year options to extend the lease which are not reasonably assured of exercise. Rent payments are expected to begin in early 2021 after an abatement period. The Company is entitled to a tenant improvement allowance of&#160;$<ix:nonFraction unitRef="usd" contextRef="i1d5b8ad9f2214bb9a3c41b2eb10f54f2_I20190228" decimals="-5" name="allo:AllowanceForTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMzUwNQ_80703fe9-864b-48e5-8692-c6d94ef35088">2.9</ix:nonFraction> million for costs related to the design and construction of certain Company improvements. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintained letters of credit for the benefit of landlords in the amount of $<ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzE0NjgyNTU5MTkzNg_45727f43-3995-4ecd-9e22-3cdf05482071"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzE0NjgyNTU5MTkzNg_47437fb2-3a7b-4125-88a9-d4f91aca4cd0">4.3</ix:nonFraction></ix:nonFraction>&#160;million which is disclosed a restricted cash as of March 31, 2020 and December 31, 2019, respectively.</span></div><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="allo:LiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY4Mw_a8109d20-1dc7-400a-84ea-f7ab42fa7f30" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"></td><td style="width:56.433%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.402%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.536%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.402%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.827%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfMy0yLTEtMS0yMjQ5_6178874a-80f0-4e98-bfd0-e5a6cae652ca">1,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfMy00LTEtMS0yMjQ5_d41c8db4-3b2f-4ad2-9ba6-f5d3287568bd">1,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfNC0yLTEtMS0yMjQ5_4bfc34e9-49a0-41f5-a8b8-145d246940f5">51,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfNC00LTEtMS0yMjQ5_091cbd0c-a3d7-42f8-acb5-a5b9a1ff5a8d">51,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfNS0yLTEtMS0yMjU0_9276cc40-131b-4191-b104-c8df94ba6120">53,343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfNS00LTEtMS0yMjU0_8605f466-773c-4039-a043-0fda025ece16">53,028</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY4NA_a45e1411-337a-4776-bc10-82f1f0a4d211" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"></td><td style="width:56.433%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.402%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.536%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.402%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.827%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfMi0yLTEtMS0yMjI3_3e9ee79e-e182-456d-9d34-0ac4a8cb62dc">1,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfMi00LTEtMS0yMjI3_cf5e227b-19ea-4673-8deb-607be943d7d5">1,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfMy0yLTEtMS0yMjI3_b11f9c9c-dd43-47ab-871f-72d01b597809">210</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfMy00LTEtMS0yMjI3_561f4b7a-9d73-467f-ae82-a99eddd1b633">139</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfNC0yLTEtMS0yMjI3_5b82d90f-e837-4a7b-accb-7fa74fcf1117">2,078</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfNC00LTEtMS0yMjI3_4fafe974-afcf-4eeb-998e-57dc303678e6">1,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzY5NjU4MTQwMzg5Nw_55eeefec-6232-4b5f-9720-05bd1cc6837f">1.4</ix:nonFraction> million and was included in net cash used in operating activities in our condensed statements of cash flows. </span></div><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNDMyMA_819adf6e-9c06-4217-977f-2c2a47c8b9b9" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The undiscounted future lease payments under the lease agreements as of March&#160;31, 2020 were as follows (in thousands:</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:84.217%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.050%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;2020 (remaining 9 months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMS0yLTEtMS0w_e39ec7c6-facc-42f7-ac3f-4bf65e25dd9c">4,236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMi0yLTEtMS0w_b03adf77-eb11-4881-8472-a66b70d4d376">7,633</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMy0yLTEtMS0w_2dad4a96-174a-4fe8-9561-c264900f6af4">7,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfNC0yLTEtMS0w_cab6c1b4-a1a1-4e7d-9655-626ea8c8a8df">8,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfNS0yLTEtMS0w_0b1d5ce6-77f6-4d35-8d91-68fcf4cd86e6">8,467</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfNi0yLTEtMS0w_4f4e278e-98a6-4e8d-b5dd-cbec71f8c793">55,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfNy0yLTEtMS0w_df0803ad-bbc8-477e-bb16-544e88b59800">91,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfOS0yLTEtMS0w_0c32c0f6-009c-40a8-a5c0-7b6d13c3ea80">34,736</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="allo:AllowanceForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMTAtMi0xLTEtMA_d853327e-4c9f-496f-8311-14ea95dc01f9">3,809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMTEtMi0xLTEtMA_adb47cdc-c6ce-411f-bb0d-359eeb466c08">53,343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was&#160;<ix:nonFraction unitRef="number" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzY5NjU4MTQwMzkwOQ_a97b159d-e936-4d8d-86c4-0d6e86933525">8.34</ix:nonFraction>%. As of&#160;March 31, 2020, the weighted average remaining lease term for our operating leases is&#160;<ix:nonNumeric contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzY5NjU4MTQwMzkxNQ_accc9e37-17ed-4672-ba22-02d53871e7ef">10.7</ix:nonNumeric>&#160;years.</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Commitments</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="ia59f676aed50447ba348fbb57db30e84"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of March 31, 2020. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of March 31, 2020, the Company had non-cancellable purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzE0NjgyNTU5MTkyMQ_ebec17a3-2d93-4c23-beb9-fdec2d034c7e">5.3</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i39d9204faee04259b4794495e3dfeace_1542"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzNDM5_aacec551-6dac-4f2f-b0da-53ba32eca894" continuedAt="i29e9090589764ec88ed8c6ea570f8e1c" escape="true">Equity Method Investment</ix:nonNumeric></span></div><ix:continuation id="i29e9090589764ec88ed8c6ea570f8e1c"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement (&#8220;Notch Investment Agreement&#8221;) with the Company acquiring shares of Notch&#8217;s Series Seed convertible preferred stock for a total investment cost of $<ix:nonFraction unitRef="usd" contextRef="ib223d885c64d4b53a8881033526b8151_D20191101-20191101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzMzc5_d83dd568-8084-4d8e-bac0-918e8a4abe55">5.1</ix:nonFraction>&#160;million which includes transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i53599948fe6c4ca5b584914643acddbc_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="allo:CostMethodInvestmentTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzMzkz_8998fcff-5db6-48ea-b94d-c9d86923ecec">0.1</ix:nonFraction>&#160;million, resulting in a <ix:nonFraction unitRef="number" contextRef="ic19af5f089974c2497122fe4a4e2e3dd_I20200331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzNDA3_f0072b3d-a4f5-4fd1-8547-5d8bcdad5809">25</ix:nonFraction>% ownership interest in Notch. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s total equity investment in Notch as of March&#160;31, 2020 and December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF8zMjk4NTM0ODg1NzA3_7a3219e7-ca17-4b21-adaf-b2d8c190c5f3">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i81bb738593bb4a4aa0333b29c524327a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzNDEy_ec593df8-7756-4144-90ef-dc623660da6f">4.9</ix:nonFraction>&#160;million, respectively, and the Company accounted for the investment using the equity method of accounting. During the three months ended March 31, 2020, the Company recognized its share of Notch's net loss under the other expenses caption within the condensed statements of operations. The Company's share of Notch's net loss was $<ix:nonFraction unitRef="usd" contextRef="i53599948fe6c4ca5b584914643acddbc_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="allo:IncomeLossFromCostMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF8zMjk4NTM0ODg0ODE1_29d6e99a-ada8-450d-9796-058cfda8ff4a">0.1</ix:nonFraction> million for the three months ended March 31, 2020.</span></div></ix:continuation><div id="i39d9204faee04259b4794495e3dfeace_70"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjkzMw_9ae82ea0-e320-4ede-b979-4b3bad3594d8" continuedAt="i8a2ab455a4894594aea2596dca702189" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i8a2ab455a4894594aea2596dca702189" continuedAt="i0b9c279ad9474965a91f5bbbdc6ade3f"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s board of directors and consultants of the Company under terms and provisions established by the Company&#8217;s board of directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to <ix:nonFraction unitRef="number" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="INF" name="allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzU1_a510031c-041f-413a-9216-ef6dc5e143a8">5</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed <ix:nonNumeric contextRef="iaf428979ee4648a58838e99d47fc80b6_D20200101-20200331" format="ixt-sec:duryear" name="allo:StockOptionGrantedPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfOTM0_ae67832a-4c80-4773-a781-443935c56363">10</ix:nonNumeric> years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than <ix:nonFraction unitRef="number" contextRef="iaf428979ee4648a58838e99d47fc80b6_D20200101-20200331" decimals="INF" name="allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTA2Nw_3ce40f0f-5018-4b8f-aabd-98a2dcbc4773">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the grant date. Options granted typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTE4Mg_4fe0cc3d-a369-4851-b84c-7f351e9ac8c3">four</span>-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTM5NQ_39524325-b7c4-4718-8e48-f4d8092688e2">12,448,841</ix:nonFraction> shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjkzNA_c72d67f6-a8ca-4242-acf2-476628ae0ffe" continuedAt="ice1abab4f5ee4838ad27a174278758c4" escape="true">The following summarizes option activity under the 2018 Plan:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="i0b9c279ad9474965a91f5bbbdc6ade3f" continuedAt="i85ab857df97d47dd9cadc902e64a5d28"><div style="margin-bottom:6pt;"><ix:continuation id="ice1abab4f5ee4838ad27a174278758c4"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:41.151%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.700%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Options</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie582f6e76ada438881e8098bffd2c1d9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMi0xLTEtMS0w_27bf86b0-e44e-418e-8b17-04116f9c54a8">9,190,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie582f6e76ada438881e8098bffd2c1d9_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMi0zLTEtMS0w_6f6a99f5-066a-4996-95f8-83dc014979d1">14.51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i5bbdece93a42441ab703824c19120916_D20190101-20190331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMi01LTEtMS0w_44b7f94c-2420-483d-a8bb-7c8150360b58">8.82</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie582f6e76ada438881e8098bffd2c1d9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMy03LTEtMS0zOTY3_a06b8329-d991-42ed-8330-15ac82e3faab">110,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMy0xLTEtMS0w_544c7ded-594f-42e2-86c8-97ccc34e9da4">2,675,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMy0zLTEtMS0w_b2ff1d72-561c-42c0-9161-dbbd6d4d3d08">18.38</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNC0xLTEtMS0w_544372bd-9cd8-48cb-aba3-8ace6ffd0acc">105,895</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNC0zLTEtMS0w_1f7d54ca-e524-433d-b554-438f20dbac46">2.87</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNS0xLTEtMS0w_41c9d59b-01ee-46b4-9866-17f5c7c7c2ad">132,910</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNS0zLTEtMS0w_d9f5badd-cd3b-4878-b6a0-4d8b8aaa8148">9.58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNi0xLTEtMS0w_06b5ae44-0b6d-4253-9db1-95d1485e3129">11,627,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNi0zLTEtMS0w_33c61d12-d5e2-4cbe-8a05-6202cb4dcbca">15.56</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNi01LTEtMS0w_ec024bad-c9f1-4dee-868d-70fe929d4f5f">8.87</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy03LTEtMS0zOTY3_3b83703c-a340-440b-aba8-d8d711dfa4d8">77,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy0xLTEtMS0w_0fcdc1f0-174b-49ec-9e5d-c7d8dadf3301"><ix:nonFraction unitRef="shares" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy0xLTEtMS0w_6f685e9d-e69c-439a-b519-64e383103bb4">6,716,452</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy0zLTEtMS0w_abaee00e-f6f0-4c99-88b8-daf8f53508d9"><ix:nonFraction unitRef="usdPerShare" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy0zLTEtMS0w_e49f0cf2-833e-42e9-a4d8-29f2479cf30d">13.66</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy01LTEtMS0w_016aaddb-99fa-47fa-8145-73f23f3eb02f"><ix:nonNumeric contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy01LTEtMS0w_df1226fb-0913-458c-a2ca-85e1f39972d9">8.90</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOC03LTEtMS0zOTY3_e2336f92-d8b7-47e8-acf9-094cfa43224a">51,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOC0xLTEtMS0w_7065033a-8f65-4fb6-aa78-6b35ecd9f1d5">11,627,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOC0zLTEtMS0w_b7b8bbb8-f89d-48f8-b63c-5a00c209639b">15.56</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOC01LTEtMS0w_15ceec32-ddde-4930-961a-7e4392be97cb">8.87</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOS03LTEtMS0zOTY3_cea1bbd8-eba5-432b-996a-ae9f196c0b69">77,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic values of options exercised, outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on March 31, 2020. For the three months ended March 31, 2020, the estimated weighted-average grant-date fair value of employee options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic177a9557377487499e270097c358bf7_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjQwNA_b93aadc7-49db-4368-95b4-094b90d48c2d">18.41</ix:nonFraction> per share. As of March 31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i521694cbaa114dddb6a6dff0b4c9abb9_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjM4OQ_0866e4b8-eb24-429a-bdb8-69f00a55af1e">98.2</ix:nonFraction>&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ic177a9557377487499e270097c358bf7_D20200101-20200331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjM2Mg_6a2a8c21-f378-4a1b-9734-d78144a89c74">3 years, 45 days</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjQxMQ_cffe6618-5197-441e-8fd0-93f5fd3667c9" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:66.676%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.294%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.295%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term in years</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.07 - 6.09</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.99 - 6.25</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjVkZGZkODQ2ZTEwNDRmODdiZTJiNDRkYTg5Mjk5MWVkL3RhYmxlcmFuZ2U6NWRkZmQ4NDZlMTA0NGY4N2JlMmI0NGRhODkyOTkxZWRfMy0xLTEtMS00MjY0_e995dbe7-ad23-483e-b55b-cba6141c0e7a">71.42</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5bbdece93a42441ab703824c19120916_D20190101-20190331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjVkZGZkODQ2ZTEwNDRmODdiZTJiNDRkYTg5Mjk5MWVkL3RhYmxlcmFuZ2U6NWRkZmQ4NDZlMTA0NGY4N2JlMmI0NGRhODkyOTkxZWRfNC0zLTEtMS0zOTAw_5bcb3983-09f9-4128-af92-ba3dcf253df8">74.84</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.80% - 1.65%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.45% - 2.62%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjVkZGZkODQ2ZTEwNDRmODdiZTJiNDRkYTg5Mjk5MWVkL3RhYmxlcmFuZ2U6NWRkZmQ4NDZlMTA0NGY4N2JlMmI0NGRhODkyOTkxZWRfNS0xLTEtMS00MjY0_ffbbf1b6-d409-44c7-ac41-add8f2c6782e">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5bbdece93a42441ab703824c19120916_D20190101-20190331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjVkZGZkODQ2ZTEwNDRmODdiZTJiNDRkYTg5Mjk5MWVkL3RhYmxlcmFuZ2U6NWRkZmQ4NDZlMTA0NGY4N2JlMmI0NGRhODkyOTkxZWRfNi0zLTEtMS0zOTAw_2bc126f4-a0c2-4dce-92ba-637702eefb08">0</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Unit Activity</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjkyOA_57126cb0-9590-4ccb-b77a-6f1c5a46bc09" continuedAt="i8275c1e57b2f4ea8a133bc75558fecbf" escape="true">The following summarizes restricted stock unit activity under the 2018 Plan:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><ix:continuation id="i85ab857df97d47dd9cadc902e64a5d28"><div style="margin-top:12pt;margin-bottom:6pt;"><ix:continuation id="i8275c1e57b2f4ea8a133bc75558fecbf"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Restricted Stock Units</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Restricted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Stock Units</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Value at Date</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">of Grant per</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Share</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb31faa7f5644ea697201adc41fddd67_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMS0xLTEtMS0w_b4c2fbd0-cd51-4e16-95f6-9aa93c9f7f92">1,941,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idb31faa7f5644ea697201adc41fddd67_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMS0zLTEtMS0w_eb5aa18e-49de-4b4b-9891-d394bb0f5c48">27.45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i945dc20d171348f08a92572145268721_D20190101-20190331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMy01LTEtMS00MTk5_cf9492e5-76fb-4017-9e65-9d15b00258e9">1.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="idb31faa7f5644ea697201adc41fddd67_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMy03LTEtMS00MTk5_c4c2962c-cd69-4ad0-86c5-53ecd7542e5a">50,431</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMi0xLTEtMS0w_71f4762b-d45b-4640-81f6-5b64f2ea5e23">885,267</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMi0zLTEtMS0w_21802a59-aab4-4c53-9a28-98fb5c751a13">18.55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" format="ixt-sec:duryear" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNC01LTEtMS00MTk5_2db540f9-64e6-44f9-a7c1-dc2734ef65e0">2.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMy0xLTEtMS0w_2237072e-e37d-4c52-8400-e8b77b551a15">270,751</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMy0zLTEtMS0w_4d3a8fbe-dd8c-49d7-a366-bef6156be846">27.32</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNC0xLTEtMS0w_33097956-2f92-4ccb-8660-af2711a93bd1">21,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNC0zLTEtMS0w_6f673f96-fb1f-4446-abdd-d9a67879422b">28.19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic1565ebe58524c9791944236e646ac49_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNS0xLTEtMS0w_917d8b9a-b82a-44b9-9874-ab9024537ece">2,534,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1565ebe58524c9791944236e646ac49_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNS0zLTEtMS0w_18202aad-27dc-454c-99bc-9d9bedb7ecdc">24.35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNy01LTEtMS00MTk5_dec42b45-b6fd-41a4-8197-dbdeaaaab23d">2.17</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="ic1565ebe58524c9791944236e646ac49_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNy03LTEtMS00MTk5_39acc865-b901-4b02-b180-5c2bc5b5d933">49,274</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic1565ebe58524c9791944236e646ac49_I20200331" decimals="INF" format="ixt:numdotdecimal" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNi0xLTEtMS0w_a2216ccb-dba8-4e19-a3f3-9337c8067420">2,534,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1565ebe58524c9791944236e646ac49_I20200331" decimals="2" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNi0zLTEtMS0w_4682da4b-02ea-46af-952a-48a95811e3d7">24.35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" format="ixt-sec:duryear" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfOC01LTEtMS00MTk5_56c727b1-f1b5-4fd5-a3b4-7b773f8c0ba7">2.17</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="ic1565ebe58524c9791944236e646ac49_I20200331" decimals="-3" format="ixt:numdotdecimal" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfOC03LTEtMS00MTk5_a8c62a21-1b03-407b-919b-cd850f5fca3d">49,274</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="ic1565ebe58524c9791944236e646ac49_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjQxMw_ac6c15d4-4629-4321-b71d-ca9d85c86800">55.3</ix:nonFraction>&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjQyNw_48a10f8c-f854-440f-a2ae-ead3fd41e4ec">3 years, 133 days</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjkzMA_79589d0c-fe90-43bf-ac01-b46bda3be420" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:70.076%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.598%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c634926bf9d49b1a097075a247d38eb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfMi0xLTEtMS0w_cbeb29e6-c1a0-47e1-93a5-d9e68a0feef8">6,657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f2a6d6310eb4804acffb0d4e70789c4_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfMi0zLTEtMS0w_cae68458-3cb1-4882-858b-952a04e6cfbe">2,732</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7c4dd589aec54659af36f7495218487c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfMy0xLTEtMS0w_7b9b5399-b36d-4c0e-a126-407071dc0c71">7,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16de5530e6d44bc99f02f418df776b94_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfMy0zLTEtMS0w_61b62f02-dcbe-4d68-bf4c-24eced1ed8af">5,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfNC0xLTEtMS0w_654aedac-232e-4250-a5f2-be7e5e02ce5f">14,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfNC0zLTEtMS0w_e175f2b2-bda7-4f22-a430-0c3e4ef8acc1">7,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Early Exercised Options</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of March&#160;31, 2020 and 2019 there was $<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjY0NA_14de139f-1ec2-4ec2-8d8f-693cd1894a4c">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8710054b59684a4391833aea00414337_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTMxOTQxMzk1MzYyODk_29ed3293-5c9b-4c01-b98d-67a18fc0a078">5.3</ix:nonFraction> million recorded in accrued and other liabilities and $<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjY5Mw_63cd5f37-2f68-4da8-9db2-dffc6f508a20">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8710054b59684a4391833aea00414337_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTMxOTQxMzk1MzYyOTg_5fcf5716-02f2-4cd4-8ed7-71f18e65b9d2">6.1</ix:nonFraction> million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed financial statements since the exercise date.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_82"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzg4OA_491f9572-f5d1-4277-bb2c-08ad1769924d" continuedAt="i73d223abb9114421bd387a09d21a4152" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i73d223abb9114421bd387a09d21a4152" continuedAt="ib25c62d6189b47b3bb086cce788d65e0"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, Pfizer held <ix:nonFraction unitRef="shares" contextRef="i8a437f63084d4bd18d9edeff003da5ff_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTg_afcbbb0c-3786-411d-a6db-0f20de029ca5">22,032,040</ix:nonFraction> shares of Common Stock and had appointed one member to the Company&#8217;s board of directors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. In September 2019, the Company and Pfizer terminated the Pfizer TSA. For the three months ended March&#160;31, 2020 and 2019, the costs incurred under the Pfizer TSA were&#160;<ix:nonFraction unitRef="usd" contextRef="id52499d716214a2699bbb179be7d9b7c_D20200101-20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNDc1_775799b6-c123-4106-ac7f-641925434cbd">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1ff5875cc6044a67885d7490df6c5659_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0NDI0MQ_f302d3f7-fdfe-44b0-8c6f-66481f9b84b9">2.7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also purchased certain lab supplies from Pfizer in connection with its research and development activities. For the three months ended March&#160;31, 2020 and 2019, the total lab supplies and services purchased from Pfizer were <ix:nonFraction unitRef="usd" contextRef="ied67c130b61d4499b7927fceb186af36_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfODY0_259c18f2-5917-4123-8984-e4a947dd6476">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i86c84a8b6258472092c7917980204432_D20190101-20190331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0NDI2MA_ff7997b3-f1a6-4b99-8692-99550c77f511">0.6</ix:nonFraction>, million respectively. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020 and December&#160;31, 2019, the Company had an amount payable to Pfizer of <ix:nonFraction unitRef="usd" contextRef="i1eea165234764f838579662624ec9d90_I20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccountsPayableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTE0MA_28aced7e-ed6f-4347-a5be-2c03931d82a7">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i56aaf1b58d7b4ec7b18900c8eb264775_I20191231" decimals="-5" name="us-gaap:AccountsPayableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTE0OA_8a001691-6596-4d7d-82b4-d4b7e09f4cd9">1.7</ix:nonFraction> million, respectively, which was recorded in the accrued and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sublease Agreement</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for <ix:nonFraction unitRef="sqft" contextRef="ic321d0b1fd1c4b0f95aed3cd5340beae_D20181201-20181231" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfOffice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0MzgyNQ_72137375-e5ed-4583-bfbc-458497084bd8">1,293</ix:nonFraction> square feet of office space in Los Angeles California for a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0MzgzMg_3cee6d69-25e1-4997-bf53-faf3f51e1036">three</span> year term. The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. The total right of use asset and associated liability recorded related to this related party lease was $0.1 million and $0.2 million at March&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company subleased <ix:nonFraction unitRef="sqft" contextRef="i56c3fcf903a048f7b77fd696a381f82e_D20190201-20190228" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfOffice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTQxMg_6c9ebc03-ef20-427c-aaf1-c9f31c67a11f">2,180</ix:nonFraction> square feet of its office space in New York, New York, to ByHeart, Inc.(ByHeart), formerly known as Second Science, Inc.&#160;ByHeart is a development-stage infant formula company.&#160;Certain of the Company&#8217;s board members and executive officers have beneficial ownership in ByHeart and <ix:nonFraction unitRef="board_member" contextRef="i5f17f2b211344d3f82185666cdfd8064_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="allo:NumberOfMembersAppointedToBoardOfDirectors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfOTg5NTYwNDY1NTkyNw_e13f38db-36c8-4298-a9d7-b25db304a513">two</ix:nonFraction> serve on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to <ix:nonFraction unitRef="sqft" contextRef="ifae2200f0f404af2a52ee56081d823e3_D20190901-20190930" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfOffice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTgzNw_ac3757e2-542f-49d1-a765-67f7fc3b2e70">2,907</ix:nonFraction> square feet. Sublease income for the three months ended March&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i30246310ab084bc99257f27e94986e6b_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTkwMA_a51e49c6-5d8c-445a-a744-1ab3b00efc9f">0.1</ix:nonFraction> million and was recognized as other income. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consulting Agreements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $<ix:nonFraction unitRef="usd" contextRef="ia2e9df642ead424798c3bcd699e0d11f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMjUwNA_00895ce0-bad3-4154-b2a9-885858785d6e">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70ed49038db9439d99e49ced4b34596f_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzI5ODUzNDg4ODcyNw_4dfd4870-df46-4cf5-8311-4b1c8e925618">0.2</ix:nonFraction> million for the three months ended March&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib25c62d6189b47b3bb086cce788d65e0">In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $<ix:nonFraction unitRef="usd" contextRef="i05acd1d072c943d799c0703a556368b1_D20180801-20180831" decimals="INF" format="ixt:numdotdecimal" name="allo:RelatedPartyTransactionMonthlyPaymentsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzMxNg_6eaa82ab-2ae9-4879-945c-4727be770f89">33,333</ix:nonFraction> per month in arrears commencing January 2019 and $<ix:nonFraction unitRef="usd" contextRef="i2664c61460fd4fa8ac2b86b83a9aaef9_D20180801-20180831" decimals="INF" format="ixt:numdotdecimal" name="allo:RelatedPartyTransactionMonthlyPaymentsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNzE0NjgyNTU4NjQ3MQ_ae35f52d-9878-46ed-8153-c73046157523">37,500</ix:nonFraction> per month in arrears commencing January 2020. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to <ix:nonFraction unitRef="number" contextRef="ibf6da9f07f2d4b2cb4f36dece4d79776_D20180801-20180831" decimals="INF" name="allo:RelatedPartyTransactionCompensationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzQ2MA_b367ef4f-c8e3-4fa0-8e37-5161709190e5">60</ix:nonFraction>% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $<ix:nonFraction unitRef="usd" contextRef="i34a074fef5cf4808a3421b475b2b6e1f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzc0Mw_69f4baba-8eef-41df-b2e9-f26083d72c23">0.2</ix:nonFraction> million for the three months ended March&#160;31, 2020 and 2019, respectively</ix:continuation>.</span></div><div id="i39d9204faee04259b4794495e3dfeace_88"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84OC9mcmFnOmNkMmMzOGRhOGU5NjRmYjFiMmQyMGYxOWNiMTQwY2ZkL3RleHRyZWdpb246Y2QyYzM4ZGE4ZTk2NGZiMWIyZDIwZjE5Y2IxNDBjZmRfMTkx_558ca493-b0f7-49ea-b05d-d7d81395015e" continuedAt="i06f9eb81d1134be6a9c3c52b1ea5aab2" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i06f9eb81d1134be6a9c3c52b1ea5aab2">The Company has a history of losses, and expects to record a loss in 2020. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</ix:continuation></span></div><div id="i39d9204faee04259b4794495e3dfeace_91"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RleHRyZWdpb246ZjI2ZmZmNDY4NTJiNDZlMWI3MDEwN2NlOTUzNTk2OTJfMjE0_0d5a6cb0-6b4b-4d28-805e-2a82b3fc4b3b" continuedAt="i9482323b21964be4b0dc15a95c413e0d" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9482323b21964be4b0dc15a95c413e0d" continuedAt="i00fad596ff674ae98f42604cee7152a5"><ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RleHRyZWdpb246ZjI2ZmZmNDY4NTJiNDZlMWI3MDEwN2NlOTUzNTk2OTJfMjE1_9df0525d-18e1-4021-abb5-7fe2293720e7" continuedAt="ic33bc4e904a145b3bb1c8f7d948c751d" escape="true">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</ix:nonNumeric></ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><ix:continuation id="i00fad596ff674ae98f42604cee7152a5"><ix:continuation id="ic33bc4e904a145b3bb1c8f7d948c751d"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:73.806%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i445474810986457d86157ac99ce513eb_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfMi0xLTEtMS0w_2081706e-da68-4a6a-a6e4-a38f222df227">11,627,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2b6ed85ff10640e0a2e3c27c4de1f868_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfMi0zLTEtMS0w_71a44500-13f6-4a50-b77f-e5aaf74be7d7">8,939,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units subject to vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifab11e5afc21498ca4e40dc435770e6f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNS0xLTEtMS0w_a2cc7eb6-233f-4713-9a34-5936923c5395">2,534,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7e5c7873bcbb436f9297d5dc64e8c936_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNS0zLTEtMS0w_a1d76b15-f98f-49f0-851d-c9adc0a35446">1,102,028</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaea9ba03c9b646619b56dd93138eaddd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNi0xLTEtMS0w_f9914622-bee8-46b1-ab07-5e9948c7bdd4">226,459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i164061d208364d798deb08ac4045936a_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNi0zLTEtMS0w_0a500d2e-6843-4c5f-8dcc-df8095258344">265,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Founder's shares of common stock subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i493f3fa88aa246efb2e80fa6c3b6d7d7_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNy0xLTEtMS0w_88b9e833-9ec4-4579-b9f3-9a510109e966">12,115,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic90aa7f4abe04f2383035e03129a402e_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNy0zLTEtMS0w_419faa44-6c65-4d7b-8132-b0469ace5605">18,173,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia7ae26fbb0794fceb415878169f539c2_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfOC0xLTEtMS0w_8173245f-7a97-4cc0-95e9-1a347f8c6cc6">2,678,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i72a829b0930b4e63aaf7cd159033b693_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfOC0zLTEtMS0w_1736d1dd-fbc3-495b-a9f9-84d7d7fed872">5,020,580</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfOS0xLTEtMS0w_29f99537-d879-4f8a-97c4-8fda1ea838e5">29,182,402</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfOS0zLTEtMS0w_f74b28d9-e229-4170-82e1-774ea97a6b2b">33,500,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i39d9204faee04259b4794495e3dfeace_94"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85NC9mcmFnOmQ2ODNjODUxMDE5NTRkYzE5MzY5ZmNiMzllMTRhNzZlL3RleHRyZWdpb246ZDY4M2M4NTEwMTk1NGRjMTkzNjlmY2IzOWUxNGE3NmVfNDAxMQ_df0b6d53-46c1-49c1-b172-b136baa8d278" continuedAt="ie2380e418b364dd58e75efeac7b2d632" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie2380e418b364dd58e75efeac7b2d632">None.</ix:continuation></span></div><div id="i39d9204faee04259b4794495e3dfeace_97"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December&#160;31, 2019 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2019 (Annual Report), which was filed with the Securities and Exchange Commission (SEC) on February 27, 2020. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;Allogene,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Allogene Therapeutics, Inc., and references to &#8220;Servier&#8221; collectively refer to Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part II, Item 1A below. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#32406b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.</span></div><div id="i39d9204faee04259b4794495e3dfeace_100"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#8217;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have a deep pipeline of allogeneic chimeric antigen receptor (CAR) T cell product candidates targeting multiple promising antigens in a host of hematological malignancies and solid tumors. In collaboration with Servier, we are developing UCART19, ALLO-501 and ALLO-501A, CAR T cell product candidates targeting CD19. Servier is sponsoring two Phase 1 clinical trials of UCART19 in patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL), one for adult patients (the CALM trial) and one for pediatric patients (the PALL trial).  We are sponsoring a Phase 1 clinical trial (the ALPHA trial) of ALLO-501 in patients with R/R non-Hodgkin lymphoma (NHL). We expect to report initial data from the ALPHA trial at the American Society of Clinical Oncology (ASCO) annual meeting on May 29, 2020. We plan to use </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">the clinical data from ALLO-501 to accelerate the development of the second-generation version of ALLO-501, known as ALLO-501A. We have removed rituximab recognition domains in ALLO-501A, which we believe will potentially facilitate treatment of more patients, as rituximab is a typical part of a treatment regimen for a patient with NHL. We plan to initiate a Phase 1/2 clinical trial for ALLO-501A (the ALPHA2 trial) in the second quarter of 2020, subject to completing the manufacturing of ALLO-501A.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We initiated a Phase 1 clinical trial (the UNIVERSAL trial) of ALLO-715, an allogeneic CAR T cell product candidate targeting B-cell maturation antigen (BCMA), in adult patients with R/R multiple myeloma in the third quarter of 2019. We expect to report initial data from the UNIVERSAL trial in the fourth quarter of 2020. In addition, in January 2020, we entered into a clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. (SpringWorks) to evaluate ALLO-715 in combination with SpringWorks&#8217; investigational gamma secretase inhibitor, nirogacestat, in patients with R/R multiple myeloma. We plan to initiate this combination trial in the second half of 2020, subject to regulatory clearance.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Due to the exceptional circumstances related to the COVID-19 pandemic, Servier has halted recruitment in the CALM and PALL clinical trials. We are continuing to enroll patients in the ALPHA trial and UNIVERSAL trial, however, enrollment of new patients in both trials and the ability to conduct patient follow-up will be impacted by the COVID-19 pandemic. We have also closed our headquarters with our administrative employees continuing their work outside of our offices and limited the number of staff working onsite. Construction of our manufacturing facility in Newark, California, was interrupted for a period of time and may in the future be interrupted due to the COVID-19 pandemic. The exact timing of delays and overall impact of the COVID-19 pandemic to our business, preclinical studies and clinical trials is currently unknown, and we are monitoring the pandemic as it continues to rapidly evolve.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have had significant operating losses. Our net loss was $54.5 million for the three months ended March 31, 2020. As of March 31, 2020, we had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xMDAvZnJhZzphMDBiZWE3YThiZDY0ODNkYWVhZDkwYTgyOTJhZWMyMi90ZXh0cmVnaW9uOmEwMGJlYTdhOGJkNjQ4M2RhZWFkOTBhODI5MmFlYzIyXzI3MTc_dccede9e-df62-411e-95c9-0de08522b64d">450.6</ix:nonFraction> million.&#160;As of March 31, 2020, we had $553.0 million in cash and cash equivalents and investments.&#160;We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_103"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Research and Development and License Agreements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Contribution Agreement with Pfizer</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, we entered into an Asset Contribution Agreement (Pfizer Agreement) with Pfizer pursuant to which we acquired certain assets and assumed certain liabilities from Pfizer, including agreements with Cellectis and Servier as described below, and other intellectual property for the development and administration of CAR T cells for the treatment of cancer. See Note 6 to our condensed financial statements included elsewhere in this report for further description of the Pfizer Agreement.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Cellectis</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2014, Pfizer entered into a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 8, 2019,&#160;the Company&#160;entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement, pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement. The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The material rights and obligations of the parties under the Cellectis Agreement are otherwise consistent with the material rights and obligations of the parties under the Original Cellectis Agreement. See Note 6 to our condensed financial statements included elsewhere in this report for further description of the Cellectis Agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Exclusive License and Collaboration Agreement with Servier</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2015, Pfizer entered into an Exclusive License and Collaboration Agreement (Servier Agreement) with Servier to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR products, including UCART19, in the United States with the option to obtain the rights over additional allogeneic anti-CD19 CAR product candidates and for allogeneic CAR T cell product candidates directed against one additional target. In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement. In October 2019, we agreed to waive our rights to the one additional target. See Note 6 to our condensed financial statements included elsewhere in this report for further description of the Servier Agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration and License Agreement with Notch</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 1, 2019, we entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted us an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in NHL, ALL and multiple myeloma. In addition, Notch has granted us an option to add certain specified targets to our exclusive license in exchange for an agreed upon per-target option fee.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to our exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. In connection with the execution of the Notch Agreement, we made an upfront payment to Notch of $10.0 million. In addition, we made a $5.0 million investment in Notch&#8217;s series seed convertible preferred stock, resulting in us having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. See Note 6 to our condensed financial statements included elsewhere in this report for further description of the Notch Agreement.</span></div><div id="i39d9204faee04259b4794495e3dfeace_106"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Transition Services Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the closing of the Pfizer Agreement, we entered into a Transition Services Agreement (TSA) with Pfizer in April 2018, pursuant to which we obtained from Pfizer certain (i)&#160;research and development services, including services relating to testing, studies, and clinical trials, project management services, laboratory equipment and operations services, animal care services, data storage services and regulatory strategy services, and (ii)&#160;general and administrative services, including business technology services, compliance services, finance/accounting services, and procurement, manufacturing and supply chain services, with respect to the assets that we purchased from Pfizer. Under the TSA, Pfizer also provided us with certain facilities and facility management services. The services were provided by certain employees of Pfizer </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">as independent contractors of Allogene. We believe that it was helpful for Pfizer to provide such services to us under the TSA to help facilitate the efficient operation of our business after the asset purchase. Pfizer began providing the services in May 2018 and the TSA was terminated in September 2019. </span></div><div id="i39d9204faee04259b4794495e3dfeace_109"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Components of Results of Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, our research and development expenses have related primarily to discovery efforts and preclinical and clinical development of our product candidates. Research and development expenses for the three months ended March 31, 2020 included costs associated with our clinical and preclinical stage pipeline candidates and research into newer technologies. The most significant research and development expenses for the year relate to costs incurred for the development of our most advanced product candidates, ALLO-501, ALLO-501A, ALLO-715 and UCART19, which include:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">expenses incurred under agreements with our collaboration partners and third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf, and consultants;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">costs related to production of clinical materials, including fees paid for raw materials and to contract manufacturers;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">laboratory and vendor expenses related to the execution of preclinical and clinical trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">employee-related expenses, which include salaries, benefits and stock-based compensation; </span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense and supplies; and </span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">other significant research and development costs including overhead costs. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expense all research and development costs in the periods in which they are incurred. We accrue for costs incurred as the services are being provided by monitoring the status of&#160;the project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are required to reimburse Servier for 60% of the costs associated with the development of UCART19, including for the CALM and PALL clinical trials. We accrue for costs incurred by monitoring the status of the CALM and PALL clinical trials and the invoices received from Servier. We adjust our accrual as actual costs become known. Servier is required to reimburse us for 40% of the costs associated with the development of ALLO-501 and ALLO-501A.&#160;Collaboration expenses and cost reimbursement are recorded on a net basis as a research and development expense in our condensed statements of operations and comprehensive loss.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase in the future as&#160;our clinical programs progress and as we seek to initiate clinical trials of additional product candidates. The cost of advancing our manufacturing process as well as the cost of manufacturing product candidates for clinical trials are included in our research and development expense. We also expect to incur increased research and development expenses as we selectively identify and develop additional product candidates. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">per patient trial costs;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">biomarker analysis costs;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the cost and timing of manufacturing for the trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the number of patients that participate in the trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the number of sites included in the trials;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the countries in which the trials are conducted;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the length of time required to enroll eligible patients;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the total number of cells that patients receive;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the drop-out or discontinuation rates of patients;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the duration of patient follow-up; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the efficacy and safety profile of the product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the case of UCART19, we are also dependent on Servier&#8217;s ability to manage the CALM and PALL clinical trials. In addition, the probability of success for each product candidate will depend on numerous factors, including safety, efficacy, competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because our product candidates are still in clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses consist primarily of salaries and other staff-related costs, including stock-based compensation for options and restricted stock units granted. Other significant costs include costs relating to facilities and overhead costs, legal fees relating to corporate and patent matters, insurance, investor relations costs, fees for accounting and consulting services, information technology, and other general and administrative costs. General and administrative costs are expensed as incurred, and we accrue for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from our service providers, and adjusting our accruals as actual costs become known.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, potential commercialization of our product candidates and the increased costs of operating as a public company, including additional compliance-related expenses as a result of no longer being an emerging growth company. These increases are anticipated to include increased costs related to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest and Other Income, Net</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest and other income, net consists of interest earned on our cash equivalents and investment gains and losses recognized during the period.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Expense</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other expense consists of non-operating expenses, including our share of equity investments' net losses for the period.</span></div><div id="i39d9204faee04259b4794495e3dfeace_112"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Three Months Ended March 31, 2020 and 2019</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following sets forth our results of operations for the three months ended March 31, 2020 and 2019 (dollars in thousands):</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.175%;"><tr><td style="width:1.0%;"></td><td style="width:50.841%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.213%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.213%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.213%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.216%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,583&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,683&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(57,683)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,461)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,222)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,564)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331" decimals="-3" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xMTIvZnJhZzoxNjQ2NzFiMzU2Y2E0YjBhOGNhNTRmNjY1YWQzNGUzMS90YWJsZTphNDQ0M2I1N2VhNzQ0MDRlOGQ2MGJmZGUzMWUyZGFjZS90YWJsZXJhbmdlOmE0NDQzYjU3ZWE3NDQwNGU4ZDYwYmZkZTMxZTJkYWNlXzktMS0xLTEtMjM5Mg_da804c14-5507-4b24-b24c-feb2355b7ae8">58</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xMTIvZnJhZzoxNjQ2NzFiMzU2Y2E0YjBhOGNhNTRmNjY1YWQzNGUzMS90YWJsZTphNDQ0M2I1N2VhNzQ0MDRlOGQ2MGJmZGUzMWUyZGFjZS90YWJsZXJhbmdlOmE0NDQzYjU3ZWE3NDQwNGU4ZDYwYmZkZTMxZTJkYWNlXzktMy0xLTEtMjM5Mg_535f6952-becd-452f-b177-d50d32bbc811">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(58)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,622)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,480)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31,636)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,844)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,480)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31,586)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,894)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses were $42.0&#160;million and $23.4 million for the three months ended March 31, 2020 and 2019, respectively. The increase of $18.6 million was driven primarily by increased external costs relating to the advancement of our pipeline candidates of $7.9 million, increased personnel related costs of $9.0 million, of which $3.9 million was increased stock-based compensation expense, and increased allocated building rent and facilities costs of $2.6 million, offset by a decrease in TSA costs of $0.9 million.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses were $15.6&#160;million and $13.1 million for the three months ended March 31, 2020 and 2019, respectively. The net increase of $2.6 million was primarily due to an increase in personnel related costs of $3.0 million, of which $2.4 million was increased stock-based compensation expense, a $0.6 million increase in building rent and facilities costs, $0.5 million increase in advisory costs including business license fees and professional consulting fees, offset by a decrease of $1.8 million in expenses incurred under the TSA.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest and Other Income, Net</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest and other income, net was $3.3&#160;million and $4.8 million for the three months ended March 31, 2020 and 2019, respectively. The decrease of $1.6 million was due to lower interest earned on our cash, cash equivalents and investments.</span></div><div id="i39d9204faee04259b4794495e3dfeace_115"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity, Capital Resources and Plan of Operations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have incurred significant net losses and negative cash flows from operations. As of March 31, 2020, we had $553.0&#160;million in cash and cash equivalents and investments. We anticipate that the aggregate of our current cash and cash equivalents and investments available for operations will enable us to maintain our operations for a period of at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations have been financed primarily by net proceeds from the sale and issuance of our convertible preferred stock, the issuance of the 2018 Notes and net proceeds from our IPO. In connection with our IPO in 2018, we sold an aggregate of 20,700,000 shares of our common stock (inclusive of 2,700,000 shares of common stock pursuant to the over-allotment option granted to the underwriters) at a price of $18.00 per share and received approximately $343.3 million in net proceeds. In November 2019, we entered into a sales agreement with Cowen and Company, LLC (Cowen) under which we may from time to time issue and sell shares of our common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0 million. From November 2019 to December 31, 2019, we sold an aggregate of 1,965,082 shares of common stock in ATM offerings resulting in net proceeds of $54.2 million, after deducting commissions and offering costs of $1.6 million. In January 2020, the Company sold an aggregate of 570,839 shares of common stock in ATM offerings resulting in net proceeds of $14.8 million.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Capital Resources</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our primary use of cash is to fund construction projects for our manufacturing facility and operating expenses, which consist primarily of clinical manufacturing and research and development expenditures related to our lead product candidates, other research efforts, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates are still in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain.&#160;Accordingly, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise capital when needed, we will need to delay, reduce or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.175%;"><tr><td style="width:1.0%;"></td><td style="width:71.732%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.749%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.751%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In&#160;thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,809)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,256)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,007)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,586&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">684&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase in cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39,230)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,316&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, cash used in operating activities of $40.8 million was attributable to a net loss of $54.5 million, partially offset by non-cash charges of $16.8 million and a net change of $3.2 million in our net operating assets and liabilities. The non-cash charges consisted primarily of stock compensation expense of $14.2 million, depreciation of $1.9 million and non-cash rent expense of $0.7 million, offset by net accretion on investment securities of $0.2 million. The change in operating assets and liabilities was primarily due to a $3.9 million decrease in accrued and other current liabilities, a $1.0 million decrease in accounts payable, a $0.7 million decrease in other long-term liabilities, and a $0.1 million increase in other long-term assets. This was offset by a $2.6 million decrease in prepaid expenses and other current assets. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investing Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, cash used in investing activities of $15.0 million was related to investment maturities of $120.3 million, offset by purchases of investments of $123.0 million and purchases of property and equipment of $12.3 million.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financing Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, cash provided by financing activities of $16.6 million was related to net proceeds from the issuance of common stock through the ATM of $14.8 million, net proceeds of $1.4 million from the sale of common stock through the employee stock purchase program and net proceeds of $0.3 million from the issuance of common stock upon exercise of stock options.</span></div><div><span><br/></span></div><div id="i39d9204faee04259b4794495e3dfeace_118"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Commitments</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our contractual obligations and commitments as of December 31, 2019, please see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Contractual Obligations&#8221; in our Annual Report.&#160;</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commitments primarily consist of obligations under our agreements with Pfizer, Cellectis, Servier and Notch. Under these agreements we are required to make milestone payments upon successful completion of certain regulatory and sales milestones on a target-by-target and country-by-country basis. The payment obligations under the license agreements are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under these agreements. As of March 31, 2020, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. For additional information regarding our agreements, see &#8220;&#8212;Our Research and Development and License Agreements&#8221; above.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we have entered into agreements with third-party contract manufacturers for the manufacture and processing of certain of our product candidates for clinical testing purposes, and we have entered and will enter into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred. As of March 31, 2020, the Company had non-cancellable purchase commitments of $5.3 million.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also have a Change in Control and Severance Plan that require the funding of specific payments, if certain events occur, such as a change of control and the termination of employment without cause.</span></div><div id="i39d9204faee04259b4794495e3dfeace_121"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</span></div><div id="i39d9204faee04259b4794495e3dfeace_124"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the assumptions and estimates associated with accrued research and development expenditures and stock-based compensation have the most significant impact on our condensed financial statements. Therefore, we consider these to be our critical accounting policies and estimates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Operations&#8221; included in our Annual Report.</span></div><div id="i39d9204faee04259b4794495e3dfeace_127"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please refer to Note 2 to our unaudited condensed financial statements appearing under Part 1, Item 1 of this report for a discussion of new accounting standards updates that may impact us.</span></div><div id="i39d9204faee04259b4794495e3dfeace_130"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate fluctuations.</span></div><div style="text-indent:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our cash, cash equivalents and investments of $553.0 million as of March 31, 2020 consist of bank deposits, money market funds and available-for-sale securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. A 10% change in the interest rates in effect on March 31, 2020 would not have had a material effect on the fair market value of our cash equivalents and available-for-sale securities.</span></div><div style="text-indent:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Exchange Rate Risk</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaboration agreement with Servier requires collaboration payments for shared clinical development costs to be paid in Euros, and thus we face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. An adverse movement in foreign exchange rates could have an effect on payments due and made to our collaboration partner as well as other foreign suppliers and for license agreements. A 10% change in the applicable foreign exchange rates during the periods presented would not have had a material effect on our condensed financial statements. As of March 31, 2020, we had $0.3 million of liabilities and $0.2 million of other receivables denominated in foreign currency.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span><br/></span></div><div id="i39d9204faee04259b4794495e3dfeace_133"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An evaluation was also performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial and accounting officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any changes in our internal control over financial reporting during the quarter ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_136"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II-OTHER INFORMATION</span></div><div id="i39d9204faee04259b4794495e3dfeace_139"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Legal Proceedings</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.</span></div><div id="i39d9204faee04259b4794495e3dfeace_142"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A. Risk Factors</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RISK FACTORS</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 (Annual Report), which was filed with the Securities and Exchange Commission (SEC) on February 27, 2020.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business and Industry</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have a limited operating history and face significant challenges and expense as we build our capabilities.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in 2017 and acquired certain rights to multiple allogeneic CAR T cell therapy assets from Pfizer in April 2018. We have a limited operating history and are subject to the risks inherent in any newly-formed organization, including, among other things, risks that we may not be able to hire sufficient qualified personnel and establish operating controls and procedures. Several support services were provided by Pfizer through a Transition Services Agreement (TSA), including certain research and development and general and administrative services, which terminated in September 2019. As we build our own capabilities, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties related to the COVID-19 pandemic and those described herein. If we are unable to build and manage our support services in a timely manner, our operating and financial results could differ materially from our expectations, and our business could suffer.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a company, we have not progressed any product candidates through clinical development to commercialization. Our collaboration partner, Servier, conducts the CALM and PALL clinical trials of UCART19 and enrollment has been halted in both trials due to the exceptional circumstances related to the COVID-19 pandemic. While our other clinical trials continue to enroll patients, we cannot be certain that any of our ongoing and planned clinical trials will be completed or begin on time, if at all.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical-stage biopharmaceutical company and investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have only recently acquired rights to an allogeneic CAR T platform of primarily early-stage product candidates and have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. For the year ended December 31, 2019, we reported a net loss of $184.6 million. For the quarter ended March 31, 2020, we reported a net loss of $54.5 million. As of March 31 2020, we had an accumulated deficit of $450.6 million.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our engineered allogeneic T cell platform. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing a pipeline of allogeneic T cell product candidates that are engineered from healthy donor T cells to express CARs and are intended for use in any patient with certain cancers. Advancing these novel product candidates creates significant challenges for us, including:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">manufacturing our product candidates to our or regulatory specifications and in a timely manner to support our clinical trials, and, if approved, commercialization;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">sourcing clinical and, if approved, commercial supplies for the raw materials used to manufacture our product candidates;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">understanding and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately affect our ability to produce product in a reliable and consistent manner and treat certain patients;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">educating medical personnel regarding the potential side effect profile of our product candidates, if approved, such as the potential adverse side effects related to cytokine release syndrome (CRS), neurotoxicity, graft-versus-host disease (GvHD), prolonged cytopenia and neutropenic sepsis;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">using medicines to manage adverse side effects of our product candidates which may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">conditioning patients with chemotherapy and&#160;ALLO-647&#160;or other lymphodepletion agents in advance of administering our product candidates, which may increase the risk of adverse side effects;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">obtaining regulatory approval, as the U.S. Food and Drug Administration (FDA) and other regulatory authorities have limited experience with development of allogeneic T cell therapies for cancer; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The gene-editing technology we use is relatively new, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cellectis&#8217;s TALEN technology involves a relatively new approach to gene editing, using sequence-specific DNA-cutting enzymes, or nucleases, to perform precise and stable modifications in the DNA of living-cells and organisms. Although Cellectis has generated nucleases for many specific gene sequences, it has not created nucleases for all gene sequences that we may seek to target, and we may not be able do so, which could limit the usefulness of this technology. This technology may also not be shown to be effective in clinical studies that Cellectis, we or other licensees of Cellectis technology may conduct, or may be associated with safety issues that may negatively affect our development programs.  For instance, gene-editing may create unintended changes to the DNA such as a non-target site gene-editing, a large deletion, or a DNA translocation, any of which could lead to oncogenesis. The gene-editing of our product candidates may also not be successful in limiting the risk of GvHD or premature rejection by the patient.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the gene-editing industry is rapidly developing, and our competitors may introduce new technologies that render our technology obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates. As competitors use or develop new technologies, any failures of such technology could adversely impact our program. We also may be placed at a competitive disadvantage, and competitive pressures may force us to implement new technologies at a substantial cost. In addition, our competitors may have greater financial, technical and personnel resources that allow them to enjoy technological advantages and may in the future allow them to implement new technologies before we can. We cannot be certain that we will be able to implement technologies on a timely basis or at a cost that is acceptable to us. If we are unable to maintain technological advancements consistent with industry standards, our operations and financial condition may be adversely affected.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The COVID-19 global pandemic is adversely impacting our business, including our preclinical studies and clinical trials.* </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Public health crises such as pandemics or other outbreaks could adversely impact our business. In December 2019, a novel strain of coronavirus, SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), surfaced in Wuhan, China. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Since then, COVID-19 has spread to multiple countries, including the United States and Europe. As a result of the COVID-19 outbreak, or similar pandemics, and government response to pandemics, we have and may in the future experience disruptions that could severely impact our business, preclinical studies and clinical trials, including: </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">halting or suspending enrollment in our clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">delays or difficulties in enrolling and retaining patients in our clinical trials; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">increased adverse events and deaths in our clinical trials due to COVID-19 related infections, which may result in increased complications due to immune suppression from our lymphodepletion regimen;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or being forced to quarantine; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">delays or disruptions in preclinical experiments and investigational new drug application-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations and vendors; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">interruption or delays in our capital projects, including construction of our manufacturing facility in Newark, California; and </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">limitations on employee resources that would otherwise be focused on advancing our business, including because of sickness of employees or their families, including executive officers and other key employees, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with COVID-19, could continue to spread to additional countries, or could return to countries where the pandemic has been partially contained, each of which could further adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">State and local government response to the pandemic has included "shelter in place", "stay at home" and similar types of orders, which have limited travel and business operations in our locations, the location of our clinical trial sites, and the location of key vendors, including our contract manufacturing organizations (CMOs).  Beginning the week of March 9, 2020, our workforce began working from home, except for a limited number of staff primarily working in our laboratories. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. While we, our clinical trials sites and certain of our vendors, including our CMOs, are currently exempt from the orders for certain essential operations, any of the applicable exemptions may be curtailed or revoked, which would further adversely impact our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. Market and economic deterioration could also adversely impact our portfolio of corporate and government bonds.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The COVID-19 outbreak continues to rapidly evolve. The extent to which the outbreak may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We are heavily reliant on our partners for access to key gene editing technology for the manufacturing and development of our product candidates.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A critical aspect to manufacturing allogeneic T cell product candidates involves gene editing the healthy donor T cells in an effort to avoid GvHD and to limit the patient&#8217;s immune system from attacking the allogeneic T cells. GvHD results when allogeneic T cells start recognizing the patient&#8217;s normal tissue as foreign. We use Cellectis&#8217;s TALEN gene-editing technology to inactivate a gene coding for TCR&#945;, a key component of the natural antigen receptor of T cells, to cause the engineered T cells to be incapable of recognizing foreign antigens. Accordingly, when injected into a patient, the intent is for the engineered T cell not to recognize the tissue of the patient as foreign and thus avoid attacking the patient&#8217;s tissue. In addition, we use TALEN gene editing to inactivate the CD52 gene in donor T cells, which codes for the target of an anti-CD52 monoclonal antibody. Anti-CD52 monoclonal antibodies deplete CD52 expressing T cells in patients while sparing therapeutic allogeneic T cells lacking CD52. By administering an anti-CD52 antibody prior to infusing our product candidates, we believe we have the potential to reduce the likelihood of a patient&#8217;s immune system from rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which the engineered allogeneic T cells can actively target and destroy the cancer cells. However, the antibody may not have the benefits that we anticipate and could have adverse effects.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on an agreement with Cellectis for rights to use TALEN technology for 15 select cancer targets, including BCMA, FLT3, CD70, DLL3 and other targets included in our pipeline. We also rely on Cellectis, through our agreement with Servier, for rights to UCART19, ALLO-501 and ALLO-501A. We would need an additional license from Cellectis or access to other gene-editing technology to research and develop product candidates directed at targets not covered by our existing agreements with Cellectis and Servier. In addition, the Cellectis gene-editing technology may fail to produce viable product candidates. Moreover, both Servier and Cellectis may terminate our respective agreements in the event of a material breach of the agreements, or upon certain insolvency events. If our agreements were terminated or we required other gene editing technology, such a license or technology may not be available to us on reasonable terms, or at all, particularly given the limited number of alternative gene-editing technologies in the market.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, under the Servier Agreement, Servier is responsible for conducting the two clinical trials of UCART19, CALM and PALL. Due to the COVID-19 pandemic, the CALM and PALL trials have been suspended by Servier and we do not know when the trials will be resumed, if at all. Other than the agreed-upon global research and development plan for UCART19, we have limited control over the nature or timing of Servier&#8217;s clinical trials and limited visibility into their day-to-day activities. Additionally, other clinical trials being conducted by Servier may at times receive higher priority than research on our programs. If UCART19 encounters safety or efficacy problems, manufacturing problems, further developmental delays, regulatory issues or other problems, our development plans and business could be significantly harmed. We also expect Servier to support our clinical trials of ALLO-501 and ALLO-501A for the treatment of patients with R/R NHL. If Servier does not provide its share of support for the ALLO-501 and ALLO-501A clinical trials, our expenses may be greater than we currently expect and we may have difficulty progressing our ongoing and planned clinical trials in a timely manner.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have concentrated our research, development and manufacturing efforts on our engineered allogeneic T cell therapy and our future success depends on the successful development of this therapeutic approach. We are in the early stages of developing our platform and there can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, since we are in the early stages of clinical development, we do not know the doses to be evaluated in pivotal trials or, if approved, commercially. Finding a suitable dose for our cell therapy product candidates as well as ALLO-647 may delay our anticipated clinical development timelines. In addition, our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The clinical study requirements of the FDA, European Medicines Agency (EMA) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. We face additional challenges in obtaining regulatory approval for ALLO-647, which we use as part of our lymphodepletion regimen, and for which we would seek to obtain approval concurrently with approval of another CAR T cell product candidate. Approvals by the EMA and FDA for existing autologous CAR T therapies, such as Kymriah and Yescarta, may not be indicative of what these regulators may require for approval of our therapies. Also, while we expect reduced variability in our products candidates compared to autologous products, we do not have significant clinical data supporting any benefit of lower variability and the use of healthy donor material may create separate variability challenges for us. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the autologous CAR T therapies that have previously been approved. For instance, allogeneic product candidates may result in GvHD not experienced with autologous products. Even if we collect promising initial clinical data of our product candidates, longer-term data may reveal new adverse events or responses that are not durable. Unexpected clinical outcomes would significantly impact our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business is highly dependent on the success of our lead product candidates. If we are unable to obtain approval for our lead product candidates and effectively commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business and future success depends on our ability to obtain regulatory approval of, and then successfully commercialize, our most advanced product candidates, including ALLO-501A and ALLO-715. Because UCART19, ALLO-501, ALLO-501A and ALLO-715 are among the first allogeneic products to be evaluated in the clinic, the failure of any such product candidate, or the failure of other allogeneic T cell therapies, may impede our ability to develop our product candidates, and significantly influence physicians&#8217; and regulators&#8217; opinions in regards to the viability of our entire pipeline of allogeneic T cell therapies, particularly if high or uncontrolled rates of GvHD are observed. If significant GvHD events are observed with the administration of our product candidates, or if any of the product candidates is viewed as less safe or effective than autologous therapies, our ability to develop other allogeneic therapies may be significantly harmed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are also dependent on Servier to conduct the UCART19 trials in a timely and appropriate manner. Due to the COVID-19 pandemic, the CALM and PALL trials have been suspended by Servier and we do not know when the trials will be resumed, if at all, or whether Servier will undertake any other previously planned clinical development work for UCART19.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">All of our product candidates, including our lead product candidates, will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. In addition, because our other product candidates are based on similar technology as our lead product candidates, if any of the lead product candidates encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Approved autologous CAR T therapies and those under development have shown frequent rates of CRS and neurotoxicity, and adverse events have resulted in the death of patients. We expect similar adverse events for allogeneic CAR T product candidates. Our allogeneic CAR T cell product candidates undergo gene engineering by using lentivirus and TALEN nucleases that can cause insertion, deletion, or chromosomal translocation. These changes can cause allogeneic CAR T cells to proliferate uncontrollably and may cause adverse events. Our allogeneic CAR T cell product candidates may also cause unique adverse events related to the differences between the donor and patients, such as GvHD or infusion reactions.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we utilize a lymphodepletion regimen, which generally includes fludarabine, cyclophosphamide and ALLO-647, that may cause serious adverse events. For instance, because the regimen will cause a transient and sometimes prolonged immune suppression, patients will have an increased risk of infection, such as to COVID-19, that may be unable to </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">be cleared by the patient and ultimately lead to death. We are also exploring various dosing strategies of ALLO-647 in our clinical trials, and higher doses of ALLO-647 may increase the risk of adverse events. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the PALL and CALM clinical trials, the most common severe or life threatening adverse events resulted from CRS, prolonged cytopenia and neutropenic sepsis. Multiple patients have died in these trials, including deaths that were attributed to UCART19. In the future, patients may experience additional severe adverse events related to the lymphodepletion regimen as well as UCART19, some of which may result in death. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an anti-CD19 CAR T cell therapy, we expect ALLO-501 and ALLO-501A to cause similar toxicities as UCART19. Other of our allogeneic CAR T product candidates may also cause similar or worse toxicities. For instance, because ALLO-715 may require a higher dose than UCART19 and could be used in a more elderly patient population, it is possible that the risk of GvHD or other adverse events for ALLO-715 could be greater than UCART19. As we treat more patients with our product candidates in our clinical trials, new less common side effects may also emerge.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If unacceptable toxicities arise in the development of our product candidates, we or Servier could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. The data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy are not normally encountered in the general patient population and by medical personnel. We have trained and expect to have to train medical personnel using CAR T cell product candidates to understand the side effect profile of our product candidates for both our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any post-approval studies.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, for ongoing and any future trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may publish initial, interim or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For instance, we and Servier have published preliminary data from the CALM and PALL clinical trials, however such results are preliminary in nature, do not bear statistical </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">significance and should not be viewed as predictive of ultimate success. It is possible that such results will not continue or may not be repeated in ongoing or future clinical trials of UCART19 or our other product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We plan to submit INDs for additional product candidates in the future, including an IND for ALLO-316 by year-end 2020 and an IND for ALLO-605 in 2021. We also recently submitted an IND amendment to initiate a combination trial of ALLO-715 and the SpringWorks&#8217; compound, nirogacestat. We cannot be sure that submission of an IND or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manufacturing of allogeneic CAR T cell therapy remains an emerging and evolving field. Accordingly, we expect chemistry, manufacturing and control related topics, including product specification, will be a focus of IND reviews, which may delay the clearance of INDs. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, we intend to prepare and submit a standalone cross-reference IND for ALLO-647, which is being used as part of lymphodepletion in all our clinical trials.  We also plan to update the IND as we finalize pivotal manufacturing of ALLO-647 at one of our CMOs. It is possible that the FDA could place our ongoing clinical trials on hold or delay our planned clinical trials after review of our IND for ALLO-647 or mandate that we change our trial protocols, which could delay development and significantly affect our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if our trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical study can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical studies;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">difficulty sourcing healthy donor material of sufficient quality and in sufficient quantity to meet our development needs;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays in reaching a consensus with regulatory agencies on study design;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays in obtaining required institutional review board (IRB) approval at each clinical study site;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays in recruiting suitable patients to participate in our clinical studies;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">difficulty collaborating with patient groups and investigators;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">failure by our CROs, other third parties or us to adhere to clinical study requirements;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">failure to perform in accordance with the FDA&#8217;s good clinical practice (GCP) requirements or applicable regulatory guidelines in other countries;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays in having patients complete participation in a study or return for post-treatment follow-up;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">patients dropping out of a study;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the cost of clinical studies of our product candidates being greater than we anticipate;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The COVID-19 pandemic may also increase the risk of certain of the events described above and delay our development timelines. Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our clinical trials of UCART19, ALLO-501 and ALLO-715 and in our planned clinical trials of other product candidates, we and Servier contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.*</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The COVID-19 pandemic, including the travel and business restrictions imposed by government authorities in response to the pandemic, have resulted in, and may continue to cause, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">reduced enrollment and may also create challenges to related clinical trial activities. In addition, the enrollment of patients depends on many factors, including:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the patient eligibility criteria defined in the protocol;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the proximity of patients to study sites;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the design of the trial;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our ability to obtain and maintain patient consents; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since we only need to conduct a limited number of manufacturing runs to generate clinical supply, the diversity of our supply is limited during clinical trials. As a result, some patients may have antibodies to certain donor specific antigens that may interact with our product candidates, which would render the patients ineligible for treatment.</span></div><div style="text-indent:36pt;margin-top:2pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, prior treatment with rituximab may interfere with ALLO-501 as ALLO-501 contains rituximab recognition domains. Since rituximab is a typical part of a treatment regimen for a patient with NHL, patient eligibility for the ALLO-501 trial may be limited. Patients may also undergo plasmapheresis to remove rituximab prior to infusion of ALLO-501, which may cause separate adverse effects. We have removed the rituximab recognition domains in the second generation of ALLO-501, known as ALLO-501A, which we believe will potentially facilitate treatment of patients who were recently treated with rituximab. However, ALLO-501A may not behave as expected and may be challenging to develop or manufacture.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our clinical trials will also compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites are also being used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic cell transplantation or autologous CAR T cell therapies, rather than enroll patients in our clinical trial. Patients eligible for allogeneic CAR T cell therapies but ineligible for autologous CAR T cell therapies due to aggressive cancer and inability to wait for autologous CAR T cell therapies may be at greater risk for complications and death from therapy.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Clinical trials are expensive, time-consuming and difficult to design and implement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our allogeneic T cell product candidates are based on new technologies and will require the creation of inventory of mass-produced, off-the-shelf product, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat patients with R/R cancer and to treat potential side effects that may result from our product candidates can be significant. We also have less control of costs incurred by our development partner, Servier, for the clinical trials of UCART19. Accordingly, our clinical trial costs are likely to be significantly higher than for more conventional therapeutic technologies or drug products.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA often approves new therapies initially only for use in patients with R/R metastatic disease. We expect to initially seek approval of our product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment. There is no guarantee that our product </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials, including potentially comparative trials against approved therapies. We are also targeting a similar patient population as autologous CAR T product candidates, including approved autologous CAR T products. Our therapies may not be as safe and effective as autologous CAR T therapies and may only be approved for patients who are ineligible for autologous CAR T therapy.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our projections of both the number of patients who have the cancers we are targeting, as well as the subset of patients with these cancers in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect ALLO-501A to initially target a small patient population that suffers from R/R NHL. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to develop additional product candidates, our commercial opportunity will be limited.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">One of our core strategies is to pursue clinical development of additional product candidates beyond UCART19, ALLO-501A and ALLO-715, including ALLO-316 and ALLO-605. Developing, obtaining regulatory approval and commercializing additional CAR T cell product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we receive FDA approval to market additional product candidates for the treatment of cancer, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional product candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, product candidate.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We utilize an anti-CD52 monoclonal antibody as part of a lymphodepletion regimen to be infused prior to infusing our product candidates. While we believe an anti-CD52 antibody may be able to reduce the likelihood of a patient&#8217;s immune system rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which such engineered allogeneic T cells can actively target and destroy cancer cells, the antibody may not have the benefits that we anticipate and could have adverse effects. For instance, our lymphodepletion regimen, including using an anti-CD52 antibody, will cause a transient and sometimes prolonged immune suppression</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">that is associated with an increased risk of infection, such as to COVID-19, that may be unable to be cleared by the patient and ultimately lead to death.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the CALM and PALL trials, a commercially available monoclonal antibody, alemtuzumab, that binds CD52 was used. Alemtuzumab is known to have risk of causing certain adverse events. The EMA recently completed a pharmacovigilance review of alemtuzumab in the context of the treatment of multiple sclerosis following reports of immune-mediated conditions and problems affecting the heart and blood vessels, including fatal cases. The EMA has recommended that alemtuzumab should not be used in patients with certain heart, circulation or bleeding disorders or in patients who have autoimmune disorders other than multiple sclerosis. The EMA also recommended that alemtuzumab only be given in a hospital with ready access to intensive care facilities and specialists who can manage serious adverse reactions. Based on the recommendations, we have added relevant new safety information to certain of our clinical trial documentation, including informed consent forms. Our product candidates will also continue to be administered at specialized centers, which are experienced at managing patients with advanced malignancies as well as toxicities associated with immunomodulatory therapies. We will continue to monitor any new safety information that will be reported or added to the product labels of alemtuzumab. If the EMA or other regulatory agencies further limit the use of alemtuzumab or anti-CD52 antibodies, our clinical program would be adversely affected.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To secure our own readily available source of anti-CD52 antibody, we are developing our own monoclonal anti-CD52 antibody, ALLO-647. We are using ALLO-647 in our clinical trial of ALLO-501 and ALLO-715, and plan to use ALLO-647 in </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">our clinical trial of ALLO-501A. ALLO-647 may also cause adverse events, including but not limited to those events that alemtuzumab may cause. In addition, we are exploring various dosing strategies of ALLO-647 in our clinical trials, and higher doses of ALLO-647 may increase the risk of adverse events.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to successfully develop and manufacture ALLO-647 in the timeframe we anticipate, or at all, or if regulatory authorities do not approve the use of ALLO-647 in combination with our allogeneic T cell product candidates, we may be unable to source alemtuzumab and our engineered allogeneic T cell product candidates may be less effective, which could result in delays in our product development efforts and/or the commercial potential of our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We intend to operate our own manufacturing facility, which will require significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to achieve clinical or commercial manufacturing and cell processing on our own or at our CMO, including mass-producing off-the-shelf product to satisfy demands for any of our product candidates. While we believe the manufacturing and processing approaches are appropriate to support our clinical product development, we have limited experience in managing the allogeneic T cell engineering process, and our allogeneic processes may be more difficult or more expensive than the approaches taken by our competitors. We cannot be sure that the manufacturing processes employed by us or the technologies that we incorporate for manufacturing will result in T cells that will be safe and effective.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, we entered into a lease for approximately 118,000 square feet to develop a state-of-the-art cell therapy manufacturing facility in Newark, California. The facility requires substantial improvements and there can be no assurance that we will complete the build-out of our manufacturing facility in a timely manner or at all. Construction of our manufacturing facility was interrupted for a period of time by the COVID-19 pandemic. While we have re-commenced construction and continue to expect to initiate manufacturing under current good manufacturing practices (cGMP) in 2021, any further delays to our construction by COVID-19 or other events will delay our manufacturing timelines.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also do not yet have sufficient information to reliably estimate the cost of the clinical and commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. In addition, the ultimate clinical and any commercial dose will affect our ability to scale and our costs per dose. For instance, because ALLO-715 may require a higher dose than ALLO-501, it is possible that it may be more difficult to scale ALLO-715 production. As a result, we may never be able to develop a commercially viable product. The commercial manufacturing facility we build will also require FDA approval, which we may never obtain. Even if approved, we would be subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with current good manufacturing practices (cGMPs), and other government regulations.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. The application of new regulatory guidelines or parameters, such as those related to release testing, may also adversely affect our ability to manufacture our product candidates. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such supply may have to be discarded and our manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We, our CMOs or any other of our or their vendors may fail to manage the logistics of storing and shipping our raw materials and product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in the inability to manufacture product, the loss of usable product or prevent or delay the delivery of product candidates to patients.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or in other markets.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We plan to globally develop our product candidates. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">differing regulatory requirements in foreign countries;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">differing standards for the conduct of clinical trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">import and export requirements and restrictions;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">foreign taxes, including withholding of payroll taxes;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">difficulties staffing and managing foreign operations;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">business interruptions resulting from the COVID-19 pandemic or other natural or man-made disasters, including earthquakes, tsunamis, fires or other medical epidemics, or geo-political actions, including war and terrorism.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These and other risks associated with our international operations and our collaborations with Servier and Cellectis, each based in France, and with Notch Therapeutics Inc. (Notch), based in Canada, may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biopharmaceutical industry, and the immuno-oncology industry specifically, is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Specifically, engineered T cells face significant competition from multiple companies. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see &#8220;Item 1. Business&#8212;Competition&#8221; in our Annual Report.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Executive Chairman, our President and Chief Executive Officer, our Chief Financial Officer, our Executive Vice President of Research &amp; Development and Chief Medical Officer, and our Chief Technical Officer. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We conduct substantially all of our operations at our facilities in South San Francisco. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock unit (RSU) awards that vest over time. The value to employees of stock options and RSU awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of May 1, 2020, we had 215 full-time employees. As our development and commercialization plans and strategies develop, and as we continue to transition into operating as a public company, we have rapidly expanded our employee base and expect to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.   Our ability to build our organization and manage our employees has also been affected by COVID-19, as our staff are working from home, except for a limited number primarily working in our laboratories. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants.  In September 2019, we terminated support services previously provided by Pfizer, and our internal build-out of such services may disrupt our operations and be more expensive than we expect. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. We may also be subject to penalties or other liabilities if we mis-classify employees as consultants. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop, manufacture and commercialize our product candidates and, accordingly, may not achieve our research, development, manufacturing and commercialization goals.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our agreements with Servier, Notch and SpringWorks require significant research and development that may not result in the development and commercialization of product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not realize the benefits of acquired assets or other strategic transactions.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including our acquisition of CAR T cell assets from Pfizer, licenses with Cellectis, Servier and Notch, and any future strategic transactions depends on the risks and uncertainties involved including:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">unanticipated liabilities related to acquired companies or joint ventures;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">retention of key employees;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">possible write-offs or impairment charges relating to acquired businesses or joint ventures.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to spend a substantial amount of capital in the development and manufacture of our product candidates. We will need substantial additional financing to develop our products and implement our operating plans. In particular, we will require substantial additional financing to enable commercial production of our products and initiate and complete registration trials for multiple products. Further, if approved, we will require significant additional amounts in order to launch and commercialize our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, we had $553.0 million in cash, cash equivalents and investments. Changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may also need to raise additional capital sooner than we currently anticipate if we choose to expand more rapidly than we presently plan. In any event, we will require additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations under the agreements. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our internal computer systems, or those used by our CROs, collaborators or other contractors or consultants, may fail or suffer security breaches.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our internal computer systems and those of our CROs, collaborators, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, cybersecurity threats, and telecommunication and electrical failures. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. In addition, our increased reliance on personnel working from home could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, statutory, regulatory and policy changes, and business disruptions, such as those caused by the COVID-19 pandemic. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the business disruptions caused by the COVID-19 pandemic described above, our operations, and those of our CMOs, CROs and other contractors and consultants, could be subject to other disruptions, including those caused by earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to manufacture our product candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster or other business interruption. Our corporate headquarters and planned manufacturing facility are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information. The U.S. healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully, offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchasing, leasing, ordering or arranging for the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">purchase, lease, or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that may be alleged to be intended to induce prescribing, purchases or recommendations, include any payments of more than fair market value, and may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act and the civil monetary penalties statute;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">federal civil and criminal false claims laws, including the federal civil False Claims Act and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal government programs that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government, including federal healthcare programs;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services&#8217; (HHS) Centers for Medicare &amp; Medicaid Services (CMS) information related to payments or other transfers of value made to physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we may be subject to state, local and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope. For example, we may be subject to the following: state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers, or that apply regardless of payor; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, some of who receive stock options as compensation, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties. We have adopted a code of business conduct and ethics, but it is not always possible to </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The collection and use of personal data in the European Union (EU) are governed by the General Data Protection Regulation (GDPR). The GDPR imposes stringent requirements for controllers and processors of personal data, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States.  Known as the California Consumer Privacy Act (CPPA), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households.  The CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. As our business progresses, the CCPA may significantly impact our business activities and exemplifies the vulnerability of our business to evolving regulatory environment related to personal data and protected health information.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">decreased demand for our product candidates;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">injury to our reputation;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">withdrawal of clinical trial participants;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">initiation of investigations by regulators;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">costs to defend the related litigation;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">a diversion of management&#8217;s time and our resources;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">substantial monetary awards to trial participants or patients;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">loss of revenue;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">exhaustion of any available insurance and our capital resources;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the inability to commercialize any product candidate; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">a decline in our share price.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. While we have obtained and expect to obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The global credit and financial markets have experienced extreme volatility and disruptions in the past, most recently as a result of the COVID-19 pandemic.  These disruptions can result in severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our portfolio of corporate and government bonds would also be adversely impacted.  Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal, regulatory, political and economic uncertainty surrounding the exit of the U.K. from the European Union may be a source of instability in international markets, create significant currency fluctuations, adversely affect operations in the U.K. and pose additional risks to our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">Following the result of a referendum in 2016, the U.K. left the EU on January 31, 2020, commonly referred to as Brexit.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">Pursuant to the formal withdrawal arrangements agreed between the U.K. and the EU, the U.K. will be subject to a transition period until December 31, 2020 (Transition Period), during which EU rules will continue to apply.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">Negotiations between the U.K. and the EU are expected to continue in relation to the customs and trading relationship between the U.K. and the EU following the expiry of the Transition Period.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">Such a withdrawal from the EU is unprecedented, and it is unclear how the U.K&#8217;s access to the European single market for goods, capital, services and labor within the EU, or single market, and the wider commercial, legal and regulatory environment, will impact our business.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The uncertainty concerning the U.K&#8217;s legal, regulatory, political and economic relationship with the EU after the Transition Period may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise). It could also lead to a period of considerable uncertainty in relation to the regulatory process for </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">drug development and approval in Europe, and make it more costly or difficult to advance our product candidates in the EU and U.K.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.*</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (Tax Act), as modified by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), federal net operating losses incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income and taxes may be limited. As a result of our private placements, IPO and other transactions that have occurred in 2018, we may have experienced, an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. We anticipate incurring significant additional net losses for the foreseeable future, and our ability to utilize net operating loss carryforwards associated with any such losses to offset future taxable income may be limited to the extent we incur future ownership changes. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices (GCPs), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ALLO-501, ALLO-501A, ALLO-715 and ALLO-647 are manufactured in the United States by our CMOs, and we manage all other aspects of the supply, including planning, CMO oversight, disposition and distribution logistics. Servier has been responsible for UCART19 manufacturing, and has experienced UCART19 supply issues that limited its ability to recruit new patients in the past. There can be no assurance that we or Servier will not experience additional supply or manufacturing issues in the future.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we have leased space to build a manufacturing facility, we must currently rely on outside vendors to manufacture supplies and process our product candidates. We do not have long-term agreements in place with CMOs for the manufacture of our cell therapies or of ALLO-647.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to contract with CMOs on acceptable terms or at all, our clinical development program would be delayed and our business would be significantly harmed. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to achieve manufacturing and processing and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for any of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any.</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. For instance, our CMOs may be required to shutdown in response to the spread of COVID-19. In addition, our CMOs have certain responsibilities for storage of raw materials, and the damage or loss of such raw materials could materially impact our ability to manufacture and supply our product candidates. Each of these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on donors of T cells to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted.* </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unlike autologous CAR T companies, we are reliant on receiving healthy donor material to manufacture our product candidates. Healthy donor T cells vary in type and quality, and this variation makes producing standardized product candidates more difficult and makes the development and commercialization pathway of those product candidates more uncertain. We have developed a screening process designed to enhance the quality and consistency of T cells used in the manufacture of our CAR T cell product candidates, but our screening process may fail to identify suitable donor material and we may discover failures with the material after production. We may also have to update our specifications for new risks that may emerge, such as to screen for new viruses.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have strict specifications for donor material, which include specifications required by regulatory authorities. If we are unable to identify and obtain donor material that satisfy specifications, agree with regulatory authorities on appropriate specifications, or address variability in donor T cells, there may be inconsistencies in the product candidates we produce or we may be unable to initiate or continue ongoing clinical trials on the timelines we expect, which could harm our reputation and adversely impact our business and prospects. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, vendors have been unable to secure donor material during the COVID-19 pandemic due to government restrictions on business activity and travel. While we have donor material on hand, if the COVID-19 pandemic continues and our vendors are unable to secure donor material, we may no longer have sufficient donor material to manufacture our product candidates. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates require many specialty raw materials, including viral vectors that deliver the CAR sequence and electroporation technology, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. We do not have contracts with many of the suppliers, and we may not be able to contract with them on acceptable terms, or at all. Many suppliers have curtailed their operations during the COVID-19 pandemic and our ability to source raw materials has been impacted. Accordingly, we may experience delays in receiving, or fail to secure entirely, key raw materials to support clinical or commercial manufacturing. Certain raw materials also require third-party testing, and some of the testing service companies may not have capacity or be able to conduct the testing that we request.  </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, many of our suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also face competition for supplies from other cell therapy companies.  Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable terms or in a timely manner.  </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier, including to meet any regulatory requirements for such qualification, could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Government Regulation</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a biologics license application (BLA) from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogeneic T cell therapies for cancer. We may also request regulatory approval of future CAR-based product candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting if our clinical trials only involved cancers of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">obtaining regulatory authorization to begin a trial, if applicable;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the availability of financial resources to commence and complete the planned trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">obtaining approval at each clinical trial site by an independent IRB;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">recruiting suitable patients to participate in a trial;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">addressing any patient safety concerns that arise during the course of a trial;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">adding new clinical trial sites; or</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">manufacturing sufficient quantities of qualified materials under cGMPs and delivering product candidates for use in clinical trials.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. The FDA&#8217;s review of our data of our ongoing clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more of our clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because we are developing novel CAR T cell immunotherapy product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies (OTAT), formerly known as the Office of Cellular, Tissue and Gene Therapies (OCTGT), within its Center for Biologics Evaluation and Research (CBER) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called the Committee for Advanced Therapies (CAT) was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) to assess the quality, safety and efficacy of ATMPs, and to </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. In this regard, on May 28, 2014, the EMA issued a recommendation that UCART19 be considered a gene therapy product under Regulation (EC) No 1394/2007 on ATMPs. We believe this recommendation is likely to be applicable to our UCART19 product candidate; however, this recommendation is not definitive until UCART19 obtains regulatory approval for commercialization.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR T cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If and when our ongoing and planned Phase 1 clinical trials are completed and, assuming positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. We expect registrational trials for ALLO-501A and ALLO-715 to be designed to evaluate the efficacy of the product candidate in an open-label, non-comparative, two-stage, pivotal, multicenter, single-arm clinical trial in patients who have exhausted available treatment options. If the results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA. For example, the FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given the molecular similarities between UCART19, ALLO-501 and ALLO-501A, we may have additional difficulties progressing any clinical trial of ALLO-501A, if emerging data from the clinical trials of ALLO-501 or UCART19 have safety or other issues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe our accelerated approval strategy is warranted given the limited alternatives for patients with R/R cancers, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to obtain regulatory approval for ALLO-647 in a timely manner or at all, which could delay any approval or commercialization of our allogeneic T cell product candidates.*</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As we are concurrently developing ALLO-647 to be used as part of the lymphodepletion regimen for our CAR T cell product candidates, mapping a path for dual approval of ALLO-647 and any of our CAR T cell product candidates and coordinating concurrent review with different divisions of the FDA create additional regulatory uncertainty for us and may delay the development of our product candidates. For instance, the FDA could place our ongoing clinical trials on hold or delay our planned clinical trials after review of our planned IND for ALLO-647 or mandate that we change our trial protocols, which could delay development and significantly affect our business. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, we cannot be certain we will be able to successfully obtain regulatory approval of ALLO-647 in a timely manner or at all. Regulatory authorities will likely require we demonstrate safety and contribution towards lymphodepletion, thereby enabling CAR T cell expansion which impacts efficacy of CAR T cell product candidates. Additionally, regulatory authorities may seek to understand the contribution of the lymphodepletion regimen, including the use of an anti-CD52 antibody, to any treatment effect. If we are unable to meet any of the requirements of the regulatory authorities, we may be required to conduct additional clinical studies. Any delays to ALLO-647 approval could delay any approval or commercialization of our allogeneic T cell product candidates. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regenerative Medicine Advanced Therapy designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may seek Regenerative Medicine Advanced Therapy (RMAT) designation for one or more of our product candidates. In 2017, the FDA established the RMAT designation to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain RMAT designation for any of our product candidates. RMAT designation does not change the FDA&#8217;s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">fines, warning letters or holds on clinical trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">injunctions or the imposition of civil or criminal penalties.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. President&#8217;s administration may impact our business and industry. Namely, the current U.S. President&#8217;s administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose restrictions on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The gene-editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product candidates. In addition, given the novel nature of gene-editing and cell therapy technologies, governments may place import, export or other restrictions in order to retain control or limit the use of the technologies. Increased negative public opinion or more restrictive government </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">regulations either in the United States or internationally, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates.  </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect physicians in the large bone marrow transplant centers to be particularly important to the market acceptance of our products and we may not be able to educate them on the benefits of using our product candidates for many reasons. For example, certain of the product candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as non-cancerous cells. It is possible that our product candidates may kill these non-cancerous cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our product candidates are accepted in the market, including:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the clinical indications for which our product candidates are approved;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the prevalence and severity of any side effects;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">limitations or warnings contained in the labeling approved by the FDA;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the timing of market introduction of our product candidates as well as competitive products;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the cost of treatment in relation to alternative treatments;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the effectiveness of our sales and marketing efforts.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">a covered benefit under its health plan;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">safe, effective and medically necessary;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">appropriate for the specific patient;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">cost-effective; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">neither experimental nor investigational.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers, and reduce the willingness of physicians to use our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.* </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably. In particular, in 2010 the Affordable Care Act was enacted. The Affordable Care Act and its implementing regulations, among other things, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs and certain biologics, including our product candidates, under the Medicaid drug rebate program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid drug rebate program, extended the Medicaid drug rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Additionally, the Affordable Care Act allowed states to implement expanded eligibility criteria for Medicaid </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">programs, imposed a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service pharmaceutical pricing program and implemented a new Patient-Centered Outcomes Research Institute. We are still unsure of the full impact that the Affordable Care Act will have on our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There remain legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, the U.S. President has signed Executive Orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty for an individual&#8217;s failure to maintain Affordable Care Act-mandated health insurance, commonly known as the &#8220;individual mandate&#8221;, as part of the Tax Act. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable Care Act&#8217;s mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018 (BBA), among other things, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. In December 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments, which are expected to occur in the fall. It is unclear how such litigation and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2030, unless additional Congressional action is taken. The CARES Act, which is designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President&#8217;s administration&#8217;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On March 10, 2020, the U.S. President's administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases.  Further, the current U.S. President&#8217;s administration previously released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">While some of these and other measures may require additional authorization to become effective, Congress and the current U.S. President&#8217;s administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We cannot predict the initiatives that may be adopted in the future. It is possible that additional governmental action is taken to address the COVID-19 pandemic. For example, on April 18, 2020, CMS announced that Qualified Health Plan (QHP) issuers under the Affordable Care Act may suspend activities related to the collection and reporting of quality data that would have otherwise been reported between May and June 2020 given the challenges healthcare providers are facing responding to the COVID-19 virus. Additionally, the continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our ability to set a price that we believe is fair for our products;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the level of taxes that we are required to pay; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the availability of capital.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We depend substantially on our license agreements with Pfizer, Servier and Cellectis. These licenses may be terminated upon certain conditions. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. For example, we are dependent on our license with Cellectis for gene-editing technology that is necessary to produce our engineered T cells. In addition, we are reliant on Servier in-licensing from Cellectis some of the intellectual property rights they are licensing to us, including certain intellectual property rights relating to UCART19, ALLO-501 and ALLO-501A. To the extent these licensors fail to meet their obligations under their license agreements, which we are not in control of, we may lose the benefits of our license agreements with these licensors. In the future, we may also enter into additional license agreements that are material to the development of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those related to:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have an exclusive collaboration with Servier to develop and commercialize UCART19, ALLO-501 and ALLO-501A, and we hold the commercial rights to these product candidates in the United States. We also have an exclusive worldwide license from Cellectis to its TALEN gene-editing technology for the development of allogeneic T cell product candidates directed against 15 different cancer antigens. Our collaboration with Servier gives us access to TALEN gene-editing technology for all product candidates under the Servier Agreement. Certain intellectual property which is covered by these agreements may have been developed with funding from the U.S. government. If so, our rights in this intellectual property may be subject to certain research and other rights of the government.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additional patent applications have been filed, and we anticipate additional patent applications will be filed, both in the United States and in other countries, as appropriate. However, we cannot predict:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">if and when patents will issue;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Composition of matter patents for biological and pharmaceutical products such as CAR-based product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope thereof, for example through inter partes review (IPR) post-grant review or ex parte reexamination before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions, which may result in such patents being cancelled, narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. United States patent applications containing or that at any time contained a claim not entitled to a priority date before March 16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011).</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This first to file system will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For United States applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the United States patent laws, including new procedures for challenging patent applications and issued patents.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to assign their inventions to us, and require all of our employees and key consultants who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue us. We are aware of several U.S. patents held by third parties relating to certain CAR compositions of matter and their methods of use. Generally, conducting clinical trials and other development activities in the United States is not considered an act of infringement. If and when UCART19, ALLO-501A, ALLO-715 or another CAR-based product candidate is approved by the FDA, third parties may then seek to enforce their patents by filing a patent infringement lawsuit against us. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. We may not be able to prove in litigation that any patent enforced against us is invalid.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, there may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may be alleged to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Presently we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, that we believe will facilitate the development of our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put one or more of our pending patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our licensors may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include IPR, ex parte re-examination and post grant review in the United States, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to protect our intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.*</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to our IPO in October 2018, there was no public market for our common stock. We cannot assure you that an active, liquid trading market for our shares will develop or persist. You may not be able to sell your shares quickly or at a </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">recently reported market price if trading in our common stock is not active. The trading price of our common stock following our IPO has been and is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the commencement, enrollment or results of our ongoing and planned clinical trials of our product candidates or any future clinical trials we or Servier may conduct, or changes in the development status of our product candidates;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our or Servier&#8217;s decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">adverse results or delays in clinical trials;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our failure to commercialize our product candidates;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">adverse developments concerning the manufacture or supply of our product candidates;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our inability to establish collaborations if needed;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">additions or departures of key scientific or management personnel;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates or pre-conditioning regimen;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">introduction of new products or services offered by us or our competitors;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our ability to effectively manage our growth;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the size and growth of our initial cancer target markets;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our ability to successfully treat additional types of cancers or at different stages;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">actual or anticipated variations in quarterly operating results;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our cash position;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">changes in the market valuations of similar companies;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">overall performance of the equity markets;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">sales of our common stock by us or our stockholders in the future;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">trading volume of our common stock;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">changes in accounting practices;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">ineffectiveness of our disclosure controls or internal controls;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">disagreements with our auditor or termination of an auditor engagement;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">changes in the structure of healthcare payment systems;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">significant lawsuits, including patent or stockholder litigation;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">significant business disruptions caused by natural or man-made disasters, such as the COVID-19 pandemic;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;">general political and economic conditions; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">other events or factors, many of which are beyond our control.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the stock market in general, and the Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently anticipate that we will retain any future cash flow or earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to various compliance initiatives.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), which requires, among other things, that we file with the Securities and Exchange Commission (SEC) annual, quarterly and current reports with respect to our business and financial condition.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted, pursuant to which the SEC adopted rules and regulations related to corporate governance and executive compensation, such as &#8220;say on pay&#8221; and proxy access. Emerging growth companies are permitted to implement many of these requirements over time, however we are no longer an emerging growth company as of December 31, 2019 and expect to incur additional compliance-related expenses as a result. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect the rules and regulations applicable to public companies to continue to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations make it difficult and expensive for us to maintain director and officer liability insurance. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Failure to comply with the rules and regulations applicable to us could have serious consequences, including civil and criminal penalties. In addition, our reputation and our ability to raise additional capital would be harmed.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for you to sell shares of our common stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have registered on Form S-8 all shares of common stock that are issuable under our 2018 Plan. As a consequence, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to the 2018 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. For instance, we have sold equity securities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">through at-the-market offerings</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and may do so in the future. We may also sell our common stock as part of entering into strategic alliances, creating joint ventures or collaborations or entering into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the 2018 Plan, our management is authorized to grant stock options and RSU awards to our employees, directors and consultants. We have registered on Form S-8 all shares of common stock that are issuable under our 2018 Plan. Additionally, the number of shares of our common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each year and continuing through and including January 1, 2028, by 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have broad discretion in the use of our cash reserves and may not use them effectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management has broad discretion in the application of our cash reserves. A number of factors will determine the ultimate use of our cash reserves, and our management may not be able to apply these funds effectively. Pending their use, we may invest these funds in short-term, investment-grade, interest-bearing securities, which may not yield a favorable return and may lose value.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div><div style="text-indent:-27pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock could be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div id="i39d9204faee04259b4794495e3dfeace_145"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Proceeds from our Initial Public Offering of Common Stock</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We commenced our IPO pursuant to registration statements on Form S-1 (File Nos.&#160;333-227333 and 333-227774) that were declared or became effective on October 10, 2018 and registered an aggregate of 20,700,000 shares of our common stock for sale at a public offering price of $18.00 per share and an aggregate gross offering price of $372.6 million. On October 10, 2018, we sold 18,000,000 shares of our common stock at a public offering price of $18.00 per share for an aggregate gross offering price of $324.0 million. An additional 2,700,000 shares were sold pursuant to the underwriters&#8217; option to purchase additional shares with a public offering price of $18.00 per share for additional gross proceeds of $48.6 million. On October 15, 2018, we completed our IPO. Goldman Sachs&#160;&amp; Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies LLC acted as joint book-running managers for our IPO.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The underwriting discounts and commissions for the offering totaled approximately $26.1 million. We incurred additional costs of approximately $3.2 million in offering expenses, which when added to the underwriting discounts and commissions paid by us, amounts to total fees and costs of approximately $29.3 million. Thus, net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were approximately $343.3 million. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily bank money market accounts. Through March 31, 2020, we have used $39.2 million of the net proceeds from our IPO. We are investing these funds in some combination of short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We expect to use the net proceeds from our IPO to fund our </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">clinical development plans and the build-out of our manufacturing facility in Newark, California. We cannot predict with certainty all of the particular uses for the net proceeds from our IPO, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including our ability to access additional financing, the relative success and cost of our research, preclinical and clinical development programs and whether we are able to enter into future licensing arrangements. As a result, our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from our IPO.</span></div><div id="i39d9204faee04259b4794495e3dfeace_148"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Defaults Upon Senior Securities.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i39d9204faee04259b4794495e3dfeace_151"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. Mine Safety Disclosures.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i39d9204faee04259b4794495e3dfeace_154"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 5. Other Information.</span></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_157"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:justify;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6.&#160;Exhibits.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:6.797%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:88.470%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Reference is made to Exhibits </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm">3.1</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm">3.2</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.</span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518290441/d548088dex41.htm">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on October 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex42.htm">Investors Rights Agreement, dated April 6, 2018, as amended September 5, 2018, by and among the Registrant and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</a></span></div></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-2020331xex101.htm">Employment Letter of Agreement, dated April 30, 2018, by and between the Registrant and Veer Bhavnagri.</a></span></div></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20200331xex311.htm">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20200331xex312.htm">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="allo-20200331xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document. </span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q has been formatted in Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><div id="i39d9204faee04259b4794495e3dfeace_160"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i39d9204faee04259b4794495e3dfeace_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:43.680%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.221%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: May 6, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ David Chang</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Chang, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: May 6, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Eric Schmidt</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eric Schmidt, Ph.D.</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>allo-2020331xex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i65fb61ff387e41db86bfff72d390daa9_1"></div><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.1</font></div><div style="text-align:right;"><img alt="allogenelogo5.jpg" src="allogenelogo5.jpg" style="height:36px;width:150px;"></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">April 30, 2018</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Veer Bhavnagri</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">344 Mesa Road</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Santa Monica, CA 90402 </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Re&#58;      Employment Letter of Agreement (&#8220;Agreement&#8221;)</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Dear Veer,</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Allogene Therapeutics, Inc. (&#8220;Allogene&#8221; or the &#8220;Company&#8221;) is pleased to offer you employment on the following terms and conditions.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Title&#59; Reporting&#59; Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">Your employment shall commence on May 16, 2018, or such other date as may be agreed to by you and Allogene (the &#34;Start Date&#34;).</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">When you commence employment with Allogene, you shall be employed in the position of General Counsel shall report directly to the Chief Executive Officer and shall perform the duties and responsibilities that the Company assigns to you. Your consulting agreement with Allogene shall also terminate upon the commencement of employment. </font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">You shall devote substantially all of your business time, attention and energies to the business and affairs of Allogene and shall not during the period of your employment be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage, that will materially interfere with the performance of your duties or your availability to perform such duties or that will adversely affect, or negatively reflect upon, Allogene.</font></div><div style="padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">Initially your duties will be performed from 270 Littlefield, South San Francisco, CA 94080. Reasonable out of pocket travel expenses incurred for visiting Allogene&#8217;s offices prior to relocation to the San Francisco Bay Area as described in Section 5 will be reimbursed by Allogene. Should Allogene implement a travel policy, such policy shall supersede this Section 1(d) and shall govern the type of travel and reimbursement process. </font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">Notwithstanding the foregoing, the Company may change your title, position, duties, supervisor and work location from time to time as it deems appropriate. </font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:20.41pt;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. You shall receive base salary paid at the rate of $365,000 per year, payable in accordance with Allogene&#8217;s payroll practices.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19.84pt;">Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. You will be eligible to earn an annual performance bonus at the sole discretion of the Company in an amount equal to a maximum of 35% of your base salary (the &#8220;Annual Bonus&#8221;). The Annual Bonus will be based upon the Company&#8217;s assessment of your performance and the Company&#8217;s attainment of targeted goals as set by the Company in its sole discretion. Following the close of each calendar year, the Company will determine whether you have earned an Annual Bonus, and the amount of any such bonus, based on the achievement of such goals. No amount of Annual Bonus is guaranteed, and you must be an employee on the Annual Bonus payment date to be eligible to receive an Annual Bonus. No partial or prorated bonuses will be provided (except as set forth below in this paragraph for calendar year 2018). The Annual Bonus, if earned, will be paid no later than March 15 of the calendar year after the applicable bonus year. For calendar year 2018, no later than March 15, 2019 and subject to your continued employment through date of payment, the Company will pay you a prorated portion of your individual annual target bonus for 2018, based on the number of days during 2018 from April 6, 2018.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:20.41pt;">Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Allogene shall withhold all applicable federal, state and local taxes and social security and such other amounts as may be required by law from all amounts payable under this Section 2.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">On or within sixty (60) days following your Start Date you shall be granted a stock option (the &#8220;Option&#8221;) to purchase 50,000 shares of Allogene&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) (the &#8220;Option Shares&#8221;) pursuant to the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;Plan&#8221;). Such grant shall be evidenced by an option agreement (the &#8220;Option Agreement&#8221;) to be entered into by and between you and the Company. The exercise price per Option Share will be equal to the fair market value per share of the Company&#8217;s Common Stock as of the date that such Option is granted. The Option shall have a 10-year term and shall vest and become exercisable as follows&#58; (i) 25% upon April 6, 2019 (the &#8220;Initial Vesting Date&#8221;)&#59; and thereafter (ii) the remaining unvested Options Shares shall vest in 36 substantially equal monthly installments as of the last calendar day of each month following the Initial Vesting Date.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">All Options shall be immediately exercisable with respect to one hundred percent (100%) of the Option Shares in exchange for restricted shares of Common Stock of the Company (the &#8220;Restricted Shares&#8221;)&#59; provided, however, that the Restricted Shares will be subject to vesting in accordance with the schedule described above. Upon termination of your employment, the Company shall have the right to repurchase any Restricted Shares that have not vested as of such termination (&#8220;Unvested Shares&#8221;) at a price equal to the exercise price per Option Share (the &#8220;Repurchase Right&#8221;).</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">In the event that your employment is terminated by the Company without Cause (as defined below) or by you for Good Reason (as defined below) at any time beginning on the date that is 90 days prior to the effective date of a Change of Control (as defined in the Plan) and ending on the date that is 12 months following the Change of Control, then (i) all unvested Restricted Stock and Option Shares shall immediately vest in full, and (ii) all Options will remain exercisable for a period of 90 calendar days following the date of such termination, after which time the Option shall expire&#59; provided, however, that no such Option shall be exercisable after the expiration of its maximum term. In order to give effect to the foregoing provision, notwithstanding anything to the contrary set forth in any agreement governing an equity award regarding immediate forfeiture of unvested shares upon termination of service or the duration of post-termination of service exercise periods, following any termination of your employment, none of your equity incentive awards shall terminate with respect to any vested or unvested portion subject to such equity award before 90 days following such termination.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">For purposes of this Agreement&#58; </font></div><div style="padding-left:94.5pt;text-align:justify;"><font><br></font></div><div style="padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(i) &#160;&#8220;Cause&#8221; will mean any one or more of the following&#58; (A) commission of any felony or crime involving dishonesty&#59; (B) participation in any fraud against the Company&#59; (C) material breach of your contractual, statutory or common law duties to the Company (including violation of any provision or obligation under this Agreement)&#59; (D) your failure to satisfactorily perform your job duties as assigned by the Company&#59; (E) intentional damage to any property of the Company&#59; or (F) misconduct or other violation of Company policy that causes or reasonably could cause harm.</font></div><div style="padding-left:94.5pt;text-align:justify;"><font><br></font></div><div style="padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(ii) &#160;&#8220;Good Reason&#8221; shall mean (A) any material diminution by the Company of your title, duties, authority or Base Salary&#59; (B) a material breach by the Company of any of the provisions contained in this Agreement, which, if capable of being cured, is not cured by the Company within 30 days after written notice thereof by you to the Company&#59; or (C) relocation of your principal place of employment more than 50 miles from the South San Francisco area.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Sign-On Advance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. You will receive a sign-on advance in the amount of $50,000, subject to standard payroll deductions and withholdings, payable within thirty (30) days after your employment Start Date (the &#8220;Sign-On Advance&#8221;). If within your first year of employment with the Company&#58; (a) you resign your employment other than for Good Reason, or (b) the Company terminates your employment for Cause (as defined below), then you agree to pay back the entire amount of the Sign-on Advance within ten (10) days after your employment termination date. </font></div><div style="text-indent:-13.5pt;padding-left:27pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Relocation Advance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. We understand you will be relocating to the San Francisco Bay Area. In connection with that relo0ation you will receive a relocation advance payment in the amount of $75,000, subject to standard payroll deductions and withholdings, payable within thirty (30) days after your employment Start Date (the </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8220;Relocation Advance&#8221;). The Relocation Advance will be considered earned only if you relocate to the San Francisco Bay Area on or before December 31, 2018, and (i) 50% of the Relocation Advance will be considered earned if you successfully complete one year of continuous employment with the Company, and (ii) 50% of the Relocation Advance will be considered earned if you successfully complete two (2) years of continuous employment with the Company. You may use the Relocation Advance to pay for relocation expenses or for any other purpose. If within your first year of employment with the Company&#58; (a) you resign your employment other than for Good Reason, or (b) the Company terminates your employment for Cause (as defined above), then you agree to pay back the entire amount of the Relocation Advance within ten (10) days after your employment termination date.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Allogene will reimburse you for all normal, usual and necessary expenses incurred in furtherance of the business and affairs of Allogene upon timely receipt by Allogene of appropriate vouchers or other proof of your expenditures and otherwise in accordance with any expense reimbursement and approval policy as may from time to time be adopted by Allogene.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. </font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">As a regular full-time employee, you shall be entitled to participate in the employee benefits made available to similarly situated employees, in accordance with the terms of such benefits plans and programs and company policies. Information regarding these employee benefits is available upon request and in the official plan documents, summary plan descriptions, and applicable summaries. The Company, in its sole discretion, has the right to amend or terminate any benefit plan, program or Company policy at any time and without prior notice.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19.84pt;">Vacation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. During each year of your employment you shall be entitled to fifteen (15) days of paid time off in addition to company recognized holidays. Notwithstanding the foregoing, you shall not be entitled to take more than two (2) consecutive weeks of vacation without the prior written consent of the Company.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:20.41pt;">Paid Sick Leave</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Upon hire, you will be credited with five (5) days of paid sick leave, which you may use during each calendar year for yourself or a family member for the diagnosis, care or treatment of an existing health condition or preventive care, or specified purposes set forth in the Company&#8217;s policy if you are a victim of domestic violence, sexual assault, or stalking.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. You hereby represent and warrant as follows&#58;</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">By accepting the Company&#8217;s offer of employment, you represent that you have no agreements, relationships, or commitments with any other person or entity that conflict with your obligations to the Company.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">You have the full right, power and legal capacity to enter and deliver this Agreement and to perform your duties and other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of the parties, enforceable against each in accordance with its terms. No approvals or consents of any persons or entitles are required for you to execute and deliver this Agreement or perform your duties and other obligations hereunder.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">You represent and warrant to the Company that you have not brought and shall not bring with you to the Company, or use in the performance of your duties, any materials or documents of any former employer that are not generally available to the public, unless you have obtained written authorization from the former employer for their possession and use and provided the Company with a copy thereof.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:24pt;">Conditions to Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. This offer of employment is contingent upon, and your employment shall be subject to&#58;</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">completion of reference checks and background check, and may be contingent upon a drug screen, each to the reasonable satisfaction of Allogene&#59; and</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">satisfying the requirements of the Immigration Control and Reform Act, which may be accomplished by showing your proof of right to work in the U.S. within three days of commencing employment, and you agree to assist as needed at the Company&#8217;s request to meet these conditions.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">execution of Allogene&#8217;s form of Employee Confidential Information and Invention Assignment Agreement attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which prohibits unauthorized use or disclosure of Allogene&#8217;s proprietary information, among other obligations&#59;</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">Notwithstanding the foregoing, this offer may be withdrawn by Allogene at any time prior to its execution by the parties.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Employment-at-will and Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Your employment shall be at-will. Accordingly, you may terminate your employment with Allogene at any time and for any reason whatsoever, with or without advance notice, simply by notifying Allogene in writing. Similarly, Allogene may terminate your employment at any time and for any reason whatsoever, with or without cause or advance notice. This at-will relationship cannot be changed except in a writing signed by an authorized officer of the Company and you. The employment terms contained in this Agreement supersede any other agreements and promises made to you by Allogene or any representative on its behalf, whether oral, written or implied.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">No Reliance by You on Promise or Representation Not in this Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. In accepting employment with Allogene and signing this Agreement, you agree that you are not relying on any representation, promise or inducement that has been made by Allogene or any representative on its behalf that is not explicitly stated in this Agreement. Allogene is not bound by and will not be liable for any representation, promise or inducement that is not explicitly stated in this Agreement.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The terms of this offer letter shall be governed by, and construed and interpreted in accordance with, the laws of the State of California without regard to such State&#8217;s principles of conflict of laws, except as provided in Section 13.</font></div><div style="padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. To the maximum extent permitted by law, any dispute between the parties, including but not limited to those arising out of, or relating to, this Agreement, shall be exclusively decided by binding arbitration in accordance with the terms of the Arbitration Agreement, which is attached as Exhibit B and incorporated into this Agreement. The Federal Arbitration Act shall govern the interpretation, enforcement and all proceedings pursuant to the Arbitration Agreement. To the extent that the Federal Arbitration Act is inapplicable, the terms of the Arbitration Agreement shall be construed in accordance with California law.</font></div><div style="text-indent:-13.5pt;padding-left:27pt;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. </font></div><div style="text-indent:-13.5pt;padding-left:27pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">This Agreement, and your rights and obligations hereunder, may not be assigned. Allogene may assign its rights, together with its obligations, hereunder in connection with any sale, transfer or other disposition of all or substantially all of its business or assets, provided the assignee entity which succeeds to Allogene expressly assumes Allogene&#8217;s obligations hereunder and complies with the terms of this Agreement.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">This Agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written agreement signed by the parties hereto. The Company&#8217;s signatory must be an officer who is authorized by the Company to enter into such an amendment.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">The failure of either party to insist upon the strict performance of any of the terms, conditions and provisions of this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions and provisions shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such party. If any provision of this offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law.</font></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">This Agreement, including its Exhibits A and B, sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter of the Agreement. This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:-13.5pt;padding-left:58.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-31.5pt;padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:19pt;">Certification of Qualifications</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. By accepting employment, you certify that the information you provided to Allogene about your experience, education and other qualifications for employment has been accurate and complete.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If you wish to accept employment at Allogene under the terms described above, please sign and date this Agreement, and return it to me. </font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We look forward to your favorable reply and to a productive and enjoyable working relationship.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This offer will be deemed withdrawn if not accepted by May 15, 2018.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Sincerely, </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:29.239%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David M. Tanen</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Tanen</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allogene Therapeutics, Inc.</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Understood and Accepted&#58; </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:44.883%;"><tr><td style="width:1.0%;"></td><td style="width:63.146%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.514%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.340%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Veer Bhavnagri</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 4, 2018</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Veer Bhavnagri</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div id="i65fb61ff387e41db86bfff72d390daa9_4"></div><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:right;"><img alt="allogenelogo4.jpg" src="allogenelogo4.jpg" style="height:36px;width:150px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">EXHIBIT A</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee Confidential Information and Invention Assignment Agreement</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div id="i65fb61ff387e41db86bfff72d390daa9_7"></div><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><img alt="allogenelogo3.jpg" src="allogenelogo3.jpg" style="height:36px;width:150px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEE CONFIDENTIAL INFORMATION AND </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INVENTION ASSIGNMENT AGREEMENT</font></div><div><font><br></font></div><div style="text-indent:36pt;padding-right:5.76pt;text-align:justify;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In consideration of my employment or continued employment by Allogene Therapeutics, Inc., its direct and indirect subsidiaries, parents, affiliates, predecessors, successors and assigns (together </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Company&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">), and the compensation and benefits provided to me now and during my employment with Company, I hereby enter into this Employee Confidential Information and Invention Assignment Agreement (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Agreement&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">), which will be deemed effective as of the first day of my employment with the Company&#58;</font></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">1.   CONFIDENTIAL INFORMATION PROTECTIONS.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;1.1   Recognition of Company's Rights&#59; Nondisclosure. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company&#8217;s Confidential Information (as defined below) and that Company has a protectable interest therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish any of Company&#8217;s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#8217;s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and&#47;or incorporates any Confidential Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions to prevent the inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#58; (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.2   Confidential Information. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Confidential Information&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">shall mean any and all confidential knowledge, data or information of Company. By way of illustration but not limitation, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Confidential Information&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">includes (a) trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code versions, data, programs, other works of authorship, know- how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">)&#59; (b) information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers, and supplier information, and purchasing&#59; (c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non-public information relating to customers and potential Customers&#59; (d) information regarding any of Company&#8217;s business partners and their services, including names&#59; representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non-public information relating to business partners&#59; (e) information regarding personnel, employee lists, compensation, and employee skills&#59; and (f) any other non-public information which a competitor of Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me. Further, notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between the Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with any federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;1.3   Third Party Information.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I understand, in addition, that Company has received and in the future will receive from third parties their confidential and&#47;or proprietary knowledge, data or information (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Third Party Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">) subject to a duty on Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During my employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of </font></div></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Company in writing.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;1.4   No Improper Use of Information of Prior Employers and Others.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">2.   ASSIGNMENTS OF INVENTIONS.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;2.1   Definitions. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As used in this Agreement, the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Intellectual Property Rights&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country&#59; the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Copyright&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country&#59; and the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Moral Rights&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.2   Excluded Inventions and Other Inventions. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Attachment 1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">is a list describing all existing Inventions, if any, that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Excluded Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">). If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development. For purposes of this Agreement, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Other Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> means Inventions in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (defined below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide license, with</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.3   Assignment of Company Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Inventions assigned to Company, or to a third party as directed by Company pursuant to Section 2.6, are referred to in this Agreement as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Company Inventions.&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Subject to Section 2.4 (Unassigned or Nonassignable Inventions) and except for Excluded Inventions set forth in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;"> Attachment 1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the period of my employment by Company. To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company&#8217;s customers, with respect to such rights. I further acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">2.4   Unassigned or Nonassignable Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I recognize that this Agreement will not be deemed to require assignment of any Invention that is covered under California Labor Code section 2870(a) (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#8220;Specific Inventions Law&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">), as detailed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Attachment 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.5   Obligation to Keep Company Informed. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others. In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment. At the time of each such disclosure, I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law&#59; and I will at that</font></div></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;2.6   Government or Third Party.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.7   Ownership of Work Product.  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;(a)     </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C., Section 101).</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">(b)     </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I agree that Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such work product. I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;2.8   Enforcement of Intellectual Property Rights and Assistance. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Company or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company's request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">2.9 Incorporation of Software Code.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company except in strict compliance with Company&#8217;s policies regarding the use of such software.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">3.   RECORDS.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">4.   DUTY OF LOYALTY DURING EMPLOYMENT.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree that during the period of my employment by Company I will not, without Company's express written consent, directly or indirectly engage in any employment or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment by Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">5.   NO SOLICITATION OF EMPLOYEES,</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">CONSULTANTS, OR CONTRACTORS. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I agree that during the period of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company solicit, induce, encourage, or participate in soliciting, inducing or encouraging any employee, consultant, or independent contractor of Company to terminate his, her or its relationship with Company, even if I did not initiate the discussion or seek out the contact.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">6.   REASONABLENESS OF RESTRICTIONS.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;6.1   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company&#8217;s legitimate business interests. I represent and agree that I am entering into this Agreement</font></div></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">6.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">   In the event that a court or arbitrator finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, Company and I agree that the court or arbitrator will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">6.3   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If the court or arbitrator declines to enforce this Agreement in the manner provided in subsection 6.2, Company and I agree that this Agreement will be automatically modified to provide Company with the maximum protection of its business interests allowed by law and I agree to be bound by this Agreement as modified.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">7.   NO DISPARAGEMENT.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree that, during my employment with the Company and after the termination of my employment for any reason, I will not disparage the Company, its officers, directors, managers, employees, consultants, shareholders, or agents, in any manner likely to be harmful to it or their business, business reputation or personal reputation. Notwithstanding the foregoing, nothing in this Agreement shall prohibit me from making truthful statements or disclosures required by applicable law, regulation or legal process&#59; or requesting or receiving confidential legal advice. Nothing in this Agreement shall limit my right to make truthful statements in the proper performance of my job duties for the Company, discuss my employment, or report possible violations of law or regulation with the SEC, EEOC, DOL, NLRB, OSHA or other federal government agency or similar state or local agency, or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the NLRA, or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to &#8220;whistleblower&#8221; statutes or other similar provisions that protect such disclosure.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">8.   NO CONFLICTING AGREEMENT OR OBLIGATION.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I represent that my employment by Company does not and will not breach any agreement with any former employer or third party, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me prior to my employment by Company. I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">9.   RETURN OF COMPANY PROPERTY. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Subject to the nondisclosure requirements of Section 1.1 above, upon termination of my employment or upon Company&#8217;s request at any other time, I will deliver to Company any and all of Company&#8217;s property and equipment and any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide the Company access to any such personal systems as reasonably requested to search for, copy and&#47;or delete such information, and upon my employment termination I agree to provide Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems&#59; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and&#47;or deletion is completed. I further agree that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time with or without notice. Prior to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#8217;s Termination Certificate&#59; however, my failure to sign and deliver the Termination Certificate shall in no way diminish my continuing obligations under this Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">10.   LEGAL AND EQUITABLE REMEDIES.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">10.1   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">breach of this Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;10.2  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> In the event Company enforces this Agreement through a court or arbitration order, I agree that the restrictions of Sections 5 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">11.   NOTICES. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, notice will be considered to</font></div></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:18pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.951%;"><tr><td style="width:1.0%;"></td><td style="width:45.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.212%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">have been given on the delivery date reflected by the courier or express mail service receipt.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">12.   NOTIFICATION OF NEW EMPLOYER.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> If I leave the employ of Company, I consent to the notification of my new employer of my rights and obligations under this Agreement, by Company providing a copy of this Agreement or otherwise.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">13.   GENERAL PROVISIONS.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.1   Governing Law. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement will be governed by and construed according to the laws of the State of California as such laws are applied to agreements entered into and to be performed entirely within California between California residents.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.2   Severability. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.3   Successors and Assigns. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, direct and indirect subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.4   Survival. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement shall survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.        </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.5   Employment At-Will.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree and understand that </font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">nothing in this Agreement will change my at-will employment status or confer any right with respect to continuation of employment by Company, nor will it interfere in any way with my right or Company's right to terminate my employment at any time, with or without cause or advance notice.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.6   Waiver. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce strict</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">adherence to all terms of this Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">13.7   Export.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">13.8   Advice of Counsel. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;13.9   Entire Agreement. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The obligations pursuant to Sections 1 and 2 of this Agreement will apply to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant (except Subsection 2.4 and 2.7(a)) or employee if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</font></div></td></tr></table></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:justify;"><font><br></font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:center;"><font><br></font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement shall be effective as of the first day of my employment with the Company. </font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:center;"><font><br></font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:center;"><font><br></font></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.911%;"><tr><td style="width:1.0%;"></td><td style="width:6.888%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.305%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.605%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.888%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.114%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">COMPANY&#58; </font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EMPLOYEE&#58; </font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ACCEPTED AND AGREED&#58;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I HAVE READ, UNDERSTAND, AND ACCEPT THIS AGREEMENT AND HAVE BEEN GIVEN THE OPPORTUNITY TO REVIEW IT WITH INDEPENDENT LEGAL COUNSEL. I HAVE ALSO COMPLETELY FILLED OUT ATTACHMENT 1.</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David M. Tanen</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Veer Bhavnagri</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Signature)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Signature)</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Tanen</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Veer Bhavnagri</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Secretary</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General Counsel</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2018</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 14, 2018</font></td></tr></table></div><div style="padding-left:15.12pt;padding-right:5.76pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div id="i65fb61ff387e41db86bfff72d390daa9_10"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ATTACHMENT 1</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PRIOR INVENTIONS</font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:59.935%;"><tr><td style="width:1.0%;"></td><td style="width:18.053%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.791%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.156%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TO&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allogene Therapeutics, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FROM&#58; </font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DATE&#58; </font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SUBJECT&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior Inventions</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.557%;"><tr><td style="width:1.0%;"></td><td style="width:3.365%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.642%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.617%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.162%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.617%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.020%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:28.5pt;">Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by Allogene Therapeutics, Inc. (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by Company&#58;</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</font></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No inventions or improvements</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</font></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">See below&#58; </font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;     Additional sheets attached.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:28.5pt;">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to inventions or improvements generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Invention or Improvement</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Party(ies)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Relationship</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1. </font></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2. </font></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3. </font></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;     Additional sheets attached.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div id="i65fb61ff387e41db86bfff72d390daa9_13"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">ATTACHMENT 2</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIMITED EXCLUSION NOTIFICATION</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This is to notify you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&#8217;s equipment, supplies, facilities or trade secret information, except for those Inventions that either&#58;</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:67.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.41pt;">Relate at the time of conception or reduction to practice to Company&#8217;s business, or actual or demonstrably anticipated research or development&#59; or</font></div><div><font><br></font></div><div style="text-indent:-31.5pt;padding-left:67.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.84pt;">Result from any work performed by you for Company.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div id="i65fb61ff387e41db86bfff72d390daa9_16"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><img alt="allogenelogo2.jpg" src="allogenelogo2.jpg" style="height:36px;width:150px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">EXHIBIT B</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Arbitration Agreement</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div id="i65fb61ff387e41db86bfff72d390daa9_19"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><img alt="allogenelogo1.jpg" src="allogenelogo1.jpg" style="height:36px;width:150px;"></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Arbitration Agreement</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I recognize that disputes may arise between Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) and me during or following my employment with the Company, and that those disputes may or may not be related to my employment. The parties understand and agree that by entering into this Arbitration Agreement (the &#8220;Agreement&#8221;), they anticipate gaining the benefits of a speedy, impartial, final and binding dispute-resolution procedure.</font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company and I mutually consent to the resolution by arbitration of all claims or controversies (&#8220;claims&#8221;), past, present or future, whether or not arising out of my employment (or its termination), that the Company may have against me or that I (and no other party) may have against (1) the Company&#59; (2) the Company&#8217;s officers, directors, employees or agents in whatever capacity&#59; (3) the Company&#8217;s parent, subsidiary and affiliated entities&#59; (4) the Company&#8217;s benefit plans or the plans&#8217; sponsors, fiduciaries, administrators, affiliates and agents (except claims under an employee benefit or pension plan that specifies a different claims process&#59; and&#47;or (5) all successors and assigns of any of them. The Federal Arbitration Act (9 U.S.C., Sections 1-16) (&#8220;FAA&#8221;) shall govern the interpretation, enforcement and all proceedings pursuant to this Agreement. To the extent that the Federal Arbitration Act is inapplicable, or held not to require arbitration of a particular claim or claims, the arbitration law of the state in which I work or last worked for the Company shall apply.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Arbitrable claims include, but are not limited to&#58; claims for wages&#47;other compensation due and any related claims&#59; claims for breach of any contract or covenant (express or implied)&#59; tort claims&#59; claims for retaliation&#59; claims for harassment&#59; claims for discrimination (including, but not limited to, race, sex, sexual orientation, religion, national origin, age, marital status, physical or mental disability or handicap, or medical condition)&#59; claims for benefits (except as noted above)&#59; and claims for violation of any federal, state, or other governmental law, statute, regulation, or ordinance. The following claims are not covered by this Agreement&#58; claims for Workers&#8217; Compensation or Unemployment Insurance benefits&#59; claims pending against the Company at the time I sign this Agreement in any forum&#59; and claims that as a matter of law cannot be subject to arbitration.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Both the Company and I hereby waive the right to a trial by jury or judge, or by administrative proceeding, for any claim or dispute covered by this Agreement.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Both the Company and I agree that neither of us shall initiate or prosecute any lawsuit in any way related to any claim covered by this Agreement to arbitrate, except that this Agreement does not prohibit the filing of or pursuit of relief through the following&#58; (i) seeking temporary or preliminary injunction relief as is otherwise available by law, (ii) an administrative charge to any federal, state or local equal employment opportunity or fair employment practices agency, (iii) an administrative charge to the National Labor Relations Board, or (iv) any other charge filed with or communication to a federal, state or local government office, official or agency.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The arbitration will be held before a neutral arbitrator under the auspices of JAMS. The arbitration shall take place in the county (or comparable government unit) in which I am or was last employed by the Company, and, except as provided above, no dispute affecting my rights or responsibilities shall be adjudicated in any other venue or forum. The arbitration shall be held in accordance with its then-current Employment Arbitration Rules &#38; Procedures (and no other JAMS rules), which are currently available at </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. I understand that the Company will provide me a written copy of those rules upon my request. The Arbitrator shall be either a retired judge, or an attorney who is experienced in employment law and licensed to practice law in the state in which the arbitration is convened (the &#8220;Arbitrator&#8221;), and shall be selected pursuant to the JAMS rules.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Arbitrator shall apply the substantive law (and the law of remedies, if applicable) of the state in which the claim arose, or federal law, or both, as applicable to the claim(s) asserted. The Arbitrator is without jurisdiction to apply any different substantive law or law of remedies. The Federal Rules of Evidence shall apply. The Arbitrator shall have the power to award any types of legal or equitable relief that would be available under applicable law, shall have the authority to compel adequate discovery for the resolution of the dispute, and shall render an award and written opinion, which shall include the factual and legal basis for the award. The arbitration decision shall be final and binding upon the parties.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Questions regarding the enforceability, interpretation, scope, applicability or coverage of this Agreement (including whether an issue is subject to arbitration under this Agreement) shall be decided by the arbitrator.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. Pursuant to the FAA, issues of contract formation and enforcement relating to this Agreement shall be governed by and decided under the internal laws of the State of California, without regard to conflict of law rules.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company will be responsible for paying any filing fee and the fees and costs of the Arbitrator. Each party shall pay in the first instance its own litigation costs and attorneys&#8217; fees, if any. However, if any party prevails on a claim which affords the prevailing party attorneys&#8217; fees and&#47;or litigation costs, then the Arbitrator shall rule upon a motion for attorneys&#8217; fees and&#47;or litigation costs under the same standards a court would apply under the law applicable to the claim(s) at issue.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the maximum extent permitted by law, all claims, disputes, or causes of action under this Agreement, whether by me or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class, collective, or representative proceeding&#59; provided, however, that this Agreement shall not apply to any representative action under the California Private Attorney General Act (&#8220;PAGA&#8221;). The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative, collective or class proceeding. If a court adjudicating a case involving the Company and me were to determine that there is an unwaivable right to bring a class action, any such action shall be brought only in court, and not in arbitration.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company and I agree that any arbitration, including, without limitation, discovery, documents produced and&#47;or entered into evidence, hearings, legal briefing and the final award, shall be confidential, although the final award may be disclosed as necessary to confirm the award and obtain entry of a final judgment by a court of competent jurisdiction. The Company and I further agree that we will execute written confidentiality agreements in order to ensure arbitration remains confidential.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This Agreement shall survive the termination of my employment and the expiration of any benefit plan. It can only be revoked by a writing signed by both the Company&#8217;s General Counsel and me specifically stating the intent to revoke this Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This is the complete agreement of the parties on the subjects covered, and supersedes any prior or contemporaneous oral or written understandings on the subjects addressed in this Agreement&#59; provided, however, that if this Agreement is held to be unenforceable for any reason, then any prior arbitration agreement between the Company and me shall survive. No party is relying on any representations, oral or written, on the subject of the effect, enforceability or meaning of this Agreement, except as specifically set forth in this Agreement. This Agreement only can be modified in a written agreement signed by the parties.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If any provision of this Agreement is adjudged to be void or otherwise unenforceable, in whole or in part, such adjudication shall not affect the validity of the remainder of the agreement. All other provisions shall remain in full force and effect.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I understand that nothing in this agreement affects the at-will nature of my employment with the Company, and that my employment may be terminated by either party, at any time, with or without cause or advance notice.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">I acknowledge that I have carefully read this Agreement, that I understand its terms and that I have entered into the Agreement voluntarily and not in reliance of any promises or representations by the Company other than those contained in the Agreement. I understand that by signing this Agreement, I am giving up my right to a jury trial. Finally, I further acknowledge that I have been given the opportunity to discuss this Agreement with my own legal counsel.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:5.532%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.762%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.326%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.957%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 14, 2018</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Veer Bhavnagri</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee Signature</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Veer Bhavnagri</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Printed Name of Employee</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2018</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">COMPANY</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David M. Tanen</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Tanen, Secretary</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image11.jpg" src="image11.jpg" style="height:0px;width:748px;"></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>allo-20200331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iac4c657e58204fb2a5d7c2d6917134ca_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, David Chang, M.D., Ph.D., certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">I have reviewed this quarterly report on Form 10-Q of Allogene Therapeutics, Inc.&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:58.322%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.678%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David Chang</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Chang, M.D., Ph.D.<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>allo-20200331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i09c83aaff139411d99c6d425c210fd6d_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Eric Schmidt, Ph.D., certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">I have reviewed this quarterly report on Form 10-Q of Allogene Therapeutics, Inc.&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:58.322%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.678%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Eric Schmidt</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eric Schmidt, Ph.D.<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>allo-20200331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i85d7567c084b40a2843fae8a49f6aa5e_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&#160;</font></div><div style="text-indent:47.25pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the quarterly report of Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David Chang, M.D., Ph.D., President and Chief Executive Officer of the Company, and I, Eric Schmidt, Ph.D., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;&#160;</font></div><div style="text-indent:-18pt;padding-left:63pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#59; and&#160;</font></div><div style="text-indent:-18pt;padding-left:63pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#160;</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:55.393%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.607%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David Chang</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Chang, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Eric Schmidt</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eric Schmidt, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="text-indent:47.25pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This certification shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liability of Section&#160;18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>allo-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:57bc89fc-7004-4307-9757-f5809462a759,g:be24e03f-ee2b-47ea-87e1-15803658ae8d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://allogene.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://allogene.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://allogene.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementofStockholdersEquityDeficit" roleURI="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Condensed Statement of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementofStockholdersEquityDeficitParenthetical" roleURI="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical">
        <link:definition>1005006 - Statement - Condensed Statement of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementofCashFlows" roleURI="http://allogene.com/role/CondensedStatementofCashFlows">
        <link:definition>1006007 - Statement - Condensed Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://allogene.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://allogene.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://allogene.com/role/FairValueMeasurements">
        <link:definition>2106103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://allogene.com/role/FairValueMeasurementsTables">
        <link:definition>2307301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2408403 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail">
        <link:definition>2409404 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://allogene.com/role/FinancialInstruments">
        <link:definition>2110104 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://allogene.com/role/FinancialInstrumentsTables">
        <link:definition>2311302 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails">
        <link:definition>2412405 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetails" roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails">
        <link:definition>2413406 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponents" roleURI="http://allogene.com/role/BalanceSheetsComponents">
        <link:definition>2114105 - Disclosure - Balance Sheets Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponentsTables" roleURI="http://allogene.com/role/BalanceSheetsComponentsTables">
        <link:definition>2315303 - Disclosure - Balance Sheets Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponentsPropertyandEquipmentDetails" roleURI="http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails">
        <link:definition>2416407 - Disclosure - Balance Sheets Components - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://allogene.com/role/LicenseAgreements">
        <link:definition>2117106 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://allogene.com/role/LicenseAgreementsDetails">
        <link:definition>2418408 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://allogene.com/role/CommitmentsandContingencies">
        <link:definition>2119107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://allogene.com/role/CommitmentsandContingenciesTables">
        <link:definition>2320304 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2421409 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseLiabilitiesDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails">
        <link:definition>2422410 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseCostsDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails">
        <link:definition>2424412 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestment" roleURI="http://allogene.com/role/EquityMethodInvestment">
        <link:definition>2125108 - Disclosure - Equity Method Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentDetails" roleURI="http://allogene.com/role/EquityMethodInvestmentDetails">
        <link:definition>2426413 - Disclosure - Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://allogene.com/role/StockBasedCompensation">
        <link:definition>2127109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://allogene.com/role/StockBasedCompensationTables">
        <link:definition>2328305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2429414 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2430415 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsDetails" roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails">
        <link:definition>2431416 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails">
        <link:definition>2432417 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetails" roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails">
        <link:definition>2433418 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://allogene.com/role/RelatedPartyTransactions">
        <link:definition>2134110 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2435419 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://allogene.com/role/IncomeTaxes">
        <link:definition>2136111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://allogene.com/role/NetLossPerShare">
        <link:definition>2137112 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://allogene.com/role/NetLossPerShareTables">
        <link:definition>2338306 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://allogene.com/role/NetLossPerShareDetails">
        <link:definition>2439420 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://allogene.com/role/SubsequentEvents">
        <link:definition>2140113 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://allogene.com/role/SubsequentEventsDetails">
        <link:definition>2441421 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="allo_SalesMilestoneMember" abstract="true" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AggregatePotentialMilestonePayments" abstract="false" name="AggregatePotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_PaymentTermsDomain" abstract="true" name="PaymentTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" abstract="false" name="PercentageOfDevelopmentCostPayableByCollaborationPartner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_NotchTherapeuticsIncMember" abstract="true" name="NotchTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_RelatedPartyTransactionMonthlyPaymentsInArrears" abstract="false" name="RelatedPartyTransactionMonthlyPaymentsInArrears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_LeaseTwoMember" abstract="true" name="LeaseTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_RecoveryOfResearchAndDevelopmentExpense" abstract="false" name="RecoveryOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_NewarkMember" abstract="true" name="NewarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" abstract="false" name="NumberOfSharesAsPercentageOfCommonSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_CellectisSAMember" abstract="true" name="CellectisSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" abstract="false" name="MaximumPaymentsRequiredPerProductAgainstSelectedTarget" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AggregatePotentialMilestonePayable" abstract="false" name="AggregatePotentialMilestonePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ByHeartIncMember" abstract="true" name="ByHeartIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_TwoThousandEighteenPlanMember" abstract="true" name="TwoThousandEighteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_CostMethodInvestmentTransactionCosts" abstract="false" name="CostMethodInvestmentTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AllowanceForTenantImprovements" abstract="false" name="AllowanceForTenantImprovements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_NumberOfMembersAppointedToBoardOfDirectors" abstract="false" name="NumberOfMembersAppointedToBoardOfDirectors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="allo_StockIssuanceMaximumValue" abstract="false" name="StockIssuanceMaximumValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AccruedAndOtherLiabilitiesCurrent" abstract="false" name="AccruedAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TwoRiverConsultingLLCMember" abstract="true" name="TwoRiverConsultingLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PaymentsCommencingJanuary2020Member" abstract="true" name="PaymentsCommencingJanuary2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PreClinicalDevelopmentMilestoneMember" abstract="true" name="PreClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_RegulatoryMilestoneMember" abstract="true" name="RegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_SubleaseAgreementMember" abstract="true" name="SubleaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AreaOfOffice" abstract="false" name="AreaOfOffice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="allo_StockOptionGrantedPeriod" abstract="false" name="StockOptionGrantedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_LeaseOneMember" abstract="true" name="LeaseOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CashEquivalentsAndShortTermInvestments" abstract="false" name="CashEquivalentsAndShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_RelatedPartyTransactionCompensationPercentage" abstract="false" name="RelatedPartyTransactionCompensationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_IncomeLossFromCostMethodInvestment" abstract="false" name="IncomeLossFromCostMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_LicenseAndCollaborationAgreementMember" abstract="true" name="LicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AccruedAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_LiabilitiesLesseeTableTextBlock" abstract="false" name="LiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_ComputerEquipmentAndPurchasedSoftwareMember" abstract="true" name="ComputerEquipmentAndPurchasedSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_ServierMember" abstract="true" name="ServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" abstract="false" name="AggregatePotentialRegulatoryAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_PaymentsCommencingJanuary2019Member" abstract="true" name="PaymentsCommencingJanuary2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" abstract="false" name="OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="allo_FounderSharesOfCommonStockMember" abstract="true" name="FounderSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" abstract="false" name="CashReceivedForAmountsRelatedToTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ResearchCollaborationAndLicenseAgreementMember" abstract="true" name="ResearchCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AreaOfOperatingLease" abstract="false" name="AreaOfOperatingLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="allo_PercentageOfDevelopmentCostPayableByTheCompany" abstract="false" name="PercentageOfDevelopmentCostPayableByTheCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_AggregatePotentialMilestoneReceivable" abstract="false" name="AggregatePotentialMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" abstract="false" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_ConsultingAgreementsMember" abstract="true" name="ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PfizerIncMember" abstract="true" name="PfizerIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CollaborationArrangementExpense" abstract="false" name="CollaborationArrangementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_BellcoCapitalLLCMember" abstract="true" name="BellcoCapitalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_MilestoneTypeAxis" abstract="true" name="MilestoneTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_RoyaltyObligationPeriodFromDateOfFirstSale" abstract="false" name="RoyaltyObligationPeriodFromDateOfFirstSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TransitionServicesAgreementMember" abstract="true" name="TransitionServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_DevelopmentAndSalesMember" abstract="true" name="DevelopmentAndSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" abstract="false" name="RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_PaymentTermsAxis" abstract="true" name="PaymentTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" abstract="false" name="ChangesInSignificantAccountingPoliciesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_ClinicalRegulatoryAndCommercialMilestoneMember" abstract="true" name="ClinicalRegulatoryAndCommercialMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_LicenseAgreementsTextBlock" abstract="false" name="LicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_AreaOfNewOfficeBuilding" abstract="false" name="AreaOfNewOfficeBuilding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" abstract="false" name="StockIssuanceMaximumCompensationDueToThirdPartyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_MilestoneTypeDomain" abstract="true" name="MilestoneTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_NumberOfOptionsToExtendLease" abstract="false" name="NumberOfOptionsToExtendLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="allo_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_EarlyExerciseOfStockOptionsMember" abstract="true" name="EarlyExerciseOfStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AssetContributionAgreementMember" abstract="true" name="AssetContributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>allo-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:57bc89fc-7004-4307-9757-f5809462a759,g:be24e03f-ee2b-47ea-87e1-15803658ae8d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20200331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9bad9a37-3541-4da3-aef0-2aadd56b24e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_434b5775-7c32-4517-861c-bdb865d96e61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bad9a37-3541-4da3-aef0-2aadd56b24e3" xlink:to="loc_us-gaap_LiabilitiesCurrent_434b5775-7c32-4517-861c-bdb865d96e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2862f9bc-c0fc-4a45-977d-89e1eeb00dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bad9a37-3541-4da3-aef0-2aadd56b24e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2862f9bc-c0fc-4a45-977d-89e1eeb00dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7fb710a8-bc5a-4ca9-940e-112fbc0edb88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bad9a37-3541-4da3-aef0-2aadd56b24e3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7fb710a8-bc5a-4ca9-940e-112fbc0edb88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_059a0fca-601e-47b1-b78f-0769abefd0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b1a59822-5d04-43f8-af6f-29a1df506cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_059a0fca-601e-47b1-b78f-0769abefd0b0" xlink:to="loc_us-gaap_Liabilities_b1a59822-5d04-43f8-af6f-29a1df506cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_420db4c5-2824-4009-b81a-0259fb4b3dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_059a0fca-601e-47b1-b78f-0769abefd0b0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_420db4c5-2824-4009-b81a-0259fb4b3dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45cc56e6-6f8e-439f-8f4b-30b12ed69abd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_059a0fca-601e-47b1-b78f-0769abefd0b0" xlink:to="loc_us-gaap_StockholdersEquity_45cc56e6-6f8e-439f-8f4b-30b12ed69abd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93ef06d3-f509-4358-9a21-e8dd8879e8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b1a823e6-6b9c-47ea-99c1-d9a7141e537b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93ef06d3-f509-4358-9a21-e8dd8879e8e3" xlink:to="loc_us-gaap_PreferredStockValue_b1a823e6-6b9c-47ea-99c1-d9a7141e537b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f5408093-f5b2-423e-a9b4-cd49ddcd1698" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93ef06d3-f509-4358-9a21-e8dd8879e8e3" xlink:to="loc_us-gaap_CommonStockValue_f5408093-f5b2-423e-a9b4-cd49ddcd1698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b5e89918-1380-4ec4-9743-81192ac2a17c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93ef06d3-f509-4358-9a21-e8dd8879e8e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b5e89918-1380-4ec4-9743-81192ac2a17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf627f02-fe31-42a5-8313-a91b20eddf7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93ef06d3-f509-4358-9a21-e8dd8879e8e3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf627f02-fe31-42a5-8313-a91b20eddf7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8205655b-6b14-4a79-8f8e-7a4a6d5988e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93ef06d3-f509-4358-9a21-e8dd8879e8e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8205655b-6b14-4a79-8f8e-7a4a6d5988e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6b081bc4-3006-4e9d-8085-84c63c5a9f49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ab848a94-0e35-4e4a-a63f-a078caa58ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6b081bc4-3006-4e9d-8085-84c63c5a9f49" xlink:to="loc_us-gaap_AccountsPayableCurrent_ab848a94-0e35-4e4a-a63f-a078caa58ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_5bb5f1ab-4faa-408a-be40-44bba8a9cb73" xlink:href="allo-20200331.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6b081bc4-3006-4e9d-8085-84c63c5a9f49" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_5bb5f1ab-4faa-408a-be40-44bba8a9cb73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_39411f1d-2c3d-4eba-8926-fc2addd8b74e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bd08dbf0-23c1-4547-b1d6-1d34b1984c64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39411f1d-2c3d-4eba-8926-fc2addd8b74e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bd08dbf0-23c1-4547-b1d6-1d34b1984c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_608bfdd0-adb9-405b-b6ba-ae25b3962f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39411f1d-2c3d-4eba-8926-fc2addd8b74e" xlink:to="loc_us-gaap_ShortTermInvestments_608bfdd0-adb9-405b-b6ba-ae25b3962f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_423285f5-aab7-4b92-90f6-8f06ad6901fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39411f1d-2c3d-4eba-8926-fc2addd8b74e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_423285f5-aab7-4b92-90f6-8f06ad6901fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dd6913a0-d8f6-466a-b95c-c03d0ee90bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_15eae73e-851f-44d5-a86a-c5de756a799d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd6913a0-d8f6-466a-b95c-c03d0ee90bb4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_15eae73e-851f-44d5-a86a-c5de756a799d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_746b856d-2a1e-4a00-bd5b-14ff5f2f65ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd6913a0-d8f6-466a-b95c-c03d0ee90bb4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_746b856d-2a1e-4a00-bd5b-14ff5f2f65ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b817de07-d183-4bb2-accc-af92cb2eee97" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd6913a0-d8f6-466a-b95c-c03d0ee90bb4" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b817de07-d183-4bb2-accc-af92cb2eee97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_16c41434-3df0-4116-a0bc-7bf6e81e9413" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd6913a0-d8f6-466a-b95c-c03d0ee90bb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_16c41434-3df0-4116-a0bc-7bf6e81e9413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e13f14e7-d085-43ba-8962-543d5e080583" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd6913a0-d8f6-466a-b95c-c03d0ee90bb4" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e13f14e7-d085-43ba-8962-543d5e080583" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a18615bf-03fb-4b0b-90cd-c8c77ea98fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d028eaee-4b04-41a7-90bc-8fcd4aba13cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a18615bf-03fb-4b0b-90cd-c8c77ea98fa8" xlink:to="loc_us-gaap_OperatingIncomeLoss_d028eaee-4b04-41a7-90bc-8fcd4aba13cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d8256191-2f07-4d9e-a393-23e1f9625039" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a18615bf-03fb-4b0b-90cd-c8c77ea98fa8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d8256191-2f07-4d9e-a393-23e1f9625039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_397e811c-afb2-4b2f-882c-9823df3b391d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b8eb9491-5cfd-4257-a13b-edc742ef61ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_397e811c-afb2-4b2f-882c-9823df3b391d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b8eb9491-5cfd-4257-a13b-edc742ef61ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c4567546-d910-4a63-b92f-0bc8e6284aad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_397e811c-afb2-4b2f-882c-9823df3b391d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c4567546-d910-4a63-b92f-0bc8e6284aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2621bc3f-0f2e-404d-af24-4b1fa985c128" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6af1efaa-62e7-4e70-b81e-902cb413dd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2621bc3f-0f2e-404d-af24-4b1fa985c128" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6af1efaa-62e7-4e70-b81e-902cb413dd6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_64ec25ae-2ace-4cee-9c1c-01a8d610eaa5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2621bc3f-0f2e-404d-af24-4b1fa985c128" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_64ec25ae-2ace-4cee-9c1c-01a8d610eaa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_96c1c9b2-ca9e-4b69-b677-7a54c0131eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_25a7872e-6c5f-4f72-8e41-fb79a18abb70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_96c1c9b2-ca9e-4b69-b677-7a54c0131eb2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_25a7872e-6c5f-4f72-8e41-fb79a18abb70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0cb89f59-222b-4749-99db-332f2f6d1f81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_96c1c9b2-ca9e-4b69-b677-7a54c0131eb2" xlink:to="loc_us-gaap_NetIncomeLoss_0cb89f59-222b-4749-99db-332f2f6d1f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f1644431-4b58-4968-9d81-83f1335295e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2d6eb329-0771-4e91-bbcf-24e84ca7ae07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f1644431-4b58-4968-9d81-83f1335295e3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2d6eb329-0771-4e91-bbcf-24e84ca7ae07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_40416b65-3938-442d-bf68-c34bedc64ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f1644431-4b58-4968-9d81-83f1335295e3" xlink:to="loc_us-gaap_OtherExpenses_40416b65-3938-442d-bf68-c34bedc64ba4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofStockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofStockholdersEquityDeficitParenthetical"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofCashFlows" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff6aa520-90cb-4c30-ad7f-0b21c2df6ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f88981e-ea9b-4e79-a554-eabcd7ccbf05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff6aa520-90cb-4c30-ad7f-0b21c2df6ae1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f88981e-ea9b-4e79-a554-eabcd7ccbf05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_75b99963-84e8-4ff6-b323-7dcb7a01b111" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff6aa520-90cb-4c30-ad7f-0b21c2df6ae1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_75b99963-84e8-4ff6-b323-7dcb7a01b111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_9ec39037-2d30-4e9f-a803-4e80823a2cee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff6aa520-90cb-4c30-ad7f-0b21c2df6ae1" xlink:to="loc_us-gaap_ProceedsFromStockPlans_9ec39037-2d30-4e9f-a803-4e80823a2cee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e94ed461-bb98-43c6-a720-0901d7c13d75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e94ed461-bb98-43c6-a720-0901d7c13d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_9fd79d52-9ee6-470b-9278-ff95e49e010d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_LeaseAndRentalExpense_9fd79d52-9ee6-470b-9278-ff95e49e010d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5248909b-fd10-43e2-ba01-b92b78a8bc67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5248909b-fd10-43e2-ba01-b92b78a8bc67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_08477cbe-4b13-4ed7-9d15-2ea997bb9410" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_08477cbe-4b13-4ed7-9d15-2ea997bb9410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_5a1ad860-e48b-4613-a369-32d81cb7b2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_5a1ad860-e48b-4613-a369-32d81cb7b2fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3049e545-52a6-484d-9070-4675f6528620" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_Depreciation_3049e545-52a6-484d-9070-4675f6528620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c5bf4340-8944-46fd-a010-ddd5102e5403" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c5bf4340-8944-46fd-a010-ddd5102e5403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bd403092-6b8b-4644-a945-a8f229478f10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bd403092-6b8b-4644-a945-a8f229478f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f46a97af-6967-4b69-854d-bb73b03083f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_ProfitLoss_f46a97af-6967-4b69-854d-bb73b03083f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_5dcb2c25-a0a6-43db-a7a2-b105887b9924" xlink:href="allo-20200331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_5dcb2c25-a0a6-43db-a7a2-b105887b9924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e3ac295b-ccb7-4863-b11b-445b0074e698" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_ShareBasedCompensation_e3ac295b-ccb7-4863-b11b-445b0074e698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7a104e76-a601-4914-a9a6-076d3bb7f7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7a104e76-a601-4914-a9a6-076d3bb7f7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61096caa-12b9-4234-87eb-f080be30a927" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff977d09-2a82-4cf7-b808-ab6261b0f4ab" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61096caa-12b9-4234-87eb-f080be30a927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7bf0231-3a25-457d-8000-a82a459ae3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1472407c-0826-42cd-a815-0b8ac76fad8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7bf0231-3a25-457d-8000-a82a459ae3c9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1472407c-0826-42cd-a815-0b8ac76fad8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_19f7d936-aecf-4a5b-a623-bed8a62f94d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7bf0231-3a25-457d-8000-a82a459ae3c9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_19f7d936-aecf-4a5b-a623-bed8a62f94d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_11a5ec5c-efe0-44e8-9b97-046c1ef98ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7bf0231-3a25-457d-8000-a82a459ae3c9" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_11a5ec5c-efe0-44e8-9b97-046c1ef98ff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38f71ddd-0613-4530-9550-13e2d8b54796" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_811dfbb6-47f4-40ad-8d67-a1543278fb0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38f71ddd-0613-4530-9550-13e2d8b54796" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_811dfbb6-47f4-40ad-8d67-a1543278fb0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42b2f7ad-5851-4328-937c-d4af8675bbc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38f71ddd-0613-4530-9550-13e2d8b54796" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42b2f7ad-5851-4328-937c-d4af8675bbc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d11d0c63-82fc-474a-aa7c-8d7d20a0da32" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38f71ddd-0613-4530-9550-13e2d8b54796" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d11d0c63-82fc-474a-aa7c-8d7d20a0da32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="allo-20200331.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#DescriptionofBusinessDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_7d83e484-9a05-45a4-b993-0f9c1c247aae" xlink:href="allo-20200331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_90b1b299-7b42-4b1a-9884-554e5a8884c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_7d83e484-9a05-45a4-b993-0f9c1c247aae" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_90b1b299-7b42-4b1a-9884-554e5a8884c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ec0d39a1-53bc-4284-b36c-5c35360a4380" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_7d83e484-9a05-45a4-b993-0f9c1c247aae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ec0d39a1-53bc-4284-b36c-5c35360a4380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fefa5208-3a10-448a-9ec0-fc1c0fbd23b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_7d83e484-9a05-45a4-b993-0f9c1c247aae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fefa5208-3a10-448a-9ec0-fc1c0fbd23b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0319149a-7c09-4d6e-8c83-2054c30370c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a547eca9-960b-4467-9ef6-b3b3784ec23a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0319149a-7c09-4d6e-8c83-2054c30370c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a547eca9-960b-4467-9ef6-b3b3784ec23a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_402a367a-16a2-4db0-8f3f-4f768c8faf4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0319149a-7c09-4d6e-8c83-2054c30370c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_402a367a-16a2-4db0-8f3f-4f768c8faf4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_520f4ce5-9204-4b52-b947-7e456e1a0263" xlink:href="allo-20200331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0319149a-7c09-4d6e-8c83-2054c30370c9" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_520f4ce5-9204-4b52-b947-7e456e1a0263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f1bec72-b761-4872-844c-a96b0f79b360" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0319149a-7c09-4d6e-8c83-2054c30370c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f1bec72-b761-4872-844c-a96b0f79b360" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponents" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponents"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponentsTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponentsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b35b93c5-c467-46ac-a14f-3bd0aab79603" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_420d2059-261d-4b10-bab6-8f268c3b6ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b35b93c5-c467-46ac-a14f-3bd0aab79603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_420d2059-261d-4b10-bab6-8f268c3b6ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_befbcb6d-200e-4c0e-83e2-67d4a34fc24c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b35b93c5-c467-46ac-a14f-3bd0aab79603" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_befbcb6d-200e-4c0e-83e2-67d4a34fc24c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:type="simple" xlink:href="allo-20200331.xsd#LicenseAgreements"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#LicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ff79a314-1483-4d03-af76-01d0f86a365e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2b6116bc-dc16-45cd-9777-a1c2f649b99c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ff79a314-1483-4d03-af76-01d0f86a365e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2b6116bc-dc16-45cd-9777-a1c2f649b99c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4d9415bf-db88-429a-adab-c4724a953c61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ff79a314-1483-4d03-af76-01d0f86a365e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4d9415bf-db88-429a-adab-c4724a953c61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_bbce5df3-fe64-4520-a457-b417412941c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b59634f7-22d3-48c0-9577-9f82dee70a35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bbce5df3-fe64-4520-a457-b417412941c8" xlink:to="loc_us-gaap_OperatingLeaseCost_b59634f7-22d3-48c0-9577-9f82dee70a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_fdbd88bd-52c1-433e-a725-ef820399431b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bbce5df3-fe64-4520-a457-b417412941c8" xlink:to="loc_us-gaap_VariableLeaseCost_fdbd88bd-52c1-433e-a725-ef820399431b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1198c84e-7297-4cfb-96b0-39a3905de8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fef82ca2-0078-49f7-aae5-060dd6b8b0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1198c84e-7297-4cfb-96b0-39a3905de8e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fef82ca2-0078-49f7-aae5-060dd6b8b0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4a89f742-afd1-4ec9-b3f3-475698eae0f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1198c84e-7297-4cfb-96b0-39a3905de8e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4a89f742-afd1-4ec9-b3f3-475698eae0f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_35fc7e8c-bee9-482d-86cf-a75f67b62c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1198c84e-7297-4cfb-96b0-39a3905de8e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_35fc7e8c-bee9-482d-86cf-a75f67b62c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_493346f6-ae0a-41dd-a2b6-bdfc766eeb39" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1198c84e-7297-4cfb-96b0-39a3905de8e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_493346f6-ae0a-41dd-a2b6-bdfc766eeb39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6d6c2d35-9599-474c-adf1-294d3c2d84f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1198c84e-7297-4cfb-96b0-39a3905de8e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6d6c2d35-9599-474c-adf1-294d3c2d84f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cf7161d3-95e4-48d7-88a4-6332637d6023" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1198c84e-7297-4cfb-96b0-39a3905de8e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cf7161d3-95e4-48d7-88a4-6332637d6023" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20200331.xsd#EquityMethodInvestment"/>
  <link:calculationLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#EquityMethodInvestmentDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20200331.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20200331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20200331.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>allo-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:57bc89fc-7004-4307-9757-f5809462a759,g:be24e03f-ee2b-47ea-87e1-15803658ae8d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20200331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended" id="i660d3211d3034996a0cb5b3c0344b55f_CoverPage"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedBalanceSheets"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedBalanceSheets" xlink:type="extended" id="ic11657200a604467bc317f74e20cf47f_CondensedBalanceSheets"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" id="i52a47179d80f4ff4a64a19c12c05f0fe_CondensedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i39ac3dcdd4ec4145bb808bfcdea4da53_CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit" xlink:type="extended" id="iaa63e69f2e5a4b5bad86b8447ff587ac_CondensedStatementofStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1d73cb22-736c-46ae-894d-0b78b258627d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d73cb22-736c-46ae-894d-0b78b258627d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6557380e-11c3-45ca-bd23-5ffc9c86b057" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6557380e-11c3-45ca-bd23-5ffc9c86b057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6d694322-d6c8-48ab-a4d7-29894f9cf7ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockholdersEquity_6d694322-d6c8-48ab-a4d7-29894f9cf7ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cc711bc2-d9ad-47fa-8f31-929120745d04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cc711bc2-d9ad-47fa-8f31-929120745d04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32d2a32f-1077-452e-aa7f-ebcb34fc2005" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32d2a32f-1077-452e-aa7f-ebcb34fc2005" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3def25b6-395a-485e-bc2b-aebc1469dbd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3def25b6-395a-485e-bc2b-aebc1469dbd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6df9571-8e47-4767-aad8-507573bbd1db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6df9571-8e47-4767-aad8-507573bbd1db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ba344329-1a0b-42ac-8e0b-31651e97a989" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ba344329-1a0b-42ac-8e0b-31651e97a989" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_149f291d-6e7b-4d67-9938-87ca248200c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_149f291d-6e7b-4d67-9938-87ca248200c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e083cb3-2dae-4f79-983e-3bb0096414f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e083cb3-2dae-4f79-983e-3bb0096414f0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_00b2a3d2-d6e0-4eb1-a603-2353f4c1f5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_00b2a3d2-d6e0-4eb1-a603-2353f4c1f5d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59375507-9c90-4264-90f4-6171d674cd25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_NetIncomeLoss_59375507-9c90-4264-90f4-6171d674cd25" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_497e2036-277a-44c0-88fd-a533fe19eff4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_497e2036-277a-44c0-88fd-a533fe19eff4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6fe994e-a063-4758-a94c-bf77f3bc32cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eff07fd7-094b-48bf-b447-499afb454185" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6c3ce1f8-14b9-4977-b433-9a0a7e58eedc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1d73cb22-736c-46ae-894d-0b78b258627d" xlink:to="loc_us-gaap_StatementTable_6c3ce1f8-14b9-4977-b433-9a0a7e58eedc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6c3ce1f8-14b9-4977-b433-9a0a7e58eedc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883" xlink:to="loc_us-gaap_EquityComponentDomain_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883" xlink:to="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e99d8d13-b0a5-4868-856e-167d1594ee52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:to="loc_us-gaap_CommonStockMember_e99d8d13-b0a5-4868-856e-167d1594ee52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0f9662ab-df18-4758-81d1-be0f4cdfedca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0f9662ab-df18-4758-81d1-be0f4cdfedca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9e91a1d7-3ae2-4ff4-b7d0-34ebcf3aa9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:to="loc_us-gaap_RetainedEarningsMember_9e91a1d7-3ae2-4ff4-b7d0-34ebcf3aa9e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5117afe0-6d8b-4c01-9fe3-9ad38a7fbf46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5117afe0-6d8b-4c01-9fe3-9ad38a7fbf46" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical" xlink:type="extended" id="iabaff2974adb403a97a89bf1725276c1_CondensedStatementofStockholdersEquityDeficitParenthetical"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofCashFlows" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofCashFlows"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementofCashFlows" xlink:type="extended" id="i938cf1f9b28446fca95278b675383190_CondensedStatementofCashFlows"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="allo-20200331.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusiness" xlink:type="extended" id="i1cb9ab19d2c9431995813cebad798d6f_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="i5b6429fcbeac4d3986da630673d5e732_DescriptionofBusinessDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i25262942d674429c9d4ffb667ebe48e4_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="if90fa290db874bb1921a60c11ef9dd99_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i390404123b884ebc9022d9e627bc77f3_SummaryofSignificantAccountingPoliciesDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended" id="ia2ab1d5464ed443b8ba3b38a10b85936_FairValueMeasurements"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended" id="iba0d5e49f53e40289a115d302577d787_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="i0dad935e6389429f87085fe6c013e280_FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e508a9a-a795-43e8-8812-353cfcf0cd49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8ca945d3-e4f7-4a72-891c-98148f3e8dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e508a9a-a795-43e8-8812-353cfcf0cd49" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8ca945d3-e4f7-4a72-891c-98148f3e8dd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b801a205-3285-4281-a496-361ef4b4d491" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e508a9a-a795-43e8-8812-353cfcf0cd49" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b801a205-3285-4281-a496-361ef4b4d491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e508a9a-a795-43e8-8812-353cfcf0cd49" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_159bacd4-bd8b-4c5c-9586-b395389809db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_159bacd4-bd8b-4c5c-9586-b395389809db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_159bacd4-bd8b-4c5c-9586-b395389809db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_159bacd4-bd8b-4c5c-9586-b395389809db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_159bacd4-bd8b-4c5c-9586-b395389809db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_75af7de1-2e8b-40b5-bebe-5f05c79086b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_159bacd4-bd8b-4c5c-9586-b395389809db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_75af7de1-2e8b-40b5-bebe-5f05c79086b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_baffe6c4-f0b9-445f-83b4-3392b0d8db94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_75af7de1-2e8b-40b5-bebe-5f05c79086b2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_baffe6c4-f0b9-445f-83b4-3392b0d8db94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0914ec49-b26c-4e63-b27f-72233e1441da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0914ec49-b26c-4e63-b27f-72233e1441da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0914ec49-b26c-4e63-b27f-72233e1441da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0914ec49-b26c-4e63-b27f-72233e1441da" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0914ec49-b26c-4e63-b27f-72233e1441da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e994da46-ab14-4908-ab62-41acd02ae172" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0914ec49-b26c-4e63-b27f-72233e1441da" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e994da46-ab14-4908-ab62-41acd02ae172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_61a6b34c-d12c-4bf6-b6ca-5810d1b5bb09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e994da46-ab14-4908-ab62-41acd02ae172" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_61a6b34c-d12c-4bf6-b6ca-5810d1b5bb09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="extended" id="i1347a7c957b84ff8bcc1a943301fb048_FairValueMeasurementsFinancialAssetsandLiabilitiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ec86ce71-81fa-4262-b8b4-d40433bce72d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5467782f-8b7a-42ea-be63-8fefe83177db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ec86ce71-81fa-4262-b8b4-d40433bce72d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5467782f-8b7a-42ea-be63-8fefe83177db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ec86ce71-81fa-4262-b8b4-d40433bce72d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8f951b67-40f9-4ee7-8352-e3803703c588" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8f951b67-40f9-4ee7-8352-e3803703c588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8f951b67-40f9-4ee7-8352-e3803703c588_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8f951b67-40f9-4ee7-8352-e3803703c588" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8f951b67-40f9-4ee7-8352-e3803703c588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2079b9a-4a85-424d-b4e1-6585812930f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8f951b67-40f9-4ee7-8352-e3803703c588" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2079b9a-4a85-424d-b4e1-6585812930f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9d0ef16b-6f11-427a-90b9-8d7830c6ae08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2079b9a-4a85-424d-b4e1-6585812930f9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9d0ef16b-6f11-427a-90b9-8d7830c6ae08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dea7b1af-07cd-44e5-a6db-619501ba1a03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dea7b1af-07cd-44e5-a6db-619501ba1a03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dea7b1af-07cd-44e5-a6db-619501ba1a03_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dea7b1af-07cd-44e5-a6db-619501ba1a03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dea7b1af-07cd-44e5-a6db-619501ba1a03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dea7b1af-07cd-44e5-a6db-619501ba1a03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9b876497-ea91-414e-9a40-1167698a9b89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9b876497-ea91-414e-9a40-1167698a9b89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4c23ad87-f2f3-4679-9f84-13bfa7bbf49e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4c23ad87-f2f3-4679-9f84-13bfa7bbf49e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_492c94e7-18f2-4e3a-9668-18a4a76ed314" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_492c94e7-18f2-4e3a-9668-18a4a76ed314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4c5895c7-cc71-44ae-a71c-6961c53d2ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4c5895c7-cc71-44ae-a71c-6961c53d2ab6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c5895c7-cc71-44ae-a71c-6961c53d2ab6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c5895c7-cc71-44ae-a71c-6961c53d2ab6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c5895c7-cc71-44ae-a71c-6961c53d2ab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c5895c7-cc71-44ae-a71c-6961c53d2ab6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d09f0180-a91a-4ade-a730-07bff0036d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d09f0180-a91a-4ade-a730-07bff0036d9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_92659d2f-dcc1-491c-9de7-2d4c7bf2c6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_CommercialPaperMember_92659d2f-dcc1-491c-9de7-2d4c7bf2c6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_86455fb2-ae56-4d1a-844b-f338ab9f8dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_86455fb2-ae56-4d1a-844b-f338ab9f8dd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1cf37438-4e95-4060-9045-fe822224c38c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1cf37438-4e95-4060-9045-fe822224c38c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f6ca2847-db97-48ee-a2b0-2c0bac3fe4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f6ca2847-db97-48ee-a2b0-2c0bac3fe4e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5b026f19-9653-4b08-a741-c7c5f47680c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5b026f19-9653-4b08-a741-c7c5f47680c2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended" id="i5bca9c6f92fc42228aa801f5f0a1e55b_FinancialInstruments"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended" id="i62ecf69f6b2744db9e9fedc422563a18_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i68b82e531c2a48aebb7d8abe464ac46c_FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d9af91a-f193-44ae-9c26-3970a9066a07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d9af91a-f193-44ae-9c26-3970a9066a07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fccd074-545c-426a-8ff4-16efd5dfdd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fccd074-545c-426a-8ff4-16efd5dfdd6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe00a8ab-3968-4ee2-9a17-79800bb17789" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe00a8ab-3968-4ee2-9a17-79800bb17789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82a79b4e-9e93-46a5-9be4-2caf3b14a968" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82a79b4e-9e93-46a5-9be4-2caf3b14a968" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_6c5283fe-58ed-44ce-b50e-6366cdc71a00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_6c5283fe-58ed-44ce-b50e-6366cdc71a00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bf0fa812-bc42-4189-8326-647ab36d69ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bf0fa812-bc42-4189-8326-647ab36d69ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6eadf2e4-0729-47f9-b167-f10734f9ba16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6eadf2e4-0729-47f9-b167-f10734f9ba16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_5780e85c-af75-4806-8b6a-85e35bd2ea64" xlink:href="allo-20200331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_5780e85c-af75-4806-8b6a-85e35bd2ea64" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_395cf40b-462d-4337-989d-f054ac9759a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_395cf40b-462d-4337-989d-f054ac9759a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_87c7be99-f439-413d-9558-1badfea9c20c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_395cf40b-462d-4337-989d-f054ac9759a5" xlink:to="loc_us-gaap_InvestmentTypeAxis_87c7be99-f439-413d-9558-1badfea9c20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_87c7be99-f439-413d-9558-1badfea9c20c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_87c7be99-f439-413d-9558-1badfea9c20c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_87c7be99-f439-413d-9558-1badfea9c20c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_87c7be99-f439-413d-9558-1badfea9c20c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8506bbad-6390-448b-848c-84133dc737d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8506bbad-6390-448b-848c-84133dc737d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_eb0402f1-a809-4c97-8db3-094155cc2924" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_CommercialPaperMember_eb0402f1-a809-4c97-8db3-094155cc2924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_34948520-083b-49c0-b6f6-92afb156f586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_34948520-083b-49c0-b6f6-92afb156f586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_221ddaf5-65a1-405c-9908-1e0e29b48d60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_221ddaf5-65a1-405c-9908-1e0e29b48d60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f147a4df-78be-4d93-8846-5a907b7b1a44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f147a4df-78be-4d93-8846-5a907b7b1a44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5dde3821-0974-44fa-84d5-e71dc8ecf7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5dde3821-0974-44fa-84d5-e71dc8ecf7c0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i8a1444866afe4c54881fe79dea32d2fa_FinancialInstrumentsAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponents" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponents"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsComponents" xlink:type="extended" id="idea1dc1502af4f2aa4a78c7cef4ece39_BalanceSheetsComponents"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponentsTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="extended" id="i3e9676986a53480890d350ebb9e45e9f_BalanceSheetsComponentsTables"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponentsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails" xlink:type="extended" id="i5ea151a00e9246cf96e70e21ba3ae368_BalanceSheetsComponentsPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5a2c1e7b-0838-416a-96fa-6b00d211ef17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5a2c1e7b-0838-416a-96fa-6b00d211ef17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2dd22e9-179d-40e6-8fff-49b20ba1d8e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2dd22e9-179d-40e6-8fff-49b20ba1d8e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c27fa7a0-fac7-40d8-aaf9-f2c6a8f83b24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c27fa7a0-fac7-40d8-aaf9-f2c6a8f83b24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e6dedc8-4544-4256-8ae1-3c28c066284e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e6dedc8-4544-4256-8ae1-3c28c066284e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e6dedc8-4544-4256-8ae1-3c28c066284e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ff7df8a2-2b05-43bc-801b-1e62f85b7837" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ff7df8a2-2b05-43bc-801b-1e62f85b7837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_12418cc7-4584-4528-88ee-610b7933ccca" xlink:href="allo-20200331.xsd#allo_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_allo_LaboratoryEquipmentMember_12418cc7-4584-4528-88ee-610b7933ccca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_bab884fe-87b9-44d9-9416-5ba1df1005fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_us-gaap_ConstructionInProgressMember_bab884fe-87b9-44d9-9416-5ba1df1005fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_b1606c01-9471-40b5-8c19-645e891a0c88" xlink:href="allo-20200331.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_b1606c01-9471-40b5-8c19-645e891a0c88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d50d6b03-5034-4189-ac88-adaa7db2ad14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d50d6b03-5034-4189-ac88-adaa7db2ad14" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:type="simple" xlink:href="allo-20200331.xsd#LicenseAgreements"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended" id="i5a60a21af102485b88212df7ab33fd42_LicenseAgreements"/>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended" id="i79857a32c99a43bba80ed7aa111a4043_LicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_581442b6-94eb-4659-8c13-9e983dcd96d9" xlink:href="allo-20200331.xsd#allo_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_MilestonePayments_581442b6-94eb-4659-8c13-9e983dcd96d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_014df846-624e-4559-84c7-6d6680050b40" xlink:href="allo-20200331.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_014df846-624e-4559-84c7-6d6680050b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_552e86ea-688c-41e2-85b1-3ad4fc3902f7" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AggregatePotentialMilestonePayments_552e86ea-688c-41e2-85b1-3ad4fc3902f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_0d50c88d-62d5-486e-8d67-9317c2e214c6" xlink:href="allo-20200331.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_0d50c88d-62d5-486e-8d67-9317c2e214c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_9106ebe8-5edf-45ea-adf8-5c408d2acb4f" xlink:href="allo-20200331.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_9106ebe8-5edf-45ea-adf8-5c408d2acb4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49b12f53-e122-4ef0-9b54-927d1032b68b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49b12f53-e122-4ef0-9b54-927d1032b68b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_4867ce95-e444-4610-869b-25caf4a92c52" xlink:href="allo-20200331.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_4867ce95-e444-4610-869b-25caf4a92c52" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_207ae45a-65f5-4c5b-9041-42d802c6c10d" xlink:href="allo-20200331.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_207ae45a-65f5-4c5b-9041-42d802c6c10d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_348ef924-cc7d-46d2-8890-4289d4a5ca1b" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_b13c8d45-49d3-482e-b93b-7b54178f4e34" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AggregatePotentialMilestoneReceivable_b13c8d45-49d3-482e-b93b-7b54178f4e34" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecoveryOfResearchAndDevelopmentExpense_b5597ae6-7db9-47aa-99a2-0aff1dd996b2" xlink:href="allo-20200331.xsd#allo_RecoveryOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_RecoveryOfResearchAndDevelopmentExpense_b5597ae6-7db9-47aa-99a2-0aff1dd996b2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d327713c-852a-461d-81d3-c3dc26cbec28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_AccountsReceivableNet_d327713c-852a-461d-81d3-c3dc26cbec28" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_90aca6f5-c525-46eb-8902-2e4975b7030d" xlink:href="allo-20200331.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_90aca6f5-c525-46eb-8902-2e4975b7030d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment_5c0cdc33-fcdc-421b-bb6c-b20c3dabaa94" xlink:href="allo-20200331.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_CollaborationAgreementUpfrontPayment_5c0cdc33-fcdc-421b-bb6c-b20c3dabaa94" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_b0309c04-abe4-4b8e-b7a2-9efd70b9c22b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_b0309c04-abe4-4b8e-b7a2-9efd70b9c22b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_73d32e36-b2d3-425f-a969-e8bcedef08d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_73d32e36-b2d3-425f-a969-e8bcedef08d2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable_af5437a8-5b8e-49c4-9686-8ec96c819904" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AggregatePotentialMilestonePayable_af5437a8-5b8e-49c4-9686-8ec96c819904" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense_42d71eec-bad6-4154-844e-b99cdd073fce" xlink:href="allo-20200331.xsd#allo_CollaborationArrangementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_CollaborationArrangementExpense_42d71eec-bad6-4154-844e-b99cdd073fce" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d879bcae-b7f1-4bca-8fa2-f8f075613ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d879bcae-b7f1-4bca-8fa2-f8f075613ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d879bcae-b7f1-4bca-8fa2-f8f075613ce1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d879bcae-b7f1-4bca-8fa2-f8f075613ce1" xlink:to="loc_us-gaap_RelatedPartyDomain_d879bcae-b7f1-4bca-8fa2-f8f075613ce1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d879bcae-b7f1-4bca-8fa2-f8f075613ce1" xlink:to="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_0a54390f-5330-4056-8385-48ddd6092acd" xlink:href="allo-20200331.xsd#allo_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:to="loc_allo_PfizerIncMember_0a54390f-5330-4056-8385-48ddd6092acd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember_0176ed86-b5c1-4a53-a238-c79a3407de7c" xlink:href="allo-20200331.xsd#allo_CellectisSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:to="loc_allo_CellectisSAMember_0176ed86-b5c1-4a53-a238-c79a3407de7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember_68692457-0fe0-4730-b665-a28c6dd7c6de" xlink:href="allo-20200331.xsd#allo_ServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:to="loc_allo_ServierMember_68692457-0fe0-4730-b665-a28c6dd7c6de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_6d679463-ee7b-499d-be25-db60817b4c03" xlink:href="allo-20200331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:to="loc_allo_NotchTherapeuticsIncMember_6d679463-ee7b-499d-be25-db60817b4c03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis_ddadade0-d199-4160-a47f-417b3df736c6" xlink:href="allo-20200331.xsd#allo_MilestoneTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_allo_MilestoneTypeAxis_ddadade0-d199-4160-a47f-417b3df736c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_ddadade0-d199-4160-a47f-417b3df736c6_default" xlink:href="allo-20200331.xsd#allo_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_MilestoneTypeAxis_ddadade0-d199-4160-a47f-417b3df736c6" xlink:to="loc_allo_MilestoneTypeDomain_ddadade0-d199-4160-a47f-417b3df736c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_83f1dd5c-b107-4a7f-bad3-e7703a0ee307" xlink:href="allo-20200331.xsd#allo_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_MilestoneTypeAxis_ddadade0-d199-4160-a47f-417b3df736c6" xlink:to="loc_allo_MilestoneTypeDomain_83f1dd5c-b107-4a7f-bad3-e7703a0ee307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember_07ff0954-346a-4473-946c-09f79b7070a4" xlink:href="allo-20200331.xsd#allo_DevelopmentAndSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_MilestoneTypeDomain_83f1dd5c-b107-4a7f-bad3-e7703a0ee307" xlink:to="loc_allo_DevelopmentAndSalesMember_07ff0954-346a-4473-946c-09f79b7070a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_129d5112-880e-4f28-bfb6-9dceb470bf4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_129d5112-880e-4f28-bfb6-9dceb470bf4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_129d5112-880e-4f28-bfb6-9dceb470bf4a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_129d5112-880e-4f28-bfb6-9dceb470bf4a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_129d5112-880e-4f28-bfb6-9dceb470bf4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_129d5112-880e-4f28-bfb6-9dceb470bf4a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_c2f57446-7483-4c68-bd47-04eda9367087" xlink:href="allo-20200331.xsd#allo_AssetContributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_AssetContributionAgreementMember_c2f57446-7483-4c68-bd47-04eda9367087" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember_b459f2ee-b0b8-435d-aee3-4659c55a857a" xlink:href="allo-20200331.xsd#allo_RegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_RegulatoryMilestoneMember_b459f2ee-b0b8-435d-aee3-4659c55a857a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchServicesMember_f77cf1c5-bdf8-493d-9a5b-9938a7e2d6e4" xlink:href="allo-20200331.xsd#allo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_ResearchServicesMember_f77cf1c5-bdf8-493d-9a5b-9938a7e2d6e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember_5f645e61-8e33-4854-a069-c9525985344d" xlink:href="allo-20200331.xsd#allo_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_SalesMilestoneMember_5f645e61-8e33-4854-a069-c9525985344d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_9b7391b2-d897-474c-a33a-14bbc7cafc2d" xlink:href="allo-20200331.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_9b7391b2-d897-474c-a33a-14bbc7cafc2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_11916da2-5c30-4549-b246-5f0b03b62669" xlink:href="allo-20200331.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_11916da2-5c30-4549-b246-5f0b03b62669" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bd21aaa6-51bc-4957-baa0-efbae81dfb27" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_srt_RangeAxis_bd21aaa6-51bc-4957-baa0-efbae81dfb27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd21aaa6-51bc-4957-baa0-efbae81dfb27_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bd21aaa6-51bc-4957-baa0-efbae81dfb27" xlink:to="loc_srt_RangeMember_bd21aaa6-51bc-4957-baa0-efbae81dfb27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51dc16b0-c346-4169-80a3-7d5e485a8a0a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bd21aaa6-51bc-4957-baa0-efbae81dfb27" xlink:to="loc_srt_RangeMember_51dc16b0-c346-4169-80a3-7d5e485a8a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bc1afbc-8983-4823-94ca-ad2c175346bc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51dc16b0-c346-4169-80a3-7d5e485a8a0a" xlink:to="loc_srt_MinimumMember_3bc1afbc-8983-4823-94ca-ad2c175346bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d8e758a-302a-4965-8483-96f4daee81a5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51dc16b0-c346-4169-80a3-7d5e485a8a0a" xlink:to="loc_srt_MaximumMember_9d8e758a-302a-4965-8483-96f4daee81a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ce8d385a-5190-4767-b65c-f988d0be3169" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ce8d385a-5190-4767-b65c-f988d0be3169" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce8d385a-5190-4767-b65c-f988d0be3169_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce8d385a-5190-4767-b65c-f988d0be3169" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce8d385a-5190-4767-b65c-f988d0be3169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99f050cd-8e4d-4a4d-b999-7965ae803c86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce8d385a-5190-4767-b65c-f988d0be3169" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99f050cd-8e4d-4a4d-b999-7965ae803c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_7f7a65db-b7d5-4ab6-bc72-3950042987af" xlink:href="allo-20200331.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99f050cd-8e4d-4a4d-b999-7965ae803c86" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_7f7a65db-b7d5-4ab6-bc72-3950042987af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_c15e5d6e-bd66-450b-96f7-3878d6f164a5" xlink:href="allo-20200331.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99f050cd-8e4d-4a4d-b999-7965ae803c86" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_c15e5d6e-bd66-450b-96f7-3878d6f164a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969b2468-7342-43e1-8c3b-b630064bc114" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969b2468-7342-43e1-8c3b-b630064bc114" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_969b2468-7342-43e1-8c3b-b630064bc114_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969b2468-7342-43e1-8c3b-b630064bc114" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_969b2468-7342-43e1-8c3b-b630064bc114_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_209f8f5d-f4f2-4e75-b678-3e22dd1372f9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969b2468-7342-43e1-8c3b-b630064bc114" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_209f8f5d-f4f2-4e75-b678-3e22dd1372f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_3cd779ce-9e32-4334-9ba5-e73763d95f10" xlink:href="allo-20200331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_209f8f5d-f4f2-4e75-b678-3e22dd1372f9" xlink:to="loc_allo_NotchTherapeuticsIncMember_3cd779ce-9e32-4334-9ba5-e73763d95f10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0388e822-3744-4031-b5fa-320b551552d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0388e822-3744-4031-b5fa-320b551552d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0388e822-3744-4031-b5fa-320b551552d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0388e822-3744-4031-b5fa-320b551552d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0388e822-3744-4031-b5fa-320b551552d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_521a89ef-6456-43c0-87c3-d14784b719e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0388e822-3744-4031-b5fa-320b551552d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_521a89ef-6456-43c0-87c3-d14784b719e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1669da13-537a-429e-8a01-28e6931d9e23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_521a89ef-6456-43c0-87c3-d14784b719e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1669da13-537a-429e-8a01-28e6931d9e23" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended" id="i9f4ff46986024228a7ed1787c70d5903_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="icd71aa76f0b54d2a9e8785d9e16e6c92_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i7f2437a3a85a4d47bfb4e8c05beb5e1f_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_f1f33578-3b94-4d87-95ad-9bbdbc99a4a5" xlink:href="allo-20200331.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_allo_AreaOfNewOfficeBuilding_f1f33578-3b94-4d87-95ad-9bbdbc99a4a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_134d43f3-13fd-4f84-95c8-a4c2005642c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_134d43f3-13fd-4f84-95c8-a4c2005642c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllowanceForTenantImprovements_580a13b6-b6ce-4a53-b03b-0f4c9b6769ea" xlink:href="allo-20200331.xsd#allo_AllowanceForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_allo_AllowanceForTenantImprovements_580a13b6-b6ce-4a53-b03b-0f4c9b6769ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dbc4d2ee-0cf6-4e99-ae2a-7ac841c9530d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dbc4d2ee-0cf6-4e99-ae2a-7ac841c9530d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease_3573620e-cbf2-4800-9032-5b7a03a8c96a" xlink:href="allo-20200331.xsd#allo_AreaOfOperatingLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_allo_AreaOfOperatingLease_3573620e-cbf2-4800-9032-5b7a03a8c96a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease_a5087e1c-4cba-4f9c-8ad1-e2eb223abcfa" xlink:href="allo-20200331.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_allo_NumberOfOptionsToExtendLease_a5087e1c-4cba-4f9c-8ad1-e2eb223abcfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8ff484f5-240a-4872-ad15-42fd1991ec2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8ff484f5-240a-4872-ad15-42fd1991ec2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ddbf2e02-a61f-4938-bd8a-1d73671c0ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_OperatingLeasePayments_ddbf2e02-a61f-4938-bd8a-1d73671c0ff0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c31e766d-8303-4861-9f60-f0f15a5d74d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c31e766d-8303-4861-9f60-f0f15a5d74d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cfee1ffe-b226-4796-8952-3a450e56bcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cfee1ffe-b226-4796-8952-3a450e56bcc8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_fbb258d4-b3d6-4047-82fe-2485e7bc6bba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_fbb258d4-b3d6-4047-82fe-2485e7bc6bba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_1dd8418b-4891-486b-8801-38007f30283d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_1dd8418b-4891-486b-8801-38007f30283d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_1dd8418b-4891-486b-8801-38007f30283d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_1dd8418b-4891-486b-8801-38007f30283d" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_1dd8418b-4891-486b-8801-38007f30283d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_40d3ad52-6e49-4dc4-bffc-e56ef64a3dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_1dd8418b-4891-486b-8801-38007f30283d" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_40d3ad52-6e49-4dc4-bffc-e56ef64a3dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneMember_686cb099-007a-4d05-a48a-9354812a2cf5" xlink:href="allo-20200331.xsd#allo_LeaseOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_40d3ad52-6e49-4dc4-bffc-e56ef64a3dc1" xlink:to="loc_allo_LeaseOneMember_686cb099-007a-4d05-a48a-9354812a2cf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember_9ac62173-250a-4dd0-baa6-99c9c7578c99" xlink:href="allo-20200331.xsd#allo_LeaseTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_40d3ad52-6e49-4dc4-bffc-e56ef64a3dc1" xlink:to="loc_allo_LeaseTwoMember_9ac62173-250a-4dd0-baa6-99c9c7578c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_130fed07-d209-4a4d-8ce8-3604abd342a8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:to="loc_srt_StatementGeographicalAxis_130fed07-d209-4a4d-8ce8-3604abd342a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_130fed07-d209-4a4d-8ce8-3604abd342a8_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_130fed07-d209-4a4d-8ce8-3604abd342a8" xlink:to="loc_srt_SegmentGeographicalDomain_130fed07-d209-4a4d-8ce8-3604abd342a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0017cc0c-9f10-40a4-9db7-893df5946f39" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_130fed07-d209-4a4d-8ce8-3604abd342a8" xlink:to="loc_srt_SegmentGeographicalDomain_0017cc0c-9f10-40a4-9db7-893df5946f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember_3c47b8ef-2776-48c0-ac9f-0ff1464bd408" xlink:href="allo-20200331.xsd#allo_NewarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0017cc0c-9f10-40a4-9db7-893df5946f39" xlink:to="loc_allo_NewarkMember_3c47b8ef-2776-48c0-ac9f-0ff1464bd408" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="extended" id="ie91866e5aa0d412fb9c694a5bf992e86_CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="extended" id="i7696e2fc571449ce9034a9df4d539a42_CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended" id="i58250cfdbfc5473388428abf4ad80be6_CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20200331.xsd#EquityMethodInvestment"/>
  <link:definitionLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended" id="i3e5bd183162b49388819a7ab230a80e6_EquityMethodInvestment"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#EquityMethodInvestmentDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended" id="i13d7a90d92344dc294269ce003be5eff_EquityMethodInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_000c9ede-26d5-4766-acba-70683f0f02f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_000c9ede-26d5-4766-acba-70683f0f02f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts_00b0bc61-495d-4d52-aa53-87dbe95d9536" xlink:href="allo-20200331.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_allo_CostMethodInvestmentTransactionCosts_00b0bc61-495d-4d52-aa53-87dbe95d9536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4c5ec49f-f7e3-4f73-b31f-1b8f6d317f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4c5ec49f-f7e3-4f73-b31f-1b8f6d317f8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_1806b77d-88fc-4e25-af28-d1fd89393143" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_1806b77d-88fc-4e25-af28-d1fd89393143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_7458198a-fb32-48cf-a10a-981e337acf81" xlink:href="allo-20200331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_7458198a-fb32-48cf-a10a-981e337acf81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f383ea6-37da-476e-95b7-57c94568b2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f383ea6-37da-476e-95b7-57c94568b2fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f383ea6-37da-476e-95b7-57c94568b2fa" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1daf13ad-41fb-4792-8bbd-a8d943a83c9f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1daf13ad-41fb-4792-8bbd-a8d943a83c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_c6a25c0d-7e70-468e-b1b4-f05f12030d9f" xlink:href="allo-20200331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1daf13ad-41fb-4792-8bbd-a8d943a83c9f" xlink:to="loc_allo_NotchTherapeuticsIncMember_c6a25c0d-7e70-468e-b1b4-f05f12030d9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended" id="id9d3266ea16a41eaacbe9ecfb13956c9_StockBasedCompensation"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended" id="i2b1ff3ef8e3f42b1921f3ffe7c0f4308_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="ia63e715e3732429486f6c693307c2f4c_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_df8b9728-2083-4058-b966-92e9ffe9365e" xlink:href="allo-20200331.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_df8b9728-2083-4058-b966-92e9ffe9365e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod_9b075cb9-b107-4be1-9db4-62d2c072a54f" xlink:href="allo-20200331.xsd#allo_StockOptionGrantedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_allo_StockOptionGrantedPeriod_9b075cb9-b107-4be1-9db4-62d2c072a54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_617789bf-fcc4-4a14-8ffd-9a4009a2e288" xlink:href="allo-20200331.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_617789bf-fcc4-4a14-8ffd-9a4009a2e288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d5d1725d-8298-450d-a877-d0a6814c2deb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d5d1725d-8298-450d-a877-d0a6814c2deb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_439b63b6-4568-47a8-970e-fa54e10ce14f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_439b63b6-4568-47a8-970e-fa54e10ce14f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbdcf3b4-6074-4ee0-a557-7a7659a87318" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbdcf3b4-6074-4ee0-a557-7a7659a87318" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bcd5e46d-7e30-4065-af16-222d8214429b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bcd5e46d-7e30-4065-af16-222d8214429b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_50bf5c3d-a171-4542-85c4-4af36bc2a667" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_50bf5c3d-a171-4542-85c4-4af36bc2a667" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_369cec48-932e-4524-a55b-a8b6568a31ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_369cec48-932e-4524-a55b-a8b6568a31ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_ea3ed921-c061-4ee0-bfab-d9f12861ac49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_ea3ed921-c061-4ee0-bfab-d9f12861ac49" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9047cf68-61a0-4a11-9a84-a7256e219148" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:to="loc_srt_RangeAxis_9047cf68-61a0-4a11-9a84-a7256e219148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9047cf68-61a0-4a11-9a84-a7256e219148_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9047cf68-61a0-4a11-9a84-a7256e219148" xlink:to="loc_srt_RangeMember_9047cf68-61a0-4a11-9a84-a7256e219148_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d56b0436-1764-485a-9835-fdf370a9752a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9047cf68-61a0-4a11-9a84-a7256e219148" xlink:to="loc_srt_RangeMember_d56b0436-1764-485a-9835-fdf370a9752a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a3fa48a5-2130-4f54-8f0a-1edc8dd169f1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d56b0436-1764-485a-9835-fdf370a9752a" xlink:to="loc_srt_MaximumMember_a3fa48a5-2130-4f54-8f0a-1edc8dd169f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c16a9809-847d-4a5d-8754-ea71048d82c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:to="loc_us-gaap_AwardTypeAxis_c16a9809-847d-4a5d-8754-ea71048d82c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c16a9809-847d-4a5d-8754-ea71048d82c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c16a9809-847d-4a5d-8754-ea71048d82c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c16a9809-847d-4a5d-8754-ea71048d82c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c16a9809-847d-4a5d-8754-ea71048d82c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_124fd63c-278e-45ca-bdcb-520a47a01262" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:to="loc_us-gaap_StockOptionMember_124fd63c-278e-45ca-bdcb-520a47a01262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4798d2ab-c3d2-4b4d-b9bc-e9e2ada78dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4798d2ab-c3d2-4b4d-b9bc-e9e2ada78dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0a772334-8f2e-480a-be75-c34922fee584" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0a772334-8f2e-480a-be75-c34922fee584" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="id1c4e76d045a48c298108dc3e500c689_StockBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17f2aa2b-188a-4300-be3a-2375676d0673" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17f2aa2b-188a-4300-be3a-2375676d0673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5a746db3-b0b8-4928-90d1-e185337fcffa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5a746db3-b0b8-4928-90d1-e185337fcffa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_333169df-fa07-439d-bc77-24d8fdd45073" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_333169df-fa07-439d-bc77-24d8fdd45073" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8cff8426-79d2-44e9-9efd-7882c82e7818" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8cff8426-79d2-44e9-9efd-7882c82e7818" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7b063064-1982-4c22-8402-692c8fce0d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a994b38a-52bb-4f90-97a1-e8e820ec0c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a994b38a-52bb-4f90-97a1-e8e820ec0c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9d39f934-106f-42d1-9df3-f8c1810c0127" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9d39f934-106f-42d1-9df3-f8c1810c0127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6d977eb-0420-40f3-b3f4-0ab242a456f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6d977eb-0420-40f3-b3f4-0ab242a456f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6084d6da-2878-4ce8-8909-8ca70b8ad27d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6084d6da-2878-4ce8-8909-8ca70b8ad27d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e8793164-12eb-4491-9b28-c2b1e396cc43" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e8793164-12eb-4491-9b28-c2b1e396cc43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_89520bc1-2da9-42b4-be5f-d58a4e5896d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_89520bc1-2da9-42b4-be5f-d58a4e5896d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635dfba0-2d7c-4cbb-a44f-eb9e33e62fde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5ec4b363-3674-4ec2-9da2-3a1e45d42af5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5ec4b363-3674-4ec2-9da2-3a1e45d42af5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f001e363-0cb5-4f78-9805-c0580503bb76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f001e363-0cb5-4f78-9805-c0580503bb76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ec452e29-2bdd-4c24-89be-f25c0d0a27d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ec452e29-2bdd-4c24-89be-f25c0d0a27d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2b82f7a0-3954-406f-ae07-0efc60c1fb1c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2b82f7a0-3954-406f-ae07-0efc60c1fb1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_09e9a259-8d06-4ce9-a842-caeb6d7109a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_09e9a259-8d06-4ce9-a842-caeb6d7109a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2470472f-aede-4fbe-b55c-1d38664232b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2470472f-aede-4fbe-b55c-1d38664232b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c3082457-a076-463c-9221-7b60b383e9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c3082457-a076-463c-9221-7b60b383e9ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e343f35b-8294-4ab0-ba0d-d87303f082ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e343f35b-8294-4ab0-ba0d-d87303f082ca" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99f48316-22a0-4d35-a37e-1ba7a78390a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99f48316-22a0-4d35-a37e-1ba7a78390a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ae83ebf7-202e-441e-8295-47dec6318629" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99f48316-22a0-4d35-a37e-1ba7a78390a3" xlink:to="loc_us-gaap_AwardTypeAxis_ae83ebf7-202e-441e-8295-47dec6318629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae83ebf7-202e-441e-8295-47dec6318629_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ae83ebf7-202e-441e-8295-47dec6318629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae83ebf7-202e-441e-8295-47dec6318629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9f4666b-0dea-4ba8-8a23-f17ccdca7375" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ae83ebf7-202e-441e-8295-47dec6318629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9f4666b-0dea-4ba8-8a23-f17ccdca7375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_49dd4a12-adcf-4f18-af06-270cb046cead" xlink:href="allo-20200331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9f4666b-0dea-4ba8-8a23-f17ccdca7375" xlink:to="loc_allo_TwoThousandEighteenPlanMember_49dd4a12-adcf-4f18-af06-270cb046cead" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="extended" id="i38707ae813ff4e2d9a69682040744a3f_StockBasedCompensationValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7eeafd05-5277-4930-964a-557ea5c595d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7eeafd05-5277-4930-964a-557ea5c595d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cf6ff33-68cd-4fbb-a515-0c4c17ef9401" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cf6ff33-68cd-4fbb-a515-0c4c17ef9401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_4d45bb9b-e4e0-4145-8561-f0ad9d0c5962" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_4d45bb9b-e4e0-4145-8561-f0ad9d0c5962" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5de3f111-057d-4c76-95a8-2956bf098fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5de3f111-057d-4c76-95a8-2956bf098fc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a1f38949-9168-4d3d-b3e2-488abe7c63e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a1f38949-9168-4d3d-b3e2-488abe7c63e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7f41212b-38bd-40db-b0b0-7ac348ac8b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:to="loc_us-gaap_AwardTypeAxis_7f41212b-38bd-40db-b0b0-7ac348ac8b0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f41212b-38bd-40db-b0b0-7ac348ac8b0b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7f41212b-38bd-40db-b0b0-7ac348ac8b0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f41212b-38bd-40db-b0b0-7ac348ac8b0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab328702-4671-4016-8621-941eaa6a433c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7f41212b-38bd-40db-b0b0-7ac348ac8b0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab328702-4671-4016-8621-941eaa6a433c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_5ca23818-b2c6-4bb8-904e-4c849e6a071e" xlink:href="allo-20200331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab328702-4671-4016-8621-941eaa6a433c" xlink:to="loc_allo_TwoThousandEighteenPlanMember_5ca23818-b2c6-4bb8-904e-4c849e6a071e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d0e83412-c477-4b1e-980c-86789d50113a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:to="loc_srt_RangeAxis_d0e83412-c477-4b1e-980c-86789d50113a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0e83412-c477-4b1e-980c-86789d50113a_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d0e83412-c477-4b1e-980c-86789d50113a" xlink:to="loc_srt_RangeMember_d0e83412-c477-4b1e-980c-86789d50113a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5d45e53-2c6c-4e72-a8a9-c7d90d629f4c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d0e83412-c477-4b1e-980c-86789d50113a" xlink:to="loc_srt_RangeMember_c5d45e53-2c6c-4e72-a8a9-c7d90d629f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_98e5f809-54ee-4d66-a600-fa08eaad3bd5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5d45e53-2c6c-4e72-a8a9-c7d90d629f4c" xlink:to="loc_srt_MinimumMember_98e5f809-54ee-4d66-a600-fa08eaad3bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_be289c81-7502-45d1-ab86-3a1590e3ce37" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5d45e53-2c6c-4e72-a8a9-c7d90d629f4c" xlink:to="loc_srt_MaximumMember_be289c81-7502-45d1-ab86-3a1590e3ce37" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended" id="ide9bc92b1f554451af1f00912e498eff_StockBasedCompensationRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_899aa065-6283-454d-a020-cbd0a8bb483e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_899aa065-6283-454d-a020-cbd0a8bb483e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bebc980-7459-4829-b245-db991d0d5ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bebc980-7459-4829-b245-db991d0d5ec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_290edb37-3fe9-4696-8ccb-f1b051bc1350" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_290edb37-3fe9-4696-8ccb-f1b051bc1350" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0217e53a-bd6c-495b-952e-6aa3200c8d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0217e53a-bd6c-495b-952e-6aa3200c8d6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a8c4c110-133e-4880-8677-f6c60628a56d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_14980822-2c6b-4eb3-932f-7bbe141ea95b" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_14980822-2c6b-4eb3-932f-7bbe141ea95b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95b10b34-cb6a-4012-b733-5efd87c03626" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95b10b34-cb6a-4012-b733-5efd87c03626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c113c424-64f7-4e56-9f38-39452c63e373" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c113c424-64f7-4e56-9f38-39452c63e373" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e8d0bff3-6f48-4f5c-b88d-46cef18ed3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e8d0bff3-6f48-4f5c-b88d-46cef18ed3ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e9e9c0fc-83f2-4ef0-b84d-7cef33958f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e9e9c0fc-83f2-4ef0-b84d-7cef33958f5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8abf7695-d96f-4740-8305-fb3d80669600" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7af80f7e-df72-4850-a383-867fe1306e39" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7af80f7e-df72-4850-a383-867fe1306e39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c252a3a6-f26c-459b-9321-50d8cbfccf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c252a3a6-f26c-459b-9321-50d8cbfccf7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_fbedd3be-55c7-4b36-825e-623f125a44f4" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_fbedd3be-55c7-4b36-825e-623f125a44f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_42211c64-459f-4f30-bc27-9a4dd51dcc89" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_42211c64-459f-4f30-bc27-9a4dd51dcc89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4fd81501-f98c-40d5-a6d2-0f44a3e1e732" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4fd81501-f98c-40d5-a6d2-0f44a3e1e732" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_a1c92f51-be42-487e-a90f-bda5923b0129" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_a1c92f51-be42-487e-a90f-bda5923b0129" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24563ac3-0e0d-4127-9cd1-1949ddef9425" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24563ac3-0e0d-4127-9cd1-1949ddef9425" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_718f3c4f-6c65-4422-b891-2e22243ac730" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24563ac3-0e0d-4127-9cd1-1949ddef9425" xlink:to="loc_us-gaap_AwardTypeAxis_718f3c4f-6c65-4422-b891-2e22243ac730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_718f3c4f-6c65-4422-b891-2e22243ac730_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_718f3c4f-6c65-4422-b891-2e22243ac730" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_718f3c4f-6c65-4422-b891-2e22243ac730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed68a152-f606-43f4-9a0f-279c5dc8522e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_718f3c4f-6c65-4422-b891-2e22243ac730" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed68a152-f606-43f4-9a0f-279c5dc8522e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8e0dd919-7f07-4932-8be3-dea28a5911ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed68a152-f606-43f4-9a0f-279c5dc8522e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8e0dd919-7f07-4932-8be3-dea28a5911ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended" id="i7bbcaaa6c4874b64add3cc0fa64dfe16_StockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_88909549-8a2f-4a88-9385-e507e1e159dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9ffa15b-eeb3-4f97-bf33-111719143653" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_88909549-8a2f-4a88-9385-e507e1e159dd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9ffa15b-eeb3-4f97-bf33-111719143653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_19e68a4e-f1ec-4aa7-93b8-04318556b168" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_88909549-8a2f-4a88-9385-e507e1e159dd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_19e68a4e-f1ec-4aa7-93b8-04318556b168" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e8b073fe-c552-47bb-8b57-bc3209bdc839" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_19e68a4e-f1ec-4aa7-93b8-04318556b168" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e8b073fe-c552-47bb-8b57-bc3209bdc839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e8b073fe-c552-47bb-8b57-bc3209bdc839_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8b073fe-c552-47bb-8b57-bc3209bdc839" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e8b073fe-c552-47bb-8b57-bc3209bdc839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3a8c7f0b-aeba-47c6-b7e3-9a52c6577262" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8b073fe-c552-47bb-8b57-bc3209bdc839" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3a8c7f0b-aeba-47c6-b7e3-9a52c6577262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37bce362-96db-4793-860b-229793592f36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a8c7f0b-aeba-47c6-b7e3-9a52c6577262" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37bce362-96db-4793-860b-229793592f36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac94f87c-7022-4e89-83ea-c85a2de77af8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a8c7f0b-aeba-47c6-b7e3-9a52c6577262" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac94f87c-7022-4e89-83ea-c85a2de77af8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20200331.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended" id="i8182fd152f0542138938ebad3ea93bf8_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i4828a196883b45b780ae2be93ff01e60_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_91cc5dcd-924d-4b49-a6ba-0034b276e330" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_91cc5dcd-924d-4b49-a6ba-0034b276e330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts_a0d9d541-5ba1-40c2-859a-4e86efd72a84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_RelatedPartyCosts_a0d9d541-5ba1-40c2-859a-4e86efd72a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_e8fd18ac-1cd1-43e8-a96b-330e17b0c6de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_SuppliesExpense_e8fd18ac-1cd1-43e8-a96b-330e17b0c6de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_c5da8135-63b1-4869-88e4-4d7978a20a68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_c5da8135-63b1-4869-88e4-4d7978a20a68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice_c663eb44-a85e-4000-8a7f-8d41a9d238a2" xlink:href="allo-20200331.xsd#allo_AreaOfOffice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_allo_AreaOfOffice_c663eb44-a85e-4000-8a7f-8d41a9d238a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_1fe87e3d-6c18-480e-978c-fd4acceea99e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_1fe87e3d-6c18-480e-978c-fd4acceea99e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_1df8cdd1-8903-4b2b-95de-0f072b0401ba" xlink:href="allo-20200331.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_1df8cdd1-8903-4b2b-95de-0f072b0401ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_092ba755-2c19-4965-92a9-498e58c546bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_SubleaseIncome_092ba755-2c19-4965-92a9-498e58c546bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_cbce56da-6b17-4d7a-a56c-4887954cfaf9" xlink:href="allo-20200331.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_cbce56da-6b17-4d7a-a56c-4887954cfaf9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_f01edcde-0448-4f55-93f4-1058bf074e6e" xlink:href="allo-20200331.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_f01edcde-0448-4f55-93f4-1058bf074e6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_54cc864d-4d36-4db2-b4d4-ef2000842faf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_54cc864d-4d36-4db2-b4d4-ef2000842faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_54cc864d-4d36-4db2-b4d4-ef2000842faf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_54cc864d-4d36-4db2-b4d4-ef2000842faf" xlink:to="loc_us-gaap_RelatedPartyDomain_54cc864d-4d36-4db2-b4d4-ef2000842faf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_54cc864d-4d36-4db2-b4d4-ef2000842faf" xlink:to="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_723b4793-e1b0-4b9c-82b7-d7bf69f525f5" xlink:href="allo-20200331.xsd#allo_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:to="loc_allo_PfizerIncMember_723b4793-e1b0-4b9c-82b7-d7bf69f525f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ByHeartIncMember_f944b290-3044-4bf4-9b11-67951f0528d1" xlink:href="allo-20200331.xsd#allo_ByHeartIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:to="loc_allo_ByHeartIncMember_f944b290-3044-4bf4-9b11-67951f0528d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember_dfd3130e-30b3-4c37-9a83-4624f78df112" xlink:href="allo-20200331.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:to="loc_allo_TwoRiverConsultingLLCMember_dfd3130e-30b3-4c37-9a83-4624f78df112" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember_0d887183-3f15-4f3b-988c-4517731e8c6b" xlink:href="allo-20200331.xsd#allo_BellcoCapitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:to="loc_allo_BellcoCapitalLLCMember_0d887183-3f15-4f3b-988c-4517731e8c6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_18f9b537-5eea-477d-85fe-06f9f9a6f5a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_18f9b537-5eea-477d-85fe-06f9f9a6f5a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_18f9b537-5eea-477d-85fe-06f9f9a6f5a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_18f9b537-5eea-477d-85fe-06f9f9a6f5a0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_18f9b537-5eea-477d-85fe-06f9f9a6f5a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_18f9b537-5eea-477d-85fe-06f9f9a6f5a0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TransitionServicesAgreementMember_3f575f81-4172-4eea-9af4-e69edba944c1" xlink:href="allo-20200331.xsd#allo_TransitionServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:to="loc_allo_TransitionServicesAgreementMember_3f575f81-4172-4eea-9af4-e69edba944c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember_b8e7c8e4-4a3d-4f85-98d3-8207ba77c50e" xlink:href="allo-20200331.xsd#allo_SubleaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:to="loc_allo_SubleaseAgreementMember_b8e7c8e4-4a3d-4f85-98d3-8207ba77c50e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember_b0d1d710-b43a-489a-b502-33dc0aac8ff1" xlink:href="allo-20200331.xsd#allo_ConsultingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:to="loc_allo_ConsultingAgreementsMember_b0d1d710-b43a-489a-b502-33dc0aac8ff1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f2c702ae-5776-42c2-808f-2a7016ed3b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f2c702ae-5776-42c2-808f-2a7016ed3b0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f2c702ae-5776-42c2-808f-2a7016ed3b0c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2c702ae-5776-42c2-808f-2a7016ed3b0c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f2c702ae-5776-42c2-808f-2a7016ed3b0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2d52f04-2792-4364-9b41-3db94586834b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2c702ae-5776-42c2-808f-2a7016ed3b0c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2d52f04-2792-4364-9b41-3db94586834b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1402ca1f-4bc6-4ce2-bad0-854196acb8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2d52f04-2792-4364-9b41-3db94586834b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1402ca1f-4bc6-4ce2-bad0-854196acb8d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cafa08af-c4e2-4e4a-8daf-3f396b550e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cafa08af-c4e2-4e4a-8daf-3f396b550e3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cafa08af-c4e2-4e4a-8daf-3f396b550e3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cafa08af-c4e2-4e4a-8daf-3f396b550e3f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cafa08af-c4e2-4e4a-8daf-3f396b550e3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1e187cb7-bc81-47d9-80fb-622e7c777aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cafa08af-c4e2-4e4a-8daf-3f396b550e3f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1e187cb7-bc81-47d9-80fb-622e7c777aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_f48fcacc-a714-4420-aeb1-e3d58218a542" xlink:href="allo-20200331.xsd#allo_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1e187cb7-bc81-47d9-80fb-622e7c777aa8" xlink:to="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_f48fcacc-a714-4420-aeb1-e3d58218a542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a2f1abfd-3ef7-4796-b78b-f81d8e247c74" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_srt_RangeAxis_a2f1abfd-3ef7-4796-b78b-f81d8e247c74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2f1abfd-3ef7-4796-b78b-f81d8e247c74_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a2f1abfd-3ef7-4796-b78b-f81d8e247c74" xlink:to="loc_srt_RangeMember_a2f1abfd-3ef7-4796-b78b-f81d8e247c74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6394069b-b833-4373-a737-4c1a09f2ad3f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a2f1abfd-3ef7-4796-b78b-f81d8e247c74" xlink:to="loc_srt_RangeMember_6394069b-b833-4373-a737-4c1a09f2ad3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87a30df6-ab6e-45df-87de-3ed246ba9495" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6394069b-b833-4373-a737-4c1a09f2ad3f" xlink:to="loc_srt_MaximumMember_87a30df6-ab6e-45df-87de-3ed246ba9495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis_9b24e6dc-aa03-41b3-a282-1e29196cc0fd" xlink:href="allo-20200331.xsd#allo_PaymentTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_allo_PaymentTermsAxis_9b24e6dc-aa03-41b3-a282-1e29196cc0fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_9b24e6dc-aa03-41b3-a282-1e29196cc0fd_default" xlink:href="allo-20200331.xsd#allo_PaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_PaymentTermsAxis_9b24e6dc-aa03-41b3-a282-1e29196cc0fd" xlink:to="loc_allo_PaymentTermsDomain_9b24e6dc-aa03-41b3-a282-1e29196cc0fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_80c54cc4-06d3-4cdf-947a-e9481657af74" xlink:href="allo-20200331.xsd#allo_PaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_PaymentTermsAxis_9b24e6dc-aa03-41b3-a282-1e29196cc0fd" xlink:to="loc_allo_PaymentTermsDomain_80c54cc4-06d3-4cdf-947a-e9481657af74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2019Member_74344b97-d037-4d10-b010-565fbb2984ac" xlink:href="allo-20200331.xsd#allo_PaymentsCommencingJanuary2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_PaymentTermsDomain_80c54cc4-06d3-4cdf-947a-e9481657af74" xlink:to="loc_allo_PaymentsCommencingJanuary2019Member_74344b97-d037-4d10-b010-565fbb2984ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2020Member_28c3293d-95a4-4566-9b95-5c2d85ad9231" xlink:href="allo-20200331.xsd#allo_PaymentsCommencingJanuary2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_PaymentTermsDomain_80c54cc4-06d3-4cdf-947a-e9481657af74" xlink:to="loc_allo_PaymentsCommencingJanuary2020Member_28c3293d-95a4-4566-9b95-5c2d85ad9231" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20200331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended" id="ic57cf62993704449bc9f3a105c2bc301_IncomeTaxes"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended" id="i32f5d2285071437fa25a5447d3a20d33_NetLossPerShare"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended" id="i241621827ec64dae8aebe9744630794f_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended" id="i755cf982912c4058a2f7a1955680e636_NetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b3858bc-242b-454f-aab9-b75dacf3ebb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48796fa7-6c15-47f2-a7eb-88bc87325b74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b3858bc-242b-454f-aab9-b75dacf3ebb7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48796fa7-6c15-47f2-a7eb-88bc87325b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_00719178-5ba7-474f-a938-2ad9134020c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b3858bc-242b-454f-aab9-b75dacf3ebb7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_00719178-5ba7-474f-a938-2ad9134020c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2a388cb0-bee6-436a-a224-1c9697f0969f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_00719178-5ba7-474f-a938-2ad9134020c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2a388cb0-bee6-436a-a224-1c9697f0969f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a388cb0-bee6-436a-a224-1c9697f0969f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2a388cb0-bee6-436a-a224-1c9697f0969f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a388cb0-bee6-436a-a224-1c9697f0969f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2a388cb0-bee6-436a-a224-1c9697f0969f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ac6fd47-c2a6-40cf-8b31-1a20aa493d88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ac6fd47-c2a6-40cf-8b31-1a20aa493d88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b240909d-3039-4e3c-93e6-b4f2bead0d09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b240909d-3039-4e3c-93e6-b4f2bead0d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_365033d7-0a15-469d-ae63-0a6838fba87e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_us-gaap_EmployeeStockMember_365033d7-0a15-469d-ae63-0a6838fba87e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember_87516dc5-a09b-4945-b4ca-3f37ef720c75" xlink:href="allo-20200331.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_allo_FounderSharesOfCommonStockMember_87516dc5-a09b-4945-b4ca-3f37ef720c75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_e8aed560-5450-4407-bc2e-5e6e5b2100c9" xlink:href="allo-20200331.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_e8aed560-5450-4407-bc2e-5e6e5b2100c9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20200331.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended" id="i660a8347a7ff44ab9d023ef7701764cd_SubsequentEvents"/>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended" id="if591d6a189674b7484caf37f0bf78655_SubsequentEventsDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>allo-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:57bc89fc-7004-4307-9757-f5809462a759,g:be24e03f-ee2b-47ea-87e1-15803658ae8d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_f1993dbf-6135-4b01-b56e-20f26f6196f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_3e7f106f-4d7d-4ff5-896f-69c8b8a4a4b3_terseLabel_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_label_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Significant Accounting Policies Policy [Text Block]</link:label>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" xlink:href="allo-20200331.xsd#allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" xlink:to="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f49e27cf-ee89-406b-83ac-d9ab5f82ad7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_df7f8bc0-cc75-4c49-86fe-cbb184412a4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining contractual maturities of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_581d5338-0cf4-4bb8-9ad4-74ed57421d2b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fc4158f6-1ca9-41d1-9b78-d09ba63afad5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5dc8c937-0717-4be9-bff3-401a97cad654_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_27c5fa17-ccb1-4c11-bc6f-e23b0956e9db_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48602c30-a993-48d5-b372-c19cd1e66f83_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c206fa67-265b-44eb-8280-c94860b93cd9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation expense, weighted average recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1bbd37f2-77cc-4d07-b1f4-16868e22bb22_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_c3c205fc-3d32-4f8d-938b-3a3d46af158a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_791262b5-6e6e-401d-914b-6ccb6c6381de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e70400ce-177c-4814-9627-ce3913c54c27_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from public offering, net of commissions and offering costs of $0.3 million</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_a961db65-02cb-4b02-98cc-84ea56c1a67d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issues during period, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestoneTypeAxis_dc321ea5-b656-4096-a2b2-a731a556f4a7_terseLabel_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_allo_MilestoneTypeAxis_label_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_allo_MilestoneTypeAxis_documentation_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis" xlink:href="allo-20200331.xsd#allo_MilestoneTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestoneTypeAxis" xlink:to="lab_allo_MilestoneTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6078ab18-524e-42c2-b129-cc3797b1d821_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PfizerIncMember_574e29cd-9136-4915-99cf-705d0fd9021c_terseLabel_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_allo_PfizerIncMember_label_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc [Member]</link:label>
    <link:label id="lab_allo_PfizerIncMember_documentation_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember" xlink:href="allo-20200331.xsd#allo_PfizerIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PfizerIncMember" xlink:to="lab_allo_PfizerIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3a712c15-12a3-4bc8-ab32-e1017f727642_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0ddc2632-e43b-4bba-b14e-71961a5d9735_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8c71ed86-b646-4cd7-b80f-f93b039370c9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a01be3fe-06da-4003-9474-e814e7eec323_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_23e02e59-bf5b-448a-884b-8baf705e4157_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_ffa9c3ae-03bf-4b7d-9551-11e62bec31c8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_a518e66d-52e2-4a8e-b708-2dc80644b13d_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0e9d880f-1606-4d91-8ea4-081075c46519_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_815d04ee-94f1-42c2-896d-4bed055aa811_terseLabel_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised stock options subject to future vesting</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_label_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercise Of Stock Options [Member]</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_documentation_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember" xlink:href="allo-20200331.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EarlyExerciseOfStockOptionsMember" xlink:to="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_68385a4e-5549-448b-94c9-d2e030d7f18e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_ddce8e73-d139-416f-b01e-4f9435561723_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers equipment and purchased software</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_007d1f29-2b43-414a-9509-9782c200aa41_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9d35327c-b07e-4804-be1f-bf099e884c04_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_61bcabd1-e8c1-47c4-95e1-4ce8ca6dfe17_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_72ba7b99-aa2f-4670-9409-746f237f172f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ce434a8c-bee0-442f-836f-32653f7ad881_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LeaseTwoMember_64ca644c-d3c4-4eec-8836-2f356941a4ce_terseLabel_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">124 Months Lease Term</link:label>
    <link:label id="lab_allo_LeaseTwoMember_label_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Two [Member]</link:label>
    <link:label id="lab_allo_LeaseTwoMember_documentation_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember" xlink:href="allo-20200331.xsd#allo_LeaseTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LeaseTwoMember" xlink:to="lab_allo_LeaseTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8b9fe420-5a19-4a15-9950-bca3cbcfc7ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bf7271a9-6f03-475d-9fa7-849a5ee1045c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_964304fe-6817-4f41-82c9-82ebcac29ee4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_36837e26-6b61-4dee-ba33-b1d16b7e2b92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a25d1d7b-d52a-4975-a80e-ad8173a44e39_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cb031708-d29e-4cc1-a01e-1e188850d68a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4165de7f-467f-4392-b83e-e1bdffe2ab70_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2fa925fe-aa8e-47c2-bf43-85af917af795_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_063c69d6-b5a2-43db-bed3-112366fadcde_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a488ff5b-2df4-41d2-993b-25b5b5d307c0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ec9e3ed8-a5af-466f-a34d-4d4b92461fbf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_31d8e396-db87-401c-914d-77f136e93aa8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_a98d2db1-f670-4aa7-84d4-a07cebf7f8f1_terseLabel_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:href="allo-20200331.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:to="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7a417c8-8949-49b2-8bd3-754cbbf5cf0d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_d2d9206c-fa98-4222-87e2-25230c1b5553_terseLabel_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_label_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Purchased Software [Member]</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_documentation_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and purchased software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:href="allo-20200331.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:to="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_4336479d-a91d-4807-9ecc-16c11175d03e_terseLabel_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, upfront payment</link:label>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment" xlink:href="allo-20200331.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationAgreementUpfrontPayment" xlink:to="lab_allo_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_cb3e2abb-15e4-4354-a645-8ede1bf5e90a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f039f541-8939-484a-97c2-54b84ad3c9c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_acb5a734-bfc2-458a-9ca0-2d5ef21f93a1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockOptionGrantedPeriod_8caeda64-73e0-4064-aafd-1f73ed256668_terseLabel_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option grant period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_label_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Granted Period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_documentation_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option granted period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod" xlink:href="allo-20200331.xsd#allo_StockOptionGrantedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockOptionGrantedPeriod" xlink:to="lab_allo_StockOptionGrantedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_11711dd1-e811-476f-81e7-99a7b262076d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e90a07f9-7d3e-48c2-b7bb-259be370de16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_582f12dc-72e9-4284-bedb-1c6e62df7a47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c800fd4c-6d88-49a0-a7a7-ff706fecb100_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5bb9f95b-bfad-436a-8b70-478be98d2f8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_abde0b97-50e0-4a6c-a801-b2978074e6b2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_59a506e4-9a8e-49a1-a3f6-98c2a061edd6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_323ba3a9-ba0d-4a51-a238-6f381e06b814_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_297f647c-0929-45d0-9712-4b85bec8215f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8d1a7e96-ea46-47cb-83d3-60f53ffc1a50_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_66ee1917-30e1-44f6-9a73-4b499af43237_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_BellcoCapitalLLCMember_ce5d4982-eb2f-4ee9-a0b3-e2fbc6cc3d0a_terseLabel_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_label_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital L L C [Member]</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_documentation_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember" xlink:href="allo-20200331.xsd#allo_BellcoCapitalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_BellcoCapitalLLCMember" xlink:to="lab_allo_BellcoCapitalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentsCommencingJanuary2019Member_c54a4d40-f91b-40ae-b09f-812540ab51cf_terseLabel_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2019</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2019Member_label_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2019 [Member]</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2019Member_documentation_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2019Member" xlink:href="allo-20200331.xsd#allo_PaymentsCommencingJanuary2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentsCommencingJanuary2019Member" xlink:to="lab_allo_PaymentsCommencingJanuary2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bf7c19af-a0c3-4122-93a3-830f5be7c8f4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_70e89cfe-1208-4835-b917-991056005647_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, vested and expected to vest</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5ec10448-b034-4b26-9b74-19afb7066566_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentTermsDomain_6116aac8-55f0-4391-a56b-11c1eef23a44_terseLabel_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Domain]</link:label>
    <link:label id="lab_allo_PaymentTermsDomain_label_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Domain]</link:label>
    <link:label id="lab_allo_PaymentTermsDomain_documentation_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain" xlink:href="allo-20200331.xsd#allo_PaymentTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentTermsDomain" xlink:to="lab_allo_PaymentTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e95b6798-9d65-4c7b-9338-25103281ba15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7f5ee27c-70ea-4f43-804b-6d106a64dc36_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 125,262,537 and 124,267,358 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a3ed6d97-3837-4f4c-8a11-47bbccc7074d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96f9216b-7238-4221-bdeb-d99b075e19a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c4cff5fd-8a91-43b9-8a41-2d13a12ddf20_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31e37e0e-864c-4a62-a10a-016f068af4b5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized&#160;Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0c30df5e-c2f9-42c9-af76-067f4cf5195a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_2c709312-8508-449a-aa1f-97db52a8767e_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Payable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayable" xlink:to="lab_allo_AggregatePotentialMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_944dab7d-24f6-4905-b60c-2746ddd8988a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_496133a8-6953-434e-b1ed-b14853f1dccc_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationArrangementExpense_d4c903de-98ac-4100-a46a-9f391ee4d1d7_terseLabel_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration arrangement, expense</link:label>
    <link:label id="lab_allo_CollaborationArrangementExpense_label_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Expense</link:label>
    <link:label id="lab_allo_CollaborationArrangementExpense_documentation_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense" xlink:href="allo-20200331.xsd#allo_CollaborationArrangementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationArrangementExpense" xlink:to="lab_allo_CollaborationArrangementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_f2a23d49-16e2-4f77-9a68-80bd548dbbe4_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_184becb9-598c-4b42-b13e-4746488d98aa_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease, term of contract</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7693e76c-eca5-49c5-8f13-d2ffc26e45ba_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_5109c66f-6984-4e23-9020-90d0d5d0bf82_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1f1a298f-fe97-432a-80bc-4b6f83cdb372_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_44a506c8-d1cb-421f-9d7a-b7fe9c46a445_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5ba39b9d-1b24-4939-8e2c-2f1dd52e7598_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_134fcb0b-d83d-401e-9dcb-fdf19b6fd836_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_64ea0463-54dc-4ecf-a82e-909907668670_terseLabel_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members appointed to board of directors</link:label>
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_label_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Members Appointed To Board Of Directors</link:label>
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_documentation_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members appointed to board of directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:href="allo-20200331.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:to="lab_allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2d97d386-4c45-4ff1-92f6-c8f5f3cd4b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b31ad661-3090-42a6-ac37-787fb68b5099_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_381587bc-541f-4d71-bfd4-ebaaabcea196_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2b4c5208-df22-4e4c-8bdb-2f121b60e0ab_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_3585b274-3e3b-45fb-b654-989138f2382d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_87950e0e-0ccf-4731-95ff-197b65adcc87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_2488e1e1-de5b-48a1-9b94-f8580eb26aa8_terseLabel_en-US" xlink:label="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances</link:label>
    <link:label id="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_label_en-US" xlink:label="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received For Amounts Related To Tenant Improvement Allowances</link:label>
    <link:label id="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_documentation_en-US" xlink:label="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received For Amounts Related To Tenant Improvement Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:href="allo-20200331.xsd#allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:to="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_71748acc-8f75-4588-aa5c-bd8b5e23af28_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayments" xlink:to="lab_allo_AggregatePotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0d13e9b6-b22e-4fb5-9bbe-f3547c4cacbf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_4409ea57-ae51-4ce5-b9d3-8730c4c8e302_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestoneTypeDomain_95e0e7e0-7d1b-4ff4-bee2-e953dadc66bc_terseLabel_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_allo_MilestoneTypeDomain_label_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_allo_MilestoneTypeDomain_documentation_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain" xlink:href="allo-20200331.xsd#allo_MilestoneTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestoneTypeDomain" xlink:to="lab_allo_MilestoneTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_c4f5f82a-e6c2-4508-8d0b-53a3cbc4fa1b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, option to extend term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6be9c4f1-2268-44ad-9c83-4aec0229dfcc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6a76deec-1b7c-4f2b-8904-7e181da513ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_47b8936b-1e95-4d9c-8641-068eda87423e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1130bdfd-b2d5-45e4-98c1-0b958bc11c63_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_037e6d20-53c8-403f-ac0f-0a4147d4ce6d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_2b2fb30b-b70e-4812-a04f-354b1f158d15_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction compensation percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Compensation Percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction compensation percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage" xlink:href="allo-20200331.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionCompensationPercentage" xlink:to="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b26ec446-1c91-4899-af80-730644036311_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f7dd345e-6acb-4e5b-9450-c66fce18e017_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_13506d22-0e6a-4921-9acf-dd040d8b31ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (remaining 9 months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b17c8bac-4bb9-4668-93f8-7638a9f262b2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_3e9efee0-c96f-49f3-8ae2-5b5a42cbdfdd_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_92d6be43-fb2a-490f-95f4-1b0d42deab77_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3c29655b-cb98-4e99-8c54-3366bc84b084_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f00eb1b5-19f1-4bd6-b63b-6ab7ac9e1bab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1eb61af9-9b10-4a63-b591-b55d2c2d2d31_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8dd1ba9-aeec-4724-862b-41cf80b45b7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e7581df5-c46c-4885-941a-231be4417f0d_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e3085b38-1d16-468c-8582-239c2f2401ac_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_7b42c545-776d-40d9-a771-8fe7bd0e566c_terseLabel_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Liabilities</link:label>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LiabilitiesLesseeTableTextBlock" xlink:href="allo-20200331.xsd#allo_LiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LiabilitiesLesseeTableTextBlock" xlink:to="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2ed70ff-066f-4801-9b9f-f23aeceb85a7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31cacf42-63c1-46fe-a61d-7e98f0d044b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_712e2fe2-28d2-4c86-abb5-dc527267497d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e2fba259-8c16-4680-9798-560b0c283cfb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_44cdb501-2cf2-4295-8a72-ff0464ab1b83_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_fb17f64e-524e-409f-b82f-4dcf15b09dcf_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d4b5d602-2978-41ae-8500-bc1053c55a30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b58820ce-9362-4f31-9470-a2a302cf8f85_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of other intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4637101e-6953-4657-86af-a72eb14b1086_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_6c7af131-ebcc-4c6a-b809-8a28453074e3_terseLabel_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc.</link:label>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_label_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_documentation_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember" xlink:href="allo-20200331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NotchTherapeuticsIncMember" xlink:to="lab_allo_NotchTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_612ee9a0-b575-41a1-9375-075ebd3f9c7b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_070932ca-29e0-421b-addd-ce68824af744_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_50811039-5fb0-4574-aec4-8f560b9c907e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e26a3b78-ff39-4d51-8956-c8cd28ba7e2d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_20970a4a-ab57-4bdb-ba93-8989f44b2f19_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b5d9d0cb-f80f-44d6-ae17-0d92f4f2dff3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e020f031-727d-48fd-a538-8412ad7eab67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_3ab6349f-743f-4d6d-b1b3-2253875dc393_terseLabel_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office and laboratory</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_label_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of New Office Building</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_documentation_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of new office building.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding" xlink:href="allo-20200331.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfNewOfficeBuilding" xlink:to="lab_allo_AreaOfNewOfficeBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_07b2615e-591b-4b75-99fb-ff501447ebdc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_95ce79db-2e0c-496d-b665-51485427c136_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52c9918-6c27-4a8a-9665-2f62b07ab019_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of RSU's (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a66e445f-ce78-418e-a4dc-aa75eba3bb92_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e848b586-3398-46b7-a6d6-a7d1526abd37_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_33061781-468b-489a-8394-24ec55532218_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_0198a1b9-3e02-469f-b62d-71556fcba8ad_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3ae5b647-9f68-4377-afa5-5efd40a49464_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_588c241b-3a37-4671-8d65-eb876319674b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2888cb75-663a-454f-97d3-a76125743f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6e076f91-a422-45ac-b028-33c6bee57b4d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenses_d7b9dc3e-0140-4b83-8cb1-9bee6bae37f4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherExpenses_label_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses" xlink:to="lab_us-gaap_OtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1b9c6bb8-5602-4f31-9c1d-de1dbdc8fb3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6bceffbf-1cbf-4ef3-aeee-01b19fb88830_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_2226532d-cdf1-4c07-9609-b233b1167427_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development cost payable by collaboration partner</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By Collaboration Partner</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:href="allo-20200331.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:to="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_956d7b77-2922-4f18-8f3b-e652277c583c_terseLabel_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Liabilities Current</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent" xlink:href="allo-20200331.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent" xlink:to="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_575fa5b9-ee2c-4af1-a859-df9bad74c6b2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_79c4d4e4-2b09-4de4-94f0-08e339c61695_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Leasing Costs, Commissions, and Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:to="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7b570bce-893d-4907-a7aa-e061742e9c7e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_851b348c-cf34-4c1f-a749-743cd05da9f5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_68e80f5c-ff34-41b6-a20b-776f810d0688_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e3f158fa-4abb-4ad6-ac1c-d22850e7244a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_553f0303-cd74-4b9b-bd98-74e30c0bd16b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e02f6b9b-a3d2-4465-ab26-83c8b139b0e0_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3b6258f7-25c6-4e78-b0b9-375088f99e1a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AssetContributionAgreementMember_9bbdaa42-2d00-48ea-8fb7-ce45a408b810_verboseLabel_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Contribution Agreement</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_label_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Contribution Agreement [Member]</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_documentation_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset contribution agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember" xlink:href="allo-20200331.xsd#allo_AssetContributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AssetContributionAgreementMember" xlink:to="lab_allo_AssetContributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_aa28ed92-ac4d-4de3-a693-3d5e20599a22_terseLabel_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_label_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAgreementsTextBlock" xlink:href="allo-20200331.xsd#allo_LicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAgreementsTextBlock" xlink:to="lab_allo_LicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_184e6d25-dd68-437e-af52-75d9993953f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_922fd830-fc37-48a6-914d-6d152d28107d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0836c95d-4949-4c97-a6c9-a53722ba448d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef688002-b471-4e7d-a969-b7caea12ceb1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized&#160;Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_da623c39-4583-461d-acf5-bf40ce3c97da_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_e9d5aff9-b6ce-4d86-80f9-1e7c9e1c7a2f_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancellable purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e7f4039d-0e7d-4bd8-8c5f-e59dac911215_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_661763ce-ba3f-4d15-9022-457b2e8e2d06_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentsCommencingJanuary2020Member_672e06b8-04a2-40e5-a24f-31980c6c38e9_terseLabel_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2020</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2020Member_label_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2020 [Member]</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2020Member_documentation_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2020Member" xlink:href="allo-20200331.xsd#allo_PaymentsCommencingJanuary2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentsCommencingJanuary2020Member" xlink:to="lab_allo_PaymentsCommencingJanuary2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ed9f71d-b7cc-4613-ba15-d4862a750973_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_a25a8887-3212-4100-933c-4d5e29c84d30_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction monthly payment in arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Monthly Payments In Arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction monthly payments in arrears.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:href="allo-20200331.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:to="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_af91cc53-156b-4940-8c14-4d230d61cf24_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_5a93e97a-78cf-40a4-b1f6-a896b12d37f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_dfd14a9f-8800-45de-b4b5-b156541ae83b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyCosts_c0149653-493d-4fce-b22e-a5a4fb76eb29_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party costs</link:label>
    <link:label id="lab_us-gaap_RelatedPartyCosts_label_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts" xlink:to="lab_us-gaap_RelatedPartyCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a261ac14-3626-43fe-bb12-8416d38f4304_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheets Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_36c3f98c-7433-4be7-9b6f-8e5b8c744957_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfOffice_f68a1773-512b-456b-8689-0958bf4f032c_terseLabel_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space</link:label>
    <link:label id="lab_allo_AreaOfOffice_label_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office</link:label>
    <link:label id="lab_allo_AreaOfOffice_documentation_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice" xlink:href="allo-20200331.xsd#allo_AreaOfOffice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfOffice" xlink:to="lab_allo_AreaOfOffice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ac13d89e-67da-428a-a968-f9456974ac79_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a05becef-3318-4fef-be6a-4b2c0e9ac7e7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares were issued and outstanding as of March 31, 2020 and December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_86d27596-f415-44da-8229-12f7d866cc8b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ffbaf8cb-e1ef-419a-98ee-59c45445b037_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_678954c1-3407-4fc1-a717-d87a0c956022_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_4026cf4c-e0c1-45ea-8b6c-89fa8e6c7d1e_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5f81b9e6-7817-4a2e-b8f1-b7c9f5db233e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9aa3e1d9-1c63-48ff-902c-48c84d6084e3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_3adbffcd-7e09-4c3e-9970-3e4ba2fe4ac5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable to related party, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockIssuanceMaximumValue_c0e9fdc8-1db7-4295-b4c9-90b6ce0dba6f_terseLabel_en-US" xlink:label="lab_allo_StockIssuanceMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, maximum value</link:label>
    <link:label id="lab_allo_StockIssuanceMaximumValue_label_en-US" xlink:label="lab_allo_StockIssuanceMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance, Maximum Value</link:label>
    <link:label id="lab_allo_StockIssuanceMaximumValue_documentation_en-US" xlink:label="lab_allo_StockIssuanceMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumValue" xlink:href="allo-20200331.xsd#allo_StockIssuanceMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockIssuanceMaximumValue" xlink:to="lab_allo_StockIssuanceMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b2877c0f-c2a6-48e2-a74f-c894a017a7d0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_bf4dd124-611f-4eb2-92fb-3b2472a5e3d7_verboseLabel_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember" xlink:href="allo-20200331.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAndCollaborationAgreementMember" xlink:to="lab_allo_LicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b2e353f2-e994-427e-9fbd-3e092ce479d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ConsultingAgreementsMember_4f0d71e2-efea-40d6-8c5d-c189835e6c82_terseLabel_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreements</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_label_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_documentation_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember" xlink:href="allo-20200331.xsd#allo_ConsultingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ConsultingAgreementsMember" xlink:to="lab_allo_ConsultingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_161924bb-d48a-4257-8980-98dfd94ac65c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d7ad11a7-ae41-48e4-a19b-40ec1cac3596_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SalesMilestoneMember_10299f1f-6e93-4ae6-be7a-913f18f2d0bc_terseLabel_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_label_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_documentation_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember" xlink:href="allo-20200331.xsd#allo_SalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SalesMilestoneMember" xlink:to="lab_allo_SalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_dcab46f0-0810-46bc-b159-7a304552f4e8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_03256931-8974-4f5d-be2b-abece50b81c7_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_78b8599e-dad4-4ff5-8433-3d696a8357f1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected shares to be purchased under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f74ec948-fa62-48ad-9304-a8cb658d5e30_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2e788b0e-b8b1-483f-968f-43b0e1bbbeaa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_31c1ccb6-abe0-4864-bd20-f5fc20a26097_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6b2611e8-d7ec-4734-bb60-3efa05705588_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_36141ae6-f621-417e-9292-c6bbfc6c0ace_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_9008ae73-27da-4456-8d5d-76aa7ca17560_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_3adbc598-c863-41e3-9cb4-93ac94a72ba6_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfOperatingLease_9f6fae57-c02b-4119-be1a-2b8b38b4daad_terseLabel_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of operating lease</link:label>
    <link:label id="lab_allo_AreaOfOperatingLease_label_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Operating Lease</link:label>
    <link:label id="lab_allo_AreaOfOperatingLease_documentation_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease" xlink:href="allo-20200331.xsd#allo_AreaOfOperatingLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfOperatingLease" xlink:to="lab_allo_AreaOfOperatingLease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_35d42d28-d69d-4f17-8d7d-2d1caada43e2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ef35e02-a88c-4fd8-ae2f-1091cced8625_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_f506eb8f-c074-46f7-81b6-9205a75d8fc1_terseLabel_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payments required per product against selected target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_label_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Payments Required Per Product Against Selected Target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_documentation_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payments required per product against selected target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:href="allo-20200331.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:to="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_27e95ec8-6ca6-42fc-8885-2866df0481b6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9cd4d8c6-040d-4c1f-9d02-3b2b2246c634_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_78fa2bfd-03a7-47d7-b4c2-68b5e874fe20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e113d7a3-4206-4e14-999e-fe57af0cb881_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bfd24f2c-48f8-4d08-9e6f-c9a0eec7093f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Lease Payments Under Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LeaseOneMember_4e0f634f-b61a-46d0-b78f-4df29b8ff397_terseLabel_en-US" xlink:label="lab_allo_LeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">127 Months Lease Term</link:label>
    <link:label id="lab_allo_LeaseOneMember_label_en-US" xlink:label="lab_allo_LeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease One [Member]</link:label>
    <link:label id="lab_allo_LeaseOneMember_documentation_en-US" xlink:label="lab_allo_LeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneMember" xlink:href="allo-20200331.xsd#allo_LeaseOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LeaseOneMember" xlink:to="lab_allo_LeaseOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_26ef9a97-fe26-46b6-943f-3217f31b301d_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_2034da54-b384-47a3-84cf-f8fb31405e20_terseLabel_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_label_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements not yet adopted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="allo-20200331.xsd#allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_4d728a31-fc8e-4a50-b9b8-d9db15a9e673_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_12ae5fe4-7c75-43e1-8a74-4928c16d83fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ef88ee0-6d7a-44ca-80ba-8742cd07ce39_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9b81d38d-1316-496d-9304-4dae53c042f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7fcc808f-fc82-4e8d-bf7c-77c4bb654550_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_4d4e27bd-2364-42b5-ae77-980a8f53cc52_negatedTerseLabel_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of losses from equity method investments</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_label_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Cost Method Investment</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_documentation_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Cost Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment" xlink:href="allo-20200331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_IncomeLossFromCostMethodInvestment" xlink:to="lab_allo_IncomeLossFromCostMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_bb2a7995-af63-413a-98a2-f4f6234ab65c_terseLabel_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_label_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_documentation_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:href="allo-20200331.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:to="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_8410bc57-66b4-4475-bbf4-10bf41d8f2c0_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction, expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a53c9a6f-1f1c-4d62-bf23-c82163c9e575_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_c9ef652c-7bce-43d5-b08b-9d935ae0a46f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2f52834d-e324-4557-9f88-fd974c51b9db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4e2d292b-0892-474d-8451-41bc6e53600a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d1c329d7-fd59-4b45-8063-cee474202a44_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2199152-4eac-4a00-a68d-ac8cbaeb049c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15ca5b91-1180-48bd-abcd-24c43c89311c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_52578880-3554-463c-8827-62c7f24deae6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_745e10a7-a261-445b-ac5e-44908da1d531_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f7147498-2551-4e27-88f6-59f7e08b7351_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a20218e6-3c5b-4625-8c57-111864b8a1c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_d4321e21-0376-4d2f-9795-d880c9905533_terseLabel_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_label_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements Policy [Text Block]</link:label>
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting pronouncements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:href="allo-20200331.xsd#allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_596e23b0-b4fe-4946-ae0c-3bc1feca8f31_terseLabel_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder's shares of common stock subject to future vesting</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_label_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder Shares Of Common Stock [Member]</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_documentation_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder shares of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember" xlink:href="allo-20200331.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_FounderSharesOfCommonStockMember" xlink:to="lab_allo_FounderSharesOfCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_343d4fb1-4c79-4c37-bf69-af1b8de59cd5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_ce5d8058-0653-4543-9bb8-1a2bb99f0951_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_75c94a11-a0ba-498f-8e92-21ccbe410123_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization/accretion on investment securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_53f92ce2-dca8-4f57-b625-f3c32c64f0ff_terseLabel_en-US" xlink:label="lab_allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents accrued and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:href="allo-20200331.xsd#allo_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="lab_allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_500b0e76-64e7-48c0-8d97-beff22b2ff6c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_cba85d8a-7eb8-4707-9a31-b6d505cfd17b_terseLabel_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_label_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone [Member]</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_documentation_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:href="allo-20200331.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:to="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_97fab233-726b-4009-98e5-02d5fb78c6b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0355222c-ccb0-4672-8fa0-a7fddf2de906_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_66333bb0-a89d-4052-9a5a-5fe48ca99f1f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_1dcc3047-35c4-4444-a021-6e19797df6fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_9f024d25-2e2f-4821-866e-f012a6d71bb1_terseLabel_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember" xlink:href="allo-20200331.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PreClinicalDevelopmentMilestoneMember" xlink:to="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_6243f5a2-c7c1-4296-b1e0-3357911483b9_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs payable by the Company</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By The Company</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By The Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:href="allo-20200331.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:to="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0f90f450-f1df-4f04-8b2a-5bb7123b746c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c59b514e-0706-4ab7-868d-87bbe77c6851_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_841a55e9-b5f5-4b5e-8652-895a6c4b2d30_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0cc40c99-d8ee-4eea-83ab-0437d7b5820b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_023a7a30-0e89-4cd2-bf0f-bb21044e5c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, unvested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7f6e035c-bdd3-4f12-b3b0-5bc6ce1813ab_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_21c01ad0-d432-437a-9e27-efb6c312fd38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5211c585-961c-4299-bfd0-dc24914cc9d9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_03fd8ec3-21a8-4da3-aa16-fb613af51e2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3659d094-1fbb-4655-b215-32509019e98a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3685d20f-028e-457c-979a-ec2b7aafec13_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_918da3df-70c5-46b4-a8e1-d2db7f021977_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_671f98b8-f192-4504-b67e-c8cbb3c9232d_terseLabel_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend lease</link:label>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_label_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Lease</link:label>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_documentation_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease" xlink:href="allo-20200331.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfOptionsToExtendLease" xlink:to="lab_allo_NumberOfOptionsToExtendLease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_19a76056-e0d8-404c-970b-1d225ec1ec41_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_13da7f06-56ec-4165-9244-150e1742d8f8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5a8b7869-68d3-4bc3-9463-80368826ba2f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_812d2dc4-b5ef-4fac-9f4a-35f104bbbc17_terseLabel_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_label_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting L L C [Member]</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_documentation_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember" xlink:href="allo-20200331.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoRiverConsultingLLCMember" xlink:to="lab_allo_TwoRiverConsultingLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_bcba7971-1296-4b7c-b6fc-421357e2e947_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d6ad0fd6-1594-4850-8e04-31793c8c011c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_69ff49d9-a1fe-4753-ae0a-29f5ffa7e5a4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_67b4a459-7296-47b7-9200-122749a577e3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3924e7ae-1fcc-4f03-ae73-f42adee94063_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_09ae63d1-ab28-4348-a258-75ff6f62b798_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_41be91cc-e8bc-4a3e-8fa5-60028aac2f9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c041717f-72e5-48c4-bb5d-66e000024c16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_687a075a-cd2f-4138-a7bf-9e42caed123d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, measurements, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_535d89e2-18ef-482b-87a9-e97f917922bf_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_91fd2907-f601-4065-8d66-b4194ec9ca75_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fe0b36a7-83ee-4eac-b4c2-7a4da3f1b312_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_eea71e88-b487-4b59-8c38-2f32624fd9a4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_41db75fe-d604-4c2e-a21e-8a341d21031b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of RSU's</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NewarkMember_f51a4b77-0870-40cd-95b1-c0712d01de75_terseLabel_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark</link:label>
    <link:label id="lab_allo_NewarkMember_label_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark [Member]</link:label>
    <link:label id="lab_allo_NewarkMember_documentation_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember" xlink:href="allo-20200331.xsd#allo_NewarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NewarkMember" xlink:to="lab_allo_NewarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LaboratoryEquipmentMember_f1025225-527c-4840-ab97-54cc08045510_terseLabel_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember" xlink:href="allo-20200331.xsd#allo_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LaboratoryEquipmentMember" xlink:to="lab_allo_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_83e73cf1-c8c8-49a3-a081-ff998fab84fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_44522f0d-fdf5-4ffe-8f2b-cfb296cc01ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3c36d26d-cefb-46e3-a025-be20331888ef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RecoveryOfResearchAndDevelopmentExpense_b5a41f48-7445-48e6-939d-4974ba13423c_terseLabel_en-US" xlink:label="lab_allo_RecoveryOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of research and development expense</link:label>
    <link:label id="lab_allo_RecoveryOfResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_allo_RecoveryOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Of Research And Development Expense</link:label>
    <link:label id="lab_allo_RecoveryOfResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_allo_RecoveryOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Of Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecoveryOfResearchAndDevelopmentExpense" xlink:href="allo-20200331.xsd#allo_RecoveryOfResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RecoveryOfResearchAndDevelopmentExpense" xlink:to="lab_allo_RecoveryOfResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_6c592472-72b8-42f9-b6d8-d9df839b9132_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1a34e7bc-8d2a-4a1f-8680-9d463e914c29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_050dd35d-b115-4542-a81d-a48b611cdef9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_6b992fa1-4cd8-48ea-8f3e-611aae29cc95_terseLabel_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost</link:label>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_label_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investment, Transaction Costs</link:label>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_documentation_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investment, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts" xlink:href="allo-20200331.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CostMethodInvestmentTransactionCosts" xlink:to="lab_allo_CostMethodInvestmentTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a00f5baf-3ee1-43af-b776-06a7debfc1df_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_29184a9d-67bd-47fe-a1a9-135e3d5c8d1b_totalLabel_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_documentation_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments" xlink:href="allo-20200331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments" xlink:to="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_15791141-c697-44c3-865c-26dd94f44356_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6c72f8d1-dbb8-474e-a764-14261b9400dd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d85e7b48-e161-4461-8dd8-f8959b8516b8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79164b55-bf4c-489d-a29d-25f8ba85acac_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_11f28ad4-5f77-4623-8074-7df30f4f83e2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_53399458-6440-4c08-84b3-32e215505798_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f3f4f778-0671-4192-8989-6b8b26f99c75_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1098ab96-6c7e-408d-ac5b-bfab6c5d5125_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_3b552981-62d7-4e55-bda8-3c35d3746ade_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DevelopmentAndSalesMember_94ce6aba-a718-4ae4-9cba-5902ce8b9e95_terseLabel_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Sales</link:label>
    <link:label id="lab_allo_DevelopmentAndSalesMember_label_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Sales [Member]</link:label>
    <link:label id="lab_allo_DevelopmentAndSalesMember_documentation_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember" xlink:href="allo-20200331.xsd#allo_DevelopmentAndSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DevelopmentAndSalesMember" xlink:to="lab_allo_DevelopmentAndSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8d6174ca-d4a4-4ba9-86e2-5bab3bdd7291_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_36b39663-8956-41f7-b099-169ed2fb4d94_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ResearchServicesMember_0e4b10c7-54bc-4a0c-85f8-ca5ad198e12f_terseLabel_en-US" xlink:label="lab_allo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services</link:label>
    <link:label id="lab_allo_ResearchServicesMember_label_en-US" xlink:label="lab_allo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_allo_ResearchServicesMember_documentation_en-US" xlink:label="lab_allo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchServicesMember" xlink:href="allo-20200331.xsd#allo_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ResearchServicesMember" xlink:to="lab_allo_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_41422bdd-5cfa-4851-9147-a52e510f8df2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Notes 6 and 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4d0686f0-5d0c-477c-af07-996bff6afd57_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_74f71f62-74e6-4e68-96e0-9393937bfeaf_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_04865f59-0d20-4008-a230-6e440d093d45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets And Liabilities Subject To Fair Value Measurements On Recurring Basis And Level Of Inputs Used In Such Measurements By Major Security Type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_148d12de-4349-45e9-bc0d-795da0b1ab66_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e2b300a0-7472-4a1e-a197-bdf4f182f89b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_57e164f4-d160-4f70-a38d-2ca241f67914_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a45b47ae-3942-42c1-ac86-ef8ef1914dc7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ae542fc7-7e2b-4863-a057-cfbaa087e81f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercised common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_909a0c3e-bbfa-43ad-b2f7-09ef93e6f747_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_991dc6b2-13a8-4b38-99da-7d0905a62756_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_0ca94ea3-c7ce-4cc0-882e-69c25aa6de9b_terseLabel_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_label_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Plan [Member]</link:label>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_documentation_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember" xlink:href="allo-20200331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoThousandEighteenPlanMember" xlink:to="lab_allo_TwoThousandEighteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6d1400b-3536-485a-af49-c6850ed5def6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_914a5dcc-1a19-4c6c-9bcc-e16cb212a922_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5eca943a-8a38-4346-9994-81f78ab67dd2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a99708f9-6b45-46a4-8d0e-8ed4bc6aebca_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_327c5a82-07bd-4a61-992b-877e007557d3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89d68c35-35a1-4d1f-9e67-6680b15d557d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1101726d-6648-4d38-8576-a15478ff1f99_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CellectisSAMember_6371ce97-0c63-4f78-8015-32f893a0647b_terseLabel_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis</link:label>
    <link:label id="lab_allo_CellectisSAMember_label_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis S A [Member]</link:label>
    <link:label id="lab_allo_CellectisSAMember_documentation_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis S.A..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember" xlink:href="allo-20200331.xsd#allo_CellectisSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CellectisSAMember" xlink:to="lab_allo_CellectisSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_276cc7a8-3ed4-42a2-b602-43f2149c3203_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_41b17ebf-0d60-4415-8f6f-5aa5ce19cb28_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4a50fb23-71fb-4dd2-a028-dff075ab40a2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c8c4c60c-ea84-4729-92ef-6c77b0216dda_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e7aa4479-2ef4-4393-a76d-eeec5b776632_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e1a0260d-368a-4c7d-9e21-e00b761485a8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_87ea4466-fe60-4acf-bd1a-ba6244031f01_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentTermsAxis_6d21e807-ecb5-440a-ba38-5aaf246846f9_terseLabel_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Axis]</link:label>
    <link:label id="lab_allo_PaymentTermsAxis_label_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Axis]</link:label>
    <link:label id="lab_allo_PaymentTermsAxis_documentation_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis" xlink:href="allo-20200331.xsd#allo_PaymentTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentTermsAxis" xlink:to="lab_allo_PaymentTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_bdf61e8d-4623-426a-9260-80de9bb0b6ae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1cbd4d36-3d4d-4bac-88d2-a50b934adcce_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_54fee231-0bc7-488f-a10a-8da071082660_terseLabel_en-US" xlink:label="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, maximum compensation due to third party, percent</link:label>
    <link:label id="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_label_en-US" xlink:label="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance, Maximum Compensation Due To Third Party, Percent</link:label>
    <link:label id="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_documentation_en-US" xlink:label="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance, Maximum Compensation Due To Third Party, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:href="allo-20200331.xsd#allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:to="lab_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f7bec4fc-eb08-46ec-bba6-54716f9f0245_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1ef8fa34-0ee0-42d8-b493-ec0f498216cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4c868359-9797-4ea0-ba7d-145548102335_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_f504dbec-abc5-4666-a181-016697e531f6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest in Notch</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61479e9f-6e71-4fc9-a8b6-46e3f962205b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_268cbb1e-91ba-4f6d-bfed-5f176a0069ec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ab7aa539-4575-4af7-b032-f20e03d05c64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_72029834-2c5a-4ae9-acd8-2a456447d598_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e1234b5-1e61-4c21-a5a4-fe94f6933c20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b66dc01c-3104-4525-99b9-0188f84ccd41_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_2a074c50-12ed-4f23-b3bc-84b1a16b23bb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TransitionServicesAgreementMember_ec424c79-89ec-45c8-acee-c3e88d01cbaa_terseLabel_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services Agreement</link:label>
    <link:label id="lab_allo_TransitionServicesAgreementMember_label_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services Agreement [Member]</link:label>
    <link:label id="lab_allo_TransitionServicesAgreementMember_documentation_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TransitionServicesAgreementMember" xlink:href="allo-20200331.xsd#allo_TransitionServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TransitionServicesAgreementMember" xlink:to="lab_allo_TransitionServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AllowanceForTenantImprovements_6bedbdb1-95ab-40e7-b52b-b69182cf8c43_terseLabel_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:label id="lab_allo_AllowanceForTenantImprovements_ff04c25b-2f6d-43f3-8da3-466c6b424258_negatedLabel_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Tenant improvement allowance</link:label>
    <link:label id="lab_allo_AllowanceForTenantImprovements_label_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:label id="lab_allo_AllowanceForTenantImprovements_documentation_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllowanceForTenantImprovements" xlink:href="allo-20200331.xsd#allo_AllowanceForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AllowanceForTenantImprovements" xlink:to="lab_allo_AllowanceForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_df2de1c6-0e76-4e91-a757-aebdb1c5a389_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, granted</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_40fd8b01-d82d-4a04-870b-13c044fac730_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_9ca27f59-f014-4626-bb2f-14631a864f12_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ddd7cb9-1f5d-4784-8623-b8310564a276_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Stock Option Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6e5a0c47-7a31-46bf-a6b9-22bead8e9a03_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_df746c90-fff8-4d1e-8ddd-eaad00c3b4e6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_383893b2-4b53-4f17-9b84-b79fc074d5f5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_75d522cd-5883-4c45-8f8e-4111e19c2d8c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SubleaseAgreementMember_7bf960bf-ebb6-4894-9ac5-b95020966ce5_terseLabel_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement</link:label>
    <link:label id="lab_allo_SubleaseAgreementMember_label_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:label id="lab_allo_SubleaseAgreementMember_documentation_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember" xlink:href="allo-20200331.xsd#allo_SubleaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SubleaseAgreementMember" xlink:to="lab_allo_SubleaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_3f398d0b-68e7-4218-ab75-4d859b5ba438_terseLabel_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation period from date of first sale</link:label>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_label_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation Period From Date Of First Sale</link:label>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_documentation_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation Period From Date Of First Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:href="allo-20200331.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:to="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b025fb4-0975-4534-9e76-ef5bef2782d5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2e5e03cd-aba1-432d-98de-53e274a66725_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_ce73113e-0eaf-42b1-9c76-517b2f373d5e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_863aff2b-a3be-49bd-9e0b-9d51f701a54b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7fb54fd8-2212-4988-b166-965f84906890_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8d07aa2c-c7cb-443b-8d9a-22e88b2f483c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_bd567440-80ca-42c1-bc0b-341ccb697f99_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_cef9e171-c4c5-4e73-aaf0-c36e0bed2131_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_94f497d0-36d8-422e-ac1e-6a88999bd612_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units subject to vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_288c4bf7-a351-48ac-9d23-fca44b45856b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of commissions and issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestonePayments_f3d2d8b4-924e-42a9-a983-c80e74d80612_terseLabel_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments</link:label>
    <link:label id="lab_allo_MilestonePayments_label_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_allo_MilestonePayments_documentation_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments" xlink:href="allo-20200331.xsd#allo_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestonePayments" xlink:to="lab_allo_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4200d2d7-7228-4ff3-b85f-26f3e3f7b493_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_833089c5-4a48-4f3e-a6fc-e0a31544d3ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4d762684-4257-4dd9-a77b-5ffdcf6e1f86_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9293333b-2b95-4825-ac23-7fed1a75610e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3a47a63b-b6b3-4469-88b5-a1b65cacf29c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c726b31b-000a-44e0-869d-fc151602f4de_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_05001ab6-069c-49b1-8a9d-199bf00c5ad0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_e4d2a55e-20c4-40d7-8cb8-0955897d996e_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5b43e053-2d78-4f99-862b-9aa2c71e8b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_75022192-6e83-4f62-a984-7ded93a38653_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4bdf85b1-45bb-4dca-abd6-71cdd24a4a02_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_28c82db9-9076-4958-ae2b-cba197406745_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone receivable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Receivable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestoneReceivable" xlink:to="lab_allo_AggregatePotentialMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d81a0b37-30c0-459b-8d36-466e9da1c771_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_04d127d3-3879-460c-9501-8b02721e0971_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_9f7c0733-c08e-4e13-aeb5-c378bf9058a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c0d86fef-f6b4-430b-bbe2-38e169684cb3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b1b16a4-2cc9-4406-a1c2-ae1a7ee8f5e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e82f0ed7-b10d-4772-9722-665bed6d67b2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e395469d-e98f-4bf5-824d-323fc4175af5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Fair Value at Date of Grant per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_efb24fb9-8aea-446f-a8bd-0ebffc4a7fe0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a152319-258c-475c-888e-6e6e68285af4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_944501a2-6e38-4bf7-a8bd-e4f25cbdb74e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_e3c6cdc7-8fdf-4533-80a9-7fd57e681e9e_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b69171c0-fee4-4c7c-98e8-5f20c37f95b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_b61d87c6-91f3-4b69-a847-92c92d111918_terseLabel_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares as percentage of common shares outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_label_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_documentation_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares as percentage of common shares outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:href="allo-20200331.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:to="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_58de47ab-e4ea-46ac-844a-5123bee2e7e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_14cfd7fa-9e30-4748-a6e0-aba18b3e8e0b_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8bbc85f1-651c-46ec-8be1-cace2d254b9f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ServierMember_273623e0-cfcb-447c-b7a8-950b9e9a71f0_verboseLabel_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_allo_ServierMember_label_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_allo_ServierMember_documentation_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember" xlink:href="allo-20200331.xsd#allo_ServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ServierMember" xlink:to="lab_allo_ServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_027a4f43-eb8f-405d-8801-b13887f6f253_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a42e675e-ee1f-49db-9cce-0e44a5c4dd14_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_588e0729-c0d8-463d-aa9f-6d48acf93290_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e99a7a02-5cb7-4a3d-a303-83ae4caa707c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ByHeartIncMember_fd4c5079-8aee-41c0-b0e4-c90b366e0efc_terseLabel_en-US" xlink:label="lab_allo_ByHeartIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ByHeart</link:label>
    <link:label id="lab_allo_ByHeartIncMember_label_en-US" xlink:label="lab_allo_ByHeartIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">By Heart Inc [Member]</link:label>
    <link:label id="lab_allo_ByHeartIncMember_documentation_en-US" xlink:label="lab_allo_ByHeartIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ByHeart, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ByHeartIncMember" xlink:href="allo-20200331.xsd#allo_ByHeartIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ByHeartIncMember" xlink:to="lab_allo_ByHeartIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_faf9b973-884d-40e5-aef5-6158e27190aa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02e47cec-3517-4751-bc96-dffe0d2806db_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3ad6ca19-effd-4f65-a457-5fe8a8e98a3e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_386d8035-b9e6-4a9d-94dc-f8f7de9a2c8c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b65b8da4-55e7-4d10-b059-175058119ed5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2b62963c-7bcc-480a-987f-d15153725a0a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_f98e4576-e6d7-4800-a33d-ebda477dae04_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_09121634-0183-4ee6-b306-996450686bbb_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential regulatory and development milestones</link:label>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_label_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Regulatory And Development Milestones</link:label>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential regulatory and development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:href="allo-20200331.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:to="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RegulatoryMilestoneMember_23ffbe3b-4698-4a2a-aba5-79132f4bd770_terseLabel_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_label_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone [Member]</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember" xlink:href="allo-20200331.xsd#allo_RegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RegulatoryMilestoneMember" xlink:to="lab_allo_RegulatoryMilestoneMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>allo-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:57bc89fc-7004-4307-9757-f5809462a759,g:be24e03f-ee2b-47ea-87e1-15803658ae8d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20200331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_faa5b53a-96a5-4a01-b8f9-82d5d8fdb01d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_DocumentType_faa5b53a-96a5-4a01-b8f9-82d5d8fdb01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e9613868-0ade-4cfc-83ed-62e9e0affa66" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_DocumentQuarterlyReport_e9613868-0ade-4cfc-83ed-62e9e0affa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d087d828-aeae-4c09-b9a4-dd4da5882a3f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_DocumentPeriodEndDate_d087d828-aeae-4c09-b9a4-dd4da5882a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_889b255b-035d-4e21-a51d-f87021dec881" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_DocumentTransitionReport_889b255b-035d-4e21-a51d-f87021dec881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_99463ea6-a691-41fe-95f5-75630431ae7e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityFileNumber_99463ea6-a691-41fe-95f5-75630431ae7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_da8bc930-e90d-4333-89d6-4ecb949aa0e0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityRegistrantName_da8bc930-e90d-4333-89d6-4ecb949aa0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_94b06245-7276-485d-abca-035f808db606" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityIncorporationStateCountryCode_94b06245-7276-485d-abca-035f808db606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c3a87748-9ae9-498d-9761-46b466f68c29" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityTaxIdentificationNumber_c3a87748-9ae9-498d-9761-46b466f68c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d5686798-199c-4260-beaf-095c17bd0b61" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityAddressAddressLine1_d5686798-199c-4260-beaf-095c17bd0b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ad49e951-8f51-4cd8-9453-88f8091a0ab6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityAddressCityOrTown_ad49e951-8f51-4cd8-9453-88f8091a0ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_672b7cb7-e366-45de-afca-7ce07823fa07" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityAddressStateOrProvince_672b7cb7-e366-45de-afca-7ce07823fa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4a9c9264-886d-412d-bb9d-f4e7c81ad80f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityAddressPostalZipCode_4a9c9264-886d-412d-bb9d-f4e7c81ad80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8948b31a-5831-4853-90a9-a0ff2d3c747e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_CityAreaCode_8948b31a-5831-4853-90a9-a0ff2d3c747e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_07cd65e6-b7a1-491f-8f1d-0c89734e9dd5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_LocalPhoneNumber_07cd65e6-b7a1-491f-8f1d-0c89734e9dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9a3346bd-52b5-4a10-bb79-1c35719358d3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_Security12bTitle_9a3346bd-52b5-4a10-bb79-1c35719358d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bf53414f-c7e0-4a06-853c-37f656fd4c64" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_TradingSymbol_bf53414f-c7e0-4a06-853c-37f656fd4c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c1b8764e-aa5a-41a2-9671-890ffd8bb93e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_SecurityExchangeName_c1b8764e-aa5a-41a2-9671-890ffd8bb93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4d30f1f9-9f73-43fb-9d79-3d47afe3bf1c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityCurrentReportingStatus_4d30f1f9-9f73-43fb-9d79-3d47afe3bf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5af52647-bbf2-427f-9625-f245d8be2cb9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityInteractiveDataCurrent_5af52647-bbf2-427f-9625-f245d8be2cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_09c2e1bd-1a6d-4bac-8b94-d308188c7b5c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityFilerCategory_09c2e1bd-1a6d-4bac-8b94-d308188c7b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cb0bc756-0cf1-4e5e-9fad-59a058561ad3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityEmergingGrowthCompany_cb0bc756-0cf1-4e5e-9fad-59a058561ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_60b05f21-470c-4325-953e-83b37c1350c5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntitySmallBusiness_60b05f21-470c-4325-953e-83b37c1350c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_51d05636-cfb5-47a1-ab42-0d88e6315f0d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_51d05636-cfb5-47a1-ab42-0d88e6315f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f7d015f9-7e3e-43f7-b882-fbee89577e1b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_CurrentFiscalYearEndDate_f7d015f9-7e3e-43f7-b882-fbee89577e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f8532d61-1979-466f-9a55-10c677840db4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_AmendmentFlag_f8532d61-1979-466f-9a55-10c677840db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d45db09e-1294-455a-a37e-b76833e927ad" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityCentralIndexKey_d45db09e-1294-455a-a37e-b76833e927ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ba128311-655c-4280-a66c-b53107ab2e7d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_DocumentFiscalYearFocus_ba128311-655c-4280-a66c-b53107ab2e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8776d86c-ca7e-4f31-b0c0-6521ffa87d1b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8776d86c-ca7e-4f31-b0c0-6521ffa87d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7a8112cf-da1a-4bad-a7fe-e5de81ffec08" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f0824f9-340d-4491-ae92-9c383abb6215" xlink:to="loc_dei_EntityShellCompany_7a8112cf-da1a-4bad-a7fe-e5de81ffec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1964ffb3-f41b-4f6f-ae16-ccc078bbba63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1964ffb3-f41b-4f6f-ae16-ccc078bbba63" xlink:to="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_aa6d2520-6889-49cf-b66e-d8b7706c2d37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_aa6d2520-6889-49cf-b66e-d8b7706c2d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f621975-3bde-422d-888b-2d20dad33b54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_aa6d2520-6889-49cf-b66e-d8b7706c2d37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f621975-3bde-422d-888b-2d20dad33b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c4bc3383-6951-4a4f-bef1-dbd43b153cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_aa6d2520-6889-49cf-b66e-d8b7706c2d37" xlink:to="loc_us-gaap_ShortTermInvestments_c4bc3383-6951-4a4f-bef1-dbd43b153cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9bf7a695-ef65-448f-a553-83e3b46a6e79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_aa6d2520-6889-49cf-b66e-d8b7706c2d37" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9bf7a695-ef65-448f-a553-83e3b46a6e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23ba42b8-7b13-4e8a-8155-cc29f66071e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_aa6d2520-6889-49cf-b66e-d8b7706c2d37" xlink:to="loc_us-gaap_AssetsCurrent_23ba42b8-7b13-4e8a-8155-cc29f66071e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2917e519-2b84-4a59-b5b3-72090b6c3e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_LongTermInvestments_2917e519-2b84-4a59-b5b3-72090b6c3e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff452873-48e1-449c-91c4-f3b44c629f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff452873-48e1-449c-91c4-f3b44c629f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ad0d3450-7bf4-4f5d-8132-0f6d1472aa7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ad0d3450-7bf4-4f5d-8132-0f6d1472aa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5078a41f-4c06-4f7d-8c8b-85b591487202" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5078a41f-4c06-4f7d-8c8b-85b591487202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9ec526b3-837b-4cd3-9a8e-f4f28d112361" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9ec526b3-837b-4cd3-9a8e-f4f28d112361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c6c1a6f6-063c-4c6e-bc8c-43bff8d9b717" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c6c1a6f6-063c-4c6e-bc8c-43bff8d9b717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9d2fcb4e-283c-4bf1-a678-a782e17c4b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9d2fcb4e-283c-4bf1-a678-a782e17c4b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9d96ada8-3634-41b2-8200-c7a6c64928e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e0b1cd4-4fd1-4115-95cb-7ca93968d86a" xlink:to="loc_us-gaap_Assets_9d96ada8-3634-41b2-8200-c7a6c64928e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1964ffb3-f41b-4f6f-ae16-ccc078bbba63" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_acd7b020-2e0f-40b2-aeed-ea555fc917e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_acd7b020-2e0f-40b2-aeed-ea555fc917e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9b9d9cc3-e3a8-42e8-8fe6-7fccceb3ccc2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_acd7b020-2e0f-40b2-aeed-ea555fc917e1" xlink:to="loc_us-gaap_AccountsPayableCurrent_9b9d9cc3-e3a8-42e8-8fe6-7fccceb3ccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_5eac06e6-3b58-4a31-9293-a41eb012a9a9" xlink:href="allo-20200331.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_acd7b020-2e0f-40b2-aeed-ea555fc917e1" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_5eac06e6-3b58-4a31-9293-a41eb012a9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2edf1244-dea4-4b73-9225-95e295bd4079" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_acd7b020-2e0f-40b2-aeed-ea555fc917e1" xlink:to="loc_us-gaap_LiabilitiesCurrent_2edf1244-dea4-4b73-9225-95e295bd4079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bfeac5c7-4f48-4288-98b9-415c12599f30" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bfeac5c7-4f48-4288-98b9-415c12599f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_be714e8b-8643-45dc-a26c-c3d85338e47c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_be714e8b-8643-45dc-a26c-c3d85338e47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fee36b81-934a-442e-925e-a231e10bf3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:to="loc_us-gaap_Liabilities_fee36b81-934a-442e-925e-a231e10bf3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_68ab80b5-ad20-4d82-8143-b9a9fe16b37b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_68ab80b5-ad20-4d82-8143-b9a9fe16b37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2bde6ce7-cfd8-4779-883b-cfc91fa5c4a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2bde6ce7-cfd8-4779-883b-cfc91fa5c4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5e2362c1-2c66-4967-94d0-828cd69f7c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2bde6ce7-cfd8-4779-883b-cfc91fa5c4a8" xlink:to="loc_us-gaap_PreferredStockValue_5e2362c1-2c66-4967-94d0-828cd69f7c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e9d69ec8-c8a4-4288-82b2-cd4094f4e373" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2bde6ce7-cfd8-4779-883b-cfc91fa5c4a8" xlink:to="loc_us-gaap_CommonStockValue_e9d69ec8-c8a4-4288-82b2-cd4094f4e373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a0ed2e6b-42f9-4cd5-9f9d-1382f4d99509" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2bde6ce7-cfd8-4779-883b-cfc91fa5c4a8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a0ed2e6b-42f9-4cd5-9f9d-1382f4d99509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7159be7a-a80e-4d29-a271-e5738ad1a7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2bde6ce7-cfd8-4779-883b-cfc91fa5c4a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7159be7a-a80e-4d29-a271-e5738ad1a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4cc0d0d-46d1-469e-b818-10da237636c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2bde6ce7-cfd8-4779-883b-cfc91fa5c4a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4cc0d0d-46d1-469e-b818-10da237636c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26578a82-802c-4fe3-a624-f22d67c0c554" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2bde6ce7-cfd8-4779-883b-cfc91fa5c4a8" xlink:to="loc_us-gaap_StockholdersEquity_26578a82-802c-4fe3-a624-f22d67c0c554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_57e7e9a4-d3bb-4ca3-a072-1a7ff5d028db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21d36d28-2684-413a-999d-b8efe9ce8d4e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_57e7e9a4-d3bb-4ca3-a072-1a7ff5d028db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_05b0c075-4a08-4b3c-89c9-459cea051207" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_05b0c075-4a08-4b3c-89c9-459cea051207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12ce9ccb-0165-4506-bae8-f928119e91c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_12ce9ccb-0165-4506-bae8-f928119e91c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_24e61b58-66ba-406c-9874-b55f6d0d16c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_24e61b58-66ba-406c-9874-b55f6d0d16c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_70709562-9058-4353-ac98-21b5604c9055" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_70709562-9058-4353-ac98-21b5604c9055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bdd5c42f-f492-459b-a3e3-5cd85a8211fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bdd5c42f-f492-459b-a3e3-5cd85a8211fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d45dfa1b-617e-4c41-9002-50be62b0a98a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d45dfa1b-617e-4c41-9002-50be62b0a98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_761282b3-1f88-4dca-b90f-3c849ed86e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:to="loc_us-gaap_CommonStockSharesIssued_761282b3-1f88-4dca-b90f-3c849ed86e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_30f650b0-f74c-4292-af34-e602a1c5ea32" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8775659-9ccb-47f3-b019-91bf1d3fe4b0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_30f650b0-f74c-4292-af34-e602a1c5ea32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e286a887-b623-48c0-a34b-a0495c43e914" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e286a887-b623-48c0-a34b-a0495c43e914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25a0501e-8cb3-419b-b63e-a40cb53118e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e286a887-b623-48c0-a34b-a0495c43e914" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25a0501e-8cb3-419b-b63e-a40cb53118e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_68c53767-c014-49ce-9c0e-fbc9375c98bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e286a887-b623-48c0-a34b-a0495c43e914" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_68c53767-c014-49ce-9c0e-fbc9375c98bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c1bc62dc-b8ef-4655-a5e6-aaba1116ee2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e286a887-b623-48c0-a34b-a0495c43e914" xlink:to="loc_us-gaap_OperatingExpenses_c1bc62dc-b8ef-4655-a5e6-aaba1116ee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29468b8c-97eb-42a7-8ed1-9ebe552b91cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_OperatingIncomeLoss_29468b8c-97eb-42a7-8ed1-9ebe552b91cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_63de05d3-721e-4852-9c8d-3e43b2564ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_63de05d3-721e-4852-9c8d-3e43b2564ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_08cb6703-8e06-4457-a917-aa04751a1f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_OtherExpenses_08cb6703-8e06-4457-a917-aa04751a1f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a6791d8a-aaff-4fd1-b476-7c59c7b466c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a6791d8a-aaff-4fd1-b476-7c59c7b466c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e6b3c8d-9846-4e99-979a-7b21f0068738" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e6b3c8d-9846-4e99-979a-7b21f0068738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_837fa209-6e83-42c4-89f4-a9815e7e2d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_837fa209-6e83-42c4-89f4-a9815e7e2d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00ad6484-0b2e-411b-9cba-54766c9b0bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_NetIncomeLoss_00ad6484-0b2e-411b-9cba-54766c9b0bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_689edcb6-5b5b-4a92-ae1c-16d366bb5519" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_689edcb6-5b5b-4a92-ae1c-16d366bb5519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dc6c414f-1c5c-4c72-93a1-6a647f11c017" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_689edcb6-5b5b-4a92-ae1c-16d366bb5519" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dc6c414f-1c5c-4c72-93a1-6a647f11c017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f1325c0-dccd-4804-abe4-bbeaaeea3aee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_689edcb6-5b5b-4a92-ae1c-16d366bb5519" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f1325c0-dccd-4804-abe4-bbeaaeea3aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_8c2ddb03-4042-4d76-8278-35b1aca4fbc7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_8c2ddb03-4042-4d76-8278-35b1aca4fbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_02789e61-7876-40f8-8769-5c5b9f238c90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_73528406-74af-4f12-a269-8c7102893084" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_02789e61-7876-40f8-8769-5c5b9f238c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bc5527d0-5175-4bde-b30d-1c942475e2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6c3ce1f8-14b9-4977-b433-9a0a7e58eedc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bc5527d0-5175-4bde-b30d-1c942475e2c5" xlink:to="loc_us-gaap_StatementTable_6c3ce1f8-14b9-4977-b433-9a0a7e58eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6c3ce1f8-14b9-4977-b433-9a0a7e58eedc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce2c62e1-0b50-4ef5-99e4-b6a58d6f0883" xlink:to="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e99d8d13-b0a5-4868-856e-167d1594ee52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:to="loc_us-gaap_CommonStockMember_e99d8d13-b0a5-4868-856e-167d1594ee52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0f9662ab-df18-4758-81d1-be0f4cdfedca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0f9662ab-df18-4758-81d1-be0f4cdfedca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9e91a1d7-3ae2-4ff4-b7d0-34ebcf3aa9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:to="loc_us-gaap_RetainedEarningsMember_9e91a1d7-3ae2-4ff4-b7d0-34ebcf3aa9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5117afe0-6d8b-4c01-9fe3-9ad38a7fbf46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e2f5c02-c99a-46ee-9e1e-306c6eb1786c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5117afe0-6d8b-4c01-9fe3-9ad38a7fbf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1d73cb22-736c-46ae-894d-0b78b258627d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6c3ce1f8-14b9-4977-b433-9a0a7e58eedc" xlink:to="loc_us-gaap_StatementLineItems_1d73cb22-736c-46ae-894d-0b78b258627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d73cb22-736c-46ae-894d-0b78b258627d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6557380e-11c3-45ca-bd23-5ffc9c86b057" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6557380e-11c3-45ca-bd23-5ffc9c86b057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6d694322-d6c8-48ab-a4d7-29894f9cf7ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockholdersEquity_6d694322-d6c8-48ab-a4d7-29894f9cf7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cc711bc2-d9ad-47fa-8f31-929120745d04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cc711bc2-d9ad-47fa-8f31-929120745d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32d2a32f-1077-452e-aa7f-ebcb34fc2005" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32d2a32f-1077-452e-aa7f-ebcb34fc2005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3def25b6-395a-485e-bc2b-aebc1469dbd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3def25b6-395a-485e-bc2b-aebc1469dbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6df9571-8e47-4767-aad8-507573bbd1db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6df9571-8e47-4767-aad8-507573bbd1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ba344329-1a0b-42ac-8e0b-31651e97a989" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ba344329-1a0b-42ac-8e0b-31651e97a989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_149f291d-6e7b-4d67-9938-87ca248200c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_149f291d-6e7b-4d67-9938-87ca248200c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e083cb3-2dae-4f79-983e-3bb0096414f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e083cb3-2dae-4f79-983e-3bb0096414f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_00b2a3d2-d6e0-4eb1-a603-2353f4c1f5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_00b2a3d2-d6e0-4eb1-a603-2353f4c1f5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59375507-9c90-4264-90f4-6171d674cd25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_NetIncomeLoss_59375507-9c90-4264-90f4-6171d674cd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_497e2036-277a-44c0-88fd-a533fe19eff4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_497e2036-277a-44c0-88fd-a533fe19eff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6fe994e-a063-4758-a94c-bf77f3bc32cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d6fe994e-a063-4758-a94c-bf77f3bc32cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eff07fd7-094b-48bf-b447-499afb454185" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39d30cd3-91ab-49fe-8342-7de7e4b91a07" xlink:to="loc_us-gaap_StockholdersEquity_eff07fd7-094b-48bf-b447-499afb454185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ec70805f-7325-41d7-a84b-5e7fe7f72e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_edcd1e04-494d-43a6-8b64-fa373dd46610" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ec70805f-7325-41d7-a84b-5e7fe7f72e6e" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_edcd1e04-494d-43a6-8b64-fa373dd46610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementofCashFlows" xlink:type="simple" xlink:href="allo-20200331.xsd#CondensedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9bb1ba9c-991c-4f6b-a5d9-9817e6a8c982" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9bb1ba9c-991c-4f6b-a5d9-9817e6a8c982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_effdce34-ee8b-43f7-acff-49595bfb88e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9bb1ba9c-991c-4f6b-a5d9-9817e6a8c982" xlink:to="loc_us-gaap_ProfitLoss_effdce34-ee8b-43f7-acff-49595bfb88e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9bb1ba9c-991c-4f6b-a5d9-9817e6a8c982" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7840bd7f-803d-4f47-82bc-0dcde92cac64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:to="loc_us-gaap_ShareBasedCompensation_7840bd7f-803d-4f47-82bc-0dcde92cac64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f3edbd70-9d56-4116-a4c7-09f5c287f03a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f3edbd70-9d56-4116-a4c7-09f5c287f03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_41724c9d-77e1-4a92-a48e-35b33a18bc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:to="loc_us-gaap_Depreciation_41724c9d-77e1-4a92-a48e-35b33a18bc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_906129e6-c8b4-4671-9657-cd5e66f61ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_906129e6-c8b4-4671-9657-cd5e66f61ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_de2a0dec-282d-4aca-8b3d-089033262a82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:to="loc_us-gaap_LeaseAndRentalExpense_de2a0dec-282d-4aca-8b3d-089033262a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_05523afb-cfe3-4feb-9b4c-4d33a1c2b2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_05523afb-cfe3-4feb-9b4c-4d33a1c2b2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_c11a5f18-0968-41ee-a532-446937323624" xlink:href="allo-20200331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e26084-ae78-4839-be38-b7700ae25c4a" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_c11a5f18-0968-41ee-a532-446937323624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b126fcc-827d-45c8-8465-6fee216cdb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9bb1ba9c-991c-4f6b-a5d9-9817e6a8c982" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b126fcc-827d-45c8-8465-6fee216cdb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4bdd82eb-1730-49da-8cff-6343d77108b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b126fcc-827d-45c8-8465-6fee216cdb3b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4bdd82eb-1730-49da-8cff-6343d77108b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c8d59547-1b37-432b-8516-014bb55d25eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b126fcc-827d-45c8-8465-6fee216cdb3b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c8d59547-1b37-432b-8516-014bb55d25eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b20c0211-b6cc-4878-a4f5-3b5fd208aeac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b126fcc-827d-45c8-8465-6fee216cdb3b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b20c0211-b6cc-4878-a4f5-3b5fd208aeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1fe9b92e-c549-41d2-8eac-dfb00b08aa96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b126fcc-827d-45c8-8465-6fee216cdb3b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1fe9b92e-c549-41d2-8eac-dfb00b08aa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e0de29a2-1879-402b-85ae-c0ccbe26d578" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b126fcc-827d-45c8-8465-6fee216cdb3b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e0de29a2-1879-402b-85ae-c0ccbe26d578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c182a87e-8391-4689-a6e7-7f97df057d05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9bb1ba9c-991c-4f6b-a5d9-9817e6a8c982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c182a87e-8391-4689-a6e7-7f97df057d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5d07da2-b0ff-41fb-9aad-56051aba1e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5d07da2-b0ff-41fb-9aad-56051aba1e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_60573452-ec05-433b-ae3b-29f8e76b4031" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5d07da2-b0ff-41fb-9aad-56051aba1e8f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_60573452-ec05-433b-ae3b-29f8e76b4031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_a7519fc9-3bf1-4e4d-be3a-81b231eeedb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5d07da2-b0ff-41fb-9aad-56051aba1e8f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_a7519fc9-3bf1-4e4d-be3a-81b231eeedb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_28f68814-384a-4760-a8f1-b8d0a78f88ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5d07da2-b0ff-41fb-9aad-56051aba1e8f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_28f68814-384a-4760-a8f1-b8d0a78f88ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f220bce8-ca3e-4e45-9f17-9d1934b1e4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5d07da2-b0ff-41fb-9aad-56051aba1e8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f220bce8-ca3e-4e45-9f17-9d1934b1e4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da2eb68a-565b-4ff7-9736-609ebe852e69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da2eb68a-565b-4ff7-9736-609ebe852e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5070e74d-a2d9-4f0b-a6bc-c10e303628b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da2eb68a-565b-4ff7-9736-609ebe852e69" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5070e74d-a2d9-4f0b-a6bc-c10e303628b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_726be0f0-7328-4f6d-a737-cca5cf70d4ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da2eb68a-565b-4ff7-9736-609ebe852e69" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_726be0f0-7328-4f6d-a737-cca5cf70d4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_79a68115-0c2c-4783-9e27-c2b98ec0f91c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da2eb68a-565b-4ff7-9736-609ebe852e69" xlink:to="loc_us-gaap_ProceedsFromStockPlans_79a68115-0c2c-4783-9e27-c2b98ec0f91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a5e8f4b3-49e9-4c69-8fd1-287977f21365" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da2eb68a-565b-4ff7-9736-609ebe852e69" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a5e8f4b3-49e9-4c69-8fd1-287977f21365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_79c53293-6653-420b-8f87-34823df52bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_79c53293-6653-420b-8f87-34823df52bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bbce766-652d-4589-ae77-3e13d74b9043" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bbce766-652d-4589-ae77-3e13d74b9043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a54e917f-79c3-447b-bb2f-117cefe991ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a54e917f-79c3-447b-bb2f-117cefe991ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ac27365d-94a6-4755-ad48-fefd993b452b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ac27365d-94a6-4755-ad48-fefd993b452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a57ba9d9-eccd-4bde-822f-85ad0692fb9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ac27365d-94a6-4755-ad48-fefd993b452b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a57ba9d9-eccd-4bde-822f-85ad0692fb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0cbd47e2-fb42-4b33-9f7d-03989648e4f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a4cec1b-95e9-4bbf-b216-73fb58826cbc" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0cbd47e2-fb42-4b33-9f7d-03989648e4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_24d2c81e-4c81-43ac-8b0f-2bc9ffb3216d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0cbd47e2-fb42-4b33-9f7d-03989648e4f5" xlink:to="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_24d2c81e-4c81-43ac-8b0f-2bc9ffb3216d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_bf00a8a9-484b-4d75-a2ce-d86432120c19" xlink:href="allo-20200331.xsd#allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0cbd47e2-fb42-4b33-9f7d-03989648e4f5" xlink:to="loc_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_bf00a8a9-484b-4d75-a2ce-d86432120c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="allo-20200331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dd10794-17b7-48f0-bb78-9673070d690e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_020fff31-48d2-4054-81ed-4c47e56cac13" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dd10794-17b7-48f0-bb78-9673070d690e" xlink:to="loc_us-gaap_NatureOfOperations_020fff31-48d2-4054-81ed-4c47e56cac13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48b9740d-6596-41d6-ad24-07815182d34b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumValue_c0ce4563-1f96-43d7-a316-cf684cbd163f" xlink:href="allo-20200331.xsd#allo_StockIssuanceMaximumValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48b9740d-6596-41d6-ad24-07815182d34b" xlink:to="loc_allo_StockIssuanceMaximumValue_c0ce4563-1f96-43d7-a316-cf684cbd163f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_ad41742e-5be7-4d17-a685-9c9c9f1d877f" xlink:href="allo-20200331.xsd#allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48b9740d-6596-41d6-ad24-07815182d34b" xlink:to="loc_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent_ad41742e-5be7-4d17-a685-9c9c9f1d877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_54036b98-18a6-4198-895d-3a5c678f6ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48b9740d-6596-41d6-ad24-07815182d34b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_54036b98-18a6-4198-895d-3a5c678f6ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fa43c30c-5a5a-4da0-bac0-3f4a5da39eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48b9740d-6596-41d6-ad24-07815182d34b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fa43c30c-5a5a-4da0-bac0-3f4a5da39eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_af4961ed-bcfc-4c65-9b6d-745fd740fe95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48b9740d-6596-41d6-ad24-07815182d34b" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_af4961ed-bcfc-4c65-9b6d-745fd740fe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ff1974b-97e8-42ff-a9a7-d3afb64344fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48b9740d-6596-41d6-ad24-07815182d34b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ff1974b-97e8-42ff-a9a7-d3afb64344fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9428f0c3-8d33-4982-8cbd-16e48f972fde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7480df57-0ff2-4aea-b22a-e5ef90f032a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9428f0c3-8d33-4982-8cbd-16e48f972fde" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7480df57-0ff2-4aea-b22a-e5ef90f032a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e83d071f-4e5e-4910-8a11-d18241120bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_26b62d66-4cb7-4375-8fde-425f01b761c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e83d071f-4e5e-4910-8a11-d18241120bcf" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_26b62d66-4cb7-4375-8fde-425f01b761c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3c4c475a-e1f3-4be6-889e-11090bec45a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e83d071f-4e5e-4910-8a11-d18241120bcf" xlink:to="loc_us-gaap_UseOfEstimates_3c4c475a-e1f3-4be6-889e-11090bec45a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_ebaa316f-cb16-4123-9b96-3c271632b924" xlink:href="allo-20200331.xsd#allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e83d071f-4e5e-4910-8a11-d18241120bcf" xlink:to="loc_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_ebaa316f-cb16-4123-9b96-3c271632b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_20b99899-781f-4c18-a4ad-4fb4c55e0642" xlink:href="allo-20200331.xsd#allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e83d071f-4e5e-4910-8a11-d18241120bcf" xlink:to="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_20b99899-781f-4c18-a4ad-4fb4c55e0642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_af48a152-e03b-4bca-a2e4-bc98ca4ad787" xlink:href="allo-20200331.xsd#allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e83d071f-4e5e-4910-8a11-d18241120bcf" xlink:to="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_af48a152-e03b-4bca-a2e4-bc98ca4ad787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd713b54-e1f2-48eb-875a-36c21e3aca42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f573c469-3d36-43c2-a1b3-2f3e3c563477" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd713b54-e1f2-48eb-875a-36c21e3aca42" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f573c469-3d36-43c2-a1b3-2f3e3c563477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34ea93c2-4dec-4063-9ce2-63334627abb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_03d4c03a-2e1c-455b-bd74-2066cae52924" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34ea93c2-4dec-4063-9ce2-63334627abb3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_03d4c03a-2e1c-455b-bd74-2066cae52924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_111e57da-af7c-4e1d-bae2-39065f50caba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4271296a-7956-4d30-b93b-65beecd74b51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_111e57da-af7c-4e1d-bae2-39065f50caba" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4271296a-7956-4d30-b93b-65beecd74b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d275147c-1cbb-483e-a669-42122d05e82b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d275147c-1cbb-483e-a669-42122d05e82b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_159bacd4-bd8b-4c5c-9586-b395389809db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_159bacd4-bd8b-4c5c-9586-b395389809db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_75af7de1-2e8b-40b5-bebe-5f05c79086b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_159bacd4-bd8b-4c5c-9586-b395389809db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_75af7de1-2e8b-40b5-bebe-5f05c79086b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_baffe6c4-f0b9-445f-83b4-3392b0d8db94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_75af7de1-2e8b-40b5-bebe-5f05c79086b2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_baffe6c4-f0b9-445f-83b4-3392b0d8db94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0914ec49-b26c-4e63-b27f-72233e1441da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0914ec49-b26c-4e63-b27f-72233e1441da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e994da46-ab14-4908-ab62-41acd02ae172" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0914ec49-b26c-4e63-b27f-72233e1441da" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e994da46-ab14-4908-ab62-41acd02ae172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_61a6b34c-d12c-4bf6-b6ca-5810d1b5bb09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e994da46-ab14-4908-ab62-41acd02ae172" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_61a6b34c-d12c-4bf6-b6ca-5810d1b5bb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e508a9a-a795-43e8-8812-353cfcf0cd49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_53d6043d-1c8d-430f-b4ce-d33d78d24a6b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e508a9a-a795-43e8-8812-353cfcf0cd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8ca945d3-e4f7-4a72-891c-98148f3e8dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e508a9a-a795-43e8-8812-353cfcf0cd49" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8ca945d3-e4f7-4a72-891c-98148f3e8dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b801a205-3285-4281-a496-361ef4b4d491" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e508a9a-a795-43e8-8812-353cfcf0cd49" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b801a205-3285-4281-a496-361ef4b4d491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="allo-20200331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_22b0db42-9e94-4509-96cd-803f04a5d086" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_22b0db42-9e94-4509-96cd-803f04a5d086" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8f951b67-40f9-4ee7-8352-e3803703c588" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8f951b67-40f9-4ee7-8352-e3803703c588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2079b9a-4a85-424d-b4e1-6585812930f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8f951b67-40f9-4ee7-8352-e3803703c588" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2079b9a-4a85-424d-b4e1-6585812930f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9d0ef16b-6f11-427a-90b9-8d7830c6ae08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2079b9a-4a85-424d-b4e1-6585812930f9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9d0ef16b-6f11-427a-90b9-8d7830c6ae08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dea7b1af-07cd-44e5-a6db-619501ba1a03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dea7b1af-07cd-44e5-a6db-619501ba1a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dea7b1af-07cd-44e5-a6db-619501ba1a03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9b876497-ea91-414e-9a40-1167698a9b89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9b876497-ea91-414e-9a40-1167698a9b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4c23ad87-f2f3-4679-9f84-13bfa7bbf49e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4c23ad87-f2f3-4679-9f84-13bfa7bbf49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_492c94e7-18f2-4e3a-9668-18a4a76ed314" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1e7bc1e-8fb7-499b-9e2b-9d85a2507a14" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_492c94e7-18f2-4e3a-9668-18a4a76ed314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4c5895c7-cc71-44ae-a71c-6961c53d2ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4c5895c7-cc71-44ae-a71c-6961c53d2ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c5895c7-cc71-44ae-a71c-6961c53d2ab6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d09f0180-a91a-4ade-a730-07bff0036d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d09f0180-a91a-4ade-a730-07bff0036d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_92659d2f-dcc1-491c-9de7-2d4c7bf2c6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_CommercialPaperMember_92659d2f-dcc1-491c-9de7-2d4c7bf2c6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_86455fb2-ae56-4d1a-844b-f338ab9f8dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_86455fb2-ae56-4d1a-844b-f338ab9f8dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1cf37438-4e95-4060-9045-fe822224c38c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1cf37438-4e95-4060-9045-fe822224c38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f6ca2847-db97-48ee-a2b0-2c0bac3fe4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f6ca2847-db97-48ee-a2b0-2c0bac3fe4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5b026f19-9653-4b08-a741-c7c5f47680c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b28e4868-066a-44fe-9866-d489ee3d41af" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5b026f19-9653-4b08-a741-c7c5f47680c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ec86ce71-81fa-4262-b8b4-d40433bce72d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c55e9f24-8fe7-4142-9caa-4bf254962a27" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ec86ce71-81fa-4262-b8b4-d40433bce72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5467782f-8b7a-42ea-be63-8fefe83177db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ec86ce71-81fa-4262-b8b4-d40433bce72d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5467782f-8b7a-42ea-be63-8fefe83177db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3389695d-e8bf-49c1-b4a4-7e43aef2ff58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_3680ac81-2251-4e2b-a03f-af0b87d17b72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3389695d-e8bf-49c1-b4a4-7e43aef2ff58" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_3680ac81-2251-4e2b-a03f-af0b87d17b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f4022aad-2e45-4743-a5f0-5273a8d0173c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_21ab0b74-fae7-4201-b19d-e68d9c8f485d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f4022aad-2e45-4743-a5f0-5273a8d0173c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_21ab0b74-fae7-4201-b19d-e68d9c8f485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_bc83aee2-288c-4daf-b685-9316c6b518a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_395cf40b-462d-4337-989d-f054ac9759a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_bc83aee2-288c-4daf-b685-9316c6b518a0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_395cf40b-462d-4337-989d-f054ac9759a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_87c7be99-f439-413d-9558-1badfea9c20c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_395cf40b-462d-4337-989d-f054ac9759a5" xlink:to="loc_us-gaap_InvestmentTypeAxis_87c7be99-f439-413d-9558-1badfea9c20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_87c7be99-f439-413d-9558-1badfea9c20c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8506bbad-6390-448b-848c-84133dc737d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8506bbad-6390-448b-848c-84133dc737d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_eb0402f1-a809-4c97-8db3-094155cc2924" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_CommercialPaperMember_eb0402f1-a809-4c97-8db3-094155cc2924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_34948520-083b-49c0-b6f6-92afb156f586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_34948520-083b-49c0-b6f6-92afb156f586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_221ddaf5-65a1-405c-9908-1e0e29b48d60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_221ddaf5-65a1-405c-9908-1e0e29b48d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f147a4df-78be-4d93-8846-5a907b7b1a44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f147a4df-78be-4d93-8846-5a907b7b1a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5dde3821-0974-44fa-84d5-e71dc8ecf7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46d0da2e-c6c3-46e2-9d39-45f664bbb55a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5dde3821-0974-44fa-84d5-e71dc8ecf7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_395cf40b-462d-4337-989d-f054ac9759a5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d9af91a-f193-44ae-9c26-3970a9066a07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d9af91a-f193-44ae-9c26-3970a9066a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fccd074-545c-426a-8ff4-16efd5dfdd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fccd074-545c-426a-8ff4-16efd5dfdd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe00a8ab-3968-4ee2-9a17-79800bb17789" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe00a8ab-3968-4ee2-9a17-79800bb17789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82a79b4e-9e93-46a5-9be4-2caf3b14a968" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82a79b4e-9e93-46a5-9be4-2caf3b14a968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_6c5283fe-58ed-44ce-b50e-6366cdc71a00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_6c5283fe-58ed-44ce-b50e-6366cdc71a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bf0fa812-bc42-4189-8326-647ab36d69ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bf0fa812-bc42-4189-8326-647ab36d69ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6eadf2e4-0729-47f9-b167-f10734f9ba16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6eadf2e4-0729-47f9-b167-f10734f9ba16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_5780e85c-af75-4806-8b6a-85e35bd2ea64" xlink:href="allo-20200331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d7a00b1a-d514-45d6-a74f-2784d8c4ba73" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_5780e85c-af75-4806-8b6a-85e35bd2ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_707693a0-c948-4a0e-a730-10757cec5a57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_2d8b95a3-58e9-4666-b00b-ef5edd3b5806" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_707693a0-c948-4a0e-a730-10757cec5a57" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_2d8b95a3-58e9-4666-b00b-ef5edd3b5806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponents" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponents"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30c2141c-5862-4521-9356-61cfbee52615" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5aef9022-12da-4387-b560-668309214241" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30c2141c-5862-4521-9356-61cfbee52615" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5aef9022-12da-4387-b560-668309214241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponentsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbe303c9-e674-4a15-a216-c4a7bd7e1dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6c003165-3e65-4dbf-978b-a78786e871e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbe303c9-e674-4a15-a216-c4a7bd7e1dd2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6c003165-3e65-4dbf-978b-a78786e871e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#BalanceSheetsComponentsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6724b0be-f848-4002-8b85-53c008abaea9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e6dedc8-4544-4256-8ae1-3c28c066284e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6724b0be-f848-4002-8b85-53c008abaea9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e6dedc8-4544-4256-8ae1-3c28c066284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e6dedc8-4544-4256-8ae1-3c28c066284e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_45575fd2-5fa5-4b0b-bf5c-87b5f76efcd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ff7df8a2-2b05-43bc-801b-1e62f85b7837" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ff7df8a2-2b05-43bc-801b-1e62f85b7837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_12418cc7-4584-4528-88ee-610b7933ccca" xlink:href="allo-20200331.xsd#allo_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_allo_LaboratoryEquipmentMember_12418cc7-4584-4528-88ee-610b7933ccca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_bab884fe-87b9-44d9-9416-5ba1df1005fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_us-gaap_ConstructionInProgressMember_bab884fe-87b9-44d9-9416-5ba1df1005fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_b1606c01-9471-40b5-8c19-645e891a0c88" xlink:href="allo-20200331.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_b1606c01-9471-40b5-8c19-645e891a0c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d50d6b03-5034-4189-ac88-adaa7db2ad14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731b7a3c-c413-4969-96b9-102fe61746d4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d50d6b03-5034-4189-ac88-adaa7db2ad14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e6dedc8-4544-4256-8ae1-3c28c066284e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5a2c1e7b-0838-416a-96fa-6b00d211ef17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5a2c1e7b-0838-416a-96fa-6b00d211ef17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2dd22e9-179d-40e6-8fff-49b20ba1d8e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2dd22e9-179d-40e6-8fff-49b20ba1d8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c27fa7a0-fac7-40d8-aaf9-f2c6a8f83b24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_852ec034-1c38-41d7-9ac3-504573358de5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c27fa7a0-fac7-40d8-aaf9-f2c6a8f83b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:type="simple" xlink:href="allo-20200331.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_2375f200-e310-44bd-ada1-4baad6610e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAgreementsTextBlock_fe637a18-1f52-4a56-bfa7-50c4de9e57b1" xlink:href="allo-20200331.xsd#allo_LicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_2375f200-e310-44bd-ada1-4baad6610e9d" xlink:to="loc_allo_LicenseAgreementsTextBlock_fe637a18-1f52-4a56-bfa7-50c4de9e57b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0fc53001-bfc6-4306-97e1-c70683a5bdf7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0fc53001-bfc6-4306-97e1-c70683a5bdf7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d879bcae-b7f1-4bca-8fa2-f8f075613ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d879bcae-b7f1-4bca-8fa2-f8f075613ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d879bcae-b7f1-4bca-8fa2-f8f075613ce1" xlink:to="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_0a54390f-5330-4056-8385-48ddd6092acd" xlink:href="allo-20200331.xsd#allo_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:to="loc_allo_PfizerIncMember_0a54390f-5330-4056-8385-48ddd6092acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember_0176ed86-b5c1-4a53-a238-c79a3407de7c" xlink:href="allo-20200331.xsd#allo_CellectisSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:to="loc_allo_CellectisSAMember_0176ed86-b5c1-4a53-a238-c79a3407de7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember_68692457-0fe0-4730-b665-a28c6dd7c6de" xlink:href="allo-20200331.xsd#allo_ServierMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:to="loc_allo_ServierMember_68692457-0fe0-4730-b665-a28c6dd7c6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_6d679463-ee7b-499d-be25-db60817b4c03" xlink:href="allo-20200331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5d9269e6-860d-4977-a8f1-2e449c6f9080" xlink:to="loc_allo_NotchTherapeuticsIncMember_6d679463-ee7b-499d-be25-db60817b4c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis_ddadade0-d199-4160-a47f-417b3df736c6" xlink:href="allo-20200331.xsd#allo_MilestoneTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_allo_MilestoneTypeAxis_ddadade0-d199-4160-a47f-417b3df736c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_83f1dd5c-b107-4a7f-bad3-e7703a0ee307" xlink:href="allo-20200331.xsd#allo_MilestoneTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeAxis_ddadade0-d199-4160-a47f-417b3df736c6" xlink:to="loc_allo_MilestoneTypeDomain_83f1dd5c-b107-4a7f-bad3-e7703a0ee307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember_07ff0954-346a-4473-946c-09f79b7070a4" xlink:href="allo-20200331.xsd#allo_DevelopmentAndSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeDomain_83f1dd5c-b107-4a7f-bad3-e7703a0ee307" xlink:to="loc_allo_DevelopmentAndSalesMember_07ff0954-346a-4473-946c-09f79b7070a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_129d5112-880e-4f28-bfb6-9dceb470bf4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_129d5112-880e-4f28-bfb6-9dceb470bf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_129d5112-880e-4f28-bfb6-9dceb470bf4a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_c2f57446-7483-4c68-bd47-04eda9367087" xlink:href="allo-20200331.xsd#allo_AssetContributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_AssetContributionAgreementMember_c2f57446-7483-4c68-bd47-04eda9367087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember_b459f2ee-b0b8-435d-aee3-4659c55a857a" xlink:href="allo-20200331.xsd#allo_RegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_RegulatoryMilestoneMember_b459f2ee-b0b8-435d-aee3-4659c55a857a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchServicesMember_f77cf1c5-bdf8-493d-9a5b-9938a7e2d6e4" xlink:href="allo-20200331.xsd#allo_ResearchServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_ResearchServicesMember_f77cf1c5-bdf8-493d-9a5b-9938a7e2d6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember_5f645e61-8e33-4854-a069-c9525985344d" xlink:href="allo-20200331.xsd#allo_SalesMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_SalesMilestoneMember_5f645e61-8e33-4854-a069-c9525985344d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_9b7391b2-d897-474c-a33a-14bbc7cafc2d" xlink:href="allo-20200331.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_9b7391b2-d897-474c-a33a-14bbc7cafc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_11916da2-5c30-4549-b246-5f0b03b62669" xlink:href="allo-20200331.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ed308f5-2b35-4426-877a-fe90f652e555" xlink:to="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_11916da2-5c30-4549-b246-5f0b03b62669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bd21aaa6-51bc-4957-baa0-efbae81dfb27" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_srt_RangeAxis_bd21aaa6-51bc-4957-baa0-efbae81dfb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51dc16b0-c346-4169-80a3-7d5e485a8a0a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bd21aaa6-51bc-4957-baa0-efbae81dfb27" xlink:to="loc_srt_RangeMember_51dc16b0-c346-4169-80a3-7d5e485a8a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bc1afbc-8983-4823-94ca-ad2c175346bc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51dc16b0-c346-4169-80a3-7d5e485a8a0a" xlink:to="loc_srt_MinimumMember_3bc1afbc-8983-4823-94ca-ad2c175346bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d8e758a-302a-4965-8483-96f4daee81a5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51dc16b0-c346-4169-80a3-7d5e485a8a0a" xlink:to="loc_srt_MaximumMember_9d8e758a-302a-4965-8483-96f4daee81a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ce8d385a-5190-4767-b65c-f988d0be3169" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ce8d385a-5190-4767-b65c-f988d0be3169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99f050cd-8e4d-4a4d-b999-7965ae803c86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce8d385a-5190-4767-b65c-f988d0be3169" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99f050cd-8e4d-4a4d-b999-7965ae803c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_7f7a65db-b7d5-4ab6-bc72-3950042987af" xlink:href="allo-20200331.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99f050cd-8e4d-4a4d-b999-7965ae803c86" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_7f7a65db-b7d5-4ab6-bc72-3950042987af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_c15e5d6e-bd66-450b-96f7-3878d6f164a5" xlink:href="allo-20200331.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99f050cd-8e4d-4a4d-b999-7965ae803c86" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_c15e5d6e-bd66-450b-96f7-3878d6f164a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969b2468-7342-43e1-8c3b-b630064bc114" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969b2468-7342-43e1-8c3b-b630064bc114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_209f8f5d-f4f2-4e75-b678-3e22dd1372f9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969b2468-7342-43e1-8c3b-b630064bc114" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_209f8f5d-f4f2-4e75-b678-3e22dd1372f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_3cd779ce-9e32-4334-9ba5-e73763d95f10" xlink:href="allo-20200331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_209f8f5d-f4f2-4e75-b678-3e22dd1372f9" xlink:to="loc_allo_NotchTherapeuticsIncMember_3cd779ce-9e32-4334-9ba5-e73763d95f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0388e822-3744-4031-b5fa-320b551552d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0388e822-3744-4031-b5fa-320b551552d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_521a89ef-6456-43c0-87c3-d14784b719e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0388e822-3744-4031-b5fa-320b551552d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_521a89ef-6456-43c0-87c3-d14784b719e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1669da13-537a-429e-8a01-28e6931d9e23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_521a89ef-6456-43c0-87c3-d14784b719e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1669da13-537a-429e-8a01-28e6931d9e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a8aa5a3e-945d-4aaf-96a9-5e35f5ff7f87" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_581442b6-94eb-4659-8c13-9e983dcd96d9" xlink:href="allo-20200331.xsd#allo_MilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_MilestonePayments_581442b6-94eb-4659-8c13-9e983dcd96d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_014df846-624e-4559-84c7-6d6680050b40" xlink:href="allo-20200331.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_014df846-624e-4559-84c7-6d6680050b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_552e86ea-688c-41e2-85b1-3ad4fc3902f7" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AggregatePotentialMilestonePayments_552e86ea-688c-41e2-85b1-3ad4fc3902f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_0d50c88d-62d5-486e-8d67-9317c2e214c6" xlink:href="allo-20200331.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_0d50c88d-62d5-486e-8d67-9317c2e214c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_9106ebe8-5edf-45ea-adf8-5c408d2acb4f" xlink:href="allo-20200331.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_9106ebe8-5edf-45ea-adf8-5c408d2acb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49b12f53-e122-4ef0-9b54-927d1032b68b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49b12f53-e122-4ef0-9b54-927d1032b68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_4867ce95-e444-4610-869b-25caf4a92c52" xlink:href="allo-20200331.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_4867ce95-e444-4610-869b-25caf4a92c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_207ae45a-65f5-4c5b-9041-42d802c6c10d" xlink:href="allo-20200331.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_207ae45a-65f5-4c5b-9041-42d802c6c10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_348ef924-cc7d-46d2-8890-4289d4a5ca1b" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_b13c8d45-49d3-482e-b93b-7b54178f4e34" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AggregatePotentialMilestoneReceivable_b13c8d45-49d3-482e-b93b-7b54178f4e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecoveryOfResearchAndDevelopmentExpense_b5597ae6-7db9-47aa-99a2-0aff1dd996b2" xlink:href="allo-20200331.xsd#allo_RecoveryOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_RecoveryOfResearchAndDevelopmentExpense_b5597ae6-7db9-47aa-99a2-0aff1dd996b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d327713c-852a-461d-81d3-c3dc26cbec28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_AccountsReceivableNet_d327713c-852a-461d-81d3-c3dc26cbec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_90aca6f5-c525-46eb-8902-2e4975b7030d" xlink:href="allo-20200331.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_90aca6f5-c525-46eb-8902-2e4975b7030d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment_5c0cdc33-fcdc-421b-bb6c-b20c3dabaa94" xlink:href="allo-20200331.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_CollaborationAgreementUpfrontPayment_5c0cdc33-fcdc-421b-bb6c-b20c3dabaa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_b0309c04-abe4-4b8e-b7a2-9efd70b9c22b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_b0309c04-abe4-4b8e-b7a2-9efd70b9c22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_73d32e36-b2d3-425f-a969-e8bcedef08d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_73d32e36-b2d3-425f-a969-e8bcedef08d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable_af5437a8-5b8e-49c4-9686-8ec96c819904" xlink:href="allo-20200331.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_AggregatePotentialMilestonePayable_af5437a8-5b8e-49c4-9686-8ec96c819904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense_42d71eec-bad6-4154-844e-b99cdd073fce" xlink:href="allo-20200331.xsd#allo_CollaborationArrangementExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1890e1d6-35f2-4194-989e-7dedf63441bc" xlink:to="loc_allo_CollaborationArrangementExpense_42d71eec-bad6-4154-844e-b99cdd073fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5cb8bead-8c66-43f4-9ce9-6224242a0907" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e8015251-2787-42c2-b532-ce23134efc29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5cb8bead-8c66-43f4-9ce9-6224242a0907" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e8015251-2787-42c2-b532-ce23134efc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_88257603-94db-4fe7-a64d-ba68310ed9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LiabilitiesLesseeTableTextBlock_18f352ce-b80f-42e7-be98-2bcbd772ceb6" xlink:href="allo-20200331.xsd#allo_LiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_88257603-94db-4fe7-a64d-ba68310ed9ca" xlink:to="loc_allo_LiabilitiesLesseeTableTextBlock_18f352ce-b80f-42e7-be98-2bcbd772ceb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_60b6db23-7c27-42b5-b9c8-f1db7af56279" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_88257603-94db-4fe7-a64d-ba68310ed9ca" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_60b6db23-7c27-42b5-b9c8-f1db7af56279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fbd3221e-fc4e-4744-b437-a25a1cd5f58e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_88257603-94db-4fe7-a64d-ba68310ed9ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fbd3221e-fc4e-4744-b437-a25a1cd5f58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f549ceb-fa7e-4f06-8a83-1acb1089608c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f549ceb-fa7e-4f06-8a83-1acb1089608c" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_1dd8418b-4891-486b-8801-38007f30283d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_1dd8418b-4891-486b-8801-38007f30283d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_40d3ad52-6e49-4dc4-bffc-e56ef64a3dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_1dd8418b-4891-486b-8801-38007f30283d" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_40d3ad52-6e49-4dc4-bffc-e56ef64a3dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneMember_686cb099-007a-4d05-a48a-9354812a2cf5" xlink:href="allo-20200331.xsd#allo_LeaseOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_40d3ad52-6e49-4dc4-bffc-e56ef64a3dc1" xlink:to="loc_allo_LeaseOneMember_686cb099-007a-4d05-a48a-9354812a2cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember_9ac62173-250a-4dd0-baa6-99c9c7578c99" xlink:href="allo-20200331.xsd#allo_LeaseTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_40d3ad52-6e49-4dc4-bffc-e56ef64a3dc1" xlink:to="loc_allo_LeaseTwoMember_9ac62173-250a-4dd0-baa6-99c9c7578c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_130fed07-d209-4a4d-8ce8-3604abd342a8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:to="loc_srt_StatementGeographicalAxis_130fed07-d209-4a4d-8ce8-3604abd342a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0017cc0c-9f10-40a4-9db7-893df5946f39" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_130fed07-d209-4a4d-8ce8-3604abd342a8" xlink:to="loc_srt_SegmentGeographicalDomain_0017cc0c-9f10-40a4-9db7-893df5946f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember_3c47b8ef-2776-48c0-ac9f-0ff1464bd408" xlink:href="allo-20200331.xsd#allo_NewarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0017cc0c-9f10-40a4-9db7-893df5946f39" xlink:to="loc_allo_NewarkMember_3c47b8ef-2776-48c0-ac9f-0ff1464bd408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af4a88c6-c922-4d95-a8e2-1150d96789b7" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_f1f33578-3b94-4d87-95ad-9bbdbc99a4a5" xlink:href="allo-20200331.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_allo_AreaOfNewOfficeBuilding_f1f33578-3b94-4d87-95ad-9bbdbc99a4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_134d43f3-13fd-4f84-95c8-a4c2005642c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_134d43f3-13fd-4f84-95c8-a4c2005642c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllowanceForTenantImprovements_580a13b6-b6ce-4a53-b03b-0f4c9b6769ea" xlink:href="allo-20200331.xsd#allo_AllowanceForTenantImprovements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_allo_AllowanceForTenantImprovements_580a13b6-b6ce-4a53-b03b-0f4c9b6769ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dbc4d2ee-0cf6-4e99-ae2a-7ac841c9530d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dbc4d2ee-0cf6-4e99-ae2a-7ac841c9530d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease_3573620e-cbf2-4800-9032-5b7a03a8c96a" xlink:href="allo-20200331.xsd#allo_AreaOfOperatingLease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_allo_AreaOfOperatingLease_3573620e-cbf2-4800-9032-5b7a03a8c96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease_a5087e1c-4cba-4f9c-8ad1-e2eb223abcfa" xlink:href="allo-20200331.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_allo_NumberOfOptionsToExtendLease_a5087e1c-4cba-4f9c-8ad1-e2eb223abcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8ff484f5-240a-4872-ad15-42fd1991ec2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8ff484f5-240a-4872-ad15-42fd1991ec2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ddbf2e02-a61f-4938-bd8a-1d73671c0ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_OperatingLeasePayments_ddbf2e02-a61f-4938-bd8a-1d73671c0ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c31e766d-8303-4861-9f60-f0f15a5d74d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c31e766d-8303-4861-9f60-f0f15a5d74d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cfee1ffe-b226-4796-8952-3a450e56bcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cfee1ffe-b226-4796-8952-3a450e56bcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_fbb258d4-b3d6-4047-82fe-2485e7bc6bba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c0ea4c55-a44f-4154-97f0-316cd7217fd1" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_fbb258d4-b3d6-4047-82fe-2485e7bc6bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_862b346c-ac96-4506-a4ee-705c62275a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f3090a72-5b0b-48fd-a55d-c36f58799720" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_862b346c-ac96-4506-a4ee-705c62275a5a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f3090a72-5b0b-48fd-a55d-c36f58799720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_556bfba6-1c5c-4f55-815f-4a382b0ec3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_862b346c-ac96-4506-a4ee-705c62275a5a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_556bfba6-1c5c-4f55-815f-4a382b0ec3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1f0f439d-7456-45ec-abce-f1998bdcafa0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_862b346c-ac96-4506-a4ee-705c62275a5a" xlink:to="loc_us-gaap_OperatingLeaseLiability_1f0f439d-7456-45ec-abce-f1998bdcafa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b9f74a43-7c0d-497c-abe5-6423f7d60be7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5a971c69-2861-4bb9-9ca5-169b837cd205" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b9f74a43-7c0d-497c-abe5-6423f7d60be7" xlink:to="loc_us-gaap_OperatingLeaseCost_5a971c69-2861-4bb9-9ca5-169b837cd205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f0d280f6-cd47-441a-9eb5-dba83cd7ff24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b9f74a43-7c0d-497c-abe5-6423f7d60be7" xlink:to="loc_us-gaap_VariableLeaseCost_f0d280f6-cd47-441a-9eb5-dba83cd7ff24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ade4b91c-4153-45d2-a562-c2253c34f844" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b9f74a43-7c0d-497c-abe5-6423f7d60be7" xlink:to="loc_us-gaap_LeaseCost_ade4b91c-4153-45d2-a562-c2253c34f844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_80b9f3af-9291-40a7-b2fe-fe32aa878a94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_80b9f3af-9291-40a7-b2fe-fe32aa878a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b31b9741-3f5c-4902-b7f7-5dd54cacc39e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b31b9741-3f5c-4902-b7f7-5dd54cacc39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3f38aa03-a6e6-49f6-825e-0630c5d5b859" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3f38aa03-a6e6-49f6-825e-0630c5d5b859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aa45b327-5715-4ac4-ae82-522d2aebf8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aa45b327-5715-4ac4-ae82-522d2aebf8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1af1bba3-c382-439d-8bc8-89bc424eba1b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1af1bba3-c382-439d-8bc8-89bc424eba1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_45ef0032-31ca-49c7-9a8a-c229c4bf5c66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_45ef0032-31ca-49c7-9a8a-c229c4bf5c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e533f9-5ec1-48db-96c9-cf8ae8d9b7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e533f9-5ec1-48db-96c9-cf8ae8d9b7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_131f2be1-c21c-4eaa-89ce-bd41dfd7e48f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_131f2be1-c21c-4eaa-89ce-bd41dfd7e48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllowanceForTenantImprovements_623f4674-46fb-4342-befa-1c3c861cd6d3" xlink:href="allo-20200331.xsd#allo_AllowanceForTenantImprovements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_allo_AllowanceForTenantImprovements_623f4674-46fb-4342-befa-1c3c861cd6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7c42a659-717c-4978-976c-af7dbb59705c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_c8043f35-9f6e-4105-be6c-b4c4d719e6d3" xlink:to="loc_us-gaap_OperatingLeaseLiability_7c42a659-717c-4978-976c-af7dbb59705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20200331.xsd#EquityMethodInvestment"/>
  <link:presentationLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_979206b2-5cea-4fa3-b6d7-7ec196d10153" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_2f8a22d4-9f2e-446e-928e-89b2fd5b1da6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_979206b2-5cea-4fa3-b6d7-7ec196d10153" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_2f8a22d4-9f2e-446e-928e-89b2fd5b1da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#EquityMethodInvestmentDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e890f3a0-0829-45e7-9e3b-370ef9d8e1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f383ea6-37da-476e-95b7-57c94568b2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e890f3a0-0829-45e7-9e3b-370ef9d8e1b7" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f383ea6-37da-476e-95b7-57c94568b2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f383ea6-37da-476e-95b7-57c94568b2fa" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1daf13ad-41fb-4792-8bbd-a8d943a83c9f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_df6eb81d-dfd3-4d46-960d-ef4c8d54b75d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1daf13ad-41fb-4792-8bbd-a8d943a83c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_c6a25c0d-7e70-468e-b1b4-f05f12030d9f" xlink:href="allo-20200331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1daf13ad-41fb-4792-8bbd-a8d943a83c9f" xlink:to="loc_allo_NotchTherapeuticsIncMember_c6a25c0d-7e70-468e-b1b4-f05f12030d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f383ea6-37da-476e-95b7-57c94568b2fa" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_000c9ede-26d5-4766-acba-70683f0f02f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_000c9ede-26d5-4766-acba-70683f0f02f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts_00b0bc61-495d-4d52-aa53-87dbe95d9536" xlink:href="allo-20200331.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_allo_CostMethodInvestmentTransactionCosts_00b0bc61-495d-4d52-aa53-87dbe95d9536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4c5ec49f-f7e3-4f73-b31f-1b8f6d317f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4c5ec49f-f7e3-4f73-b31f-1b8f6d317f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_1806b77d-88fc-4e25-af28-d1fd89393143" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_1806b77d-88fc-4e25-af28-d1fd89393143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_7458198a-fb32-48cf-a10a-981e337acf81" xlink:href="allo-20200331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e83e546e-26cb-4304-880a-9e0c3eca67a9" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_7458198a-fb32-48cf-a10a-981e337acf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1effc11-aa87-4282-89ec-8c7917c6f4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f27a4675-29ad-4038-87f1-9e613f7cf53c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1effc11-aa87-4282-89ec-8c7917c6f4bf" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f27a4675-29ad-4038-87f1-9e613f7cf53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5846e8f4-f1be-49e8-a1e2-59836351f792" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ba9c21e3-8058-4204-9147-ce66f85abb68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5846e8f4-f1be-49e8-a1e2-59836351f792" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ba9c21e3-8058-4204-9147-ce66f85abb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6f45c733-f1fb-4f15-893e-b1a33114fec3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5846e8f4-f1be-49e8-a1e2-59836351f792" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6f45c733-f1fb-4f15-893e-b1a33114fec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_64be0ed7-f97e-43ed-b9ba-cc08040c2eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5846e8f4-f1be-49e8-a1e2-59836351f792" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_64be0ed7-f97e-43ed-b9ba-cc08040c2eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1c183a7a-69b4-4855-8691-6cff532fee83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5846e8f4-f1be-49e8-a1e2-59836351f792" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1c183a7a-69b4-4855-8691-6cff532fee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c46d38e0-2ca6-482b-a6f0-c4cea267d15b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c46d38e0-2ca6-482b-a6f0-c4cea267d15b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9047cf68-61a0-4a11-9a84-a7256e219148" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:to="loc_srt_RangeAxis_9047cf68-61a0-4a11-9a84-a7256e219148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d56b0436-1764-485a-9835-fdf370a9752a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9047cf68-61a0-4a11-9a84-a7256e219148" xlink:to="loc_srt_RangeMember_d56b0436-1764-485a-9835-fdf370a9752a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a3fa48a5-2130-4f54-8f0a-1edc8dd169f1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d56b0436-1764-485a-9835-fdf370a9752a" xlink:to="loc_srt_MaximumMember_a3fa48a5-2130-4f54-8f0a-1edc8dd169f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c16a9809-847d-4a5d-8754-ea71048d82c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:to="loc_us-gaap_AwardTypeAxis_c16a9809-847d-4a5d-8754-ea71048d82c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c16a9809-847d-4a5d-8754-ea71048d82c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_124fd63c-278e-45ca-bdcb-520a47a01262" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:to="loc_us-gaap_StockOptionMember_124fd63c-278e-45ca-bdcb-520a47a01262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4798d2ab-c3d2-4b4d-b9bc-e9e2ada78dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4798d2ab-c3d2-4b4d-b9bc-e9e2ada78dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0a772334-8f2e-480a-be75-c34922fee584" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27e3b720-4566-4f37-a054-27dc8ecac7f5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0a772334-8f2e-480a-be75-c34922fee584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_593fe50a-01e4-41ad-a645-9d77d086da4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_df8b9728-2083-4058-b966-92e9ffe9365e" xlink:href="allo-20200331.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_df8b9728-2083-4058-b966-92e9ffe9365e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod_9b075cb9-b107-4be1-9db4-62d2c072a54f" xlink:href="allo-20200331.xsd#allo_StockOptionGrantedPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_allo_StockOptionGrantedPeriod_9b075cb9-b107-4be1-9db4-62d2c072a54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_617789bf-fcc4-4a14-8ffd-9a4009a2e288" xlink:href="allo-20200331.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_617789bf-fcc4-4a14-8ffd-9a4009a2e288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d5d1725d-8298-450d-a877-d0a6814c2deb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d5d1725d-8298-450d-a877-d0a6814c2deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_439b63b6-4568-47a8-970e-fa54e10ce14f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_439b63b6-4568-47a8-970e-fa54e10ce14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbdcf3b4-6074-4ee0-a557-7a7659a87318" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbdcf3b4-6074-4ee0-a557-7a7659a87318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bcd5e46d-7e30-4065-af16-222d8214429b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bcd5e46d-7e30-4065-af16-222d8214429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_50bf5c3d-a171-4542-85c4-4af36bc2a667" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_50bf5c3d-a171-4542-85c4-4af36bc2a667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_369cec48-932e-4524-a55b-a8b6568a31ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_369cec48-932e-4524-a55b-a8b6568a31ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_ea3ed921-c061-4ee0-bfab-d9f12861ac49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d2b4052-9723-44be-a863-6f2c52b120ad" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_ea3ed921-c061-4ee0-bfab-d9f12861ac49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dac3f4b0-391a-4c44-8a3c-9bf48fbfa02b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99f48316-22a0-4d35-a37e-1ba7a78390a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dac3f4b0-391a-4c44-8a3c-9bf48fbfa02b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99f48316-22a0-4d35-a37e-1ba7a78390a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ae83ebf7-202e-441e-8295-47dec6318629" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99f48316-22a0-4d35-a37e-1ba7a78390a3" xlink:to="loc_us-gaap_AwardTypeAxis_ae83ebf7-202e-441e-8295-47dec6318629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9f4666b-0dea-4ba8-8a23-f17ccdca7375" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ae83ebf7-202e-441e-8295-47dec6318629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9f4666b-0dea-4ba8-8a23-f17ccdca7375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_49dd4a12-adcf-4f18-af06-270cb046cead" xlink:href="allo-20200331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9f4666b-0dea-4ba8-8a23-f17ccdca7375" xlink:to="loc_allo_TwoThousandEighteenPlanMember_49dd4a12-adcf-4f18-af06-270cb046cead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99f48316-22a0-4d35-a37e-1ba7a78390a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17f2aa2b-188a-4300-be3a-2375676d0673" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17f2aa2b-188a-4300-be3a-2375676d0673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5a746db3-b0b8-4928-90d1-e185337fcffa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5a746db3-b0b8-4928-90d1-e185337fcffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_333169df-fa07-439d-bc77-24d8fdd45073" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_333169df-fa07-439d-bc77-24d8fdd45073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8cff8426-79d2-44e9-9efd-7882c82e7818" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8cff8426-79d2-44e9-9efd-7882c82e7818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7b063064-1982-4c22-8402-692c8fce0d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c06185-16df-4133-ad7c-1e1f129c45d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7b063064-1982-4c22-8402-692c8fce0d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a994b38a-52bb-4f90-97a1-e8e820ec0c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a994b38a-52bb-4f90-97a1-e8e820ec0c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9d39f934-106f-42d1-9df3-f8c1810c0127" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9d39f934-106f-42d1-9df3-f8c1810c0127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6d977eb-0420-40f3-b3f4-0ab242a456f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6d977eb-0420-40f3-b3f4-0ab242a456f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6084d6da-2878-4ce8-8909-8ca70b8ad27d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6084d6da-2878-4ce8-8909-8ca70b8ad27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e8793164-12eb-4491-9b28-c2b1e396cc43" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e8793164-12eb-4491-9b28-c2b1e396cc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_89520bc1-2da9-42b4-be5f-d58a4e5896d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_89520bc1-2da9-42b4-be5f-d58a4e5896d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635dfba0-2d7c-4cbb-a44f-eb9e33e62fde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743ae9b5-d940-494a-b506-510bce009fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635dfba0-2d7c-4cbb-a44f-eb9e33e62fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5ec4b363-3674-4ec2-9da2-3a1e45d42af5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5ec4b363-3674-4ec2-9da2-3a1e45d42af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f001e363-0cb5-4f78-9805-c0580503bb76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f001e363-0cb5-4f78-9805-c0580503bb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ec452e29-2bdd-4c24-89be-f25c0d0a27d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ec452e29-2bdd-4c24-89be-f25c0d0a27d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2b82f7a0-3954-406f-ae07-0efc60c1fb1c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2b82f7a0-3954-406f-ae07-0efc60c1fb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_09e9a259-8d06-4ce9-a842-caeb6d7109a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_09e9a259-8d06-4ce9-a842-caeb6d7109a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2470472f-aede-4fbe-b55c-1d38664232b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2470472f-aede-4fbe-b55c-1d38664232b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c3082457-a076-463c-9221-7b60b383e9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c3082457-a076-463c-9221-7b60b383e9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e343f35b-8294-4ab0-ba0d-d87303f082ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_932d7150-03a3-4d37-a72c-060b44c72c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e343f35b-8294-4ab0-ba0d-d87303f082ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60ee524b-04f1-4668-9d36-53d894d8cd64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60ee524b-04f1-4668-9d36-53d894d8cd64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7f41212b-38bd-40db-b0b0-7ac348ac8b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:to="loc_us-gaap_AwardTypeAxis_7f41212b-38bd-40db-b0b0-7ac348ac8b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab328702-4671-4016-8621-941eaa6a433c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7f41212b-38bd-40db-b0b0-7ac348ac8b0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab328702-4671-4016-8621-941eaa6a433c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_5ca23818-b2c6-4bb8-904e-4c849e6a071e" xlink:href="allo-20200331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab328702-4671-4016-8621-941eaa6a433c" xlink:to="loc_allo_TwoThousandEighteenPlanMember_5ca23818-b2c6-4bb8-904e-4c849e6a071e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d0e83412-c477-4b1e-980c-86789d50113a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:to="loc_srt_RangeAxis_d0e83412-c477-4b1e-980c-86789d50113a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5d45e53-2c6c-4e72-a8a9-c7d90d629f4c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d0e83412-c477-4b1e-980c-86789d50113a" xlink:to="loc_srt_RangeMember_c5d45e53-2c6c-4e72-a8a9-c7d90d629f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_98e5f809-54ee-4d66-a600-fa08eaad3bd5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5d45e53-2c6c-4e72-a8a9-c7d90d629f4c" xlink:to="loc_srt_MinimumMember_98e5f809-54ee-4d66-a600-fa08eaad3bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_be289c81-7502-45d1-ab86-3a1590e3ce37" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5d45e53-2c6c-4e72-a8a9-c7d90d629f4c" xlink:to="loc_srt_MaximumMember_be289c81-7502-45d1-ab86-3a1590e3ce37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_089bbe94-e1ae-4fc0-a957-0b23097b9ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7eeafd05-5277-4930-964a-557ea5c595d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7eeafd05-5277-4930-964a-557ea5c595d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cf6ff33-68cd-4fbb-a515-0c4c17ef9401" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cf6ff33-68cd-4fbb-a515-0c4c17ef9401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_4d45bb9b-e4e0-4145-8561-f0ad9d0c5962" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_4d45bb9b-e4e0-4145-8561-f0ad9d0c5962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5de3f111-057d-4c76-95a8-2956bf098fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5de3f111-057d-4c76-95a8-2956bf098fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a1f38949-9168-4d3d-b3e2-488abe7c63e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f819f2ae-dd2f-4a25-9673-8f3ff2a8672d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a1f38949-9168-4d3d-b3e2-488abe7c63e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7cf3da8-3b2d-4222-b8b1-683f564f3401" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24563ac3-0e0d-4127-9cd1-1949ddef9425" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7cf3da8-3b2d-4222-b8b1-683f564f3401" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24563ac3-0e0d-4127-9cd1-1949ddef9425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_718f3c4f-6c65-4422-b891-2e22243ac730" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24563ac3-0e0d-4127-9cd1-1949ddef9425" xlink:to="loc_us-gaap_AwardTypeAxis_718f3c4f-6c65-4422-b891-2e22243ac730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed68a152-f606-43f4-9a0f-279c5dc8522e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_718f3c4f-6c65-4422-b891-2e22243ac730" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed68a152-f606-43f4-9a0f-279c5dc8522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8e0dd919-7f07-4932-8be3-dea28a5911ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed68a152-f606-43f4-9a0f-279c5dc8522e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8e0dd919-7f07-4932-8be3-dea28a5911ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24563ac3-0e0d-4127-9cd1-1949ddef9425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_899aa065-6283-454d-a020-cbd0a8bb483e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_899aa065-6283-454d-a020-cbd0a8bb483e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bebc980-7459-4829-b245-db991d0d5ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bebc980-7459-4829-b245-db991d0d5ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_290edb37-3fe9-4696-8ccb-f1b051bc1350" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_290edb37-3fe9-4696-8ccb-f1b051bc1350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0217e53a-bd6c-495b-952e-6aa3200c8d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0217e53a-bd6c-495b-952e-6aa3200c8d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a8c4c110-133e-4880-8677-f6c60628a56d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f0d85c7-12b8-4a6a-a0b3-fbedd9b91403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a8c4c110-133e-4880-8677-f6c60628a56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_14980822-2c6b-4eb3-932f-7bbe141ea95b" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_14980822-2c6b-4eb3-932f-7bbe141ea95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95b10b34-cb6a-4012-b733-5efd87c03626" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95b10b34-cb6a-4012-b733-5efd87c03626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c113c424-64f7-4e56-9f38-39452c63e373" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c113c424-64f7-4e56-9f38-39452c63e373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e8d0bff3-6f48-4f5c-b88d-46cef18ed3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e8d0bff3-6f48-4f5c-b88d-46cef18ed3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e9e9c0fc-83f2-4ef0-b84d-7cef33958f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e9e9c0fc-83f2-4ef0-b84d-7cef33958f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8abf7695-d96f-4740-8305-fb3d80669600" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c50fe77-0337-4b52-97f4-9160f17f1e0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8abf7695-d96f-4740-8305-fb3d80669600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7af80f7e-df72-4850-a383-867fe1306e39" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7af80f7e-df72-4850-a383-867fe1306e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c252a3a6-f26c-459b-9321-50d8cbfccf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c252a3a6-f26c-459b-9321-50d8cbfccf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_fbedd3be-55c7-4b36-825e-623f125a44f4" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_fbedd3be-55c7-4b36-825e-623f125a44f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_42211c64-459f-4f30-bc27-9a4dd51dcc89" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_42211c64-459f-4f30-bc27-9a4dd51dcc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4fd81501-f98c-40d5-a6d2-0f44a3e1e732" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4fd81501-f98c-40d5-a6d2-0f44a3e1e732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_a1c92f51-be42-487e-a90f-bda5923b0129" xlink:href="allo-20200331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9baf16c4-cbe1-4ad7-b6eb-ffde8760abff" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_a1c92f51-be42-487e-a90f-bda5923b0129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9fefe740-3aea-42c6-8b67-b63431f663f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_19e68a4e-f1ec-4aa7-93b8-04318556b168" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9fefe740-3aea-42c6-8b67-b63431f663f6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_19e68a4e-f1ec-4aa7-93b8-04318556b168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e8b073fe-c552-47bb-8b57-bc3209bdc839" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_19e68a4e-f1ec-4aa7-93b8-04318556b168" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e8b073fe-c552-47bb-8b57-bc3209bdc839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3a8c7f0b-aeba-47c6-b7e3-9a52c6577262" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8b073fe-c552-47bb-8b57-bc3209bdc839" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3a8c7f0b-aeba-47c6-b7e3-9a52c6577262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37bce362-96db-4793-860b-229793592f36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a8c7f0b-aeba-47c6-b7e3-9a52c6577262" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37bce362-96db-4793-860b-229793592f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac94f87c-7022-4e89-83ea-c85a2de77af8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a8c7f0b-aeba-47c6-b7e3-9a52c6577262" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac94f87c-7022-4e89-83ea-c85a2de77af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_88909549-8a2f-4a88-9385-e507e1e159dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_19e68a4e-f1ec-4aa7-93b8-04318556b168" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_88909549-8a2f-4a88-9385-e507e1e159dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9ffa15b-eeb3-4f97-bf33-111719143653" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_88909549-8a2f-4a88-9385-e507e1e159dd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9ffa15b-eeb3-4f97-bf33-111719143653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20200331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9fa65022-71a9-475b-a043-84d8b3389fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a8f3c539-ff02-4563-8fd8-a04377c269b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9fa65022-71a9-475b-a043-84d8b3389fdb" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a8f3c539-ff02-4563-8fd8-a04377c269b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2f573709-ad8e-44de-8f5f-e8ad1004e45d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2f573709-ad8e-44de-8f5f-e8ad1004e45d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_54cc864d-4d36-4db2-b4d4-ef2000842faf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_54cc864d-4d36-4db2-b4d4-ef2000842faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_54cc864d-4d36-4db2-b4d4-ef2000842faf" xlink:to="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_723b4793-e1b0-4b9c-82b7-d7bf69f525f5" xlink:href="allo-20200331.xsd#allo_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:to="loc_allo_PfizerIncMember_723b4793-e1b0-4b9c-82b7-d7bf69f525f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ByHeartIncMember_f944b290-3044-4bf4-9b11-67951f0528d1" xlink:href="allo-20200331.xsd#allo_ByHeartIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:to="loc_allo_ByHeartIncMember_f944b290-3044-4bf4-9b11-67951f0528d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember_dfd3130e-30b3-4c37-9a83-4624f78df112" xlink:href="allo-20200331.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:to="loc_allo_TwoRiverConsultingLLCMember_dfd3130e-30b3-4c37-9a83-4624f78df112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember_0d887183-3f15-4f3b-988c-4517731e8c6b" xlink:href="allo-20200331.xsd#allo_BellcoCapitalLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3deceff1-5215-4b70-808a-4dba2b483b16" xlink:to="loc_allo_BellcoCapitalLLCMember_0d887183-3f15-4f3b-988c-4517731e8c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_18f9b537-5eea-477d-85fe-06f9f9a6f5a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_18f9b537-5eea-477d-85fe-06f9f9a6f5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_18f9b537-5eea-477d-85fe-06f9f9a6f5a0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TransitionServicesAgreementMember_3f575f81-4172-4eea-9af4-e69edba944c1" xlink:href="allo-20200331.xsd#allo_TransitionServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:to="loc_allo_TransitionServicesAgreementMember_3f575f81-4172-4eea-9af4-e69edba944c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember_b8e7c8e4-4a3d-4f85-98d3-8207ba77c50e" xlink:href="allo-20200331.xsd#allo_SubleaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:to="loc_allo_SubleaseAgreementMember_b8e7c8e4-4a3d-4f85-98d3-8207ba77c50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember_b0d1d710-b43a-489a-b502-33dc0aac8ff1" xlink:href="allo-20200331.xsd#allo_ConsultingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_89c78988-e7e9-4200-b5aa-6acf5520fc3a" xlink:to="loc_allo_ConsultingAgreementsMember_b0d1d710-b43a-489a-b502-33dc0aac8ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f2c702ae-5776-42c2-808f-2a7016ed3b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f2c702ae-5776-42c2-808f-2a7016ed3b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2d52f04-2792-4364-9b41-3db94586834b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2c702ae-5776-42c2-808f-2a7016ed3b0c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2d52f04-2792-4364-9b41-3db94586834b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1402ca1f-4bc6-4ce2-bad0-854196acb8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2d52f04-2792-4364-9b41-3db94586834b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1402ca1f-4bc6-4ce2-bad0-854196acb8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cafa08af-c4e2-4e4a-8daf-3f396b550e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cafa08af-c4e2-4e4a-8daf-3f396b550e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1e187cb7-bc81-47d9-80fb-622e7c777aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cafa08af-c4e2-4e4a-8daf-3f396b550e3f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1e187cb7-bc81-47d9-80fb-622e7c777aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_f48fcacc-a714-4420-aeb1-e3d58218a542" xlink:href="allo-20200331.xsd#allo_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1e187cb7-bc81-47d9-80fb-622e7c777aa8" xlink:to="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_f48fcacc-a714-4420-aeb1-e3d58218a542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a2f1abfd-3ef7-4796-b78b-f81d8e247c74" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_srt_RangeAxis_a2f1abfd-3ef7-4796-b78b-f81d8e247c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6394069b-b833-4373-a737-4c1a09f2ad3f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a2f1abfd-3ef7-4796-b78b-f81d8e247c74" xlink:to="loc_srt_RangeMember_6394069b-b833-4373-a737-4c1a09f2ad3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87a30df6-ab6e-45df-87de-3ed246ba9495" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6394069b-b833-4373-a737-4c1a09f2ad3f" xlink:to="loc_srt_MaximumMember_87a30df6-ab6e-45df-87de-3ed246ba9495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis_9b24e6dc-aa03-41b3-a282-1e29196cc0fd" xlink:href="allo-20200331.xsd#allo_PaymentTermsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_allo_PaymentTermsAxis_9b24e6dc-aa03-41b3-a282-1e29196cc0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_80c54cc4-06d3-4cdf-947a-e9481657af74" xlink:href="allo-20200331.xsd#allo_PaymentTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsAxis_9b24e6dc-aa03-41b3-a282-1e29196cc0fd" xlink:to="loc_allo_PaymentTermsDomain_80c54cc4-06d3-4cdf-947a-e9481657af74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2019Member_74344b97-d037-4d10-b010-565fbb2984ac" xlink:href="allo-20200331.xsd#allo_PaymentsCommencingJanuary2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsDomain_80c54cc4-06d3-4cdf-947a-e9481657af74" xlink:to="loc_allo_PaymentsCommencingJanuary2019Member_74344b97-d037-4d10-b010-565fbb2984ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2020Member_28c3293d-95a4-4566-9b95-5c2d85ad9231" xlink:href="allo-20200331.xsd#allo_PaymentsCommencingJanuary2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsDomain_80c54cc4-06d3-4cdf-947a-e9481657af74" xlink:to="loc_allo_PaymentsCommencingJanuary2020Member_28c3293d-95a4-4566-9b95-5c2d85ad9231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c7cebb01-7df9-4371-83a6-8284c6942dce" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_91cc5dcd-924d-4b49-a6ba-0034b276e330" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_91cc5dcd-924d-4b49-a6ba-0034b276e330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts_a0d9d541-5ba1-40c2-859a-4e86efd72a84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_RelatedPartyCosts_a0d9d541-5ba1-40c2-859a-4e86efd72a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_e8fd18ac-1cd1-43e8-a96b-330e17b0c6de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_SuppliesExpense_e8fd18ac-1cd1-43e8-a96b-330e17b0c6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_c5da8135-63b1-4869-88e4-4d7978a20a68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_c5da8135-63b1-4869-88e4-4d7978a20a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice_c663eb44-a85e-4000-8a7f-8d41a9d238a2" xlink:href="allo-20200331.xsd#allo_AreaOfOffice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_allo_AreaOfOffice_c663eb44-a85e-4000-8a7f-8d41a9d238a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_1fe87e3d-6c18-480e-978c-fd4acceea99e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_1fe87e3d-6c18-480e-978c-fd4acceea99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_1df8cdd1-8903-4b2b-95de-0f072b0401ba" xlink:href="allo-20200331.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_1df8cdd1-8903-4b2b-95de-0f072b0401ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_092ba755-2c19-4965-92a9-498e58c546bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_us-gaap_SubleaseIncome_092ba755-2c19-4965-92a9-498e58c546bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_cbce56da-6b17-4d7a-a56c-4887954cfaf9" xlink:href="allo-20200331.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_cbce56da-6b17-4d7a-a56c-4887954cfaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_f01edcde-0448-4f55-93f4-1058bf074e6e" xlink:href="allo-20200331.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_be33b018-ab86-4992-b82f-992b2619932e" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_f01edcde-0448-4f55-93f4-1058bf074e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20200331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4e6b88f0-ec2b-48b7-b488-1026d7dbc876" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6e47e667-a107-45b9-bb01-796ac0926b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e6b88f0-ec2b-48b7-b488-1026d7dbc876" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6e47e667-a107-45b9-bb01-796ac0926b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_76a17ea4-cda0-4dd8-8bb2-8ebc5376363f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_08687abc-2c47-430e-9331-80f76f7b312a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_76a17ea4-cda0-4dd8-8bb2-8ebc5376363f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_08687abc-2c47-430e-9331-80f76f7b312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cacf9ffa-6055-4cd6-b37d-daa1f550cb5c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c7b4e0cb-2312-427a-9703-7db02ea7bc40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cacf9ffa-6055-4cd6-b37d-daa1f550cb5c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c7b4e0cb-2312-427a-9703-7db02ea7bc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d412dffa-0827-4c71-9e7a-26aa513092f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_00719178-5ba7-474f-a938-2ad9134020c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d412dffa-0827-4c71-9e7a-26aa513092f2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_00719178-5ba7-474f-a938-2ad9134020c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2a388cb0-bee6-436a-a224-1c9697f0969f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_00719178-5ba7-474f-a938-2ad9134020c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2a388cb0-bee6-436a-a224-1c9697f0969f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2a388cb0-bee6-436a-a224-1c9697f0969f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ac6fd47-c2a6-40cf-8b31-1a20aa493d88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ac6fd47-c2a6-40cf-8b31-1a20aa493d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b240909d-3039-4e3c-93e6-b4f2bead0d09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b240909d-3039-4e3c-93e6-b4f2bead0d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_365033d7-0a15-469d-ae63-0a6838fba87e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_us-gaap_EmployeeStockMember_365033d7-0a15-469d-ae63-0a6838fba87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember_87516dc5-a09b-4945-b4ca-3f37ef720c75" xlink:href="allo-20200331.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_allo_FounderSharesOfCommonStockMember_87516dc5-a09b-4945-b4ca-3f37ef720c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_e8aed560-5450-4407-bc2e-5e6e5b2100c9" xlink:href="allo-20200331.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cea52b5-5a4b-46d0-8f7f-3e17e9f19605" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_e8aed560-5450-4407-bc2e-5e6e5b2100c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b3858bc-242b-454f-aab9-b75dacf3ebb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_00719178-5ba7-474f-a938-2ad9134020c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b3858bc-242b-454f-aab9-b75dacf3ebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48796fa7-6c15-47f2-a7eb-88bc87325b74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b3858bc-242b-454f-aab9-b75dacf3ebb7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48796fa7-6c15-47f2-a7eb-88bc87325b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20200331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_60fb44c3-3b02-4cb3-ad13-35a436c52b52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_921187ac-50d7-423b-a467-0ed6c2aacc8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_60fb44c3-3b02-4cb3-ad13-35a436c52b52" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_921187ac-50d7-423b-a467-0ed6c2aacc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="allo-20200331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>allogenelogo1.jpg
<TEXT>
begin 644 allogenelogo1.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
M?6SUO3HBX[$V*UCHQ_9GRMD5D2Q-4K:DNRD&T'',XUFF[=/D" ^777(DDH@1
M!7W,6;YW7J&FY:Z5IK>4P0,[V!8]5[*MP;  7)'$DV%K&_1/X0/APV3OO;,W
M<7?T U"%LMX,7%+.L*B(+US2A&4R,SL42-CY:JI9E=G7R\<>&#RO\CMO\BXC
MBQR,M;C;##943:'>O[E*L(MI:JK8:=5Y>YOHR1D(EA'EG*],5^ >CW/"JNT'
MA$0(KZ1C)YYMD[NU+,U)=)U)S,LH;H8@=2E5+$$@"X(!YW(-N-JS_P 6GPS;
M!VML*7N1L+&73)]/EA7)@1G:&:*>9(%=5=F\N5)9(^"%49"UUZ@&JV!DN5S-
MIBE,4IBE,4IBE,4IBE,4IBE1O^5KF"7A?PRV3L2%E4X[9]O0#66GR@< >DO5
MM;.D"SS,G4?SE*@$'LR4QBBD*S%-(_\ A2@.Q;7TG\\:Q'CN+XR>_)Z.E?#]
MT;+["3X5%G>3?']P]B9>J8[A=7G'D8WI\Z0$=8_)('E]%T /.N;L8QCF,8QA
M,8PB8QC"(F,81ZB8PCU$1$1^(Y8:N5Q))N>=?\Q7\JP;]/-S"'27*24XYVJ2
M3;:_Y,-6T=#F=K%3;Q.W:PW>NJBJDHJ(D2"VQB[R(,F0 .Z?JQX=>B8 .A[^
MTCZ;I@U"(7GQC<^N,VZOWILWJ'5Z:LS\,>^/S!O!]K9C@:;JP"K<\%R8P3'[
M/,4M'8<6<Q>BKSN0G70RF*4Q2F*4Q2F*5S9/+-^(]R\_:W(_HN*RQ.UOT>Q/
MR0^R:Y4]Z/UIZW_36_!6H\,S]1A73'\9WX?/#;^[OK#^+#'*X[D_K[,_I#_9
M-=8^T_ZL]"_LO'_U8K>/,+4A5S[//I^)ON7]4M/?T7U?)YV+^C</WTGX;5S1
M^)'];6?^0QO]WCJ&C-OJ"*Z"7@+_  R=-_K=N#^D^SY V^OTDF^\C_ %=+_A
MN_5+@?E\G_>)*F8S4*G:F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2JR?D,\"EQY![ZMV
M]^,NQ]=U1;:,R[M%_HVTE[/$Q;*X21Q<3UAK-@JE9N+MPC9I YGCAFY9IB@[
M56.1P9-0B*,7;C[?S:CJ#ZAI<L:&5NIUDZ@ QYE2JM\X\2".!OQL;#H;V*^-
M72MC;*Q=E]P\#/R4TZ)8<;(PQ"[M G".*6*::!085LBR)(>I H*!E+O(;XLO
M&3&>/2E71W8K='[!W)M \,6X6"&8NV-;@H6 !X>+JE7"1,$B]:%?2*[AT^61
M:*/#BB46Z8-R=VQ[3VNNW(',KB3-EMU$"R@"]E6_$\222;7X<!:H*^)'XA\C
MOIJ^)%@8LF#M33A)Y$4C*TLDDO2'FFZ?=5NE%5(U9Q&.HAV+FVX_+3EEJ'AA
MIR9W3N.3=MH-BX1B8*!AT47EFN=H>HN%HRKUEBNNU0<2;Q)HJH8ZRJ+=LW24
M664(F0Q@S6KZOAZ)A-G9I(C!L .+,QY*H])]? "Y)M44]L>V6Z>[6ZX=I;4C
M5LQU+R2.2L4$*D!YI6 )"*6  4,S,RHBEF JN_'?4U=]M0++<1/;44\@";E:
M.W#[ZVMHH3 0SU!LYU['P[V0(3\Z#4RK=,P_FO<%_P +D<+W1_'>_AVQ[^$E
MVMZ?F $^KAZ+^-7LR/\ #RMIA.+NGJUD1W ?!Z82_P!R2,EI%7PZPK$?.Z#\
MVK)/'3D1JSE1J&I[NT[.'G*5;6ZXH [0!E-0DHQ7.TEZY8XOU5C1<]#/4S)+
MI=ZB9P[545%6ZB2RDF:;J6)JV&F=A-U0./801P*L/ @\_J@D$&J []V)N3MM
MNG*V?NN$0ZOBL+])ZHY$8=22Q/8=<<BD%38$<5=5=65:SOF0\SN[=6;NM'%/
MB=8D-?IZ]38QNT-J-8R/DK7(VU\R3D']3J2DPU?L8**@&;U%%T^30"04D053
M14121 [B8]H[/PLK"75-57S/,N42Y"A0;!FM8DFQL+VM:]R>'/[OIWXU_1]P
M3;-V9*,88H"Y&0%5I&D(ZC''U A%0$!G ZR_4%*A;M%/Q>\W/.K06P(6:O.V
M;+O_ %R+Y +?KS:,@E.+RT2=<@O1K]Q>-'-EK,XBV$_M%2+JLRJB KM7!  F
M;1J>S-$SX&2&)8,BWNN@M8^M1P(]/"_H(J&]H?$!W$VWJ<>1J&;+J6E]0\V'
M(/666_'HE(,D;@7Z2"5O\Y&'"K\VL]@TW=^K*-L^H*A,43:E(@+E B_;) =Y
M7+?"MI5HWE&!CN$D77LGP).FQQ-Z2H'3-\2CD%Y./-A93XTO">)RIMZ5-N!]
MHX&ND6DZG@[@T?'U?!/7IV9CI*EP.*2J& 8<;&QLRGD;@U5JY:?376*P;&F[
M9P\VOKZL4FPR*\DCK+<"MLC4J0+I4RR\57KA5Z_=GDW!H*'$&:3Q@BY;H 5-
M1PY, JFDW2NXL<>.L6KQ2-,HMUQ])ZO658K8^FQL3R Y53_>GPIY63JDF;L?
M-QH=/E8L(,GS%\J_$JDL:2ET'VH9 RBP+,?>K;#Q]^'O5'C;E7W+CEEN>ASM
MXH<4]&#EQ<GJ^H]4%EVJD)(SYIZU'C'MEL<@TD3L62KELQ2;^Z,5)NLY.BJE
MK^[=^)G8301VQM,%B[N0"P!X ^"B]N ))-A?P,I]B?ABSM$W-!ED2:SO:3J3
M%Q\6*1U1F4AV1;>9*_1U>\418TZF*W ==Z8OS->-.7M9:@VY/0:#]1TBR1E)
M2C[2A:HH[47<-U"&M\O1V5::M6PH%.=VNZ29"FJ0Q%CAW]D0)O7;#S>2,I>J
M]KE9 O[XJ%^4FWKKH7D_";\06+IGYUDV[,T 4L43(PY)@H (_$)D-*2;D!%0
MR74@H.%XP.>/@+A>4.PY?D?PVVUKVIFVXX/>9ZH6Y>4>:SFYBRF&7>W6C7>F
ML;2Z8Q5I4="],T+'O&HK+G4;+IH&3;ISAMWN F+A1XVH(TT"J.B2,J24M[H(
M) :PY,&%Q:]SQ/,CNQ\+F3JVY,K4]N3)IVK23O\ 2<3*21%2?J/FD%4:2)B]
M^N)HCTOU6*BR#]OCZ^GN2T-MBK[LY7;#I6S9BA2;6P4[6&O6DX[I'WJC7"3N
M%L-HLMGC:[)SS6%=I NC&%BFZ*KDB9EUE42G;*_O7M_?3L5L/2XWC2069WMU
M=)YA0I(%^75U$VO8 \1YNV?PRC;FLPZ_O+*Q\N?&</%CPAS%YBFZ/))(J,X0
M\1'Y:@L 68J"AG<Y?\FJCP\XX[0Y$71DO+Q>O81%>/KS1RFT>6>SS,BRK]3K
M;=THFO[0LQ8I1LDNX!)?V;457 IG*D8HZ/I.FRZOJ$6GPFS2-Q/W( NQ^0 V
M'"YL+\:L5OC=N%L;:V9NC/4O#BQ@J@-C)(S!(T!XVZG906L>E;M8A;50OV_Y
ME?(CMN\O;BGR)MVM&!I$7D+2-5JI4ZHP#0BG>VC"-6:1I&P-DNGVSR[E^JMU
M$#F$O0H3EB;0V_B0"'Z.DC6XL_O,?7QX#]R!7.36^^O<_6M0;.&J3XD?5=(L
M>T4:#P6P]YQZ3(SD^)MPJQ-X3O+ALOES9Y_C1R8=Q<WM:'JZ]NU[L>.B64&X
MO4+#*MT+) VJ+B4FL*G:(E%XD[:N6;9LD\9$7!9,JR *.8_WEM3&TJ)=2TT%
M<4MTNA)/23R*D\>D\B"38VMP-A9_L#WKU;>V7)M/=C))K*0F2&=5"&95L'21
M5 7S%!#*RJH90W4 RW>8GF=S/T[P;U"XVUMUU(.4W<@2 I].KZ;9S:;O9EVZ
MSI*)AV[MRU:H-VK5N==X\74(W:(%ZB)E3HHJQ)K>MX6@X9S,PD@FRJ/G,WH'
MV23P ]=@;[=INTNZ^\>Z5VQM98U98_,GGE)$./$" 7D*AB220L:*"SL?!0[K
M #7/J:4E;:V3MW$=1A1%G_IO'=<VX67ML;%F6+_CC:/DZ'"0\V_0;]1]L=U'
MIJG$ ]=, ZC'L7= &8>=AVQ[_:R78#TV* $^JX]HJ[N?_AYLNELVE[H#ZT$N
MJRX71 [V^:63)DDC4G[<)*5'VC59ATGNC7/(;5M.W)J:PH6>@WF++*0<JDFH
MW6 "+*M'T=(LEP*XCI>(D6ZK5VV5 %$'")R&^(9)^#G8VHXB9N&W7CR"X/V0
M1X$'@1X&N>^[]I:_L7<>7M3<\!QM;PY.B1"01R#*RL.#(ZE71QP96!'.HA_*
MUX@'/.ZTUS<VHKS6:!N:$KC>G3;*[(2Y*9=X%@\=O85P^EX!E,2L!-PAI!PE
MZY(Y\#ML=),P) @0QM.W;LTZ_*N;AR+'FJO20U^E@#<7(!((N>-C<6'"U6D^
M&GXIH^S&FY&T]T8>1G;3FR#/&V.4\_'D9560*DK(DD<G2IZ3+'T,&8=760/$
M>+/PN3'"W:A^0.]+]3KSM&(AYN!H=?UZG.NJG4_O T-%2]F4L-BBZW+2TV\@
M7+E@FA\M;H-T'2QA.L<Y!2^&U-D/HF7^<<^1),L*0@2_2M^!:Y"DDBXMT@ $
M\_#+_$A\6V+W;VV-C[-P<O#VY++')DRY)C$TWE-UI"(HGE1(UD"2%O-9F9$%
MD /58"R0ZI!3%*8I3%*8I3%*8I3%*8I3%*H>_4!\PC;^Y<_R'568%WK;C"A(
M4]9%N<?9R.W)-5!39#]3M.'KJ5X[)I! 54G<V<QSP4Q[5S":<-AZ3] TGZ;*
M+9&39O9&/F#Y;EO6"/17.CXE=\'<N]?[O8;]6E:0&B(')LEK>>?7T66'B/=9
M'MP8W@7S>*KC7N;]K.^:N?P$9L"KRM6?6FEU'8E=0E6XH#,4J]PK:P56Q,#=
M1(O'RT6[*8I@'J0Y3IG JA#E+\8,F#)5F@8,JNR&W@RFS ^L&LCJ6DZCH\D<
M.I0O#)-CQSH&%NJ*9 \;CTJRGY#<&Q!%>>KU@FJG/P=JK<DZAK%6IB,L$!,,
M5/2>Q4U#/4)&+DF:O0?3=,7S9-5,W0>AR@.?22-)8VBD ,; @@\B#P(^45Y<
M7)R,+)CS,5S'E1.KHPYJZD,K#U@@$>NNFYP8Y10W,CBQJ/?\85HUD[=72-;M
M"LU"G3KNP8%4\+=84J?J*+HM$9UFJLR];M55CUFZH@ *!E;M;TQ](U.7 :Y5
M&]T^E#Q4_4Y^L$5UI[>;O@WUL_"W+#TB6>*TJC[29/=E7T@!P2M^)0JWC6VV
M8JMUIBE,4IBE,4KFR>6;\1[EY^UN1_1<5EB=K?H]B?DA]DURI[T?K3UO^FM^
M"M1X9GZC"NF/XSOP^>&W]W?6'\6&.5QW)_7V9_2'^R:ZQ]I_U9Z%_9>/_JQ6
M\>86I"KGV>?3\3?<OZI:>_HOJ^3SL7]&X?OI/PVKFC\2/ZVL_P#(8W^[QU#1
MFWU!%=!+P%_ADZ;_ %NW!_2?9\@;?7Z23?>1_@"NE_PW?JEP/R^3_O$E3,9J
M%3M3%*8I6I?*SG%QCX6UI.P\@-G156>/VJKFNTM@16=V!; 3,HD4*]4(P%I5
MPU.Y2%$SU8J$:@J( NX2#XYE=+T74M8D\O C+ 'BQX*OM8\/D%R? &M+WEW"
MVEL+$&5N7+2%V!*1#WYI/O(ENQ%^'6;(#\YA59'D7]3%M><?2$3Q:TA5*'7_
M ,XW9W#;RSJXW)TGWF,G(MZQ79*'JU;=]G:46Z[J>2#H(]X]P 22-/[<8J*'
MU.9I)/N8_=7V=1!8^T!:J5NCXL=9R)&AV?I\.-C<A+DDRRG]L(T98XSZBTP]
M?HBOMGF4\EUQD32+_E7<HH?46.BRJ<!1*?'-TUA3 $"M*U58PCA- B12D,OZ
MJH?$1.)CG,;9XMH;<A7I7%0_?%F/^<Q^M4/9O?7NQG2^;)K,Z<381I#$HOX6
MCC6]O"]SZ[DD_P JQYCO)=4Y LC'<K[P_5 2B9O9X2B6^/4*!5""0T?::G+M
M"@<BI@$2$*?KT, @8I#%_LNT=N2KTMBH!^U+*?JJPK^8G?3NQA2^;%K.0Q]$
MB0RK^]DC8?4%_'F!4GG'7ZEO>59>,HKDYIRF;1K_ 'II.;5K51Q0+NV1[1]9
MZXAW[B:J-A<]P!VH(EA"=!'JIFM:AVYPI 6TV9XI/N7]Y?9<68>WWO94M[7^
M*_<.(ZP[MP8,S&Y&2"\,H'B2I+QN?4/*'KJS1Q"\@O%?F_!'D=$;':O[(Q9%
M?6'65F1)6]F5A(12*HI*59RNL+^/047(F>0C%I"+]4X)@Y$_4H1QJV@ZIHK]
M.=&1&38.O%&]C>!]3 -ZJMGLCN9L[N#C^;MW*#92K=X)!T3QC]M&2;@7 +QE
MX[FW7?A6Z>8:M]IBE,4IBE,4K7_D;RET'Q,HBNQN0&RH#7E<$ZK>+)(JJNIZ
MS2")"'/$U*LQR3N?L\H4BA3'19-UA02$55?32*8Y??I^F9VJS_1\"-I)/&W(
M#TL3P ]IX\AQK6MT[PVWLO3CJFY<N+%Q>(7JN7D8?:QQK=Y&](538<6L 357
M7D[]2_>I5W)0/$?2\/5(7HLW:["W1W3]J<$/W%(_CZ+6Y5O78!TCT 2 [D9I
M(_7[:0?O<DO3>W,"@/JLQ=_N(^"^PL1<_(%]M5"W=\6&HS.^-LK CAQ^($V5
M[\A]:PHP1"/#J>4'Q%1!7KR]^2383M1W,\LMCQ'>L"I&U%)7-<-$"E+V)HIH
M4*#KH&1(3H'YP3F.(=QQ,<1,.VP;3V[CBR8L9^^N_P"$34(ZCWN[JZFY>?6L
MI./*'H@ ]5H43A[;WYFYXU\"M>5CR,5-^22B^7^YG3@ATS@G9;"E=& F2[^T
M#Q5Q9SL6H0?4'N*9$2G^'< ] Z?N3:^WY5Z6Q(0/4.D_56QKS8G>3NCA2>;#
MKF>6_P#$?S1^]E#K];CXU*#QI^I(Y+T9]'1/)J@4W>=5]1).0LU79MM;;*02
M.;L</@)%I*4"8%N3[:;,D5%^J8!*9T0# 8FM:CV[TV=2^FR/!+X!O?3V<?>'
MMZF]E2[M/XJ=V:=(L.[<:#4<.XZI(P()QZ3[H\EK<POEQWY=8YBU_P 3^9O'
MGFKK\=A:!O36RM&(M4+15WZ81-YH\B[(J9"-N%765.]BU%Q;+ W<D%9@]]%0
MS5PN0AC!%NJZ/J&C3_1\]"I/S6'%6'I5O'UCF+\0*N9LS?FV-_:;^<]M9 E1
M;"2,^[+$QO998SQ6]CTL+H]B49@":J8^0SR]>1#1G-;D;J/5G(7[KZ]H>Q'L
M%5*__)-HZ;^512+"/63:_-;%K27FWW:JN8>]RY64'K\3= #)4T#:>W\W1L?+
MRL?JR)(P6/7(+FY\ X ^052_N=WM[G[>W]JFB:/J?DZ9C912-/HV(_2H"FW4
M\#.>?-F)]=:9_P#GH^4_^U'_ /1+CI_LBS+_ -R=L?S;_P#9+_M*T3_J'[P_
M\8__ (F%_P#&J]QQ"O5JVCQ-XO[,O4I\\N^Q..^E+U<9OV,=&?.+5;M:UJ?L
M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
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MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
M<%F !9D%E879  &5; F:'5EJ8I3%*CY\BOD+U;X^=.&NUK(G:-DVL'\9J75[
M9V#>0M\\U1(9=_)+%!16(IL 9PDI)/A(82@H1%(IW"R1!SVW] R=>S/)B]W'
M6Q=_!1Z!Z6/@/E/ &HS[H=S='[9Z%^<,RTVJS77&QP;-*X'$L?M8DN"[V\0J
MW9@*YZ_)/DWNGEKM*:V_O2YOK=;)8YTF:)S&;0%6A2K**LJQ4(,JAF<!78WU
M1]-!(.Y0YCK+G5<**K*3YIVFX>E8JXF$@2(?58^+,?$GT_(+  5S+W7NW7MZ
M:Q)KFX9VGS7X <DC6_".).2(O@!S-V8LQ9C@//=6M5[[7NJ=H[<EU*_JG6U^
MV=/)$345A->TZQ727336.*:)U(VMQTD\(150HE*(DZ&$.@?'/AD96-B)YF5)
M'$GI=@H^J2*R6F:-K&MSG&T;$R<O)'VD,3RMQY>ZBL>/LK9:2\<'/N)8N)%[
MPVY(@U:$!1<S74-UD5R)B<I!.5I'1#IVH1/NZG$J9@(0!,;H4HB&.7<.A,W2
M,S&N?_$4?9-;9+VL[DP1F630M5Z%YVQI6/U%4GV\. XGA6HMBK5CJ$N\KUL@
M)NKS\<H*,A!V**?0LNQ6*(@9)Y&R2#9ZU4*(" E.0HATS*QR1RH)(F5HSR((
M(/RBM)RL3*P9VQLV*2')4V9'4HP/K5@"/E%9SXI\I-K\/-U5+=^H9I:/GJZ[
M3)+PJSET2 NU:653&8I]K9-E4@D8*80)T,4WVVZY4W"(D7124+XM4TS%U?#?
M"RQ>-AP/BI\&7T$?7Y'@36P[-W?K.Q]?AW!HDA7)B;WD)/1+&?G12 ?.1A\H
M-F6S*"/0<X]U5CD9ROW5O2G(/6=;VG9VMQCH^2*!9&*^:P$.J\AWXE $E'L.
M_!5JJ=/JDH=$3)F,02F'YZ+AR:?I<.%-8R1+TDCD;$\1[1QKU=PM?Q-T[SS]
MQ8(9<7,F$JJWSEZD6ZGUJ;J2.!(N+BU:I9E*TRNGKP$_W$N%7]TKCC_0[3<K
M9KO]=YG]+F_UC5UP[;?JZT#^Q<'_ ':*MM<Q5;K7_#&*0ICG,!2E 3&,80*4
MI2AU$QA'H   !\1Q0D 7/*J;_E[\VUBNDW:N+_#6VKP6OHM20K>S]VUYR=":
MOK](ZC*4K.N9ANH56*H[8P'2<RS<2N)@_4&JB;$/4?R[M/9D<*+J>KIU9!L4
MC/)1X,X\6]"G@OC[WS:+][N_^5GY$VT=BSF/3$+)D9:&S3'DT<##YL0XAI![
MTI^81'QDJ[F,8YC&,83&,(F,8PB)C&$>HF,(]1$1$?B.2750R23<\Z_LU:N7
MSENR9-UW;QVNBU:-&J*CARZ<N%"I(-VZ"13JKKKJG I"% 3&,(  "(X)"BYX
M 5_41Y'$<8+.Q   N23P  ',GP%;>U;QZ\ZKI&(S5:XA\BI")<IF6:2*FI+I
M'M'R!417]=@O)Q#,C] Y $"'1$Y5#_8*(G^SF)EU_1(6Z),O'#CP\Q3;VV/"
MMWP^V7<3/A&1B:)JC0D7#?1I5!%KW!91<>@B]SP'&L4[7XT<B=$^F;=&C-MZ
MK07.1-J^ONOK55HQZ=3X$!A*S$6UC7_<8!+^95.'<42_O@$ ]6+J.GYW_HYX
MI3Z%=6(]H!N*PVL[3W1MVQU[3LW#4\C-#)&I]C,H4_(36$<]E:_6:^/W(G<?
M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
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M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
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M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
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MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
M1Q!8$<:YUN6 KE]4^7TZ^XKU3.=A=3Q#]VK0]QZ[N:%Q@C++C&$DJ3#N;96K
M0#4G5$)>-68+L$U3= !O)K%^(F+TT;N!B03:']*<#SX9%Z3XV8])7V&X/M45
M9'X7]<U' [B?F:!F.G9V+*)4N>GJB4R1R6Y=2D% ?N9&'HK>_P"IH8W89?B7
M)'*Z/KE.-VLQ;G1!86;>[*NJ6N\+("4PMTW3R"10%GW@!SD0<]@B!5.E,^Z"
MS]>&W'Z-:0>KJ]WG\EK>P^NO])7^'I-I Q=SXX*C7C)AL;VZCC@9 7I\2%D+
M==N +1WYK>JSD3UTFJ\O]/ TN+;@"_6LY7Y820WYL9WKL7A#%;GIQ(*C,'QH
MHPID!1@&P&4Z4Q@$P>Z!8.O4!*$\=N%F&WB9;]!R'*7^YLH-O5UA_EO7'#X[
M)=*D[W(FG='TQ-$Q5RNGGY_F9#+U\>#?1FQ[<O<Z#;C<SL9OM4RIBE,4K&%4
MTCI>AVVQ7^CZBUA3;W</4^]MUJE!JE=MMH]99-PK]XK)$1+.9F_5<(D.;W*R
MO<<H&'X@ YZ9<W,GB6">65X$^:K,Q5?8";#Y*Q&'M_0=.S9=2T_!PX-1G_A)
M8X8TDDN;GK=5#/Q%_>)XUD_/-67IBE,4K\4E(Q\/'/Y>6>M8V+BV3J1DI%\N
MFU9,(]B@HY>/7CE8Q$6[5JW2,HHH<0*0A1$1  S^JK.P1 2Q-@!S)/A7SEEB
M@B:>9@D**69B; *!<DD\  .)/@*YGOD2Y7R'-#EUMG>!E5PJCZ8^Z^LH];U"
M_*]95,5(JI$!!7[;1U,MDSRKU+J)22$@X[?L],L=M_2UT?28L+_O0.ISZ7;B
MWU/FCU 5R>[G[SEWYO;-W!<_0V?RX%/VL$?NQ\#R+"\C#P=VM6DF9FH_J_)X
M#>)']7;A='[2L<5['8_)]VPV7)J+H^F^::W:-G#74\0<P'.15HZAGKJ?1, %
M.!9_L.'5, "#-]:K^<-8.-&;X^,"@]'7]N?J@+^YKI#\-^RO[K["76,I.G5=
M783M<<1  1CK["I:8?EK'E4XV:55A*8I3%*8I3%*8I7_  Q2G*8AR@8I@$IB
MF #%,4P=!*8!Z@(" _$,4(!%CRKFV>5/B2?AMS3VIK:*C%(_75G>AL[4@^F<
MK0=?W1R[=M8EB=3J95"GSB#Z$[C"8Y_EW>81[^HV(VQJOYWT:+)8WR%'0_WR
M^)^^%F^6N5?>+91V+OW,TJ%"NES-Y^-Z/)E)(4>J)P\7I/1?QJ.G-@J+JO8?
M3Y<PR[VXH.- 6J54=[&XQKLZ\R]XL"CJ5U'.G>+T)R@8P$,HG556KJ#%,@&*
MU9LV/<;JL4,A+?ND?0=4^GQ"V/D\3ZI!\[]]P;UDMZ*Z)?#/OD;BV8=M9CEM
M4T@A!<\6QGN82/R=FBL/FJL=S[U3]9HE63KFR>6;\1[EY^UN1_1<5EB=K?H]
MB?DA]DURI[T?K3UO^FM^"M1X9GZC"NDUXF/PX>(?[)8_]*RV5WW5^D.7^5/V
M!75;LO\ JLT3^A+^$U2(9K]2?5!GZAC\1ZS?LEU7^BGN3IL']'E_*O\ 9KF]
M\3?ZTY?Z%C_@FH.\W2J]U?D^GG_#AK7[6]J?I1AD&;^_2%OR2?8-=(OAD_59
M%_3<C\(5.-FE58.F*5C_ &EJK76[*'8]8;7I\)>Z%;8]6-GZS/M?<L7K=0/L
MJ)G(9-TPD&BG15L[;*(NFBY2JHJ)J$*</OBY61A3KDXKLDZ&X(YC]D>D'@1P
M/"L9K&C:7K^G2Z1K,$>3ILR]+QN+@C[(8<U92&4V*D$ U3FYZ?3S[AU=(3>P
M^&;AUN;6ZBZSXVJ9-TW0VU4FZJA3>SA'"WMHK8D4S Q^PQ3M98J8$3]N\.!U
MQEW0]_8F2JX^L6AR.76/X-O;XH?JKZQRJC/<?X9-<TB634]B$Y^E$D_1V(&3
M&#X(399U'&W%9+6'2YNU5S;15+31Y^3JMTK<_4+1"N3,YBMVB'D:_/Q+LG03
MM9.'EFS218.2 /Q(JF0P?^C)!BEBFC$L+*\1Y%2"#[".!JKF9AYFGY+X>?%)
M!F1FS)(K(ZGT,K ,#ZB*^!G[KS4Q2OK0,!/6F8CZ[6(27L=@EW)6<5!P,:\E
MYB3=G 1(UCXR/1</7KDX%'H1,AC#T_)GY>1(D,DK!8P.))L![2>%??&QLG,G
M7%Q(WER7-E1%+,Q]"JH))]0%6$^!WT^F^=U/H2_<M1D^/VJ/4;/QHHE;&W3<
M6?<FH+(\4K[AIK-JX()BJ+2I%91(Q.WY:!3E7)H.N;]P<-6@TJV1E<NK_NU^
M7[?]S[O[;PJS7;GX9]QZ_)'J6]>O3-&N#Y/#Z5*/1T\1 #XF0&06MY7$,+EN
MEM):LX[ZWKFI-,TN'H5 JK7VT3 PR)BD%0X@=W)23U<ZS^9FY-?JJ[?.U5G;
MI8PG54,81'(AS,W*U#(;+S',D['B3]@>  \ . \*O9H.W]'VQI46BZ#CIC:;
M"+*BCZK,3<L['BSL2S'B2365,\M9BF*4Q2OYK(HN$56[A)-=!=,Z*Z"Q"JHK
M(JE$BB2J9P,11-0AA Q1 0$!Z#@$@W'.OXRJRE6 *D6(/(BJMGD=^GSBKR_G
MMR<%_DM2L;PZLE/<>Y5RA#U"6=G[U'*^L9Q<2,JD[<J]!"(?"2*[CF]!RR3(
M1N:3=O;]:!5P];NT8X"4<6'WXYM]\/>]()XU4#NG\,\.H22:[V\\N'*:[/A,
M0L3'Q..YX1D_Q;VCXGI>, +53G;.EMMZ'MKJB;FUQ<M8VYH'J*05S@)"">K-
MQ'HF^8>]021DXU?\J3IL95NJ40$AS (#DI8N9BYT0GPY$DB/BI!'L-N1]1XU
M3'6M!UK;F:=.U[%GQ,U?M)49"1Z1<693X,MU/@36,L]-8BF*5[S6FK=D;EN,
M5K[4]&M.Q+M-J>G&5FGPK^=EW!0.0BKDS5@BL9LP: H!G#E7L;MT^IU3D( F
M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
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MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
M=UC14C7J=V=B  !Z+DD@*"3:HQT?J ?'4JJDF>T[3;D44(0[A;5LP9) IS 4
MRRH-W*ZXII /<8"$.?H'P*(_#-6'</;9-NN4?_C-6';X(._*J6&-IK$#D,R.
MY]0N +GUD#TD5)7QSY7<>^6=2<W7C[L^!V+"QSA-G,HL22$5/U]XL4YD&UBJ
MT^RBK)!G=%2.*!G35)-R4AC(F4* FS:--U?3M7A,^G2K+&#8VN"#ZU(##U7'
M'PJON_>V>^NV.J+I&^=.GP,N12T9;I>*51S,4T;/%):XZ@CDH2 P4FU82Y?>
M23BSP@L%1J>]K-9&5FND,[L,1"U>J2=D=IP35Z:-"4D%&_H,V;=W((K)(E%4
M53F04'M I>H^#6=S:3H4B0Y[,)76X"J6X7M<^ XWM[#6X=K.P'<CO#@Y6I[,
MQ\=]/Q)5B>2:9(E,A7KZ%!NS%5*LW"P#+QN;5I[_ ,0)X[/\I-L?S72?_;LP
MW_,3;?W4W\F?V:E3_H>[\?S?3/\ WB?Z-27<8>4VE^8&KFVWM%V92R5%67DJ
M\^(]CW,1-05@B?04>PL[$/"E<Q[\C1X@X( ]Q%6SA)4AC$.4<V?2M6P=9Q!F
M8#=4/40;BQ!',$'D>(/L(-5\[B]M]V]J]QMM;>6.,?5!$DJ]+!XY(GN%DC=>
M#+U*RGD0ZLI ((KQ''WG/QSY/;-W'J/4%LDIVYZ,E%HN[-WE>E8J.5,VFI&O
M.GU?E'B!&DU&MYF,41%4@E[NXAR 9,Y3C\-.U[3=5RI\/#<M/CFS7! YD7!\
M1<6_^E9C?/9K?O;K;ND[HW3BQPZ3K,8?'*RH["\:RA944]4;F-PUC>W$$A@1
M6Q6Q]@U/4VO[KL^^2I(2E:]JT[<K5+&17<BP@:Y&N964<)-&J:SMZX*T:F])
M!$AUEU!*FF4QS%*.2R<B'#QWRL@],$:%F/H %S[?8.)\*T/0-#U/<^N8>W-%
MB,VKYV3'!"EP.J25PB L2%4=1%V8A5%V8@ FL3<7N56G.8.JD]QZ2FI*6I@S
MLO6G2DW#/:_)1TW!E:JOV+YB_*7M$C5\@L51,ZB1DEB_:[@,4ODTK5L+6<3Z
M;@L6@ZBO$$$$<P0?:#\M;-W&[:[K[5[E.U-WPQQ:MY*2J(Y%E1XY+A65E_;*
MRD$ @J>%K$QZVGSS^.VKV2=K9KW?)\\#+/XA2:K6O):3KTFK'N5&JSR%DSK-
M@DHQ95(11<%(":Z?0Y!,0Q3#KDO<#;<4K1>9(W22+JA(-O0?$>@^-3IIOP5]
M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
M&J*:AJFF:3",C5<B#&QR;!I9$C4GT=3D"_JO>O'7:E:2Y4:BEJ?:V5-W'IW8
MD9Z#DK.29S]<FVA5@4;2$/.PCQ0J+V/>H%6:OF3@CAJY2*HDH10@&#QZAIT6
M3$^!J,5XV%F1@0?\A!','@0>(K9-F[TU3;>JXN\-E9YAU&!NN'(@=6'B"+CJ
M21&%U=&#(ZDJP()%0^L_IV.!C:Y?>1>?W_(UX'0.BZ^=WZMIUL0%10QXY248
M41G=#1?IB0I +*$=E$HB+@W=T+HR]M]OB;S2V08[_,ZUZ?9<(&M^ZOZZM[+\
M=_>F32?S>D&B1YW3;Z2N-*9>0]X(V2V/UWN3>$IQL(Q;C-K0*!2M5TNMZ[US
M68BFTBH1;>%K=9@FA&47$QS8!$B*").ICJ*J',HLJH)UEUCG55,=0YC#O./C
MP8D"XV,H2!!95'  ?]OE)XGC50=;US5]R:OD:]KV1+EZQE2&2661NIW<^)/H
M L%4655 50%  ]AGVK%5\N+@X6#352A8B+B$ES@HNG%Q[2/364*7M*=4C1)(
MJARE^ "("(!GZ9W?BY)/K-Z^,./CXX(@1$!Y]*A;_4 KPNY-RZRX^ZUM.W]P
MVV/I&NZ8R2?6&QR*;QPDT3<NV[!F@W91S9[)R4A(2#M)NW;-D5G#A=0I$R&,
M(!GWP\/)S\E<3$0OD.; #ZO,\  .))X"L=KNNZ3MG2IM;UR9<?2X%N[M<VN0
M  %!9F9B JJ"Q)  )K7/B%Y#>*G.,;6UX^[ <SL]22-W5DJE@K\S5;*RB7KE
M5HQG6\?,-4$Y2%=.$NP5FBB_MCG3(X!$ZJ93Y#5M U31>@Y\86-^3 AA?Q%Q
MR/MM?PO8UJ^R.YVS>X7G)MG),F3CV+QNC1N%)L' 8#J4D6NI/22 W22 =VLP
MU;_3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*U+YJ\.=8\Y]%RN
MBMJ/['#1"\Q'6F!L-4>HM)BNVV%;2#:(ETT7C=W'2C5)&4727:.$C)K(JF I
MDE0363RNC:ODZ)FC-Q0I>Q4AAP*FUQZ1R%B/KCA6E[^V+I/</;K[=UAI8X#(
MLB/&0&21 P5K$%6%F(*L+$$V(-F%-+D_X N<6C'\A(ZLAX?DO0DE%%&<OKM=
M&)NZ#(#&*D,YK>?>(R02"@E_P,,ZG" 4P"*@?: LO:9OO1<U0N43C3^A^*W]
M3CA;[X+5$]W?#7W"V](TNCHFK::#P: A90/V\#D-U>J)I1Z_1#Q?M1[7U2^-
M&;1UCL+6TD1<6IX^_4NR4Y\5R4%!%N9I8HV.7*N )'ZD$O=]D?A\!S;H,O%R
MEZL:2.1?2K!A]8FH.U+1-9T:3RM8Q,K$EO;IFB>(W]%G53?ARK'N?>L77K:=
M0+WL23+":_I5MO,R<Z*9(FG5R8LTF91P)RH$*PA6;UT8ZYDS 0 )U,)1Z=>F
M?*:>#'7KG=$3TL0!]4VKW8.FZCJDOT?3<>?(GX>[$C2-QY<$!/'PX5+-QJ\%
M//O?SV/=VC7J''JDN%&QGEGW.N:$FTVB@>HY!AKED#R\JR2"/3L1?M(QNHH8
M""X)T4,35M1WOH6 I$4GTB;[F/B/E<^[;V$GU5,^U/AW[D[ED5\S%&F:>2+R
M91Z'MXV@%Y>H#D'6,$\.H<;6NN OB"XQ<$A87*.:N-N;X3:*(NMP79DV36AC
MND 0>HZ[JB2KN,I#1PEW$%?U7LL9-55([XR"@HA%VN[LU+6[PL1%@W_@U//T
M=;<V]G!>1Z;\:N7VV[(;2[==.?$#F[C"V.3*![MQ8B"/BL0/*]WDL2#(5/34
MKN:M4RTQ2H^?*S^'7RU_91(?I2*S7=V_HWF?D3]D5.7PT_KXVQ_::_@/6J'T
M_?X=E;_:QM'])L<Q';O]&U_+2?9%29\</Z^,C^S,/\!JVO\ *S^'7RU_91(?
MI2*S+[M_1O,_(G[(J,_AI_7QMC^TU_ >H8/#YXS.$/*7AC";8WOI/[]; =["
MOL&XG_Y2-N5CU(N%?-48QK\JIU]KT*3VR:A@[RM@4/U^V8PYI.S-KZ%JVB+F
M:A!YF09'%^N1> /#@K@?6JVOQ4_$-W@[;]VIML[+UCZ%H:X.-((_HN%-9Y%8
MN>N?&EDXD<NNP\ *U<\Z7!'BIPXJG'*2XX:L_DY>WRP[)8VM;[\;'M_S5K 1
MM.<1"7IWNWVA)C[165<#W-BHF4]3H<3 4O3$[]T#2=%BQFTR+RFD9PWO.U[!
M;?/9K<SRM4C_  :=Y^Y?=?4M?Q]_:E]/APH,1H1]'Q8.@RO.'-\:"$MU!%^>
M6 MPM<WMB\MO]U3DU_=\W/\ T<63)=UC^J,K^C2_@-7,KMA^LO;O]NX'^]15
M5'\,N@/'1MS1.TIKF2VTNM>HW;2D75S;+VP>@2H5,*=679081I;M6 >Q_P X
M<N?S_HJ?G.XG?]GM")-E:=MK,P)7UOR//$UEZY.@]/2O(=2W%[\:Z7_%EO?O
MUM?>>FXG:=M7&C2:6'F^B80R4\[SYE]Y_H\W2W0$]WJ'"QMQN;!G&30_BNTU
MM!E/<7R\;&.W)B/D("%5JFW(N]7!9FZ0,YE&E;CY.\65\U<.&+0_KJ,4B+F:
M@H0QO2,H49$TK3]IX66)-*^BC,8$#ID#M;QZ068\N=N-K^%4;[B;T^)/=FW'
MPNXW]X'VO%(LL@FPGQX P-D:5DQXE(#,.D2,5#]) Z@IK4[ZB;_<#AO[P>NO
MXL[!S$=R/T>7^DI^"]2;\!_Z[I?["RO]=C5&-!^ %ELKA70>0.I-Q6>8W)?]
M!ZZW#!ZVG8.#:5B4G+;2X*Y2%+:S:+E)ZT46)(K-8]RL IBX!+U^TACG+JT?
M;Q<K0X]1PYG;-DQTD"$#I)90Q6_/Q(!/C:]6(S/C>FV_W<SMC[HTK&BVI@ZW
ME8,F7')(TR1P9$D"SF,@JP!17E1>/3U=%R #ESZ>.W\9ZY;=G:=M.MFE$YL1
MAYYJ6U6<\G\_N-$BWW?8J7!L)I<R-0L]*DFH_.(UFBU<2#-%)PH"_L7(M_9V
MYFTN*:7"EB$>N"_O->[(#Q4 _-92/>4 $BQ-^DVU?XZ]*[A9^F:=NO3=0;-[
M0R",^3#T>7!DNMHIY&C%YX<A&_$2NSK%(S(I3SH_,WU\]7*]31/$0VF:N].E
ML7E ^>4)!)HJ(/V>M(XK-ULEZFD0#BJ2:;/6<"9(Q>BK>87,4>Y+-@[@:N=/
MT?Z%$?\ S.62GK""W6?EN$]C'T5"GP5=LQO/NC_>W44!T';B+DDL/=;+?J&(
MI)Y>65?)!!X- @(LU1I\5N,_GGXJZH9ZZT%2M;46ERLFYNKJ+F'?']]8'$Y8
M&C '3JP.K"Y=S(R:+)DW:BDN?N;IMRI   3IFL:3I?<#2<08VGI%' 3U6/DD
MW-N?5QO8 <>5K58/N5W"^"ON5N9]>WMF:AFZO%&,<.BZFL0CB9K")8@L?069
MGNH]XL6XWK!/$::Y'^+OR;TPG+2O0U C^61'[#8"$$_K"]*^5[,N;TL+9XP*
M@Z7JL C3]DQZ)E4$RIC&PRJZ9")I+D$?!H[ZGM7=*?GA5C7,N'L5Z;.QLPZ?
M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
M,2?-G",69D-IM?J!/P[+)^UC5WZ3?9O/<3]&V_+1_9-5!^![]?&/_9F9^ M1
MF<9_![LGD'QHTQLE?G]L"JU#:FM*G:E-7HZUGIB&@HB>C&S_ .ZZ#D^]8R,>
MMF2*GI$4&,12'M WH 'V<U?2]B96HZ7!E'49$AEB5NCH) !%^G^% -OO?DJP
MW<+XQ-O[&[A:MM]-D8.3JFFZA-",PY<<<DCQN5\XC\W.ZEB+D><Q\.OQJ=#@
M1XRN/_C_ (V<>Z\4G;ILRW1K>(MNT;@++YT[B4'*3X:_7XZ/018UFM*R""3A
M5LF*R[E5%(SAPOZ"'I[YM_:^G;>1FQNI\IQ9I&M>W.P X*M^-N))M<FPM37O
M7\0^^.]^1##KHAQ-O8LA>##@ZO+5R"OFRLQ+32A25#GI5%9A&B=;]4&GG8BZ
MG.>2'@]"WT(\U%F*MK.+NA9=\,9%&J<AOB?:6,).2!RS&/CQAUEO67]9+TD^
MX_>7IW!H>_DADW-@)D6\AD0-<V'293>YX6%KW-7(^#+)U/#[ [QR]$\S\\Q9
M.6^/T+UOYRZ=$T70EFZFZPO2O2>HV%C>U27?U*?!3_\ L.*'_P!RBW^UO-G_
M #'L'T8G\O\ _P!RJ]_\W?C-^[W-_P#ZD?\ PJENU$CJAIK:HQNCEJ0KJB&B
M4H*E%UR^B)&F-HF%44C 8PCR"7<QBJ3%PU.DIZ:AC L0X''O[LW'#&(N*BX'
ME_1%%EZ""MAPL".'#[-5@W0VYI=P961O$9@W--*9,CZ4KK.7DL_5(L@#@L"&
M%P/=(MPM53C@AN>C>/?RT\P]5\AI%GK*I;,LM]KL%<[,X&.K\0=S?OOWK25G
M)5^)48RKVVFR0F*_7."**R[<5C$3%15.(M S8-N[OS<34B(H96<!FX >_P!:
M$D\E93S/*XOPN:Z;=Z-I:SWS^&+:NY=BQOJ.J:=CXTLD$0ZI7MC?1LM(T7B\
MT,Z6,:CJ95?H!8*K2W^6'GAQ>J'"?=U%B=QZ[OVP-Q4"3U]2J70[E 6V;=GN
M+<D<O87R%??2(1%>AXATJ],[="B@X](J*1CK*ID'<-W:_I4.ASP)-')D31E%
M5&#$]7"YL38 <;FP-K#B:J_\,W9;N-JG=[1]9RM)S\+0]*SDR<C(R8)((U$!
M+")3*J=<LCJL81.IEZB[ (K$?T\"VLK)KGQXTN0LC1>//M"_7O9L*S=(*-W1
M*W)KQM9AG:B2I2']"9;U3W[8X?969NDE"B)3@..W^++C;<1I18RR.X'[4V4?
M5Z;CT@@U^?C5W#I^O=]LN#3V#C3L+'Q)&!!'FH'ED4$>,9F\MQS5T93Q!K97
MRL_AU\M?V42'Z4BLRF[?T;S/R)^R*C[X:?U\;8_M-?P'K5#Z?O\ #LK?[6-H
M_I-CF([=_HVOY:3[(J3/CA_7QD?V9A_@-6U_E9_#KY:_LHD/TI%9E]V_HWF?
MD3]D5&?PT_KXVQ_::_@/6J'T_?X=E;_:QM'])L<Q';O]&U_+2?9%29\</Z^,
MC^S,/\!JB1C-@/?$;YE-NV?;\?,HZ&Y"2-Z>*6QO&OWR)==;:M32_1=GB6Z*
M)EIMQKFZ,DXR5(@51T""#P44U#J(D5T],@[/WK-+F!OS?DE_>L3[DC!PP]/0
MPZ6MQL&L#PO9_(T.+XH?A/TO3MK/$=ZZ%'CJ(2ZJ?I6%"V,\+DFT8RL=C-"6
M(3J:+K90KE;/,CSFX:Q5!'9[WE%HHM']BH_3FF^S:F^,Y*D@5PHQ8Q3&3<S3
M^;*4X$^7(MU'_K#Z7H^I]C)3;7M%3'^E-EX_D6O?K4_( #<GU 7\+7KG9C]F
M^[&3K?\ =V';FM?GGK"F,XDRVN;!F=D$:Q^/FLPCZ?>Z^GC7Q.''.?1'.BJW
M6W:+<VQ2.H5L-4IUO;ZVK7GPKJMO>Q<LQ*5U(,W,3-,P,H@'K%>) 00<MT#"
M0IOGHNO:?KT+S8!?IC?I/4MCZ01SX$<N-_2!7L[K]FMZ=FM2Q-+WDN*)\W&\
MZ,P2B5; ]+HW!6#QM8-[I0W_ !;N 2-.+US-\3_,3:M]XM[]6UQ+V355CEJP
MQDM[5YC4*[(ST>M\MM#?6.R9IRQ<Q,A'RS<6"Q!=1#M^LD(LR.T !7,-D:WM
M'6LN32=0\II86*@R@*I(X-T.;6(/ \5)/S;CC4K:-VF^)GM5MK"[D;)&?%@:
MECI,R:=*T\JQL.N$Y>)&&#JR'S%/1.D:FTIB?W:@&\N7%G@YQ$D-3;%X3[?^
M0;4D;H#Q?6-,VD:]_<V)AF:LM&;#A+ E)2]PIKYA8F[9% 'TFL9V=;U&8$]H
MN(Q[O#2=!T=H<G0YNG++_,63KZ0!<.#<LI#6 NW&_N_--7<^%[N1WC[HP:GH
M/=[2O/VU'B=(RY\/Z-Y[R,$?%DB*)!.K1%V;RX5"!>F6_FI5S31\U:K+I;4%
MBO:2B-WG]74":N2*S0(]9*U2M3B7UA258%*0K)1.776 R(  )B';T^&35@23
M2X,,N1_#M$A;P]XJ">'AQO7)K>.)ING[NU7 T4@Z/!J63' 0W4#"DSK$0WVP
M*!?>\>=91SUUKE,4IBE,4JL!Y0?!SO;EYR\G>1FDMD:Q80VTV5+;WR'V-(62
M&?U*5I]1@J*F_@@@*O9$9^'>U^L-5C)J';.4WISD #)&!1.2MM;UP=)TE=/S
M8Y2\1;I* $,&8M8W86(+'TBWKJHW=WX>]Q;VWO)NG;^5B+!F+$)EG9U,;11I
M#=.B-PZE(U-B58.2.(-Q8$XM:-:<9^.VF]",YQ>S)ZJH4%45K"X0]H>:?Q[8
M!DY--GZJXL6KR255.@W%104$1*F)SB7N'0]3S3J6H39Q7I\V0M;T \AZ^',^
M-65V?MY-I[7P=MQR&48>,D9<BW60/>:W&P+7(%S86%S:]9[SPULE5A_*-YO-
MJ\>-]63CCQA@*:B]UR+!CL/8UUAW5A<.;0\8Q\PK7ZA#DDV$8T80C5X5L^=/
M4G2CAV*A$4T2(%7<1;NO?67INH-IFE*G5%8.["_O$ V47 L+V)-[F]K6N>B7
MPX_!]MK?>RL??W<6?+,.?U-BXN.ZQ 0JS()9WZ&=FD92\:1E J=)=G+E(]O?
M$1Y6)[GJ-[U;MZM5FL[KU] M;@W>TXKYG7KO23R+6#DI1*$DGLHZA9:NS$BQ
M3=@5TJW<!(I&2(EVG)F8V=NV3<'F8F8JKG1KU76X#+>Q-B38@D7XV-Q:U1;\
M4?PU879486Y-K9&1D;1SIC 5GZ6EQ\CH:1$,B*@D25%D*>X&7RF#%K@U-WF]
M53^N=+YE-][-W3S[WU"WF;D5JYIZ\S>K]=54SEP$)6JW6%R1YG,;'G[44GUH
M=-S2+QQVBHNHN4O>*22)26!VA@XV'H4#P*/,F0.[>)+<>)]"\@/"WI)KEYWU
MW)JVO=R=2Q]1D8XN#D/CP1W/1''&>FZKR!D(ZV/,DVOTA0,^?3_\@]GZXYY4
M32U?EYAUK+>["[15[IR:QG$29_5M?6>XP%Q1CUEB-6LQ"O*V1!5V7HK\M<.$
M_M]2$SP[[P,;(T-\R0 9,!4JWC9F"E;^@@WMZ0*V3X:]S:OI?<;&T'&=SI.H
MK*LT5[K>.&25)0I-@R%+%N?0S#CP%78N2O&?3_+;4\WIG=U;&QTZ77;R+<[5
MXM&3==L$>1<D39ZU+-_ST9.Q7NE 3.)5$54E%$%TUFZJJ)Z^:GI>%K&(V%G+
MU0GCZ"I')E/@1]3F"""1757M]W"W5VPW-#NS9^1]'U6(%3=0\<L36ZX94/!X
MWL+C@RD*Z,DBJRP40WTT^@&ES+)3?(O;4Q0DW8K$J;2N5.(LJK4IDS)LW=V_
M]X,%.X"F*HHE"(&,4WV/3$.N:$G;'3A/U29,S8]_FV4-[.KB/\T?)5S<O_$%
MWO+I/T?#T'3(M;*V\YI9GB!XW9<?W6'@0&R& (X]0X582U3JK7^D-=5+4^K*
MRQI^OZ-$IPM8KL>=RJA'LB*JN%3*.GJ[I^_?/7CA5PY=.%57+IRJHLJ<ZAS&
M&1,3$Q\#&3$Q$"8\8LJCP'R\22>))XD\3QJC&Y=RZYO#7LK<VY,A\K7,R4R3
M2M8%FL +!0%554!410J(BJJ@* !SL?*[R"V=OWG9R)4V',2BT=JW;&PM1Z_J
M[IPI\LIU.U];).JL&4;' NNS8NYCY/[^1.D(@Y?N%#B8Q>SI9':V!C8.B8_T
M<#JEB21F\69U#&Y\;7L/0!7)#O+N;5]R=Q-4.J.YBP\V;&AC)]V**&1HU"K<
M@%NGK<CYSDFYX5O-].YOW:%.YJM-#Q,Q)/-5;@J-V>6RJK.%5H6+GJ=67MDA
M+FR9G6!)A,=\5\L562+U<-WH%5 WIHF2PF_\#&FT8YS@#*A=>EO$AF *GTCC
M?U$</&\A_#!N35\'?R[<AD=M&SH)3)&3=%>*,NDH%^#>[Y9(^<&L;V4B]3D)
M5T0JN=Y:/,ML+B-MW^K=QTKM/>7R$@(:;V->;JQ>S;>NNK,Q3F(.M5ZOMGT8
MV/*%@'+5^X=NSN4/2>II$0[RG.$;;OWKDZ/F?FS350Y"J"[,";=0N% N.-K$
MDW'$"U7T^&/X3]#[H;7_ +_[\GRDT6:>2/%Q\=EC,HB8I)++*5<]'F!XU1 C
M7C9B]B!7L?$3Y?+GS4NT_H+?M;K$3M6-K#NWTVX4IB]B82Y0\*M'M)V)FX1Y
M(R@1UJ9@_*\26:G39.FI5B^BW.@3W/VV=O&?7)VT_4%0983J5E! 8"UP02;,
M+WN.!%^ MQQ/Q1?"UI/:/2(-[;)R,F7;4F2L$\&0RO)!)(&:-XY%5.N%NGRR
MK@R(Y0]<@<^78 R0ZI#6C'D:X?O.<O%&]:!B+6UI=EE9"N66J3TFBY<P:-AJ
MTJC)-&=@09$4>FAY- %6ZBB)5%6QE"KE35%+TCYO;VK#1-43/="\8!# <[,+
M7%^%QS]?*XO>H\[I;'?N%LW(VU!,,?+=DDC=@2@>-@P#@<>EA=21<K<, ;6,
M:/AR\0NW^!>U-D[OWG>:'*VFQT![JVK576\C.3<4E REGK=FFI^?EYNOUA0K
MY1Y3F2;-JB@L0$%%%%3E4[4R;'N[=F)KF+'A82.(EDZV9P ;A2   3P]XW-^
M?*HG[&=D=;[<:QE[@W#D8SYDN,<>..!G=>AI(Y&=V=(^-XE"J 18DL0; 6%<
MT&K-TQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2OXN&Z#M!
M=JZ01<M7**C=RV<)D60<(+$,FL@NBH4R:J*J9A*8I@$IBB("'3/Z"0;C@17Y
M95=2C@%"+$'B"#S!'B#6.W6F-//GY95[JC6KN4(=%0DDZHM7</RJ-NWVYRO%
M8L[@IV_87L$#=2= Z=.F>@9F6J] ED"^CJ:WV:QCZ#H<DGG286(TW#WC#&3P
MY<2M^'A7O8^-CHEJ1C%L&4:R3$YDVD>U09M4S*'%10Q&[=--(@J',(F$ ^(C
MU'/.S,YZF)+>NLC%%%"GEPJJ1CP4 #Z@X5^W/Y7TIBE,4IBE8TW)J6E[XU9?
M=.;%9.I"D[&K4C5K$V8O58Y_["12[/<,'R/4[1^R6 BR!^ABE53*)BF+U*/E
MS<.#4,23"R03!*I5K&QL?0?2.8K8=I[GU?9>Y,+=>@NJ:Q@9"31%E#+U*>3*
M?G*PNK#@2I-B#8C'O%7BWJWAUIR%T=I].?\ N?"R4S, [M,L2:GY*5GGIGL@
M^D7J#..9BH8PE3(1!N@D1-,H 3KW&-Y])TK$T7"7 PNKR5)/O&Y))N238#Z@
M%9SN5W'W)W6W7-O'=1@_.LT<<?3"GEQHD:]*JJEF:W,DLS$DGC:P'OMTZAI>
M_=47W3.Q&SYW2MCUQ_6+"E&/E(V2*Q?%#_&(]^F506KYHN0BJ1Q*<@*$#O(<
MO4H^C.PX-0Q),+)!,$JE38V-CZ#Z16%VCNG5MD[FPMV:$R+J^!D+-$74.G4O
M@RFUU875A<&Q-B#8CPO%GB_JSA[IN!T=IYO-IT^!?3$J#NRRH3,_*RTZ_5?R
M,E*ODFK!H=PJ<Y4RE0;MT2))$*4@" B/GTG2L31L)<#"#>2I)]XW))-R2>'U
M@!68[D=QMR=U-V3[QW4T)U69(TZ8D\N)$C4*B(I+-8<22S,Q)))\!C;F3P)T
M#SKB]=Q&]FUO6:ZRL,A/U\U1LAJZLX+,(L&\W#2IQ9/RN(F72BVX*"D5%XEZ
M0"@X1$Q^[RZUM_3M?2-,\/:)B1TM;G:X/ \#8>@^@BMA[3]Z][]F<G/RMEMB
MB348%BE\^+S0/++&.1/>6SH7:URT9O[Z-86VTM59A+K6+'3;,Q))UNVP,Q6;
M!&J**I)R$)/1[B*E6)U6ZB2Z9';!VHF)B&*<H&Z@(#\<S$L4<\302B\3J5(]
M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>allogenelogo2.jpg
<TEXT>
begin 644 allogenelogo2.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
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MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
M$JT>FJ4_HNEDR]^3E@[ZT+)QA+E2&"<#WD*L>/CTE00P]'(^D"N<NX_AN[DZ
M5JSXFCXJZCIA<B*:.6)+J3[OF)*Z-&P!'5S0&_2[ 7JS5X</&]8_'YIN\.-H
M2T1)[KW9*5N6N[&NNE']?J$%4FDNE4J@VDE$TBR\NP6LLBXD7B)2-CKN2H(B
MLFV(Z<1ON[<4>O9B#&!&'""%)X%BUNIK> -@ .=A<V)L+9]B^U>5VTT+(?5W
M1]?U!T:4(;I$D8;RXPWVS R.SL/=)8*O4$#M,5FHU.5,4IBE,4IBE,4IBE,4
MK7CEAR&K'%+CIMOD#;/05CM;5!_,,(Q=<&P6&SN!3C*?5TEORIKV:TOF;$I@
M >P5^[IT*.9#2M/DU34(L"+YTC@$^A>;-\B@GY*UC>>Y\39NU\W<N;8Q8D!8
M*3;KD/NQ1W],DA5/5>]<PF_7BS;-O-QV/=)):9M]]M$[<;/*KF.961G[))NI
M>6>'$YCF#UWSLY@#J/: ]/W,LG!#'C0)CPBT2*%4>@ 6'UJY'ZEJ&7JVHSZK
MGN9,[)F>61CS9W8LQ^4DU[#06F+9R)W5K#1U'2[[1M"YPE0C5C(G7;QI91V1
M.0G7Z:9BG^5UZ,*L^=F 0$C9NH;K\,^6=F1:?ARYL_\ !1(6/KMR ]9/ >LU
M[=MZ#F[HU_$V]IX_\YF3I$IM<+U'WG/[5%N[?M5-=0S4VL:GI;6&O]1T1C\N
MIVM:?7J36VANPRY8FN1;:+:+/5B$3!U(NR-O6<KF#O7<'.H?J8PB-:<K)ES,
MF3+G-YI'+'VDW^IZ!X"NN^BZ1A:!I&-HFG+TX.) D2#QZ44*"3XL;78\RQ)/
M$UD'//63JHO]2EQ#]K):OYI5*, $)0&NGMO&:MU.XL@U1>2.N+2],D!R"#I@
MD]B7"ZGI@3VT>B F%0 +*_;K5KK+H\IXC\9'[.3K]6S >MC5)_BLV3T2X>_<
M)/=>V-DV'VP!:"0^T!HV)M;IB7C?A4]R4:IE5K3Z;+F*6,G]C\*+G,"#:R@Z
MVOI5%VL'82=C6A4MEU-B*ACJG4DX1JUF6S=,"))%CI)8>IU?C%_<32.J./68
M1Q7W)/8?F,?8;J3ZU'A5R?A4WR(LG*V#GR>Y+?(Q03]NH_'QC[Y LJJ+ =$K
M<VJWMD3U=RF*4Q2F*5S9/+-^(]R\_:W(_HN*RQ.UOT>Q/R0^R:Y4]Z/UIZW_
M $UOP5J/#,_485TQ_&=^'SPV_N[ZP_BPQRN.Y/Z^S/Z0_P!DUUC[3_JST+^R
M\?\ U8K>/,+4A509^H8_$>LW[)=5_HI[DZ;!_1Y?RK_9KF]\3?ZTY?Z%C_@F
MH.\W2J]UT$O 7^&3IO\ 6[<'])]GR!M]?I)-]Y'^ *Z7_#=^J7 _+Y/^\25,
MQFH5.U4A?J1.1;J_\KZ-QWC9 YJWH"B,Y.;CR*&(7^4;:3=C9'JCI(A@37]K
M0T($6QC@)D1=. +T!4W=,_;S3Q!I;Z@P_&3O8']HEP/\[JO[!Z*Y^_%1NA]2
MWGC[8B;_ ,KIN,&=?_'R '-_3:$0]-^74UN9O7/R0:JY5PWZ;_A5$1%$MO."
MZPY'%GMLC-ZVTJ=ZW(H2'J$,L5C?+A%'.*A0?6.Q)*PA5B@FNV0BGB0&%)XH
M48E[AZR[SIHL)_%H \EO%CQ53Z@/>]!+ \Q5X_A8V#!!ITW<'/2^7,SP8MQ\
MV-3::5?6[WBOP*B-Q>SFK3N1C5PJ8I3%*8I59[ZC#A3%WS3$%S,I<*BE?-/N
M8NJ;2<,FY@<6/5U@DDXZ$DWX(E.+EW1K7(HD3/VE,$?)N#*J"FU1*61^WVLM
M!F-H\S?B)@62_@X%R!]\H^JHMS-5.^*+8,.HZ#'OO C U'!*QY! XOCNW2C&
MW,Q2, #]Q(US9% I;9,-4+J?#Z>#D>[U+S:<:9D)!1&G\DZ;)5I1D=7TV1;_
M $5G(W&E2J_4! RY8IO-1B)?AWJRI0Z]0 !T;?\ IPR]&^F*/QV,X-_'I:RL
M/J]+?N:LA\,.ZGT7?YT&5B,'58&CMX>="&EB8^OI$L8])D%7NLA"NBM09?4&
M;_=Z>X%2-#A7BC6?Y"7J UD8[<_IN4:@Q3=7.XKE-U !:O6U>;Q3@OQ$Z,H(
M=.@B(;ML+ &7K@G<7CQT+_NC[J_9+#[VJ\_$QN5]#[<-IV.Q7)U/(2#AS$0O
M+*?80BQGTB2J$63E7."I0O$-PR8\U>9-/IUNC_?ZFURQ7VIM=NH0XMI>NUUX
MR;Q-15,  0Y+?9W[-FX3[R*#&B[43'N3#-:W9K#:-I#S1&V5(>A/43>[?N5!
M(]=O34O=DMAQ[^WU!@YJ]6BXJG(R!X,B$!8__P LA56%P>CK(XBNC$W;H-$$
M&K5!%LU;(IMVS9NF1%!N@B0J:*""*92II(I)E I2E "E*   =,KZ22;GB374
M555%"( $ L .  '( > %?VS^5^J8I3%*UKY>\:ZARZXY[2T#<D&@-;U6GC:!
MEW3<JYZK<V9!>T^VLQ[#JIN("?107-Z?0RR *(CU(J<HY'2=1ETG4(L^&]T;
MB/NEY,ORBX]O'PK5-[[4P=[;7S-MYP7HR(B$8B_ERCC%(/&Z. >',77D37,(
MM=8G*1:;+3+.P6BK+49^8K%ABW!1*XC9R D7,5+,%RB "59F_:*)F#]PQ1RR
MD4J31+-$;QNH8'T@BX/U*Y'9F)D:?F2X&6I3+@D:-U/-71BK ^L$$5\#/W7F
MKIZ\!/\ <2X5?W2N./\ 0[3<K9KO]=YG]+F_UC5UP[;?JZT#^Q<'_=HJVUS%
M5NM<U7RC<AG?)KG9R%V+[T7==C+O(:YHH%4[VB5)UNJ>H0KAB7N/Z2$\:+5E
M3EZ_]8?J#\.O0+%[9T\:;HF/CVM(4#M]\_O&_LOT^P"N4O=_<[[M[BZGJG5U
M8J9#00^@10?BD(]3])D/K<U'_F=J-*Z,'A]X?0W$3A7K9DYB$VFTMP0\1MO;
M4BL@0LH:;M,:B_@*HY5$HK)-:+6W2##V_J'1(_\ >+I]!<GZU]W;JSZMK,A!
MOC0DQH/"RFQ;]T;F_.UAX5U%['['@V3L+$C= NL9R+DY+$>]UR*"D9\;0QD)
MTW(#^8P^>:E*S6:F"F*4Q2F*52)^HJX<16G>0%0Y/4:(3CJIR+3DVM\;,DBI
M,F6WZRDT4?RXID$B3=2^UYRDZ.4A.JT@P?.5#"HN.3/V_P!7?+P'TV<WEQ[=
M/I\L\A^Y/#U J/"N?WQ0[%AT/<L&[M/0+AZH&$P X#)C NWJ\Y"&-AQ=)')N
MU5R\D&JMU=D^FNY!N[WQEVMQ\FI$73_0]]9SM806/VG:43:Z4G)IQS0A@#UD
M&-VKTRY5,43"F:2(4P% R?=#?<7 $&I19Z"RSQV;[Y+"_P JE1\E7\^%/<SZ
MCM+-VS.UY-.R0\8/A#D!FZ1Z0)4E8^CK -N%[(V1W5J:JK?5"_P%X=_K;N;]
M#ZZR3^VG\-E_>Q_9>J=?%W_5VA_E\K\&"J?V2S5'ZW?\=O#R8YR<J]?:,:JO
M(^J*G<7#:4^R* N*]K*M+-%+(\;G$BA4)&66=MHE@H8BB:<C(MS*%%,#9A=P
M:NFB:7)FFQE^:@/BYY?(.+'U U(/;#8T_<+>6-MY"RX9O+D..:01D=9'H9B5
MC0V(#NMQ:]=*.DTJJ:XI]9H%%@8ZKTRF0<96JO78E'V\;"P<.T28QL<S2ZF,
M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
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M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
MX+<=^4>K'=;HW(>&K$H1%I**+)UV1E&K]2$V1J^:D6I'DE&L6EQ@%GE?>+I+
M"DDJ J)IIOU5DZ@]R=BME9;X<+ 9^,Q\MFX!XV 8*Q'(VL0>(#=0Y$D?Z _@
MA^+*'96F1:UJ\,LVS=;B3Z7%$0TF+EPEHVFB1B P#!D="R-)%Y;W+1JC5WE?
M$#Y($;*>K#Q8NJCXC_Y?\P2F*4I6CJ=?@X):RV<:X+ 2CU]?W/I!^01 WPR#
M3LW<PE\KZ(_5>U[KT_ONKIMZ[UUJ7XINP3Z>-2_O)AB$IU=)3($MO1Y/D^;U
M?M>B_JMQJU/XA_%T\X&U>T;#VK)Q$[R"V=%M8681KZYWM?U_3&[Q.4)4(R44
M0;*3,K*2+=NYEG12 U]9J@BW[R(&<NI9V=M4Z!$^3EE6U&46-N(1;WZ0?$DV
M+'E< #E<\V/BC^(V+O3J6-H6VHY8=CZ=(9(S*.F7)G*E//= 2(T1"R0I?KZ7
M=Y+%Q''H=YT?%+N/?FPF7+CC36G.PK"M5X>K;9UC$>F-M>C6R+-8&\51FNJ0
M;$?Y,9&.>QS<?>$*T;JH)+@HX]&P6R=T8F#CG2=181Q]19'/S>/-6]''B">'
M$@D<+\B_B'[-Z[N34UWKM2(Y6485CR8%_A#T7"2Q@GW_ ';(Z#WATJRAKMTU
MVM->,3GEO"[-:/6>,&WJTX/(_+I:R;.HUFUG3*R*2I$WZU@LERBHED@>-3,*
MBK1#W$B<I1*BW54$I#2!F;ET/"A,\F3$PM<!&#L?18*2>/I-AZ2*K!H7:3N-
MN#4!I^)I&=$W5TL\\4D$4?'B7>55 Z>94=3GDJDV%7H*$UT3XC. U*@-CW Y
M:5IBM&:2\TW9I*3VQ-D6F3D[+-,:E"'6;J/96TVR4>?+6:BW1FQ*7W#@C=LL
MX)7;=>Y<?SLC7M1/1"6X*.)L!THBCQ8@#T"]R;"Y'6/L'V4U[5(M*[4[*C^E
M:HL9ZY&]R-;L9,C)E:Q\N%7=CR9@I2-0\A56A\)]336!N@MU.(T\77?N%$ F
M";>CU+H+0%3"E)C6S4%.#!P=$ *9C\U$I3")@=F .T8E_P":$7GV.&WT:_/S
M!U>WIZ+?)U?+71P_X>>H_FGS%W1"==Z0?+^@L(.JW%/-^DF2U^4GDW(X>4.=
M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
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MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
M1Q!8$<:YUN6 KE]4^7TZ^XKU3.=A=3Q#]VK0]QZ[N:%Q@C++C&$DJ3#N;96K
M0#4G5$)>-68+L$U3= !O)K%^(F+TT;N!B03:']*<#SX9%Z3XV8])7V&X/M45
M9'X7]<U' [B?F:!F.G9V+*)4N>GJB4R1R6Y=2D% ?N9&'HK>_P"IH8W89?B7
M)'*Z/KE.-VLQ;G1!86;>[*NJ6N\+("4PMTW3R"10%GW@!SD0<]@B!5.E,^Z"
MS]>&W'Z-:0>KJ]WG\EK>P^NO])7^'I-I Q=SXX*C7C)AL;VZCC@9 7I\2%D+
M==N +1WYK>JSD3UTFJ\O]/ TN+;@"_6LY7Y820WYL9WKL7A#%;GIQ(*C,'QH
MHPID!1@&P&4Z4Q@$P>Z!8.O4!*$\=N%F&WB9;]!R'*7^YLH-O5UA_EO7'#X[
M)=*D[W(FG='TQ-$Q5RNGGY_F9#+U\>#?1FQ[<O<Z#;C<SL9OM4RIBE,4K&%4
MTCI>AVVQ7^CZBUA3;W</4^]MUJE!JE=MMH]99-PK]XK)$1+.9F_5<(D.;W*R
MO<<H&'X@ YZ9<W,GB6">65X$^:K,Q5?8";#Y*Q&'M_0=.S9=2T_!PX-1G_A)
M8X8TDDN;GK=5#/Q%_>)XUD_/-67IBE,4K\4E(Q\/'/Y>6>M8V+BV3J1DI%\N
MFU9,(]B@HY>/7CE8Q$6[5JW2,HHH<0*0A1$1  S^JK.P1 2Q-@!S)/A7SEEB
M@B:>9@D**69B; *!<DD\  .)/@*YGOD2Y7R'-#EUMG>!E5PJCZ8^Z^LH];U"
M_*]95,5(JI$!!7[;1U,MDSRKU+J)22$@X[?L],L=M_2UT?28L+_O0.ISZ7;B
MWU/FCU 5R>[G[SEWYO;-W!<_0V?RX%/VL$?NQ\#R+"\C#P=VM6DF9FH_J_)X
M#>)']7;A='[2L<5['8_)]VPV7)J+H^F^::W:-G#74\0<P'.15HZAGKJ?1, %
M.!9_L.'5, "#-]:K^<-8.-&;X^,"@]'7]N?J@+^YKI#\-^RO[K["76,I.G5=
M783M<<1  1CK["I:8?EK'E4XV:55A*8I3%*8I3%*8I7_  Q2G*8AR@8I@$IB
MF #%,4P=!*8!Z@(" _$,4(!%CRKFV>5/B2?AMS3VIK:*C%(_75G>AL[4@^F<
MK0=?W1R[=M8EB=3J95"GSB#Z$[C"8Y_EW>81[^HV(VQJOYWT:+)8WR%'0_WR
M^)^^%F^6N5?>+91V+OW,TJ%"NES-Y^-Z/)E)(4>J)P\7I/1?QJ.G-@J+JO8?
M3Y<PR[VXH.- 6J54=[&XQKLZ\R]XL"CJ5U'.G>+T)R@8P$,HG556KJ#%,@&*
MU9LV/<;JL4,A+?ND?0=4^GQ"V/D\3ZI!\[]]P;UDMZ*Z)?#/OD;BV8=M9CEM
M4T@A!<\6QGN82/R=FBL/FJL=S[U3]9HE63KFR>6;\1[EY^UN1_1<5EB=K?H]
MB?DA]DURI[T?K3UO^FM^"M1X9GZC"NDUXF/PX>(?[)8_]*RV5WW5^D.7^5/V
M!75;LO\ JLT3^A+^$U2(9K]2?5!GZAC\1ZS?LEU7^BGN3IL']'E_*O\ 9KF]
M\3?ZTY?Z%C_@FH.\W2J]U?D^GG_#AK7[6]J?I1AD&;^_2%OR2?8-=(OAD_59
M%_3<C\(5.-FE58.F*5C_ &EJK76[*'8]8;7I\)>Z%;8]6-GZS/M?<L7K=0/L
MJ)G(9-TPD&BG15L[;*(NFBY2JHJ)J$*</OBY61A3KDXKLDZ&X(YC]D>D'@1P
M/"L9K&C:7K^G2Z1K,$>3ILR]+QN+@C[(8<U92&4V*D$ U3FYZ?3S[AU=(3>P
M^&;AUN;6ZBZSXVJ9-TW0VU4FZJA3>SA'"WMHK8D4S Q^PQ3M98J8$3]N\.!U
MQEW0]_8F2JX^L6AR.76/X-O;XH?JKZQRJC/<?X9-<TB634]B$Y^E$D_1V(&3
M&#X(399U'&W%9+6'2YNU5S;15+31Y^3JMTK<_4+1"N3,YBMVB'D:_/Q+LG03
MM9.'EFS218.2 /Q(JF0P?^C)!BEBFC$L+*\1Y%2"#[".!JKF9AYFGY+X>?%)
M!F1FS)(K(ZGT,K ,#ZB*^!G[KS4Q2OK0,!/6F8CZ[6(27L=@EW)6<5!P,:\E
MYB3=G 1(UCXR/1</7KDX%'H1,AC#T_)GY>1(D,DK!8P.))L![2>%??&QLG,G
M7%Q(WER7-E1%+,Q]"JH))]0%6$^!WT^F^=U/H2_<M1D^/VJ/4;/QHHE;&W3<
M6?<FH+(\4K[AIK-JX()BJ+2I%91(Q.WY:!3E7)H.N;]P<-6@TJV1E<NK_NU^
M7[?]S[O[;PJS7;GX9]QZ_)'J6]>O3-&N#Y/#Z5*/1T\1 #XF0&06MY7$,+EN
MEM):LX[ZWKFI-,TN'H5 JK7VT3 PR)BD%0X@=W)23U<ZS^9FY-?JJ[?.U5G;
MI8PG54,81'(AS,W*U#(;+S',D['B3]@>  \ . \*O9H.W]'VQI46BZ#CIC:;
M"+*BCZK,3<L['BSL2S'B2365,\M9BF*4Q2OYK(HN$56[A)-=!=,Z*Z"Q"JHK
M(JE$BB2J9P,11-0AA Q1 0$!Z#@$@W'.OXRJRE6 *D6(/(BJMGD=^GSBKR_G
MMR<%_DM2L;PZLE/<>Y5RA#U"6=G[U'*^L9Q<2,JD[<J]!"(?"2*[CF]!RR3(
M1N:3=O;]:!5P];NT8X"4<6'WXYM]\/>]()XU4#NG\,\.H22:[V\\N'*:[/A,
M0L3'Q..YX1D_Q;VCXGI>, +53G;.EMMZ'MKJB;FUQ<M8VYH'J*05S@)"">K-
MQ'HF^8>]021DXU?\J3IL95NJ40$AS (#DI8N9BYT0GPY$DB/BI!'L-N1]1XU
M3'6M!UK;F:=.U[%GQ,U?M)49"1Z1<693X,MU/@36,L]-8BF*5[S6FK=D;EN,
M5K[4]&M.Q+M-J>G&5FGPK^=EW!0.0BKDS5@BL9LP: H!G#E7L;MT^IU3D( F
M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
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MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
M57'3=A;JU/>Z=NH,5DW>^<<0P.RH4G5BCJ[$]("%6+-<BP)!/"_Y>-?)/4_+
M/4L'NK2\T\FZ1.O)>-15DXMW"RK*4@WZL=)QTG%O2%7:NFZZ7<'Q,11(Y%"&
M,4P#GYTS4\/5\-<[!8M Q(X@@@@V((-?7N!V_P!S=L=SS;1W;"D.L0HCD(ZR
M(R2*&1D=>!!!MX$$%2 0:Q]RQYQ<>.%+'7TEO^SRU<:;+L+RO5M2)K4O8NT\
M6BS7F962"*;K"RB8=*1;BL;[:YO6#TDE.A^WSZOKNFZ&L;:BY42L0ME)Y6N3
M;D!<7\>/ &LYVR[.[[[NS9V/LC'BR)=/@664/*D7SRPC1.LCJ=RC=(X*.D]3
M+<7VAL5@A:E7YVU621;P]=K,-)V">EG8F*TBX6&9+R4I(NC$*<Q6[)BV45.(
M (@4H_ <RLLB0QM-*0L:*22?  7)^05'.!@Y>J9T.FZ?&TN?D2I%&B_.>21@
MB*/6S$ >LU#.M]0#XZDE54R6G:;@B:AR$<(ZMF"I+E(82E62!PY07!-4 [B@
M<A#]!^)0'X9I)[A[;!MURG_\9JV*_!!WY90QQM-4D<CF1W'J-@1<>HD>@FLC
M:>\V? K=FSJ5J:JW2[QEIV!/,JO6EK3096&A'$_*']O#QCF4!1VFR5EI R;9
M ZA02]=4@'.0HB8/5A;YV_G928<+R"61@J]2$"YY"_A<\!ZZP.ZOA"[U[0V[
MF;GU+$PY--P8&FE$.2DD@B3B[A+*6"+=V -^E38$\*WDY/\ *33O#_5;K<6\
M)U_!TY":BJXW-$PTA/2LG/30N#,(N/CH](YCKJ-V2ZQC*&22(D@<1. ] '.Z
MKJN%HV(<W/8K#U!> )))Y  >PGY*ASMUVWW7W4W(NU-G0I-JK0O*>N18T2..
MW4[,Q' %E4  L2PL.9$:/_$">.S_ "DVQ_-=)_\ ;LUC_F)MO[J;^3/[-6#_
M .A[OQ_-],_]XG^C4@G&'G'Q;YBLY9QQ\VS#7:0@$B.)^L+LIBM7"&:'5(W(
M_>56SQ\1-GB3.%"I@]1159"J8" KWCVYL6E:]I6M*3ITRR,O-;%6'K*L ;>L
M"WKJ#NXO9SN1VIEB3?.F2X<$YM',&26"1@+]*S0L\?78$^6S"2P)Z;<:VQS+
MU&5: \NO)AQ4X2W>AZ\WC9;(UM%]8DFT&-6K+BQ_=NKJR:L0C:K3Z+ANHTAE
MW[1R1,K4KQZK[182-Q H=VO:QNC2=#GCQL]F$L@O95ZNE;VZF]5[\KG@>%3?
MVN^'ON5W?T?-UW9V/CMIN$_EEII1%YLP0.88;@AI K(27*1CK6[BYMOE'2+"
M7CV,M%/6LC%RC-K(QL@R73<LG[!Z@1RS>M'*)CI.&KINJ4Z9RB)3D, @(@.9
M]65U#H04(N".1!Y$5"L\$^+.^+DHT>3&Y5U8$,K*;,K \00000>((M6$N2?)
M34O$S4\UNC=4X\@J1"/(N,56C8A_.2CV5FG9&47&1T9')*KN'3I<P_$W8DF0
MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
M,2?-G",69D-IM?J!/P[+)^UC5WZ3?9O/<3]&V_+1_9-5!^![]?&/_9F9^ M1
MF<9_![LGD'QHTQLE?G]L"JU#:FM*G:E-7HZUGIB&@HB>C&S_ .ZZ#D^]8R,>
MMF2*GI$4&,12'M WH 'V<U?2]B96HZ7!E'49$AEB5NCH) !%^G^% -OO?DJP
MW<+XQ-O[&[A:MM]-D8.3JFFZA-",PY<<<DCQN5\XC\W.ZEB+D><Q\.OQJ=#@
M1XRN/_C_ (V<>Z\4G;ILRW1K>(MNT;@++YT[B4'*3X:_7XZ/018UFM*R""3A
M5LF*R[E5%(SAPOZ"'I[YM_:^G;>1FQNI\IQ9I&M>W.P X*M^-N))M<FPM37O
M7\0^^.]^1##KHAQ-O8LA>##@ZO+5R"OFRLQ+32A25#GI5%9A&B=;]4&GG8BZ
MG.>2'@]"WT(\U%F*MK.+NA9=\,9%&J<AOB?:6,).2!RS&/CQAUEO67]9+TD^
MX_>7IW!H>_DADW-@)D6\AD0-<V'293>YX6%KW-7(^#+)U/#[ [QR]$\S\\Q9
M.6^/T+UOYRZ=$T70EFZFZPO2O2>HV%C>U27?U*?!3_\ L.*'_P!RBW^UO-G_
M #'L'T8G\O\ _P!RJ]_\W?C-^[W-_P#ZD?\ PJENU$CJAIK:HQNCEJ0KJB&B
M4H*E%UR^B)&F-HF%44C 8PCR"7<QBJ3%PU.DIZ:AC L0X''O[LW'#&(N*BX'
ME_1%%EZ""MAPL".'#[-5@W0VYI=P961O$9@W--*9,CZ4KK.7DL_5(L@#@L"&
M%P/=(MPM53C@AN>C>/?RT\P]5\AI%GK*I;,LM]KL%<[,X&.K\0=S?OOWK25G
M)5^)48RKVVFR0F*_7."**R[<5C$3%15.(M S8-N[OS<34B(H96<!FX >_P!:
M$D\E93S/*XOPN:Z;=Z-I:SWS^&+:NY=BQOJ.J:=CXTLD$0ZI7MC?1LM(T7B\
MT,Z6,:CJ95?H!8*K2W^6'GAQ>J'"?=U%B=QZ[OVP-Q4"3U]2J70[E 6V;=GN
M+<D<O87R%??2(1%>AXATJ],[="B@X](J*1CK*ID'<-W:_I4.ASP)-')D31E%
M5&#$]7"YL38 <;FP-K#B:J_\,W9;N-JG=[1]9RM)S\+0]*SDR<C(R8)((U$!
M+")3*J=<LCJL81.IEZB[ (K$?T\"VLK)KGQXTN0LC1>//M"_7O9L*S=(*-W1
M*W)KQM9AG:B2I2']"9;U3W[8X?969NDE"B)3@..W^++C;<1I18RR.X'[4V4?
M5Z;CT@@U^?C5W#I^O=]LN#3V#C3L+'Q)&!!'FH'ED4$>,9F\MQS5T93Q!K97
MRL_AU\M?V42'Z4BLRF[?T;S/R)^R*C[X:?U\;8_M-?P'K5#Z?O\ #LK?[6-H
M_I-CF([=_HVOY:3[(J3/CA_7QD?V9A_@-6U_E9_#KY:_LHD/TI%9E]V_HWF?
MD3]D5&?PT_KXVQ_::_@/6J'T_?X=E;_:QM'])L<Q';O]&U_+2?9%29\</Z^,
MC^S,/\!JB1C-@/?$;YE-NV?;\?,HZ&Y"2-Z>*6QO&OWR)==;:M32_1=GB6Z*
M)EIMQKFZ,DXR5(@51T""#P44U#J(D5T],@[/WK-+F!OS?DE_>L3[DC!PP]/0
MPZ6MQL&L#PO9_(T.+XH?A/TO3MK/$=ZZ%'CJ(2ZJ?I6%"V,\+DFT8RL=C-"6
M(3J:+K90KE;/,CSFX:Q5!'9[WE%HHM']BH_3FF^S:F^,Y*D@5PHQ8Q3&3<S3
M^;*4X$^7(MU'_K#Z7H^I]C)3;7M%3'^E-EX_D6O?K4_( #<GU 7\+7KG9C]F
M^[&3K?\ =V';FM?GGK"F,XDRVN;!F=D$:Q^/FLPCZ?>Z^GC7Q.''.?1'.BJW
M6W:+<VQ2.H5L-4IUO;ZVK7GPKJMO>Q<LQ*5U(,W,3-,P,H@'K%>) 00<MT#"
M0IOGHNO:?KT+S8!?IC?I/4MCZ01SX$<N-_2!7L[K]FMZ=FM2Q-+WDN*)\W&\
MZ,P2B5; ]+HW!6#QM8-[I0W_ !;N 2-.+US-\3_,3:M]XM[]6UQ+V355CEJP
MQDM[5YC4*[(ST>M\MM#?6.R9IRQ<Q,A'RS<6"Q!=1#M^LD(LR.T !7,-D:WM
M'6LN32=0\II86*@R@*I(X-T.;6(/ \5)/S;CC4K:-VF^)GM5MK"[D;)&?%@:
MECI,R:=*T\JQL.N$Y>)&&#JR'S%/1.D:FTIB?W:@&\N7%G@YQ$D-3;%X3[?^
M0;4D;H#Q?6-,VD:]_<V)AF:LM&;#A+ E)2]PIKYA8F[9% 'TFL9V=;U&8$]H
MN(Q[O#2=!T=H<G0YNG++_,63KZ0!<.#<LI#6 NW&_N_--7<^%[N1WC[HP:GH
M/=[2O/VU'B=(RY\/Z-Y[R,$?%DB*)!.K1%V;RX5"!>F6_FI5S31\U:K+I;4%
MBO:2B-WG]74":N2*S0(]9*U2M3B7UA258%*0K)1.776 R(  )B';T^&35@23
M2X,,N1_#M$A;P]XJ">'AQO7)K>.)ING[NU7 T4@Z/!J63' 0W4#"DSK$0WVP
M*!?>\>=91SUUKE,4IBE,4JL!Y0?!SO;EYR\G>1FDMD:Q80VTV5+;WR'V-(62
M&?U*5I]1@J*F_@@@*O9$9^'>U^L-5C)J';.4WISD #)&!1.2MM;UP=)TE=/S
M8Y2\1;I* $,&8M8W86(+'TBWKJHW=WX>]Q;VWO)NG;^5B+!F+$)EG9U,;11I
M#=.B-PZE(U-B58.2.(-Q8$XM:-:<9^.VF]",YQ>S)ZJH4%45K"X0]H>:?Q[8
M!DY--GZJXL6KR255.@W%104$1*F)SB7N'0]3S3J6H39Q7I\V0M;T \AZ^',^
M-65V?MY-I[7P=MQR&48>,D9<BW60/>:W&P+7(%S86%S:]9[SPULE5A_*-YO-
MJ\>-]63CCQA@*:B]UR+!CL/8UUAW5A<.;0\8Q\PK7ZA#DDV$8T80C5X5L^=/
M4G2CAV*A$4T2(%7<1;NO?67INH-IFE*G5%8.["_O$ V47 L+V)-[F]K6N>B7
MPX_!]MK?>RL??W<6?+,.?U-BXN.ZQ 0JS()9WZ&=FD92\:1E J=)=G+E(]O?
M$1Y6)[GJ-[U;MZM5FL[KU] M;@W>TXKYG7KO23R+6#DI1*$DGLHZA9:NS$BQ
M3=@5TJW<!(I&2(EVG)F8V=NV3<'F8F8JKG1KU76X#+>Q-B38@D7XV-Q:U1;\
M4?PU879486Y-K9&1D;1SIC 5GZ6EQ\CH:1$,B*@D25%D*>X&7RF#%K@U-WF]
M53^N=+YE-][-W3S[WU"WF;D5JYIZ\S>K]=54SEP$)6JW6%R1YG,;'G[44GUH
M=-S2+QQVBHNHN4O>*22)26!VA@XV'H4#P*/,F0.[>)+<>)]"\@/"WI)KEYWU
MW)JVO=R=2Q]1D8XN#D/CP1W/1''&>FZKR!D(ZV/,DVOTA0,^?3_\@]GZXYY4
M32U?EYAUK+>["[15[IR:QG$29_5M?6>XP%Q1CUEB-6LQ"O*V1!5V7HK\M<.$
M_M]2$SP[[P,;(T-\R0 9,!4JWC9F"E;^@@WMZ0*V3X:]S:OI?<;&T'&=SI.H
MK*LT5[K>.&25)0I-@R%+%N?0S#CP%78N2O&?3_+;4\WIG=U;&QTZ77;R+<[5
MXM&3==L$>1<D39ZU+-_ST9.Q7NE 3.)5$54E%$%TUFZJJ)Z^:GI>%K&(V%G+
MU0GCZ"I')E/@1]3F"""1757M]W"W5VPW-#NS9^1]'U6(%3=0\<L36ZX94/!X
MWL+C@RD*Z,DBJRP40WTT^@&ES+)3?(O;4Q0DW8K$J;2N5.(LJK4IDS)LW=V_
M]X,%.X"F*HHE"(&,4WV/3$.N:$G;'3A/U29,S8]_FV4-[.KB/\T?)5S<O_$%
MWO+I/T?#T'3(M;*V\YI9GB!XW9<?W6'@0&R& (X]0X582U3JK7^D-=5+4^K*
MRQI^OZ-$IPM8KL>=RJA'LB*JN%3*.GJ[I^_?/7CA5PY=.%57+IRJHLJ<ZAS&
M&1,3$Q\#&3$Q$"8\8LJCP'R\22>))XD\3QJC&Y=RZYO#7LK<VY,A\K7,R4R3
M2M8%FL +!0%554!410J(BJJ@* !SL?*[R"V=OWG9R)4V',2BT=JW;&PM1Z_J
M[IPI\LIU.U];).JL&4;' NNS8NYCY/[^1.D(@Y?N%#B8Q>SI9':V!C8.B8_T
M<#JEB21F\69U#&Y\;7L/0!7)#O+N;5]R=Q-4.J.YBP\V;&AC)]V**&1HU"K<
M@%NGK<CYSDFYX5O-].YOW:%.YJM-#Q,Q)/-5;@J-V>6RJK.%5H6+GJ=67MDA
M+FR9G6!)A,=\5\L562+U<-WH%5 WIHF2PF_\#&FT8YS@#*A=>EO$AF *GTCC
M?U$</&\A_#!N35\'?R[<AD=M&SH)3)&3=%>*,NDH%^#>[Y9(^<&L;V4B]3D)
M5T0JN=Y:/,ML+B-MW^K=QTKM/>7R$@(:;V->;JQ>S;>NNK,Q3F(.M5ZOMGT8
MV/*%@'+5^X=NSN4/2>II$0[RG.$;;OWKDZ/F?FS350Y"J"[,";=0N% N.-K$
MDW'$"U7T^&/X3]#[H;7_ +_[\GRDT6:>2/%Q\=EC,HB8I)++*5<]'F!XU1 C
M7C9B]B!7L?$3Y?+GS4NT_H+?M;K$3M6-K#NWTVX4IB]B82Y0\*M'M)V)FX1Y
M(R@1UJ9@_*\26:G39.FI5B^BW.@3W/VV=O&?7)VT_4%0983J5E! 8"UP02;,
M+WN.!%^ MQQ/Q1?"UI/:/2(-[;)R,F7;4F2L$\&0RO)!)(&:-XY%5.N%NGRR
MK@R(Y0]<@<^78 R0ZI#6C'D:X?O.<O%&]:!B+6UI=EE9"N66J3TFBY<P:-AJ
MTJC)-&=@09$4>FAY- %6ZBB)5%6QE"KE35%+TCYO;VK#1-43/="\8!# <[,+
M7%^%QS]?*XO>H\[I;'?N%LW(VU!,,?+=DDC=@2@>-@P#@<>EA=21<K<, ;6,
M:/AR\0NW^!>U-D[OWG>:'*VFQT![JVK576\C.3<4E REGK=FFI^?EYNOUA0K
MY1Y3F2;-JB@L0$%%%%3E4[4R;'N[=F)KF+'A82.(EDZV9P ;A2   3P]XW-^
M?*HG[&=D=;[<:QE[@W#D8SYDN,<>..!G=>AI(Y&=V=(^-XE"J 18DL0; 6%<
MT&K-TQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2OXN&Z#M!
M=JZ01<M7**C=RV<)D60<(+$,FL@NBH4R:J*J9A*8I@$IBB("'3/Z"0;C@17Y
M95=2C@%"+$'B"#S!'B#6.W6F-//GY95[JC6KN4(=%0DDZHM7</RJ-NWVYRO%
M8L[@IV_87L$#=2= Z=.F>@9F6J] ED"^CJ:WV:QCZ#H<DGG286(TW#WC#&3P
MY<2M^'A7O8^-CHEJ1C%L&4:R3$YDVD>U09M4S*'%10Q&[=--(@J',(F$ ^(C
MU'/.S,YZF)+>NLC%%%"GEPJJ1CP4 #Z@X5^W/Y7TIBE,4IBE8TW)J6E[XU9?
M=.;%9.I"D[&K4C5K$V8O58Y_["12[/<,'R/4[1^R6 BR!^ABE53*)BF+U*/E
MS<.#4,23"R03!*I5K&QL?0?2.8K8=I[GU?9>Y,+=>@NJ:Q@9"31%E#+U*>3*
M?G*PNK#@2I-B#8C'O%7BWJWAUIR%T=I].?\ N?"R4S, [M,L2:GY*5GGIGL@
M^D7J#..9BH8PE3(1!N@D1-,H 3KW&-Y])TK$T7"7 PNKR5)/O&Y))N238#Z@
M%9SN5W'W)W6W7-O'=1@_.LT<<?3"GEQHD:]*JJEF:W,DLS$DGC:P'OMTZAI>
M_=47W3.Q&SYW2MCUQ_6+"E&/E(V2*Q?%#_&(]^F506KYHN0BJ1Q*<@*$#O(<
MO4H^C.PX-0Q),+)!,$JE38V-CZ#Z16%VCNG5MD[FPMV:$R+J^!D+-$74.G4O
M@RFUU875A<&Q-B#8CPO%GB_JSA[IN!T=IYO-IT^!?3$J#NRRH3,_*RTZ_5?R
M,E*ODFK!H=PJ<Y4RE0;MT2))$*4@" B/GTG2L31L)<#"#>2I)]XW))-R2>'U
M@!68[D=QMR=U-V3[QW4T)U69(TZ8D\N)$C4*B(I+-8<22S,Q)))\!C;F3P)T
M#SKB]=Q&]FUO6:ZRL,A/U\U1LAJZLX+,(L&\W#2IQ9/RN(F72BVX*"D5%XEZ
M0"@X1$Q^[RZUM_3M?2-,\/:)B1TM;G:X/ \#8>@^@BMA[3]Z][]F<G/RMEMB
MB348%BE\^+S0/++&.1/>6SH7:URT9O[Z-86VTM59A+K6+'3;,Q))UNVP,Q6;
M!&J**I)R$)/1[B*E6)U6ZB2Z9';!VHF)B&*<H&Z@(#\<S$L4<\302B\3J5(]
M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
M<KLYYF/M'+C;2)GZWQ,A/-QV>P'F!0R/&Y  9HI$ZP 'ZNE;:8:I^GWX!ZTM
MC&U3!=R;@3CET'3:K;6NM;=5,[ILIZJ*CZ-HE&H3J60]0"BHV=N%V:Q2]BJ1
MR&.4V#Q.W>WL683/YTP'VLC+T_*$5+^PD@^(J6MR_'%WNW#ICZ;B?FG2FD4@
MS8>/*LUB+$*^3D9(0VY.BJZDW5@0")M8Z.CX>/8Q,2Q9Q<5%LVL=&1D<U091
M\='LD"-F3%BR;$2;-&;1LD5-)),I2)D*!2@   9O*JJ*$0 (!8 <  .0 ]%5
M!GGGRIWRLIWDR9'+.[$LS,QNS,QN69B222223<\:\!N34M+WQJR^Z<V*R=2%
M)V-6I&K6)LQ>JQS_ -A(I=GN&#Y'J=H_9+ 19 _0Q2JIE$Q3%ZE'SYN'!J&)
M)A9()@E4JUC8V/H/I',5G-I[GU?9>Y,+=>@NJ:Q@9"31%E#+U*>3*?G*PNK#
M@2I-B#8C'O%7BWJWAUIR%T=I].?^Y\+)3,P#NTRQ)J?DI6>>F>R#Z1>H,XYF
M*AC"5,A$&Z"1$TR@!.O<8WGTG2L31<)<#"ZO)4D^\;DDFY)-@/J 5G.Y7<?<
MG=;=<V\=U&#\ZS1QQ],*>7&B1KTJJJ69K<R2S,22>-K 9"W)J6E[XU9?=.;%
M9.I"D[&K4C5K$V8O58Y_["12[/<,'R/4[1^R6 BR!^ABE53*)BF+U*/HS<.#
M4,23"R03!*I5K&QL?0?2.8K![3W/J^R]R86Z]!=4UC R$FB+*&7J4\F4_.5A
M=6' E2;$&Q&/>*O%O5O#K3D+H[3Z<_\ <^%DIF8!W:98DU/R4K//3/9!](O4
M&<<S%0QA*F0B#=!(B:90 G7N,;SZ3I6)HN$N!A=7DJ2?>-R23<DFP'U *SG<
MKN/N3NMNN;>.ZC!^=9HXX^F%/+C1(UZ555+,UN9)9F))/&U@')CB;H'E]1TM
M?[_U[&W>%8.E9"">F7>1-CJ\FLD5)61K5DB7#.8AUUR)D!=--7V[HJ92+IJD
M*!<:II&GZS!]'U&,2(#<'B&4^E6%B/7X'Q!IV][G;W[6:R=<V1G28>6ZA9%L
MKQ3(#<++$X:-P+GI)7J0DE&4F]1-,OIR^!K6<2EE[CR5D6";P71ZP]V!0B0:
MZ B80CE7$?JEA909E >@&)(D<= #JJ(]1'4%[:[?$G67RBM_FETM[.$8:WRW
M]=6<E^/;O3)AG%3$V_'.4MYRXV29 ?N@&S&BZO;$5_:U,AHKC_IWC1KR+U9H
MZA0FOJ3%',X)&1"2JCF2D54D47,U8)AZJZF;'/.TFZ9%7SY=PZ4(F0@G["$*
M7=,#3L+2\88F!&L< \!XGTDGBQ]9)-51WGOC=?<+79-R;QS9L[6)!;K<@!%!
M)$<4:@1Q1J22L<:J@))M<DG2[E9XC>$W+RPR-WOE E:3L>8446FMB:FF$:?8
MYQRJ02G?3S%S&S=0G94QNAC/7D6N\.)0 ZIB?9S":ML_0]9D,^1&8\EN;QGI
M8^LBQ4GUE2?74M]M/BA[O=K<&/1]%SH\S0(@!'BYJ&>*,#[6-@\<\:> C298
MQ<D*#QK#6@O!%P-T->8G8!HO9>XYFOOVTK ,=SVF G:Y%RC-5-9H^-7*A3J/
M$S@MU4^XJ,HD^;=P]PI")2"7Q:?L';^GSC(M+,ZFX$C J"/'I55!]C7'JK;-
M[?&AWIWKHTNAB33]*Q)T*2-@0RQRNC AE\V>?(>.X-BT)C>W -8F\S&;K53:
M8I3%*8I3%*8I3%*8I52_RL>&#DQMGDO<>0O%R"B=H0>W';.;M-*<V^L5&S5"
MV(1C*-EW"#F]3-?@9:N31V17:)DGWND%UE41;@DFDHI$.[=DZIF:H^HZ4HEC
MF(++U*K*U@#\\@%3:XXW!)%K $].?AI^+3M[MCM[B;%[CS2Z=F:6K1PY @FG
MAGA+LZ C'CED26/J*,#'T,JJ_669E7<[PM>+;:O"Z4OV\^00P\+M&^4Y&@0%
M!@YEA83U"JN9N-L5A-9YJ).[@7<W*RU>CO12CG;ML@@W,)EE#J]B.;V1M3+T
M1Y,_4>E<N1.@("#TK<$]1' DD+R)  Y\>$2_%O\ $?MKNWC86S=C^;+MS"RS
MDR9,D;1">81O%%Y,;],BQHDLO4941V9@ BA;O8"R0ZI!4%OD7\'.J^<&S76]
M*1LQ[HW;<VR8M+NM]U$+E3KRK$,T(V+EWL.G-UF1A+(2,;)-EW:+I=!PBW2$
MS4%@465W;;^]<K1<88,T8GQ5)Z?>Z66_$B]B"+\0+ BYXVL!7CNC\/>C]P=6
M.XM/RVT[6I% E/EB6*8J JL5ZXV1^D!2P8A@%NG5=CD7QK^'+4?C[L$OM!]>
M)'=&[I>&7KC6Y2%>;U2O4ZOOS-UY5C4:L25L"Z$I*JMRI.I-R^664:D!)!-J
MFJZ*X\^XMW9>O1C&5!#A WZ0>HL1R+-8<!X "U^)O86RG:GL9HG;3)?5Y,AL
M_<#QE!*R"-(D-BPCCZG(9K6:1G)*CI4("X:8I11-),ZJIR)))$,HHHH8I$TT
MR%$QSG.80*0A"AU$1^ !FH\N)Y5.BJS,%4$L38 <R:U"@/(!PGM6PT=4UWE!
MIF7OKJ4-!L8-G=8I0DE-%."18F*EQ5+!RDDNN/I)(MW*JBRWYM,#'^SF&CW#
MH<N3]$CRH#D$V ZAQ/H!Y$^H'B>%2EG=D.[VFZ$=RY^W-6BT18_,:1L=QT1\
M^MTMYB(!Q9F0!5]YB!QK<#,S465 GY"O!'JSF;M>7WSKK:3W1>SK6#52_-%J
MFG=:3<Y-DU;1Z$^2+2GJS(UBPN&+<I7JR*[EL].D146R;@[APOO.@;WRM'Q1
M@Y$0GQE^;[W2RCG:]B"+\A8$<KVL!7#N;\.NC[[UE]QZ7F-IVKS6\X&/S8I6
M "A^GKC:-R![Y!96(!Z Q9FSSXUO$1J/QXO;%?"724W!NJTPPUEW?9.#;U:'
MKU66=,Y![!U*JHRDZHP/*R#% SUXY?NEUB-DB) W(*Q%O#N/=F7KZK!T"'#4
MWZ0>HEN0+-87L";  #B;WX6V/M3V2T3MC)+J0R'SM?FC\LS,@C5(R0Q2.,,]
MNI@.IF=B0H Z1U!I<\U2ILJKYYAO#]OSD9OE[R>XP1L1?9B\Q%7BMB:YD++7
MZG/(S=6AF%5C;+7Y2V2$'6'D0O6(AFDY;KOD'2*S83I N5;L1BO>>S=0U+4#
MJNE!9'D50Z%@INH"A@6(6W2!<$@@CA>_#HO\*OQ3[)V%LM.W7<627"Q<.69\
M7*6*6:,QS2-,\4J0K),KB9Y&1EC9&5[-T%+O[3PR>)G>'%7:D_R/Y+M(NG6M
M&I2E+H>MHJQP]HD6AK X9FG+-9IBKOY2MIE2CF/M631N[>>I[I557T3(I ?[
M[)VAGZ3EMJ>J )+T%40,&/'FS%25Y"P )YDFUA?$_%G\3FSNY6VH-@]OFDR]
M-.4F1DY;Q/"K>4&\N*%)E24W9NN1V1+="JO4&8BR?DFUS^IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE?X44323.JJ<B221#
M****&*1--,A1,<YSF$"D(0H"(B(] #'/@.=?PD*+G@!6/*#N'4FUS31-7;2U
MSLDU:=)L;&6@W>LW$T ]6%8$F<T%=DY$8ITJ+93M37],YO3-T#[(]/1/B9>+
MT_2HI(^H7'4I6X]5P+_)6,TW7-%UDR#1\S%RS$;/Y,L<O03>P?H9ND\#P-CP
M-9&SSUE*C"\R4EL>*\</)%SK(\HE*JP=:8V1>%*J:21UY(W2NL=A=H(CZ@1J
M]2<.DI$P 8I(Q1P8W:0#'+JV]&R4VUDG%OU]*AK<^@L _P G3?J_:WJQ7PH8
M^@9/?S0(]PB,XPFE:(26Z#E)CRMB\^'6)@AB'C,(P+D@'GG%,8IBF*82F*(&
M*8HB!BF >H&*(?$! ?R#E<Z[I$ BQY5TWN'<AL66XG\;9/;@R9MFR&C]8O+P
MI.$43G5[&XI\2K(N9Y-;\\G/.5C>H]*<"G*Z,H!BE'J4+1:*V2^D8SYE_I1@
M0M?GU=(O?U^GUWK_ #Q=U8-!QNYFX,?:_EC;R:QEKCB.QC$0G<*(R.!C X1D
M7!0+8D<:V0S)UH%8VLNY=04RVP%!N&U=;52]6L$35>E66\UB"MMD*X<':(&@
M*Y*2C68F 7=)&2(+=%3N4*)0ZB AGICP\N:)IX8I'@3YS!6*CVD"P^6L5EZ[
MHF!FQZ;G9F)#J,UO+BDFC21[FPZ$9@S7/ =(/'A62<\U96F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2M(O)+1+?L
MO@ERAI5&M,+3;',ZJFC(S]CL[*F0",5%K-)BRQTU:Y1VPB(&+GZU'O(]=R]7
M08IINA%RHFAZAPS6W9X<;7,::=2\8E' *6-SP!"BY)!(( !/#@+U'_=73L[5
MNW6KX&G31P94F&UG>01(%4AI%:1B%17C5D+.0@#>^0MS55?Z>73FQDN<DM=X
M^Z4F,JU'UG>6-ZKT+M*ASTW<FDJ,;$QD>WJM9M,G,RM=CK(Z9R)Y7VQXI)=F
MB0%_651*:3]_9>/^9!"R.97D4J2C +:Y)ZBH )%QTWZK$\+ U3KX8]"U0=PG
MU"/(QTP\?$F$R+D0N\H;I50(XY&9D5RKF3I,8*J.KJ9:O"Y"U=!:^?+_ "KY
M5)_/OE_R/Y>]^<_-_;?*OE7ME?F/S/WG^)_+_9]_K>K^;]/N[OL]<_+]'0?,
MMY=C>_*WC>_"UN=??%^D_28_H7F?3/,7R^B_7UW'3T=/O=75;IZ>-[6XU#90
M]&>">$V]$;%H4WP@6V<ZL+!>M1[#D149^(+9G#Y (<M7U<YV;)45G*ED_2]B
MFQB"*)..ST *?IFEX^!L),Q<G'; ^E%AT@3*1U7X=,?65!ORLO/E5K]:WE\9
MN9M:70=;AW@-NK PE9M+GB?R0I\SSLP8B9#)T7\PR3D%;]9(O4T>;M52:8I7
M/E\MV@=KG\EFZ6<_L#6DR^V5=XZ:ILI8MVZNKGW:JLU&12E6@;:C:+I&/->H
M56)519I!*ILDUFS<KAOZB*A#C/6U<_%_NY"T<<BK&A# 1N;L">HKTJ>OJ-S[
MM^)L>-<SN]6V]9/=?/3)R<1Y,O(5XF?*QT\N-U7RTD$DJF$1K91Y@0%0&6ZD
M&KZ6FH"S534&JJM=9].UW*M:WHT!;;0BZ7?(V2S0U8BXZ>GTGKHB;IXG,2K9
M5P550I5% 4[C  B(9!V9)'+ERRPKT0M(Q5>5@6) MZAPKHYH6-EX6AX>'GR"
M;/BQ(4DD!)$DBQJKO<\3U,"USQ-[FLD9YJRM,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>allogenelogo3.jpg
<TEXT>
begin 644 allogenelogo3.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
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MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
M$JT>FJ4_HNEDR]^3E@[ZT+)QA+E2&"<#WD*L>/CTE00P]'(^D"N<NX_AN[DZ
M5JSXFCXJZCIA<B*:.6)+J3[OF)*Z-&P!'5S0&_2[ 7JS5X</&]8_'YIN\.-H
M2T1)[KW9*5N6N[&NNE']?J$%4FDNE4J@VDE$TBR\NP6LLBXD7B)2-CKN2H(B
MLFV(Z<1ON[<4>O9B#&!&'""%)X%BUNIK> -@ .=A<V)L+9]B^U>5VTT+(?5W
M1]?U!T:4(;I$D8;RXPWVS R.SL/=)8*O4$#M,5FHU.5,4IBE,4IBE,4IBE,4
MK7CEAR&K'%+CIMOD#;/05CM;5!_,,(Q=<&P6&SN!3C*?5TEORIKV:TOF;$I@
M >P5^[IT*.9#2M/DU34(L"+YTC@$^A>;-\B@GY*UC>>Y\39NU\W<N;8Q8D!8
M*3;KD/NQ1W],DA5/5>]<PF_7BS;-O-QV/=)):9M]]M$[<;/*KF.961G[))NI
M>6>'$YCF#UWSLY@#J/: ]/W,LG!#'C0)CPBT2*%4>@ 6'UJY'ZEJ&7JVHSZK
MGN9,[)F>61CS9W8LQ^4DU[#06F+9R)W5K#1U'2[[1M"YPE0C5C(G7;QI91V1
M.0G7Z:9BG^5UZ,*L^=F 0$C9NH;K\,^6=F1:?ARYL_\ !1(6/KMR ]9/ >LU
M[=MZ#F[HU_$V]IX_\YF3I$IM<+U'WG/[5%N[?M5-=0S4VL:GI;6&O]1T1C\N
MIVM:?7J36VANPRY8FN1;:+:+/5B$3!U(NR-O6<KF#O7<'.H?J8PB-:<K)ES,
MF3+G-YI'+'VDW^IZ!X"NN^BZ1A:!I&-HFG+TX.) D2#QZ44*"3XL;78\RQ)/
M$UD'//63JHO]2EQ#]K):OYI5*, $)0&NGMO&:MU.XL@U1>2.N+2],D!R"#I@
MD]B7"ZGI@3VT>B F%0 +*_;K5KK+H\IXC\9'[.3K]6S >MC5)_BLV3T2X>_<
M)/=>V-DV'VP!:"0^T!HV)M;IB7C?A4]R4:IE5K3Z;+F*6,G]C\*+G,"#:R@Z
MVOI5%VL'82=C6A4MEU-B*ACJG4DX1JUF6S=,"))%CI)8>IU?C%_<32.J./68
M1Q7W)/8?F,?8;J3ZU'A5R?A4WR(LG*V#GR>Y+?(Q03]NH_'QC[Y LJJ+ =$K
M<VJWMD3U=RF*4Q2F*5S9/+-^(]R\_:W(_HN*RQ.UOT>Q/R0^R:Y4]Z/UIZW_
M $UOP5J/#,_485TQ_&=^'SPV_N[ZP_BPQRN.Y/Z^S/Z0_P!DUUC[3_JST+^R
M\?\ U8K>/,+4A509^H8_$>LW[)=5_HI[DZ;!_1Y?RK_9KF]\3?ZTY?Z%C_@F
MH.\W2J]UT$O 7^&3IO\ 6[<'])]GR!M]?I)-]Y'^ *Z7_#=^J7 _+Y/^\25,
MQFH5.U4A?J1.1;J_\KZ-QWC9 YJWH"B,Y.;CR*&(7^4;:3=C9'JCI(A@37]K
M0T($6QC@)D1=. +T!4W=,_;S3Q!I;Z@P_&3O8']HEP/\[JO[!Z*Y^_%1NA]2
MWGC[8B;_ ,KIN,&=?_'R '-_3:$0]-^74UN9O7/R0:JY5PWZ;_A5$1%$MO."
MZPY'%GMLC-ZVTJ=ZW(H2'J$,L5C?+A%'.*A0?6.Q)*PA5B@FNV0BGB0&%)XH
M48E[AZR[SIHL)_%H \EO%CQ53Z@/>]!+ \Q5X_A8V#!!ITW<'/2^7,SP8MQ\
MV-3::5?6[WBOP*B-Q>SFK3N1C5PJ8I3%*8I59[ZC#A3%WS3$%S,I<*BE?-/N
M8NJ;2<,FY@<6/5U@DDXZ$DWX(E.+EW1K7(HD3/VE,$?)N#*J"FU1*61^WVLM
M!F-H\S?B)@62_@X%R!]\H^JHMS-5.^*+8,.HZ#'OO C U'!*QY! XOCNW2C&
MW,Q2, #]Q(US9% I;9,-4+J?#Z>#D>[U+S:<:9D)!1&G\DZ;)5I1D=7TV1;_
M $5G(W&E2J_4! RY8IO-1B)?AWJRI0Z]0 !T;?\ IPR]&^F*/QV,X-_'I:RL
M/J]+?N:LA\,.ZGT7?YT&5B,'58&CMX>="&EB8^OI$L8])D%7NLA"NBM09?4&
M;_=Z>X%2-#A7BC6?Y"7J UD8[<_IN4:@Q3=7.XKE-U !:O6U>;Q3@OQ$Z,H(
M=.@B(;ML+ &7K@G<7CQT+_NC[J_9+#[VJ\_$QN5]#[<-IV.Q7)U/(2#AS$0O
M+*?80BQGTB2J$63E7."I0O$-PR8\U>9-/IUNC_?ZFURQ7VIM=NH0XMI>NUUX
MR;Q-15,  0Y+?9W[-FX3[R*#&B[43'N3#-:W9K#:-I#S1&V5(>A/43>[?N5!
M(]=O34O=DMAQ[^WU!@YJ]6BXJG(R!X,B$!8__P LA56%P>CK(XBNC$W;H-$$
M&K5!%LU;(IMVS9NF1%!N@B0J:*""*92II(I)E I2E "E*   =,KZ22;GB374
M555%"( $ L .  '( > %?VS^5^J8I3%*UKY>\:ZARZXY[2T#<D&@-;U6GC:!
MEW3<JYZK<V9!>T^VLQ[#JIN("?107-Z?0RR *(CU(J<HY'2=1ETG4(L^&]T;
MB/NEY,ORBX]O'PK5-[[4P=[;7S-MYP7HR(B$8B_ERCC%(/&Z. >',77D37,(
MM=8G*1:;+3+.P6BK+49^8K%ABW!1*XC9R D7,5+,%RB "59F_:*)F#]PQ1RR
MD4J31+-$;QNH8'T@BX/U*Y'9F)D:?F2X&6I3+@D:-U/-71BK ^L$$5\#/W7F
MKIZ\!/\ <2X5?W2N./\ 0[3<K9KO]=YG]+F_UC5UP[;?JZT#^Q<'_=HJVUS%
M5NM<U7RC<AG?)KG9R%V+[T7==C+O(:YHH%4[VB5)UNJ>H0KAB7N/Z2$\:+5E
M3EZ_]8?J#\.O0+%[9T\:;HF/CVM(4#M]\_O&_LOT^P"N4O=_<[[M[BZGJG5U
M8J9#00^@10?BD(]3])D/K<U'_F=J-*Z,'A]X?0W$3A7K9DYB$VFTMP0\1MO;
M4BL@0LH:;M,:B_@*HY5$HK)-:+6W2##V_J'1(_\ >+I]!<GZU]W;JSZMK,A!
MOC0DQH/"RFQ;]T;F_.UAX5U%['['@V3L+$C= NL9R+DY+$>]UR*"D9\;0QD)
MTW(#^8P^>:E*S6:F"F*4Q2F*52)^HJX<16G>0%0Y/4:(3CJIR+3DVM\;,DBI
M,F6WZRDT4?RXID$B3=2^UYRDZ.4A.JT@P?.5#"HN.3/V_P!7?+P'TV<WEQ[=
M/I\L\A^Y/#U J/"N?WQ0[%AT/<L&[M/0+AZH&$P X#)C NWJ\Y"&-AQ=)')N
MU5R\D&JMU=D^FNY!N[WQEVMQ\FI$73_0]]9SM806/VG:43:Z4G)IQS0A@#UD
M&-VKTRY5,43"F:2(4P% R?=#?<7 $&I19Z"RSQV;[Y+"_P JE1\E7\^%/<SZ
MCM+-VS.UY-.R0\8/A#D!FZ1Z0)4E8^CK -N%[(V1W5J:JK?5"_P%X=_K;N;]
M#ZZR3^VG\-E_>Q_9>J=?%W_5VA_E\K\&"J?V2S5'ZW?\=O#R8YR<J]?:,:JO
M(^J*G<7#:4^R* N*]K*M+-%+(\;G$BA4)&66=MHE@H8BB:<C(MS*%%,#9A=P
M:NFB:7)FFQE^:@/BYY?(.+'U U(/;#8T_<+>6-MY"RX9O+D..:01D=9'H9B5
MC0V(#NMQ:]=*.DTJJ:XI]9H%%@8ZKTRF0<96JO78E'V\;"P<.T28QL<S2ZF,
M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
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M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
M 8;#;2G;(VYBR-S$97Y$9D'UEKECWQTZ/2^Z^M8T0 5LE9N'IR(8YV^7JD-_
M7Z:C3S8JBBNGKP$_W$N%7]TKCC_0[3<K9KO]=YG]+F_UC5UP[;?JZT#^Q<'_
M ':*L[;7MQM?ZMV5?"F1(:DT"XVXIW"B:+<AJW79&9 RZRJ2Z22)19=3&,0Y
M2EZB)1#X9X<6+Z1E1P?=R*OU2!6QZSF_FW1\O41:^/C2R<> ]Q&;B>/#AZ#7
M*8665<*JN'"JBZZZAUEEECF55655,)U%55#B8ZBBAS")C"(B(CU'+0@ "PY5
MQN9F9BS$EB;DGF37ZXITU8RD:]>L$Y5DS?LW3N,65.@E)-6[A-9PP563*8Z*
M;Q(@IF,4!$H&Z@&?Q@64A38D<_1ZZ_<+I',DDBAXU8$J> 8 W(OX7'"K-"?U
M.F\TDR))<7=0I))$*FFFG;;@1--,A0*0A"%2 I"$*    '0 R-_^6V">)R9K
M_>K5LQ\6VX5%AH^" /\ Q)?V*_W_ ,3QO?\ LP:D_P [[C_T6/\ EM@_SF7]
MZM/^K?<7_",+^5EI_P 3QO?^S!J3_.^X_P#18_Y;8/\ .9?WJT_ZM]Q?\(PO
MY66G_$\;W_LP:D_SON/_ $6/^6V#_.9?WJT_ZM]Q?\(POY66G_$\;W_LP:D_
MSON/_18_Y;8/\YE_>K3_ *M]Q?\ ",+^5EK1WG]YD;[Y M)Q>E[UHG7]);0E
M]A-@P]FKM@L$C*L96'BI^$,W(A)I>@9J_C+&X(H'4!Z]H_'MS-:%M&#0<PYD
M$\CEHRA!  ()!\/00*C[N5WTU+N7H":#J.G8V.D>2DRR([LP95=+686L5=@?
MDJ&?-OJ"*L6_31W%>)YH;;IAU3ECKCQTGI#T2@<Q59FJ; U\I''4Z&!,A$HJ
M9D?M" CW&  Z=P]8_P"XT(?1XIOMDR /D97O]<"K1?"AG-#OS-P"?Q4^ENUO
MVT<T/3_FL]7?<A>N@=55OJA?X"\._P!;=S?H?762?VT_ALO[V/[+U3KXN_ZN
MT/\ +Y7X,%4_LEFJ/U;9^E[I\(=+F!?U&Q5;&W4T_3V3PY2"9E"/"W^:DVS<
MP%[REE'[%H98!$0'V:70 Z#UBON7,_\ Y2 '\6?,8^LCI ^H"?JFKJ?")@XY
M&N:D1?*!QH@?0A\YV ^^(6_WHJVCD5U=&F*4Q2F*5#)Y]TTS^,K<!CD(<R5P
MT^HD8Q2F,DH.RZVD)TQ$!$AQ25,7J'0>TPA^01S<-B_I)#]Y)^ :@CXD@#VE
MSB>8GQO]>E<_#)XKFC4^7TXGX@TS_=WV1_&?7F:-W"_J$?TA/L/5D?A9_69)
M_9<_^LAJ]QD(5T4JH;]4);UEK+P^H2;GM0CH+<5O>-"E7#U5IE_K^&C7*YC!
M[93T"03LJ0$'O)ZBG?\  Q,ECMI$!%ES^):-?J!B?LBJ2?%WG,V7H>F@^ZL>
M3*1QYL854GPX=#6\1<WYBJH^2A5-:DF\>_DQV=XZOY55M7ZTUE>'^V?N<G-2
M5_2LZKN,:4O[S&8,8<T!/PQ4&SU:T+*.0.!Q5,DE\?S89KNO;<QMP>4,F25%
MBZK!>GCU6N3<'[GA\M2MVS[LZMVO^F-I&)B9$F;Y74TWF741>98+T.M@3(2U
M[WLOHJ2;_B:^6?\ J$X[?_H[*_T[S7?^6^E?Q^1_F?Z-2K_U:;T_X;I?U)_]
MM7E5/J8.=(J'%+4O$PB0G,*9%*/N%10B8B/84ZA=ZI%4.4OP$P%* C\>@?DS
MZ_\ +C1/XW*_?1_[*O&?BP[B7X86BV_)9/\ \L5_C_B7^=O^J?B5_F)N+_;S
MC_ESHG\;E_OH_P#95_/^K#N+_,M%_D<G_P"93_B7^=O^J?B5_F)N+_;SC_ES
MHG\;E_OH_P#94_ZL.XO\RT7^1R?_ )E/^)?YV_ZI^)7^8FXO]O./^7.B?QN7
M^^C_ -E3_JP[B_S+1?Y')_\ F5"!O_=%AY%[HV1O.VP=5K=HVC:'UOL4/2&,
MI&U=O-2G8I)K13*:F;#*($?O"G<*^L]7,9=4YNX $"ANF!AQZ?AQX43,T42A
M06(+6'*Y  X<N0X57W<NO9.Z->RMPYL<,69F3&5UB#+&';YQ4.SL.HW8W8\2
M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
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MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
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M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
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MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
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M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>allogenelogo4.jpg
<TEXT>
begin 644 allogenelogo4.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  E@    $  0"6     0 !_^%$)6AT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XV+6,Q-#,@-SDN
M,38Q,C$P+" R,#$W+S X+S$Q+3$P.C(X.C,V(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SII
M;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&1F+S$N,R\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+VIP96<\
M+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD
M969A=6QT(CY0<FEN=#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QX;7 Z365T861A=&%$
M871E/C(P,3@M,#(M,C94,3,Z,S8Z-# M,#4Z,# \+WAM<#I-971A9&%T841A
M=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$X+3 R+3(V5#$X.C,V
M.C0U6CPO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T
M93XR,#$X+3 R+3(V5#$S.C,V.C0P+3 U.C P/"]X;7 Z0W)E871E1&%T93X*
M(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#
M0R R,BXP("A-86-I;G1O<V@I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @
M(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z
M=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XV,#PO
M>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O
M<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%904)G04%$+S=1
M07-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%904%!04%%
M028C>$$[05%"9T%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E1
M04)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!
M341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF
M2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF+SA!04519T%0045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!
M445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%1
M14%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G
M8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD
M55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4
M,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+
M5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"
M0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*
M1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&
M53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L
M6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ
M;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O
M84%!=T1!44%#15%-4D%$.$$Y531Q:#E2=F].4# K-G8W:6]T-R8C>$$[4TM3
M95EQ2VYH17!D<40U1$%4471N:F=:>452>DIP:75R96%02E=P95-B6'IB<5IM
M6%),86%+.71I=VMJ;#EA2U5X>"]U-'HX5E@R-"8C>$$[;7%K8CE..&QH:UIF
M5#%A*S!-27=%:DPO04%%8VQD-S-54$YM;#9(<E!L3%=&=$Y/931%.3!8:#5'
M94)#565+:E4T:TUP56HX9'0T-28C>$$[25-"<FLS-DQ5-%1%>6Q(:31O-V1+
M2VIE*UIV275Q965R4'EX8WET2C5H,'%1,V1O9SE215=8,%-X6&UP0W5F4UEK
M<6%J.5=7:4UH1R8C>$$[*VIR<%IC8W-G9V9Q1S9B,DAM-U-B-WI.<5!L>4@Q
M4G%/;5)P3&-H,#1P>&M!2SA72C,R661S;T5W4U(S3S!N<$IX>%)Y2#9:8VLV
M>28C>$$[8FI/>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9$,S)O-F9P.$@Q:28C>$$[+W5O
M<E,S0D-M865266MQ96<U3U%-0DE(3FY$2$M:<4E*4&MX:E5.46PX;GDK5R],
M+VPO>3-0939497IM,VUM='I+63=#37EX,6MK4"8C>$$[<'IF1"LK6G9I6F9S
M;F9W=$$T<DI,:%-L-%A$0T5B:69S63%R=FU0>DYD+VU*3#51,4A166)J>59+
M9RMS>5-W=55-26I%<E1M879P:B8C>$$[:$E01'14-U<K66]Y5$=39TYN;UIA
M2%13,%IY4VPV*S8O4&Q8-#<R2S8R;FQN.'<T<EI02BMR:E).3#AP4G9,8U<X
M,%5K2U)W9S@O<B8C>$$[54%J<E5J:65T1RLO3$Y4<'!Y24YU2C)(,C-P<TU*
M>#1B1F9:*W!/3E$X*RM89%(P;E5F3C-K6%-L=CA!>EA9=$1B6&0Q4&)(-G=S
M128C>$$[:6Q06#1O9FI"0V-A,7%/*S)3,4AI631/3C).2%,V=E583# O67E9
M964O3C%P-4LP5%=:=DLP.2]R1W!396YF5TYQ<W-B47)69W,W2R8C>$$[234R
M0W-Q2V%.,'(Q>'=$:4AQ,EAT56I":TUC44]33C!Y>4]$>3EP=714>D(T8F)6
M.6)+3DMR4T%3,T)T:T5A;%5:="M#140T4C@X5"8C>$$[4&M#=VAG4'%M0C=Z
M.7EA67$W1EA9<3A-."LO;E)C85(K82MN,DYR8T@Y0F%5=V<Q94Y45EI(;3)L
M63 V*V=P2$5F>D$U;%DX3G<X,R8C>$$[5&%N6&U/8T%F4T]F-#AN=5-/:F]R
M;W=:1T%:5U4Q0D(S0D)'67)U5SA69E!8+T]04&Y,>EAR9FY3.71D6#%A-G8W
M6DY.;&Q31V56<"8C>$$[1D1I94)1=T)05VI%6FUA:4%%9&<V4'-Z4$]E46E2
M2CE0-E%T,7)Z9#5P6#@O=T-(4C Q83=44VAQ9')(.5)385)94VIP1U=5;T-&
M2R8C>$$[;7!Q1&E)1'<W<$=43E X04YC3FYH-&AS*V@X=S-E=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W-..#!A="8C>$$[-4HQ
M3'E59%0X,C)S,71O:7I":F)8<U5S53-Q>'E'3U Y,T=E6C5D5G!S5D\K,6--
M<U!%94AM:D0R9V-!.%5%=S9C;4\K6DYE+TU/-R8C>$$[.'DV1'%0;$=62F9*
M53A-33!L,5-.651'6%!R1S1A64-22U(O2VYB-'$U4FM'451!2$HS1VAL;S5A
M855S:#EE.6,O:%@T.39+=4Y2."8C>$$[>C96-2]N=B]!1$1R9&YB*U$W,4=3
M=W0W:6%"435A2F5G241-3U939FDW-6MZ;D%2,S)K-DA4-EA5-6-X-%%:62],
M9&<S-6=45W8U828C>$$[87!(6F54.4AG5W<Q-C(U6&LX+W$S2S-#<S=+8EI/
M5&YI9U5G;FIU95%Z1S%/<6U#2&8X05EF64]M>5%M6EAD,58Y4'@Y>DPU3D<X
M=B8C>$$[95502TTQ;#56;'1V3&YM,UAO8F57,V=U<FM'6#%#>2]"5S1,-TQY
M9%)T,3DX>5!(0DDT>391.6QZ:D-F-65*3D@V=F0K>%$Q*V(X-28C>$$[3$QY
M4F\Q;EDS2S-0;71*6FTQ:W='0U-C>$=6>D%65F=&-&-A0FE&.%!F2W16>&,T
M8VY99&A$1'DQ4CE69G X=DI0-&16.&Y89FUF>28C>$$[.7 S;4YO;2]-0WIT
M16Q724-53$A02D1Y;55&4#-*2BM)<7!*.%(R>5%W:V=3235/4%!T0TU*>G<T
M-65M4C5D-#9F67DV=S%:3'DX=B8C>$$[-U9B831H3FA)<U13>E)M3T]5<V=F
M;$-X*S)O-55*.&-K4E1J>&Y:26\W23=!>E-(>C$U<&<X<F563E$Q<5=H93)J
M271O>BLS3R]W>"8C>$$[3%1W3&M6.7-N0U!%86%D4FU'3T)K*U=.2SAG-C$U
M:CAM*UEF3VIY4$I,6E1#5#1T>F-B;#=T>B]!2V=D5W(X.'IJ:T%K279.=S P
M<R8C>$$[;4]75'4K,W9E-R\X-"\X06Y,.5!E4S P-C1F;&8V259T6$)/-U%%
M9G5(+S1%1E Y:FU,;FA5<C<S8SEM-2M02%(U>"]!96Y:43=&."8C>$$[>&8X
M04]-4"]!0VXQ+W=$.7-Q8B]!2VEB9DTW52]4.%AN97E0-S O,68P:&8U:6DY
M3"]N2FE*83%R<61G.68X05AH:&(K3T-0.3!N2R8C>$$[2S%N*V-0,%!C9GI'
M."\V8C5*,$)T4W5K.64U;&(P<D=Z0C1M5U=L9'IV4D9'-TXO16I-8DAJ36I4
M=4Y6<5)H:EHU.4AI;6TS6#4Y+R8C>$$[;4YZ,4Q4-S945$Y-2DEI:VAL87AT
M-F<W<D=9-GI354EP6#1V0W5:2D=/1WAD4D$V;E!U1%$K4RLS+TUJ.#)F>34Q
M<4=X.#5*2G%/;B8C>$$[4VUT2GES:D]G4'A00F-R.7!H6#=,:R])5G)J-&-*
M:C!P1W%Z-$I6:S-(-#5&.4-A5G)/;39P<$9V<3EN37(R1GI%2C0U:G-/0D94
M>28C>$$[<C!P,W(P>D1)24Y/.&AK16\X4350;B]Z5"MC4&YR>FPU:6)14$E+
M4W<R;DER1DQ!04QI6E5/.')33E0P62]$<#=N96U:8V--66DU3R8C>$$[:WIA
M-TIL;G<T=5@T*U,Y.4<O-7E).&XR+W=#;3(Q1UA68F5!97!D5W(S3%AW0TQU
M,T]/6#1Q539M33%(6$<X8W1L.%!666AX6&9X="8C>$$[0V9L9"M9+VUZ>D0K
M8C%M;'IQ5C!.3'8U-S)985DP>E!#:4=#85=/34$P0D5:<%1B=&AY-'=)361*
M<7!Z>FEY84XW9D%V5G9Z8R].3R8C>$$[1'E0<'-+5S!36%=T6'9,-G!!-5!"
M15A9>7E!8FQ19&=T4EAX,GEJ1FDT:C5/>3%U<T=%8F)Y3'EV5&1%+W=#8VAF
M3TYS3F%85G)M=R8C>$$[=#4Q.5,R0G5M<U9K46I9<$1">#))-D9G2SEC=DUS
M8V1Q9&1$2'%S;S1R22M.9F-I9DPS-75E9F9*2&U.3D$O34)*3&EZ<4$X,&]6
M<"8C>$$[-#!B65-X>7!T36YJ5W X1%55=U-X4FM,:6Y&<F-U1V9$;#5F:C5V
M52]W031T679B1#AS9%8Q4%-B=#=E-%57<E<Y,T$O1F=S;#%%<"8C>$$[2W-V
M.'ES4CAS;W=I-4%&,E=U;5DT5$M*-W9V1'A8>6HK868U;39N;S,K1TY#930Q
M3'I(95A5<WHV:DU22SA.<C9C87%Q3DHX0T1M1R8C>$$[2EIT:%AB8S5K>GA2
M0G,X;E4T3EIM;$AG:EIM5'HX:U0U:#!(."]V2U9K,G8S3W585GAB=T508V5L
M97E80WA!;G$X379W1F$K0VM$-28C>$$[64EY>'DR<$]82'%S431J22]/,W)N
M-5!F;4TS;F)Y-C@Q,FEX-G193W-..'%B2R])5E-64C)$,$\S:40R>DAZ62M%
M=3 P3W$X84<O,28C>$$[1&UX8C@S+WIN,4Q2.59(;%AY;V=K,6QU0UA.,$8Y
M5F\U2DMC25E9-D5.26%J<414<%-V4WI$:$)&;FLT,G4Q-6A,9V@Y5$9L+TQR
M+R8C>$$[04IY1VYT+S!S,G,S0UAL038R8F%J27,R*R]%2T0V22\Q4S%-;C1M
M4&Q4:B]!2EA616-816(Y+S1#92]L6"MC,G5T-6=8>6@U,E5R<28C>$$[1'EF
M5C=A.&M14GEI8T=G:&Y504$X:G-R061E=&$Q16-U159C5S=2-BM81C1E5&TY
M1W98,'9Z6G%'<V55=%HP3S1F5')265A.,4]#:R8C>$$[135B-&@V5&]6649A
M8D94-#E/*TI$25),8F\W-U4V2TIW>&Q)>&QX9$]O<#59;71X+VU(-5HQ9GEF
M2&)2954Y33!14E,R,#AR:U%X<"8C>$$[1$HV66=U=5A(:517=E@W43<T3DYQ
M5$M:<TXS8F998TU/;6IW>D9(-68R27I6+WE9<V)N>5@U8W17.# R,&8Q1#%5
M4SEL24YT2W1Z2B8C>$$[-G1)4UA(,F4R+WAE,E(Q8U!%;&9*=3EN9%ED2FI-
M0DAX3#,R+TA*-3<U-#@O96-T1S%W*U<Y3C%793 P-WDV1C K,$5*.4UY9E8Q
M0R8C>$$[97,Y3W)04W9G0G-09EE934520618:T\Q3S!S=5155&M$=RMO-T)L
M1VYE54IF>D]T3D<X>39Z<G-/;C,Y=T19,TU4<6]K=5!Q>FQ22B8C>$$[079*
M4GE:4T%W07!Y<69B3F1Q.4U0135V63EG9'1Z:G!A34]):3DK;GA:3G%V:U-0
M4W9Z3W8O3VEA.4AC,T9H0DQQ2S9%<B\V9DE)<B8C>$$[66=2535-,T)Q535C
M96TQ3RM:8W-T639P-3-$;U)05F<X64A%4CEU,WE2,S5E-C5O,VY'5%504$YZ
M-5HT*UED24)I:&YT,F0R;5@P:28C>$$[46MA<U91>6AF:#-&9'AV;4QI,45P
M4DQV*S!E>'-71%!(8UA,<65N5&0V2#57,7E46$Y"=$Y6;'-:=$]E-E1K,7!C
M0VIP=E0R<7!P5B8C>$$[5%%62&)*46Q9='AD5F='3$E906E69%%M=5-A2'IH
M+WIK=C5Y3C-R1G(U5W1P4#-';D%81CA",$YX278W=%0O<5)T6"]!1U=:;6UH
M="8C>$$[8F]/,6,Y>45",#5S:3AN+T%*=V9L4C5F.&\R4&PT4UA%<V-%2' S
M6"MJ359L:VM"37I%13E(9&TV.7-H4$1-;3-)=V$W0D1'26(O2B8C>$$[-7 K
M5R]M+U,O2V8U;F5V651S,VQY.&UE,%HU86]28E1/4%-D=V5H:5!%<V99*T]8
M-4E'569.,2ML>FI&;7-F461V9RMU33$W,#<U:28C>$$[+W=#8UEF.$%L4'(O
M05 W6E4S+U548C5N86XV9FDX-S)2+V5N*W(K:TEJ>E8O=T-T3G=F.71$5&8K
M;V%$0D@K-EI:=CAC*TUF=41F+R8C>$$[041L1F0S3&5B3DIS,G(Y5VAS4%=J
M+VPU>7I/<C Y-E),6$A41%ER,G9).%E(:RMI9$HP*WHP,U,W5%0W2E%T<&%W
M<$1!1C9C155!9"8C>$$[37=Y8DQV;U)%66=$:T=!+S@U0V%D6C-8-5I8.7I-
M;TTY:$QB>E=R9'<W>DI#,5!M:VI:8G!Z-FY"-U1I1&A*4%-M1"M13E5V4B]Z
M:B8C>$$[<#5L05ER.59E-W1O1"]X5DQ(1WHP*VU:.'1Y1#DT2$0P,'HK56PU
M5VIV.$%N1G948DEA5G)E<#A18C5P-#=9<V9T3$5Q8W="-$)M8B8C>$$[9C5$
M0G%J=4%Z-TEG3T=2-G9C>4LW2'!M2S=L.'=E43=',7-0*V-J;7,W4E%L=$)F
M-FUK2TPP5E)"8U5152]L-EIN5$XT+VLX-W!O:28C>$$[3W)O9#AV=4M"+U!A
M-W5P9GID=4DS9RMT0S%7>FET<EIQ<TI&36%3.$%Q-S!:-4=&0FAW1#!-3S!:
M134K*W%:8W8U,V9M,G%H5CAM:"8C>$$[5E555E)A6&]!03=$9DLO0F@S=58O
M2T=F*UHY:%EH*UEF;5 X=V9034YM;6\K535B85=Y6GI&4&(R;#%Z2WE!0FM0
M4&QT5E%C<WAX:B8C>$$[2&M81C%76$QM<31C=DEV42]-6#922"]/35E455DU
M26)U2S-T25AI;%9K9%9I=C0T,$1+,C0K0E)L36$X6%IZ<W0O:SDK9$0W,2\X
M028C>$$[>FDY<'1K=FQ85DY415DK=7I8>'1N;#<K;$9$139Q4#EL2WA/3W!/
M-$-E>4E$9TUU='969DY%154O;')6;TI61'A3,F1W:G%E:%9O;28C>$$[0D=5
M4C5H,E=96$%J>4QW,R]N1F-N-B\U:49D:D9A:VHO6E,U;&%R;S9F<V9N3#1-
M03!R5SEF=&9Z4W9D63 S4WIR5W)X,VPS3DAA928C>$$[;$Q-951--$PX279J
M*T1L565'5VU)-$M/=V-'1U-1>D=12$9+>3E/+S580BMD;B]5:7DO.4E.+R]!
M1GEJ=UED-W-F>C)O+S%0-T,X*R8C>$$[.#519FU:-6\X>5(K65I02T8O66%G
M:7A!=&$R3C)!>G=M<5-(;7)(:T)29FM";#!/1TEQ,T)Z:DYK;G@X0D(Y>&91
M,VUA.3@Y87 U1B8C>$$[;'5F3$9N2G!8;4=2<4IA6%IH.5954U%Q+T5S5VEQ
M-FEQ:VYO9FQM2$52170K5'9-<W-K<V1W1E,X,D4K9G11,')59DQU:RM29DXR
M;R8C>$$[=%DK83<Y8F%E-W4W5T9:249U0U-I*W9W2T%H=2](;V0K;$UR+TU1
M>#5(3VHR3G%.6'!E22]W05 V16@Q,SAS.4XQ0U!2=DEM:"M:628C>$$[2CED
M,$9B:C8S85AA5%)+9EA95',V8T5L5F%C=6Q4554S>4=R=WEY97!Y+UHO=%1$
M;V=C37)L3'DO2&UH=GI:,#-Y6#5A=DY",'959"8C>$$[1V96=%5H,"M$-C=Q
M0S-$,G9R4GA6:%5%2TAQ,S=O-VYC3%%B.6]N5GEW9U)'-V9I-T%X9&]Y;FYL
M-DQK95AZ,U1B.'=0>7%S-WE,5"8C>$$[4$TR;C9H0F]8;&4R<W)94U)4<DQZ
M=%EY95-M3EDQ:S5->&QQ,5-$>7%35%A)6DU-<W-G465B:S9(=%A$;TU-<U5O
M+U-4>35F2#A&<B8C>$$[5F)(>4IO+VTK>"].2U18-VDW,#-56C-E>'1,94%M
M4U-72E1$251)-THK-U9L,W%T93):;5A594A(:&M(;2MZ*W@U879-8W5)-V,O
M,"8C>$$[339T6F9Z0G9F4'5M-FIP37-0.$%Y<G4V=$5N0V=22U=%<TIC17%2
M-C--=7EK53)P,3<T>$U$1'I9-6]A:4]O;R]13FHX4#)S>'-.4B8C>$$[=4QQ
M.78W95=X;719-T]6631B:5AJ=W5!>4)Y.%A%:S!"3DXO-F=126)9>4I*1E98
M,G%8;6)8<E1Y+V]&+W).,R]C5TU,4VQA,$Q-3B8C>$$[:U%%.3-9:%(W;D1'
M3FUK6F-G:$5Y4%(X-"]K-3505#AW4$]/<38U-6MI*W5735A/8396:7ER3&,S
M2E!"87%63D9(2G1J=%%:;5IP."8C>$$[15%!-DA1-%!(>4=5.7@K:W9A=BM6
M2V9L9"\Q65EV.$%K6E O04Y637AV1VXS=3(O25EF-78S=DXO=T$X+W=!;R],
M*VME5TED8SAT,B8C>$$[07,O<55V2%5),&%2=S!5=$96>GI:+W-0468W3$QS
M1U5K,%A!-U$P55EW-&]#<35S+W=$>5(X-68T;#AJ,G=N8W9Q3VPP<S=W='5Z
M8R8C>$$[0BLV:SDK4U5Q9D5(2W,P3T=4;3EN-2]%>&DK63)E4F8X-'<O.' Y
M9B]W1&)+;2\V:6)F36I5+U0X6%8Y:V8S<"]Q+W!#<#5V;$58+R8C>$$[041K
M>D%X1E%D4S!T9'9&-$QD4BMV0D0K-BMA8S4O=WHO3VHK:&XO+T%$:T(K6%8O
M-6LP:3(Q:E-9:E!Q5VQ">$IB2G4X='4S>$AG4"8C>$$[,FU2:%5,,W%E.4)L
M5T1*=VUI-3-A5VQ/4TEL2&U'3V9L.2]Z:U1P,6AO,$=K96$W931&>EI)25DW
M-D922GI336-6.59#5EI8049#4B8C>$$[5W9E;51Y86-K,DA(,#-A66I(:&U.
M>#%31#AY4'I1,4PX>7)M,#AR*U9T4&XK<'9+2#E.9U!7;FM'>6QG<%I5:E-P
M3S=E-7!42C0X428C>$$[:'57;E9A<S9G:45"<SEP.' O;#%A850K6$$X;S-B
M0U0V,6)Y<'%-<60U8FM(,4-T8699<E)4-T1-5V53-5<W8D1P4DA&-%HV:F8T
M=B8C>$$[0G9,4&U$>DPK5&YN1S@P+U9,3G W0S1O='I%2W%S,&%%*VQC5S=N
M63!Q9GA5,%!43&Q%6DDW3VQX6EHV6$E226)F:F-04F1B+W=#8R8C>$$[;5!,
M;C9/9&1!<TQU-3%A56-,84\T:E)),61T9U<T3S=.46XW2VIF>$=5>#!X=F1Z
M.&YA,$LY25!%.#(O2BM(531V>G0P-4Y61')Q6"8C>$$[<3-P=D)*.78Q;71*
M:2]0+T%#=5(S>3=.6$)S-B]19VI51&DU-R]C5V9F.$%/46XU96%R9%A6=#5X
M,$]*-6)I,5)9.5%J:'%:1D523"8C>$$[4C-#9V)N:C!A;E19*T]6869)4'!,
M;F1P-E=227E2-F,O=T)A+W=!<B]W1$]496AT<&MC9FU3>759.5-J54Q*3F%)
M:GA3:V9T8U=D0R8C>$$[:%!H=5!F1U=M3C=,:#=7:EAR0G9Y4G9L<C@O<GIZ
M2C5Z:#!J4V9,<S%X<&,S1F96-6=835ER.&,P9S-I0T%F<SAV.$%:8C!W4W=C
M328C>$$[8DI:-'4P:FMY8TU9-V9A>5@X.3!:+WEP,3!+2VM#,DY06F)U16XX
M0FQE1#9W-4AA4#EX3#1F94=09CA!3TU0+T%#9TXO=T0Y=%=B+R8C>$$[04MH
M<F9*-FXV=F<P9&MF,U(O<F9O1# O>D0O>'=.5"]!3UE39B]K,C)54C5U>'DO
M4V9C.$DO-7A8+S0V2&U,+T%)>%=V+T5P37DY5B8C>$$[,&1,,E!Z;#A%1BM:
M+VQF>D@U0B]-065E9$-I3#9D3F-'-CE107-K8W-T4E!$348V2DIY86@R,F%G
M,T=(1DE4:G=L:G$X33A/6'A)."8C>$$[;5A7=B]/5"]!2E%B5'A*9&%B9E(S
M=TAX5S!9:650;"]K>48P3E!M=C!:5V1-6$I(82M/='=B5%@X<79Z8C$S>G1Q
M;#="3F]8,694628C>$$[:5=J,4-*>5DT>"MZ1DM8<'IC*TMF.$149DDU8U%I
M3V)B;SEB3$Y):F@R-S)B96)R1'I,9F%4-E!L>E59.4TQ15-O-'5:545I.$9R
M>28C>$$[6&E1=S,R-UII>D)),DY/-C!M5$9'9#5).%5A-4U:.#EJ>59A96)V
M2S R<S9*2G%7<U@X-C)T:F92,31W=$A,1T9A9%%Y2WEH<"M1<28C>$$[<'!V
M:WAG1796,TY*-U9Y64%-55-E2$EE:5-3-B]W0U-,3#@U8FEX<SE&:UAZ5F-Q
M651R3'I3;4EZ>5%";%5W8RM01&E&0EE$-D\K428C>$$[+TYE<F<V3U5/=W8S
M2C%1<FDK4'4Y>5,K5S=0>FI**VPO=T1L6E)S1&0K;38K5VIR4G1.-S=F.$%U
M2SE9-CA/44AW.4UY32]H8F-N5B8C>$$[9&U(6&=4-&50;# O6C!75U=R*V-D
M23AH-C@O-7%752MP85IC>C(Y=%HR36MI>'EU-4Q/+S=Y16=P2#A#:TAX-EE.
M4FQJ:G%55UA9,R8C>$$[6BMB5GE/3$MD:C,O04Q09VTQ+V8O;&E0>7@X='EY
M*U<W;34P0S5U6%14.5!2-4=L=#57:VM-<$UP:T1L4S1B.7)F8F)+-'A'8U=8
M3"8C>$$[>EIP.6Q434E(>3(S-3<Y6&]D-6\R=DIR1VEN4C<V2W@X=C)#3DAE
M-EHV86XQ1D-H26Q19U952U X<6UW,D]13519<FLS47I9>D-F1R8C>$$[1$Q*
M3&Q,-S O=T%M-&E",7)1=$DQ>7A.:'$Q<6PU6G-W9&]*2SA3>3E#845D34U:
M16-M1U1(1UEQ47-,3D,X=6%&;T9O.6YO,6Q&628C>$$[,C!J;58T;VA11GE!
M<%DK.49'1U5I96%-94M-0E524UDU1G-53"MW<SE1<W W1SEH5S1T3&Q$2%!#
M-'%R27=O46-)3DU:4D5H4C5*8B8C>$$[-68X04HS;&IY.#AZ-DIP,%9G,7=&
M12]P5DA-2EAJ545N<'E.34UP:S@R1U!"0T@P:6Q0469)=FQ$44QX-WI2=$QG
M<V)Q4TUW=DQ%0R8C>$$[1TUB34=+-VLW5E%(1$M:4$UO>#9F2$$S15586%AK
M6'EH9#8T=74S3VQW4S9W<VMC>3-R02MO2DE1;VIB<C%89W10;&E*;7%V6E1P
M."8C>$$[6FQX165P4&-G,TUC,7HX=79)*W5Z;30Q5%)B831U5TY8;D,K;DEX
M+WEN:DM-,S!N2GAY4TA)=$=44S0U;3520T\P2'EP-6(P0TYO.28C>$$[1S R
M,W-1-'!),$M!3W<O>6XK,#,P;D)+6E!.;&IW=V@Y27!.8VDR<T8O36YZ8BM8
M*VQ81FAP6&Y/>E<T<S<Y6DI)6G!)0F-2>&U-<28C>$$[1%5!3DEP4%!Q9WDS
M2$-2,VDT97%Z66]K4GE$67-:9S@R9CA!3U!F;&5.=%<P;$Q/4RM51C1&=#1:
M2F)J;#%O:&M".4PV4W54-$UK="8C>$$[:30T>F%82#9O,6)#4'E4<SE5.'HO
M;7AE*V-(:$UD=&)V9%AC-4<V0U<W5C!314UE-%=5;C5,;'59:4U+8U!S*TIY
M6GIK-F)N-79:3"8C>$$[6#AY:V5(5W W=E),*WEG,$=.,W9N:TYU,4A21FLY
M2E%K<E9D:V--3S-V;71'6&YT>65Y;#)D4F="3TUJ:S5C+VYY4V)Z3$0K53 Q
M,28C>$$[<3%Z8S9$8F%J8S9B0F(S3GI.8G!#0DMB<59O55AM<F]P8TUV>$8K
M9S<U6BM:275J>6-/4%EO>4=*;$5$:DI'-#=H85IA6')M:S9$<"8C>$$[3F]U
M:V56;71*3E)U6'0W9E0W3C=#<W!H:&5D<%=L:6U-4F]K8F9A9FQT,'E-<WA/
M-6)S6%IS26MX:DM):D575%5H,7)L=S,Q5DY9."8C>$$[*RM48C-Y4$1R3B]A
M>5AU:F%L25E$679%2&M9>$]X;#5X5DEP14E79'0K:3102$%(14=2-TMN4$MC
M2G%W4&@U9D]W;S,O;6YY;C5%0B8C>$$[<V1-,%9X<#5T>'%T,TIP<5%,16M5
M:G)"-GA5=D=82DE8-TE/,D]44%(S,U)O=7EU3U!P35EE<7$S,TY8,TIJ0C4T
M<W15,7EF43=B5"8C>$$[<&)Q0E=70S5U5VQT56IP3$-S=3!-:W%Z=79#458T
M;V-2;',P135.05DT*T]21R]3:C,Q>G%V=%%0;')59DI';E%A6F,K6#E%1FY*
M-28C>$$[:DYX2$)(8GA24D\U<VML:TMY2&M"=C940F0K*SE-:V,O1EAM,&IS
M=G=J341H2$)6+T=V,7$Y:"M9;'9E,D=P,TXW;W0U85=E;E1#>B8C>$$[=6I.
M.5AC3DTP:7=T14974G$X9E5"4&%M44=8<EA*>6-V6C%'35)+36I)6#$U5F9C
M:S4P2#AT-WIZ2$Y"82M3:&5P8EA+,FPU<55&=B8C>$$[0CE6:75';U=6;WDV
M1F=N3#0R5TUG6F%.4DLV1G5#97E-46E*>31!4TQ!-FMF2W0K:DEF2UAM=E-.
M4W5R<E-D23!Y5S!S=$]E5T):5B8C>$$[5T-/04Y!+W!U;VIJ8WE2,6%V14UG
M<4XX:$A,>$9Y32MG3T=%4U1(971H9EAF=7(U1FQ/5&-22S1).6$P,WDX-&UN
M3W0V=F)1>4US<B8C>$$[26QS8FE50FU24W-92TI86F1H-S1Z4%5"8T5.=TIY
M.34O67AF5EEF33DS-4]B>DAP,VPV,',O>D%A24-*6E5H:VYJ55,X0T9M8G%4
M1"8C>$$[57%P8G91*T=$0T%31$E5,CEO5&Y#37-E1UIL2' S2#1C:VHQ>CAV
M6E!/3VIE5V)N>GIQ03!J>D-V2S-N:&E-6$=:;F-S<V%!;FE*4R8C>$$[:6<O
M1%AE=3)1,4=+37!C,TTW1S=2>C1-4CE016%S*UAN<VY%='(U.79F>D)L,')5
M9$YT3'8X=2]20554<$1+1TMX07%32$Q/6#E9528C>$$[;U)3;2]V;5%9=TU0
M3C P33)O:G%,1S!/.&)F=%I$;S$S<3AE=E@R:B]O5DQ$>2]9>%(O;WDY:EI6
M4U-Q:7%,16=O;U4X=D1T='9L128C>$$[4V)Q=&Y:-6]13TU4-"M,2DDK;V9T
M5$\Q=&11:3%#*VYN=FIC5VQW67I:,EIJ4D)B:$4T=4$V+T9*-FIF1CA85&]-
M<TIC14$R4U1T.28C>$$[>4UW33-9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67%K4&UZ>4XU6#@R5SAC1W4R4S-0;S$Y0U5->5-X.'%6-'5H53<P1E(P>6-*
M;28C>$$[4$IP>F%E1U5624U/='8X06Y(4#AT66)N,7!)<G4T4W1F<3AT=U%N
M>2]D:$@O=T-'>7<V:51I1'-V0T0Q*V(P4%-.1S!R4C=#3W<P=28C>$$[,6IS
M-T],-T5-4VA6<C-*.%-E-4\K56MK.#-/:&IJ059%545Q=69*5VXS1FPU:71(
M;FQ#95DR6G)L:'AR2'EG4T0Y,W0T4C$S>6\T>"8C>$$[=C5U9DA74T5S6F]F
M=2M8>G1"-FHK5W5H6$DQ65=O1F=U<E<Y=&)Y4E<X55-X26)75G!68U(X94Q&
M:7=$5C=$06-1,S@R>D@R:FMJ=R8C>$$[,S9U06LW:SE24S O;'9P9#%95V1J
M<D5I86AA,F1Z2F1,8FDR9W0T5SE30F]E1%)W<6\R3#AW,U=U4&A!:6EN*U5:
M4FM:43E*27$W2B8C>$$[4$\K6BM3>%!Y<S!"-U13-T<Y;75B=7DP94-E,W-O
M0DLY=E%4=E5S>E=X:%IM168W=G)U2S$S3U!G:EED>50R;FMU56]G0U5Y0V1R
M-28C>$$[92LK=38V,R]!0W4X=$-E=VLQ0E<Q4DY.<WA95W-.-$5K45)*2UI)
M>7=P.%1)<#1#=EEE3TEW:G)U:5AA95=P0U!P-'!C4G(S9F=Q<R8C>$$[9FM+
M2T1Z6% U9W1R=TDQ,4]L>$Y!.71B>4Y663%I2WAZ<W9Q>'%Y<"MY9DA(=R]6
M8D4V-&Y%35I(259Z4&9F3&M7=$<O3#(S,'I63"8C>$$[3S5';S-%.6IP8C-%
M;6LV8S9X0DQD<G--2E!J5E))-$%D9W9)-U9X:FEO."M38S-A0FY%:FA!;$MU
M23<W,7DY>4Q0:W)4,C!Z5DY0328C>$$[.'9P87)F2%5:;2M(:W-H:U-8:74Q
M3TY9:#%W*T=+23<R=CA!3U,T;WEO96U01#EH2#963U!Y8E!B87I.939F<D8Q
M6E=.,V1#*W9D328C>$$[:E=&;S5*.75D2DA2<$575&E/86<W.7%9*TAV<U5N
M5T-50D=50DM11D$W.'9U,C9+96UE46)A>3@Q=C5J92]M=6)J,#59;S0U23=D
M0R8C>$$[0DUW6G5C:U5C8GEG8V9G-6LX8U)J<59S<VUV37-8:#A)03(W*VYK
M4V$X-EI4;&IG3WA622].;C9:.4149C!8.5HU+W!#,BMT+U9F4B8C>$$[<CE8
M-4@Q4%4Y8B]D9E1L=RM,-DLU2T9D5VY.>%5/1RM9-61Y0C@W+T%/02]R3VEF
M-'$Y2#$O<F<O4DAQ.'$K=G0O3"MX6&IY-69$6"8C>$$[:EA+8VY$='A/,3!8
M-6EP*T9D8U!Q.3,V+W12,VU,.4TO<$A1+W="2"]79G$O=T)D+W=">4@Q9C!/
M2&\K;3,Y.39V>&-/6#AM+W="3B8C>$$[375J5D<S5EIE2S0Q9E!D4$UI,T]X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>"8C>$$[5C)+=7A6,DMV+R]:/"]X;7!'26UG.FEM86=E/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT
M/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.F1D9F-F831B+35B9C4M-#0R92TY,#DW+60U
M8F5C,V$W,S Q9#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#ID9&9C9F$T8BTU8F8U+30T,F4M.3 Y-RUD
M-6)E8S-A-S,P,60\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T
M03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]X;7!-33I2
M96YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HQ9F0R930Y-BUF-S,Y+31D,#DM8C(S,2UC8S9F
M-V%E.65F,3$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z,69D,F4T.38M9C<S.2TT9# Y+6(R,S$M
M8V,V9C=A93EE9C$Q/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q
M,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO
M<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E
M9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#IC.6,W-S$Y-RTT-&$W+30W9F,M.#ED,RTU
M9#4Q-3EE83 Q.#@\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3@M,#(M,C94,3,Z,S0Z,SDM,#4Z,# \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-#(#(R+C @*$UA8VEN=&]S:"D\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.F1D9F-F831B+35B9C4M-#0R92TY,#DW+60U8F5C
M,V$W,S Q9#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C Q."TP,BTR-E0Q,SHS-CHT,"TP-3HP,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0T,@,C(N," H36%C:6YT;W-H*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I
M;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" @(" \<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C
M97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E
M;F0](G<B/S[_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="
M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
MX'7K.[HEEL-J_$# ( ZL[GV&QDB '4O:WFT"B!OB B!1+A\W9NWLT'\0(G],
M9Z+?N>*?54UOFW^_W=+;[BVHMFXXYQY:B8'VR&TX_<RC[%K$O"WZA[CUNU_%
M47D[72<;KP^.W9-;H,H>=TS+O5/33$\A..$&TSKSW#A3[(2*;N-;I%$Z\F3X
M ,?ZQL#/PE,^FM](A'VMK2#V#D_R6)\%JT&POB=VQN"1-.W;%^:M0:P$O5UX
MK'UN0&AN?NPR <6E%6&X^082S!E*Q3UI)QDFT;2$=(Q[E%XPD&#Q$CEF]9/&
MQU&[MH[;J%4343,8BA# 8HB @.: RLC%6!# V(/,'T&K.12QS1K-"RO"ZAE9
M2"&!%P01P((X@C@17Z\_E?NF*5I^_P"?O#*,WF3C8_Y%ZW;;K/-H5C[DGE5Q
M43M3E<&B-37GBM#5=O;#OC V^5J/BOP=F! 4?6$"#EET'6&POSBN/)]"Z;]5
MOM?NK?.Z;<>JUK<;VK1Y.Y.Q(=P_W4DU3%&O^8(_*ZC_  A-A&7MY8DO[OEE
M^OJ]WIZN%;@9B:WBF*4Q2JP7U,M=NKO6O%&U1Z+P^O8*Z[2A+6JD)Q8HVZRP
ME+>43W9"D$GKJ1-9L (G,(=H=X!U[OA%G="*<XN),M_HRO(&]'4P4I]97M71
M7_#US](BW!N;39R@UV;$PY(0?G&"*2=<GI]0>7&ZA[#X54-R':ZCU=5^F_K5
MWB.(6U9V<2?-:7;-Y23ZBHNR*)H/E(JI5J$M,Y&=X]JS%S(L46)E2!VBYC52
M=>Y,P!-_;2*=-&FDDN('G)7UV50Q'JN+>T'T5R-^/K4-'RNZ6FX6&4;5\71D
M7(*V)4//+)#&_H8*S2 'CT2J>3"J[?FMXV7[0G/7<EFL,3(_<?>UHD]LZZMJ
MC<WRF>;63VTA:(AL\3(#8)2HV5XNS<-C&]PFW]LN<H)N43GN)LW48,[0X8XR
M//@4(Z^(MP4^Q@ 0>5[CP-?YVN_FU-2VWW'S\O*1OS?J,S9,$EO=</8R*#RZ
MHY"59?G =#$6=28MJ?3[3L"TP%(I$!*VJW6J59P=<KD&S6D):9EI!8K=FP8,
MVY3JKKKJG    Z '41$  1S9I98H(FFF8+$HN2>  'B:B#!P<S4LR+3]/B>;
M-F<(B("S,S&P  YDUT[N&6EI;CKQ1X^:1L#A%U8];:JJ-<LZK9?W3/[T(Q:+
MBRI,'/4?7CF\XX<)MS_ #(%(/0/R!6W6,Q-0U3(S8^$<DK%?O;\+^NUK^NNM
MVP]!FVOLW3-OY)!RL3#C20@W'F!09+'Q4.2%/HM6S.8VMLJE9]1#R3N=RY0P
M7&I"2=L];:<J-:L3J!3.9-K,[$NL<O,+V)Z!1*1Y\MJ<BR9LRG PM3&=B0?\
M8. 0AW'U.>?55TP$C%A13;TNPOU'TV4@#T<?377+X$NW^DZ3VYF[@O&K[@U7
M*EB$AXF/%QV$8B7[GKF2222UNL"($?BQ5>/(YJ]56R?IN>2EUFT]T\6+%(N9
M:HU&"C]JZZ2<J'4^ZP/9X(2[PS0YP/VQ<Q(S$>]20*)"(.@=* 4QG)Q++O;/
M4YY!/I,A)A11(G[6YLP]A)!MX&Y\:YE?'[V_TC#.D=R<"-8M4RIFP\H@6\[I
MC\S'D;]NBI+&S&Y9/+4D",7M39+%<V*C0\O''&\<H^!6Y-<:T9.9>_QGW:V!
M5Z\U.8J]G<T:?93<G7VZ8&+[J1D:^D\*Q0'KZT@"!/@(@8-CVGJ,&F:Y#D9)
M @-U8^CJ! /L!M<^ O43][=K:AN_MQGZ5I*E]23RYHT'.0PN'9!Z69 W0/%^
MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
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M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
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M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
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MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
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MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
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M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
MV \6-E4<20*N3>)OP?I<;IRO<DN6:,-8=VQ7H2FOM6LEV4[5]52)T3B6>L<@
MF5S&V?8,<90OLQ:'4CHA<@KHK.G'H+M8BW3O0ZBC:=I5UPCP=S<,X] '-4/C
M?BPX$ 7!O3V8^'U=JY$6ZMZ".77TLT.."'CQVM\]VXK),OVO22D9'4K.W2R5
MK/+-^(]R\_:W(_HN*R1=K?H]B?DA]DU5/O1^M/6_Z:WX*U'AF?J,*Z8_C._#
MYX;?W=]8?Q88Y7'<G]?9G](?[)KK'VG_ %9Z%_9>/_JQ6\>86I"IBE8%Y'\9
M=*<LM82^H][4B.NE1D_\8:BN M9NM3"::B;.QU.=;]LC7Y]@"A@(X0.'J)F.
MBL55!15(_NT[4LS2LD9>"Y24?4(]##D0?0?:+$ UKFZMI:!O32'T3<6.L^$_
M$7X/&W@\;CWD<>!!XBZL"I(-,SG!]/\ \F= /)FY<;B/N2NI$3KNT8N);MT-
MT5I@4IU?0EZ<@"*%V]N'8D5Q >L[='ZJ#&MDP'I+^B[[TW/ AU&V-E^D_P &
M3ZF^U]C<!]T:HCW!^&O=FVGDSMJ]6K:*+D*H RHUYV:(6$MN75#=F/'RD%0*
MS4)-5N5?P-BB)2 G(IR=G*0TTP=Q4K&NTO\ "-7\<^20>,W*?7[1%"%,'[H9
MO*.DBAXR&0C@0;@^PBJXY&//B3-C92/'D(;,KJ593Z"I (/J(KYF?JOC3%*]
MQKO66Q=N6EA2-646V[%M\H<",*U2Z_*62:<AW !U2Q\2U=."MT>[JHJ8H)I%
MZF.8I0$<^.1DX^)$9LITCB',L0!]4UD=+TG5-;S%T_1\>?*SGY1Q(TC']RH)
ML/$\AS)JRIP'^G9O-K>PNR.<[XU%J22B#YOHBKRZ#J[V-'H19)&[6Z$>+1]-
MC%RB *M(Y9S*G(8Q#+1ZQ/C'6N]P((E./H@ZY>7FL/='WJGBQ]9LOJ85:WMO
M\,&HYDD>J]PV^CX0((Q(V!E<<[2R(2L2GQ5"TA%P6B85;QH="I6KJ?7M?:ZJ
MT'2J15(Y*)KE6K<<VBH6'CTC'.#=DQ:$313]190ZBA^@G55.90XF.8QAB>>>
M;)F;(R&9YG-RQ-R3[:NUIVFX&D8,6F:7#'CZ?"O2D<:A451X #ASXGQ)))N2
M37K<^5>VF*556^J%_@+P[_6W<WZ'UUDG]M/X;+^]C^R]4Z^+O^KM#_+Y7X,%
M4_LEFJ/U;?\ I<7KH[+F_''5$6;5UQP>MT.A>U-T_2WJ@[5 P%[Q%9*-0 0$
M1 /3#H =1ZQ5W, OA-XD3?6\K]FKK?"#(YCW!$3^+!P2!ZR,L$_*%'U*MEY%
ME7/IBE,4IBE0S^?3\,G<GZW:?_I/K&;?L7])(?O)/P#4$_$C^J7/_+XW^\1U
MS[<GFN:%3B?3S_B/5G]DNU/T4RS2]_?H\WY5/LU83X9/UIQ?T+(_!%7YL@NN
MD-,4IBE0T>1?PQZ$YQK26R:JY0TGR(50$RU_A(I)S6[ZNDF4K9+9M:;F:FE'
MI4TP1)+M5$9)-,2@M[Q)%% NW[?WAG:*!C2CSM/^Y)XK]X? ?M3P]%B2:@GN
MCV'VWW"9]5PR-/W.1QF104F(Y>?&+=1\!(I#@6ZNL*JBG)RH\9/-#A\]DE=K
MZ:GWU)8JK AM2A(+7;6[UFD*GIOW$_#(JK5DC@J1C$0FV\8\$I1-Z/;T$9=T
MO<FCZLH&+,HF/VC>ZX]5C\[VJ2/75&=X]I=^;'D=M9P)&T]2;9$(,L!'I+J+
MQWMP$HC;]K:M!\SE1M3%*_Z4ICF*4I1,8P@4I2@(F,81Z 4H!U$1$1^ 8K^@
M$FPYU*)Q)\/O-_EJ^B9"'U?(ZJUF^60.[VIMYJ\IT$6..?\ ./*[ O4"VVYG
M41(H"!H]DHR,L4"+.FX&[PUK5=VZ+I2E7E$N2/M(_>-_61[J^NYOZ :E[978
M_N#O61)8,-L/26(OD9(,2=/I1"/,EX7MT(4OP9UYU<S\??BQX[^/^"^8U1J?
M8>ZY:.*QM>Z[5'-$IY9!4B?O86F1:9W:%%JKA<G>=J@LN[<]" [=N@21].(-
M>W/J&O/TRGR\,&ZQJ>'M8_;-ZS8#P N;WM[:=GML=M<?S<,?2M?=;294BCK(
M\4B7B(8R>/2"6;AUN]EM)EFMU+-,4IBE,4JHEY)_.)R2H?)/8VCN+<A6]>5+
M3=MD*).6^0JD);K3;[A5W8QMQ2.A;&$K!0T!&S[5Q'H)(-#.EBMS.!<E]8B*
M$/;GWWJ>/J<N!I16.&%RA8J&9F7@WS@0 #<"PN;7OQL.HOP__!WV_P!:[?X&
M\>X\>1GZIJV*N3' LTD$,$$R]<!O"R222O&5E8LX12PC\L]!9Y.?#EY-KKSO
MK6Q:)N6'A6>X-4(0<NM8ZPP/%0=VJ4\J[8HOUXGW#I&*L4/)L1(\!$R35PFZ
M1.@DF)52AM&R]T3Z_%)CYJJ,V&QZE%@RFXO;P((X^!N+#G5=_BM^'C2.R^H8
M&L[3EF?:NIF1!%,W7)CSQA6*A[ O$Z-=.J[J4<.S74F5/?&A=4\E]86+3VZ*
MDSN5$LR:'O8URHX:.F;YFJ#B.F(:49*MY&'FHQP4#H.6ZA%"_:(/<F<Y#;9J
M&GXFJ8K86<@?';F/01R((X@CP(JMFR]Z[F[?;B@W5M+*?$UK')Z7 #*RL+-'
M(C K)&XX,C @\"+, 1!DQ^FTXJ-[B65>[KWI(4I-^+HE0%2DM955H4P'3C7=
MM1K0@H@8P=JJB4>@L9(1 ADS]% T->V>DB;K:?(,%_F^[?V%NG_(#[.=7)F^
M/_N4^E?1H=(T9-7*6\^V04#<BZP&7@?$!I64'F&'NU/;JK56OM(Z]JNJM5U>
M/IM!I<82)KE=C/6,W8M"J*+JG4<.E7#U\^>.EE%W+EPHJX<N%#JJG.H<QAD#
M$Q,;!QDQ,1 F.@LJCP_RDGF2>)/$U2C<NY=<WAKN3N7<F3)EZWER=<LKVNS6
M %@ %55 "HB@*B@*H"@"J]?EP\)%LY4;-?\ )GBU)5EAL^RM626T-;6E^%?B
M;B^B(UO%QMJJ<V1HLPC;,Y8,D&[]J^%!H\%,'/N$E_6!Q)VU-YQ:9C#3=3#'
M&4GH=1<J";E6',B_$$7(Y6(M:FW>OL!F[QU9MV;/>%=7E &1!(>A92JA5DC>
MQ"R$ !U>RM;KZ@W5U1C\:_IT>75VV)%)<DG53TMJM@]:N;,]AK= W:\SL:10
M#N8JGL*ZI+PK&0>)D%(7DDX329]_K%;NQ)Z!]EU'N#I,..3IW5-E$<+J54'T
ML38D>H#CRN.=1+M3X7=[:AJB#=30X&CJP,A61)977Q6()U(&/+JD("WZNE[=
M)NK1,91]-ZWC8:.3CZ?K;55(9QC!$RATXJK4>C0*;5JF954RBA(^$@8LH"8P
MF,":741$<AMFFS,@NUWR)7N?2S,?LDFK[PPZ?H6E)!$%@TK#QPH'VL<426'R
M(B_4%4R>6'U%W)RV[*FF?%!K5M3:CAY-RTK4K8JC%V^_W%BV57;ISEB"R)R$
M# H2R8$<)1S1GZ[+KZ:CMP/4<F#2^WVFQ8X.J%I<LCB Q55/H%K$VY7)L?0*
MHCO/XHMVYNJR1[,$.%HD;D1L\:RS2@7'6_7=$#<"$5;KR+M6]7BJ\W]MY-[0
MBN+',&#I[JR;%;NX77NRJ_#$AXVT37L3G5I%_JO<Z@O<V5HFX*T>LRM&IUP3
M9G:"*Y5BX+=6R,?!PVU#3.HXZC\9&WO64\"5)XD#Q4WX7-^%JDGLI\16J[BU
M^#;.[1&FJRM_Y;*A!C)E7WE210;*[6)CDCZ &"IT78,)T8G@9PG@K,C<8?B;
MQXC;(V>!(M)1IJ*CI*,9 IP5(^8(%A?:,7B2I0.15%,ATS_:*(#\<A]-OZ''
M+YZ8>,)0;W\M>!](X6!]E= LGO3W>S=..E9>Y]=DT]DZ61LW((9>72Q\SJ92
M.!#$@C@>%5M/(A]03M^O[CMVHN%Z-2KU,U]./JS*[<L4 VML]=;!"NP:3"]6
MB9@#UN&J2#]!=LBHNU?N9!(A72:C8IRI!.&W]AXDF(F7K'6TTB@B,'I"@\NH
MCB6M8FQ '*QYUS4[G_$OK>-KL^B;#$$6!BR&-LET$CRNALQC5O<6,$%02KLX
M <% ;5_'QZ_4&[AF]PU#4O,YO3['2M@3\?66&W8"%:TR=HLS-O!:1CVT1<20
MM9FZD+U=!NN=%M'N6")C.CJN03%(?[K^PL1,1\K1^M9HU),9/4& YA2?>#6N
M1Q()X6'.OSVR^)C7,C7(-%WX()<#)E6,9**(GA9S93(J_BWCN0"0J,@NY+6Z
M:M-\B-$43DYI+9&A=EMEW-,V97%X"5.S,D20C7!5V\C"S\4==)=NG,5N>8M9
M!F91-1,KILF)BF* E&,=/SI]-S8\[&/XZ-KCT'P(/J()!]1JX6Z-N:=NW;^5
MMS5@3@9<11K?.4W#(ZWN.I'"NMP1U*+@U2@VO].[SYIUVDX76C+7>X:45PH:
M#NT?=X&EKNHXRIBMOGE9N#^/?1$N5'H9=!LK(MB&^";E7\N3)B[_ -"FA#Y)
MDAFMQ4J6X^HJ""/038^H5076?AA[D8.H/!I*XN=@7]R42I$2OAUQRE2K6YA2
MZCP<U/GX@_$0MP,-8=R;FG8"V\A;A!JU9JTK!UW]2UM4'3QG(/HV*DY!@P=S
M%HG7$>A[YZ5%%)!%+VK?O3,LLXT7=F[!KG3AX:LF C=7O<&=N0) )LHN;#QY
MGP LAV1[)-VY,NNZ])%-N>>,Q@1W,<$1(8JK, 6D<J.M[  #H6X+,TKG(_C5
MIWE?JZ7U!N^J)6JGRBJ3Y "+JL)B FVB2Z4?8JY+-A!S$S<<5RH":I>I#D.=
M)4BB*BB9HYU/3,+5\0X>>G7">/H(/@RGP(_^AN"15O-@]P=U]L]QQ;IV?DG&
MU6,%3P#))&Q!:*5#P>-K"X/$$!E*NJL(3ZO]-SQ1B+HVF;%N+=MMI;1\+HM*
M<*U*&=2+9-4JB$;,VJ(@D7:K10A1(X.R;1[A0IA%)1 W0P:/%VSTA)P\DT[P
M _-]T7]18#ZM@#Z"*MYJ/Q^]S,K2&Q,#2M'Q=69+?2 )Y I(L7CA>0J&'-1(
M\B@_.5QPJ?J@T*FZMI=8UUKVN1E2I--AF4!6:Y#H>A'Q,2P2!)NV0*)CJJG$
M $RBJACK+JF,HH<ZAC&&0L?'AQ($QL90D"* JCD /^WM/,U2/6];U;<>KY&O
M:[D296L9<K232N;L[L;DGP'H  "J %4!0 *__F/\MVV>(>QZ]QUXXMH"+O:]
M2CKM>=B6&';6,T$VG'4BW@JU6X.2 T0,H=K&B\>.GB#M$$'*":1 4]4Q(\WI
MO#,T?)73=,"C(Z S.1U6O>RJ#POPN2018@#QJ[_PI?#!MCNEH$^_-_-/)HHR
MFQ\?%B<Q>88U4R2RR)[_ $7?H1$9&ZD=F;IZ0<?>('S$[MY+[R9<8>39Z_:;
M!<8&PRFN-CPD!'U>9=3M4AW=EEZY9H:!;LJTX:/*O%O7;=VU:LCH*LQ2.1<'
M!3(>?9N\\[5,\:5JG2\CJ2C@!3=1U%6 LOS02" +6MQOPS?Q3?"IM#M]LY^X
MG;P3XV#B31)E8LDC31B.9UB26*20M*&69XT9'>0,'Z@4Z"'LWY*-<\:8I3%*
M8I3%*\3LG7=0VY0+CJ^_QKB9H]_KLK4[;#M9F<KRTM79QHHPEXOYS6I*'G6*
M,@R6.BH9LZ14,F<Q>[H(@/VQ\B7$G3)@($T;!E-@;$<0;$$&Q](K'ZKI>#K>
MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
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M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
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M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>allogenelogo5.jpg
<TEXT>
begin 644 allogenelogo5.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M 1$  A$! Q$!_\0 Z@ !  (# 0$! 0$!          D*!P@+!@4$ P(! 0$
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M9JU;(E(BW;-T2%(0A"@4A0    #,<26)9B2Q/$UM:(D2".,!8U   %@ .
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M'B5( 8^L@VO^UJ^_PIZYJVH[2SM*SF>3!P<I! S$GI61"SQ*3]JC*' \#(?
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M@]>F?W(BBG@>'( ,#H0P/+I(L;_)7\TO-SM-U/'U#3&9=1@G22(KQ82(P9"
M.9Z@.'CRKJ,[ST3JWDIJZQZ?W14F-OHUJ;HDDHI=5P@NT>M5"N&$M"RK0S:0
MB9B*=E!1NZ0,FJ00$!ZD,8AJH9^GXFIXK86:@?'?F.7L((X@CP(KM]LO>FY>
MW^XL?=6U,EL36\8DJZV8$,+.CJP*R1N.#(P((X\" 1!JP^FVXG-KD26>;FWM
M(TI)X5T6G*.:0VDG"!%"*!'/;:VJR9CLU>T4U#(L6[@4C?85(< 4S0U[9Z0)
MNMI\@P7^;[M_86Z>7L /KJY$WQ_=S9-).+%I.BQZN4MYX&04!M;J6$S'WAS
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MNKQQM&L476INK2*&<R=) (7J521[X8<*L'9H569JL-YN/*5OWCQMB$XP\<;
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M,I\MAV<?$1_S"7D%EO0:MT&R7?VI)D(!2A".K018VJY.- .F&/(D51<FRJY
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M(.&RKXY#J$*JZ74;1S05"BY<HE,!LU72M&U#69_(P4ZK?.8\%4>ECX>P7)\
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M%QR#_P"&G^C6#3?.]HV#QZQJJN#<$9<X(/J/F5NAI'S9>1O23IJ">]WFV()
MX'7K.[HEEL-J_$# ( ZL[GV&QDB '4O:WFT"B!OB B!1+A\W9NWLT'\0(G],
M9Z+?N>*?54UOFW^_W=+;[BVHMFXXYQY:B8'VR&TX_<RC[%K$O"WZA[CUNU_%
M47D[72<;KP^.W9-;H,H>=TS+O5/33$\A..$&TSKSW#A3[(2*;N-;I%$Z\F3X
M ,?ZQL#/PE,^FM](A'VMK2#V#D_R6)\%JT&POB=VQN"1-.W;%^:M0:P$O5UX
MK'UN0&AN?NPR <6E%6&X^082S!E*Q3UI)QDFT;2$=(Q[E%XPD&#Q$CEF]9/&
MQU&[MH[;J%4343,8BA# 8HB @.: RLC%6!# V(/,'T&K.12QS1K-"RO"ZAE9
M2"&!%P01P((X@C@17Z\_E?NF*5I^_P"?O#*,WF3C8_Y%ZW;;K/-H5C[DGE5Q
M43M3E<&B-37GBM#5=O;#OC V^5J/BOP=F! 4?6$"#EET'6&POSBN/)]"Z;]5
MOM?NK?.Z;<>JUK<;VK1Y.Y.Q(=P_W4DU3%&O^8(_*ZC_  A-A&7MY8DO[OEE
M^OJ]WIZN%;@9B:WBF*4Q2JP7U,M=NKO6O%&U1Z+P^O8*Z[2A+6JD)Q8HVZRP
ME+>43W9"D$GKJ1-9L (G,(=H=X!U[OA%G="*<XN),M_HRO(&]'4P4I]97M71
M7_#US](BW!N;39R@UV;$PY(0?G&"*2=<GI]0>7&ZA[#X54-R':ZCU=5^F_K5
MWB.(6U9V<2?-:7;-Y23ZBHNR*)H/E(JI5J$M,Y&=X]JS%S(L46)E2!VBYC52
M=>Y,P!-_;2*=-&FDDN('G)7UV50Q'JN+>T'T5R-^/K4-'RNZ6FX6&4;5\71D
M7(*V)4//+)#&_H8*S2 'CT2J>3"J[?FMXV7[0G/7<EFL,3(_<?>UHD]LZZMJ
MC<WRF>;63VTA:(AL\3(#8)2HV5XNS<-C&]PFW]LN<H)N43GN)LW48,[0X8XR
M//@4(Z^(MP4^Q@ 0>5[CP-?YVN_FU-2VWW'S\O*1OS?J,S9,$EO=</8R*#RZ
MHY"59?G =#$6=28MJ?3[3L"TP%(I$!*VJW6J59P=<KD&S6D):9EI!8K=FP8,
MVY3JKKKJG    Z '41$  1S9I98H(FFF8+$HN2>  'B:B#!P<S4LR+3]/B>;
M-F<(B("S,S&P  YDUT[N&6EI;CKQ1X^:1L#A%U8];:JJ-<LZK9?W3/[T(Q:+
MBRI,'/4?7CF\XX<)MS_ #(%(/0/R!6W6,Q-0U3(S8^$<DK%?O;\+^NUK^NNM
MVP]!FVOLW3-OY)!RL3#C20@W'F!09+'Q4.2%/HM6S.8VMLJE9]1#R3N=RY0P
M7&I"2=L];:<J-:L3J!3.9-K,[$NL<O,+V)Z!1*1Y\MJ<BR9LRG PM3&=B0?\
M8. 0AW'U.>?55TP$C%A13;TNPOU'TV4@#T<?377+X$NW^DZ3VYF[@O&K[@U7
M*EB$AXF/%QV$8B7[GKF2222UNL"($?BQ5>/(YJ]56R?IN>2EUFT]T\6+%(N9
M:HU&"C]JZZ2<J'4^ZP/9X(2[PS0YP/VQ<Q(S$>]20*)"(.@=* 4QG)Q++O;/
M4YY!/I,A)A11(G[6YLP]A)!MX&Y\:YE?'[V_TC#.D=R<"-8M4RIFP\H@6\[I
MC\S'D;]NBI+&S&Y9/+4D",7M39+%<V*C0\O''&\<H^!6Y-<:T9.9>_QGW:V!
M5Z\U.8J]G<T:?93<G7VZ8&+[J1D:^D\*Q0'KZT@"!/@(@8-CVGJ,&F:Y#D9)
M @-U8^CJ! /L!M<^ O43][=K:AN_MQGZ5I*E]23RYHT'.0PN'9!Z69 W0/%^
MD>NN<6Z:N6+EPR>MUVCQHNLU=M'2*C=RU<MU#)+MW""I2*H+H*D$IR& #%,
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M]0T^[:<3[PYF,D\./,H>0)X@\#X$] NR/?2/?'3MC=!2+=BK^+< *F4JB[$
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M%W9D'MO1]WEZ/<X-8G^,QZQC1LU'>JFJZK]GAU!-'6*NR(I%!=FZ341.(%,
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MKN72@B/<H.0MFY^9J,QR,V1I)3XD\O4!R ]0 %=!=O[9T':NGKI>WL6'$PE
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M'H# -;Y+V'J%=5.T6[,S>O;[3]>U+CJ3H\<IL!UO#(T1>PX#K"AR   S$
M5NS<ZE"7ZGVRB65N=W7+K6IVI6!HFJ9!1U"6.+=0\JW(L3[2)UF#Q0H&#XE$
M>H9A897@F2>/A(C!A[0;CZ];_GX6/J6#-IV6.K%R(GC<<KHZE6%_"X)JAAOC
MP&<_=:[-DZQJO7;'>FOW,NLC4-A5NWT>OE=Q*S@H1XVJ#M]E@)&LRZ#98@/
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M"+9JB4O4PF.80[C")A$1KM--+D3-/.Q:9V)8GF2>)-=6-/P,+2L&'3=.C6'
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M-46($$PP@]1#E25\R1@I903T!%%^HLJ^8\POB#N'+&UI\EN-IHE?<80D=![
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M#S!XBLIHVLZEM_5(-9T>9X-2QW#HZFQ!'@?2K"ZLIN&4E6!!(JZ#R*XTQ/G
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M6*../(O57*O457W9IN>/.TNTI+%(5VW]C-0<NR/Z$M6['&"HL:,GH9U^;72
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M.NO);RTK\<1%-O(7^)O:A4#'.07VTJ-5-FRAS"=-(P+*R=N6,H'00!01 !,
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M:P_GKK!U9&_K:S7_ 'DM_P#\^'\BO_5Y3^$W_?\ _P#$_P#XY_\ SO\ !?\
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M#W*)\=U45M1'Z47,[.V5,4%)\*@%+35I%DS,=@DH4HHL'5P8RZQ>G4JAU#*
M(@?)^[>I.FVT,M^AI7*7^YN!P]74&^S7%SXV\O2<KOODKII0Y,.G8D>25M_#
MA6;WB.;"!H%/B  IY5-5F[U4:F*4Q2F*55L^I_93!]4\3)% CH8!KL+9K*35
M(J(,B3#^MUA>#(X1[P!1THRC9 43=HB0A50ZAW=#2;VU9/I64IMYAC0CTV!:
M_P!<CZU5 ^+F.<Z-HLJW^C#*G#>CJ*1E+CTV5[>@7]-4Z,ENJ,TQ2F*5?)^G
M2;2J'CP%60*Z*T>;VV8Y@A<*&.D>*+'U%FL9B4QS DU";:/ $H 4!6!0W3J(
MB,']P2IU^RVN($O[;MS^2WR5T:^%U)E[87EOT-J,Y2_+IM&#;U=8;Y;U/#FC
MU8NF*4Q2F*56I^I9B+FZT)QRF(U-ZI0HG:]F;VST0,9DA992J)A27+XI2& A
MP8,YM)%0QBE 53%^(G#(Q[G).=/QG6_T<3-U>CJ*^[?Y.JU=!/\ #ZRM)CWK
MK^+D%!K<NF0F&_SC$DQ^D!?W38Y8#C[H/(&J<V0Q75BKDWTU<-=&?'/D%,R9
M'"5"F=PPZ-1(L"I$E['%4]HG=7K4A^B:B2C-U#(&5( @91N8@CU3$"S3VQ2<
M:;D.W_IVF'3]\%'4?J=(^3U5RA_Q \O2)=^Z'B8Y4ZW%I3F>UKB)YV..I\00
MPG:QY!@;6;C+SY%*_LRU\'.4%=U C).M@2^I+(SB6$,FX6F)6/.FD:T0T0@S
M,5VYE)FIE?-6Z2751598I"E,(@4=QW)'E3:#E18=SD-"P ',C[8#UE;@>VJM
M]A\[;VF=X]N9^Z3&NAQ:I$SM(0$1KGR9'+>Z$CF\MV)X!5)) %ZYL)BF*8Q3
M%$IBB)3%, @8I@'H)3 /Q 0'\H966O\ 0$""+CE71X\7E<V74N '%RO[=;R3
M*\,-;IBNPF$W"$K&5IY.3+^@Q4BU=K+.V3R+H#J,;J-U>Q1N9,4S)I"44B65
MVK%E0[>Q(\P$3B+D>84DE ;\B$Z1;PY6'*N!WQ&9^WM4[W[CSMKM&^COJ!LR
M$%'E6.-<EU*@*RODB9@PN&!Z@S ]1WVS8*A2F*4Q2F*4Q2L8;KV[3-!ZDV+N
MC83[Y=3-9U*9M\\N44_<K-8AHHX3C8Y-0Z97,O+N@3:,T 'N<.UDTR_:, 9Z
M</$FS\N/#QQ>:1PH^7Q/J',GP O6(U_6\#;>BY6O:FW3@8D#2N?$A1?I7TLQ
MLJCQ8@#B:Y?>]=QV_D)N/96[;XX(O;=GW":M\P5$3"U9*2KLZK6(CP/]M.+A
M&/I,VI!^)&R!"_N997"Q(L#$CPH/X*) H^3Q/K)XGUFN1>XM=SMS:[E[@U(W
MS<N=Y6MR'4;A5_:H+*H\% %8HSU5A:E4XY>8_F9Q5T_5-&Z:>:L@J#3@E31C
M9]KB/E)1T[FY=].2LC+2KAZ#F2?O)&14,*A_WJ?8F0"ID(4NL:AM'1]4RVS<
MP2M.]KV<@<   !X"P_RU,>UN^F^]G:'#M[0FPX]-@ZND&!68EV+LS,3=F+,>
M)\+ 6  K.'_$,>1[_*;4O\U<5_VW/%_<';WW,O[\UL/_ %-]T_XW"_\ ;K^S
M3_B&/(]_E-J7^:N*_P"VX_N#M[[F7]^:?]3?=/\ C<+_ -NO[-/^(8\CW^4V
MI?YJXK_MN/[@[>^YE_?FG_4WW3_C<+_VZ_LU%+R&WS=N3>W[?O#9#6LM[U>E
MV#VSJU*"1K<1(2+",9Q/S/Y0V55;(2#ULP3.Z4)V^X7[E3@*ASF-M&GX,.FX
MB86.6\A+VZC<@$WM?T"_#T#A4-;GW'J&[=;GW!JHB&HY!!D\M BLP4+U=(-@
M2 "Q'SC=CQ)-85SV5@*N%?39\P_GU-V+PKN,L09&C'=[3TVBZ5Z*+U.<DNS8
M]99]XD2*2#M+]O+(HD[UEAF'J@]$T!Z1+W$TCHFCUF$>Z_N2?? >X?E4%;_M
M5'C5XOA5WQ])P,K86<_XW'OD8H/C&[?CXQ]Y(5D XD^;(>2U:@R,:N'3%*8I
M7-D\LWXCW+S]K<C^BXK+$[6_1[$_)#[)KE3WH_6GK?\ 36_!6H\,S]1A72:\
M3'X</$/]DL?^E9;*[[J_2'+_ "I^P*ZK=E_U6:)_0E_":I$,U^I/J@S]0Q^(
M]9OV2ZK_ $4]R=-@_H\OY5_LUS>^)O\ 6G+_ $+'_!-0=YNE5[KH)> O\,G3
M?ZW;@_I/L^0-OK]))OO(_P  5TO^&[]4N!^7R?\ >)*F8S4*G:N7AS8BEX+F
M5RUA71B*.(GDSO>-643 X)*J,MI6EN95+U"D/Z*HI]Q!$ $2B&66T9Q)I&*X
MY'&B/^8M<B-_0MC[[UK'?YR:MF*?DR)!<>KT5K)F2K4:ZH7&^19R_'?0LM'+
M@YCY/2^K9%@Y*50A7#-[1X)RU7*14B:I 505*8 ,4#!U^( .5CU%2FH3HW!A
M,X/R,:[#[5ECGVQILT1O$^!CL#Z08D(/RBLT9XZSU,4IBE,4KXMDG&E9KT]9
M'YB%85Z%E)QZ919)NF5I$L5W[DQW"PE10("+<W4YQ I0^(_ ,_<:&618U^<S
M #Y3:OAE9"8F+)E2?P<4;.>-N"@D\3P' <S7)ORTM<8:S)QT9.I+D'HF.8HB
MX>O]R:P9-$"F(4RSIU=H-!NB4RAB$**BJ@  B( '7XCGDU!@N!.S?-$+G_--
M9[:\;R[FTZ*,7D;/QP!Z294 'U:ZHV5BKL/5-GZGMDZ3W5Q8D3HB5DZU=>V3
M=?N)VJ.F%LC5W:(% PG 44I) 1$0 !]0.@CT'I+W;5A]"RE^V$JGZJG]@U17
MXN(W&OZ/*1^+.', ?6)%)'R!A]6JO>2551*NV?3,3[1SPYWA5B=/?0W)>8GW
M/YSJ;VEEU;K".9=4NP.P/6J;CH;N'N^(= [?C#7<>,C5X)?M3C ?4=R?PA5_
M_A-R4?8VH88_A(]69S[),?'4?7C/_858^R/*M-3%*8I3%*8I7/%\Z4TE,^4/
MDD5O[0R$.EJ*%*LU3,0ZZK/26N57OO#&,;U7;60<+-Q, % $T2%Z#V]PS]LE
M"FV<:][GS#_^Q[?6XUS%^(?(6?N]JH7IZ4&,EQXD8D%[^DAB5]@ \*B/S:JA
M2NF3XT#&-X^N&PF,)A#CMJXH"81$>TE68$(7J/[A2E  #]P RN.X_P"OLS^D
M/^$:ZR=IR3VST*__  O'_P!6*SCR<A7-DXV<A*ZRZ^\GM'[8A6G:DHN;W,I0
MI]BAVHI *JP^JN'0I0$QOR!\<\6FN(]1QY&Y+.A^HP-;!NV!\K:NIXL?SY-/
MR5'CQ:%P. Y\ZY8N6;KCW7]6[==VN@U:H+.73E9-NV;-TSK+N%UCE310013*
M915950P%*4H"8QA  #K@D 7/*OTJL[!$!+DV '$DGD /$FLJ_P @6]O]2NVO
MYN+C_P"#9Y?IV%_'1?OU_9K,_P!V]Q?S#-_D)?\ 1I_(%O;_ %*[:_FXN/\
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M@F$B_N:BCS:*AJNAWX1N147O_P ?&G8_Y@FXMVC62FC;A'>L)UXXE'(DC1U
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MFJ?G4D6':)G$H K+4NP2[DXE'N-\K3+T'X"6/.XFGM/IT6H(+F!R&^]>PO\
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M)3D$/W,LC&Z2HLD9!C8 @CD0>((]HKDMDXT^'DR8F4C1Y43LCJPL592592/
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MN6UO75FQE4;??HU"1;/(J*<+'2*BV2(O*.DCF6;M5DTS#FPZ1M?5M:@?(Q$
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M?:JM-:NS!VH'8#AVTBK<?7[B.(?[1B-SO'0EZ 45S=1,$?97;;*#$X63&R^
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M,Y-OW<K,2\F]6.X>2,G)OE5WK]\[74,=594YU%#B(F$1'KF[(B1H(XP%C46
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M((\@ QKU/8^)4$CZAL;>JH;[^:[J&@=K]0R=,9DR9O+@ZUYHDTBI(;\Q=.I
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M#X9.3CX<)R,IUCA7F6( ^OX^@<SX5DM)T?5==SDTS1L>;*U"0^['$A=CZ38
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MFSZ1J2&33\F)HY%#.A9'%F7JC97 8$@]+ V-KU&5_P"1=XL/[+G_ -;>1?\
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M6D%5ZG!RUFLDY(*>DPAH"!8.)28E7JH ;TVD='-5%E#=!Z$((YO,4<DTBPQ
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MZ;\%???4M/AU 86% )XE<1RY2)*@8 A9$L>AP#[RDW4\#8@BOAE^H#\=9C%
M;+M8@"( )C:NE1*4!'H)C=KPQN@?E'H C_R9\_\ F'MO[J;^3/[->T_ _P!^
M +_1],/_ /F)_HU*):.1>GZEH!_R?D+<@\THQU^WV<G<(=F_E$Y*GOHY"3C'
M\9'MVPR+E>30=I%20%(BH*J 0X$$#=NURZEAPZ<=59[X(CZ^H FZD7! Y\?
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MICJ'*4HCGAU/4\/2,-L[.8K I X DDDV  %;AV_[?[G[G;FAVEM&%)M8F1W
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M]]2T^'4!A84 GB5Q'+E(DJ!@"%D2QZ' /O*3=3P-B"*^&7Z@/QUF,4!LNUB
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MNW6#\?Z[ZUHO$8:U[TV)8M=>[$_IJTHD-2ZXY68D.0OILU+Y7ISH =2F5[S
M/VOA//;F*>/;W5-?H?(=D^]LJ\/5UAJXV?'3GZ1F=[UATPH<O&T;%BRNGF,C
MS,B4!O2PQI<?V"P\*W"Y*^*S@MRRMZNQ-OZ28K[!=^F$I=*?8;-1)N>*DF")
M360*K+1D98W8))ID!V^;+O2)I$3(L5,!*,MZ=N?6]*A^CXDQ^CCDK ,![.H$
MCV @>JN=&Z^SO;S>F<=4US3U.IM\Z6)Y(7?P]_RV57/(=3J6   8#A7XX_7G
M 7Q%:*M^QH&GUW3%*[V+2=FTE9:V;'V)/*%<*0M69S%CDI6U6>5>K)KJM(TC
MDC%F4%UP(V;)K*$PFY=US?1SJ.O9!,*<%%@!<\E1% !8^R]A<FP)$H]D^P<6
MI:['LKM1I2#5<H=4C]3$B-+=4N1D2%V6%"PYMTAF"1H7=4:,^#^I3XZ/;N6+
MG./VWX*@*NRH)W%*9J4M86[=10I"O9&D(KM6J*2)3"=4C>8=JE*4?3*H;H48
MOC[G::T_1)CS+CW^==2?:5_88_+5^\S_  _-^0Z/])P]<TJ;7 MS 8YTB) ^
M:N0022>2EH$%_G%1QJ33:_#KQ_\ DSI=%W9;Z'5]L1UAK[5Y2-N4^:L%2L[J
M#!95,L:\G:Q(P<G()13HKALK&3!%_ECL%TQ00<%/VR[H.ZL[%Q5R-&R+X4HZ
M@+!E/KLP/2;\#:QN+'E:N;G=/L;H.=K\^A]Q](,6Z,!_*DN7BG0CB 7B9?,C
M*D-&27C9&#QW#!C[GBSXZ>'?#1\_F]!Z<BJW;91!1H^O$W)S=RN8L5@*5:.8
M6"UR,L\@HUR4A06;1XM$' D*94AS!W9Z=3W!J^L*$SIBT0Y* %6_I(4"Y]9N
M1X5A-G]KMC;$D;(VW@I%FN+&5V>66QYJ'D9BBGQ5.D'Q!-0O_4R5^[.]9\4K
M/')OCZ[@[MM"&MITC*?+TK?8X2FNZ$9XF4HI^X-$5RPE0.80[0%0H=>\<A+N
MA'.<7$E6_P!&61PWHZF"]%_D5[?+753_  ]<[1XMP[FTZ<H->FP\.2"]NHP1
M23KD])YVZY<4L!S]T^%5#,AVNI%73_IO*[=HKB/MN<FR/6U)M&\GSJCH.R*)
MH/',74*U$VR;C"J)E!=BZ>-FS(RQ#&(+F.53^!TCY-W;2.=-'FD>X@><]/R*
MH8CU7L/:I]%<C_C[S]'R>Z&EX>&4;5\;1E&05L2H>>5X8WL>#!2\@4@'HE5N
M3"M8_J3>*FV;F\TWRBI->G+=0Z+3)G7FR4H1BYDAH:9)U>R05ME&S0BR[> F
M!EG35T^,0K=HLU;D5. N$@&S';O5,6%9M,F94G=PZ7-NKA8J/6+ @<S<VY&N
M)'Q5[-UK/DP-WZ?%)/IN/ T,_0"WD^^721@+D(W4RL_S5*J"?>%5D.,_&?;G
M++;E5T[IVJREBL%BE&+:1D6S%PM"4^$6<%)(VRV2)"@UAX"':@=9558Y!5$@
M)) =8Z:9I)U+4L32L1LO+8+&H-A?BQ\%4>)/_P!3PJI6T]IZWO36X="T*%Y<
MF5P&8 E(D)]Z21N2HHN221>W2MV(!ZC4/')P\3%Q"2RSA*+CF4<FNX$IG"Z;
M%LDV(LN8H%*990J0&,(  "81RL[MUN7/,DGZM=>X(A! D )(10MSS-A:Y]=?
M1S\U]:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*@,^H\_#ZA
M?[Q.N/XK[$S>NWG]?-_1W_"2JW?%-^K./^U(/]7/5'BC;#O^L+ UMFM;Q<->
M6EE_U*RT:S352L#3[13_ .*S, ]CY%O]L@#]A0/B #^YDTSX\&3&8LE$DB/@
MP##ZA!%<^=/U/4M(R1FZ5D3XN8O*2*1XW'L9"K#Y#4HNK_.=Y*=9-FT>?>;3
M8T4T]($6.T*/4;.Y$J8CWE<V5O%1-R?>X#H!Q7DE#!TZD$HB81UG)V3MW));
MR#&Q\49E^M<J/D%2_I'Q#=UM)01'45RH5Y#(BCD/RR!5E-_6Y]5N-;-MOJ4^
M>J$?[)77G%EXY]-<GS9S0-G%D.Y4RADUO3:;F:Q7J-@. $#VW8($#O*<>X38
MT]NM#+7$F4!Z.I+?ZN_UZVU?BL[CK%Y9Q='9['WC#D=7'QX907AX>[;AQOQK
M5+>'FV\C&\8YW!NMWFU?7GR9DW43I>!C]?.C@8! ?2M[4'NP6I1(82B1&733
M, _:*/PS*86S-O83!Q#YL@\9"7_S?F?YM:9N#O\ ]T=PQ-COJ'T/&8<5Q46$
M_P J+S#Y)0/544;ITY?.7#UZX7=O':ZSIV[=+*.'+IRX4,JNX<+JF.JNNNJ<
M3'.81,8PB(B(CFT@!18< *AIW>1S)(2SL222;DD\223S)\37Z(J*E)V3CX2#
MC7\S,R[UM&Q41%,W$C)R<B]6(W9L(]@T36=/7KMPH4B229#'4.8"E 1$ S^,
MZHI=R @%R3P 'I)K]PPS9,RX^.C23NP554%F9B; *!<DD\  +DU>Y\*OBS>\
M+*3);QW='MPY);2@T(T(,%$G2>HZ Y4:29JEZZ7<BO<)Y\V17FEB'420!L@T
M0$ 3<JNH0WCN8:Q,,+"/_P#3HFO?^,;EU?>@<%]-R3X =%.PG9^386 ^X=P*
M/[U9D87HX'Z-";-Y=QP,KD RD$@=*HO)R\\6:/5C*AC\I'#7BA#\-^6>Y8GC
MMI^+VJ2DS5L)L".HD RM)+.^F&*SV?++-F:3DLL\6<J'57 ?44.H8QA$3"(Z
M3NO1=(31<S-3&A&7Y9;K" -U$BYO;F?35M/AP[L=S,KNOMC:>5KVJR;:.9'#
M]&;)E:'R5C8+'T%B.A0  O(  #@!6J7A)X;\4]U<&8"^;<X]:DV1<UME[#CE
MK-<J3"3\PJPC9%F1@R5>R#1=51JT(80(01$H (ATS$;&T72,[05R,S&AEG\U
MQU,H)L"+#C4E_%_W7[E[1[R3Z+M?7=4T_21I^*PB@R)(T#.K=3!58 %O$\ZD
M[\IS1I'^.'E6P8-6[)BRU Y:,F31%-LT:-&TA$(MVK5NB4B+=NW1(!"$( %(
M4     S:MV +MK+50 HAX#Y15=OAMEEG[^[:FF9GF?50S,Q)9F*N223Q))XD
MGB3Q-1#>&SR(<,>-O"B#UCN_>D#0+VUV+?YEQ7I" NL@Y3C)=^T5CG8N8.LR
MC 2.DTQ$ !43!T^(!FF[*W)HFF:&N+GY"QY D<V(8\">')2*M)\6'8CNSW [
MO3;BV?HTV=HK8&-&)5DQU!=%8.MI)4;@3]S;T&M5?/+S3XP<L*GQLC^/6VHC
M9;RE6+9CRT(1D/:8LT0VG(VEH12JQK%!0Y%@>*QBX%!(5!+Z8]P!U#KB=_ZY
MI6KPXJZ=,)3&SEK!A:X6WS@.=C4E?!9VC[B]LM3W!/OK2Y=/BS(,182[POUF
M-YRX'E226Z0Z\[<^%^-6KN6W^ZIR:_N^;G_HXLF2UK']497]&E_ :N:G;#]9
M>W?[=P/]ZBJI=X>-N>,;7NC]G1G.&*X_/]@O=K*/JDIMW2;79TV2G#4*TW*2
M,EG%"MAH^+^=HNQ]L"R8>L)S]GVNX8@V9F;6QL&5=>&.<@S77S(NL]/2O(]#
M6%[\+UTZ^*K:_P 1&N[QT[([.RZXFAII@6<8.H'$C\_SY3[Z#)AZG\LI[W2?
M=L+\+"P?Q/V!XC]K[121XBU?B<.XJK&/+!&N*#HRKZ[OD=&F3-%R<C79)U0*
MM,+$3;/Q1="P5.9-%?HJ $/\9%TC)V?EY=M'3$^FH"1T1*C@<B0>A3XV-O \
M:HSW-T/XH-L[<+]T<G<_]U<F18G&3J,V5C.]^M%E1<F:,7*]2>8 "R^[<CAK
M)]1-_N!PW]X/77\6=@YB^Y'Z/+_24_!>I$^ _P#7=+_865_KL:LV\.N W!RT
M<-^+%ZNO%S0\S8+%QFTA;+;:)Z@5M=]*S$OJRL3$]/S4D[:=RSM\]<*N'*ZA
MNICF,<P_E'/=HNWM!ET7$R)\3':1L6)F8H+DF-223ZSQ)K3^ZW>SO'IO=?<F
MC:1N/6HL&#<.H0P0QY,H5(TS)DCCC16X*JA550.   J#W5]6U)J+SYZ_IG!V
M106UF:P?+;)$TV74L53BV[_5TH^VS6XZ4.Z>HR-=AO05=*$,X<)Q\@F9%(2F
M:IIIZ+BQ8>'W!C@T(CZ+U68*>I1>,F10>-P.?,V/ <@!<3<>I;HW3\$V=JW>
M*-AN'R.N)YT$4SE<Q%PI62RE99+J@/2IEB(9KB1F:Y)+RT9 1,G.S;]I%0T+
M'/9:7E'ZZ;5C&QD:V5>/W[URJ8J3=HS:(G44.80*0A1$1Z!DTNZ1H9'("*"2
M3R '$D^RN4.+BY&;DQX6&C2Y<TBHB*"6=W(554#B69B  .))M5(UCH+8GF8V
MUY#^6D?\]:Q.O:DJAQ^A@0.B>:GH-9!QKK7Y4007;KNG.LZB[))((]IB3<ZU
M<&,4J@]\%KI^3O7,U+6%Z@D:?B1Z2/F)^\4W ^V<&NP,V]M"^$W;&Q.V$_DM
ME9V4#J<E[^7'(",K)O<$ 9<Z&)FN#CXTB $J+3H^"/EH/(CAPPUG8Y3WNQN,
M[MAKB4*NN=9\]UZZ;+N=6S2H&#HFW1B63J#3+U,8?D0G-T]0.N^[!U?\Y:*,
M64WR<4A#Z2G_ '9^H"O[BJ:?&?VQ_N)W6?<.GQ]&@;A5LI+"RKE @9D8])+L
MF0?#_P Q8?--?X^H$_#LLG[6-7?I-]CN)^C;?EH_LFO[\#WZ^,?^S,S\!:^[
MP/X \*-C\(^,5LO/%W2UGM-PT70Y6S664HT.M/S,K*UQJI(2CR8*@20-).55
M3'%<JA50./<!@-T'/WH&WM#R="Q9LC$@>5\="S%1<DCB2>=_77B[T=[^[V@=
MX-Q:9HVX]7Q]-Q-9R4AB3(D$<:)*0J*E^GH %NFW3;@1:HCO'3"TG2_G(VSJ
M+BY87DEQ],PVI7W:$;*N9^$" BJHTL)X9654<OC2<;2]G-R1C&076674*B4#
M+',N<RFG[;2#!WY-AZ4Q.G6D!L;BP6]K\;A7]T$DGASXU:'OSEZONWX.-,W1
MW'@2/?/7ARJ7012>:\S1>8$ 7H>?$)EDB554%C9 $ 7T7G=?4Z+\CG".3V*2
M+5U]'5+6SZ])SD<68A%*<TWM8'%G),1)FKTLI%GA$UP<-A16!='N)V'[NT?I
MO]H4W+@MDV^CA$+7%QT^:W5<<;BU[BW&O#\%\.K9/8/>&/H)D&N2966N.8VZ
M)!.VG1"'H>Z]#^85Z6ZEZ6L;BUZD'_K-?3X?Y-\)?_M)C?\ 8QFQ_G3MU]S@
M_P#MQ_LJ@S_EY\<W\XW?_P#[I_\ Y]3%Z29:7::NJ"W'F)UW#Z=F(PM@I+?5
M,/ 0-#<1L\H>4-(P<;66C&'1)(N7)UE132(8RQSBH'?W9NF"N",1#IPC7"87
M7RP ECQN MAQY^VJI[OFW;+N/*3?4N?+NJ*3RL@YLDDF2'C'1TR/,S2'I "K
M<D!0.GA:JS/@7_WY/(!_^$O_ $OSF1?V_P#Z^U'Y?]8:Z&?&K^IS8_[C_<8Z
MGA\DO^X'S!_N^;-_BR^S?MS_ */9O]'?\$U2WX?_ -=VU?[=Q/\ 6K4?/T[/
M^X',_P!X/8O\6=?9KO;?]'F_I+_@I4Y?'A^NZ+^PL7_79-9$\I'#7BA#\-^6
M>Y8GCMI^+VJ2DS5L)L".HD RM)+.^F&*SV?++-F:3DLL\6<J'57 ?44.H8QA
M$3"(^G=>BZ0FBYF:F-",ORRW6$ ;J)%S>W,^FL%\.'=CN9E=U]L;3RM>U63;
M1S(X?HS9,K0^2L;!8^@L1T*  %Y   < *U2\)/#?BGNK@S 7S;G'K4FR+FML
MO8<<M9KE282?F%6$;(LR,&2KV0:+JJ-6A#"!""(E !$.F8C8VBZ1G:"N1F8T
M,L_FN.IE!-@18<:DOXO^Z_<O:/>2?1=KZ[JFGZ2-/Q6$4&1)&@9U;J8*K  M
MXGG4G?E.:-(_QP\JV#!JW9,66H'+1DR:(IMFC1HVD(A%NU:MT2D1;MVZ) (0
MA  I"@    &;5NP!=M9:J %$/ ?**KM\-LLL_?W;4TS,\SZJ&9F)+,Q5R22>
M))/$D\2>)K5CZ?O\.RM_M8VC^DV.8GMW^C:_EI/LBI(^.']?&1_9F'^ U1+2
M5*F/+_YB]FZ\V5,SH<>..3^]QAJ\P>/(]!OKO5=G8T=:.A#]4CQ<OM:^.47C
MYP'9( Q64 @E!F@5'4&@?>6])<;*9OS;C%Q8$CW(V"V'H,CV)/.Q/W(M9W'U
M?$^%CX4].UW;\,/]^]?3&?S656)RLR%L@-)SZTPL8-'&O&+S%6X/FN7LA3'C
M:X%3E #6CSB7HY&L$9G9(K1E$AX:V-@42314>MK_ !*#*^(2ZQ$2>H]+) [5
M$@"=0W0,DM]L[?DQ_HK8<'E6MP0!O;UBSW]?5?UU03%^(#O7AZW_ 'ABW/K)
MU$OU$/DO)";$D*<9RV,4%S:,Q= N;**_1PHX'Z7X%U"\4K2TIL"5B+]</OE+
M*;!GXJ==LG:<<WBVD9$FAJ]6VC>+9M&_0HJHKO%!,/JKJ 4@$_NAZ!@[?AD@
MP3(4D?J/602.%K"P7@/83Z2:^?=[O3NWO5JN'J^[H\&+*PL7R$&-$\:LI<NS
MOYDLK%V8\;,J"WNHMS>K)M^Z:BX\>:_>5[\@FK)/9&LY.SSTI5FDO7F=PB6<
M'/LHMKJ>[*U615;Q-TJU=JS3V)VW8[%LLF8Q45GC,$\BC,GP]-WQ/D;BB,N*
M7)6X#  @>6W2>#*J\+<;'P+"ND>UM(W3OOX0]&T7L=J4>G[ACQXTF*2M [21
MLYS<<3*"\$TLS>8'NG6I +K%+U5-=3])^$;GY=:C9M61&AIR]UF2:61&GT,K
MK34_9V\<<'BS6WZD!K3'MOA2JH$%X=>*5,!"@F=8$E#D4WB'!V+N&=)<1<=L
MA#U=*?BRUN/O1^Z6'INOJO8\:B:KN_XP.R.D96G;DEUJ'1<B-HC/DVSXH2_N
M@P9O5.L$EB>@+,HN>H(64%9P<WNJ=TQ2F*4Q2F*5'ORA\H_"SAYL>%U-O#:3
MF'O<JTCY1_"5^IV:W*52%E15"/E[8M7XQ\E%HNR(BH1L45I R D6!OZ*B9S9
M_3-LZSJ^.V5A17@!(!+!>HCF%N1?V\K\+WJ,MW]W]A;'U6/1=PYACU%U5BB1
MR2>6C?-:0HI"@VN%XO:S=/203O/4K96[Y5J[=J=-1]CJ=NA(NR5J?BERN8V:
M@IIFC(1<FQ<%^"K5ZR<$4(/P'M-\0 <PDL4D$K0S K*C$$'F".!!J1,+-Q=1
MPXM0P9%EPIXU>-U-U9& 96!\00017[7D'"R+MF_D(B+?/X\Y%&#UY'M'+MBH
MFJ59,[-RLD=9L=-8H' 2&*(& !#XY^0[J"JDA3S%^=?M\?'E=9)41I%Y$J"1
MX\"1<<>/"OJ9^:^U8@WKH74G)76TYJ3=E+C+U1)_T5743("X;N&;]J)C,9B%
ME6"S65@IM@8YO1=M%D5R%.8O=V'.4WCS]/P]3Q6P\Y!)CMX'P/@01Q!'@00:
MVG9F]=S]OMP0[GVAER86M07"NMB&5OG)(C I)&W#J1U938&UP"(?JU].]P,@
M;FG9I*:WS;H)!XD\2H%AO=;1K"I2KG64CWSZN46 M[F-$O8F0I)-%<" ;O54
M$P"738NW&WXY_-9LAXP;]!=>GV$J@:W[H'UU:?4/CM[TYNDG3L>'1<7,9"IR
M8L:4S#A8,JRY$D ?F3>)EO:RJ!8S+/9C4.@J)",I::U[IS6]99Q=8KZ<Q+5Z
MB4^%9M4",XB#C5))S&1+---NB":"!! >A>A0R0,3#=E7%P8B0JV"(I-@/0%'
M(52[<&XU;(FU[=&<HR,B8O+/DR@&21R2S/)(PZG8DDW-R:]35K;5+S!LK-2K
M-7KA6Y$%#1]AJTU&V"#?E24,DJ9E+1+EVP= FJ02F$BANA@$!^(9^I8I8',4
MRLD@YA@01\AXUY\/-P]0QUR]/FBGQ7^:\;*Z'PX,I(/R&JN_U-2MS",XBHI"
M\#7AG^WU7Q4#+_+U+F1OK\D4,H0IO;"\1@U'OL!,7O BCSM'H)\B+N@9^G#
MO]&O)?T=7N6OZ[7M^ZKIC_AYKI/TC=#MT?GWHP0M[=0@OD]?1X])D$?F6X7$
M5^-JJ<Y$==-*NX_3EFN0\(KT$^9X-7+R!MI:(#P5!(6/^Y]#-.EBP4^ 1'WB
M,N( 3['O1<_\_OR<^VOG_F*3S+^5](;HOZ.E+V]5[_+>N0'QZC21W@POH71^
M<3H<'TGIM\[S\GR^NWV_E=//CY?E^%JG,N^Q=?:SBDIW8][INOX19T1BC,W>
MSPE4BE7JI3'39I2$\^8-%'2A"&$J8'$X@ B ?#)(AQ\C);HQT>1[7LJEC;V
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M='2X'#[5;\@:W/NAB;!^(WX>,L]L)Y<Z?;!5L8R+,,CKQ(%\R%_/ FE,^(S
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M((L1\HJ,--U',TC4<?5M.<QZABSI-$X /3)&P=&L00>EE!L01PXBH/U/IV^
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MR"#*/0]*/CVS9-)HU;(@DW*8Q#*F554VK1]'PM#Q/H6"&\KJ+$L;DD^)Y#D
M.  X>FYJN?<_NCNON[N;^]6[V@.H"!(46&,1QI&ER%479C=F=R7=VNQ (4*J
MXKYC>-SBISD^5R6ZJ=)-KM!LPBXC95&E2UJ]-(<JBZY89P_49R<3-Q:3AP=1
M%&19/"ME#G%#T_45[_+K6V=)UZS9R$3J+!U/2X'HO8@CT @V\+7-;)VI[_\
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0E,4IBE,4IBE,4IBE,4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image11.jpg
<TEXT>
begin 644 image11.jpg
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MUY"Y7T/??@V9^S7T[=>0N5]#WWX-,QJV[]>0N5]#WWX-Y_:_77]?#0
M             , */IX                     */4 \"B"R!L#@J$
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633326448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Maximum remaining contractual maturities of available-for-sale securities</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617150464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in accrued and other current liabilities</a></td>
<td class="nump">$ 1,807<span></span>
</td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">51,536<span></span>
</td>
<td class="nump">51,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 53,343<span></span>
</td>
<td class="nump">$ 53,028<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617209696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company has a history of losses, and expects to record a loss in 2020. The Company continues to maintain a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6653356736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. The lease term is 127 months beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $4.5 million of tenant improvement allowances up to March 31, 2020. The rent payments began on March 1, 2019 after an abatement period. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of 14,943 square feet located in South San Francisco, California. The lease term is 124 months beginning November 2018 through </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February 2029, with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $0.8 million. Rent payments began in November 2018. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of 188 months and is expected to commence in April 2020. Upon certain conditions, the Company has two <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY3Ng_1448f1a5-3854-48ed-9be5-baf156294104">ten</span>-year options to extend the lease which are not reasonably assured of exercise. Rent payments are expected to begin in early 2021 after an abatement period. The Company is entitled to a tenant improvement allowance of&#160;$2.9 million for costs related to the design and construction of certain Company improvements. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintained letters of credit for the benefit of landlords in the amount of $4.3&#160;million which is disclosed a restricted cash as of March 31, 2020 and December 31, 2019, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:56.433%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.402%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.402%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.827%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,679&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,536&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:56.433%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.402%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.402%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.827%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2020 was $1.4 million and was included in net cash used in operating activities in our condensed statements of cash flows. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The undiscounted future lease payments under the lease agreements as of March&#160;31, 2020 were as follows (in thousands:</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.217%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.050%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;2020 (remaining 9 months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,633&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,467&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,736)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,809)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was&#160;8.34%. As of&#160;March 31, 2020, the weighted average remaining lease term for our operating leases is&#160;10.7&#160;years.</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Commitments</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of March 31, 2020. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of March 31, 2020, the Company had non-cancellable purchase commitments of $5.3&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617940576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:-31.5pt;padding-left:31.5pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs except for investments in U.S treasury securities which are classified as Level 1.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no Level 3 assets or liabilities as of March&#160;31, 2020 and as of December&#160;31, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">293,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">539,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:48.662%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.784%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">304,794&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">231,835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Included within cash and cash equivalents on the Company&#8217;s balance sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617267024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under Plan</a></td>
<td class="text">The following summarizes option activity under the 2018 Plan:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:41.151%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.700%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Options</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,190,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.82</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,675,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(105,895)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(132,910)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,627,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.87</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,716,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.66&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.90</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,627,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.87</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Stock Option Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:66.676%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.294%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.295%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term in years</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.07 - 6.09</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.99 - 6.25</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.42%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.84%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.80% - 1.65%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.45% - 2.62%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity Under Plan</a></td>
<td class="text">The following summarizes restricted stock unit activity under the 2018 Plan:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Restricted Stock Units</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Restricted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Stock Units</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Value at Date</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">of Grant per</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Share</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,941,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.98</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$50,431</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">885,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.44</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(270,751)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,534,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.17</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$49,274</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,534,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.17</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$49,274</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.076%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,732&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,867&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814822592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets And Liabilities Subject To Fair Value Measurements On Recurring Basis And Level Of Inputs Used In Such Measurements By Major Security Type</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">293,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">539,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:48.662%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.784%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">304,794&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">231,835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Included within cash and cash equivalents on the Company&#8217;s balance sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>25
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $N"IE ?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ 2X*F4"?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " !+@J90<$D &NX    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!2L0P$(9?17)O)VVQ0NCFLN))07!!\1:2V=U@TX1DI-VWMXV[
M740?P&-F_GSS#4RG@] ^XG/T 2-93#>3ZX<D=-BP(U$0 $D?T:E4SHEA;NY]
M=(KF9SQ 4/I#'1!JSEMP2,HH4K  B[ 2F>R,%CJB(A_/>*-7?/B,?889#=BC
MPX$25&4%3"X3PVGJ.[@"%AAA=.F[@&8EYNJ?V-P!=DY.R:ZI<1S+L<FY>8<*
MWIX>7_*ZA1T2J4'C_"M90:> &W:9_-IL[W</3-:\Y@6_+7B[JUI1W8FZ>5]<
M?_A=A9TW=F__L?%%4';PZR[D%U!+ P04    " !+@J90F5R<(Q &  "<)P
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M_DMU[T9&)B!SXQ1U@WR>U%GJ1E*!GW$C Q@X@1TE\*2YF\<CRT9293//$L@
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M9T \$YL&L6N(;8/8-\3&0>P<8NL@]@ZQ>1"[A]@^B/U## #$!"!& &(&&#-
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M8^N@%R>]V()Y<=)+JIF37VL^&,FAD5P:2=GLK7/925ZPE;"1HK 0L),".BF
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MNJ/Q'IM9*J% 6X&:&*AS>K_=']*0'Q-^"ACLPB:ADQ/B:W">JYQN@B"04+K
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M/[#9D5"[8-YZVXQK-CH.N^D%L?D9%[\!4$L#!!0    ( $N"IE F& 8,M0$
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MJ%TX[OW9C&,V&@Z[Z0>Q^1L7OP%02P,$%     @ 2X*F4&B\TOFS 0  T@,
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MLYG&;#(<]O,/8LLW+G\"4$L#!!0    ( $N"IE#!:*TQM $  -(#   9
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M)1?$IVA\J NZBX) 0>4C@PC;%1Y J4@49'R?.>F2,@+7YQ?V=ZGV4,M%.'A
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M8CR^;.Q_;8P'E+*YP1%J\8/-AH3:A^,MGNTX9J/A33?](#9_X^(74$L#!!0
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MX >;#0F5#\<[/-MQS$;#FV[Z06S^QOD'4$L#!!0    ( $N"IE#=AKM^M $
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M4/MP_(1G.XW99'C3SS^(+=^X^ M02P,$%     @ 2X*F4/2U?RSN 0  9@4
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MX .;'0F5#^8GM.VX9J/C33>](#8_X_PO4$L#!!0    ( $N"IE#A]?>_MP$
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M8+,AH7+A>.O/9ARST7#833^(S=\X_P=02P,$%     @ 2X*F4&_/F^2S 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL;5-M;YLP$/XKEG]
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MF3GQ(ND"U_MW]F^^=EO+F6FXE_Q/6YHFPWN,2JC8P,V3'!]@KB?&:"[^!UR
M6[C+Q&H4DFO_1<6@C10SBTU%L-=I;3N_CM-)',]AX0 Z!] E8.]UR"3D,__*
M#,M3)4>DIKOOF?O%VP.U=U,XI[\*?V:3U]9[R6E$4W)Q1#/F.&'H"K-=$,2R
M+Q(T)'&D'\)I.#P*9ACY\&BM_N43@EV08.<)=O^5&%V5&,+LPB)Q4"0.$,17
M(B%,$A9)@B))@.#V2B2$V5^)D%5W"%"UGPN-"CET?B97WF7T[JCOKG_P:6X?
MF:K;3J.S-+9'?2=54AJPJ6QN;,&-?2H6@T-EW/;6[M4T,)-A9#^_!61YD/*_
M4$L#!!0    ( $N"IE#-<R^\X0$   $%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;'54;8^<(!#^*X0?<+CHKGL;-;F]IFF3-ME<T_8SJ^-+#L0"
MNU[_?0$]:RS](LSPS//,(#/9*-6K;@$,>A.\USENC1E.A.BR!<'T@QR@MR>U
M5((9:ZJ&Z$$!JWR0X(1&T8$(UO6XR+SOHHI,W@SO>K@HI&]",/7[#%R..=[A
M=\=+U[3&.4B1#:R!;V"^#Q=E+;*P5)V 7G>R1PKJ'#_M3N?4X3W@1P>C7NV1
MJ^0JY:LS/E<YCEQ"P*$TCH'9Y0[/P+DCLFG\FCGQ(ND"U_MW]H^^=EO+E6EX
MEOQG5YDVQT>,*JC9C9L7.7Z"N9X]1G/Q7^ .W,)=)E:CE%S[+RIOVD@QL]A4
M!'N;UJ[WZSB=I,D<%@Z@<P!= HY>ATQ"/O,/S+ B4W)$:KK[@;E?O#M1>S>E
M<_JK\&<V>6V]]X+&CQFY.Z(9<YXP=(79+0ABV1<)&I(XTW_":3@\#F88^_!X
MK?YX#!,D08+$$R1K_23:E!C"_*?(?5!D'R"@&Y$0)@Z+'((BAP!!LA$)8?9A
MD30HD@8(#AN1$";=B)#5$Q2@&M]\&I7RUOO&7WF7_GZB_@G_A4_#X2M33==K
M=)7&-H)_KK64!FPJT8.]U=;.H\7@4!NW3>U>35TY&48.\\ AR]0K_@!02P,$
M%     @ 2X*F4/>^>NNW 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL;5/;CML@$/T5Q <L#O%VT\BVM-FJ:J56BK9J^TSL\44+C LXWOY]
M 3NNN_4+,,,Y9RX,V8CFQ;8 CKPJJ6U.6^?Z(V.V;$$)>X<]:']3HU'">=,T
MS/8&1!5)2C*>).^8$IVF119]9U-D.#C9:3@;8@>EA/E] HEC3G?TYGCNFM8%
M!RNR7C3P#=SW_FR\Q1:5JE.@;8>:&*AS^K@[GM* CX ?'8QV=2:AD@OB2S ^
M5SE-0D(@H71!0?CM"D\@91#R:?R:->D2,A#7YYOZQUB[K^4B+#RA_-E5KLWI
M@9(*:C%(]XSC)YCKN:=D+OX+7$%Z>,C$QRA1VKB2<K .U:SB4U'B==H['?=Q
MNDEOM&T"GPE\(1PB@4V!8N8?A!-%9G D9NI]+\(3[X[<]Z8,SMB*>.>3M]Y[
M+7AZR-@U",V8TX3A*\QN03"OOH3@6R%._#\ZWZ;O-S/<1_I^34\>M@7238$T
M"J3_E/C^38D;F/OD31"VZJD"T\1ILJ3$0<=)7GF7@7WD\4W^PJ=I_RI,TVE+
M+NC\R\;^UX@.?"K)G1^AUG^PQ9!0NW!\\&<SC=ED..SG'\26;US\ 5!+ P04
M    " !+@J90BL4)QG0"  #O!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6R-5=F.VC 4_94H[QUG<Q84(@TPJ)5:"<VH[;,!0Z))XM0V9/KWM1V3
M9C%H>"#VS;GGW,7Q35M"WUF.,;<^JK)F2SOGO%D P XYKA![(@VNQ9L3H17B
M8DO/@#44HZ-RJDK@.4X(*E34=I8JVXYF*;GPLJCQCEKL4E6(_EWADK1+V[5O
MAM?BG'-I %G:H#-^P_QGLZ-B!WJ68U'AFA6DMB@^+>UG=[%U'>F@$+\*W++!
MVI*I[ EYEYMOQZ7MR(APB0]<4B#QN.(U+DO)).+XHTGM7E,Z#M<W]JU*7B2S
M1PRO2?F[./)\:<>V=<0G="GY*VF_8IT0M"V=_7=\Q:6 RTB$QH&43/U;APOC
MI-(L(I0*?73/HE;/5O/?W,P.GG;P/NO@:P>_=W"#APZ!=@@^ZP"U ^P='N-#
MC0\G J"KE2K^!G&4I92T%NW.3X/D,747H6CO01I5-]4[47\FK-?,@VX*KI)(
M8U8=QAMAO#%F;<",$9LY L9CR-8DY/<8(!+IL_&,V7B*P!\0N!$T$_A& E\1
M!*,(@DF4'294F%IC'/$SZP1&G<"@ R<%,V%"LP@TBD #033I;8>!@V1@Y,1^
M8M8)C3JA06?2VE4X*YH;Q(.:=:?(B KN=# R!A,9@DDF,M$\:>C?[6!LU(EG
M.G$XD8EGV7P)H!,ZTR_#@/.3T/4FN)>Y)+S3IV02\NBEF /&F\!Y1*]O@CDF
MF58-#*Z>"M.SFAO,.I!+S>5G-[!VLVGC+E[4))G8GY/%-C'8112W80;^"W2C
M\ >BYZ)FUIYP<66JB^U$",<B>.=)-#P7T[??E/C$Y3(2:]J-H&[#2:/'*^AG
M?/8/4$L#!!0    ( $N"IE"MQ$BDW $  & $   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;'U4VXZ;,!#]%8L/6(/))E$$2 M5U4JM%&W5[K,#PT5K
M8VJ;L/W[^L*R-$%]P9[Q.6=F[!F22<A7U0)H],99K]*@U7HX8:S*%CA5#V*
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M$=JTC7O<6@@-)L/PP31T:\9],1C4VFX/9B]]TWM#BV&>9[S\5+*_4$L#!!0
M   ( $N"IE WH0<RZP$  &@%   9    >&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;(U4[6Z;,!1]%<0#U'R31H"T9JHV:9.B3MM^.W )J 93VPG=V\\?! &U
MHOZ)?2_G',ZY,<Y&REYY R"<]X[T/'<;(88]0KQLH,/\@0[0RR<U91T6LF1G
MQ <&N-*DCJ# \Q+4X;9WBTSWCJS(Z$60MH<C<_BEZS#[]P2$CKGKN[?&2WMN
MA&J@(AOP&7Z!^#T<F:S0K%*U'?2\I;W#H,[=+_[^D"J\!OQI8>2+O:.2G"A]
M5<7W*G<]90@(E$(I8+E<X0"$*"%IXVW2=.=7*N)R?U-_UMEEEA/F<*#D;UN)
M)G=WKE-!C2]$O-#Q&TQY8M>9PO^ *Q )5T[D.TI*N/YUR@L7M)M4I)4.OYNU
M[?4Z3OHWFIT03(1@)OC174(X$<(- 1EG.NI7+'"1,3HZS/Q9 U9GPM^'<IBE
M:NK9Z6<R+9?=:Q$D?H:N2FC"/!E,L,2L$8>/B'@W0Y T,+L(K"X"S0]7+@*[
M0&@5"+5 M!((-S$,)M&8WI@,'X/=SO.\31P;,DF"QR5R92JRFHHLIB*[0&P5
MB#\_EL0JD'QB+ 83+\)NQW$/L3*16DVD%A/QQD3Z8>);$_<0Q@1:G'EU!_W$
M[-SVW#E1(3\??<AK2@5(->]!IFGDM3<7!&JAMJG<,_/QFT+08;K7T'RY%O\!
M4$L#!!0    ( $N"IE SG9RU_ 0   $@   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;)69[VZC1A3%7\7R RS,_R%R+#6N5JW42M%6;3^3>!);"\8+
M)-Z^?0$3RWC.)3-?@L%G+O=>SR]S!E:GJO[>[)QK%S_+XM#<+W=M>[Q+DN9Y
MY\J\^5(=W:'[YJ6JR[SM3NO7I#G6+M\.@\HBX6FJDS+?'Y;KU7#ML5ZOJK>V
MV!_<8[UHWLHRK_][<$5UNE^RY<>%;_O77=M?2-:K8_[J_G+MW\?'NCM++E&V
M^](=FGUU6-3NY7[Y"[O;6-D/&!3_[-VIN?J\Z$MYJJKO_<GOV_MEVF?D"O?<
M]B'R[O#N-JXH^DA='C_&H,O+/?N!UY\_HG\=BN^*><H;MZF*?_?;=G>_M,O%
MUKWD;T7[K3K]YL:"U'(Q5O^'>W=%)^\SZ>[Q7!7-\'?Q_-:T53E&Z5(I\Y_G
MX_XP'$]C_(]A>  ?!_#+ "9G!XAQ@+@9D)PS&TK]-6_S]:JN3HOZ_&L=\WY2
ML#O1-?.YOSCT;OBNJ[;IKKZON=:KY+T/-&H>SAI^K9DJ-KY"V8LDZ1*X9,%A
M%GP8+R99<!Q P !B"" G <1-&6>-'C2'<Y(BX]:F:7I3#E)JS;-KY20I"9.2
M("F# R@80(6W1<, .J M9XVZ*I8QP:3PVP*4?&@*U18#DS(@*6*V6!C AK<E
M@P&R@+9D7K%<&:O)6EF*^4K!O3(B!($H"Z^78;X8#ZAX%$U^WRRU2OHS 4AY
MJE+&Z/9@;AD UU A,&5,1K0'<\942'N4WQZ;"@9 @5)F,TFW!_/+ ,"&$2$P
M;<Q$M ?SQFQ(>ZP_)3*6<= =H%26SS0'4\P QH:HC&,Z>1K>'([IY.SSYFQ&
MT61"I#/_.#FQ3 *,C2!"8."XB*@8 \?1NG8['4;1=#H(J;0_'X!4I-+,T,(Q
MQAQ@;"01 @/'=41[,' <K6]>>TSPJHND\\LNQQAS@+%11 B,',\BC!I&3J %
MT;-JJ5<S4:O 5 I I=%$" R;B#&EA"L-LJ5BIM;1C\Y)IHE@9 5 UA!65&"X
M1(09%1@N$6)'!7"9Q#(+I;/+K,#("H"L(2RIP'")"%,J,%PBQ)8*WY=Z;9F3
M3+<M&%$)$#6$9Y68/QGA627F3P9XUHWTC2A5*T94 D0M%8+8YD484(GADB$&
M5/JNDDME!;!82"J8%8K>P6)D)4#6$@948KADA &5&"X98D"E;RN]MLQ)IHE@
M1"5 U!*U* R7BK"<"L.E BSG@_(MY_P&5F$,%<#0$IY38<94A.=4F#$5XCF5
M;R2I#2R0?K*!5<0C&D"N)3RGPHRI",^I,&,JQ',JWTAZ;9F33!/!I"I JB4\
MIL*,J0B/J3%C.L1C:M]C$AM6I)S=L&K,K0;<6L*4:DRCCC"E&M.H TSI1ON.
M<W;#JC&V&F%+T*$Q8#KF(2CQ%#3H,:AO)KUY,">9)H(QU0!32]APC0'3$3Y3
M8\!TB,_4G_O,6<GT.3#&U !,+6&[#4;*1/A,@Y$R(<]&3;#/-)@Z@WPFX:D-
MALE$^$R#83(A/M/XYO'VIY^53!/!2!J 9$:%(%XC1/A*@V$R(;[2?.XK9R73
M1#"2!B"9$3;;8IALA*^T&"8;XBM'D9YIA_6M)]$.BY&T ,F,J@7S9B,\I\6\
MV0#/N1E%N!WGNR17[V+[E^-_YO7K_M LGJJVK<KAY>M+5;6N"Y=^Z9JV<_GV
M<E*XE[;_V!-7GU]*GT_:ZCB^<$\N;_W7_P-02P,$%     @ 2X*F4!1/BM!.
M!   =18  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULE9AO;ZLV&,6_
M2L3[7NS'-G^J)-+*-&W2)E5WNMMKFC@-NA RH,W=MQ\0&B5^CC/ZI@GTV#[&
MAU\>>WFJF^_MWMIN\:,J#^TJV'?=\3$,V\W>5GG[I3[:0_^?7=U4>==?-J]A
M>VQLOAT;565(0D1AE1>'8+T<[STWZV7]UI7%P3XWB_:MJO+FWR=;UJ=5((./
M&U^+UWTWW C7RV/^:O^TW;?C<]-?A9=>MD5E#VU1'Q:-W:V"G^1CILW08%3\
M5=A3>_5],4SEI:Z_#Q>_;5>!&!S9TFZZH8N\_WBWF2W+H:?>QS]3I\%ES*'A
M]?>/WG\9)]]/YB5O;5:7?Q?;;K\*DF"QM;O\K>R^UJ=?[30A$RRFV?]NWVW9
MRP<G_1B;NFS'OXO-6]O5U=1+;Z7*?YP_B\/X>9KZ_VB&&]#4@"X-I+[;0$T-
ME-,@/#L;I_ISWN7K95.?%LUYM8[Y$ KYJ/J'N1ENCL]N_%\_V[:_^[ZF5"W#
M]Z&C2?-TUM"UYE:1<85)+I*P-W!Q0= %C>W5C0N-.U"P S5VH&\Z,,XTSIIH
MU!S.)E5,RI%E2&:$)FQ'0SL:V(D<.V>-N1J'E!*.&2Z2YFIB-U8,M&* E=BQ
M8M@H#Q0[H@R(/&L<02,1,)(X1B(^72*II6,%RE(AL)T8VHF9G<A)]5/,AE$F
M%N0L9(9D1HL8NTF@FX2[<>.;L&$B(<E]-%QE$D6>\*;02PH6*G7,I'P8E5+B
MK&>&9%%$*;8C!4:4X(8BS].5'LK)^8"1&%&29B!F$MTD4RJIE<M+H+N38(FA
M)Q'U7,Q,HNNA7,C<E=P:P;B3B'<N9"1G&3-R3W)K!,-.<MHI(5PCG&1XD8#N
MWB)A[$G O<@#3HE1)>-/I!?S17+ @/1R>)")$Y=W2":TU#Y'F#(288:%EP.$
M989+DEAB*X0!0P P++Z3Z)X5('GP/!3"G"(Y([^3Z/^6"<F$$=+W;#R5&<!>
MY.$W84R1FA]?PH A!!@WO@2*I51$Y!9X2)=(I3WO-6'4$"JLW/P21X@1S \0
M&<_O&V'($"JN6()YV=27>2PV0*4\9C"NB)=6(,2\:NH7*S':M0-TB4R\^<'X
M(X"_V+?>F%>4?F*/@CFC$&?8+H5#1/8OMZO+@(Y,Y-MV*<P;Q7G#0ZPX2&0D
MW5(/JCPI5I@U"I58;HH5+YU<#@/)@X=ZRK.=Y)45C[#B99-,A))N'0%T9!+R
M90<34 $"^G[F%":6,I](,.:,0IQA">8$H22]^GVZ'0E#1'&(@&1R.)!OWZ4P
M&10JC%CF>,7C#12FA^+5#@A4RHX>*)6I[^0!0T8#R,2^+C 5]"=V2QJ_RGK&
M;BG38!<D?.6UQF^JGK$'RO3L#8[VG.?,V.!D>O;N1>,75,_8O623*+K_T,*K
M\[_A0/:/O'DM#NWBI>ZZNAH/_'9UW=F^1_&E[W%O\^WEHK2[;O@:]]^;\T'H
M^:*KC],A;W@Y:5[_!U!+ P04    " !+@J90^ Y38I<!  !8 P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S,RYX;6QM4]%NHS 0_!7+'U"#29LJ J2F5=63
M[J2HI[L^.[ $*S:FMA-Z?W]K0Q&M>,'>]<SL[-KD@[%GUP)X\J%5YPK:>M_O
M&'-5"UJX&]-#AR>-L5IX#.V)N=Z"J"-)*\:3Y(YI(3M:YC%WL&5N+E[)#@Z6
MN(O6PO[;@S)#05/ZF7B5I]:'!"OS7IS@-_@__<%BQ&:56FKHG#0=L= 4]"'=
M[;. CX"_$@:WV)/0R=&8<PA^U 5-@B%04/F@('"YPB,H%830QOND2>>2@;C<
M?ZH_Q]ZQEZ-P\&C4FZQ]6]![2FIHQ$7Y5S.\P-3/+253\S_A"@KAP0G6J(QR
M\4NJB_-&3RIH18N/<95=7(?Q9+N9:.L$/A'X3$@C@8V%HO,GX4696S,0.\Z^
M%^&*TQW'V50A&4<1S]"\P^RUS)(T9]<@-&'V(X8O,'Q&,%2?2_#5$CS2LP4]
MO=^L"V2K ED4V'SQR+]Y7,-DWXJPQ5#"F_LE[$EVCAR-Q_G&*33&>$"]Y 8O
MLL5G/@<*&A^V6]S;\;+'P)M^>L=L_IG*_U!+ P04    " !+@J906<PW]^P"
M  ":"P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R55F%OFS 0_2N(
M[RN<#7:HDD@MU;1)FU1MVO:9)DZ""C@#)^G^_6Q#&#''1+\$;+][?G?Q,[>\
MR/JU.0BAO+>RJ)J5?U#J>!\$S>8@RJRYDT=1Z96=K,M,Z6&]#YIC+;*M#2J+
M@(0A"\HLK_SUTLX]U^NE/*DBK\1S[36GLLSJ/X^BD)>5#_YUXEN^/R@S$:R7
MQVPOO@OUX_A<ZU'0LVSS4E1-+BNO%KN5_P#W3X28 (OXF8M+,WCW3"HO4KZ:
MP>?MR@^-(E&(C3(4F7Z<12J*PC!I';\[4K_?TP0.WZ_L'VWR.IF7K!&I+'[E
M6W58^0O?VXI==BK4-WGY)+J$8M_KLO\BSJ+0<*-$[[&116-_O<VI4;+L6+24
M,GMKGWEEGY>._QJ&!Y N@,P-H%T [0,@^F] U 5$?8#%!VTFMC1/F<K6RUI>
MO+K]=X^9.41P'^GB;\RDK;5=T]5I].QY3<-H&9P-48=Y;#%D@"&WB'2,B!<]
M)- ">A4$54%L/+U1$>,$%"6@EB"Z(6!.&BV&64QE,9QR<))-QR@&"0%<3(2*
MB1 QW!'38N+!-A\X9;$C!D'%$2>XF!@5$R-B%HZ8>+0-8S1*'#%C5,PB%_4T
MWB].<+T,U<L0O1,$'"7@\\_2 B58S#A+BU$M*,3@H-(QBB0)B7 Q"2HF&8N!
M$"> $'=X.+\@,'%)P(R2=*!AMD 3QMVK H,!\ E!^'T!!"G+A$<!OS& OJ,L
MN,\!,_JH+&,/4\[=6P=%$38A!W<Z(%:'B;L"</,!>T=1</L!GU,4/G;&POWN
MI!B*LPG[ &YF0-P,=(("MR D\XM"< ^2<$91.M#PTT. Q=2I"@(#0I.)2X&X
MCKY=G?@<C^T5)Z[:,6:D(1AT(:6H][;!:[R-/%7*%'0PVS:1J6XB;<OGS#\0
MTUUB*UK'M>\,_FW1=JU?LWJ?5XWW(I5NGVR7LY-2"2T_O-.GZJ ;Y7Y0B)TR
MKUR_UVVWV Z4/':=<-"WX^N_4$L#!!0    ( $N"IE"\6U+-2@4  'X>   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;)69ZVZC.!B&;R7B @9\)E$:
MJ6F39J5=J9K1[OZFB=M$ R$+M)F]^^74+-BO*4A5$YS7W\'X\0?V\IIF/_.C
MUL7L5Q*?\SOO6!27A>_G^Z-.HOQ;>M'G\I?7-$NBHKS,WOS\DNGH4'=*8I\&
M@?23Z'3V5LNZ[3E;+=/W(CZ=]7,VR]^3),K^7>LXO=YYQ/ML^'YZ.Q95@[]:
M7J(W_4,7?UZ>L_+*OUDYG!)]SD_I>9;IUSOOGBQVBE4=:L5?)WW-.]]G52HO
M:?JSNOCM<.<%540ZUONB,A&5'Q_Z0<=Q9:F,XY_6J'?S677L?O^TOJV3+Y-Y
MB7+]D,9_GP[%\<X+O=E!OT;O<?$]O>YTFY#P9FWVO^L/'9?R*I+2QSZ-\_K_
M;/^>%VG26BE#2:)?S>?I7']>6_N?W7 'VG:@8SNPM@.[=:!DL -O._"Q'43;
M08SM(-L.<FP'U790MPY\4!^V^M!PX#=WH[Z]CU$1K999>IUES0R]1!4(9!&6
M$VA?-=;SI?ZMO,-YV?JQ8H0O_8_*4*M9-QK:T9";PB^MWUQ0Y&)-K>Z,B+Z+
M!UM#..MK'I$=V==L1OC:(HWJ:W9($^*D&1Q75AM@/0-S;(!# [PVP+LC$I@W
MIM'(6G.N-9P&Y5\0&,-K"RGC >L*>R$)&)*P0E+&V&Z$Y8C,)9E;$6UM(64A
MM85/ME/A&$<)@Y9VT,0(6MK#B$+9-CK1T\WMT7ZR7;I"5C!D-7CK>P9":" <
M/_GFT,#<BH!1(\OUW!JU:CZY9A0)\/(3 $^.U84X5C R/EL"5ZA[0K^<)-M6
MT[O[\W["S=+1"KL#(X*AD<$+"&%@9*BQ)$*1L6YNQHAV7XCZ$>,5B]A+%J..
M>4OP"D/$A'N)>2<V?8P:R]0:BJ3##X:4V)0RJAPF,*9D J<$@TH0J:&9+4"5
M#LY)BFFEB%9'P!332B?02C&MU*;5SIG:N#;+DS-EC"$%7#"7"<P%Y1-2QEQ0
MNPJ"E(65LAQ.&1-$ 1R,F,[L8ACR86^8(PHX8M1A G-$)W!$,4<4<,28F?/<
MRIF$@QPQS!$#'#''2LDP1VP"1PQSQ&R.[$=,9G-D/EP.2OJ!.)Z5$6/"80(S
MQB8PQC!CS&8,#(?-F#4<0Y)^()@_AOAS%">&H6)JPG!@J%@X8LEI1;W'^# 8
M7 88!I A !WEE&.J>##AG0M3Q<G7<^"A%7635@,)<TP?!U6,F>,+1:Z4,%P<
MP,7-9WDH<CR&<\?[*GCZX]3T8[^(DJ')PC&J')1#<[M@P\$KYI K#",'[X_F
MA@*W7R#IH"L,+0>5D#NJ L?0\@F5D&,0.0"1FZ_YW*Z$G [=2(&1%: 0<L=2
M)S"R8D(A%!A%,>:!4MA5CC EAG+&0 K$FF.E$Y@U,:':"<=>#D+(N,V/K:AZ
M2>\L==^L31^[XBG%AT8&LR9 X>..73>!&1(3"I_ #(DQA:\5]5(.!P' M E$
MFVM_"S,D)Y0]B1F2=MECPJ@1&PG*7O,6Z?"%89, -N$H-1(3)"=LKDI,D!RS
MO=J*A%VM7"ECUB1@31BE<2?!UNFP,\=^)X!(.#9R)(9(3H!(8HCD&(BD#1$?
MS!@S) %#PE$W%69(36!(88848,C*6-D,T9 -Y:Q,BOJ_8D"476(Z.]!M*+9F
M;L;@=TZ1$IV]U8>,^6R?OI^+:O.ZTWH[R+RGU2F4T;XFBP<"VA_)8H/:MV3Q
M!-OIX@G9OU=TL5/0LV*?9ZO^_RDT)[-_1-G;Z9S/7M*B2)/Z%.PU30M=#D]9
MY+S944>'VT6L7XOJJRJ_9\V):'-1I)?VM->_'3FO_@-02P,$%     @ 2X*F
M4&8.O<8\ P  4 X  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULE5?M
M;ILP%'T5Q ,4;#Y3)9&:M-$F;5+5:=MOFC@)*N ,G*1[^QGC4F*.T^Y/P,ZY
M]]Q[?8^QIV=>OS1[QH3S6A95,W/W0AQN/:]9[UF9-3?\P"KYSY;792;DL-YY
MS:%FV489E85'?3_VRBROW/E4S3W6\RD_BB*OV&/M-,>RS.J_"U;P\\PE[MO$
M4[[;BW;"FT\/V8[]8.+GX;&6(Z_WLLE+5C4YKYR:;6?N';E=T;0U4(A?.3LW
M@W>G3>69\Y=V\'4S<_TV(E:PM6A=9/)Q8DM6%*TG&<<?[=3M.5O#X?N;]Y5*
M7B;SG#5LR8O?^4;L9V[J.ANVS8Z%>.+G+TPG%+F.SOX;.[%"PMM(),>:%XWZ
M==;'1O!2>Y&AE-EK]\PK]3QK_V]FV(!J ]H;!.2J0: -@MZ QE<-0FT0OAM<
M9XBT0?1N$%XUB+5!;!AX7;%4]>\SD<VG-3\[=== AZSM4W(;R_5=MY-J.=5_
M<@$:.7N:!U$T]4ZM(XU9=!AZ@8DO,<LQAO0(3T;0AT%1& L**!*# F"($>H]
MPAA^'A!7>HE9(<P$)Q3 N@;*03!T$/O800@=A,I!>.& &!7I,+'"5!TF]2UA
M1I E BS48.DPT8 E#'S?*'PT"N4"=!%*#$.)02B!$4H\8B&AC26!+ E@"0T6
MA(DP20I)4N# % S"))AD DDFP('1QLO)J%Z1=56(CS<('_!8>HQ8]ACR>3$0
MN#_<$3J.(O'-?0J!+-L0P;(EP<>R6VC0L*QT8BTKEC<!^DZH281 @84'"YP
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MW1VG&PA^T/<WK[]$SO\!4$L#!!0    ( $N"IE!EEO1C+ (  "H&   9
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M2G]/]M57G"O0&J,'W:A&S\'I0*%29KO1>^&F@3LHWH^##DW3MO@'4$L#!!0
M   ( $N"IE <M\&?20(  'H'   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;'V5VX[;(!1%?\7R>P<#OD:.I295U4JM%$W5]IDD)+8&&Q=(,OW[ G:L
MQ."^A(OWV>L<PJ6\<?$F:TI5\-ZR3J[#6JE^!8 \U+0E\H7WM--?3ERT1.FA
M. /9"TJ.-JAE $51"EK2=&%5VKF=J$I^4:SIZ$X$\M*V1/S=4,9OZQ"&]XG7
MYEPK,P&JLB=G^H.JG_U.Z!&87(Y-2SO9\"X0]+0./\+5%B(38!6_&GJ3#_W
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M(#8'A8$!8C,0B6(6Q190A((B! 0&*)J!/D# DI3AH!@%Q0C(N+^;& &%)(4
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M&@8N^R_B*DH#;R,Q'#M9-O8WV%T:+2OGQ812\9?N6=3V>7/^7\U@ ^P,<&^
MR;L&B3-(W@SHNP;$&9#> %F&J$O%UF;+-5\ME+P%JGN]9][>(C0GIOJ[]M 6
MV_YGRM.8T^N*I/DBNK:.'&;=8?  @WI$9+SW%!BB6..1.;XGV(P1*/8PVS&&
M,CB*!$PTL?;),-$LAAT0T &Q#LB= ^15JL-0BZF[1'*"$*4P$06)*$#D56--
M1T2,49QF,$\*\J0 3^+QI".>#SB+,SIQ 3*0* .(B$>4 40HCB?>$ -Y&,!#
M/1XVXL$T(6DVD5 .$N4 4>H1Y?]'A&)8GC%P;2?>,II0. *B9;[$.U Z##<C
M=*+\"!3Z \( TZB9=""$AB)ALRF)(%C-*!E3L=BG2L94.)LE>((*UCT"A,]\
MX3O0/16;H7R""E8^ J3/?.D[T#T5F253!83%CP#U,U_]#L3^D0E6/P+DSWSY
M@R!/NQL0E$X$ [<(!/0(EOG!0*")CPV".P0"6@0;20$"3107P_T!QV,7N:\#
M!QJ*F^38;\%; $9CDDQ]Z^%N@X%N0_TKC,?=YCZ@CBD:##&54$<[(#;!3EYJ
MW8X"@]-^"'W [1#DG:_1?-.-DF]NNLGV*U?'HFZ")ZG-B&4'H8.46I@HXYD1
MVLD,T_VF% ?=+C.S5MU$V6VT/+MI.>I']M5?4$L#!!0    ( $N"IE \ONB^
M+P(  (4&   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;(U5[8Z;,!!\
M%<0#G,%\)2>"=$E5M5(K15>U_>V034!G8VH[X?KVM0TAA/BJ_(GM979V9HF7
MO./B358 RGMGM)$KOU*J?49(EA4P(I]X"XU^<N""$:6/XHAD*X#L;1*C" =!
MBABI&[_(;6PKBIR?%*T;V I/GA@CXN\:*.]6?NA? J_UL5(F@(J\)4?X >IG
MNQ7ZA$:6?<V@D35O/ &'E?\2/F_"P"18Q*\:.CG9>\;*CO,W<_BZ7_F!4004
M2F4HB%[.L %*#9/6\6<@]<>:)G&ZO[!_MN:UF1V1L.'T=[U7U<I?^-X>#N1$
MU2OOOL!@*/&]P?TW. /5<*-$UR@YE?;7*T]2<3:P:"F,O/=KW=BU&_@O:>X$
M/"3@,4'7_E]"-"1$UX38FN^56:N?B")%+GCGB?YMM<3\*<+G2#>S-$';._M,
MNY4Z>B[B99BCLR$:,.L>@R>8*P)I]K$$=I58X[MT?%M@<X\( ^PN$3E=1)8@
MNG'Q 4'L)(@M03Q5@!>S-O28U&*:'A/C,)EYN4=EBS1S:TF<6I)[+4'L)DB=
M!.GCW<B<!-D#W>@QR<1GFB;9K!GW()Q%'TA9.*4L',U(W 1+)\'R\6;H<>2\
M(L$#[1A -^\]26:HC0.5A-'<#YI<7@;B:.><]$I^:I2Y)I/H.$M?L+G\L_C:
MS%@[%*XT_8#^3L2Q;J2WXTJ/%CL #IPKT"*#)_V^*OU-& \4#LIL,[T7_6#L
M#XJWP]!'XY>G^ =02P,$%     @ 2X*F4(=[2)+G P  .Q,  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&ULE9C;CJ,X$(9?!?$  Z[BV$HB=?J4E7:E
MUHQV]YI.G(,&<!9(9_;ME],PQ/S.)KE(P/Q5KBK[LX-G9U5\+_=25M:/+,W+
MN;VOJN.#XY3KO<R2\HLZRKQ^LE5%EE3U;;%SRF,ADTUKE*4.N6[@9,DAMQ>S
MMNV]6,S4J4H/N7POK/*494GQ[U*FZCRWA?VSX>MAMZ^:!F<Q.R8[^4U6?Q[?
MB_K.&;QL#IG,RX/*K4)NY_:C>%AYU!BTBK\.\ER.KJTFE0^EOC<WOVWFMMM$
M)%.YKAH72?WS*9]DFC:>ZCC^Z9W:0Y^-X?CZI_?7-ODZF8^DE$\J_?NPJ?9S
M.[*MC=PFI[3ZJLXKV2?DVU:?_>_R4Z:UO(FD[F.MTK+]MM:GLE)9[Z4.)4M^
M=+^'O/T]=T]"[LVP ?4&-!B(\*H!]P9\JX'7&WBW&OB]@3\8D+AJ$/0&P6#
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M;76^0H)&J'HK)' 4:C/AS;Z"A<":MEE[!QBH-QP&7'@,>?9%GM[D!>@NF8\
MP'Y0[C? M!]3V%C@=U"NUH&#-$;M/\V>!]_2&<D''@&<5;D*LU07; >G[WD
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M\M?1IJZV$>P+CAN@AE_D)2K;M'S8M2!&&JV]2]MH#5]Z)DRG^#S[D"+3N,O
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MK+&WZ:/P8N?H+:KX7W)&LA<==RU]C2!^ =\M^=#>U=7^5LZ/'*@EJ&W3^B<
MP-GEIQ_/E1'!)P,XE=["ZF\9%X5]L0/N27#?[W 9S\:ST7 D[0P^-?V6:7DK
M5@=O"2@TYA;! I00(XT-T+QHQ"R3X>BW[)O/HML:M5I^5"T&?Q"[!]:P5MO-
MB>^BS&P):/B8?2Q#/-1_3TL@JD>R8.PSI=$<2$2SQ2A>3BX,>%NP!N@". UH
MPD/[@L0&_(3JQ4X*=;33DNEPJ0'X+A.LU7#_"+>/11(@2J(&5/\T1U36VJ/0
M9$GV?,'H$5D *XHQ[@GXM^29Q9VX+TEZ1 ]FDV5T6IL]:'^918XB2@.' YO:
MXDC-?K5"WKC.X+AQ6\S&@#>1<U,@9-WA.C:$Z=#9HY#2H1P!9HE:S218SF83
MC8W!6-LPNL:4*63&&3-WB2OV<S8:W#'[WE,40WC2T&TFK2S&@F=3((:Y/LL?
MTQ*0>2L-$'$6-$Z4ZN,5 PC>SP#'!S=[W"'NS/;^PV$2<Y-,KANNI/"LJEN0
MG1D36YDQXZM35#Z-18C@(<^+/!P$.&L:M(0;*?Y0C728,[ ]//3>406,<0FF
M#BML+6W&Q;"!FU;KH V*4;8UFPHT*&%NU:3MXE)KMD/[%OMOP&WNLQJDZP8Q
M]<[0<$&PE%6KW>' >;.2@"1"MR@SULB+ ,L+!&UC(\8#2@T%U"S#T!0^:QP;
M,DWT)N)PR,9O,GB0C61\:0TB_M$3LX)D?#EFPUZA%0HW8OI'DPNM_ 9I=X->
MEXPY9 CG2!@(U1@7!E.AJ@B+! G\B#E.*KZ*2^1 ZTKH$KC]?2GCKBOE+0E'
M8 'Q-WD!/Y.P)%5(H0;M0.7?72GS+#J[?G5U/O23(/;;+3)U]/B P*<<4=BD
MR#G!=7T +7(5T',#C_3XAXZ?)WJ1-CEQ"DMA_?1D>-VEP(-N,D#9'>8^"9T0
MQZK71&($QE2O! 0F#+)#"<AB "D=?@=6J,V"SR7-34HHK?82M#W85'3VP^7E
MAW/"!R3Z.M\:R\I+3A27.KDI=U_#+Q$F6=,OES7HB4!KR8B<LMDM<5,,@PS^
M6PIS.-(A@;!&=V/Q2%3W&*TKHE=AR*!R*5]PI]]455M2*HTB-K!M<0.T?H1V
MD;59$*ZD$[0!@8?Z)YD@.'%JN-[.X*#@:-F17!:$#"6NIT &#&*#]%;]PGE$
M+ZQ)7RPS%)Z(0DQIFS2OHYUCTN!R6(^@(W%%@N$0$4*<Z;61 \$\&END(<C,
M1"-9*+LB)!;U&XT5IO8$E1LSU"K_'3#+:,N5 !E6 H1R8K2.W35C=_9(=Z;-
MX5$#X#QEP?@7B7*%6VM,U]4QZ3#5"'M>$R+CK]!;CV"=BF_PN8;1Y80-U;0$
MA9\Y:@4@AU:L^SA("<L$:<("2:BP^#/)AXR#!DZ*$V(3/,6VQJ,$#:L_:0D:
M>1$9G(;QF7;6'(1&<U?M07$G49N*.''YMWVY(D KX>+2=W]Z$&E3[.?@DW'W
MF 6SN%ROBSOI)6^5\\)1=9;<\C\\6?CJBG[/;FHV5Q92I_W,GL17#2OD#9T_
MRP3%08*;8L@@#B+)T$S$(P73;$!C43HLG/ V_0G.6,U"&A*H<UL1;V,;&^P>
M4%D8-W!/V5KYB5!["#K(18Q>.K38IA)YD6WG.XU$PK6PS&RJ<PZO:T4J7WB]
M5RZ/6F7I2[PS97LW!+:@+<J#MF1Z!_19CMWL6T5M1;[-I2L-=X/"@!.>/$^U
M_[OE2@X] $ %5;BEB TCL3#+8R,3!1C)"AX"TY)5<N+E_ 4[*=/"U4.%WMN0
M[M@-'A+.\/_;BH.(J ZALGX;W8'TK%#+*.@\:E!(5YG),D'UJFHQ(@E21#?@
MECVSD3*/+PIQE-=@NF$:%IH1P,?P(%#+:/<DIYF/K8ASK'.TWJ5B:TTS/*CF
MH6<P,\0MYKT:KZQ$W$B<L*F>R1$,3#S(IV.D \*T6J.-.5]P O)NWC!7PI3C
M*)'T@XQI//K^G10^(6<J/9-\W\72>OFHR0\16RS^%VMNEWV1%KJ2-"L8 !76
M=47ZJJ785F6%:*O8&D$A8X9_ W;5PQ"F$ -<B@',P[,'0*?0'LP;8.%SIJ/7
ME]<O9/;?Y?5G^F603&(#/F]*,!'V"D#)^/LK.)*\I0R]K'D>_6@[W*U?B;.'
MAF*T+II*SM[L;QI@S\08946+PB904%L<X':?DPGP7"YV.4!A)#Y<#+".4G^8
M,9&K+Y*$Z9MR%M-Z;<@#8PN&?T&>DY+_*]Z;X5G2R"#8.>CC/"PIQZ4.$PA=
M H>NUYR9C5QCLX'7%-5P>)ALI(:@2:8]#SU$&1I*<B/G@NEMZ%BOUA\DV:^9
MF_@<E2UW:UAT*Q#*X8_P+"RJPM!WMG:635P4'E9@AK\S$I^H8#'0J!8(-8S&
M"'VE&U"*M+*1S*2R0=3#>2Q$)>1XS5"ZX^QZ !:4-4!.A!-P*SA$V--G*JP:
M,95+79+;"O1,,A@U?4ARCSN$7"SX.X>5\+0$PA\\/%L"29[06O"LM&_75-/3
MW:[(,]8(MA7P>OQ09VU=R81[?*2NTM7=D)F%P8;*[$%1%[DH'?:>PX)6K?2!
M=D/2L3<O][<@U(A2 PQ',ZIKL;<F^KPCM>==-13T/<,PE$S(:#BV"4SZAZI:
MD[='2U/Y$^7+EFDQ0 7RNMJT%&PZN][?M&#KKJ+);#28CLZC6(0DB-]D["%2
M,&![6J0=*4\<1VI G]NOC21-#*ZASSZM:Q2"BHVD!4"P$6R>6 VC&(W-3L3\
M'^2QD^.S7LOS*M<L*B@1B&N>W9B#'608 I,K0/42_3E:X'S-Q.3((_<=.2QO
M2%?*)72Q_*L1T!4DCUBDT)2XNV*Q*\ #T,1JXNE".6434*X'=QI:#JK7IVZ?
MZN9)T<#")H'C@3&8W-2A_[R<ZFFT'9-^B;J (F-6,<G$1)I?D9,W!+M?C,[-
M &*(TI6T7F*DNP >6''>?'2I#Z.)SCX1@2Y'R_/GT54!UOGF43)V52A,JD_[
M@#JH>IS(C3_-1W-%V2L:(I>!4JGN8^U_PT,U:BS0-%M0(V&_K&H!F5L+-3%/
M2U*AK0G?  <Z+Z^O:!5*MO(C-<[P*$+6@AH(>#*T$!O[P;PRE#"D)&1<!LNY
MD^SYXJQ(]K;Q@=.OJ;FW0[M(T8U(M?[\LJ2>AM%84VR^"6Z#@@SJ,>$X # ;
M2W@:RO]B:*LH6'O/3A10H%6.8Y%HCJT;,H7$"Q QS\&J K(TL-@8$N%EOZ@U
MU;&63@V/D(M85VH/8%9:@.*'*DA)9J/$=65P\*EB&!?0$Q9GKUK8PXI>E&7<
M<"Q&G(,L0%5G <P<.-.VHK@X>8O!Q'U$C1 6J/T-A,%"O<D-*2OC-3;7-6-1
M,H#HJW7CI(,S\EX<+IPW78S8>-##37;&N-I6!T,.1"D0UN,9P-HX=YEA29&?
MNJ8^(0!59D<BV4"NFNUWS\V&Z(]UNP *#-,1<J&L1FF'&20D^=(O JQ,W4[!
M3&-5S!#821\U[0A&0. X]WFU;PJ.79/Q[WEU TYGUW>.?.^FJTJ(]RW)F)%-
MGUUYI',W%XP>G^Z<ZH0EA]W],,L_LKJRW!..Q9ABIGJB8O9X%FH]Q[FJT6AA
MT[['H'\''/@O8#Y*TS^8]7& H]D,;3P:C!)D#3JF*M5JD5-NQ"X%IYN,D_/>
M5W[DK&,$Y[]7H#]&?X:G]K4YPN0\*+0S5C==64UZ?(,3TZ#P.A$?*$/$: '"
MB*"<'B(YKYT!C6?D<E*U_F_+I4YD1WDCN6RA7)!R#S9]6$*QDBL(B#HWN/L:
M;?T_DZUO.&^\B+'QV$OEQ.X+&D^&4<?0U@Z%MT4&'U!&-#K.;X3W8S>S-?8"
M_D#LVG,QQ"Y<&>:54?X7AOTYAB1F7-N/,Q_7H4S3<_OW?8634BZ6L-UA'$#-
MIF'#&MC96[2-HF1HH7[/=%RX1?P,#,=&6*W L$IG.B.KSRCUKF[0S"%N+3:H
M G!=:QO+J5@+</$<T?;S\)I2%6'!9LJ*-(V[-\W^8.IY -*(OYY(+QC,X\<T
M J%%N];=8'VO7;^:&R9I]C=_HXA,98)X:^)<\'AES(3R7CBIGR D2Q;(X68-
M<X,(]3>4C[)?4ONXRT[>$\%2QZTEQZC0/TCT36ZBY^Z( M[J0"6@#4([H[%$
M <ZY ;I+[E 3HHJS!"MWDF02)],)_"53QLV_Y*]7*C,6C*2==+3 (^-9O%C.
MW8]7,A\XNJEP*OES<C&*E[.I]QDP<!A$P60YBB?)1+V@7A3?TXN86+FR7E/+
MN8B3B['[D0N@/;?M,_A]$D]G<_QK.HN7D[$%B]GD(AXOEX%C_7D/:#R.+T:C
MK@,2OW9!?#R:Q:,D\3[W0#R)EQ?3 ,3Y^T,0![B-I^['*PS-42\[3KQ9 \=O
M0!%2@U/K$OM3YRE-1M-X 2N!4X(36$YFSBG-X_GX@H#W1D9DA-G3G436835:
M>2.^< Q%-?S27\5K8TQ:%U7*IKSHEJ;!&3[9KGJCYLP(&@33Y *^9^,(_V>9
MW*7:PA5NX;,V57X@4\7X0L25NJDK0$M/9G0.@SO Z)"AS<>S:#::16?CQ?S\
M"!:W6,;SBQE@_3Q9'LO@QLOX J8?CQ:$Z!9C.Y@AB42RB,=$..-X,D'> HM=
MG!M,[LJ4^,^Y[-,<DSE/,DVB< ^S:#);Q*/Q/ KV%XOFHS@!S?V$!7?QWI\?
M;Y[$?\? I)+I-%HNDNAL>GX<WYU,1]%L!D<*IM !?@OX-Y\MHV0N$*"?S]K\
M-<1GCSH#V,(496(2SRX0><Z6YP;'/0YE$%B=*#.+IX#18929+>/)^"0<YV5=
M=F;[@78'*"+<J,2 ,5YOEX7VLTQ2?0O,R"85?L)1@N&A1 F%D86*D/?/8^<^
M:NXZ[-B=X>CIG2)WK!9RY[9@;MWL1:J."!_7>?.3;:/>9$4.:HY*T4:C%4@Q
M&Q3Y3UGQ.$" #' \_MVV. !6SA*CG6P4)2WMNZQ81VB<JR.ATC.1,('1G4?E
MDD3*OY$YR.PRD//UK=J*S5-@S J6HR58ZB36FVR5[D7$*@A@Z3 5:W"5">8K
M9+P91TLV'A>P2,;#&4&P\(KRO_R*#02K3B(HJ:8!F!JYKU9W6/I%ZPE.Z'D"
MG)Y?. ^P05^3"5<3=KX=6>6BKU2Y:,?7PG.L<MVDNF#J"1;S/WMCL6[J>8CY
MLF:!)FF+P*P24NDOX@MDD15I4BHZ @_?4F?D,0C@V01X5#RY )N+XR45G+LN
M=04=X0(8+JH*R8+V"F12-\83(D&<"F+7*C0:3>+%8HK_!X'X>E^7N<@%Q4RB
M+^P&&\?+T13^OYA/!8];P//)-)HGL&ZT+1I@JJG5\\[H/'"VB"?SV7ET!BQT
M,3X70X3+XKD4_%DTGX/$N4!6.8^G\(?7]RE?48CV4M:4><JMU33KI5'F<6)-
MJC\3VT740Y*X$>[QTBXY_+ !^JLIQ6!7 Y?0<<=PX6+9/R;5N(HQU;?GUE1F
MZK]?RB@[1!B!$^YFRIDB)&?$+SK,QG*KS8HB8_&CCDSR?+?PR6PZQI[FU5U.
MA0SP<YN#ID Y)SO W>CLZO+CN:@=/:TLU:SDH>38;0YRKL7*F%WZR$=$!?^B
M1&ZS+V3M@5A5S?4/2$%4R$GEB6H4X9KA.M7!#<@+KEC5<6T.8."7C0'!JY=H
M8<!X+P94$$NB059'\.[/7ES]>'D>1R0CN#PB=+1N3>>N:C%$A1K J5N]3VN,
MCIA;-C8:K#Z1/JA7>SQOP,W/)>T!V,*SB5%YBB+OV=SX(A;%B%R184!)9!Z$
M-N0<A8E1YH&HVM?EU)I0-5%0@14#45 653=%?BOKY %F<+ :AGB6Y@(P_^B>
M$JY" ) %NK#P 9^UKK,&9';JH&.9-9=]P;U&UY@$ H=\QYFCTI*C=L64=4*N
M/6 *( MA,:>C % .4)M!R2*?'QDJ8SC&=!H41 UGH-88 N0ZHUAL-@9&E,.G
MRSU2<9&S _?]"J  ?Q,?^B27>"YJ9^1\NE^<I(T#:"Y0:CPS< KM6GY=9$.Z
MM*F,=@!,Q>E-6 Q)^4V9*GBN.+> +CA $A9_2B<ZJ6[D9\6:.D[YR3D%'G%'
M+/1C]9@6>.<!Z/N4\:LS>"G5,%9U%+)F4'IHY71BL9_TJ8)(> \ZE!W55[]3
MSP)82TH!-Y0,6"!/@^5Z[P]578!^_:XR< $Q62Q7H069 &9V_/$%-58?W*$$
M"#JH,6T*-%5N0,2A1>Q-H?. $! (<@D3#E.&3R(6BQ:;P]@&V !K&+U%3,#X
M8BHT1@^;$?9BCL.8)I,_4$F6^"HW%11Q7,\FVP*DL@,2\A(NL\7PUKK>W\HD
M)U9UWKQ[>8Y@XE ;UY(PIQ1-*ED?F!.X)^'$3WF.@G6IZAEQ)(06T2W O#3Q
M3GZEX(OI8((UZ. ?F58R<;<+:TDC,VK*4:<CNC[+SYE2K!(YHJ%5D>9;23]&
MWM<N;07\SW)X.QF+;#55OGK\NC#B+'0Z(TE+U!YZ:IKH_<!'FZ/21CE4<M$N
MAL3R&W04J%85I@IUVNS$*M\#=\^IFX!>AJ.^Z5^NAY=#T(KDY_-A]+X4Y+F,
MHX.M+SJ6<,3,Q)1 [2LSIU0K^P*FF7G2@<&([GM626TWU&O,/>R%@ZZ"Z)7:
MZW[+W^I%QX=47'LB?$_TQJDYZ2@Z="),C7U/Z#J*5'< 6%G8P(T?"'TIR$^^
M #*]ZFP@6\%T=&*P.D5HC0+K9FK.F$<=1\C6)BOXNQO,$4*JP<0WF:7P(.I3
ML-Z6'-VRLF*)+5;L[AS!4]5?WN)51 %ZH.2M8M\0\R>1])!CSKE@7X,;  \U
MNF#$C/NT:J$@-M3\!9-9,#V+-2-.6C2L$\Y&;&+G%ZSMD&M6K#3(VTVK!^/Z
MGR[?OGK'3 \?A:?486:KNY+:],32V(A1A,34^R5&>Y[J9U22]P/V8@ .652Y
MW[9'GJD26N:QJN1//EYSC6@SQ-'KMY\F<?3R[=L)H_K+Q8@I13='XE?/62VY
MVV^I[(O:#(&&VNK62:"GY^EMB?G&*U*A=W>/!:+A2F!J)7Y$DMM53=8XB:!R
ML1I)PD)4'*'$H)M'XPT/G0C#I);L=I!Y)5%-\3GNYV.2GB;3&QY/YN/(0:EM
M%7'YF+Q7:Z6*B6Y0<TD^!V1!;MOUY!9L]C#)?:;2NI'G&*RSG_$<19+F"B1(
M#8Z'5VD,^DER V/%J%CM,CHHLO#K.KNO6%@K4OT6U&@L]_>=E-A-50Y1/960
M7"DHB42H7@$>+TQ*5C!=#X=CCFA=6RB>JA&9,EB3I6O>2/5&%@CHU5/F(_E^
M':+N,:"/7F&+;C=J=2&Z2 V7T8ULFV-0<K>.'X&00L&M=7:MERML,S1TH0VJ
M8U*)0]9AKEW8<3(\&"F$2+79PRWF!"8T:3@1"NTO3@+*MZAJUX8E$!_D3P+?
M/?K6G1U#"&)SW0]B=\!V8=DU%^2RWGP'---ITPRC:]1M-2Q5GQH8+EL+<:E6
M:!A6[G<'+"Q$8](J@)]G2K\GZTFB!CKY><]B;!&LR.LUJQ5"C6^.Y%2$ASH#
MRD_VMIF9X]/+827;,M\\6OJ<( UJ9J?710=O]T*T_9(Q5M/O,6ZQYV;.@49Z
M-9F% EO=@V44RQG;]FUW! 5;)@!RW9 ?1M?/FDU%4,^A$@<F'D;6DDHZT/N[
M(8^,S*7N JQ%JA)N\4%XFW"U!.\O MD>ANWQY@#$?<WNEX"W:.FA*-1P,'T[
M\C1]48:9S?97T-2VW%7TK9J1J91Y(/G&#'/Z>[; Z06,:MI^<*DX4!>7S8;C
M=WW6.",C#"G&Q)G145*"H*B;5$= [3X1:.P;[L]C[/[OHSO538SBU5@5A%5.
M*:E=%A.],4[(=YIP$15LN?9.#F^Y:=B##$HC(DQX-^$=4'V"L85A]-+UA+MH
M[H=.4U:RN&\(SE)GFWW#'5F<7\KLMFIS97&JAL.5VA@[6/2DVL\L:R9]\T21
MI^0)M"6//H?1YS[YZ&],\J-U7F 4!-/!E6NK$34Z'.AT@THNYS";BPJ+P=X"
M:CSV&ZAQ.=H4M;,K,Y%2)D+;DBP?*#_"W8+JP!L(%X!Q9,D$Q9N*1\&=:+6/
MLL%<& PDE-.\X-Z1&(,5F8$7(R"A1Q:9OB?0LQLYC,#[),-D12V&N;S?URQ%
ME*]IL6>/R&^@8I34.W@\=THHP6(!M*>4:R78 @VWBD](81_0I&@^R<N>Y#X6
MC;U-/HE<P7&%6X!V(4@ \YBVYWO\Y& $21NB2L_)%-IJ*G9+"Y[SD<KF66!*
MHJ>YQG(+9'# HX!]97G+[?ZYOPNPI#KC/),>1\HP>L6OL1!'G?+@VN(3YQ!0
MOSB\"2E;F6$+#EKI]>FNIEC3G:U=J=YMI.'&R$RYR4PT="P)6J>S),JM>12]
M?,WED=FAYV(RP#S;\J=ZOVO9$FFJXE[XLT.#"Y(5Y\NE5I@^@NT*=?&5:*<H
M^BW556&I.-0_6A27VTX'77#O>VNESY/I"EF8ZD*ZYE+:CH:ELA,3]^\X+4H4
MRTJS1D:;U"(=O1%#D]F]JF+37;'#$5]E@9G;^L8K-#J$2); $!+E^E0"A5VZ
M7,]5>&W'^*5H'NF-^NJ 1'FB5XSL5C6[X5BG9;V%#<O,(FJ)()^\OKRF83'-
M.V]!'P?C^V,&0JTFP2;:67!4S'GM#'WC,HH8RY_.#2W$-"*R@$JB8MDZU*[C
M[W[0W= /3 _J9WCR$_>%"^0[J'B'*'Z#U8EF$HK'-]RRP>BRJU?1H9I0:+@O
M0<!\P7,!(0T8L\F(>#!ZK"TY&?-X2.EZNM94^VB#X5&U.N=A1T!+-?S^2MD\
M_D#%4>B21$RE)-,;X-GNMP@UJD*\EZWRV7']&#P[Z1<SUQ0\Q2;=JJ.DDS&N
M<O6/HRLMAMH92QBMJXQ33"AJ(-1P[ UO*;!UN',_]S<+3RUQGA53OL<2'6N"
M4=BK,AWE>. ZVM+W5HK,L"B\U"K.WG32J[@W@G'UK7(H*EB022IN5\&HPXZ[
M*SAZ,7S=X)5ZE/$FU  7 K&5*&,I6>(XG8P9;P2U\X[,)G$ALG5,+!]<*TZ/
M>0*-.,ZLO>6[+K#]5MH '-&SFJ&=[1ME8I]\_-3/Q<E+LC=U.B41 9@-I>5^
M/3:$#(X-?;GK7V![=MJ5B*Z5F;HE6:76I'@QP7Y'_@/0YCF_7V?+.!3@IK.)
M+#>'GWP#:)JR:IWR*P[K]UW^.J;&>#10\5W)I5]7 7(Q.@J8%=K5P+B[P]0Z
M@E+Q\NW;]X/9B*O5Y8?+ %HW.TR%E@T9YOJ"" U^GZH\[+%'8:^=K':8'C>F
M=M ;J2:W177#327#FBYWIK_V_:2RC)L]ACJ8[K,@&=HW8_8RJ"'6NY*<6*7R
M60SIF$4B.C$?LHPDL#TRJ:X[ 5ECS3D_2*1H0]H71,8VA FH%WW,&CYU\[VN
MQ%Q#:'Q5CBY/[O%B.WH7BI=U1>R,A1G!N\EB.%/!NZ_(M&4N]M7K62R-6.)Q
MR_$!=YW#)^SW$'=Q]9\GJ]I*V+-26HQXFO0T. E]_D$SW;%9V8BZ> <[6BXT
M\$%-[QI[MY*$:?.= 4%_(5\'%$J!G8[U_2GP$%#;9#[]?C$R<._LV6(QG,J/
MY[&3H(G;U2FQSOB!T)#92#]WM#22SXVI+<NWU.GU*I<$$ $GQ3A(FN%&J.Y*
MZ<KLOJ>9AM$KBXL])0JM8\]Y:6@"PBV#2P4<H-ZU%E?3L#2Y-L<#7<]@;QA;
M<TS]E(OI,C%!#6R_UX-J9CSJ482:12O0-*+&:3JMDCJA9J4R_2@6W5(GN:-C
MT/K6"?98D92EG->,(T"VXU6D>@J\$;7?XL:]W+Z<P@LS#YPPL[E1(P\6%V3(
MNJZTV) WU\V/Q?AHZLFW("98CA,S*?R\(\OVQ "73KCESHTI: 0;NF-*I]2+
MZLV3// ]UHK/QCA6(.ZL^CG"FR$ >B?(MKH!LD..>1$^.,5]:2NVJECQ66*6
MMFSX!M^J:65))]*')D[\98"&)/4-P#"'9(8^:#FVAS0E/1/?SAOK.H'T=D;#
MA;D=H8P?Y0D.5^Y*:E[+CHR&?@*S:1FFW,^U:#DN+#?1G4]TRPAU[.^X%D6N
M*'#3@[DH6V5Z-NY;DKSX4_?GE<LSV_B$UF@WWGA*4OJ[JH7'WQM]28-'Z>1)
M'YUUSL.[Z=[\[2?C DUQ?R;]$$ROYE>,_%\5.SPV^3?6281F@J&?+$A3]:?M
M.D[&HU)Q;=]CJS=/&5&#C%OF"^,<7OT.B*ZDLKV"+J>$19Z]^X]SRWA7%T&S
MC-P5^SIG'3-JVFP;2-E6IOWE1R7]6;1RWWBS@H0R',K!OU7KVY_@[^)QN[NK
MMBEL;+7'^]#H\PWF@< FBFS_4[8515I;O!IPA^VW'@%&V]0Q$?DPT:*5!VJ>
MIG::PAMJP=H$E\L6MJWO >9T(PYLJ9LLR1\-AR>5>C'+)A.VHX.I,KV^.2J]
MWN)CIV;7&[>E.N=EH+E67M5V59A=I-F+A@!B36$QK$&AEJPNI[O9KQ$P6JZ@
MI&EDLD<:_8T:$MH.D"WUY<N,>V9I&766;V^ AC.'F +MNIT%LFYB+TE84$9_
MZHX3,6/X2@V2^HF1S+3)-X?S@QR$B#EE"4C(/Q)A3\1F^QX8H0=@ZEW9B52@
M%"KJ2K%TC]HDG&VF:5E>O[D"'1%#UK$H<1*[?>(R>N"\ M"!Z<37*[&+]5%8
M46;F\*.W RD:J9B!Z",O-S!$3E*.@OU-NLG(Z(+!3B@'\DY+(21EZ&(GC1WP
M2O3*B#P,6 :_A/(Y,6N)R0T'C%>4V9J1I90A32_^OC&*,DBUD-=2>FS!+2%P
M5FM[K\Q@^4$-2:Q>K=VX.8:NI8() ZVG&C-73W:)-J]]!<')D=1[=2/IWO/T
M.2".GLTL(,K6(ES@:[*!AC78)B,?N;Z1"#CG)B/.(&XXLF[.5=/=I?=\N\!X
M]MNH>@ VVMSE.[8.84Y_/G018 ]74NO$E:3BJB0T+?C"TW5>4#<7T:$8A/4:
M(_+%HT/59L^4('92BK=\)HY>PFK7W,HXCGX<OAS&T8<[^L=0L'[?T)V0H+=0
MP=-=GFVB5XSC< +O\8I.433RHL).M%LZT9AJJT!D(X6SO+ W?D,/8X<C$BE5
M;27,>33#7Z@>K@%_A_3]#<>.*Y*]7U;)MR-G3 >D&&;J5"-X[*)CZ$X)ZSHY
M97G!<G)H)K(<Z7IR;.9VE@\S.""AC $3>/<?].=YUXKD:F+7R6:8WZ9+D"%M
M5"'F;9&M>SU+0O_?YO28D<\?<3X_.UVJTI=/J@+"\Q\%4[65=2@2]E,2O7%G
M';NHTW*3Y83130#@VW91W7JR3\+H46RG*7,W'"G:28)S.I0LRZPS#B=C(\!\
MK:N##1:HTY7=J7%IN$11"(+Z@K766&<R.ZE_.AA$S6?5/<8=B<Y=$RM1KCTQ
MHKV54[9\(E"U4M5TR%#;#?.DI$AQ5!Y&'IT+V841U#.,-;TU^B<D@Z:']$'$
M_M12Z/5.9^Q)Y';?9+I6+38+U6(A/LBON.>PLEGC-C3%I)<!V9$>E2/Z5GSZ
M77 7 $94+P$M (4.ID!*^1#(S"0^=-SB"'+.R+0,MPY"Q$N,)$M]![=X1+;I
MHO9OG'<I'.0>NE,  WFC.F>9G4KFZW')G3)K<A7(HE67 H@.+DP.$O_E#:<I
M1;/X'AFI<&1\ZTCXOGES&I6G0_A+,8#J@75&EM#"Q:/L1&9B6W3]&9WQBD=Y
MRZ941$%E+*LM5LERGB :5,X%RD=?_&I[?M8Y77=*J:-5D8L&^ @9L]&;>MJ!
M(<BE!W'$M-LZWW*/..SP#[P*^9#;+>N*K!/1;8]R",5%H*&[NGL?-IJQ]W2/
M[1^".J8UP1NZNOIGZ8O?"\IWU\FP> ;8K*,BA8YF*W0'->KW)5O[<Z.W1HB2
MNOI"U]#!R<^7U(^RP=[Y&?HOL!'?2OK=KT'7O8NN816O:^R)VZPJT"=!\,'4
M99XR.O*RN'5D$R7CA40'?6^3L5G$F&H/ZH:^>'8TOE#^!.VNH>Y"G,E"8[/O
MA<FP0=(4_39XARK%2UF0>'<GPK':J PNGTK)UE"5!E1!9?6R,[-*B)B$N4+Z
MCP-K5A*MF@K026>FJ]J?0?=";(1^&:)X<M_J>'IV2P7PXE%EAW&(!9C=C;Q6
M0UXW:V=7_L((ETSCB^GDFZ+8U$<QZR:L,)+%_[]@V7YW6Z=<8K51WOM>H-.^
M!)A@+!0A]YG19Y,#&4N)B^C;]S$J=^X3([PQ('C C1_"%IO9)(G/;2C%+5V9
MF;:4,T9%FYR'9E5C8J=.=N_@<K.'M/ZI"U^X]$QZ^I+E4F(-508U^KI.66Q5
M<F&'[(! =V&C*A+J"M Z9]P^H,93VA=NX*7'*<DO[@7#]\%SOU,I0>7]-,11
MRG51U6L=GJ$8$)W>=#C1,1^)C/HZH-2]LJ.[A7@@UN2G7%BQ('45Q4H9)-6^
M%E VHTH4C$H;X>-HG%;/7OMQWY?TWN$]YN!7@A#H;BOR">FK?X\+>F$3Y>5H
M0?_.%Q=&SV,Y)AZ"-_$LB6>3.?Z#G3NYR:?+).UI9A-X=,)_C,9+@NA*=VE5
ML^CL7&<\[8=W"EYRDS_+N&9\$/"?2$W[D='_E:6F\5$$H4]!8@+:?$G_3F9)
M]&>IL!K/C)-1E$PD;,R]8;/ST8+?GEZ,N$$U63?$'D2,T[W5WKP7.'@D1ZN?
MI# ^2W2"$:$(?FG.21%Q7)F\C43#V,XD1+0/W%_%=(T#;!#\3$+[DOHDB5L*
MV>W).]%I9\I[YC#/CJM;>H_Y>?07]-&*XER#MI[SRV<Z&?5"@ P[B4_C\63.
MU[HMXOED@G^.X<^+&:'&)%K&XQ%].X4_I_,%_CF36<8@"DGMF,WBR<52(("U
M<V?+%X!-P(FYL^X'+FF7ERJHU*WH;#*-%Y/YN7CN4X_>!,\"45_([KN*^/I8
M"4H?=2L0@A\18&<M1L6&),R<?:B;3MTGD)^0Y)36BY3JWOCVB$C$W%0 <$Q?
M% UHRH2 EG!5U^R9J"EU'['L(<.8&K(^6%!ZFT42]/0,(W3KWE'7Q;VX3>-R
M.)G^MBM7H@W-&8(!L[6]S]I(A<,<#I'YPW=SF':3JS]9BH84QM+U8M",S.KR
M(^Q*8A(\4EV@A@MT&\W8^@:,@5&:3*;Q,6(TF9E19=(MH!8'8]&/0XU^"[[J
MSTZ#I=.SER\25;4_:R.S_U3I>R9J/=#)(AB8UDK"+52)S]I%BBJA6[K38UVU
MZ+B9R0<B_-]N&T[A],.K+V]9+\4N]/E=)>YY@],S&_ ?6&>HSR>5JN+H&.F3
MIC\<R V'E0YZ2 AQ&H$WJOVS$#(E>C:H"6G-D:\;[+PC[A4P0_;F3;E\0ZL$
ME@I'5#4HT"+Y'* %0%M7M4P,SOSG$5KF0Q;*!5!#8Q3Q/7&A-..6CA:Q"ZN/
M<C55K2D;P\1/U6MA99 BJIXSK7IZC>SMFP;U!3O'/L?H[-Q.V.U=Z1I&Q,[^
MMB]/#.U&9TU&7V;1_-RI.@RT=+RF JL/$E+&,.@4'(^^Y^&-A:E'Z('D^W.]
M-KN'.3DB<?C&3QNZYA#G]8$0IPRPD" T0J;R?B(XR<0U(B26F_<7J_N_S<LT
MG?CIP7AIN 4LKTW<"1F(ZIY@MK!J-]56+3T&7UQ82][I,EU9&:4!;UXB;8=C
M11LNPJ'N&RR'T4L=(G]"?J;4ZK%O#Z&6//K?-Z234#\;(X>&1*54^S'ZK+ ]
M[[Q<E0"J;U>USN7W??,2?,WK5(_6NCTV<8WH.7A!*A=.C6ESN!KW.</%BIT#
MC">CCZ+N'F\< A9+E#A@)>Z#E!?=C*-K 71UJ^P@ZM"_NIF8?Y6WJKY1_I4/
MF%ET1K_AGZ+UGOJL>[B[UY9BA$C$@BDUA5@N%EMP&D%M&?/&3Q2=P&RO.N6D
M,K$0\9ZX;QJ]=%7Y]WU:<(J;_:NZUD:UUMDX<Z!;;+LKJL<,34M.#E!A/9>@
M_:0 &6!%9I$*]#,W+]"98H4BVGN?-[0VV#6(HKRYR]R.%[U)"$'WY@OYX$N]
M,*K')#<!F)Z N$KE0W@;=Q&WYC'&K(.GBA]H+FT=&YXD"5)-KQH51%TR94S+
M\*+,)MRW%3;16$EM3TRG:G7$?#0^&CRA\64W"G8897CX^-U,%1TRX]5I]QV;
M,)-;JM)DNG(@U&<RD?Q29'B5,2GR=EH=Z7X&VJG4S-#:10(8-G6#)Y*1<:&3
M;@NJ%" :J>'1!?VG#W1#/*?\<8\+PU<'^T"OUGN!_QR!56$S2O@5!=YT#:QQ
MM50RTD6;=/F?Z*AD68@N@MK@9*[,],KUUG(=*OOX<8>Z(>SLGK(/J!T#X,:^
M[M;CY 6PR3B>3I?Q<IK(\Q2WN_@-8P)PEYQ ^"84?J$OFUD= W88$?<4*X\N
MV2/R*$JS=+!\"^ !<=;(,T_E@X')GT?O#4R3,'FGT%-^\U_"U!Q$E\+6?"5/
MZP.=EO& JD',L3JJ;("B[M6-<X13Y^[E<^(FI3B@7>#M?J-X-J:[UZ;#60)V
M\9(^)"-R9?T@#G <SQ<S^&\<)6 Y+]4"U]%9,IK%RXO9>30>+A=8^+#)*"_[
M+)F,XXMD=!Y=#&=+O0I'[4F2>#Y>Q),EWA>4S(:S.:X!_9>+13RZF,NI.'/
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MKHX6[;]>TO M+VDX?$;4>O3HT_GUP@?LDM>3NOV:\] 9MJJ'*]\H:A/%X]%
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M?M2B1X1PL#_CA%3LO$DX?'-$OP!02P,$%     @ 2X*F4--C1*L,!   EQ\
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V<U.PD 8A>%;(;T
MA^\'_(FX<L-6O8$&!DJ MNF,4>_>RL:::(\+<MBT:=I\\ZZ>3*;W3_%0YEU3
MIVK7ILG[\5"G15'EW-Z%D%95/);IJFECW;_9--VQS/UCMPUMN=J7VQAT.IV'
M;CBC>+@?SIPLUXNB6ZZEF+R4W3;F11'>#^&MZ?:IBC&G<+K)5;] _\E'&_^S
M?+/9[%;QL5F]'F.=?ZGX7J (OP?I>)#2@VP\R.A!/A[D]*#9>-",'C0?#YK3
M@Z['@Z[I03?C03?TH-OQH%MZD$R!C%-^$L*:K[4 KH7OM0"PA2^V +*%;[8
MM(6OM@"VA>^V +B%+[< NH5OMP"\A:^W KV5K[<"O?4">VVTV>;KK4!OY>NM
M0&_EZZU ;^7KK4!OY>NM0&_EZZU ;^7KK4!OY>MM0&_CZVU ;^/K;4!ON\!9
M"3HLX>MM0&_CZVU ;^/K;4!OX^MM0&_CZVU ;^/K;4!OX^OM0&_GZ^U ;^?K
M[4!OY^OM0&^_P%DW.NSFZ^U ;^?K[4!OY^OM0&_GZ^T#O5-5=G']G+M=O4WG
M+ODQ_,^: =PI?QSB^3-.4__\:3-0.O>KQ'"ZGAW"T]2OB/#CE^;#)U!+ P04
M    " !+@J90_=  &KX!  #M'   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-
MV<MNPC 0!=!?0=E6Q/A1^A"P:;MMD=H?<).!1"2Q91L*?U\G0*4B*E$!TMT0
MDG%F;H)U-HP^-I9\;UU7C1\G10CVD3&?%51KGQI+3:S,C*MUB*=NSJS.%GI.
M3 P&0Y:9)E 3^J'MD4Q&SS33RRKTGK;7V];C1%M;E9D.I6G8JLD/FO9W#5-'
M5;?&%Z7U-W%!TGM9QRX^7ALGL>H3=L*$PQO;\WC?VXJ<*W/Z5S0SFY49Y29;
MUO&6U%M'.O<%4:BKU!?:4?X>7-G,=WFGVH577<?&;%VQ7PO2Z^4(FXJ.!^@J
MEYP<XK:@8Z.ZPO:3GS5POQLRXZAO7:RZ4!YYO!AI&JN>M0LO^8C4;IV<\I.&
MQ];7^V&_C%MTWX^]\)^B9]WAO+=^N1P")(<$R:% <MR"Y!B"Y+@#R7$/DN,!
M) <?H 1!$96CD,I13.4HJ'(453D*JQS%58X"*T>15:#(*E!D%2BR"A19!8JL
M D56@2*K0)%5H,@J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4616*
MK I%5H4BJT*15:'(JE!D52BRJBO*VAW36I?-7TD^C5GLY[/N7\[)-U!+ 0(4
M Q0    ( $N"IE ?(\\#P    !,"   +              "  0    !?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( $N"IE GZ(<.@@   +$    0
M  "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 2X*F4'!) !KN
M    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 2X*F4)E<G",0!@  G"<  !,              ( !M@(  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !+@J90ZT(?*C,#   [#P
M&               @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 2X*F4'[(;I;%!   3Q8  !@              ( !8 P  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $N"IE"%+X]-/P(
M +D'   8              "  5L1  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !+@J90\Y7T@0X#  #N"P  &               @ '0
M$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 2X*F4 TR
MJ<Y<!   ^Q,  !@              ( !%!<  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( $N"IE"&*Z]<N0$  -0#   8
M  "  :8;  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !+
M@J90/#;'YV\$   !%0  &               @ &5'0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ 2X*F4%Q!!K2Q 0  T@,  !@
M         ( !.B(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( $N"IE F& 8,M0$  -(#   8              "  2$D  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !+@J90:+S2^;,!  #2 P
M&0              @ $,)@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( $N"IE#!:*TQM $  -(#   9              "  ?8G  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 2X*F4*F3S&&Q
M 0  T@,  !D              ( !X2D  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !+@J90#[E$=[8!  #2 P  &0
M@ ')*P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $N"
MIE"D.04!LP$  -(#   9              "  ;8M  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ 2X*F4 >O!K:U 0  T@,  !D
M         ( !H"\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !+@J90]UE:8+4!  #2 P  &0              @ &,,0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $N"IE!]5;D,M $  -(#
M   9              "  7@S  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ 2X*F4!_?!@>T 0  T@,  !D              ( !8S4
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !+@J90P<"9
MC+0!  #2 P  &0              @ %.-P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( $N"IE#=AKM^M $  -(#   9
M  "  3DY  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M2X*F4/2U?RSN 0  9@4  !D              ( !)#L  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !+@J90S7#HG+,!  #2 P  &0
M            @ %)/0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( $N"IE#A]?>_MP$  -(#   9              "  3,_  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 2X*F4&_/F^2S 0
MT@,  !D              ( !(4$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !+@J90(70<TM,!  "<!   &0              @ $+
M0P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $N"IE#-
M<R^\X0$   $%   9              "  15%  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ 2X*F4/>^>NNW 0  T@,  !D
M     ( !+4<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $N"IE 43XK03@0  '46   9              "
M 2Y5  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 2X*F
M4/@.4V*7 0  6 ,  !D              ( !LUD  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !+@J906<PW]^P"  ":"P  &0
M        @ &!6P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( $N"IE"\6U+-2@4  'X>   9              "  :1>  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 2X*F4&8.O<8\ P  4 X
M !D              ( !)60  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !+@J9099;T8RP"   J!@  &0              @ &89P
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $N"IE %BF%A
M$ (  'D%   9              "  ?MI  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ 2X*F4!RWP9]) @  >@<  !D
M ( !0FP  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !+
M@J90+^V\A)4"   4"0  &0              @ '";@  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( $N"IE#JHZC$SP(  &,+   9
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M970T-2YX;6Q02P$"% ,4    " !+@J90AWM(DN<#   [$P  &0
M    @ $P@   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M $N"IE#IFJ?CL@(  .H)   9              "  4Z$  !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ 2X*F4 Q/'C>:4P  >E\! !0
M             ( !-X<  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%
M  @ 2X*F4#3!@W-B @  @ P   T              ( ! ]L  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !+@J90TV-$JPP$  "7'P  #P
M@ &0W0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 2X*F4!\A^M[* 0
MXAP  !H              ( !R>$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ 2X*F4/W0 !J^ 0  [1P  !,              ( !
MR^,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #@ .  Z#P  NN4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6828912016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 135,897<span></span>
</td>
<td colspan="2" class="nump">$ 175,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">357,026<span></span>
</td>
<td colspan="2" class="nump">355,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,491<span></span>
</td>
<td colspan="2" class="nump">14,043<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">504,414<span></span>
</td>
<td colspan="2" class="nump">544,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">60,121<span></span>
</td>
<td colspan="2" class="nump">58,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">43,836<span></span>
</td>
<td colspan="2" class="nump">44,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">66,349<span></span>
</td>
<td colspan="2" class="nump">56,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">4,299<span></span>
</td>
<td colspan="2" class="nump">4,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">4,675<span></span>
</td>
<td colspan="2" class="nump">4,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="nump">4,829<span></span>
</td>
<td colspan="2" class="nump">4,892<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">688,523<span></span>
</td>
<td colspan="2" class="nump">717,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,199<span></span>
</td>
<td colspan="2" class="nump">9,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">19,619<span></span>
</td>
<td colspan="2" class="nump">23,829<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,818<span></span>
</td>
<td colspan="2" class="nump">33,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="nump">51,536<span></span>
</td>
<td colspan="2" class="nump">51,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">3,650<span></span>
</td>
<td colspan="2" class="nump">4,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">82,004<span></span>
</td>
<td colspan="2" class="nump">88,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Notes 6 and 7)</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares were issued and outstanding as of March 31, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 125,262,537 and 124,267,358 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">125<span></span>
</td>
<td colspan="2" class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,055,386<span></span>
</td>
<td colspan="2" class="nump">1,023,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(450,602)<span></span>
</td>
<td colspan="2" class="num">(396,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,610<span></span>
</td>
<td colspan="2" class="nump">1,145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">606,519<span></span>
</td>
<td colspan="2" class="nump">629,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 688,523<span></span>
</td>
<td colspan="2" class="nump">$ 717,802<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812944224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statement of Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>allo-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:allo="http://allogene.com/20200331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="allo-20200331.xsd" xlink:type="simple"/>
    <context id="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic5bdd569810d4befa6a36d1e4004d538_I20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="i42aa16303efb4bc6861242f37d3e85a3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3daf6576012d44c8b3f0de79aadb808c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b243d5d14ca428a81206fb743a2faa3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24719ab8a31244cdb4cba2ecccb072dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87661f5bec634fb2b877c2938198f6a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i749043ca65e44bea947b65e2c95571ac_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i767920b98e2f4003b8475671f78d9345_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9497157f0a8641b5a4e3470cb9b6fd0c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i69502d27e52e465e989f7e07ee489c5f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7a2956e8ab954ea0b941e529700743f1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6173f0f328164026a81e07620570a7af_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i66ce85bfa375439480cf635174a723ff_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i01d2750238b547a5986767e128f298e1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i817b1dd844554db0a5646a5dd9119801_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie98374caa36d418b8ca406c7fd775cf0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i05344e9e256b4ef59dbf389eedbe08a6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i40cd434f10fa4889b2c48316c97c4704_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if197a8d8554d43febd171636f2d48955_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i200487f1142e4fa4b0efb617a113945d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3a7f172d70c2466aba3c80b6dbcb2add_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9b220cfada114841ac5d4351643cf0a7_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifc6459e8c9e94fe7835b12bb81b8b9c9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia3f4f44335274501a6f0ba4b9f3d78e0_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if2d8ec996eb94984af0eecc13ed46271_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8710054b59684a4391833aea00414337_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i95e2b42df48e469fab49a7cae3c52280_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ib5acde4df4b6477ebafbbb5d30553ac7_D20200106-20200117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2020-01-06</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="iacebb076771044bc98c51c446b109263_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2f16cc2983b042dfb0cb862ba0b07d6a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93a112586aa5424895bcba47c2513994_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i40d6b66797f34f81b5840fec178a1bc8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i853b0c71982b4d179054c90adbd2cc10_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1260b9ca85a04e0bae3d00635ba471c8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if4837ec01c954862a0cbeef2ee46566d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if130ef65efeb433abd2824aa7335e2d2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3b7527e5965c407c93e541d90cc5482a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2777e669ef784ebc95aca7676abd3f3f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i81f5a98d93ba478caf983096343142d2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3b6c4c7c5daf45f4babd1352a4271518_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2bc7562bce744e5ea5f471db41840a69_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i363eee17eaa248bbbcb21c694cf72a07_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if3e236ed56584d6a81223bb2f2ab2d5f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibba7a439b13144ebb18a81a73851f2bb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i90490ce088944c1d8583aa65de02a75d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i49cf82683efa4c01a1df81a844831a04_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7720fa13a9c5481da95a3fb62d3f993d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id74207d979464bf4853a5a3515777c63_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i93e27bd09a004d319f93b738f2239aa5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iafa17b9dd5da493ebcc56be63f41e109_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6b1f6c595d5743cc81b052ef7f75068e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1df7b51138624b92826dfe6b7fea694a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i31a451c6e18e41cd9cdd174e7f67d1d4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic600adb00bc948368ce4b74fbe96ddb6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee733965a28948da8136b97f1eddbd10_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c4ef25a178d487e8f1f527c4f4c862b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf0641a17bd2409fa5a15a2678a01bf3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief0866696c6849e992758e967b5a3373_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa95fa7e31a642ad9cd96a1b3fcf9c53_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4de41313418040828be43e5a80c4efe2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64a094d14f3345cf98071f778c000dee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i79f3f7be17bc46db883ba607846df111_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf394f5d90a047168042ea66bcdd28a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37dbdde627f041b198d1ebf46adee969_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id01aefa120cb41b1a07c570b285b6778_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c461309afd84ba1ba2d93c6c1318f70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie2c3f56a38964674b3be5794ce01fbe8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i26d3828189e540c3b1a53ffca0d571b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8580644452b94e12ab9e3485cfc60784_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i792bbadca48943bfaf71a2bb11414136_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17d9949e90384e369f45910b88cec3f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id601068b37f04845aafc46fd43f5e853_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0d8b29ad214b4978b3bc65dd87a1284c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i55f0d72dfa6c42f5bba2b89d78731ebf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i04aad2f3e4fe42c98e0232d3eae8a9d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifcd82b2e8101404ab7f516da762fb5d1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia10fb1c7bf324168ab0a2db735f79147_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia8c15b3ab1e74889b26989029ae6d673_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i364cd7afc1844168ad816a8621088d26_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i01d8447678cb4fc0b136d8049103aa1b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8c64460a47e84af39d4f40bacaa2fd75_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7b8466b8753547e7a17d250705529eae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c611e2c37aa4636b1d74f643ed27edd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i639bc019200d423cac9e1f1b8acfbaa7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ab02fe568304455a85402d84dbb39c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib0de266e8b9e4b318c1b6289ecb6ce00_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iff732cfa26a242859b76df19609edf5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77059c64b65f479fb071a0e986cf7b09_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i80325903deab4700b1323494502a9120_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c1f1460cc8942cf818d575042f8c4f0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i10f2b6782cf247b5a11b92d52590baed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie075cc2a67084ac1b3eb62f94228b0ef_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9ca85fe9deb54d98b46c30a75fb18924_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i790b82aa47544194a8a63de2efdb8636_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9d7a98f96eeb4c94afb207c3aad9d5b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e45882827dc473d9cccdddf46d4bc37_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iccb902fc0cbf494384e4080a72eb2561_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia733fa51ba7647a6aba865395e1556a1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i789c0228925e4672b7ac566e5e3afc54_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i600ae8e97f094c078004eb149339e911_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8c687c20085e4f9daaa84f4f372fadd1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:DevelopmentAndSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i98399c769a4a488aaa46d0a7c26a9054_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib28fed9c91714dbea81ced010fd4dff8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i64e12e6daa2c4fb5b8ad43e1cd9547e8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ResearchServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i73435ce9243740bd8574ccf58e1a1558_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ResearchServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i7c737287cec94ddba5b57cbf684bfb99_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia5d5e7c43ae443da8eacbed133ea82c3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i25eec7c7b62e480a8a24e1d2fc01cb00_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4bf058e9146a44db8d47e1921229a153_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iec4bd58ba39b42698636440287c1b64f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3e0de113752c4ee3912070b56b2b88e7_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2f6403cfdee14280a2a1c6dc64afba04_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i53d07d0342c54b11b26f9a2900615150_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a48ecd5e6aa4995bcfa8af46e4b858e_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="i3a11830e93d74ad8a671b309eacfb9e7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia387f6863fef4d76b7a4661c9545f04d_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="ifdb5da102c704b2ab704e75453c50364_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6012c21655b348b4b23bf36d66ffd9cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4cad33ed23754ac189892f31dc1b6c1a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ClinicalRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5c634926bf9d49b1a097075a247d38eb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5ac8b68de98741d19e6456e14a0805cf_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i9b47b163f76a4417a683c3539110e2f9_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ieeeba5c202074b8680a92945d8d5cdcb_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i1d5b8ad9f2214bb9a3c41b2eb10f54f2_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="ib223d885c64d4b53a8881033526b8151_D20191101-20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="i53599948fe6c4ca5b584914643acddbc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic19af5f089974c2497122fe4a4e2e3dd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i81bb738593bb4a4aa0333b29c524327a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf428979ee4648a58838e99d47fc80b6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie582f6e76ada438881e8098bffd2c1d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5bbdece93a42441ab703824c19120916_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i936160ad8bb942058d8f222ec9ddc536_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic177a9557377487499e270097c358bf7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i521694cbaa114dddb6a6dff0b4c9abb9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idb31faa7f5644ea697201adc41fddd67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i945dc20d171348f08a92572145268721_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic1565ebe58524c9791944236e646ac49_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7f2a6d6310eb4804acffb0d4e70789c4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i7c4dd589aec54659af36f7495218487c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i16de5530e6d44bc99f02f418df776b94_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8ef7c7c1fbbb4a6d8c7680dee4a924e5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic1365263cdfd4531ba6410ef52ae2d7c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i533d042f0e4b4aa0835939c4b7b40375_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i65deebc5365d4675bec1b4bf6d5257f9_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i01f52e60f0bd4993a35a31633444b2b1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8a437f63084d4bd18d9edeff003da5ff_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id52499d716214a2699bbb179be7d9b7c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1ff5875cc6044a67885d7490df6c5659_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ied67c130b61d4499b7927fceb186af36_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i86c84a8b6258472092c7917980204432_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1eea165234764f838579662624ec9d90_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i56aaf1b58d7b4ec7b18900c8eb264775_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic321d0b1fd1c4b0f95aed3cd5340beae_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i69081a2c4b1044628425bb0109c6e671_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i56c3fcf903a048f7b77fd696a381f82e_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i5f17f2b211344d3f82185666cdfd8064_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifae2200f0f404af2a52ee56081d823e3_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i30246310ab084bc99257f27e94986e6b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia2e9df642ead424798c3bcd699e0d11f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i70ed49038db9439d99e49ced4b34596f_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i05acd1d072c943d799c0703a556368b1_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i2664c61460fd4fa8ac2b86b83a9aaef9_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="ibf6da9f07f2d4b2cb4f36dece4d79776_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i34a074fef5cf4808a3421b475b2b6e1f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6952a438f572450bb5403156594291a9_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i445474810986457d86157ac99ce513eb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2b6ed85ff10640e0a2e3c27c4de1f868_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifab11e5afc21498ca4e40dc435770e6f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7e5c7873bcbb436f9297d5dc64e8c936_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iaea9ba03c9b646619b56dd93138eaddd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i164061d208364d798deb08ac4045936a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i493f3fa88aa246efb2e80fa6c3b6d7d7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic90aa7f4abe04f2383035e03129a402e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia7ae26fbb0794fceb415878169f539c2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i72a829b0930b4e63aaf7cd159033b693_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewal">
        <measure>allo:renewal</measure>
    </unit>
    <unit id="board_member">
        <measure>allo:board_member</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl81LTEtMS0xLTA_3c5c847b-3cfb-4ff2-ab02-671baa06a620">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl81LTEtMS0xLTA_ff357e67-b11c-42d7-9d34-2ee335cd5301">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl83LTEtMS0xLTA_5313a180-6cf6-46f0-b510-2df5d705ff4c">false</dei:AmendmentFlag>
    <dei:AmendmentFlag
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl83LTEtMS0xLTA_ce146290-2394-4be8-8f50-1c6f058964aa">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl84LTEtMS0xLTA_54e49ed3-7e9c-4cc5-a258-131a40ce43f0">0001737287</dei:EntityCentralIndexKey>
    <dei:EntityCentralIndexKey
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl84LTEtMS0xLTA_bac79e7b-789f-4b4f-a782-46454d424771">0001737287</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl8xMS0xLTEtMS0w_657400ac-93d9-4f96-888a-2ec2c9499535">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl8xMS0xLTEtMS0w_923ae766-b3f2-4acc-9bd0-b18becbbf3e6">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl8xMi0xLTEtMS0w_2d738991-2fa3-402e-99b5-439601b547bb">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80L2ZyYWc6YTk1NmZjZTgxZDZkNGZkMjliNmMyYjA1MmNjMDgzY2EvdGFibGU6ZDgyMTdkYWFkMjBiNDFkYTk4MzJjZDYzODY1ZDdkYzYvdGFibGVyYW5nZTpkODIxN2RhYWQyMGI0MWRhOTgzMmNkNjM4NjVkN2RjNl8xMi0xLTEtMS0w_77f5a9d0-c899-4798-8c3d-49f5be0e3c24">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMi0xLTEtMS0w_df6e510e-895a-457d-8673-26432ff56386"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMi0yLTEtMS0w_4c56aa4d-4a0a-4cd0-8387-bbf21335215d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMy0xLTEtMS0w_b822c5b2-0013-4238-bde4-e13a086ae724"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMy0yLTEtMS0w_7c4b733c-107d-466d-9499-2a422a9051df"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNC0xLTEtMS0w_943bea65-0cac-41aa-8615-39674b00d555"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNC0yLTEtMS0w_78e2437d-6111-4bc8-8371-ae102aef8553"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNS0xLTEtMS0w_d517d755-a48d-4dd8-876f-ee39c70d0a67"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNS0yLTEtMS0w_32440c3f-6777-4a3f-9ed8-0504c439aabc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNy0xLTEtMS0w_ac9e6bd2-5d6b-4fed-9d1c-73bde6a20c95"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfNy0yLTEtMS0w_a3baa691-2f00-4431-a245-f010e311c4f8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfOC0xLTEtMS0w_97b5245c-88fb-4f84-bd1b-37438b855262"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfOC0yLTEtMS0w_2cfda621-8ddb-4002-b4fb-2a1f3804cdd2"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfOS0xLTEtMS0w_288c4ad4-ed0e-4fdd-beb7-635cb64353ed"
      unitRef="shares">125262537</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfOS0yLTEtMS0w_e6b3a84e-8444-4a76-9a32-6ada028d28cd"
      unitRef="shares">124267358</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMTAtMS0xLTEtMA_ca55e953-f0a3-49b0-b318-6daf953ed5ae"
      unitRef="shares">125262537</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xOS9mcmFnOmVlNjMwNWRkYWViNDQ3ZjVhZGUyYjQzNWZiYmU1MmM1L3RhYmxlOmFiMDk1MTRiZjQ2MzQyMjFhMjE0ZWE3YTJkYTgyOTMyL3RhYmxlcmFuZ2U6YWIwOTUxNGJmNDYzNDIyMWEyMTRlYTdhMmRhODI5MzJfMTAtMi0xLTEtMA_7191bdf6-4ca7-4bf0-8187-26cc8630bdcd"
      unitRef="shares">124267358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yOC9mcmFnOmFjMGRjYmJmNTBlMzQ2NWI4NDJlZDA3MzBkYmJkODc0L3RhYmxlOjVlZmZiNWQ1MjY3MjRjYmM5ZDY0MGQ3YzQ4N2M2YWUyL3RhYmxlcmFuZ2U6NWVmZmI1ZDUyNjcyNGNiYzlkNjQwZDdjNDg3YzZhZTJfMS0yLTEtMS0w_f2bdcdc9-637b-4b48-be76-df3f7964f14b"
      unitRef="usd">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i1d5b8ad9f2214bb9a3c41b2eb10f54f2_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY3Ng_1448f1a5-3854-48ed-9be5-baf156294104">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTE4Mg_4fe0cc3d-a369-4851-b84c-7f351e9ac8c3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8ef7c7c1fbbb4a6d8c7680dee4a924e5_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfMi0yLTEtMS00MzA3_76d239eb-abb8-4d27-aa98-0ac40ebdce44">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic1365263cdfd4531ba6410ef52ae2d7c_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfMi00LTEtMS00MzA3_557281b8-1ce8-47d5-9d36-d342927f0861">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i533d042f0e4b4aa0835939c4b7b40375_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfMy0yLTEtMS00MzA3_d665a2ab-1c36-46db-bb38-05809ebd9836">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i65deebc5365d4675bec1b4bf6d5257f9_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfMy00LTEtMS00MzA3_8a097832-7d9f-446c-a5b8-72126d629bf1">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfNC0yLTEtMS00Mjk5_09e78b19-e800-49c9-bc7b-a6279261c339"
      unitRef="number">0.080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RhYmxlOmNkNGViNDQxNDllMDQzMWZiNDk2NTFhYjEzYjdkNzExL3RhYmxlcmFuZ2U6Y2Q0ZWI0NDE0OWUwNDMxZmI0OTY1MWFiMTNiN2Q3MTFfNS0yLTEtMS00Mjk5_50ab2878-7ef6-4396-8955-e29547dadffe"
      unitRef="number">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i01f52e60f0bd4993a35a31633444b2b1_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83My9mcmFnOmZhNWNlZDZmZjFjNzQ1ZjJhMmZhMjM2ZWI3MDNjMzcxL3RleHRyZWdpb246ZmE1Y2VkNmZmMWM3NDVmMmEyZmEyMzZlYjcwM2MzNzFfNA_f01bbb1b-a4f2-471b-96f8-b73d62230db1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="i69081a2c4b1044628425bb0109c6e671_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0MzgzMg_3cee6d69-25e1-4997-bf53-faf3f51e1036">P3Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:SubleaseIncome
      contextRef="i6952a438f572450bb5403156594291a9_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84NS9mcmFnOmJlMjVlYmM4MWQ1NTQ2ZWJiMTA5N2Q4MGYxNjRmMWRkL3RleHRyZWdpb246YmUyNWViYzgxZDU1NDZlYmIxMDk3ZDgwZjE2NGYxZGRfMzA_663b68d8-2a04-40de-b357-2e93f49d0008"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <dei:DocumentType
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF8xMzk_267f65d1-6e05-4681-bb33-db3663077929">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6MGRiMDdmM2FjZDYzNGQ3YTkzMzBlMDA1MGZiMDZkMDcvdGFibGVyYW5nZTowZGIwN2YzYWNkNjM0ZDdhOTMzMGUwMDUwZmIwNmQwN18wLTAtMS0xLTY0Mw_1f041a89-19c1-4af6-a1de-69321ed355bb">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF83MTQ2ODI1NTgyODE2_cffc8aef-41d5-4ff1-b38d-f9d4bcf8eaa5">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6YzQ3NjBmZWM1MTcyNGRmN2FlNTk1NGE1NDgyNGRmNjgvdGFibGVyYW5nZTpjNDc2MGZlYzUxNzI0ZGY3YWU1OTU0YTU0ODI0ZGY2OF8wLTAtMS0xLTY0NQ_4b841b77-d887-4595-adeb-660652ca2403">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF8zNTM_0533fc89-4f08-43c1-87b3-2b8ddfc7e5dc">001-38693</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF80MTQ_2c3aa228-0a4a-403a-8fe0-e4bec091ff75">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6MmNjNThlZDA4ZmI5NGZkNGFlZjFhNWQ0MTNjYWM1NzgvdGFibGVyYW5nZToyY2M1OGVkMDhmYjk0ZmQ0YWVmMWE1ZDQxM2NhYzU3OF8wLTAtMS0xLTY0OQ_e83c2deb-2371-40cb-8761-9d292a785df9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6MmNjNThlZDA4ZmI5NGZkNGFlZjFhNWQ0MTNjYWM1NzgvdGFibGVyYW5nZToyY2M1OGVkMDhmYjk0ZmQ0YWVmMWE1ZDQxM2NhYzU3OF8wLTItMS0xLTY1MQ_0e97de4e-fc24-4c82-8115-b86f9123e015">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF85ODk1NjA0NjUyNDYw_07d0bc89-8f98-42a9-8caf-7d64645cddd8">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF85ODk1NjA0NjUyNDYx_edf2ee57-4a65-45e9-82f0-8338d1b8c7b9">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF83MTQ2ODI1NTgzMDQ5_604e91e4-80e7-4b10-a6f7-51c2b2a75798">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF85ODk1NjA0NjUyNDY1_6ae10715-87ff-4311-9ca7-b15e9af1fe67">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDE4_55464353-1a0b-4f53-8368-8fd1cbeb37c1">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDIy_c264f609-9243-4d91-b104-68c46cb9ab5b">457-2700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6OTgyNWY2ZjJkY2E2NGI0MGIxMjU5ZmE1YzY1MWNmNmQvdGFibGVyYW5nZTo5ODI1ZjZmMmRjYTY0YjQwYjEyNTlmYTVjNjUxY2Y2ZF8xLTAtMS0xLTY2Ng_bde0e6c6-9db7-4797-acab-02ed248af57e">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6OTgyNWY2ZjJkY2E2NGI0MGIxMjU5ZmE1YzY1MWNmNmQvdGFibGVyYW5nZTo5ODI1ZjZmMmRjYTY0YjQwYjEyNTlmYTVjNjUxY2Y2ZF8xLTEtMS0xLTY2OA_b370397c-7d74-464a-874c-c574fb242d50">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6OTgyNWY2ZjJkY2E2NGI0MGIxMjU5ZmE1YzY1MWNmNmQvdGFibGVyYW5nZTo5ODI1ZjZmMmRjYTY0YjQwYjEyNTlmYTVjNjUxY2Y2ZF8xLTItMS0xLTY3MA_6ca53bc1-8b14-404f-bca8-365017cf0267">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDIz_b099272e-3f12-4d49-b008-bdde011863b8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDI1_7ec81648-ce49-4c62-a129-cf22160bc78a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6NmNlZTY5ZWRmYTc0NGY1YWE4YmFjMWZkZTRiYzdkNDgvdGFibGVyYW5nZTo2Y2VlNjllZGZhNzQ0ZjVhYThiYWMxZmRlNGJjN2Q0OF8wLTAtMS0xLTY4NQ_d9d8e6f0-4d2c-4df3-8c63-5b2e8036e698">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6NmNlZTY5ZWRmYTc0NGY1YWE4YmFjMWZkZTRiYzdkNDgvdGFibGVyYW5nZTo2Y2VlNjllZGZhNzQ0ZjVhYThiYWMxZmRlNGJjN2Q0OF8xLTQtMS0xLTY4OQ_3442d7a1-b4f0-473f-9ef7-dd6b61c1b293">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGFibGU6NmNlZTY5ZWRmYTc0NGY1YWE4YmFjMWZkZTRiYzdkNDgvdGFibGVyYW5nZTo2Y2VlNjllZGZhNzQ0ZjVhYThiYWMxZmRlNGJjN2Q0OF8yLTEtMS0xLTY4Nw_b132cc97-cc65-41f6-84f7-632d58b1fd4a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF83MTQ2ODI1NTgyODQ1_4b2538b0-735e-4fde-8fe6-a347ec99afdf">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic5bdd569810d4befa6a36d1e4004d538_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xL2ZyYWc6YmMyNDlhZjhhNGIzNDRmOGI4ODNhOGNiNTE2ZTdmYWQvdGV4dHJlZ2lvbjpiYzI0OWFmOGE0YjM0NGY4Yjg4M2E4Y2I1MTZlN2ZhZF84Nzk2MDkzMDI0NDI3_fdd61473-367b-4176-8e86-2dd7cdc6857f"
      unitRef="shares">125331495</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMy0xLTEtMS0w_88331008-e33a-4db5-b8a5-bf926f561465"
      unitRef="usd">135897000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMy0zLTEtMS0w_19730378-fffb-446a-a6ce-58998e797b13"
      unitRef="usd">175126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNC0xLTEtMS0w_cb9888b1-1a19-4cb2-ac4d-73f30f356d43"
      unitRef="usd">357026000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNC0zLTEtMS0w_4190bc71-19e9-46da-8b2b-b8bf1692e9f2"
      unitRef="usd">355407000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNS0xLTEtMS0w_ee26067c-fea2-45bd-88ad-5e3eed056b43"
      unitRef="usd">11491000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNS0zLTEtMS0w_7204c4ce-4dfd-4201-a4a5-485fb92a1764"
      unitRef="usd">14043000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNi0xLTEtMS0w_fe7b49f7-4c14-4c71-bc9b-f06fa6e8a3c7"
      unitRef="usd">504414000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNi0zLTEtMS0w_3e2c1b39-dcfd-41c9-9ad2-aea84a1d357c"
      unitRef="usd">544576000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNy0xLTEtMS0w_d5e1a8bb-94b9-4236-b63a-633684b7e40d"
      unitRef="usd">60121000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNy0zLTEtMS0w_75b3f085-32a3-42ca-ac9c-2a466790768e"
      unitRef="usd">58322000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOC0xLTEtMS0w_a7e3bc24-b588-48c7-992b-866dbff794dd"
      unitRef="usd">43836000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOC0zLTEtMS0w_c2fb4451-14a9-493a-bc41-f0aac362dd76"
      unitRef="usd">44495000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOS0xLTEtMS0w_df5c5674-025e-49ce-a50f-bbfb4225d53f"
      unitRef="usd">66349000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOS0zLTEtMS0w_267729df-178c-4f99-9da9-08c858d420e1"
      unitRef="usd">56449000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTAtMS0xLTEtMA_44303252-f501-4afd-92ea-3389a39d8d10"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTAtMy0xLTEtMA_6fdca938-4822-4f97-902b-5eaedc185973"
      unitRef="usd">151000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTEtMS0xLTEtMA_8a2668d3-dadf-4d2a-aac6-ad8c593c78df"
      unitRef="usd">4299000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTEtMy0xLTEtMA_65611136-94ce-4f40-b42a-634c2ec07a01"
      unitRef="usd">4299000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTItMS0xLTEtMA_f3f7507e-0f74-4700-ace9-3336f402dfe9"
      unitRef="usd">4675000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTItMy0xLTEtMA_fd6b51e2-07a6-4019-bc10-3ebf9006a359"
      unitRef="usd">4618000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMS0xLTEtNzE4_7c701b96-72bd-45fa-90ab-14a4dff530de"
      unitRef="usd">4829000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtODM_3a8f62bf-21ae-4179-ad0f-b5632893bbb7"
      unitRef="usd">4892000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMS0xLTEtMA_e2383eb9-e3a5-4b9c-8f4b-2d761e2d443f"
      unitRef="usd">688523000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtMA_3b8f6973-beef-4821-be9f-842b90aa6f3d"
      unitRef="usd">717802000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTYtMS0xLTEtMA_283a0e4a-94db-47ba-a047-325c2c7f96e1"
      unitRef="usd">7199000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTYtMy0xLTEtMA_a5219db8-6479-4e10-b6c3-6b8ba31424c3"
      unitRef="usd">9250000</us-gaap:AccountsPayableCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTctMS0xLTEtMA_f9ee452a-81e6-495f-b174-1c18e998547c"
      unitRef="usd">19619000</allo:AccruedAndOtherLiabilitiesCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTctMy0xLTEtMA_16ee153e-c141-48c9-98ce-f7206b3a4d50"
      unitRef="usd">23829000</allo:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTgtMS0xLTEtMA_cf5eab1e-24b0-480c-9ccb-8c258a249627"
      unitRef="usd">26818000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTgtMy0xLTEtMA_81b602ae-51d9-4c69-b1c9-c803ec52daad"
      unitRef="usd">33079000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTktMS0xLTEtMA_1fb5b932-ec8e-4b5e-b4a8-97e519c05cfc"
      unitRef="usd">51536000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTktMy0xLTEtMA_87a46259-4c6c-4db3-b6f9-c82bb6d3e074"
      unitRef="usd">51349000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjAtMS0xLTEtMA_9b5b7ff2-194a-4522-a7ba-ede9d2eea951"
      unitRef="usd">3650000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjAtMy0xLTEtMA_1394a926-75d4-427f-a343-84f5ae0e6eff"
      unitRef="usd">4351000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjEtMS0xLTEtMA_2a8c0aee-96c2-41ff-883c-ba870e7ce605"
      unitRef="usd">82004000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjEtMy0xLTEtMA_13d32409-3d89-4e8f-ad03-a1d493d78e05"
      unitRef="usd">88779000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjItMS0xLTEtMA_02a38a36-820e-4ec4-9d9a-558e978c0212"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjItMy0xLTEtMA_8b82c55b-7a84-40c6-8c00-231a48d41b4d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjQtMS0xLTEtMA_38d1b268-ccd8-41bb-8320-36de1e4dadc0"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjQtMy0xLTEtMA_5443e109-d7f3-458b-9032-8f06e3e3c545"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjUtMS0xLTEtMA_a47725d3-eb01-4814-8c3c-e234e2a0fb2c"
      unitRef="usd">125000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjUtMy0xLTEtMA_09558e9b-3c8f-445b-9177-a021bc68441f"
      unitRef="usd">124000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjYtMS0xLTEtMA_77086fb3-df58-4765-bdd3-ee560d285aa6"
      unitRef="usd">1055386000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjYtMy0xLTEtMA_3344a037-4917-4d6f-8623-c66f16b6fdfc"
      unitRef="usd">1023876000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjctMS0xLTEtMA_7b8eb25f-4e43-421b-9d83-2e2631fc0a71"
      unitRef="usd">-450602000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjctMy0xLTEtMA_64c8cf6c-0199-4bb8-9d42-b7039e300df2"
      unitRef="usd">-396122000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjgtMS0xLTEtMA_c3a14aa5-d569-4785-bc8f-a11041024463"
      unitRef="usd">1610000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjgtMy0xLTEtMA_52a0de29-628f-48a4-9b43-a03917898152"
      unitRef="usd">1145000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjktMS0xLTEtMA_ba3971df-9573-4039-9151-a8d031dba88b"
      unitRef="usd">606519000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjktMy0xLTEtMA_16c931b2-01bb-4c23-9851-4a88affb89ca"
      unitRef="usd">629023000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMzAtMS0xLTEtMA_4c6ee7bc-6be1-4cb6-8616-8712758b56c3"
      unitRef="usd">688523000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMzAtMy0xLTEtMA_25c2142d-611d-401e-b3b3-bc2affec8f73"
      unitRef="usd">717802000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMy0xLTEtMS0w_0dfcb0af-dd7b-496c-9c2a-b07e6b5e50c9"
      unitRef="usd">42042000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMy0zLTEtMS0w_301824ce-2039-400d-b06f-960e6253517d"
      unitRef="usd">23403000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNC0xLTEtMS0w_7d590733-fde8-4fb4-8755-3216cf2851cc"
      unitRef="usd">15641000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNC0zLTEtMS0w_8b63eb3e-0938-4030-8d3d-f011efbf7752"
      unitRef="usd">13058000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNS0xLTEtMS0w_fac78693-906a-45a3-9b02-7fb9144caf97"
      unitRef="usd">57683000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNS0zLTEtMS0w_6138e1d5-11d0-445b-8b4e-f472e0ceeeef"
      unitRef="usd">36461000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNi0xLTEtMS0w_3d3e5abc-1e56-4db6-9709-a286e9844da0"
      unitRef="usd">-57683000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfNi0zLTEtMS0w_827adc92-6f32-49de-875c-1a29db61728d"
      unitRef="usd">-36461000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMS0xLTEtMA_e4d4dde6-583c-499b-ac6f-7682a5f0f5b1"
      unitRef="usd">3261000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMy0xLTEtMA_03340b92-282c-44db-b3a9-fc3a9491b89c"
      unitRef="usd">4825000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherExpenses
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMS0xLTEtMTE0_da804c14-5507-4b24-b24c-feb2355b7ae8"
      unitRef="usd">58000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMy0xLTEtMTE0_535f6952-becd-452f-b177-d50d32bbc811"
      unitRef="usd">0</us-gaap:OtherExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMS0xLTEtMzU2Mw_d7495ea3-8152-4e30-9c02-e0279cc65f46"
      unitRef="usd">3203000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTAtMy0xLTEtMzU2Mw_cbde23d3-62ed-4843-8588-43f788e9200d"
      unitRef="usd">4825000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTEtMS0xLTEtMA_9fe1c62b-3fc4-4551-b8b7-4aa3814be630"
      unitRef="usd">-54480000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTEtMy0xLTEtMA_0f499474-3e78-4324-96b6-91accf0a2f9e"
      unitRef="usd">-31636000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTItMS0xLTEtMA_0198ec80-26d5-4540-93a5-b9fcb02bd423"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTItMy0xLTEtMA_ad4ceb59-13f0-488d-bc04-4fbc30360edd"
      unitRef="usd">-50000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTMtMS0xLTEtMA_23eaf08f-5c16-4291-b6b6-26f6a68ce7e6"
      unitRef="usd">-54480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTMtMy0xLTEtMA_ba786467-6c64-4dba-9ed2-b5308f635f60"
      unitRef="usd">-31586000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTUtMS0xLTEtMA_a45d031e-b1c8-4ec7-94d2-33679c2a369f"
      unitRef="usd">465000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTUtMy0xLTEtMA_db2870a0-c7e3-4f85-886d-ca20fdefbf1f"
      unitRef="usd">1099000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTYtMS0xLTEtMA_f2aecc98-5319-4f97-aa26-b7b04ceba9c3"
      unitRef="usd">-54015000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTYtMy0xLTEtMA_799396ef-4be5-4eb3-818d-392801272cf1"
      unitRef="usd">-30487000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTctMS0xLTEtMA_b1d5801e-8a40-4887-806d-02a9ff898565"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTctMy0xLTEtMA_4509b67d-d396-4156-a6e5-a047bfdf011a"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTgtMS0xLTEtMA_e0ea7d84-068c-4e52-b1c8-1de2e46310a6"
      unitRef="shares">108963522</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yMi9mcmFnOjgwZjFkMWQ2NmM4MzRjNWZhOGExNmY4NDk0YTUwZmFlL3RhYmxlOjhmMDY2MGU5MWVjYzQwM2ViMTFmNGE2MDdhMTMzZjM3L3RhYmxlcmFuZ2U6OGYwNjYwZTkxZWNjNDAzZWIxMWY0YTYwN2ExMzNmMzdfMTgtMy0xLTEtMA_5a9d2f95-dc74-42ea-a63a-02376798e52e"
      unitRef="shares">97315890</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3daf6576012d44c8b3f0de79aadb808c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi04LTEtMS0w_a463a3d8-e939-4c64-8ead-98eb109a22da"
      unitRef="shares">124267358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3daf6576012d44c8b3f0de79aadb808c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0xMC0xLTEtMA_8be4e9e9-4591-4c5b-b900-b5ffb7c537f5"
      unitRef="usd">124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b243d5d14ca428a81206fb743a2faa3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0xNC0xLTEtMA_3c7b894a-c9ab-44fb-979b-c3dddf10af69"
      unitRef="usd">1023876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24719ab8a31244cdb4cba2ecccb072dc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0xNi0xLTEtMA_f97490a5-5f5a-4116-a3a6-230b6f5230fe"
      unitRef="usd">-396122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87661f5bec634fb2b877c2938198f6a7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0xOC0xLTEtMA_efa714fe-68fa-438d-bbd4-83a0ce571417"
      unitRef="usd">1145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMi0yMC0xLTEtMA_eba98ffa-cbcd-4fe8-b036-b0a8bde5dfe5"
      unitRef="usd">629023000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMy04LTEtMS0w_483b6acf-10ec-48a1-93ef-c00c1c90fe2a"
      unitRef="shares">339775</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMy0xMC0xLTEtMA_1c88b84a-75bd-4a99-bacd-559cdb3e4e8a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMy0xNC0xLTEtMA_7d0fa841-0267-46f9-a7ff-15de2b564f96"
      unitRef="usd">303000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfMy0yMC0xLTEtMA_b79aac40-babe-4a38-8ad7-9bd27e9b1e58"
      unitRef="usd">303000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNC0xNC0xLTEtMA_b59b4bba-77c8-4046-97e7-4408d33cfd8d"
      unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNC0yMC0xLTEtMA_641d93c4-aaad-4335-859b-a57083f94a0a"
      unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNS0xNC0xLTEtMA_508d260b-4468-4d1c-8643-78b63789bc8c"
      unitRef="usd">14215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNS0yMC0xLTEtMA_11fb4eac-2f10-4807-880e-cf385e1da8d9"
      unitRef="usd">14215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNi04LTEtMS0w_d7ddfa14-a11e-4b38-bcf9-6a3d04981507"
      unitRef="shares">84565</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNi0xNC0xLTEtMA_67f8cc5d-b55b-481f-a97e-252e0b5657c5"
      unitRef="usd">1438000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNi0yMC0xLTEtMA_9c7cef7a-d2b6-44d1-9d3f-90ba5d5f49ae"
      unitRef="usd">1438000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0xLTEtMS0xMzU_9f7c96ec-f9b2-41d0-aa29-9f7b20f4a6d3"
      unitRef="shares">570839</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4d0016e0811f46dfbdc594a86896a577_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0zLTEtMS0xMzU_73ad705a-e501-478c-abdd-6769bd25434b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1bd394ae32a441ca8989a3022c2c91b2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy01LTEtMS0xMzU_3e8f6255-09b7-4834-abd4-7cc0d2194089"
      unitRef="usd">14844000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0xMS0xLTEtMTM1_f8f54242-eab7-4c09-9533-496ea41da3eb"
      unitRef="usd">14845000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="i749043ca65e44bea947b65e2c95571ac_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0xNi0xLTEtMA_6fb33f5e-2c58-4065-9827-8eeee6f0ba7a"
      unitRef="usd">-54480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfNy0yMC0xLTEtMA_df4df3d6-87ad-494d-a47e-f9aad7e54e0d"
      unitRef="usd">-54480000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i767920b98e2f4003b8475671f78d9345_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOC0xOC0xLTEtMA_e61c18bb-8d2f-4b5f-a98c-1eeae42d6410"
      unitRef="usd">465000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOC0yMC0xLTEtMA_d34edc9d-ff9f-4c82-b266-54e6b6ce064d"
      unitRef="usd">465000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9497157f0a8641b5a4e3470cb9b6fd0c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS04LTEtMS0w_33bc1274-ee65-466e-acc8-2e2195f9eadd"
      unitRef="shares">125262537</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9497157f0a8641b5a4e3470cb9b6fd0c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0xMC0xLTEtMA_a74a0832-e163-4e9d-9b7b-af3a821cfdb3"
      unitRef="usd">125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69502d27e52e465e989f7e07ee489c5f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0xNC0xLTEtMA_bf608c28-9fbb-45fe-bbe2-0edbdd900cb2"
      unitRef="usd">1055386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a2956e8ab954ea0b941e529700743f1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0xNi0xLTEtMA_7d051b95-fef4-44a1-917f-8bbb7090f512"
      unitRef="usd">-450602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6173f0f328164026a81e07620570a7af_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0xOC0xLTEtMA_3bc154a9-3ca6-4920-b2a5-99082a27593b"
      unitRef="usd">1610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjI3ZmJiMDA3YjdmNjQxYjdiMzliMzFmZDQ2OTZlY2E0L3RhYmxlcmFuZ2U6MjdmYmIwMDdiN2Y2NDFiN2IzOWIzMWZkNDY5NmVjYTRfOS0yMC0xLTEtMA_b7c07cb6-fc4d-4991-a7cc-26d60f2141ef"
      unitRef="usd">606519000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i66ce85bfa375439480cf635174a723ff_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi04LTEtMS0w_70eda19a-6b9d-42fb-92de-77127298e143"
      unitRef="shares">121482671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i66ce85bfa375439480cf635174a723ff_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0xMC0xLTEtMA_8a7449f7-2945-4888-9e68-46b08522b2f3"
      unitRef="usd">121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01d2750238b547a5986767e128f298e1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0xNC0xLTEtMA_31d6d9aa-948b-4c95-ab49-672f5ee12056"
      unitRef="usd">914265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i817b1dd844554db0a5646a5dd9119801_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0xNi0xLTEtMA_114c62d5-e30d-4283-9677-3998b56b6ab5"
      unitRef="usd">-211528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie98374caa36d418b8ca406c7fd775cf0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0xOC0xLTEtMA_231d26e4-7f90-4300-b914-7026fbe5e520"
      unitRef="usd">306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05344e9e256b4ef59dbf389eedbe08a6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMi0yMC0xLTEtMA_3b43c4b5-cb50-4aa9-9246-df6557860617"
      unitRef="usd">703164000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i40cd434f10fa4889b2c48316c97c4704_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMy0xNC0xLTEtMA_e2f58b37-ffa7-48fa-99d2-0244af8e5334"
      unitRef="usd">7867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfMy0yMC0xLTEtMA_4f3b6094-2c00-46cd-9573-ea28094c2d9c"
      unitRef="usd">7867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if197a8d8554d43febd171636f2d48955_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNC04LTEtMS0w_f8e5fd1a-9f98-44eb-9eb6-becf80995f56"
      unitRef="shares">44649</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i40cd434f10fa4889b2c48316c97c4704_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNC0xNC0xLTEtMA_354358c2-9102-43c9-bd91-8983fd2b6070"
      unitRef="usd">684000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNC0yMC0xLTEtMA_0f56f973-4ec0-4424-a05f-9cb2531d3478"
      unitRef="usd">684000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i200487f1142e4fa4b0efb617a113945d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNS0xNi0xLTEtMA_3d741618-9345-46aa-a9ba-5f2f0f2b10aa"
      unitRef="usd">-31586000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNS0yMC0xLTEtMA_403bd614-448d-4e4c-9a57-8720439f76ad"
      unitRef="usd">-31586000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3a7f172d70c2466aba3c80b6dbcb2add_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNy0xOC0xLTEtMA_a98f3ffe-3cde-4cb9-a8c7-0685c09656f8"
      unitRef="usd">1099000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfNy0yMC0xLTEtMA_c0a79016-2425-4513-9a0b-a6e2f575f9a4"
      unitRef="usd">1099000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9b220cfada114841ac5d4351643cf0a7_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC04LTEtMS0w_ff75ef0c-36c8-485c-a34a-ca251b9f789b"
      unitRef="shares">121527320</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9b220cfada114841ac5d4351643cf0a7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0xMC0xLTEtMA_d3fdba38-b24d-44d1-85a6-6dcdbaf86d01"
      unitRef="usd">121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc6459e8c9e94fe7835b12bb81b8b9c9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0xNC0xLTEtMA_cba48bf8-88f3-4563-b763-9a732ba120d7"
      unitRef="usd">922816000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3f4f44335274501a6f0ba4b9f3d78e0_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0xNi0xLTEtMA_364db832-4742-4283-868e-1813a0815d22"
      unitRef="usd">-243114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2d8ec996eb94984af0eecc13ed46271_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0xOC0xLTEtMA_d19d825b-1112-4029-8c59-ea4838427c8c"
      unitRef="usd">1405000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8710054b59684a4391833aea00414337_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8yNS9mcmFnOjk4ZmZiMmU4MmQ0MDRhMmU5YmVlNGExNzIxZGFlMjY1L3RhYmxlOjE3MDI5Zjc3ZDAyMDQzN2Y5NTVkNzU5MDk3NWM3ZGZlL3RhYmxlcmFuZ2U6MTcwMjlmNzdkMDIwNDM3Zjk1NWQ3NTkwOTc1YzdkZmVfOC0yMC0xLTEtMA_9c16fddd-9811-4eb9-89d2-9f1a2beb97d2"
      unitRef="usd">681228000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMy0xLTEtMS0w_8e4a067c-a268-4f26-b5be-afdeb20e8c2a"
      unitRef="usd">-54480000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMy0zLTEtMS0w_d6912687-4491-4dea-a13a-50e302102237"
      unitRef="usd">-31586000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNi0xLTEtMS0w_18e30120-fce5-4271-8a5c-7d33c60aa797"
      unitRef="usd">14215000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNi0zLTEtMS0w_c9a9d032-ea7e-4c8d-894a-d460fa058c64"
      unitRef="usd">7867000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNy0xLTEtMS0w_97b66e30-f0b3-4b93-85d8-be1b0ed54a8c"
      unitRef="usd">151000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNy0zLTEtMS0w_2dd6a66a-46d0-4b2c-84f4-e0a320b1c62d"
      unitRef="usd">151000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfOC0xLTEtMS0w_01662e9f-190e-48ab-99bd-3e357eaf6250"
      unitRef="usd">1893000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfOC0zLTEtMS0w_76037e07-25a9-41f9-8242-5ca358a4dc58"
      unitRef="usd">544000</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfOS0xLTEtMS0w_e7f80da9-e2e9-4610-805c-6d9d5c11f366"
      unitRef="usd">207000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfOS0zLTEtMS0w_0013026d-b29d-4653-882a-7893bf43bbba"
      unitRef="usd">1223000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:LeaseAndRentalExpense
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTAtMS0xLTEtMA_0e81f06c-e71f-448e-9227-8195aaf18f9c"
      unitRef="usd">718000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTAtMy0xLTEtMA_262ef924-69bf-49d2-b7f8-cdfc95190891"
      unitRef="usd">1275000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTMtMS0xLTEtMA_567c81ea-ccc4-4358-ba05-5bfd14777d0d"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTMtMy0xLTEtMA_a16a86db-9e27-4f84-b8cb-f30ac0b9e5fc"
      unitRef="usd">-50000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTEtMS0xLTEtMjgz_a77b8e14-3547-4ffe-aa9e-4056aaba813a"
      unitRef="usd">-64000</allo:IncomeLossFromCostMethodInvestment>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTEtMy0xLTEtMjgz_cae1fb57-4aab-4e03-899f-da5241a43d06"
      unitRef="usd">0</allo:IncomeLossFromCostMethodInvestment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTUtMS0xLTEtMA_187dbedf-86dc-42b2-8176-eec1d7e640bf"
      unitRef="usd">-2552000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTUtMy0xLTEtMA_f1ca72ec-7eed-426f-b33b-e3c32f2c8313"
      unitRef="usd">1892000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTYtMS0xLTEtMA_f444aa26-911c-4dc6-9486-955866276a2b"
      unitRef="usd">57000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTYtMy0xLTEtMA_48ed48e6-c84d-454b-93ea-d76b4345507f"
      unitRef="usd">188000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTctMS0xLTEtMA_c9b24969-a66d-4e2f-b633-6934149448de"
      unitRef="usd">-1044000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTctMy0xLTEtMA_f617efc2-ef14-49fe-8644-0b03df753c1e"
      unitRef="usd">-348000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTgtMS0xLTEtMA_d5ffc30c-63b5-4d51-aa64-a399858c3c09"
      unitRef="usd">-3913000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTgtMy0xLTEtMA_52dab935-3104-4106-a394-02979eddad10"
      unitRef="usd">-4095000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTktMS0xLTEtMA_6b7b07c9-992d-4f47-9abe-eb2c51db903b"
      unitRef="usd">-701000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMTktMy0xLTEtMA_02e25543-088e-44f4-9036-9d080cb86a26"
      unitRef="usd">-711000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjAtMS0xLTEtMA_0c3b4cbd-a1ee-43f3-a63a-b2f7c4d5d9f7"
      unitRef="usd">-40809000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjAtMy0xLTEtMA_2c2395a8-df9d-4b0a-8211-a4579b294fad"
      unitRef="usd">-30256000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjItMS0xLTEtMA_07ba44e7-8027-47bd-bf9b-5e00ab8656b5"
      unitRef="usd">12253000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjItMy0xLTEtMA_93870386-08cd-4aae-8142-64b1c43f2793"
      unitRef="usd">10423000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjQtMS0xLTEtMA_791ae932-ccae-4c1a-8d13-018430ff5de2"
      unitRef="usd">120261000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjQtMy0xLTEtMA_45f8f15c-4fb8-4523-9f4b-e894225af34c"
      unitRef="usd">95708000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjUtMS0xLTEtMA_49176044-16b1-4de4-9ec6-3ae070c3a6c7"
      unitRef="usd">123015000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjUtMy0xLTEtMA_61fb8405-9dea-4379-a6cf-828e789bb30f"
      unitRef="usd">52397000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjYtMS0xLTEtMA_5e1d1648-4907-4e9e-b6df-d807dd7ee1a5"
      unitRef="usd">-15007000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjYtMy0xLTEtMA_ebc8bd63-13f0-42b3-b2c3-31377c828bdf"
      unitRef="usd">32888000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzItMS0xLTEtMA_4bf1f115-053a-450f-9451-b6151260b9ea"
      unitRef="usd">14845000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzItMy0xLTEtMA_32bd4b8f-56cc-48db-9385-0faf7628747e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjYtMS0xLTEtNzYz_01039699-8978-4a7d-be6c-5599130c6896"
      unitRef="usd">303000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMjYtMy0xLTEtNzYz_f8a0f241-3463-4099-b566-d58f391e8dae"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromStockPlans
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzMtMS0xLTEtMA_dc145671-9f15-436a-aefb-ccee21181b4e"
      unitRef="usd">1438000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzMtMy0xLTEtMA_22c082d2-4049-442f-8fb5-a80ecdcba6c8"
      unitRef="usd">684000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzQtMS0xLTEtMA_2510fb85-c6e2-46fc-a3e7-ea701460080a"
      unitRef="usd">16586000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzQtMy0xLTEtMA_b6059ae6-77d7-47dd-b53e-6e9e41fa43b4"
      unitRef="usd">684000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzUtMS0xLTEtMA_123e83ce-49a3-4c1a-948e-d215dc8f20e1"
      unitRef="usd">-39230000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzUtMy0xLTEtMA_77717191-4304-43e0-8f84-b5dd47397b5b"
      unitRef="usd">3316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzYtMS0xLTEtMA_b9726b67-82e8-4304-9621-692ab9aec9f8"
      unitRef="usd">179425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i05344e9e256b4ef59dbf389eedbe08a6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzYtMy0xLTEtMA_807c2983-b39d-4672-a6db-09dd83c68971"
      unitRef="usd">93731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzctMS0xLTEtMA_c212ddfe-f633-436f-8de8-ac36dc129d54"
      unitRef="usd">140195000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8710054b59684a4391833aea00414337_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzctMy0xLTEtMA_ba358622-a153-4bbb-8565-5aea6ded77bd"
      unitRef="usd">97047000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzktMS0xLTEtMA_3b48f00e-09d0-4d51-8103-2dae949b027f"
      unitRef="usd">4208000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfMzktMy0xLTEtMA_d322418d-b169-46e0-9c76-9c128ef08bd0"
      unitRef="usd">5134000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNDQtMS0xLTEtMA_2af661d0-3971-4a0c-ae10-3770186a6c9a"
      unitRef="usd">1396000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNDQtMy0xLTEtMA_c4f5e49c-872c-4a25-a66a-da0f2dda0082"
      unitRef="usd">391000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNDUtMS0xLTEtMA_c70ef285-3c01-448e-8c4d-f7a0d2a193c6"
      unitRef="usd">532000</allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances>
    <allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zMS9mcmFnOmQ3OTMwZTFmOWMxZDQwOTRhNzA1YWE2NmFjYWY3YzRlL3RhYmxlOjFmODQ4NzhhNTIwODQ3M2E5Y2I0NDYyYTQwZjliMmMyL3RhYmxlcmFuZ2U6MWY4NDg3OGE1MjA4NDczYTljYjQ0NjJhNDBmOWIyYzJfNDUtMy0xLTEtMA_60ee4e24-eda2-4caf-a961-e81165f4068b"
      unitRef="usd">0</allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances>
    <us-gaap:NatureOfOperations
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfNzE0NjgyNTU5NDg4NA_738ef1e2-38fc-4836-8d72-3dcbab67487a">Description of Business&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Public Offerings &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0&#160;million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. In January 2020, the Company sold an aggregate of 570,839 shares of common stock in ATM offerings resulting in net proceeds of $14.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Need for Additional Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#x2019;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of $553.0 million as of March&#160;31, 2020. Since inception through March&#160;31, 2020, the Company has incurred cumulative net losses of $450.6 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed financial statements are filed with the Securities and Exchange Commission (SEC). &lt;/span&gt;&lt;/div&gt;In March 2020, the World Health Organization declared the global novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 outbreak on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#x2019;s results may be adversely affected.</us-gaap:NatureOfOperations>
    <allo:StockIssuanceMaximumValue
      contextRef="i95e2b42df48e469fab49a7cae3c52280_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfOTg5NTYwNDY2MjE3NQ_221ddd31-be77-4057-a025-b7e79c30bc74"
      unitRef="usd">250000000.0</allo:StockIssuanceMaximumValue>
    <allo:StockIssuanceMaximumCompensationDueToThirdPartyPercent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfOTg5NTYwNDY2MjE5MQ_e452fbc7-5d7e-4f23-8700-de60c5eb68ad"
      unitRef="number">0.030</allo:StockIssuanceMaximumCompensationDueToThirdPartyPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib5acde4df4b6477ebafbbb5d30553ac7_D20200106-20200117"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfOTg5NTYwNDY2MjIzNw_dcdbd92c-b4e6-4e48-95fd-24f8b71f4f7c"
      unitRef="shares">570839</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib5acde4df4b6477ebafbbb5d30553ac7_D20200106-20200117"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfOTg5NTYwNDY2MjI0Ng_0f2fbcd3-7b59-4edf-a13e-442d9a094339"
      unitRef="usd">14800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfMTc3MA_cd8badf0-eb5b-4cc8-b68f-6e4c9ab26984"
      unitRef="usd">553000000.0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8zNy9mcmFnOjk5NDRjNWVmNzg2ODQ4NzM5ZGRjZWZhZmYzOGIxMzBlL3RleHRyZWdpb246OTk0NGM1ZWY3ODY4NDg3MzlkZGNlZmFmZjM4YjEzMGVfMTg2MQ_dccede9e-df62-411e-95c9-0de08522b64d"
      unitRef="usd">-450600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzYzNg_a83dc3a5-bddc-4687-9dbe-90712c89bb90">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&#x2019;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The condensed balance sheet as of March&#160;31, 2020, the condensed statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed statements of stockholders&#x2019; equity as of March&#160;31, 2020 and 2019, the condensed statements of cash flows for the three months ended March&#160;31, 2020 and 2019, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;December&#160;31, 2020, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and related notes for the year ended December&#160;31, 2019, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February 27, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2020, as compared to the significant accounting policies described in Note 1 of the &#x201c;Notes to Financial Statements&#x201d; in the Company&#x2019;s audited financial statements included in its Annual Report, with the exception of the recently adopted accounting pronouncements in the section below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&#x2014;Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. This standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted beginning the first quarter of 2019. The Company&#x2019;s financial instruments that are in the scope of ASU 2016-13 include, but are not limited to, other receivables and available-for-sale debt securities. The Company adopted this standard on January 1, 2020 and applied the modified retrospective approach. Adoption of the new guidance had no significant impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles &#x2013; Goodwill and other &#x2013; Internal-Use Software (Subtopic 350-40)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard on January 1, 2020, on a prospective basis for applicable implementation costs. Adoption of the new guidance had no significant impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU 2018-18,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard on January 1, 2020. Adoption of the new guidance had no significant impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued Accounting Standards Update No. 2019-12,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company early adopted this standard&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;as of January 1, 2020 on a prospective basis in accordance with ASC 250, Accounting Changes and Error Corrections. The adoption resulted in the Company no longer needing to determine the tax effect from unrealized gains on available for sale securities, which previously had been disclosed in the condensed statement of operations as a benefit from income taxes. The impact of the adoption in the three months ended March 31, 2020 is that the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;benefit from income taxes in the condensed statement of operations and comprehensive loss is zero compared to recognition of a $0.1&#160;million tax benefit for the three months ended March 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, the FASB issued Accounting Standard Update No. 2020-01, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments &#x2013; Equity Securities (Topic 321), Investments &#x2013; Equity Method and Joint Ventures (Topic 323)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which clarifies the interactions between topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance will be effective for the Company in the first quarter of 2021, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNDUxNw_a783282a-b20c-4912-9932-a0aefcd63777">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&#x2019;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The condensed balance sheet as of March&#160;31, 2020, the condensed statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed statements of stockholders&#x2019; equity as of March&#160;31, 2020 and 2019, the condensed statements of cash flows for the three months ended March&#160;31, 2020 and 2019, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending &lt;/span&gt;&lt;/div&gt;December&#160;31, 2020, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and related notes for the year ended December&#160;31, 2019, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February 27, 2020.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNDUyMQ_011b5377-7470-47ba-a97d-990e751884ae">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <allo:ChangesInSignificantAccountingPoliciesPolicyTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNDUyMg_69620c0c-5e73-4e08-a746-0d314bd8e190">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2020, as compared to the significant accounting policies described in Note 1 of the &#x201c;Notes to Financial Statements&#x201d; in the Company&#x2019;s audited financial statements included in its Annual Report, with the exception of the recently adopted accounting pronouncements in the section below.&lt;/span&gt;&lt;/div&gt;</allo:ChangesInSignificantAccountingPoliciesPolicyTextBlock>
    <allo:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzYzNw_ccf6c2e8-0f48-4c0e-aa7a-12e22cf5a543">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&#x2014;Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. This standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted beginning the first quarter of 2019. The Company&#x2019;s financial instruments that are in the scope of ASU 2016-13 include, but are not limited to, other receivables and available-for-sale debt securities. The Company adopted this standard on January 1, 2020 and applied the modified retrospective approach. Adoption of the new guidance had no significant impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles &#x2013; Goodwill and other &#x2013; Internal-Use Software (Subtopic 350-40)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard on January 1, 2020, on a prospective basis for applicable implementation costs. Adoption of the new guidance had no significant impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU 2018-18,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard on January 1, 2020. Adoption of the new guidance had no significant impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued Accounting Standards Update No. 2019-12,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company early adopted this standard&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;as of January 1, 2020 on a prospective basis in accordance with ASC 250, Accounting Changes and Error Corrections. The adoption resulted in the Company no longer needing to determine the tax effect from unrealized gains on available for sale securities, which previously had been disclosed in the condensed statement of operations as a benefit from income taxes. The impact of the adoption in the three months ended March 31, 2020 is that the &lt;/span&gt;&lt;/div&gt;benefit from income taxes in the condensed statement of operations and comprehensive loss is zero compared to recognition of a $0.1&#160;million tax benefit for the three months ended March 31, 2019.</allo:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzY0NQ_7930a47f-5cbe-4291-a29a-06fdcfdcdf09"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzY0OQ_72dbd0d6-292c-4120-9155-fb3bbcb8212a"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <allo:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80My9mcmFnOjE3NWJhYjdkYTEzNjRiZjFiZjM2ZDE0N2Y2OGRiYTAwL3RleHRyZWdpb246MTc1YmFiN2RhMTM2NGJmMWJmMzZkMTQ3ZjY4ZGJhMDBfNzE0NjgyNTU5NzYzOA_b2c3171c-f412-448a-884f-047b8b67cdc4">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, the FASB issued Accounting Standard Update No. 2020-01, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments &#x2013; Equity Securities (Topic 321), Investments &#x2013; Equity Method and Joint Ventures (Topic 323)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which clarifies the interactions between topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance will be effective for the Company in the first quarter of 2021, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.&lt;/span&gt;&lt;/div&gt;</allo:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfODky_99d20754-48c3-4c57-9820-c066de0c1dd4">&lt;div style="text-indent:-31.5pt;padding-left:31.5pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs except for investments in U.S treasury securities which are classified as Level 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no Level 3 assets or liabilities as of March&#160;31, 2020 and as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;293,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;539,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.784%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;231,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;"&gt;Included within cash and cash equivalents on the Company&#x2019;s balance sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iacebb076771044bc98c51c446b109263_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfNDI3_4235526a-cecb-4ee5-a845-eb8ab9738bc5"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2f16cc2983b042dfb0cb862ba0b07d6a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfNDI3_6112e11e-7acf-4a36-a9fe-d8f77a995777"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f16cc2983b042dfb0cb862ba0b07d6a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfNDI3_7b7bcca1-d81d-40fb-9587-91d9daafb0ea"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iacebb076771044bc98c51c446b109263_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfNDI3_98269e50-dba1-474b-9a39-5077cd0d53eb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RleHRyZWdpb246MjEwOTI4YjQ3YzY4NGNhMmJhM2ZjZjQ4NmE2YTBiNGNfODkz_6a93a9e0-b9ed-40d3-81bd-fce2640401aa">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;293,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;539,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.784%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;231,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;"&gt;Included within cash and cash equivalents on the Company&#x2019;s balance sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i93a112586aa5424895bcba47c2513994_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNC0xLTEtMS0w_eed140a8-d562-4fdb-90a4-f080ac590f85"
      unitRef="usd">113143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i40d6b66797f34f81b5840fec178a1bc8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNC0zLTEtMS0w_ba210004-8678-4c53-8e93-753180aaf073"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i853b0c71982b4d179054c90adbd2cc10_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNC01LTEtMS0w_449ca65d-aa67-4792-a763-de18e54ccc86"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1260b9ca85a04e0bae3d00635ba471c8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNC03LTEtMS0w_4fd4431d-d4db-43d9-adc4-58b2d29260b4"
      unitRef="usd">113143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if4837ec01c954862a0cbeef2ee46566d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNS0xLTEtMS0w_2bb2afd5-4da5-41ab-a208-c7cb40ec4c57"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if130ef65efeb433abd2824aa7335e2d2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNS0zLTEtMS0w_dd441467-4ef4-4a6d-bbfa-bcf58f88d537"
      unitRef="usd">25786000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b7527e5965c407c93e541d90cc5482a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNS01LTEtMS0w_45f99793-3bd8-444b-b44a-990ff4e1f442"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2777e669ef784ebc95aca7676abd3f3f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNS03LTEtMS0w_9758cfc4-3783-4f0d-894e-b7db7223b940"
      unitRef="usd">25786000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i81f5a98d93ba478caf983096343142d2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNi0xLTEtMS0w_88cd1cb6-8d2d-4234-be26-dada1c4f8902"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b6c4c7c5daf45f4babd1352a4271518_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNi0zLTEtMS0w_31be5c00-4ed1-4883-ae19-1ca81ab4b3b7"
      unitRef="usd">190854000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2bc7562bce744e5ea5f471db41840a69_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNi01LTEtMS0w_50d08e53-751e-4587-8e08-0978547b2f49"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i363eee17eaa248bbbcb21c694cf72a07_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNi03LTEtMS0w_1d45c345-be1c-40f1-ad36-f72b7a8f21b7"
      unitRef="usd">190854000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if3e236ed56584d6a81223bb2f2ab2d5f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNy0xLTEtMS0w_b4542b4c-f5a5-46c0-9efb-e1e4e4648582"
      unitRef="usd">180313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibba7a439b13144ebb18a81a73851f2bb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNy0zLTEtMS0w_ea940f8a-9e40-4e51-959e-a432b7b12c5b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i90490ce088944c1d8583aa65de02a75d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNy01LTEtMS0w_c9227a3c-c495-4f6a-8176-a1a36fcec573"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i49cf82683efa4c01a1df81a844831a04_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfNy03LTEtMS0w_c9939df2-0fbd-4a38-ac2c-e7d56497bad7"
      unitRef="usd">180313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7720fa13a9c5481da95a3fb62d3f993d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOC0xLTEtMS0w_0dc390b9-eac9-43b6-a91f-a1642a80b971"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id74207d979464bf4853a5a3515777c63_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOC0zLTEtMS0w_853941a6-ed55-4f1e-85b5-54a6f33f7e24"
      unitRef="usd">29192000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i93e27bd09a004d319f93b738f2239aa5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOC01LTEtMS0w_778aa1cd-9999-46b3-a048-72381459d010"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iafa17b9dd5da493ebcc56be63f41e109_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOC03LTEtMS0w_901b5d47-dd87-42a0-a10b-a9e70639930d"
      unitRef="usd">29192000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6b1f6c595d5743cc81b052ef7f75068e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOS0xLTEtMS0w_43ea9b52-014e-4616-8547-2b5c8da36db5"
      unitRef="usd">293456000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1df7b51138624b92826dfe6b7fea694a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOS0zLTEtMS0w_3f47da6c-490d-4e46-865a-76bdbe0e343e"
      unitRef="usd">245832000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iacebb076771044bc98c51c446b109263_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOS01LTEtMS0w_8346f361-5667-4104-bd3c-1fe22b173da4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31a451c6e18e41cd9cdd174e7f67d1d4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmFlYjllZjJjM2MwMDQ1M2NiYzdkZDVmMDUyYjRiN2E3L3RhYmxlcmFuZ2U6YWViOWVmMmMzYzAwNDUzY2JjN2RkNWYwNTJiNGI3YTdfOS03LTEtMS0w_f4548671-2691-4e0e-9a8e-2827828ec139"
      unitRef="usd">539288000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic600adb00bc948368ce4b74fbe96ddb6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNC0xLTEtMS0w_2148bfa3-1358-4342-9b0c-cc868f164e5b"
      unitRef="usd">122900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee733965a28948da8136b97f1eddbd10_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNC0zLTEtMS0w_3c18596a-3a5a-4b32-a3f4-9a5e1abccce1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c4ef25a178d487e8f1f527c4f4c862b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNC01LTEtMS0w_a05318e3-d217-4a95-916f-c72496808486"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icf0641a17bd2409fa5a15a2678a01bf3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNC03LTEtMS0w_ef775494-4da6-4971-9570-a47d075f397d"
      unitRef="usd">122900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief0866696c6849e992758e967b5a3373_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNS0xLTEtMS0w_b9fd16b8-a73c-42eb-a63f-3c2dc748c52e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa95fa7e31a642ad9cd96a1b3fcf9c53_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNS0zLTEtMS0w_23d9b4c1-def5-40ba-8cf0-d555b279ab6b"
      unitRef="usd">205011000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4de41313418040828be43e5a80c4efe2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNS01LTEtMS0w_5867ce89-2e17-4fb7-91a3-2d709ff0ca51"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64a094d14f3345cf98071f778c000dee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNS03LTEtMS0w_ca7eb338-303d-4dc5-bf73-a6d87c5e8307"
      unitRef="usd">205011000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i79f3f7be17bc46db883ba607846df111_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNi0xLTEtMS0w_316ea2eb-edb0-4f19-89b4-d9abfe4ca199"
      unitRef="usd">181894000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf394f5d90a047168042ea66bcdd28a8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNi0zLTEtMS0w_2f35afc7-2714-4e92-965c-0af21027a5ad"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i37dbdde627f041b198d1ebf46adee969_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNi01LTEtMS0w_28342acd-3cf6-4855-ab90-a5c2fb89dae7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id01aefa120cb41b1a07c570b285b6778_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNi03LTEtMS0w_a676e897-7a8d-4e2a-ab7d-abbba951fc96"
      unitRef="usd">181894000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0c461309afd84ba1ba2d93c6c1318f70_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNy0xLTEtMS0w_cfb4be9c-fe7d-4d91-a44a-81100cdfea4c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie2c3f56a38964674b3be5794ce01fbe8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNy0zLTEtMS0w_22ae3b73-2cac-4f5a-9002-0570ad708f66"
      unitRef="usd">25824000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i26d3828189e540c3b1a53ffca0d571b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNy01LTEtMS0w_c124ce0a-c1b3-4cb2-a5df-5e9145d01cb9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8580644452b94e12ab9e3485cfc60784_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfNy03LTEtMS0w_86388af0-28fe-4ef1-b7c5-357021c25bee"
      unitRef="usd">25824000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i792bbadca48943bfaf71a2bb11414136_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOC0xLTEtMS0w_04a5c3c2-b414-41be-ba96-c79a80b79130"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i17d9949e90384e369f45910b88cec3f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOC0zLTEtMS0w_47c42dd4-6ea6-4542-9549-bce63825afcc"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id601068b37f04845aafc46fd43f5e853_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOC01LTEtMS0w_e7cacc27-bd7d-4192-b292-505e5218698d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d8b29ad214b4978b3bc65dd87a1284c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOC03LTEtMS0w_33489b54-25b2-4aa4-a9ca-1c2e6085eceb"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i55f0d72dfa6c42f5bba2b89d78731ebf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOS0xLTEtMS0w_d121b2f3-2750-4e7d-a9de-fd8fd13f5b00"
      unitRef="usd">304794000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i04aad2f3e4fe42c98e0232d3eae8a9d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOS0zLTEtMS0w_9e57577c-c223-4dfe-898b-0f520ef5f367"
      unitRef="usd">231835000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f16cc2983b042dfb0cb862ba0b07d6a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOS01LTEtMS0w_fcfd0e10-0bd1-4476-94a8-66c917507b73"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifcd82b2e8101404ab7f516da762fb5d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV80Ni9mcmFnOjIxMDkyOGI0N2M2ODRjYTJiYTNmY2Y0ODZhNmEwYjRjL3RhYmxlOmUwYTJmMDkwMzFlYTQzYjI4ODM2ZTU2NmU1MTkzMDA1L3RhYmxlcmFuZ2U6ZTBhMmYwOTAzMWVhNDNiMjg4MzZlNTY2ZTUxOTMwMDVfOS03LTEtMS0w_fedb172e-8363-4d74-8f17-8288c899f8dd"
      unitRef="usd">536629000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RleHRyZWdpb246ZTQ3NzFlNTY5YmZkNDBlMWI3Y2JhYjcwN2ZjYzI4ZTlfODgy_6ce85372-7cd2-402f-a90a-4120499f09b7">Financial InstrumentsThe fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;537,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;539,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;357,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;539,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;204,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;535,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020,&#160;the remaining contractual maturities of available-for-sale securities were less than 3 years. There have been no significant realized losses on available-for-sale securities for the period presented. As of March 31, 2020, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#x2019;s marketable securities are due to market factors. To date, the Company has not recorded any impairment charges on marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RleHRyZWdpb246ZTQ3NzFlNTY5YmZkNDBlMWI3Y2JhYjcwN2ZjYzI4ZTlfODgz_4f1033e2-734f-4b19-8716-de7ec7ebbe52">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;537,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;539,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;357,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;539,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;204,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;535,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia10fb1c7bf324168ab0a2db735f79147_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMy0xLTEtMS0w_2b5c6f78-dd4a-4a8b-9761-a3c10494b5e4"
      unitRef="usd">113143000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia10fb1c7bf324168ab0a2db735f79147_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMy0zLTEtMS0w_ef953e39-0d6a-429b-827f-a22eaaba5ed2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia10fb1c7bf324168ab0a2db735f79147_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMy01LTEtMS0w_4313c5ae-f27a-43af-a6e2-3fdbbc3c5ebf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia10fb1c7bf324168ab0a2db735f79147_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMy03LTEtMS0w_74bd2804-8cf5-4d9a-b67a-72f09619582a"
      unitRef="usd">113143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia8c15b3ab1e74889b26989029ae6d673_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNC0xLTEtMS0w_350591be-fbf7-435a-9518-1b79d31f603c"
      unitRef="usd">25786000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia8c15b3ab1e74889b26989029ae6d673_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNC0zLTEtMS0w_44d56867-fb6f-49a9-ad1e-a9ccf1fccb43"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia8c15b3ab1e74889b26989029ae6d673_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNC01LTEtMS0w_5c99cbdb-add8-465e-a7ff-0b7012790f63"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8c15b3ab1e74889b26989029ae6d673_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNC03LTEtMS0w_cad5ee97-ba20-4bcf-96ea-ac8b12b73f83"
      unitRef="usd">25786000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i364cd7afc1844168ad816a8621088d26_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNS0xLTEtMS0w_2b1b6ac1-fc67-4fab-bff1-f0d5b389e885"
      unitRef="usd">190625000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i364cd7afc1844168ad816a8621088d26_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNS0zLTEtMS0w_7a4a0111-d9dd-4740-b2db-f4b133c237c7"
      unitRef="usd">505000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i364cd7afc1844168ad816a8621088d26_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNS01LTEtMS0w_f2e4b3e5-854d-41ae-9aa5-800de6257de5"
      unitRef="usd">276000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i364cd7afc1844168ad816a8621088d26_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNS03LTEtMS0w_ce95ca19-6d47-4882-a9aa-cb90328bdbd9"
      unitRef="usd">190854000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i01d8447678cb4fc0b136d8049103aa1b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNi0xLTEtMS0w_03a7a5e9-c7db-425d-8967-bf606daf00a9"
      unitRef="usd">178695000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i01d8447678cb4fc0b136d8049103aa1b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNi0zLTEtMS0w_7f024cf2-537e-4b0f-9d23-8173b25b9748"
      unitRef="usd">1618000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i01d8447678cb4fc0b136d8049103aa1b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNi01LTEtMS0w_a6020029-d094-4eec-b61e-8ec7ffff7135"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01d8447678cb4fc0b136d8049103aa1b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNi03LTEtMS0w_a2514043-ddb1-4b3c-90d0-94218b4ea83b"
      unitRef="usd">180313000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8c64460a47e84af39d4f40bacaa2fd75_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNy0xLTEtMS0w_f374b51f-813f-46ee-8551-2392b355aeea"
      unitRef="usd">28986000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8c64460a47e84af39d4f40bacaa2fd75_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNy0zLTEtMS0w_c60019ae-f40f-4c5c-af8a-ed7a5befd48b"
      unitRef="usd">207000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8c64460a47e84af39d4f40bacaa2fd75_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNy01LTEtMS0w_8ac0b7bf-7d65-4777-8e5b-e31ab6753ad5"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c64460a47e84af39d4f40bacaa2fd75_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfNy03LTEtMS0w_40266466-fb73-42e1-a13e-467cfb8503b2"
      unitRef="usd">29192000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfOC0xLTEtMS0w_380c4645-7243-4f5a-8352-ee790ad173ed"
      unitRef="usd">537235000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfOC0zLTEtMS0w_1085552d-f2bf-4f61-ad31-6db8d954f4db"
      unitRef="usd">2330000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfOC01LTEtMS0w_e10ca7d1-147b-4784-810c-f28490262c80"
      unitRef="usd">277000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfOC03LTEtMS0w_5cddaf98-2295-4055-9413-65f790cc03f3"
      unitRef="usd">539288000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMTEtNy0xLTEtMA_fccf9bb4-f5fa-48fa-9ab5-4eee606c02e9"
      unitRef="usd">122141000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMTItNy0xLTEtMA_13aceb1f-be09-4e82-9b99-d640537a064e"
      unitRef="usd">357026000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMTMtNy0xLTEtMA_f2e7df67-c327-4066-b9c7-8dc1c71b9269"
      unitRef="usd">60121000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjI3NGQyM2EyYmE0MzRmMWI4M2I1MWYzMzc1YWYzMDE1L3RhYmxlcmFuZ2U6Mjc0ZDIzYTJiYTQzNGYxYjgzYjUxZjMzNzVhZjMwMTVfMTQtNy0xLTEtMA_2a5e3fb5-cbc5-4eb8-bb94-93ab5b23c0fa"
      unitRef="usd">539288000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7b8466b8753547e7a17d250705529eae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMy0xLTEtMS0w_1491c01a-3b9a-4510-9bba-9ba679e2f2f4"
      unitRef="usd">122900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7b8466b8753547e7a17d250705529eae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMy0zLTEtMS0w_6ea33fbc-2fb0-4c70-904c-a5c95b476fbd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7b8466b8753547e7a17d250705529eae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMy01LTEtMS0w_d93482fd-13f9-4808-98bc-897c7c68d5e3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b8466b8753547e7a17d250705529eae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMy03LTEtMS0w_d6357fd1-6df8-4eac-9095-4cbb8cd645c0"
      unitRef="usd">122900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNC0xLTEtMS0w_92cf601f-b6a8-40ed-b842-3b9134b03ba8"
      unitRef="usd">204144000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNC0zLTEtMS0w_cdff2e6b-89e5-42f5-b41a-a2decc51756b"
      unitRef="usd">871000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNC01LTEtMS0w_f4751714-8aa8-4599-a57f-5206edf2a4c0"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadce1f7dfcfd462abd4c714b0657d0e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNC03LTEtMS0w_38e30d5a-0cb9-410b-bcdb-4b0abcd12770"
      unitRef="usd">205011000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5c611e2c37aa4636b1d74f643ed27edd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNS0xLTEtMS0w_5c5978ac-89a2-4b4d-adbd-a537f3f120a2"
      unitRef="usd">181340000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5c611e2c37aa4636b1d74f643ed27edd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNS0zLTEtMS0w_e1ea41d2-b380-4d66-b106-99cffdca26e9"
      unitRef="usd">557000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5c611e2c37aa4636b1d74f643ed27edd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNS01LTEtMS0w_192eeeed-a552-4763-8ad5-543547df5c97"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c611e2c37aa4636b1d74f643ed27edd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNS03LTEtMS0w_ab75c9c7-c7a8-49c9-8e1c-9e18c7c6cecc"
      unitRef="usd">181894000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i639bc019200d423cac9e1f1b8acfbaa7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNi0xLTEtMS0w_22b65429-f36b-42d4-80c9-dba94f115e5e"
      unitRef="usd">25658000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i639bc019200d423cac9e1f1b8acfbaa7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNi0zLTEtMS0w_068b7a00-66c4-4335-b942-4a3fd4e6b898"
      unitRef="usd">167000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i639bc019200d423cac9e1f1b8acfbaa7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNi01LTEtMS0w_a2721f8c-54e6-4c1f-b900-c9b8b642a3af"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i639bc019200d423cac9e1f1b8acfbaa7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNi03LTEtMS0w_bc57ab4c-b11e-49f9-bfb6-10913faf5be2"
      unitRef="usd">25824000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3ab02fe568304455a85402d84dbb39c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNy0xLTEtMS0w_540fad64-9a6f-45c3-8d4a-f2f7b874b2e4"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3ab02fe568304455a85402d84dbb39c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNy0zLTEtMS0w_9940ce1c-27f8-494e-bcb4-c03a378af318"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3ab02fe568304455a85402d84dbb39c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNy01LTEtMS0w_fe920f87-229e-4150-a020-16b1581d49b6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ab02fe568304455a85402d84dbb39c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfNy03LTEtMS0w_d0e452b0-5fe4-4b84-9fd7-94f8461774c1"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfOC0xLTEtMS0w_cdc64684-ea25-4fcd-963e-6826fd7587e3"
      unitRef="usd">535042000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfOC0zLTEtMS0w_b32287f6-10dc-4708-9259-f3e6390f3071"
      unitRef="usd">1595000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfOC01LTEtMS0w_386bff25-517c-4aef-ab5d-516524a31b7f"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfOC03LTEtMS0w_c4ce2e9c-60a1-4315-9589-1d547c28daa4"
      unitRef="usd">536629000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMTEtNy0xLTEtMA_4ee6ed83-3c50-43b2-9c62-36c5ee12c432"
      unitRef="usd">122900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMTItNy0xLTEtMA_cb0872f5-1a30-4c18-8651-19606cf4cdcd"
      unitRef="usd">355407000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMTMtNy0xLTEtMA_46c0c5f3-67bc-426d-a56c-ab7ab2e04a1b"
      unitRef="usd">58322000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RhYmxlOjk3NjQ5NWQyN2NkYzQxYzg4NGE1OTQzMDZjODU4ODgxL3RhYmxlcmFuZ2U6OTc2NDk1ZDI3Y2RjNDFjODg0YTU5NDMwNmM4NTg4ODFfMTQtNy0xLTEtMA_b3f9f700-d262-4252-b705-b5fa5e80dce1"
      unitRef="usd">536629000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81Mi9mcmFnOmU0NzcxZTU2OWJmZDQwZTFiN2NiYWI3MDdmY2MyOGU5L3RleHRyZWdpb246ZTQ3NzFlNTY5YmZkNDBlMWI3Y2JhYjcwN2ZjYzI4ZTlfMzE3_753efe3b-e4e3-45ad-ab93-2f1703c7c4ce">P3Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RleHRyZWdpb246OTViY2FjMzYyNDY1NGMzODhhMjczNTYwNmVjMDZhNmZfMjk0_77914a15-a3c5-422a-a74c-9a23e87c1fcd">Balance Sheets Components&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and Equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.114%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computers equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RleHRyZWdpb246OTViY2FjMzYyNDY1NGMzODhhMjczNTYwNmVjMDZhNmZfMjg5_bb5f30f3-c81b-4e63-976b-ec079b1a969f">Property and Equipment consist of the following:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.114%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computers equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib0de266e8b9e4b318c1b6289ecb6ce00_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfMi0xLTEtMS0w_a12cc1f4-8df6-4875-b7c4-a5636cad0a76"
      unitRef="usd">31516000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iff732cfa26a242859b76df19609edf5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfMi0zLTEtMS0w_7abc8fdf-8fa4-4a33-bfb3-963010fadcfd"
      unitRef="usd">29924000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i77059c64b65f479fb071a0e986cf7b09_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfMy0xLTEtMS0w_fc3d808f-0642-4a55-9eb7-f184db011a09"
      unitRef="usd">21653000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i80325903deab4700b1323494502a9120_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfMy0zLTEtMS0w_6d0379c5-0e5f-4507-8f9f-ce2e157a7967"
      unitRef="usd">12390000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2c1f1460cc8942cf818d575042f8c4f0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNC0xLTEtMS0zMzI_d2069822-f469-4361-8a39-92db02f3bf23"
      unitRef="usd">13967000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i10f2b6782cf247b5a11b92d52590baed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNC0zLTEtMS0zMzI_468174f0-e1ad-4356-86e0-ae445a8c2903"
      unitRef="usd">13117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie075cc2a67084ac1b3eb62f94228b0ef_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNC0xLTEtMS0w_23a26e18-a5bc-49b6-8015-cb0e325d3873"
      unitRef="usd">3774000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9ca85fe9deb54d98b46c30a75fb18924_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNC0zLTEtMS0w_41b2b724-b5a0-4767-8acf-e2aff4974acf"
      unitRef="usd">3726000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i790b82aa47544194a8a63de2efdb8636_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNS0xLTEtMS0w_a4b2cf10-4d34-4d83-8dc4-d66d98b97be1"
      unitRef="usd">2804000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9d7a98f96eeb4c94afb207c3aad9d5b1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNS0zLTEtMS0w_0258645a-f6f4-4077-a21a-a1397ff20908"
      unitRef="usd">2764000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNy0xLTEtMS0w_2b6929a4-1c6f-4dee-88cd-76520d7f1065"
      unitRef="usd">73714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfNy0zLTEtMS0w_efe86942-d99d-4a10-812a-d4dd23ea085a"
      unitRef="usd">61921000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfOC0xLTEtMS0w_50a0283f-fa97-48c1-ae67-f21c925d7806"
      unitRef="usd">7365000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfOC0zLTEtMS0w_61f11eae-ba66-451f-83e5-b5ff9f0583b0"
      unitRef="usd">5472000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfOS0xLTEtMS0w_829a06aa-bbdd-4fa7-98c6-9cb54dfa6827"
      unitRef="usd">66349000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81NS9mcmFnOjk1YmNhYzM2MjQ2NTRjMzg4YTI3MzU2MDZlYzA2YTZmL3RhYmxlOjQzNDA0OWUyMjQ1ZTQ5NTY5MjIzYjIxZmU1ZWNkNDViL3RhYmxlcmFuZ2U6NDM0MDQ5ZTIyNDVlNDk1NjkyMjNiMjFmZTVlY2Q0NWJfOS0zLTEtMS0w_b4cf81d7-5406-4de3-8f25-020f2fe4be5c"
      unitRef="usd">56449000</us-gaap:PropertyPlantAndEquipmentNet>
    <allo:LicenseAgreementsTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNzE0NjgyNTYwMTM0OA_5d0a13af-10c7-4360-9409-7f175f3c9e11">License Agreements&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Asset Contribution Agreement with Pfizer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $30.0 million or $60.0 million, depending on the target, with aggregate potential regulatory and development milestones of up to $840.0 million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $325.0 million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three months ended March&#160;31, 2020 and 2019 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#x2019;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research Collaboration and License Agreement with Cellectis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#x2019;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $185.0 million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $2.8 billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#x2019;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#x2019;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#x2019; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#x2019; prior written notice in the event of the other party&#x2019;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All costs the Company incurred in connection with this agreement were recognized as research and development expenses.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended March&#160;31, 2020 and 2019,  zero costs were incurred related to the achievement of a clinical development milestone under this agreement. For the three months ended March&#160;31, 2020 and 2019, zero costs were incurred associated with research services performed by Cellectis under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;License and Collaboration Agreement with Servier&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for 60% of the specified development costs and Servier is responsible for the remaining 40% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#x2019;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#x2019;s sole expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $137.5 million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $78.0 million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $42 million and &#x20ac;70.5 million ($77.4 million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#x2019;s election not to pursue such rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#x2019;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#x2019;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended March&#160;31, 2020, the Company recorded $1.0 million&#160;of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. For the three months ended March 31, 2019, the Company recorded $0.7 million of costs as research and development expenses. As of March&#160;31, 2020, amounts due from Servier of $0.2 million were recorded in other current assets in the accompanying condensed balance sheet. As of December&#160;31, 2019, amounts due to Servier of $2.2 million were recorded in accrued and other current liabilities in the accompanying balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research Collaboration and License Agreement with Notch&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#x2019;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#x2019;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#x2019;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#x2019;s election, following the joint development committee&#x2019;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#x2019;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $10.0&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $10&#160;million during the year to December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $5.0&#160;million investment in Notch&#x2019;s series seed convertible preferred stock, resulting in Allogene having a 25% ownership interest in Notch&#x2019;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Notch Agreement, Notch will be eligible to receive up to $7.25&#160;million upon achieving certain agreed research milestones, up to $4.0&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283.0&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#x2019;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#x2019;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#x2019;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#x2019; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#x2019;s insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company has determined that Notch continues to be a variable interest entity as of March&#160;31, 2020. The Company does not have the power to direct the activities which most significantly affect Notch's economic performance. Accordingly, for the three months ended March&#160;31, 2020, the Company did not consolidate Notch because the Company determined that it was not the primary beneficiary. &lt;/span&gt;&lt;/div&gt;For the three months ended March&#160;31, 2020, the Company recorded $0.3 million in collaboration costs as research and development expenses.</allo:LicenseAgreementsTextBlock>
    <allo:MilestonePayments
      contextRef="i3e45882827dc473d9cccdddf46d4bc37_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNzg5_05b957fd-9738-49a4-9516-2d5415893dbd"
      unitRef="usd">30000000.0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="iccb902fc0cbf494384e4080a72eb2561_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNzk1_cc91b008-2d06-460b-9c5c-3ac6d699efb0"
      unitRef="usd">60000000.0</allo:MilestonePayments>
    <allo:AggregatePotentialRegulatoryAndDevelopmentMilestones
      contextRef="iccb902fc0cbf494384e4080a72eb2561_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODk2_018773c3-8bce-438a-b4e8-d0b4e1280b4e"
      unitRef="usd">840000000.0</allo:AggregatePotentialRegulatoryAndDevelopmentMilestones>
    <allo:AggregatePotentialMilestonePayments
      contextRef="ia733fa51ba7647a6aba865395e1556a1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTM1MA_5195b2a2-447d-4b1c-bb30-c532da5beaf3"
      unitRef="usd">325000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:RoyaltyObligationPeriodFromDateOfFirstSale
      contextRef="i789c0228925e4672b7ac566e5e3afc54_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMjMzNQ_8a778ac1-93ec-41ca-abb0-8f15a7deb8fe">P12Y</allo:RoyaltyObligationPeriodFromDateOfFirstSale>
    <allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget
      contextRef="i600ae8e97f094c078004eb149339e911_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNDYwNA_18ad2141-bba4-4d51-aa63-bb48b2f493c5"
      unitRef="usd">185000000.0</allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i8c687c20085e4f9daaa84f4f372fadd1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfNDc0NQ_360bce44-698f-4de9-9fa3-b89d013d332c"
      unitRef="usd">2800000000</allo:AggregatePotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i98399c769a4a488aaa46d0a7c26a9054_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNzI5MA_4562c0da-6619-4373-8374-6732237c9cb3"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib28fed9c91714dbea81ced010fd4dff8_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNzI5MA_4d2613b1-82b8-4fa6-ae0b-a7518822572b"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i64e12e6daa2c4fb5b8ad43e1cd9547e8_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNzMxMQ_0c36eef0-76ce-4474-86a3-4c653d6c399d"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i73435ce9243740bd8574ccf58e1a1558_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNzMxMQ_c6f5c573-1e9a-4aeb-8e53-05c5bfb018f1"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <allo:PercentageOfDevelopmentCostPayableByTheCompany
      contextRef="i7c737287cec94ddba5b57cbf684bfb99_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTEyMTI_60ed3cf7-80c9-47d1-9a0e-fc8f40dc828f"
      unitRef="number">0.60</allo:PercentageOfDevelopmentCostPayableByTheCompany>
    <allo:PercentageOfDevelopmentCostPayableByCollaborationPartner
      contextRef="i7c737287cec94ddba5b57cbf684bfb99_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTEyOTU_e3edd897-a6d8-44c4-a52f-73a76ec6ab86"
      unitRef="number">0.40</allo:PercentageOfDevelopmentCostPayableByCollaborationPartner>
    <allo:AggregatePotentialMilestonePayments
      contextRef="ia5d5e7c43ae443da8eacbed133ea82c3_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTE5MzY_db26b1cc-1530-4b9a-b823-9b02d500e729"
      unitRef="usd">137500000</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i25eec7c7b62e480a8a24e1d2fc01cb00_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTIwNjg_250cef34-e96b-452e-8872-ecbeb762fe31"
      unitRef="usd">78000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="i4bf058e9146a44db8d47e1921229a153_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTI1Mjg_fb2cf80d-e329-4155-baa2-d4c5c87c87f7"
      unitRef="usd">42000000</allo:AggregatePotentialMilestoneReceivable>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="iec4bd58ba39b42698636440287c1b64f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTI1MzU_dc2b3d5d-0b60-4b31-8540-999bf6541f93"
      unitRef="eur">70500000</allo:AggregatePotentialMilestoneReceivable>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="iec4bd58ba39b42698636440287c1b64f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTI1Mzk_2bc0ba12-a60e-4f06-9ba3-9e2f12e00597"
      unitRef="usd">77400000</allo:AggregatePotentialMilestoneReceivable>
    <allo:RecoveryOfResearchAndDevelopmentExpense
      contextRef="i7c737287cec94ddba5b57cbf684bfb99_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTM4NzI_733bcee0-298f-4c87-a7b1-4759a82b7e0e"
      unitRef="usd">1000000.0</allo:RecoveryOfResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3e0de113752c4ee3912070b56b2b88e7_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzg0ODI5MDcxNjk2MQ_09c6dc59-4bb3-4da1-bd95-ae332706f328"
      unitRef="usd">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNet
      contextRef="i2f6403cfdee14280a2a1c6dc64afba04_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMTQxNjI_12c29ca7-201a-4ab1-b21e-9a4148d2cc9f"
      unitRef="usd">200000</us-gaap:AccountsReceivableNet>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i53d07d0342c54b11b26f9a2900615150_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzI5ODUzNDkwMzY1OA_6e7c9e9e-4b90-4304-a0c8-41537d126cbf"
      unitRef="usd">2200000</allo:AccruedAndOtherLiabilitiesCurrent>
    <allo:CollaborationAgreementUpfrontPayment
      contextRef="i8a48ecd5e6aa4995bcfa8af46e4b858e_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTIxMg_a9198527-3425-452e-b846-db9c1e55cb04"
      unitRef="usd">10000000.0</allo:CollaborationAgreementUpfrontPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3a11830e93d74ad8a671b309eacfb9e7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTIyNw_19f8e97c-a6e3-47a3-a29a-27ccf193c379"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ia387f6863fef4d76b7a4661c9545f04d_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI0MA_d5add150-cd39-4c87-879a-59f935044d2e"
      unitRef="usd">5000000.0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia387f6863fef4d76b7a4661c9545f04d_I20191101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI1NA_977050bb-9110-4513-9874-ec0589bdc194"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <allo:AggregatePotentialMilestonePayable
      contextRef="ifdb5da102c704b2ab704e75453c50364_I20200331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI1OQ_054aac9d-286a-4233-9aeb-cad4c1b780d2"
      unitRef="usd">7250000</allo:AggregatePotentialMilestonePayable>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i6012c21655b348b4b23bf36d66ffd9cf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI3NA_591bab66-42e5-4f46-b637-253543ba3647"
      unitRef="usd">4000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i4cad33ed23754ac189892f31dc1b6c1a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfODc5NjA5MzA0MTI4OA_9b1a4bc1-c8b8-4843-86ee-f95189b43589"
      unitRef="usd">283000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:CollaborationArrangementExpense
      contextRef="i5c634926bf9d49b1a097075a247d38eb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV81OC9mcmFnOmRjZTExZWVmOTI0NTQ1NDk5OWY2NWZhMmRiZjQxMDc1L3RleHRyZWdpb246ZGNlMTFlZWY5MjQ1NDU0OTk5ZjY1ZmEyZGJmNDEwNzVfMzI5ODUzNDkwNDEyMg_630c0ec7-c34b-4dcc-944b-ce8fcb23c101"
      unitRef="usd">300000</allo:CollaborationArrangementExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzE0NjgyNTU5MTkzNA_90cc7977-f502-4ebe-9d85-e6c78bc6dc9c">Commitments and Contingencies&lt;div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. The lease term is 127 months beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $4.5 million of tenant improvement allowances up to March 31, 2020. The rent payments began on March 1, 2019 after an abatement period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of 14,943 square feet located in South San Francisco, California. The lease term is 124 months beginning November 2018 through &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;February 2029, with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $0.8 million. Rent payments began in November 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of 188 months and is expected to commence in April 2020. Upon certain conditions, the Company has two &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY3Ng_1448f1a5-3854-48ed-9be5-baf156294104"&gt;ten&lt;/span&gt;-year options to extend the lease which are not reasonably assured of exercise. Rent payments are expected to begin in early 2021 after an abatement period. The Company is entitled to a tenant improvement allowance of&#160;$2.9 million for costs related to the design and construction of certain Company improvements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintained letters of credit for the benefit of landlords in the amount of $4.3&#160;million which is disclosed a restricted cash as of March 31, 2020 and December 31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.433%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.402%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.402%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.827%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.433%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.402%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.402%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.827%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2020 was $1.4 million and was included in net cash used in operating activities in our condensed statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The undiscounted future lease payments under the lease agreements as of March&#160;31, 2020 were as follows (in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.050%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;2020 (remaining 9 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 and thereafter &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was&#160;8.34%. As of&#160;March 31, 2020, the weighted average remaining lease term for our operating leases is&#160;10.7&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of March 31, 2020, the Company had non-cancellable purchase commitments of $5.3&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <allo:AreaOfNewOfficeBuilding
      contextRef="i5ac8b68de98741d19e6456e14a0805cf_I20180831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTUz_3e09f38d-ae5c-4036-b541-0eb813bf0e84"
      unitRef="sqft">68000</allo:AreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5ac8b68de98741d19e6456e14a0805cf_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMjMw_6afc2b7c-c8cd-4469-8561-b4f862328b10">P127M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5ac8b68de98741d19e6456e14a0805cf_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY1Mg_63f2d84c-5fee-41d3-9c30-152331d85b14">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:AllowanceForTenantImprovements
      contextRef="i5ac8b68de98741d19e6456e14a0805cf_I20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNTE1_1ada7f99-dc86-4a79-b31c-5cccbf4f4764"
      unitRef="usd">4500000</allo:AllowanceForTenantImprovements>
    <allo:AreaOfNewOfficeBuilding
      contextRef="i9b47b163f76a4417a683c3539110e2f9_I20181031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTE1MQ_1e3b8303-0ab0-4603-96ea-cd72b5d58f7b"
      unitRef="sqft">14943</allo:AreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9b47b163f76a4417a683c3539110e2f9_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTIyOA_c766418b-691e-45b9-ad8d-aa98f7befc74">P124M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9b47b163f76a4417a683c3539110e2f9_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTMyNA_63083420-f51a-40f4-9d38-3dbf5a94bc60">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:AllowanceForTenantImprovements
      contextRef="i9b47b163f76a4417a683c3539110e2f9_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMTUyNg_50470d01-f9f5-40e5-8768-781bfeb1cb82"
      unitRef="usd">800000</allo:AllowanceForTenantImprovements>
    <allo:AreaOfOperatingLease
      contextRef="ieeeba5c202074b8680a92945d8d5cdcb_D20190201-20190228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMjk2NQ_5ed64a05-ca6d-4aa1-8e59-1b062920d422"
      unitRef="sqft">118000</allo:AreaOfOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i1d5b8ad9f2214bb9a3c41b2eb10f54f2_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMzA4NQ_84095c6d-60e4-48a4-97c5-2b95de7cd33e">P188M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <allo:NumberOfOptionsToExtendLease
      contextRef="ieeeba5c202074b8680a92945d8d5cdcb_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY2Mg_833803c1-0172-458d-b108-d9cd24ddb78f"
      unitRef="renewal">2</allo:NumberOfOptionsToExtendLease>
    <allo:AllowanceForTenantImprovements
      contextRef="i1d5b8ad9f2214bb9a3c41b2eb10f54f2_I20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfMzUwNQ_80703fe9-864b-48e5-8692-c6d94ef35088"
      unitRef="usd">2900000</allo:AllowanceForTenantImprovements>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzE0NjgyNTU5MTkzNg_45727f43-3995-4ecd-9e22-3cdf05482071"
      unitRef="usd">4300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzE0NjgyNTU5MTkzNg_47437fb2-3a7b-4125-88a9-d4f91aca4cd0"
      unitRef="usd">4300000</us-gaap:LettersOfCreditOutstandingAmount>
    <allo:LiabilitiesLesseeTableTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY4Mw_a8109d20-1dc7-400a-84ea-f7ab42fa7f30">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.433%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.402%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.402%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.827%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</allo:LiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfMy0yLTEtMS0yMjQ5_6178874a-80f0-4e98-bfd0-e5a6cae652ca"
      unitRef="usd">1807000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfMy00LTEtMS0yMjQ5_d41c8db4-3b2f-4ad2-9ba6-f5d3287568bd"
      unitRef="usd">1679000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfNC0yLTEtMS0yMjQ5_4bfc34e9-49a0-41f5-a8b8-145d246940f5"
      unitRef="usd">51536000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfNC00LTEtMS0yMjQ5_091cbd0c-a3d7-42f8-acb5-a5b9a1ff5a8d"
      unitRef="usd">51349000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfNS0yLTEtMS0yMjU0_9276cc40-131b-4191-b104-c8df94ba6120"
      unitRef="usd">53343000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7fcf59ab558a4ba0af8035ddf2c055bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOmFmZWVhYTY5MmZhZDRhMGNhNDliNzNmNjAwY2Q2MzRhL3RhYmxlcmFuZ2U6YWZlZWFhNjkyZmFkNGEwY2E0OWI3M2Y2MDBjZDYzNGFfNS00LTEtMS0yMjU0_8605f466-773c-4039-a043-0fda025ece16"
      unitRef="usd">53028000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfOTg5NTYwNDY1OTY4NA_a45e1411-337a-4776-bc10-82f1f0a4d211">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.433%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.402%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.402%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.827%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfMi0yLTEtMS0yMjI3_3e9ee79e-e182-456d-9d34-0ac4a8cb62dc"
      unitRef="usd">1868000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfMi00LTEtMS0yMjI3_cf5e227b-19ea-4673-8deb-607be943d7d5"
      unitRef="usd">1351000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfMy0yLTEtMS0yMjI3_b11f9c9c-dd43-47ab-871f-72d01b597809"
      unitRef="usd">210000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfMy00LTEtMS0yMjI3_561f4b7a-9d73-467f-ae82-a99eddd1b633"
      unitRef="usd">139000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfNC0yLTEtMS0yMjI3_5b82d90f-e837-4a7b-accb-7fa74fcf1117"
      unitRef="usd">2078000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjM4ZjM4NzU2ZWNmNzQzZjg4ODFlYWRiZTE3YjFkNmM4L3RhYmxlcmFuZ2U6MzhmMzg3NTZlY2Y3NDNmODg4MWVhZGJlMTdiMWQ2YzhfNC00LTEtMS0yMjI3_4fafe974-afcf-4eeb-998e-57dc303678e6"
      unitRef="usd">1490000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzY5NjU4MTQwMzg5Nw_55eeefec-6232-4b5f-9720-05bd1cc6837f"
      unitRef="usd">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNDMyMA_819adf6e-9c06-4217-977f-2c2a47c8b9b9">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The undiscounted future lease payments under the lease agreements as of March&#160;31, 2020 were as follows (in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.050%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;2020 (remaining 9 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 and thereafter &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMS0yLTEtMS0w_e39ec7c6-facc-42f7-ac3f-4bf65e25dd9c"
      unitRef="usd">4236000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMi0yLTEtMS0w_b03adf77-eb11-4881-8472-a66b70d4d376"
      unitRef="usd">7633000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMy0yLTEtMS0w_2dad4a96-174a-4fe8-9561-c264900f6af4"
      unitRef="usd">7951000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfNC0yLTEtMS0w_cab6c1b4-a1a1-4e7d-9655-626ea8c8a8df"
      unitRef="usd">8203000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfNS0yLTEtMS0w_0b1d5ce6-77f6-4d35-8d91-68fcf4cd86e6"
      unitRef="usd">8467000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfNi0yLTEtMS0w_4f4e278e-98a6-4e8d-b5dd-cbec71f8c793"
      unitRef="usd">55398000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfNy0yLTEtMS0w_df0803ad-bbc8-477e-bb16-544e88b59800"
      unitRef="usd">91888000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfOS0yLTEtMS0w_0c32c0f6-009c-40a8-a5c0-7b6d13c3ea80"
      unitRef="usd">34736000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <allo:AllowanceForTenantImprovements
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMTAtMi0xLTEtMA_d853327e-4c9f-496f-8311-14ea95dc01f9"
      unitRef="usd">3809000</allo:AllowanceForTenantImprovements>
    <us-gaap:OperatingLeaseLiability
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RhYmxlOjIzMmZjOGE1MGZlZTQ5MmNhZGVkNWNmNTE5NmEzMGU2L3RhYmxlcmFuZ2U6MjMyZmM4YTUwZmVlNDkyY2FkZWQ1Y2Y1MTk2YTMwZTZfMTEtMi0xLTEtMA_adb47cdc-c6ce-411f-bb0d-359eeb466c08"
      unitRef="usd">53343000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzY5NjU4MTQwMzkwOQ_a97b159d-e936-4d8d-86c4-0d6e86933525"
      unitRef="number">0.0834</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzY5NjU4MTQwMzkxNQ_accc9e37-17ed-4672-ba22-02d53871e7ef">P10Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV82NC9mcmFnOmE4ZmFkYWRkY2U4MTRkNzM4ZmZlZmY3MjM3YmU2MTI2L3RleHRyZWdpb246YThmYWRhZGRjZTgxNGQ3MzhmZmVmZjcyMzdiZTYxMjZfNzE0NjgyNTU5MTkyMQ_ebec17a3-2d93-4c23-beb9-fdec2d034c7e"
      unitRef="usd">5300000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzNDM5_aacec551-6dac-4f2f-b0da-53ba32eca894">Equity Method Investment&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement (&#x201c;Notch Investment Agreement&#x201d;) with the Company acquiring shares of Notch&#x2019;s Series Seed convertible preferred stock for a total investment cost of $5.1&#160;million which includes transaction costs of $0.1&#160;million, resulting in a 25% ownership interest in Notch. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s total equity investment in Notch as of March&#160;31, 2020 and December&#160;31, 2019 was $4.8 million and $4.9&#160;million, respectively, and the Company accounted for the investment using the equity method of accounting. During the three months ended March 31, 2020, the Company recognized its share of Notch's net loss under the other expenses caption within the condensed statements of operations. The Company's share of Notch's net loss was $0.1 million for the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ib223d885c64d4b53a8881033526b8151_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzMzc5_d83dd568-8084-4d8e-bac0-918e8a4abe55"
      unitRef="usd">5100000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <allo:CostMethodInvestmentTransactionCosts
      contextRef="i53599948fe6c4ca5b584914643acddbc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzMzkz_8998fcff-5db6-48ea-b94d-c9d86923ecec"
      unitRef="usd">100000</allo:CostMethodInvestmentTransactionCosts>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic19af5f089974c2497122fe4a4e2e3dd_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzNDA3_f0072b3d-a4f5-4fd1-8547-5d8bcdad5809"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF8zMjk4NTM0ODg1NzA3_7a3219e7-ca17-4b21-adaf-b2d8c190c5f3"
      unitRef="usd">4800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i81bb738593bb4a4aa0333b29c524327a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF84Nzk2MDkzMDIzNDEy_ec593df8-7756-4144-90ef-dc623660da6f"
      unitRef="usd">4900000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="i53599948fe6c4ca5b584914643acddbc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNTQyL2ZyYWc6NmRhYmZkNjkwNDE2NGJmZjlmODg2YmY3NjA3MjZiNDgvdGV4dHJlZ2lvbjo2ZGFiZmQ2OTA0MTY0YmZmOWY4ODZiZjc2MDcyNmI0OF8zMjk4NTM0ODg0ODE1_29d6e99a-ada8-450d-9796-058cfda8ff4a"
      unitRef="usd">-100000</allo:IncomeLossFromCostMethodInvestment>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjkzMw_9ae82ea0-e320-4ede-b979-4b3bad3594d8">Stock-Based Compensation&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#x2019;s board of directors and consultants of the Company under terms and provisions established by the Company&#x2019;s board of directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed 10 years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than 100% of the fair market value of the Company&#x2019;s common stock on the grant date. Options granted typically vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTE4Mg_4fe0cc3d-a369-4851-b84c-7f351e9ac8c3"&gt;four&lt;/span&gt;-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, there were 12,448,841 shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes option activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.151%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contract&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,190,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,675,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(105,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(132,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,627,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,716,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,627,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The aggregate intrinsic values of options exercised, outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market on March 31, 2020. For the three months ended March 31, 2020, the estimated weighted-average grant-date fair value of employee options granted was $18.41 per share. As of March 31, 2020, there was $98.2&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of 3 years, 45 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.294%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.295%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.07 - 6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.99 - 6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.84%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.80% - 1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.45% - 2.62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected term&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected volatility&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected dividend&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes restricted stock unit activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Restricted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Average Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Value at Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;of Grant per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Vesting Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,941,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$50,431&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;885,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(270,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,534,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$49,274&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,534,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$49,274&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March 31, 2020, there was $55.3&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 3 years, 133 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#x2019; common stock was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Early Exercised Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#x2019;s lapsing repurchase right upon termination of employment or service on the Company&#x2019;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of March&#160;31, 2020 and 2019 there was $2.8 million and $5.3 million recorded in accrued and other liabilities and $3.2 million and $6.1 million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed financial statements since the exercise date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzU1_a510031c-041f-413a-9216-ef6dc5e143a8"
      unitRef="number">0.05</allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding>
    <allo:StockOptionGrantedPeriod
      contextRef="iaf428979ee4648a58838e99d47fc80b6_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfOTM0_ae67832a-4c80-4773-a781-443935c56363">P10Y</allo:StockOptionGrantedPeriod>
    <allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate
      contextRef="iaf428979ee4648a58838e99d47fc80b6_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTA2Nw_3ce40f0f-5018-4b8f-aabd-98a2dcbc4773"
      unitRef="number">1</allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTM5NQ_39524325-b7c4-4718-8e48-f4d8092688e2"
      unitRef="shares">12448841</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjkzNA_c72d67f6-a8ca-4242-acf2-476628ae0ffe">The following summarizes option activity under the 2018 Plan:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.151%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contract&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,190,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,675,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(105,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(132,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,627,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,716,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,627,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie582f6e76ada438881e8098bffd2c1d9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMi0xLTEtMS0w_27bf86b0-e44e-418e-8b17-04116f9c54a8"
      unitRef="shares">9190522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie582f6e76ada438881e8098bffd2c1d9_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMi0zLTEtMS0w_6f6a99f5-066a-4996-95f8-83dc014979d1"
      unitRef="usdPerShare">14.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5bbdece93a42441ab703824c19120916_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMi01LTEtMS0w_44b7f94c-2420-483d-a8bb-7c8150360b58">P8Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie582f6e76ada438881e8098bffd2c1d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMy03LTEtMS0zOTY3_a06b8329-d991-42ed-8330-15ac82e3faab"
      unitRef="usd">110490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMy0xLTEtMS0w_544c7ded-594f-42e2-86c8-97ccc34e9da4"
      unitRef="shares">2675672</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfMy0zLTEtMS0w_b2ff1d72-561c-42c0-9161-dbbd6d4d3d08"
      unitRef="usdPerShare">18.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNC0xLTEtMS0w_544372bd-9cd8-48cb-aba3-8ace6ffd0acc"
      unitRef="shares">105895</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNC0zLTEtMS0w_1f7d54ca-e524-433d-b554-438f20dbac46"
      unitRef="usdPerShare">2.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNS0xLTEtMS0w_41c9d59b-01ee-46b4-9866-17f5c7c7c2ad"
      unitRef="shares">132910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNS0zLTEtMS0w_d9f5badd-cd3b-4878-b6a0-4d8b8aaa8148"
      unitRef="usdPerShare">9.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNi0xLTEtMS0w_06b5ae44-0b6d-4253-9db1-95d1485e3129"
      unitRef="shares">11627389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNi0zLTEtMS0w_33c61d12-d5e2-4cbe-8a05-6202cb4dcbca"
      unitRef="usdPerShare">15.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNi01LTEtMS0w_ec024bad-c9f1-4dee-868d-70fe929d4f5f">P8Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy03LTEtMS0zOTY3_3b83703c-a340-440b-aba8-d8d711dfa4d8"
      unitRef="usd">77096000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy0xLTEtMS0w_0fcdc1f0-174b-49ec-9e5d-c7d8dadf3301"
      unitRef="shares">6716452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy0xLTEtMS0w_6f685e9d-e69c-439a-b519-64e383103bb4"
      unitRef="shares">6716452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy0zLTEtMS0w_abaee00e-f6f0-4c99-88b8-daf8f53508d9"
      unitRef="usdPerShare">13.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy0zLTEtMS0w_e49f0cf2-833e-42e9-a4d8-29f2479cf30d"
      unitRef="usdPerShare">13.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy01LTEtMS0w_016aaddb-99fa-47fa-8145-73f23f3eb02f">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfNy01LTEtMS0w_df1226fb-0913-458c-a2ca-85e1f39972d9">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOC03LTEtMS0zOTY3_e2336f92-d8b7-47e8-acf9-094cfa43224a"
      unitRef="usd">51873000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOC0xLTEtMS0w_7065033a-8f65-4fb6-aa78-6b35ecd9f1d5"
      unitRef="shares">11627389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOC0zLTEtMS0w_b7b8bbb8-f89d-48f8-b63c-5a00c209639b"
      unitRef="usdPerShare">15.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOC01LTEtMS0w_15ceec32-ddde-4930-961a-7e4392be97cb">P8Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i936160ad8bb942058d8f222ec9ddc536_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjU2N2UzZmYxMDYxNDQ0NDA5M2FjNDhjNDUxNTBmYTY0L3RhYmxlcmFuZ2U6NTY3ZTNmZjEwNjE0NDQ0MDkzYWM0OGM0NTE1MGZhNjRfOS03LTEtMS0zOTY3_cea1bbd8-eba5-432b-996a-ae9f196c0b69"
      unitRef="usd">77096000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic177a9557377487499e270097c358bf7_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjQwNA_b93aadc7-49db-4368-95b4-094b90d48c2d"
      unitRef="usdPerShare">18.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i521694cbaa114dddb6a6dff0b4c9abb9_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjM4OQ_0866e4b8-eb24-429a-bdb8-69f00a55af1e"
      unitRef="usd">98200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic177a9557377487499e270097c358bf7_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjM2Mg_6a2a8c21-f378-4a1b-9734-d78144a89c74">P3Y45D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjQxMQ_cffe6618-5197-441e-8fd0-93f5fd3667c9">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.294%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.295%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.07 - 6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.99 - 6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.84%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.80% - 1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.45% - 2.62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjVkZGZkODQ2ZTEwNDRmODdiZTJiNDRkYTg5Mjk5MWVkL3RhYmxlcmFuZ2U6NWRkZmQ4NDZlMTA0NGY4N2JlMmI0NGRhODkyOTkxZWRfMy0xLTEtMS00MjY0_e995dbe7-ad23-483e-b55b-cba6141c0e7a"
      unitRef="number">0.7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5bbdece93a42441ab703824c19120916_D20190101-20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjVkZGZkODQ2ZTEwNDRmODdiZTJiNDRkYTg5Mjk5MWVkL3RhYmxlcmFuZ2U6NWRkZmQ4NDZlMTA0NGY4N2JlMmI0NGRhODkyOTkxZWRfNC0zLTEtMS0zOTAw_5bcb3983-09f9-4128-af92-ba3dcf253df8"
      unitRef="number">0.7484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjVkZGZkODQ2ZTEwNDRmODdiZTJiNDRkYTg5Mjk5MWVkL3RhYmxlcmFuZ2U6NWRkZmQ4NDZlMTA0NGY4N2JlMmI0NGRhODkyOTkxZWRfNS0xLTEtMS00MjY0_ffbbf1b6-d409-44c7-ac41-add8f2c6782e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5bbdece93a42441ab703824c19120916_D20190101-20190331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjVkZGZkODQ2ZTEwNDRmODdiZTJiNDRkYTg5Mjk5MWVkL3RhYmxlcmFuZ2U6NWRkZmQ4NDZlMTA0NGY4N2JlMmI0NGRhODkyOTkxZWRfNi0zLTEtMS0zOTAw_2bc126f4-a0c2-4dce-92ba-637702eefb08"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjkyOA_57126cb0-9590-4ccb-b77a-6f1c5a46bc09">The following summarizes restricted stock unit activity under the 2018 Plan:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Restricted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Average Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Value at Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;of Grant per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Vesting Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,941,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$50,431&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;885,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(270,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,534,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$49,274&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,534,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$49,274&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idb31faa7f5644ea697201adc41fddd67_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMS0xLTEtMS0w_b4c2fbd0-cd51-4e16-95f6-9aa93c9f7f92"
      unitRef="shares">1941155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idb31faa7f5644ea697201adc41fddd67_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMS0zLTEtMS0w_eb5aa18e-49de-4b4b-9891-d394bb0f5c48"
      unitRef="usdPerShare">27450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i945dc20d171348f08a92572145268721_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMy01LTEtMS00MTk5_cf9492e5-76fb-4017-9e65-9d15b00258e9">P1Y11M23D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="idb31faa7f5644ea697201adc41fddd67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMy03LTEtMS00MTk5_c4c2962c-cd69-4ad0-86c5-53ecd7542e5a"
      unitRef="usd">50431000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMi0xLTEtMS0w_71f4762b-d45b-4640-81f6-5b64f2ea5e23"
      unitRef="shares">885267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMi0zLTEtMS0w_21802a59-aab4-4c53-9a28-98fb5c751a13"
      unitRef="usdPerShare">18.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNC01LTEtMS00MTk5_2db540f9-64e6-44f9-a7c1-dc2734ef65e0">P2Y5M8D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMy0xLTEtMS0w_2237072e-e37d-4c52-8400-e8b77b551a15"
      unitRef="shares">270751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfMy0zLTEtMS0w_4d3a8fbe-dd8c-49d7-a366-bef6156be846"
      unitRef="usdPerShare">27.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNC0xLTEtMS0w_33097956-2f92-4ccb-8660-af2711a93bd1"
      unitRef="shares">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNC0zLTEtMS0w_6f673f96-fb1f-4446-abdd-d9a67879422b"
      unitRef="usdPerShare">28.19</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic1565ebe58524c9791944236e646ac49_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNS0xLTEtMS0w_917d8b9a-b82a-44b9-9874-ab9024537ece"
      unitRef="shares">2534671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic1565ebe58524c9791944236e646ac49_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNS0zLTEtMS0w_18202aad-27dc-454c-99bc-9d9bedb7ecdc"
      unitRef="usdPerShare">24.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNy01LTEtMS00MTk5_dec42b45-b6fd-41a4-8197-dbdeaaaab23d">P2Y2M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ic1565ebe58524c9791944236e646ac49_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNy03LTEtMS00MTk5_39acc865-b901-4b02-b180-5c2bc5b5d933"
      unitRef="usd">49274000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ic1565ebe58524c9791944236e646ac49_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNi0xLTEtMS0w_a2216ccb-dba8-4e19-a3f3-9337c8067420"
      unitRef="shares">2534671</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ic1565ebe58524c9791944236e646ac49_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfNi0zLTEtMS0w_4682da4b-02ea-46af-952a-48a95811e3d7"
      unitRef="usdPerShare">24.35</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfOC01LTEtMS00MTk5_56c727b1-f1b5-4fd5-a3b4-7b773f8c0ba7">P2Y2M1D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue
      contextRef="ic1565ebe58524c9791944236e646ac49_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjYxNjU5NzA0N2RjYjRkNjQ4YzBkMjEwYWU0Y2FiZjZmL3RhYmxlcmFuZ2U6NjE2NTk3MDQ3ZGNiNGQ2NDhjMGQyMTBhZTRjYWJmNmZfOC03LTEtMS00MTk5_a8c62a21-1b03-407b-919b-cd850f5fca3d"
      unitRef="usd">49274000</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic1565ebe58524c9791944236e646ac49_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjQxMw_ac6c15d4-4629-4321-b71d-ca9d85c86800"
      unitRef="usd">55300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ica89cc3399e34b5daf968c48a00297bf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfNzE0NjgyNTU4NjQyNw_48a10f8c-f854-440f-a2ae-ead3fd41e4ec">P3Y133D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjkzMA_79589d0c-fe90-43bf-ac01-b46bda3be420">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#x2019; common stock was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c634926bf9d49b1a097075a247d38eb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfMi0xLTEtMS0w_cbeb29e6-c1a0-47e1-93a5-d9e68a0feef8"
      unitRef="usd">6657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f2a6d6310eb4804acffb0d4e70789c4_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfMi0zLTEtMS0w_cae68458-3cb1-4882-858b-952a04e6cfbe"
      unitRef="usd">2732000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c4dd589aec54659af36f7495218487c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfMy0xLTEtMS0w_7b9b5399-b36d-4c0e-a126-407071dc0c71"
      unitRef="usd">7558000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16de5530e6d44bc99f02f418df776b94_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfMy0zLTEtMS0w_61b62f02-dcbe-4d68-bf4c-24eced1ed8af"
      unitRef="usd">5135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfNC0xLTEtMS0w_654aedac-232e-4250-a5f2-be7e5e02ce5f"
      unitRef="usd">14215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RhYmxlOjQwYjc3ZmY3ZGEwOTQwM2M5ZDMwMTM4ZGY5OGQ4ZTg0L3RhYmxlcmFuZ2U6NDBiNzdmZjdkYTA5NDAzYzlkMzAxMzhkZjk4ZDhlODRfNC0zLTEtMS0w_e175f2b2-bda7-4f22-a430-0c3e4ef8acc1"
      unitRef="usd">7867000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjY0NA_14de139f-1ec2-4ec2-8d8f-693cd1894a4c"
      unitRef="usd">2800000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i8710054b59684a4391833aea00414337_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTMxOTQxMzk1MzYyODk_29ed3293-5c9b-4c01-b98d-67a18fc0a078"
      unitRef="usd">5300000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMjY5Mw_63cd5f37-2f68-4da8-9db2-dffc6f508a20"
      unitRef="usd">3200000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i8710054b59684a4391833aea00414337_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTMxOTQxMzk1MzYyOTg_5fcf5716-02f2-4cd4-8ed7-71f18e65b9d2"
      unitRef="usd">6100000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzg4OA_491f9572-f5d1-4277-bb2c-08ad1769924d">Related Party Transactions&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, Pfizer held 22,032,040 shares of Common Stock and had appointed one member to the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. In September 2019, the Company and Pfizer terminated the Pfizer TSA. For the three months ended March&#160;31, 2020 and 2019, the costs incurred under the Pfizer TSA were&#160;zero and $2.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also purchased certain lab supplies from Pfizer in connection with its research and development activities. For the three months ended March&#160;31, 2020 and 2019, the total lab supplies and services purchased from Pfizer were zero and $0.6, million respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020 and December&#160;31, 2019, the Company had an amount payable to Pfizer of zero and $1.7 million, respectively, which was recorded in the accrued and other current liabilities on the accompanying condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Sublease Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for 1,293 square feet of office space in Los Angeles California for a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0MzgzMg_3cee6d69-25e1-4997-bf53-faf3f51e1036"&gt;three&lt;/span&gt; year term. The Company&#x2019;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. The total right of use asset and associated liability recorded related to this related party lease was $0.1 million and $0.2 million at March&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2019, the Company subleased 2,180 square feet of its office space in New York, New York, to ByHeart, Inc.(ByHeart), formerly known as Second Science, Inc.&#160;ByHeart is a development-stage infant formula company.&#160;Certain of the Company&#x2019;s board members and executive officers have beneficial ownership in ByHeart and two serve on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to 2,907 square feet. Sublease income for the three months ended March&#160;31, 2020 and 2019 was $0.1 million and was recognized as other income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Consulting Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#x2019;s President and Chief Executive Officer, the Company&#x2019;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $0.1 million and $0.2 million for the three months ended March&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#x2019;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $33,333 per month in arrears commencing January 2019 and $37,500 per month in arrears commencing January 2020. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to 60% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $0.2 million for the three months ended March&#160;31, 2020 and 2019, respectively</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8a437f63084d4bd18d9edeff003da5ff_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTg_afcbbb0c-3786-411d-a6db-0f20de029ca5"
      unitRef="shares">22032040</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RelatedPartyCosts
      contextRef="id52499d716214a2699bbb179be7d9b7c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNDc1_775799b6-c123-4106-ac7f-641925434cbd"
      unitRef="usd">0</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i1ff5875cc6044a67885d7490df6c5659_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0NDI0MQ_f302d3f7-fdfe-44b0-8c6f-66481f9b84b9"
      unitRef="usd">2700000</us-gaap:RelatedPartyCosts>
    <us-gaap:SuppliesExpense
      contextRef="ied67c130b61d4499b7927fceb186af36_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfODY0_259c18f2-5917-4123-8984-e4a947dd6476"
      unitRef="usd">0</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i86c84a8b6258472092c7917980204432_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0NDI2MA_ff7997b3-f1a6-4b99-8692-99550c77f511"
      unitRef="usd">600000</us-gaap:SuppliesExpense>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i1eea165234764f838579662624ec9d90_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTE0MA_28aced7e-ed6f-4347-a5be-2c03931d82a7"
      unitRef="usd">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i56aaf1b58d7b4ec7b18900c8eb264775_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTE0OA_8a001691-6596-4d7d-82b4-d4b7e09f4cd9"
      unitRef="usd">1700000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <allo:AreaOfOffice
      contextRef="ic321d0b1fd1c4b0f95aed3cd5340beae_D20181201-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0MzgyNQ_72137375-e5ed-4583-bfbc-458497084bd8"
      unitRef="sqft">1293</allo:AreaOfOffice>
    <allo:AreaOfOffice
      contextRef="i56c3fcf903a048f7b77fd696a381f82e_D20190201-20190228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTQxMg_6c9ebc03-ef20-427c-aaf1-c9f31c67a11f"
      unitRef="sqft">2180</allo:AreaOfOffice>
    <allo:NumberOfMembersAppointedToBoardOfDirectors
      contextRef="i5f17f2b211344d3f82185666cdfd8064_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfOTg5NTYwNDY1NTkyNw_e13f38db-36c8-4298-a9d7-b25db304a513"
      unitRef="board_member">2</allo:NumberOfMembersAppointedToBoardOfDirectors>
    <allo:AreaOfOffice
      contextRef="ifae2200f0f404af2a52ee56081d823e3_D20190901-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTgzNw_ac3757e2-542f-49d1-a765-67f7fc3b2e70"
      unitRef="sqft">2907</allo:AreaOfOffice>
    <us-gaap:SubleaseIncome
      contextRef="i30246310ab084bc99257f27e94986e6b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMTkwMA_a51e49c6-5d8c-445a-a744-1ab3b00efc9f"
      unitRef="usd">100000</us-gaap:SubleaseIncome>
    <us-gaap:RelatedPartyCosts
      contextRef="ia2e9df642ead424798c3bcd699e0d11f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMjUwNA_00895ce0-bad3-4154-b2a9-885858785d6e"
      unitRef="usd">100000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i70ed49038db9439d99e49ced4b34596f_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzI5ODUzNDg4ODcyNw_4dfd4870-df46-4cf5-8311-4b1c8e925618"
      unitRef="usd">200000</us-gaap:RelatedPartyCosts>
    <allo:RelatedPartyTransactionMonthlyPaymentsInArrears
      contextRef="i05acd1d072c943d799c0703a556368b1_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzMxNg_6eaa82ab-2ae9-4879-945c-4727be770f89"
      unitRef="usd">33333</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
    <allo:RelatedPartyTransactionMonthlyPaymentsInArrears
      contextRef="i2664c61460fd4fa8ac2b86b83a9aaef9_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNzE0NjgyNTU4NjQ3MQ_ae35f52d-9878-46ed-8153-c73046157523"
      unitRef="usd">37500</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
    <allo:RelatedPartyTransactionCompensationPercentage
      contextRef="ibf6da9f07f2d4b2cb4f36dece4d79776_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzQ2MA_b367ef4f-c8e3-4fa0-8e37-5161709190e5"
      unitRef="number">0.60</allo:RelatedPartyTransactionCompensationPercentage>
    <us-gaap:RelatedPartyCosts
      contextRef="i34a074fef5cf4808a3421b475b2b6e1f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfMzc0Mw_69f4baba-8eef-41df-b2e9-f26083d72c23"
      unitRef="usd">200000</us-gaap:RelatedPartyCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84OC9mcmFnOmNkMmMzOGRhOGU5NjRmYjFiMmQyMGYxOWNiMTQwY2ZkL3RleHRyZWdpb246Y2QyYzM4ZGE4ZTk2NGZiMWIyZDIwZjE5Y2IxNDBjZmRfMTkx_558ca493-b0f7-49ea-b05d-d7d81395015e">Income TaxesThe Company has a history of losses, and expects to record a loss in 2020. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RleHRyZWdpb246ZjI2ZmZmNDY4NTJiNDZlMWI3MDEwN2NlOTUzNTk2OTJfMjE0_0d5a6cb0-6b4b-4d28-805e-2a82b3fc4b3b">Net Loss Per ShareThe following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,627,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,939,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units subject to vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,534,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,102,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected shares to be purchased under Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;226,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;265,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Founder's shares of common stock subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,115,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,173,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,678,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,020,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,182,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,500,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RleHRyZWdpb246ZjI2ZmZmNDY4NTJiNDZlMWI3MDEwN2NlOTUzNTk2OTJfMjE1_9df0525d-18e1-4021-abb5-7fe2293720e7">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,627,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,939,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units subject to vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,534,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,102,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected shares to be purchased under Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;226,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;265,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Founder's shares of common stock subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,115,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,173,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,678,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,020,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,182,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,500,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i445474810986457d86157ac99ce513eb_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfMi0xLTEtMS0w_2081706e-da68-4a6a-a6e4-a38f222df227"
      unitRef="shares">11627389</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2b6ed85ff10640e0a2e3c27c4de1f868_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfMi0zLTEtMS0w_71a44500-13f6-4a50-b77f-e5aaf74be7d7"
      unitRef="shares">8939556</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifab11e5afc21498ca4e40dc435770e6f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNS0xLTEtMS0w_a2cc7eb6-233f-4713-9a34-5936923c5395"
      unitRef="shares">2534671</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7e5c7873bcbb436f9297d5dc64e8c936_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNS0zLTEtMS0w_a1d76b15-f98f-49f0-851d-c9adc0a35446"
      unitRef="shares">1102028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaea9ba03c9b646619b56dd93138eaddd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNi0xLTEtMS0w_f9914622-bee8-46b1-ab07-5e9948c7bdd4"
      unitRef="shares">226459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i164061d208364d798deb08ac4045936a_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNi0zLTEtMS0w_0a500d2e-6843-4c5f-8dcc-df8095258344"
      unitRef="shares">265455</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i493f3fa88aa246efb2e80fa6c3b6d7d7_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNy0xLTEtMS0w_88b9e833-9ec4-4579-b9f3-9a510109e966"
      unitRef="shares">12115382</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic90aa7f4abe04f2383035e03129a402e_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfNy0zLTEtMS0w_419faa44-6c65-4d7b-8132-b0469ace5605"
      unitRef="shares">18173066</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia7ae26fbb0794fceb415878169f539c2_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfOC0xLTEtMS0w_8173245f-7a97-4cc0-95e9-1a347f8c6cc6"
      unitRef="shares">2678501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i72a829b0930b4e63aaf7cd159033b693_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfOC0zLTEtMS0w_1736d1dd-fbc3-495b-a9f9-84d7d7fed872"
      unitRef="shares">5020580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfOS0xLTEtMS0w_29f99537-d879-4f8a-97c4-8fda1ea838e5"
      unitRef="shares">29182402</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85MS9mcmFnOmYyNmZmZjQ2ODUyYjQ2ZTFiNzAxMDdjZTk1MzU5NjkyL3RhYmxlOjY2N2E5NTAxNmYzZjRlZWQ4YWM4NTQ4NDcyOTBmNTdkL3RhYmxlcmFuZ2U6NjY3YTk1MDE2ZjNmNGVlZDhhYzg1NDg0NzI5MGY1N2RfOS0zLTEtMS0w_f74b28d9-e229-4170-82e1-774ea97a6b2b"
      unitRef="shares">33500685</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV85NC9mcmFnOmQ2ODNjODUxMDE5NTRkYzE5MzY5ZmNiMzllMTRhNzZlL3RleHRyZWdpb246ZDY4M2M4NTEwMTk1NGRjMTkzNjlmY2IzOWUxNGE3NmVfNDAxMQ_df0b6d53-46c1-49c1-b172-b136baa8d278">Subsequent EventsNone.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i42aa16303efb4bc6861242f37d3e85a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xMDAvZnJhZzphMDBiZWE3YThiZDY0ODNkYWVhZDkwYTgyOTJhZWMyMi90ZXh0cmVnaW9uOmEwMGJlYTdhOGJkNjQ4M2RhZWFkOTBhODI5MmFlYzIyXzI3MTc_dccede9e-df62-411e-95c9-0de08522b64d"
      unitRef="usd">-450600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OtherExpenses
      contextRef="if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xMTIvZnJhZzoxNjQ2NzFiMzU2Y2E0YjBhOGNhNTRmNjY1YWQzNGUzMS90YWJsZTphNDQ0M2I1N2VhNzQ0MDRlOGQ2MGJmZGUzMWUyZGFjZS90YWJsZXJhbmdlOmE0NDQzYjU3ZWE3NDQwNGU4ZDYwYmZkZTMxZTJkYWNlXzktMS0xLTEtMjM5Mg_da804c14-5507-4b24-b24c-feb2355b7ae8"
      unitRef="usd">58000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="i11baba13e32c4aabad7b7c20d027fe66_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xMTIvZnJhZzoxNjQ2NzFiMzU2Y2E0YjBhOGNhNTRmNjY1YWQzNGUzMS90YWJsZTphNDQ0M2I1N2VhNzQ0MDRlOGQ2MGJmZGUzMWUyZGFjZS90YWJsZXJhbmdlOmE0NDQzYjU3ZWE3NDQwNGU4ZDYwYmZkZTMxZTJkYWNlXzktMy0xLTEtMjM5Mg_535f6952-becd-452f-b177-d50d32bbc811"
      unitRef="usd">0</us-gaap:OtherExpenses>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtODM_3a8f62bf-21ae-4179-ad0f-b5632893bbb7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtODM_3a8f62bf-21ae-4179-ad0f-b5632893bbb7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOS0zLTEtMS0w_267729df-178c-4f99-9da9-08c858d420e1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOS0zLTEtMS0w_267729df-178c-4f99-9da9-08c858d420e1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTctMy0xLTEtMA_16ee153e-c141-48c9-98ce-f7206b3a4d50"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTctMy0xLTEtMA_16ee153e-c141-48c9-98ce-f7206b3a4d50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjAtMy0xLTEtMA_1394a926-75d4-427f-a343-84f5ae0e6eff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjAtMy0xLTEtMA_1394a926-75d4-427f-a343-84f5ae0e6eff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOC0zLTEtMS0w_c2fb4451-14a9-493a-bc41-f0aac362dd76"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOC0zLTEtMS0w_c2fb4451-14a9-493a-bc41-f0aac362dd76"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTAtMy0xLTEtMA_6fdca938-4822-4f97-902b-5eaedc185973"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTAtMy0xLTEtMA_6fdca938-4822-4f97-902b-5eaedc185973"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMzAtMy0xLTEtMA_25c2142d-611d-401e-b3b3-bc2affec8f73"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMzAtMy0xLTEtMA_25c2142d-611d-401e-b3b3-bc2affec8f73"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNy0zLTEtMS0w_75b3f085-32a3-42ca-ac9c-2a466790768e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNy0zLTEtMS0w_75b3f085-32a3-42ca-ac9c-2a466790768e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjYtMy0xLTEtMA_3344a037-4917-4d6f-8623-c66f16b6fdfc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjYtMy0xLTEtMA_3344a037-4917-4d6f-8623-c66f16b6fdfc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTEtMy0xLTEtMA_65611136-94ce-4f40-b42a-634c2ec07a01"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTEtMy0xLTEtMA_65611136-94ce-4f40-b42a-634c2ec07a01"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTktMy0xLTEtMA_87a46259-4c6c-4db3-b6f9-c82bb6d3e074"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTktMy0xLTEtMA_87a46259-4c6c-4db3-b6f9-c82bb6d3e074"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNC0zLTEtMS0w_4190bc71-19e9-46da-8b2b-b8bf1692e9f2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNC0zLTEtMS0w_4190bc71-19e9-46da-8b2b-b8bf1692e9f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjItMy0xLTEtMA_8b82c55b-7a84-40c6-8c00-231a48d41b4d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjItMy0xLTEtMA_8b82c55b-7a84-40c6-8c00-231a48d41b4d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjctMy0xLTEtMA_64c8cf6c-0199-4bb8-9d42-b7039e300df2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjctMy0xLTEtMA_64c8cf6c-0199-4bb8-9d42-b7039e300df2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTItMy0xLTEtMA_fd6b51e2-07a6-4019-bc10-3ebf9006a359"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTItMy0xLTEtMA_fd6b51e2-07a6-4019-bc10-3ebf9006a359"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjEtMy0xLTEtMA_13d32409-3d89-4e8f-ad03-a1d493d78e05"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjEtMy0xLTEtMA_13d32409-3d89-4e8f-ad03-a1d493d78e05"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjgtMy0xLTEtMA_52a0de29-628f-48a4-9b43-a03917898152"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjgtMy0xLTEtMA_52a0de29-628f-48a4-9b43-a03917898152"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjktMy0xLTEtMA_16c931b2-01bb-4c23-9851-4a88affb89ca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjktMy0xLTEtMA_16c931b2-01bb-4c23-9851-4a88affb89ca"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjQtMy0xLTEtMA_5443e109-d7f3-458b-9032-8f06e3e3c545"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjQtMy0xLTEtMA_5443e109-d7f3-458b-9032-8f06e3e3c545"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNi0zLTEtMS0w_3e2c1b39-dcfd-41c9-9ad2-aea84a1d357c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNi0zLTEtMS0w_3e2c1b39-dcfd-41c9-9ad2-aea84a1d357c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTYtMy0xLTEtMA_a5219db8-6479-4e10-b6c3-6b8ba31424c3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTYtMy0xLTEtMA_a5219db8-6479-4e10-b6c3-6b8ba31424c3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjUtMy0xLTEtMA_09558e9b-3c8f-445b-9177-a021bc68441f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjUtMy0xLTEtMA_09558e9b-3c8f-445b-9177-a021bc68441f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMy0zLTEtMS0w_19730378-fffb-446a-a6ce-58998e797b13"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMy0zLTEtMS0w_19730378-fffb-446a-a6ce-58998e797b13"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNS0zLTEtMS0w_7204c4ce-4dfd-4201-a4a5-485fb92a1764"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNS0zLTEtMS0w_7204c4ce-4dfd-4201-a4a5-485fb92a1764"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtMA_3b8f6973-beef-4821-be9f-842b90aa6f3d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtMA_3b8f6973-beef-4821-be9f-842b90aa6f3d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTgtMy0xLTEtMA_81b602ae-51d9-4c69-b1c9-c803ec52daad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTgtMy0xLTEtMA_81b602ae-51d9-4c69-b1c9-c803ec52daad"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtODM_3a8f62bf-21ae-4179-ad0f-b5632893bbb7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOS0zLTEtMS0w_267729df-178c-4f99-9da9-08c858d420e1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTctMy0xLTEtMA_16ee153e-c141-48c9-98ce-f7206b3a4d50"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjAtMy0xLTEtMA_1394a926-75d4-427f-a343-84f5ae0e6eff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfOC0zLTEtMS0w_c2fb4451-14a9-493a-bc41-f0aac362dd76"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTAtMy0xLTEtMA_6fdca938-4822-4f97-902b-5eaedc185973"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMzAtMy0xLTEtMA_25c2142d-611d-401e-b3b3-bc2affec8f73"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNy0zLTEtMS0w_75b3f085-32a3-42ca-ac9c-2a466790768e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjYtMy0xLTEtMA_3344a037-4917-4d6f-8623-c66f16b6fdfc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTEtMy0xLTEtMA_65611136-94ce-4f40-b42a-634c2ec07a01"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTktMy0xLTEtMA_87a46259-4c6c-4db3-b6f9-c82bb6d3e074"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNC0zLTEtMS0w_4190bc71-19e9-46da-8b2b-b8bf1692e9f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjItMy0xLTEtMA_8b82c55b-7a84-40c6-8c00-231a48d41b4d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjctMy0xLTEtMA_64c8cf6c-0199-4bb8-9d42-b7039e300df2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTItMy0xLTEtMA_fd6b51e2-07a6-4019-bc10-3ebf9006a359"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjEtMy0xLTEtMA_13d32409-3d89-4e8f-ad03-a1d493d78e05"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjgtMy0xLTEtMA_52a0de29-628f-48a4-9b43-a03917898152"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjktMy0xLTEtMA_16c931b2-01bb-4c23-9851-4a88affb89ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjQtMy0xLTEtMA_5443e109-d7f3-458b-9032-8f06e3e3c545"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNi0zLTEtMS0w_3e2c1b39-dcfd-41c9-9ad2-aea84a1d357c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTYtMy0xLTEtMA_a5219db8-6479-4e10-b6c3-6b8ba31424c3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMjUtMy0xLTEtMA_09558e9b-3c8f-445b-9177-a021bc68441f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMy0zLTEtMS0w_19730378-fffb-446a-a6ce-58998e797b13"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfNS0zLTEtMS0w_7204c4ce-4dfd-4201-a4a5-485fb92a1764"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTMtMy0xLTEtMA_3b8f6973-beef-4821-be9f-842b90aa6f3d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RhYmxlOjJjMjkyNjk4NDE1OTQ2MzJhMTk2NjFiYjg4ZGRmMTVlL3RhYmxlcmFuZ2U6MmMyOTI2OTg0MTU5NDYzMmExOTY2MWJiODhkZGYxNWVfMTgtMy0xLTEtMA_81b602ae-51d9-4c69-b1c9-c803ec52daad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV8xNi9mcmFnOjMzNTg4MTZjMzk0NTRiM2JiMzhjNGU2ZWIzMWUxY2Y4L3RleHRyZWdpb246MzM1ODgxNmMzOTQ1NGIzYmIzOGM0ZTZlYjMxZTFjZjhfMzI1_40de91ea-9394-4ef5-9434-b0be4434a801"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797593296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions (Details) - 2018 Plan<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.42%<span></span>
</td>
<td class="nump">74.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk-free interest rate, minimum</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk-free interest rate, maximum</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788193472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">29,182,402<span></span>
</td>
<td class="nump">33,500,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">11,627,389<span></span>
</td>
<td class="nump">8,939,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units subject to vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">2,534,671<span></span>
</td>
<td class="nump">1,102,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Expected shares to be purchased under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">226,459<span></span>
</td>
<td class="nump">265,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember', window );">Founder's shares of common stock subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">12,115,382<span></span>
</td>
<td class="nump">18,173,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember', window );">Early exercised stock options subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">2,678,501<span></span>
</td>
<td class="nump">5,020,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617105696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares</a></td>
<td class="text">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:73.806%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,627,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,939,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units subject to vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,534,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,102,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">265,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Founder's shares of common stock subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,115,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,173,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,678,501&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,020,580&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,182,402&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,500,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617110016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value and Amortized Cost</a></td>
<td class="text">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:<div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(276)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">537,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(277)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">539,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">539,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">557&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">535,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>183</ContextCount>
  <ElementCount>322</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Statement of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statement of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Statement of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Statement of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementofCashFlows</Role>
      <ShortName>Condensed Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Balance Sheets Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsComponents</Role>
      <ShortName>Balance Sheets Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Equity Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/EquityMethodInvestment</Role>
      <ShortName>Equity Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2137112 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2140113 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://allogene.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Balance Sheets Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsComponentsTables</Role>
      <ShortName>Balance Sheets Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/BalanceSheetsComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/CommitmentsandContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2338306 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/DescriptionofBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Balance Sheets Components - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails</Role>
      <ShortName>Balance Sheets Components - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/LicenseAgreements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Commitments and Contingencies - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/EquityMethodInvestmentDetails</Role>
      <ShortName>Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/EquityMethodInvestment</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="allo-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossPerShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="allo-20200331.htm">allo-20200331.htm</File>
    <File>allo-20200331.xsd</File>
    <File>allo-20200331_cal.xml</File>
    <File>allo-20200331_def.xml</File>
    <File>allo-20200331_lab.xml</File>
    <File>allo-20200331_pre.xml</File>
    <File>allo-20200331xex311.htm</File>
    <File>allo-20200331xex312.htm</File>
    <File>allo-20200331xex321.htm</File>
    <File>allo-2020331xex101.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617273360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - 2018 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance (in shares)</a></td>
<td class="nump">9,190,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, options granted (in shares)</a></td>
<td class="nump">2,675,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, options exercised (in shares)</a></td>
<td class="num">(105,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, options forfeited (in shares)</a></td>
<td class="num">(132,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance (in shares)</a></td>
<td class="nump">11,627,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">6,716,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, vested and expected to vest (in shares)</a></td>
<td class="nump">11,627,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 14.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options granted (in dollars per share)</a></td>
<td class="nump">18.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercised (in dollars per share)</a></td>
<td class="nump">2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options forfeited (in dollars per share)</a></td>
<td class="nump">9.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">15.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">13.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 15.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contract term, outstanding</a></td>
<td class="text">8 years 10 months 13 days<span></span>
</td>
<td class="text">8 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, exercisable</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, vested and expected to vest</a></td>
<td class="text">8 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, balance</a></td>
<td class="nump">$ 77,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">51,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 77,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6830964640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>board_member </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,262,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,032,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Accrued and Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable to related party, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Transition Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Transition Services Agreement | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Related party transaction, expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartIncMember', window );">ByHeart</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfMembersAppointedToBoardOfDirectors', window );">Number of members appointed to board of directors | board_member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartIncMember', window );">ByHeart | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfOffice', window );">Area of office space | ft&#178;</a></td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember', window );">Two River | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfOffice', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Sublease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Payments Commencing January 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears', window );">Related party transaction monthly payment in arrears</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Payments Commencing January 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears', window );">Related party transaction monthly payment in arrears</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionCompensationPercentage', window );">Related party transaction compensation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfOffice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfOffice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfMembersAppointedToBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members appointed to board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfMembersAppointedToBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction compensation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction monthly payments in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionMonthlyPaymentsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888428&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=allo_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=allo_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_TransitionServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_TransitionServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6828228144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">125,262,537<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">125,262,537<span></span>
</td>
<td class="nump">124,267,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6829230144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (54,480)<span></span>
</td>
<td class="num">$ (31,586)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">7,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of other intangible assets acquired</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization/accretion on investment securities</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(1,223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Non-cash rent expense</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeLossFromCostMethodInvestment', window );">Share of losses from equity method investments</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,552<span></span>
</td>
<td class="num">(1,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,044)<span></span>
</td>
<td class="num">(348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(3,913)<span></span>
</td>
<td class="num">(4,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(701)<span></span>
</td>
<td class="num">(711)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(40,809)<span></span>
</td>
<td class="num">(30,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(12,253)<span></span>
</td>
<td class="num">(10,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">120,261<span></span>
</td>
<td class="nump">95,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(123,015)<span></span>
</td>
<td class="num">(52,397)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(15,007)<span></span>
</td>
<td class="nump">32,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of commissions and issuance costs</a></td>
<td class="nump">14,845<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock and upon exercise of stock options</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">16,586<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(39,230)<span></span>
</td>
<td class="nump">3,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; beginning of period</a></td>
<td class="nump">179,425<span></span>
</td>
<td class="nump">93,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; end of period</a></td>
<td class="nump">140,195<span></span>
</td>
<td class="nump">97,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases in accounts payable and accrued liabilities</a></td>
<td class="nump">4,208<span></span>
</td>
<td class="nump">5,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances', window );">Cash received for amounts related to tenant improvement allowances</a></td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Received For Amounts Related To Tenant Improvement Allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IncomeLossFromCostMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Cost Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IncomeLossFromCostMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6827892160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 537,235<span></span>
</td>
<td class="nump">$ 535,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">122,141<span></span>
</td>
<td class="nump">122,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">357,026<span></span>
</td>
<td class="nump">355,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">60,121<span></span>
</td>
<td class="nump">58,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CashEquivalentsAndShortTermInvestments', window );">Total cash equivalents and investments</a></td>
<td class="nump">539,288<span></span>
</td>
<td class="nump">536,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">113,143<span></span>
</td>
<td class="nump">122,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">113,143<span></span>
</td>
<td class="nump">122,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">25,786<span></span>
</td>
<td class="nump">204,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">25,786<span></span>
</td>
<td class="nump">205,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">190,625<span></span>
</td>
<td class="nump">181,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(276)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">190,854<span></span>
</td>
<td class="nump">181,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">178,695<span></span>
</td>
<td class="nump">25,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">180,313<span></span>
</td>
<td class="nump">25,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">28,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 29,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6829747872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Non-cancellable purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=allo_NewarkMember', window );">Newark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">188 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfOperatingLease', window );">Area of operating lease | ft&#178;</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfOptionsToExtendLease', window );">Number of options to extend lease | renewal</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember', window );">127 Months Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of office and laboratory | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">127 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember', window );">124 Months Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of office and laboratory | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">124 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfNewOfficeBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of new office building.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfNewOfficeBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfOptionsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfOptionsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=allo_NewarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=allo_NewarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816348960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investment</a></td>
<td class="text">Equity Method Investment<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement (&#8220;Notch Investment Agreement&#8221;) with the Company acquiring shares of Notch&#8217;s Series Seed convertible preferred stock for a total investment cost of $5.1&#160;million which includes transaction costs of $0.1&#160;million, resulting in a 25% ownership interest in Notch. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s total equity investment in Notch as of March&#160;31, 2020 and December&#160;31, 2019 was $4.8 million and $4.9&#160;million, respectively, and the Company accounted for the investment using the equity method of accounting. During the three months ended March 31, 2020, the Company recognized its share of Notch's net loss under the other expenses caption within the condensed statements of operations. The Company's share of Notch's net loss was $0.1 million for the three months ended March 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816348960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial InstrumentsThe fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2020 and as of December&#160;31, 2019 are presented in the following tables:<div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(276)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">537,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(277)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">539,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">539,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized&#160;Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">557&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181,894&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">535,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">536,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020,&#160;the remaining contractual maturities of available-for-sale securities were less than 3 years. There have been no significant realized losses on available-for-sale securities for the period presented. As of March 31, 2020, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#8217;s marketable securities are due to market factors. To date, the Company has not recorded any impairment charges on marketable securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6616886816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareThe following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:73.806%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,627,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,939,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units subject to vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,534,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,102,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">265,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Founder's shares of common stock subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,115,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,173,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,678,501&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,020,580&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,182,402&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,500,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6656091408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6616952224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LiabilitiesLesseeTableTextBlock', window );">Schedule of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:56.433%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.402%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.402%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.827%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,679&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,536&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:56.433%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.402%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.402%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.827%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Lease Payments Under Lease Liability</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The undiscounted future lease payments under the lease agreements as of March&#160;31, 2020 were as follows (in thousands:</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.217%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.050%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;2020 (remaining 9 months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,633&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,467&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,736)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,809)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617101088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed balance sheet as of March&#160;31, 2020, the condensed statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed statements of stockholders&#8217; equity as of March&#160;31, 2020 and 2019, the condensed statements of cash flows for the three months ended March&#160;31, 2020 and 2019, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending </span></div>December&#160;31, 2020, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2019, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 27, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Accounting Policies</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2020, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report, with the exception of the recently adopted accounting pronouncements in the section below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. This standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted beginning the first quarter of 2019. The Company&#8217;s financial instruments that are in the scope of ASU 2016-13 include, but are not limited to, other receivables and available-for-sale debt securities. The Company adopted this standard on January 1, 2020 and applied the modified retrospective approach. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles &#8211; Goodwill and other &#8211; Internal-Use Software (Subtopic 350-40)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard on January 1, 2020, on a prospective basis for applicable implementation costs. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard on January 1, 2020. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued Accounting Standards Update No. 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company early adopted this standard</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">as of January 1, 2020 on a prospective basis in accordance with ASC 250, Accounting Changes and Error Corrections. The adoption resulted in the Company no longer needing to determine the tax effect from unrealized gains on available for sale securities, which previously had been disclosed in the condensed statement of operations as a benefit from income taxes. The impact of the adoption in the three months ended March 31, 2020 is that the </span></div>benefit from income taxes in the condensed statement of operations and comprehensive loss is zero compared to recognition of a $0.1&#160;million tax benefit for the three months ended March 31, 2019.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the FASB issued Accounting Standard Update No. 2020-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which clarifies the interactions between topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance will be effective for the Company in the first quarter of 2021, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently adopted accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6765455952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeLossFromCostMethodInvestment', window );">Share of losses from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in Notch</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CostMethodInvestmentTransactionCosts', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeLossFromCostMethodInvestment', window );">Share of losses from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CostMethodInvestmentTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Method Investment, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CostMethodInvestmentTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IncomeLossFromCostMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Cost Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IncomeLossFromCostMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634496208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Unit - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, beginning balance (in shares)</a></td>
<td class="nump">1,941,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares)</a></td>
<td class="nump">885,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units, vested (in shares)</a></td>
<td class="num">(270,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units, forfeited (in shares)</a></td>
<td class="num">(21,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, ending balance (in shares)</a></td>
<td class="nump">2,534,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Restricted stock units, vested and expected to vest (in shares)</a></td>
<td class="nump">2,534,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Fair Value at Date of Grant per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 27,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, granted (in dollars per share)</a></td>
<td class="nump">18.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, vested (in dollars per share)</a></td>
<td class="nump">27.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, forfeited (in dollars per share)</a></td>
<td class="nump">28.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, ending balance (in dollars per share)</a></td>
<td class="nump">24.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 24.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining vesting life, unvested</a></td>
<td class="text">2 years 2 months 1 day<span></span>
</td>
<td class="text">1 year 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining vesting life, granted</a></td>
<td class="text">2 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining vesting life, vested and expected to vest</a></td>
<td class="text">2 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value, unvested</a></td>
<td class="nump">$ 49,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 49,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814780320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed balance sheet as of March&#160;31, 2020, the condensed statements of operations and comprehensive loss for the three months ended March&#160;31, 2020 and 2019, the condensed statements of stockholders&#8217; equity as of March&#160;31, 2020 and 2019, the condensed statements of cash flows for the three months ended March&#160;31, 2020 and 2019, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December&#160;31, 2020, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2019, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 27, 2020.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Accounting Policies</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2020, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report, with the exception of the recently adopted accounting pronouncements in the section below.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. This standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted beginning the first quarter of 2019. The Company&#8217;s financial instruments that are in the scope of ASU 2016-13 include, but are not limited to, other receivables and available-for-sale debt securities. The Company adopted this standard on January 1, 2020 and applied the modified retrospective approach. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles &#8211; Goodwill and other &#8211; Internal-Use Software (Subtopic 350-40)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard on January 1, 2020, on a prospective basis for applicable implementation costs. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard on January 1, 2020. Adoption of the new guidance had no significant impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued Accounting Standards Update No. 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company early adopted this standard</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">as of January 1, 2020 on a prospective basis in accordance with ASC 250, Accounting Changes and Error Corrections. The adoption resulted in the Company no longer needing to determine the tax effect from unrealized gains on available for sale securities, which previously had been disclosed in the condensed statement of operations as a benefit from income taxes. The impact of the adoption in the three months ended March 31, 2020 is that the </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">benefit from income taxes in the condensed statement of operations and comprehensive loss is zero compared to recognition of a $0.1&#160;million tax benefit for the three months ended March 31, 2019. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the FASB issued Accounting Standard Update No. 2020-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which clarifies the interactions between topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance will be effective for the Company in the first quarter of 2021, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6828096240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,331,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6829235680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statement of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">121,482,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 703,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 914,265<span></span>
</td>
<td class="num">$ (211,528)<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,867<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">44,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,586)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on available-for-sale investments</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">121,527,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">$ 681,228<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">922,816<span></span>
</td>
<td class="num">(243,114)<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">124,267,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">124,267,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 629,023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">1,023,876<span></span>
</td>
<td class="num">(396,122)<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">339,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSU's</a></td>
<td class="nump">303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">84,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">570,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from public offering, net of commissions and offering costs of $0.3 million</a></td>
<td class="nump">14,845<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,480)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on available-for-sale investments</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">125,262,537<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125,262,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 606,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 1,055,386<span></span>
</td>
<td class="num">$ (450,602)<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816348960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, Pfizer held 22,032,040 shares of Common Stock and had appointed one member to the Company&#8217;s board of directors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. In September 2019, the Company and Pfizer terminated the Pfizer TSA. For the three months ended March&#160;31, 2020 and 2019, the costs incurred under the Pfizer TSA were&#160;zero and $2.7 million, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also purchased certain lab supplies from Pfizer in connection with its research and development activities. For the three months ended March&#160;31, 2020 and 2019, the total lab supplies and services purchased from Pfizer were zero and $0.6, million respectively. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020 and December&#160;31, 2019, the Company had an amount payable to Pfizer of zero and $1.7 million, respectively, which was recorded in the accrued and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sublease Agreement</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for 1,293 square feet of office space in Los Angeles California for a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV84Mi9mcmFnOjgwOTIyNDY1NGYxZTRmYzFiZDlmOTlkODA1ODc5Mjk4L3RleHRyZWdpb246ODA5MjI0NjU0ZjFlNGZjMWJkOWY5OWQ4MDU4NzkyOThfNTQ5NzU1ODE0MzgzMg_3cee6d69-25e1-4997-bf53-faf3f51e1036">three</span> year term. The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. The total right of use asset and associated liability recorded related to this related party lease was $0.1 million and $0.2 million at March&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company subleased 2,180 square feet of its office space in New York, New York, to ByHeart, Inc.(ByHeart), formerly known as Second Science, Inc.&#160;ByHeart is a development-stage infant formula company.&#160;Certain of the Company&#8217;s board members and executive officers have beneficial ownership in ByHeart and two serve on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to 2,907 square feet. Sublease income for the three months ended March&#160;31, 2020 and 2019 was $0.1 million and was recognized as other income. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consulting Agreements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $0.1 million and $0.2 million for the three months ended March&#160;31, 2020 and 2019, respectively.</span></div>In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $33,333 per month in arrears commencing January 2019 and $37,500 per month in arrears commencing January 2020. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to 60% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $0.2 million for the three months ended March&#160;31, 2020 and 2019, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816348960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Contribution Agreement with Pfizer</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $30.0 million or $60.0 million, depending on the target, with aggregate potential regulatory and development milestones of up to $840.0 million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $325.0 million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three months ended March&#160;31, 2020 and 2019 respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Cellectis</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $185.0 million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $2.8 billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All costs the Company incurred in connection with this agreement were recognized as research and development expenses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March&#160;31, 2020 and 2019,  zero costs were incurred related to the achievement of a clinical development milestone under this agreement. For the three months ended March&#160;31, 2020 and 2019, zero costs were incurred associated with research services performed by Cellectis under this agreement. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License and Collaboration Agreement with Servier</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for 60% of the specified development costs and Servier is responsible for the remaining 40% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $137.5 million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $78.0 million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $42 million and &#8364;70.5 million ($77.4 million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March&#160;31, 2020, the Company recorded $1.0 million&#160;of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. For the three months ended March 31, 2019, the Company recorded $0.7 million of costs as research and development expenses. As of March&#160;31, 2020, amounts due from Servier of $0.2 million were recorded in other current assets in the accompanying condensed balance sheet. As of December&#160;31, 2019, amounts due to Servier of $2.2 million were recorded in accrued and other current liabilities in the accompanying balance sheets. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research Collaboration and License Agreement with Notch</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $10.0&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $10&#160;million during the year to December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $5.0&#160;million investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#8217;s board of directors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Notch Agreement, Notch will be eligible to receive up to $7.25&#160;million upon achieving certain agreed research milestones, up to $4.0&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283.0&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has determined that Notch continues to be a variable interest entity as of March&#160;31, 2020. The Company does not have the power to direct the activities which most significantly affect Notch's economic performance. Accordingly, for the three months ended March&#160;31, 2020, the Company did not consolidate Notch because the Company determined that it was not the primary beneficiary. </span></div>For the three months ended March&#160;31, 2020, the Company recorded $0.3 million in collaboration costs as research and development expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608680640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - Fair value, measurements, recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 539,288,000<span></span>
</td>
<td class="nump">$ 536,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813181728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets Components - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 73,714<span></span>
</td>
<td class="nump">$ 61,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(7,365)<span></span>
</td>
<td class="num">(5,472)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">66,349<span></span>
</td>
<td class="nump">56,449<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">31,516<span></span>
</td>
<td class="nump">29,924<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">13,967<span></span>
</td>
<td class="nump">13,117<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Computers equipment and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">3,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">2,804<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 21,653<span></span>
</td>
<td class="nump">$ 12,390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812924224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,868<span></span>
</td>
<td class="nump">$ 1,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 2,078<span></span>
</td>
<td class="nump">$ 1,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001737287-20-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-20-000027-xbrl.zip
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MG;<)V8A^N;$/7T0QONNL1^% NKN^V8YTBK]UQ;0/Q-O)P:M3OT+/C8Y(1Y<
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M;KNVV3RI'OQSNGW0X- 65EW;9[7+T]%V_3C6ZM#FRWVXUSKX&T>7U:-#ZD(
MST)GA <,)D#+S,8TEV(BC1P'C)+'^I%^:\#E(>/@0D.DS*B*$%TQGLP A#V8
M"ZXAJL+F;O_UOG'PO:%M)V%N=5VOLS"Y7ZQV-1_R3[MZ\JG=Z%19]6 '0[>#
MCOT#5+G*@2I9%41<.]D%?=H]_6IHM+,_JAU\:C4NT\K7?5Q;@_9TMBZJ:Z>T
MN79TWCQ9)V.(;.Y&<!D/A:!6**\R8E+-0^1#9BF7&0F:1J8]0DC=F>3Y]F8Q
MM7$2;NBZT'_W9ZK\MM(?U_@# 5;&E>!6!J,SZ.)^JW/63@7_QK\=YTF^-ZJ[
M+5^ ^.'N-^\Q>=SU9XR_]GO#?/QM7/=P90J:B1"?,AP[NU$85Q29?6OY]#VV
M0EX9-RC<6:#P_=;_NUD@X_;%[V8_W;S[V9CJ9]_Z Y,/4G&P\6K]5)HOI<W=
M/G;53'_M5#HN?'7SR.S[["%O;W34[#Y)]<:=-IVNG/W> 1T9YN'=]/'C@[-;
MS([-OJ=[W"D'QZWW7&B%D6<V1",,%1X'AA#SG*KIS#A/0^YS[_Y)1<K!M$=Y
MAMC5C:9''MFCPS&:;W;9M)+DRO[>VJ-[\Q%Y!HO6F]?Q^;C>O-$#CY@]7Z0>
M@"!I6IKN1_%TE;(\.^A;GZ%9UT\=VU@SZ.5/A-Y7UZ<?UT*WUVEU[[KM0PGB
MQBW>WFS]]Y#_E,GP^0/@.I]/2JT^B,_3J4_G\QO]1KV)@DN!,/&,.65I!",O
MM3'>*J3<S].7Z5N'HQ3R3+YZ>-C%6;OE6H-J2&%_Q;?@Z*38\Y6WEM+UTS7K
M_QFF0E\05O6Z*8UA]:(%QNJ.E)?)O?Y\>^<CKGKMJB4_49%OB$:#PT8]]Y@Y
MPX@R$(0@$:UDU)!H)F3^*D2SZGTK>8VF_=&T_%;WO3EK#4R[(&(B$(:"P5&&
M@JUESEOFK"'!.6>1)/[U:-!N&)A6-_AUDW<AWNT71#Y*"H%3N1PG*(N66"7!
M,&BJL%91&/EJY+/JW+ S;*?%2]N#XY"G\_)PG.[V>1K+%D1D#.)*+ )2&$<F
M?+3>03!OE%!:&"[E'(*S(ENGN42--[TSZRD($)PSPQAV1FFE#46$I.*"V)+7
M)]"?9M/F+US)-&+4&<$#@Q#>:"8M? ;)<BZQ<:]/N"]O"1= JD)J@JQ6@40&
M0K.*22XDCE)Y3=F=627%ENI<[.?\!:V9EIC+B,"^,FRY88$RB9S55D2/W,\;
M,RJRC7V1P2RA.2*>R,!)8$"I8#6C#$B&P)1V/+X:T<PA GS.,4=#-!=!&:LY
M"P9(DV$0F98(0; >\:L1T\^, )]3C:#'(HJ4*"P8(L(H#$HD".(2&6E>D1K-
M-P)\3I$)%Q2WT5#)&80."KDH*,>2&4EHC-=FY8LMLI\U+*F>+3A'&"P2V"6J
M4FUIP[42X"L&3%0DX"WB5R.:>0Q+/I^8%)86>Z\8XYQYBPP73!CNO<98*_1Z
MQ/13AR6?3S[@S%')G$G3W0PKJYQA2#@9O93<1?1JY#/O8<EG9#Y.&0LZ$"XL
M"Y%K;R-5.@1O U)&_#R1S:L'&'*>418QBH8II2UQ3%$LG)8.8D8VAUG6UV($
MYC\5'+&61GF5[ 6$+<%Z++&@(A+/4EKMZQ/N3QMUGX] (:9A2D:,&0D,%-:B
M$"T$0P9C<*FY?WT"_;D#LW/*V# @4DF\1(XP(8PUU"EDA;?.$N-?H53G/C [
M'T&#=240]AH/^LH4P\9QX&6.!:/@'\XFKE^!?']>:LYS#4]$)QC703D=-(M!
M*LHM)M:FQ;U6._UJ1#.?U)SG$I.AD47&TN8GDG&$C8C(@AW4D7JI GHU8OK)
MJ3G/ID;$J^"T%L%JIA4S$87@'*;!,T&F:V]>@WSF'0,_G\B4Q AQ9KD6("]&
M-5:4FF# U<2@:#_1*,VK!S0/Q#+B(U.!"1V-9=I(9P)UG! U)15PL=&B]0#&
M&45/ZX&K#//I\MO9[S=3O,_@X^P&#UZS8+EQ/C#H3RN8E,&:5$B'>XHXI\9]
M2?82DT0#C.4"=.P=\_;B >[AY%0LOSSBR>ZA<<%:)(64:>&B=5HYCAUCPF*D
MB?B):SV>2IY7BZ7_'E4G:!EO&IF'_PQ#UXUN4NC5R==.[>\&-\QSL'C?8<^G
M-.GJX[_A)4WNCD<?PN?0_D:KMKIGPT%_? 8MR!P;B5@X1[2B%B4^L\A9)8@U
M"&#EA5G\Q-@20$_R!9YM@0*%R)1P)8SAC*0Q0NO O9:.<$RU9H5BH-5^/PS>
MMTW_ENM6!7]N5#7Y:1AL#+O^>Z[UKXY=7!#R8\@+*X34,E(6(6[GBJ$8');*
M8.M4B=T7!@HIGB(M"G85!XOM)-8* A&/I8: S&EDO/4$HF=48G<AX/)Z?(9G
MQ"XF EGMC.(&L8 LA,T>(4%Y<AQPR;L+@MU%@4MDBLK@$'::,PA.#,0H(402
M4CZT$/Y5P"7-?X3<M=(@._1-\=!2>IAW01=3%*+@(0;+*#5@G!5AQDA*>2">
ME- M'<P%A2ZUDJ=5)UIPQY!TF@;.L-?(.6!A8DKH+@):2O_R#N@2*6400H<H
M%0L6W ;CC!12 /_22 NPUN-7@.ZBH$7AR(U."UI3^*&<B5I1I 5E%+.BV>@%
MI)MO S@_Z^5F$/[N=?U>:D!KT H+-3Y5%#>36N&8DXY[$QF/S +189HJ8A*)
M.2Y60/TK.7OSUZ=%@3"Q3G(!?X-D+/!@ ,82>\NP8L@(72@(+R!J7LSI*R%\
MQ<*"AA"P#,80IJQ-N=C8"<U<E,0@64*X1,T=0T0T$"J"YX(KYM.Z=$*HM202
M8XDO0GV'!XAH?Z^>CU$R>E%';P%!^^I]3VN-3#F@%D.X!-&VQ:E*I9%4<1R)
MM25^2]=WD?&K$=/(!:249LQAK[BBQJ3]L! QDK^.V:62?U_M8"?3+BHB% W1
M,(>PP3X"_RJ6%F4;]#H2\%X'?A<%,E(2% VF1J>I'.R-YH9&*XBG46OZ6BAO
ML_<YY-UTYUF$D';B6NWZU2,0+""HR%@J?=$[@.TE(TAZ+343S$:F.#4 ;8ZY
ME-(5;#G$H@*[=%+GX*320*3U2*<U=IYB'36U$&)%0J@VAI? 7GPLE=[K'< V
MX(=(J[WGWC! N76."QL$C2QM#%>L8?]?%-B+@B5A<12.:^ZY9-0YA2WB)$09
M)4="A4)AZ36145'<1XB<I>484R4(LYI 6.UC$%;&8(1FQ4IY*]VT.<P 8L,X
M=B)@%1AV7COOL61!1B$]]L4:B_E%9.8$2JNF$+).,T6%<H%9R:(-6GAO1:%6
M0+_>Q2BOQV ]X^+K$"2E6G!#%&#7&X6IL%I&' "Y'J,2NZ6M7%3L<L=")!S"
M/^69DD%%'#F1CD7F4@6*$KL+ 9?7,VKQC-AU$0F&T\B%)PSI: #&0,)"*H.P
MC078E?.7P.ZBP"5$I(006CBAF Y:$\D5N)<0;!I*9;'@LH!\4ZXP>'$(&Z-Y
M-#) A"L8,2FRU<)@2Z.+VO%B0?A7<O?FKT^+ F'F \,44X858D@190.C@1N%
MDB<:2*$@O("H*5<8O#B$!3-(,X]9I)1Q8%Z%TF:<4CD G ^AA'")FJ]1(W6D
M4=H X8ICPENEJ#4"296VU<88%PHUKSM#L/0][\ O!-2:1>XU,HA)+,!\DV"$
ML,Y[HHPJ\5NZOHN,7RJ]]3X((B-BV&*M/ XV,F' 9&NA2_PN#&06RN]=%/QZ
MA$V(!A/D;,*O0=)QB2Q1W IP/DO\+@Q^%P4R$%(+3)$VT2MF#;:&>$V=<!"
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M'YGPS#HJ#]?&^H81SA95\?KY8&77=(^F(DI?JZUNJS/L/%="TFYHFT'P'PW
MHYZ;;M^,R;7_]^CZD6L(^1A;ER'?ZKH7;L&U1TX2,T&T><L.Q\> ]L/+>%2
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MAV;?T_5WHCTX9CU7UE!M62K9(JA@#"7/'5O!"I!-70RT/Z]%>+U OY4BB7S
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MVW&)LAMGV^S59[_]A:VHAQ*UMS.K5A#>%R!J)X.]-1[KS6ZH#_F/(P4F&X^
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MML';U( + ORO@'R/XW\%Y+LOY)L1KT(20IA$IDZ&D#A&+I,8DHQ[&CU6%A-
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MP3' ?,#\I?)7 >;?"^9/_5=64&*"TTAR91"/!",G/4/2:6<9X91[MK9A\IS
M@/G-]%'=U@Y?'KNE/XJA]E'UZB-T_K)U#J?HEE?0VTZG]VPRRF>%X6><DP#R
MMP%Y?^$XG8F1"VJ1)E$B;D1"CBB.B"<Z&J,%+W4QB6E+L@AEO_('2Q[;.P8
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M(RQ+VMW<O#+=;"=KYRJ@JMOR]K@:V@ZX@!NK06^>2/U\=%_EP=WNOA@/[0S
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M)8KJ<*V8!NQLM(Y>82]T7=1C4L"J]<O$!_VO=JL;A[<[8;$(I\Y3O#_8A[=
MALL_M\N)LS@8UN%%O9G)7T_Y9EB0RR9TFKJ]4D9WM]?M790YL*]^BQC2_0LY
M8",//(0HD=#,9ZUC'+)>)J2DIE8DG(0C6>NTZ4+\ABN_L?YDS<$5!L*%;ID
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M#4;:DDG WR72]+?=3R#K=!FR;OX6NS%5P_&1ZD4(>X@$?9@=@^OVA\]Y8.+
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MFF,P&U9L-G@_.AIU;-DV+U/@94R5KZXO=@M38.6G0)W-8(P'LV=FZK^,#\[
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MS)K<FG[OZWT<*WIB,V@S-Z](8-NI)=(K6X6L1.K7+^QQ-<Q_OX4K!F; $LT
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M&BVG EK08)UA C&"LX F6!:@S *:&F5B"#80O+;!V]A<SN4": E>X<6&,BQ
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MA.IG[0V?,2A;CA$ER5@)>T](AVQY6,]D\(2:('A)5H/;Q#0O6\V*^:L:L($
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MPK+D) TL 6H4-;8%6/Y^N8(K#IX9[ R*UAO$F<NG3I,$:JSDU&JXHD@)P)<
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M]]1HYC '0\MA[_)1:Q8[K(*T)3S3"JY:A&>23P%'@A%V@2#.E42&6XVD](:
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M$7XQ^&Q:# =1,Q-Y.44OLX00]WT.&,Q&$DVEI07"CL L\LBY0(1%4U7%;..
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M)F*=]_!CF?^Z6J#Z=J.Q2H,K0:4T62H54TP(I11+;:(R0U(EDULB<F\WP<8
MW>[HX@K$$6C-LT5IRJB_Z:2O#SG]C VPR1LSP#9O3I+]]Y\Y/.='ZP;^W3MF
M/"4FL0JE*9:(T8PB03.&THP20C,CC:8K51S21'AGI9$XP\QJIP0VSL*^>LNL
M]R+L,Y;%/L,O]3Z_S#Y;DF*J,1)$BU "+T7*)1JIC&,A".$9T5N[-Z[?F[.Z
MSYOA<X8?.?>8T\^8VT(2'&Q(J:> /%P4-3GQ\I36ZZILV&D\F#.MXL ,>8XN
MM4H1P[SF6BC+J,/&2LXR)VK&]-($V_S1_'*<&)HZYQ.4I2$QE0%/$JFBB)F4
M4YL:D"9VM5)HE%%NG"3 Y%BBK> 9,\9SX;#"G->,Z>?LLTD]-QS$#G92(::<
M1L)QBA+X5'N=8.'QHQB3&@QZH82YLV.M,$>7@Q#O9 !'7;I^V-C9H-#%+.GU
M9ILL$\P:5[ (%*M33,K8\]4"@J,KM@RVJ^9'Q,7]-TSMW_EM/5#4!^,K_]C[
M(S[V<W<P; ]'0^!-C:_.@)X=36B?0\ANM\@MG+GM[R&[H4PIW2Z_^D?%;%MU
MB;D%-MQQ,OLDUWZ2@#^?=5^Q1%:#Q[_!E0=!/"\L4C-.6^E=EA;HGL[-=Z49
M!K3M[V$KBN#O&-16CN(6(VA,%KZK0D#UAHEWKS!5!VA2>5N9([TXH7CBF"QS
M5ZY4((I@=ID8RN,,%SZV#@U_JC.-DSHVO(X-?UQL^+VQWC.QX48J+M+,^LP[
MT+:D-&G*?>( <W*MI-[HV/")3VM.<"WP.%:RL<:.P^5E32$EQC4GVJYC\Q@7
M8/7#T45@Z#;(B,!:+RY&W5Z>3G2]4*R4D8?5,2T4, / [R6;CD)CPI\72(K;
MRJR!;//C-;(]EY>_B1&IA4MU,)KQXO47Q9\$,-(;N%M>78KCW#LW",$F@Q#&
M5F"8Z5%5TY>"*)KDP-UUEPHXNM.9*]47IC-7KB]*O<IZ34(VQVL1XR7")",Z
M*K9@SCD('P]0.VZ-ZA9.A-D5V)XJXC/EHBFV<Z::S]P3QC._I5)>+P0S]*>W
M*5<M9@,+)L]\-1;]I8_Z3/#;:"INOW,=*B$-@!P"#W8AC&4^3J#8KIR* T"<
M+?TTO3>K,X1XCH>-CE,%EBNW;0[H!0B9Q]&4LWZ!Z4U7MBI2-[NE]ZQ2SD8U
M H5<QLB<2V?:L 2EPS3&ATT?Y-DJCT7QQQFV^ 2K6=4&K,IOF0'7<PL]*515
MT!$:YT OA,&;>Y ^]A8PK\'"$FFFAPK""6125;(7JD][__[W/N()CEM;_K&W
MX'0.+GO=00R(#GMWJ[$L+QDV:R\S&<V(R(PSDEFK%=<\,]JG@FFOI;S'+DJF
MPN)_'\<0[_N*/>PW8*J_Y_%AOUZ#H"D&/[:/(?+6#&0''ZZ;!Y^/T\19:GR&
M1&(D8IG%2*K$(6^$9XDU@@@?BD#.F<#^JV0"$SXQ+\7FV-PTG>3AJ!=P1@/5
MK3G53%E9?E?]83>,Z2W3S_[!MV-'G;5"9DBE5B#&#$.*$X\RJK+4F51ID6[M
ML@?2SR35H%*=Z:33T[&.Z"W.^\N.ZH;\@;E@;[@#Q)@IPIXG53#FX5U9DZ-:
M;*-,SRC&:TJ4.R[A. 7VEAEDD'$YQIL*7QGT.JZ,0)@I05 9<SN_,.*#Z5,U
M#_(KTRB"<R:#7F(,KT5.'MR.*6^K!5[1*QY5%CS7;N9P[G0ZY:*DM=M2*"L#
M>U VI>*6N\PPJAQCU"H!I*6=Q90Z)8BA=6G-%^*BO'ES>&PU234V!F%.$\2T
M5$@+0I'4";$\25Q&Y-8NIMG.?*_J<>[D(XJYYQK!2](?X<X9D.$Z)8Z)1 E%
MF,,V%&_&1B=)37\O0W^?KUIG)\>$)\9YRI"3J4:,$X>$R ARP!-TEA+O8/EW
M,W%7ZNYRY#?/&/]HPU^J7_$7O4RCAJFBG%,ELRH)C&6HZDS1SGE&GL.#/!9E
MD$O46>X_S/O9SA^M>&]E[E,UK./D;\W G!_(XQ9EU0K-@+43+IS$+%6,62TL
MRQR6!!,B%3"S6SJ5ID]P>+_&7(" "-_R\<5-.+Y>$^-%8I&C!)0XS#G22A%D
MF>$&5"21^0Q ^'P/[_'A#<0 X(^F[)=;=]^-9G4P9YBV7&A%I68DE2*%![ D
M:&58I\S?LON\WOTGV_V;;\?6$$TMMRC1:0 /%"/!68*DE* .<X:]I,"\D[NP
MP]]7.?3UMO_\;3\_)MHD6F$"FG?B$/-)"G!1 69TQ&/BDH1+./19ML-NW?9_
M;$_7 (]B:E)Z?48N+$B?5O9L-!CF4JP]XV")-NE!U=%5WC66NG?ZA:(@*^3;
M6"^-%MQ GL$[-'%SY<F@\4VO1EO],*7K/Z3JQ*361+M;,>(7:25AQ0&"A(V>
MUOTG)%&U;>2I_[.937>6K9C8%297S0*MLI[2^,'3]]V!=')J+7.S\M(2*L;C
MA4S4F!,S+O+<Z5V%/.5Q6$RL/3$,51*7KSD123A4RNCG&3?1%A7+JKL\-WHZ
M<:RH(5Z0?U2O+L(6A""PMIWRE<Z5E4#YY,<5):H3K519#P.J6(1N*[J^*!MM
MMOIZ*(6@YJQ "REA*JJLVD/A'[?4<%\QZWM2SCW&RL!0K?/M$ \W:3@2:WB_
MFI.^4B+D'?[2>64@SSPMHD>>HY+!(CJ8(\0\Z*&R\_?E1Q99G*]GAU=++YCV
MKX64M5B9816(]DCOR/)8#0!9+%J][Y<+1'][:*W)6C>?CS-*M7$N0236H@*5
M#*E,8\0R+I4@.G-):%=PAX$EIQ$X0EV7NT<B983*'Z[J* G?H!!5$@1[S)@N
MX=4\>\B+-@3Q5H8IW9\1>6^J3",GX]E8U0>1,76)=1C3C!/#G*,2SE.6:)YJ
MHH5PV3VI%$N1\6J)%&^.?JN)%&?G)"3,2)-:PR6HFIHB9A5&VDJ.E*.49$GJ
M*1%;N\E.=D>+2%\ZB)=)PFWL11I>R"E+4!6*=$6X5[%*KV2/]BE+J/'6.<R(
M2!11.$PS9<IKE;!'Z+0E@>V9*-X&$QVV]8:K1C8/O@!!?3[&Q!!I5!8.<$C+
M 9ZH"79(*H:9L,08Z0,UW6&\&F=V1_X2JHKD84TA+2=RN4'>;+?(%S0Y1XJM
M\WJA/7U4.U0G8JS!J0MQ]SG%O8>="I"S2G0Q>JM"=-..D%5(CE.;9#:AC!C.
M-,::I%XJ(I,DQ1SS)) <!H[W8#.*,?T0,]RU^V$]_MU6NMV)7N#?\I5YN[1W
M\YGOO_]V \^^:MX<XOV]X]1E1CKI@O,M08PF#*G$B&!,I9G%) 7P%&I%KD*&
M*M^ 2<GA,4EV)GNQD"ZGJ''PFG/!5N\\U.H-S>DK20G;#VTYOT<>TUB(FF8Z
MX"S=6B@NTEQ/G_S3@TE/C)#-978:?X]?+&R<D]]2Z88R+ERT;"N4[4G%[VHU
M\/G*WO%5=S<QF0GN7ZHQR73,_W R^5CW$SD;C8Y%-"G<^D_ M]W8?KW3.(>C
M#8/\>^O__6,JVK3H'];NYI:AR\ZHW\X=>T!I[F)!'YYQ+.K>U['-*S<HM:,S
ML-J:+Q:[ZZ+_[=F3<_B]<WUQ>0K$!A,SHZ$K_M:A."!,HN-&Y^ZB:-QZ,>H,
MVY>PR'6&UY-E>.$ZPZO.\'I<AM>]&5LS&5Y8$LD 'EJ&?6BTJWF&,Y[93&16
M4BYNS?#: )%W<0W<^T+-!#;F8B;$89:BIBIG)FE4<,>8E4X"1TN&6D1DSN>$
MY95^\T)995OO/'<6Q$H9XU&\Q;O7%?$X P7*IG2#I9K232GGJ_:D<UU8*Q?Q
MRXQ K."(B6MOO&OC(HI%<[J\'&(YIL5F\<F.CH><A]B&CE@C&_9W8B,+5K-!
M69%4-<YZ #9FHH\O+D(I-K<SH<,XC+YK7V@ 26X&K>36C&HULMD!YBZ/Z2$5
M<4'!9CXNSKQP1ZJE#<?>E=)?D-<1+APN_OY:O#,$L9TWN06,,K\EA;<UE$F'
M[ZZB21&><,>"C>^UKMIU)_K_QOZJV:VNGO\+-P%+11A3P_3;L9+?=M&2MYCM
M X=QQSH;6+K>,'?Z%4E7UX6/N9)8U+V>FT%I"HB]\^+Y:'=!> S:4<V+-1 '
MRKOHRX6'O1[/QK(-0>>(;GRN8K\"%>(' 5.'D.BBRB:L9G[3BF85H9APQG*7
M*L6DY-IX)91GJ6-:<.$*LPI.'FA6F=+!QA/ZEH^^B"A]LY:5_3#NLSW>O(%Q
M'7S^T3PY5A)+P4F&*("K/+94"Y8BJZ7!CG.C$Q8**2QP?>1VM]*^$C,X0"_+
M'=^JFO"M<CX1Z>6_!Y4.EM$:V+=Y6O"<4)OMMSA#I-,IR=72D?<:K5<E6JHP
M%C1QDMJ,*2M4FF%-$PGLTFN9.SH>ZZ^K'1TK4.YUZ^H82Q_Z31FD4D<1RQ1%
MBDB%2&:,QY(:FLF\!,B==&M'_5)PAKB%0&RE87GL*VL4&4@E39\J&PK>AUBL
M@<M#352GJ+L#0L>/8DF#T5R"T Q772TEA(K,IR*EWGEFLU1GBJ4I-I(S4%:8
M?03C+$GO<_>[*^+%/G?WO ?A&.)V_ACI0=NV57!E[I55M 9 G_\*$OY/N!QF
M^W:C]&=(,VGN'5L>NDGQ!!E+9>Y.%AF0)I<>%,2$@9;IMG87M=J:Y:GEA@1.
M.8UI![EK>>!B"CA<V!_&X#-0 [R+,'<P[)GS&$,8[$ZAL7"EL/FI^AY3T5?,
MZWP8%9)92OOPGQ'@KJ8;GO;LA.KVKT U&9RV+R<)GV\WA7.&K'!K[UAF6<(3
MK5%88)#5F"(I,H:<2;B0VAHL05:3^4#B_VKTRJ7-8^1@P><I*L1[#E7>5L*H
MR^ ER&DHCTSRHU#NP+:#*='FL4:A,("S@1UTKF>4D GI1AZXL/KSY)KMQGN@
M1]OX+1@!MAO-G?<[VXW?3^,_%8,[@(??8>QM&V_Y[;3M?.-#CF6![>X#QS)%
MX])?>ZIO05L))+P=&ZBKR\O KG+U=GKB.EX,F"#7@'NO*GBMU*KG('[^0:F^
M+PI>73UOS%O-K<(),5G"-%$:_G$9\ 9J>$+3V_ST[&FRQ=YTX/DLO]C_<IQP
MII21%A&1*L0(!7X1"FL:99G!.A.))5N[V<X"CC$MAZ)1(T^?BLRAC"^?,>E4
M,Q8?TD$T!!O@E'--F=! /E1[FMHT]=Y*XY\L**Y..5R:BBA('2ZQ5CI-@8 <
M:(B@JB.=T@P13CFC6L&Q#NE+]X*9T&-FSC!S"V7=:LN<38I=G<P84#^ESA(*
M?$D9+*20Q%-L0W:,P:HFLY<G,[8/X$9CQ;3!R(A0F5PPBD3J'/*2PQYI1@'B
M +@1]&&$%D.F@X]X>'WI&G]O[SB %H5;N==OM/Y?_/4?MQ%D28S;LSF:E?#Y
M:D9I+ES'F2&P_<-.#CUNS0PI(DTNVO&R2O_-1MY_,T^:Z'7G#<'CCJ5S^1\+
MNRJ.0TJ+!ILJVKB+^/,%8>6Y<V&N64\1;1X7H&N*7F0/SRDH?&RQL>]4*[[!
ML&I#CZ;RO!U+=#\,8R>J6)"N\5UU8/%BW\=;N_'-OCH,+0RQ:-P:#/-38RWL
M[\.Y#H"5DB<P)A7[Z,0HHEM:^-WVXK'-?))) 03<[ME)?LR#%O750-C2"3.X
MQ5@]G4;QH-Y2!<7-':RE6TK=1MB@91=TXVR(S2XUI'C1A)ZVYU]=FIKN?%UE
M3D7?Q=!HT?4O78C+V6ZT^WWWO6?ROHNY_A;3FT9Y8;HR%,CWIUQI"QI)W5+"
MNAU.82\GXMO6O5C@<&*[L+EP$N[M)%4J: L:7$5VNMS@XLK-/#D.8[;S:E$U
MH-*K*E;OC"M=7!)<7[GK*61EQ?9519[>W*F-:?R!Q8_WN6SR%>.)ENN153:?
M,J_A&&,^6]XG+&?I^@M2,?#>_%27QWA0]N*+I2DBEQT;+J(TO0XVV<5AY]..
M@7'QU7@68UIE[RKW..3J?A'?.?:1YW+E(J1PA$KOH9B4Z@X[L0EKN+QT8S@8
M:^^B;<J^ <&9#*<H.I:#W+[>'E=1>TABD6W;..S04JS7R>N5YFNDG5&A#.74
MU3.K"7CAJJ#9..4^P-/ [>!\PWS:*G2Y6R$*;<-H;7&<S_UQ.R^>",9-2IDD
MJ?;2LH" $YDE&5>$998*IY],&9EVB_8CEJS]2M.QYO#9=?/D.*6)29S)D*%,
M(V:-09+!;\8);S2A)ABW=Y,=>GNL>4SHGHI<6#Z=9OX@-A8$F,=-NC<T+F5;
M"P1'#+L+O=2[PW>(AJ"TR^"BZIZ@CO/#=_&3M8M<OSM./=O)C^:J/XNCVAH!
ML@9./FW+3&2BI".6IK"J5FB-G9'<2B5XYM+%G>JFW1R_Q8"7J.KO=>UO<5-#
M4UL0,^_; ]/I#0!*', ;?^WTS/G//7JD-3YZ'QA<?W[XU]?S0_*--0^^GK=N
MFO#94>?H D9TUJ2'%]\(Z.UD]N@='IS"V+Z>'GT*Q_?D1^O3%]J\.;TXNOCS
MXNC,7#=O;/OHX/!'\^S(MVX^)*VS$YC#-]X\.+\)#H[$F$QF&?(\(8@Y[9"T
M@B.7FDSHD/ ES6PT)F4)ETKY3%/.>"H4 0XOO:$6CD)F_5;# 6^[#'3?'[FM
MW<J>%.U9*KM2'NF"(&9B2!=*E?O?/SW>C*?,PSQ@M1*6$"J!QD1*C.)):A1+
M%@1D;]I97;GC4&B^/'@E22.?00<9G8P /9($B[OR14+D; C%#(I")_:?GK1#
M#<BQ"R/J19]6)-1"G 2[ LP_!"Y&H!KP83M(E]PFT>_]:%_D#KE;<<C@/WXX
M"T24$3H5U@6'(K98 H/CJ<-,)2+A)A8-PB(1,_B#+FT,!3UJW\,:YTZZ7T?M
M3J#B=>F ]N+,KWGP[>:8ND1Z*BQ2CAO$$IHBS1E&B=,"4^T3)T" IV(;2'8>
M; S^,PH%5;QSPP:(C[(BQ1^]42@;#M0%EP)3&YC>=N,W.(JP4=VVRI6CG-QB
M:"LHYW=)P54(8[8MGAWU(X:>%8O_=H.!<_LE\<?C'TI3[/O C,,$WQHUG#6O
MCE/E#=&90488BQA+)1(\Q4@S#_*!$J$Q" =,LEDA52HJL;Y+K-5=84!!E^F-
M3DX;'YWNCX(."&!%CJ.R)['[L..NZ! 0Z2(/Q,^-$\]((+?T35Q$(E]!>;U2
MG4 I;XP^]@].>.O@$#240[Q_<(BCEN*)%<P@#@P P<)3) U-$.8$@"B )HV!
M=PR"I2FOQS-'-;GX&+=R&0=4J\$@&KA GI2=6J8M*C$./ 2PE0X%()P0IMF^
M"/62H_R::O<6[2M%#%ST4LP(LMR3=QJUH^@;65&'?ICH6MZ/%XRVP;CSL=<_
MB#/]7)GHNFC.+P_?#S[@8ZRLRKR4R!J1(J8RB33%0)3&&.V99UE00=E=M0V#
M%72.?F)+D;CH@\+%6RU>4IKX8K+VI 2R.PD,K5M<.@[=S,M4=1M*@XC,RWI'
M2^V2>=MK;>X:0\Y*%\(7QIRKH,Q@H= 86%<6ZM'B3*6"&LIIB&=SQ,O\J.)D
M^J@F-<A\*,C\@)M?CK&C6M"$HD3I!(':":(B=0H9FQ'-+1>@NP*P8-N2+;!I
MO0S,7(4R:ICY8'KX?+V_=VRR-&58:)1*#-"!:XF4#5J(DH$4G#=92/D@['Z@
M.2Z/, 4UZ_3V)TMO)W5Z>YW>_KCT]GL-CC,&2L6E3X$-.QLR%3*M*!->:YY9
M37.+Q 9#I2DM>/L)U>!'"K!:#5Y*?C6O6WO!02<H(PGR/-0D2SQ#TE*!J-6>
M*\FT29,U4GU'ER=]%?\*=?6*$E-W8NQ(E 5X@F>%>(?O;J(2K9J]^##4'13D
M6@M>PHY[W3HY!DZ9)3;!R$O/@20=1R)+!<H$UMZ%6 -!@L]8W*H'[S2^+M!F
MV]UIB/6J=-8*+[ZGL-8B3?7AO@[GG%;<!#M"QK1(1:)B9 A@8&ZLT4794E*6
M+25$/,;I,<V]WZXR>G9.6E^.N;,I4PE'1J46,:4P$HY+A'62$D!"EA$2RCHM
MX?2(77"5J?84CVUE.YU&V:IVTF$\\%_X+:_W$(X5R-#^^6TJ:VQ?/B[]<9?<
MQY9KH:STA&"FM534,*P)G/G$<^9)GA"9TU"MN#Z4=F[V&-".8(GD!L@F31Q#
M3"@0_)GAB&C)K<M,R.L VA'B-L4UB-OV(,;:E(5NBO#U6(1H[[+?[A3VQ6\A
M4G0<_=_KYN;KP7R7^ULY3S_':4_+?&8[JT4Z @XT@Q\C^VG%!-[ @.+0#WH?
M(K9]VVQHQI5"FB?'@E*14(-1@C."&!<6P>D5R$IC22C/GH4FN\.KWCP[FA*Q
M82]0^P<Z;5OKNN_>ZI)2P$.8@<Z(%4=4\'!2G452N]#WRF,.?)[A4%4$J+&
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MN'78_RBW%A@1-M2'7#$@C(5Q+EY=CLLJ4K:<_1W=>H*J7W8:J7Z%Y<KMT%Y
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M4Y6I+.\6<E]AH1<3"9$N!I^[>=FK3_W>8%#;IE83!A.O#V?,9!;8/Y?,!T%
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M%)XJV(F.NARX=^4O<UIS_+L-D^@.WX55M^T!3/;Z7;L;USN^]Y>KMAV>PJ[
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M5#\W0\^"\]/C*.2Z$WN^'B9.I%L.CWAL\MAGR:/?W9$Y9 MMJ\R[XSV5KX^
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M;AD4K/GSWS#6<^/XX- X>OTAL0T0SY.QGH!*I#M.:.A^Y,&A>XX/@F7H.V&
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MGH21K3N!&^HL2 +=QWZ\XX3'_MAZ]+L[ LXX<M<T9!MHYE:(UO<U79M[EOL
MQ.LS[+BY'9;H:^/^Y8]R.AM^CPML"/639._<JP#6P#8>"-OHQF%;P","UQ[K
M,=:T=Q*?Z<$X<G0_B9G)F6_[6![:"D:F;XT<8_OLV%_G&F\KO1RLX /!OE6
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M=*NLT))!8YFP_)QZ7DQ3L=W'I\^?/:%%\+ 4+=7&(]D>X^\\PRZ1LB\G7DB
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M#C<(0_>BL%'$>9_"KD,6&/+K L_Y#L [6?&Y/+V7L'$[$'V7^_2%B_O1\P_
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MSW[5P32<]Y8M=?UYRYR<HNRE[E#6'IVYBE,JN;+Y-T[0#9CPD*[^/B[YYT8
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M\RY0'&$?-3A3UB4.;U.G4+0W6EVF&V)"O+\)=JE11+=H!PTQC3=ACW[LBKL
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M2Y\=A1NT*K2?)[RG8#OR;2)$*-RC4JUR+T4B=+LO=!E4XH!(8POBI9BV'DI
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M\A\.\W!K9B)S(D\^L9RX HI1C(;'.]]]]3)XG@T-DJVZ&;>S+96#CO@+'$J
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M'%VEL@4(D]!$]7$J)6MJXF>-T[*V@]MM<U-XD.A<YCGCWQWP(KOMZFIUCM]
MIMQER:4"(/6-F)QG8J6M,DZLBUSQHU@W\[IK2'P)R&R&Z'MRAB\RB8]\6@]U
M%#P2*C@A_PU6?+/I&-6L08W7ALE$.6S?5BM%T?VBU'%60'6U[ID5<ED,CWPQ
MI#T.K,LZ!$Z)6,AX2B,Y83RJ+]/ZR*<UL2H,L0H9M#B5ZI@UH4X/ZO56,Y^L
MWDUX8Z:V,.T09]_V;;?Q"K$?UR@;Z E>5MEC7V4[HMWE;."/F7<@F3$!<2 @
MN\SG(Y]/4%DUNVJ%ZO?;FET%&?O 5BD)4,)N$(>+"%W"7ZAZC."?HFNHE\V2
M))?%\-@7PQ",U1>_++5]0Z6"=KOJUH$LI;B^+1[$@]!.CQ*JA/=:@P@GS'U)
M.-S%PC^)16!;.$Q^SF>-)7'7;->:3M\71VKT\7.767TBLRJ%P]5QL=D>@/TW
M/IO)IMCD4J8,CS2.E7;4BP^H:7R/A&YNMH#YD0])F<:EPZB1WG3)RK$7IS:2
M4*03CI>E],B74A9>!$<@_$OCA1AHV&K397-Q!!__K#XT[5M6&!=HOR!9E7AW
M,<L7C 3*/'+F'VJX^4#T.VU:+=--!(27Z7_DTY^20N%<)]EPM;M!_=1Z6? $
M2]??0FGAHX)L+8CORNWF*OQ::5"UT4S2B99!O"R%1[X4$I7%-K;J24<IF[#4
MM+]HV/6Z>!W;H9Y+WO#9'W[W.R4%0(N%JO ,^S4NJ^"1KX+57;'=EBP52"N.
M56:YC[5OE-($=5^&3\HO0(U0HN;>XOH0VU*F0>F,DOZ:4?U(ZH[:+]OR*[U!
M_'O\?.H>EDCL0'7#UI/>)(HN1]!36G&N:2VUD$DP0I^2FDOUT=K,$Z^J[RN)
M#5+#YJ4<_BBI"*RQRZIXW*O"18I*M,"0<K N)AD64OM/#>TMX:H)3WFU*]@U
MV16=M/^E' >(<>_^?BC>PMGINT,=WC/\M&&;:KR<":R4^XHW$G#?;=E<I1RI
M$LEF"91"%9W9*%EUN[-&A'6EKQ5/HH0:MMHY5(\+&%V;?H14XM?\HFI-\S,O
MY&3 -)7%ZDX5WL)A\UTKG?RDC\*W_MKTX>\_)DWH;O%]O;I>?,(_?+I,7WT1
M MEU(=V>[P(8N<Z@HA>.7P=-,UTM@"?CNUU:@#ZV!>CWEQ:@2PO0OVH+$,'+
M68N$ S+S&!1CF[<ST(_.>QYBAT.B$$L)7CE9M25:Q L5>6V-O]94$0'JVX_4
M4GT"X$JP"HP9+<+['+J^/28B'>$SOVKJE8RZ?4*8UC%?%+\$ T:X5' .PO/\
M0YJ6A;T^AZ4SN5X$]R+\M6[NM2?^5<[&-E2KB:!/T]S:8QSIMZS;PZTQOK9C
M,C]3!X8*0-GWI8E-&=-\S CXNQO]Q*[X&TX\NF-VCL\ON(C@+F?[;I9&3Q].
MU;D+B<1'C?;I+K4T&3!-$<>H4U?]00DB7CIF0/\>2LX4R<C"\7X+00BTC5=D
MM0?[A!"+6,=0O)')OEH3^19J.FT.>L[5J8+K8/")R+&?-U#D@8MOHC(NS.WV
MRH]CWA_R V0^A=,,$M;'8&J*V](-7>RW]C*R4W:E(1C0LYN8@M^)7ARZ6AR&
M?++C_<-,E!@D[4);_?U0=945BH3([5T&3'>7O4RJ6%';FQGIU!UV4S+^"UNS
MK,E4',DT,F;#%V[[92S$1H<V:"Q7 IKXT(Y;26E(')6*)SO$^]@"4Y+[^$%K
M>MNPHP!<&3L5=93&]/3B(VL01KN2Y]Q"*#)<0)'X?J8PF35C'KPBNWUD.!)]
M_E*F1-?>(KP(B"*%N)/D'F'7DS@R>,O!G,&RT&Y4?+]5HM")UB;7!5R2H[%=
MZJ_#14:"@[ROT/9T/5==4<\V^8CJK]D^X>8L>W B9J/>M"8T !9D$9WLE5_*
M8.^1U<3@D /.(3S":"IC9^39!G,_9$>8HV&."F;O=$RB((RS F,)Y!EIQ;EV
M8)(E^0V4B@UC,Z]";6EY2K$[Z7<(AVP\T.4Z@VX]G-VWIQ298]?<H$>Y NN5
M+"/7DR)]&]5&J?@@KEG4JU,\-17,S5UUP[SFS3&65M)PZ\H-\6/XJEUM?W?L
MJK"[:F9+NV 8T.R&B2E_J<ALM-B5_5VS%@7V*(>DU(^3FIKT"MV%]:KXBN1<
MPNJ;-PXH$-PU9,\CE4<(Z&<9-3#<!QJ_R)U+Z:*=</6ID%RF1)WH%5-KJ%\0
M(C56E@MFQS[[^GN(]CV[7OQ19X:KY?.OW9G #S[[VHZ.YW6-7/0;RLR<<:^7
M2J. [I!M16@OY3*687A;'C-B+]0#8H\K]D!J*"74HV?IP!P=Z:'&O_3ZDVQA
MTUW_&0/XS/8R*="SC4Y>Y?DG"\S4(]%!C6O^_L,\*YGL3IJ)QYDN3*3OA!]-
MH;3JM_2>._*>XG@0#]<4JF.G_.(="RWU_;_[8C[GBN]^^TLX^/GZ+^Z**KQM
M+9P^KX/=$5P2\X@A%-JXS[X"RH72NV#(XA^_LW @_V/ZSO\+:YPN&VSI&PL$
M_KW8[;\V>?%=?M.7^@;QJA:5RY]_C*&'?D#([HQLBL4O)$1795(-EA.DC$_6
MR#=AN&F=L7$C7-/CMF8&-WB[$'IS&8.,$2L$2B$,.6BFLRVI"2WQP+S2PI3*
M JZ.%9GW;IZM:_5S:KG)(]!B&UT?GQ/OO<B!MG?\T!R0$B\TXPW*0"R0BOW+
M[''OH/BW!M,WZAW*8'9,V:*3038_6JP**:DHP'\JOO8!%([L[FT5XE!GRNWL
M5+J7JHNI#[G/4;VQ@:VYJ]KRI*%)-T"((FX43XFRW76.VOML5]&/#>UVL#W!
M8S[PW1,4F_[5CK0E??2!PIPN>2"KTR1B"EM$36S3+LC;@8 9C?!)NT"YS]9H
M$UJ]#4LS926L[2/^$0+KBT_>_/#3IXOB@5UFC+,0U"IU!"E;8,KPV$*M$1];
M6I$&]P@7.W$MRX>Y2,1IZ,%=WD6.>>-]X"W$BX[QZDUY;&+Q2:@N;($J_:00
MN^.@=:3>/(!))H>3D=%M\,$U\&Z01^U\EM9%0M^44+<4_]=H)#AM7._C.0VQ
M<[F[4?[:=YR.WKCV9;&3C FV!K)UI?([)I"_9 T.U$UG&1Z.5Q@>J+B&" ')
M'UL,[DM#BB?S#=TC2P)C^CM&J4<"T;#:D7KV?0?*4U(R@#$.4#OCXI+1B*XL
M-)3P]TKSMM0GE/Q(<T@O&(RQ8E!B^4[#@^3FIC# *"Y0\EVIT+P(A=^77:(2
M#!NS"N]V -N!QF;Q$^XME$'?WD6R.^KC*IV\NF-C9\QK ZACMK3%PX4;WN\>
M<ZV6TPSSW\(.!6'OKEI?;;%,E($+OS7O+=/S//F%=[IX9QTD<4.$IX2 )?+V
M2H8OO+)*E.OG"1\5SPT4))%N-:5ZM6XM1LVQ<IUH[@P'*B[;WYTOU\5S[IN7
M84B>+:%8\=G2*($^?_;E L'@%6VSVTC/1;Y@Z&3ZC*-D"I",T<[5)&BG7UL:
M8]I#F4VC2,PKDU#&A,%L\?YP$Y90.G&CUH<ND3"O!9F2O2$C#"&6""+[1A9/
M19^0P97P:LW5'!SCUC)5-)S+[Z*P%\I[3Y9MLA_KDD*(3;$^G^8S]6/0['=5
MXNFI_?GDSZ;W( *Y("!.(R#^<$% 7! 0'X. N. 9'P6>D9FA:G.D-59V2?Z,
M6/A6#H]E=$!C25A<./XSY;GC*7?!-C_R68]>FH,\;B?E11VH9JB DDD?08VG
M+>^K\- F<C)?EF($I=6W[=&:>4=P?M^SJ?YJJ\3YR5O(^!$O$.HGL/A$7,]6
M7^8ZYNZ@(]>U;BW8*)2X2!<D35U)6&<-3MX/2*OIY/[G_[QI?_.?'_RUQS?D
MS[ZT(HSZRFDXPR"S!EFODN!87JEQ#)2G1$DD[%\:S\9R(OYW)L-$.? )<=Q3
MPM[-;D0 &4_R&D"JX-!3**%M..,-\T/%#CDM^!H5FBYZ(L&09WV % C26>OB
M&+;OU1K7Q&/$Q'33LFF,P+0&E\HD'].%31S&\Q1U,?!(U[Q>+!:#BI=HE0UC
M9[>8!RFBNT*S*3=E66>I0>L>H#J1I :)U&HA7=:^C9T&=PU22.4OR#*KX*,5
MI>L#@AYD$X-1 ZK%OJC)QDA"RG?Y\<Y ,:F*TX>A+/HKW$-&+\'@<:TK/('\
M-6:=!+-R6^C\A[V.[*/UTMQ3"CE,*GOULN*H1(FFTNB/HO#EX(CLN/<3(&,R
M9HYRCDLE @[!80]08'@CQ^\]M8B9"2OKV_Y.LTAA!3KE*<\BY$X?CK4>49.9
M,*$O\R^JU5#R72+!O2(O\/E6 S)Z^)9^1%$G3!.Z[[JRE,9,,5LJI9K2&JUZ
M']F&Q<QAS+4[')G-5*7U(,5EK!;JJJE1^X.H5=C!W]>+'\+687X@J=;&?/0Z
M"BK'DB:D<ZKFT&V/J?P0-NSK31B4UM<CU:O*9&!%[LHN1:28VPR#=A.39QR(
M(T=^5&[:4TS'PU+L1PS1>#)N(LI)D ^2FX\*M@+#>[@+]@R)1L@M<J8%TH9'
M97$VE<M\=3;BE=0H>L;7\.#%UHB7;?>E'CK!>>RJ[FJU!47VQF7[1=G-37NF
MYUE-B4M,GV%A%@7&N?9GBV"/,-@F2P<[#.6N8G4<E<3]HO$#K6J$P:162;P,
M.Z;H&D4(#.F*M<!D F=+,: "6$Q+.$O=#F K'X-TB^/_4"$Q*+C3O$#^KH4Y
M0<'MST<#@?GA:5I9.*E:5?:"L.D!;QA%!]EW(P,808,ZIJDHN_Q7J,I^GP&A
MIA:ZI'_'[DM8J'<"P 6(SNTJR0D7=82VX'WWG4I%QN'7Z;#I^4 (%=79"_3K
MU27^3BAMXU2A-2,^% M^+Y^V@!M0>/9I>S#K11!9 $EE+X=Y[*':\=@CN6W"
M1CWO6A-%^!I@9(!I+M_&>L4*&ZH25/I @B<EC1*@.X/M9Y*'(PL6-C!GE>C\
MLBXWE9-VR&XZ??FS1>"]YW0L%RLB_A=_:\)\0)^0>C;"DY'UMW[HO$TI*JG%
MOPFN>7D?W;N$D0RV]W ;X9+OKHQ9;HKW,GZ&66RPE,JH(^\5$C.-/ >XU]N+
MKDDLF^>2#EY[^]")D"AT.NNFOFJ!ZH\&04\KXK2E^5J:./"H=:D-V-NFOKW"
M0300%Z*$J+0)5&DDUQ6*2?E!2=P(R/!*(<#Q3J6+L^E4QC,Z<X(>WM'/!^<[
M+":^UUZZ&K!^TMJR5HZ(6 ]18!,<=:EE:DHP^#AP$Z]X.NR<U80(\_7B9?!V
M&ZK@Y"=$CMH=P%*2!D<Q\3AAOI*_&/Q':>X>-@G-IRJC\#K5<-3A6@,H8F*S
M\+.;1GJ;B*)82(-3^-$OY4V^M^Y-#$?'RV\8>W-F4^<6-1O%+!7+Q=@!LY-Z
MXYCHV(D8)6:JV)3:DU"B9!]<4UGC"0#)C2X)@O!EG/73X^F0,EYU8?I!!07C
M14;?M;U/M!ND:.^V1%)@?U<I(-]%@:JX'&D$1?5RA.+$#6@Z.I]W1,CN>AZU
M^12/]![M\N?A(HIE+[/F"!NT>=F[B2,YB2T!EJ ,%)/A5N[Z:>6)U]JETD"T
M=H,PV33C@$*!/C+;+\@)3+X%YF0&># E;%@J!P.N\L,>2__GIJ66R%C_;;:%
MDD8Y.29>I?>]UOI,UXZJ34/-6I<V;A26:K AS0--I]N>;H23UU,FS3+S9C65
MA46]C&I7<!2TIRKL>CS]"CD]OMC?#AU 5$!:#&;R_)W:4YZF-"4B#Q V1>]R
M$I-S<MYR/T4,((D-[4L*,C6';F8PM'4S>#U"OHJ,4<K\R, :&MS9'6^/\K;'
M! E4;;ZQ6YNZ5^48B>XGPLET%\F#&]!13Z+IMQBV=;C.84(AGK_1AD1;(LS7
M6YI0=ZC:(T<:X[ED:)V60P=V9E =().[7"ANV)9N!)I2"+EOMO?LLKV GW[=
MTO_M9Q?PTP7\= $_/5DD0G! @U%<57O&,+Z:X.*:>-*G/J1PGN0GS 7P],AG
M>@!3C]"V-+NN77/$J> "#H%5^VC$G(?+&GCD:Z M#2P2C'76#729ND<^=6LA
M5I*I<PE-0G4$3; Z6#M;['G(LCVQQ&CL*3-5BG'HX!W[:#H /(B4Q)?U\\C7
MC^7=8Z/E6#8D,CZQT(Z&TX1R8'IX0 7*\/3072;_T4^^%D.<O/J$0/<J$^5&
M1@S$S95V''JB+:DQ^MC[@CI^ JM@WW1=A<W\T%9]>=5L-I(7"CY]U0K&6*IT
MNCI067'.?TH1C0^)LRX(%%D9E$DEZJWXG%(#K--RKD#O8RQ7&1 >!Y<SFTFT
M72^>QZHS !I&UY\Q]<$D#TYN5!A."(;GW0R-U7@EYO/'?%;["7=MP7,B^B1<
M-5)UD$?8%O7MH6"I-RI;Z=UB82X1-T.KC$"9\N^'LE:,7L,_ ?2;'S@B3AJ5
M#0W/M'0ZB'*6)17D29+KF.F/<@?GNWR_DX1IME*D.F[YR3$?C)\GEMI1JD4E
MOH@S!/\A7+$_NMJ\ (X) VA+I3E;ES?]4K&3MU@K/L, QW('7+N!&LPC 1.
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MQA];K)/K_];DPKOS(!R:Q2//@/ A7Q_:[E#4CI@QF/ZM*R8,"!412H&BJW]
MNTVV$60ZW233-QG&QFPY%><<3F@#]R!X%HMOPCG(ICE; XM/?DP??<V/?KHT
MX+08Z[!XI)W5^$CH@O ^X%N\K))_UBKYJZ8"!*4Q/_F,]257H>!XFY.)'D 1
M5^V,3WPM32])XOGDC3:9W0FWK-HH,#%:-Y>%\,]:"#\PR>+-0SJE?Q(5=&E"
M52D@DD/W\@>RX2_NF@>;T @P*(A\MW41CWLT$:>H 8FMVZ99XR"7S,\RT;:R
MX13I&SZ:]0W_M!02%G>91%&%1MK6Y1.ASW>K#LMT[]52[,Q$U]?YYH615_!>
M&_50$@>(G\7M>[N!V2Z/K;DP'P!,3^_A]W#[I"3S:UT_I?^)73LC7]!LE4LK
M.JJ?C !EU5Q%SS$_2#]YN"L9I=B@A'.S^ 5Q6+>*:]$/YL(_U*?D[W*M,F%K
MK37W+*.E+9U8XTJ7G^9PPA:[^U@3-O;;I5/@(SL%OKQT"EPZ!?X%&"-)=)VQ
M(* !V^C @J&1P]ST2=]2T<FGWBA7HTDY&K#U/3-/,VV8\63G!>$4GF]:Y56>
M=#H@._\/&9FZ[%WFB="@53A>CL%F"[Z/B3IMF5=>GN(7Y*W:ZN9@G"0W6J\K
MUQ]2%]%Q_,__>=/^YC\_^&N/;R$_^U)J4SBO/;&$D4U(\N)W2^NEIPH,BH/B
M1OX8QO7%0?/U_ZNY$5G.3_#K\,.G%$W9-6LP $0>KQ=-\"B+X%<>PJ<A/OFF
MW%;E1G9)5+OZP=@<A&?B^9MO?]!+&F/B>!D(-<2!"1/LE? 4((!!T!8V ]TV
M\;$&X3;>3Y<$%A*>5=<2ZYH;P/9+T'* 9+JGY!RV9I5X#%@Y>,>#O?_S( 54
M=;8\L?Q__YFPX12_*(0*;:M&8QJ]&Y1\"VF]?I :-17EK'[?.59!U%8@K*4>
MD$Y8E ^RX1[DJZ4/^8=2V3N_^/WGO-\7O__"HL_OQ0/=ADDE4B_,MI!W/_O#
M[[_R FA*F->T0IZC"A+-?=59MW:4(5CRO6(- LN3#W+;,/8QEI,DR@,VG-M(
M=O*)5H0<KP@+=]8Y3U'I+S^3OO:Z1R%_WU3PD7F9Q2=AW5)@X5,SP%I>23?T
M%!TH&( ]A&PBX!PJ%L;9VX?SL[S"$E!']=.EPCKBFZ6HT-D^=-B#F*TMK_29
MWLL$:B$@?6M@!47ANRM[N7HXDNR#LKYD+16_C TF*$-\Y5/.*Y'_($<+W?SE
MXOO7KX:2%<;\JLPU@'JLTI8->_'W.5C#56N7)R;[VF;[YS*A5])W%\//Q\-4
MH1"#4B[0XZRU]XOPI8TP Q .)1S^=C72U0-E3K[74LT/%=Q=L.7RXY@XM0@J
M94?ZS:XLA="73[.,R,B)$_#=4V\:>NL$^! 69KEOFG9]]]RJ#.;:+(3:D@=]
M1_ON:%R'JNE]%&D(EX2K9%4OO8ULA"Y/;2K!)HEAW_6Z$%8_='M15<QB5WV#
MO+B%;,M665^Y#</I*=5\JXCKP\K";QX&R]VS9AQJ ^C@88.%$8:'6(DDPVXB
M/_B 39OOU.6[26T-T5-TX1S:-D^*R/6T(_B&%:4WB?@'GB%<!O&4:S"7A8/Z
M-5HYRNY]WOI1.&0?Z@__S/:R)-:;)?SY%]*!F4!3E$I2TOHQ)L[0!UTY^-JZ
M68P(1+A.28LIE)09,?7!N$!V9=FG!/BZ+-9;(<YV\+81JLUG7V+LA!WCTY/F
M^D_PAYPMJ.EG^)FP:]-SKG\[[(FF22(OJ:O4E)XS<%\BD#S4TODFI'VF0&D$
M\)(/?/'F5:<X"&(E@F,>@06#Y87,MZTP41[+EIOZCD,TXB&LP[--'_]<)ABI
M B$BLHG;1P?!C?)A#9HU9_-S^DQ"36)]W:<>$CVP2%(:(8H*'OQ<R@JBI;@K
M0_AE%F-L .BUBE\*PJ (0AEB:A6X&M7)4; V-[@0OD8-"ZK6,<-=A_$-=PB_
MWA*YJ+H"D41S*S!>TEB*UXQ01CF3Q <[K/&<550"4I#N*CC2Z\1XZ:A+ <1N
MPKQ/I98Y\ 354H8;78-K',?)"VO=:3.TE:KZC8^$MP(B2)_2W2'C!S61(ZW$
MC$9?QB(Q*GG&5E2 TCPDG8E/_O3B=?>I+1FY0B(M)60KR=VIK$6,Q[_[YKE1
MUX=G*'3\R0CO1\D)8&R:N?34%/+IVABZAY?1!]%1P"L@0@)5G7J%%$47D6B-
M"07OS=%LA$8QK/3@>F\GS)Y^MB+)5)3'4B[^J9$'W]=PQ-T:"@^8"VAG_&UD
M(91(4Y?CQ)XQQW$-&XC:/U>6(05M,N3D>\^Y$/O@X6BFF>VBCN%CW)2XJAZW
MIM#A5"3WJD1'D.+/D5.,R,YR<6P.W)1+.WQLBO1LF7E2VA\"&7?H+Q%T?%)&
M&#[CD*EX,/R#.&-RL,'&?E,Z(\&+F?9R7,+RWTBSMOK3R]>.;<\&MUALP^D3
M+/J!F1JLH1(M'=HR+*!)HXS3A6;_E)TV6G!C/N8NW[F($*D?UQZ E/7X__08
M]@032Z$-7D$8Y7$WA+1A"-J/Z,5!&2PZ8EH/NUZ\# L&!\,RY^S4!5VI=J&P
M")[88RHDU\5D66.\=A-:-F,1U"'S>3-0MYQ@@SVM:O'470SP(>8CK*O==O5P
M4Q1MF=:V.N299"#^NE0M15IZ .1YWJ9&#D:\)DDXT6-",Y ]UM)1$YK#8$5@
M=-LTC"R0H;MO4*I."SWR+\3N4'-_FOJVD;1A]#R7B\P'A3Y7.BU%5>=:\?CY
MJ.4=3[Y$KZ\D<;G3231:84^J+]U HOO,\TEZG@0C<DPW248IX\$TQR;*.(T+
M3(YF.\L):'&>KI;',%N?2'E7;#?_&T*^C&OY1 18;60(ZK(T:M!@G) J9-)&
M_KSX>[BX$64B*XC-/"1*5<[T\FCQ8R5G1=OL*C( 2GC$S%K"G!=K)IUTY?A%
M0;_0JY.)Q^9I\5OI*^.4P*WFZ7_B>&>NC#EN&E=Y13GW:"(''5\N).9Q$([(
M;-*;S?+=L7(^=^\3..=9+2:1(@S>J-C-+?'ZH,;%?H)D48^6&XJN[C 0LC-
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M!><&-360A!,=4,ER14X6'BH:ZAG+Z,(4#84B'X6P<&P8RV=?KNYJ>+_!P^Q
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MJDCO%X^%&"ITP>L"+#[YYF\7GR;]\_A:"4^%)VS##6$JD:*_E(<M%O%;VDZ
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M^/&3BW??O^D^Y9;JCBSD/FG>+">A/W'AXDMR*C8G),A';H<OGIV0("<DR+\
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M80#P)9,'5"Z/Z62L*VFH^!"L>@6>9>;?2(]##O4ER;T*R&!Q 0E+DC\XI %
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M^RKRZ:21M;SW-4G2E*5CO9TC.X$%@-.,D4=-ZW9]4X?C"<UT, X.*%T#)A0
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M>_Z%1$:(@"BCS6*^?/#&8))G.+JRT2=0;U8/[@+5,N.&F9@":MF@UJ^_1L^
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M[U[M\="9A?OJ/,SH^G[VQ>)2/%^4=/%VM!K$U?)SDLP\894%;R:=#3;4H4M
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M9A\R4TJBA9YW$$J')0X_(=B*]O7I<J)?3(VF2L9@;FCH()]85E7&^CB>.<B
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M]1#.YX@M82DATX" (T>!&+HN#0-!@ND=]<&U8R.0##GI[:=OJ[PM U?,6"U
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M8G6D2U7D<6"Z':0CU]O%P,[[K12W^-Q7BM\[*%(+YL%!.1-M@-#K]O,E%"U
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MHG8T=RY.[5",^A6KRJ$WA"0)//(]EC+"=?G0NM1CB'RY@+U^(>TM9:T_ GK
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M,; W NYI\?;M%!0?=C4\"U*\M;5'$OZ)E1;U&A?NSD"8SQ_^#U!+ P04
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MBJKVAO3"/5^GW2F7,&4@:@O.FHM\%RS&&()W:KDP-K(ZEP_N#G%PIF#/YRV
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M^!1 TD8=:U,7_^.')5F1,_W/YG5#_97=;?^V0U84=2_2@PBER. TY*BY@N#
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M590N23,"IU-3AV(4:BY] "%,5EP:Y[+S;K4T[].\ITQO[H!>C<IX<C[/,E_
MOC=!;WI'"^EWYFE))3Q##LJ@53Y40\<[[DU!2SZL0NGY:I5L>MM^=R#7KWLQ
MG2*]:)1?DT<V/)MG<5R2D-^,WM7,CIJ)1G_PVW@TN?KQ1Y@.IZ^OH] &#?=
MGC^X8)A6Z)GWM:^84:FDPE/639+K>^5B[VNE.0W7)/TTG-9(.%$P\.1C:5J
M#'5Q3(.3S >16/!"^T+2RKE)''HM18>_-CH>WNY=-_6BI@:1BEL"645=]%R
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MA3N8)75@@'6WJ4X#7]NHJB6N7HT^7\RF<PFHRT/<"MJ?E4XL"TE"B(7,2IN
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M6BD'@NIQ5M96.#NI#,8N_43NLFJYU^3E 9/>>7(!T3,?:F)> L>CARS=<5S
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M)HAL0?A@G8Y.>]I^:/,I/!;GK3'WA'>+UDL(UB\1IOB?__9_ 5!+ P04
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M@G&<8&PEGAJI[SP,1"WD2%XJUB,\L"/*$.,V?5^35D;IEMZSO;])HSHPND_
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M:<HY:2(P2H!W77/!8.D3G^/W$FD4=S),,IWB<X3ZIE4\:N>:2KWS3"":2I)
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MHB2$6$4($IP&D(::N4.N,I59%;&PZVYRE-R2UIBS31+S1NK&R*95@65'NKX
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M6N1Z;X4R4Z<\ P5.%$@0S%4"61)#J_21ZT--C:2JA+A-(^P-*7$7H;4SI_P
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M[&#Q24=71AR5?>RT/R8;R[L&.,P_K67K='EK]DRK*G/AV$]8J!AA@5* )%(
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M2Z7N[J*=IE&MZMW![ZNXWEV[V;VN'BO#A)X.KX5D@@D[;MV9T)B?E*D)/N
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M;;EBI5Q_-_7*JCJ/^M=:I_EB7KT=/[]4M[]9T+)\NS*=Q&<HSSC/39M<*3#
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MS.YWELF4QASG(*<)U.8@4X!FFOH18I(*(@L:6X7.6(TV->KNB>BM!?83$]U
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MF_0N']ZQ#B,>MQW7LF+RZWQ9'94PNJBJ"H]2S<K3&Y,RR&!&,4"<Z^T%CC-
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M1S 70>RG$A_0A-ZZNZ%BS1/75-\S0ME20BGYG[^NOO^GOM6P06'^8DB@Z)#
MQ<>.\KE?4ZK]L*]>YWXJ4F_9?I6;;RM1QZ[(ZI%-14.9\(P+G@.BA (X31)
M8EJ 7(DTU[8$E(75QWQ]J*E]UOM GKOJU;U>]- 5V^M'*_X0"_RUNX/E=.AB
MA\.MIS!71AGM6,9.V^XYC>4=@XO*KDU-IK>R_O-#W4_[VVJAGU'60W>=WBPK
M8 YY#)24&&"><U 024"J4,R37!4I<TH^<!Q_>CQ2BQW]U"KP)^-/Z>KP'ZV7
MVK(LC9=ILMNL! 0_."5YQWU(5=LAZ'FN<^LDPMB5;X?@<Z86[J#'#,C./VAA
M4-Z;N']N<HB_R@?U9O7TM%K6O^F$LVA"A(+D/ ,%5(G>$&6%WA#A'!2(%TA
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M.DC;2^(-G'JE_<)XG6 M)<.S:;&Q,(V%%6U]L#0HXA,Z!3)93BS#'1#0V<O
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M^1]^GD;")4%C0O$P/+HE;@%BA41N$QA  3)?ISOCGG0V$L8="(OG)6C5=-0
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MO'E^&2_B['JZ/)NF3W.X'%]?CAS5C#O0)-H@B=2&$:>5(3$IT#IK!E"E2/4
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M'U?'W&RC]11&AS$&RB1T<[-!Q0-+)'B$E'!4JZQH],&_6J.SGG.W$7/Z.,7
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M!"EK(27K=!'85S']A[VZ[)Y@#OW [S<.4]30GOM=\<PG?[/*"XV495+R\NI
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M'YY?XOHKF6W_+3U42:6"MY!8M8BI7H,P^J*-+B$([Q3&0R#PV,LZP<0QDGP
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M9L*W \RX/.[ ]3DQ8GES,_0[2*==O094-3%!U\ ;:Q*!U0ECD3D$VV)+&XN
M7F:5S/T4Y#A$S%\37GVJU5(+Y:PWA9AN8O4O;!& -@=PKJ;F2*'#H&9SSZT&
M5ZOO,59M#;QQT7\$"GJ\'7Q_&3;YORYKH^,O-7GYF'O!OSSCY!O!QU<UTEW@
M_9=<W\<85H)248(,=:![K-V2$J<?R8>0)E9WHLE=X+X%C5!A<N>Y-W?;7G#N
M+$;0C (E)60 5(9"IIQ,%(@QNE;%)@^O:.(;BC$0\4"]R0C<GX/M."&U8-^C
M1K<DCR<7T.MV_*E? F[R__F/_P502P,$%     @ 2X*F4(!4P[NP"   7RP
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M$@1_<4>R#&G^9R[ ?!N^>1K:TZ3C'_HEIET_/&@?T>-#PW:S<N9;Q_828+G
MN@5@%\\Q\$PD%!S 5K"3U5YTSND=T@W'>BWAL'S='KLOSQ*?!>%BV^C.D7:D
M7LI 4?-5YGT2[@7+!Q7 +)!QSW$>#81'YU- $[C)3J:H>#M/77\X*Q\D=(,#
MA&ZCZ: +O"52D-H\ !*WV1B@:']W*3#KN;(OTIE,9AQK?THGQ<]'JDC@?)HE
M<L&A=1Y+E[7I1D0 @O\OQ*BR]T_RQ7,@C9'3SHE#D;&;W4T-ZQ":&[E4L3=W
MW)L XH K7+Z$9IIWEE^Z:]<A4+^[CFI<#JA964(7'9':A;#C%A>+SLXJIZV&
MO5MD%/QG2WN*>T<5=^^H:MAV8^NTTJC7GV[_IO(W&QOMRDG[=$_EJC7<&0\N
MT1E-WY4:I:7&$FJX%O7L?@6]8BWPU9ZQ\=C-,R0*0%F+=S# (YZ^ED[<,OK;
MZ>,[D;-W!&X&[IXS@BT$Q)6M[N0S79 3S]YY6\&Z\/T_Z577X=_D6"O:$0:&
M"O]V5[]]TX3L8C_7+\!L./L[6/X'7/J",%#D/YM4,UAG/! GRV4XP,C;?0<*
M+W9>*^!AF+XMQ>G'@D=D>,_#' ^(R)7;E:#@T;4[?(2JM-5^O(VLJDW]^U\A
MVW'+=$TID^Y>;L?]CC'CZY=5'UUC+>W6I &L8FYXM\!,[=GW78M/=_767@*^
M^ M02P,$%     @ 2X*F4/W5KS*G"   =2P  !<   !A;&QO+3(P,C P,S,Q
M>&5X,S$R+FAT;>5:;6_;.!+^?K^"Z^*Z"2"_R"]Y<=( KNU>#723;.*@NY\.
MM$A91"112U)V?+]^9TCY+792![W#Q4F!N)8X)(?#9V:>H7G^2^^J._SSND\B
MD\3D^N[SMT&7E,K5ZO=&MUKM#7ODZ_"W;Z19J?EDJ&BJA1$RI7&UVK\LD5)D
M3-:N5J?3:67:J$@UK@YOJCA4LQI+J7F%&5:Z.,<W\,DIN_C'^2_E,NG)($]X
M:DB@.#6<D5R+=$R^,Z[O2;E<2'5E-E-B'!E2K]5KY+M4]V)"7;L1)N87\W'.
MJ^[YO&HG.1])-KLX9V)"!/M4$K73X*1!:1CZC=.F[[/3T^"(->NMH.[70G;$
M_NV#DE40=WVTF<7\4RGB.'>[6:\<MS)S-A7,1&V_5OOG6<G*79R',C4PF8+.
M[JL;8V,DPQ],F<9BG+;M>G  [#!O']'@?JQDGK)R(&.IVFH\.JBW6M[\C]0J
MM<,SU_:A9O^=X0#ED"8BGK5_'8J$:W+)I^1&)C3]U=.P5V7-E0B=H!;_X: \
MK,,^3MW:CF&<6*2\7*S5K]O5]1\B,1*&-/Q*?7UIVQ<5P!9P=990-19IV<@,
M!LI>_2J[_9OAX,N@VQD.KBX!^S>W=YW+(1E>O6#)KWR)-W??^K?$;]"RWSR@
MAZ1SV2-^BQ5/=Y>]_@T9?NV3VW[W[F8P'(!P_X_NU\[EO_JDTQV2JR_$/VTT
MO;=CD<XMZ?2NKH?]WNJ.HP$L"AJU.B[:VJ1S\[ESV;\M7_WQK?_GW!SU6FW3
M)9Z,!"N6>JW.T=QNIX%'^DH$Y#:($@A\'KF.*KV*1P*NC AGQ$34?/S0.CE[
M'AHB90"+=KEQ!--FE#$(\^68AZ9MW^R94?S*?+6O5\LU(]=/*BUKU@&)Z(03
MQ2>"3R'?FDAH\E=.%;AL/(/WF52&R)1\D2HA?JW\.Y$AZ<2Q'/.4DV'$%<UX
M;D2@/3)(@PKL_>F[VOOZWN[]9ZIAQV%ODQFY3^4TYFS,/0>!8N.9!!U2"7P,
MIJ B)32=D3PU*N>P4F!HEJP!(BA)X$D)&I.0!O!*$9D 4S#2R6T(I#S@6E,U
M0Y&$WG.8=V5,#>\8* -3QI;IP1PH$ @%S [$4N@.FC"NR#02041TCA_+_E.N
M>#$(+B 1.@8*B&QR*DP$"]09#ZR".&X&JDD&RYQ -T9&LU4SO#M,-]X>ICD)
M10JH00 N4>(!H$$<FM5*NTA#B'84*QKX'L0Y@S$!B2N0\ #% B-D!D!"'T#?
MB.,ER M\Z4=3@Q\Q6RIY*)''( #(E@ _.YVV^@141R2,Y53/8:_X6&@#=98A
M%%\ZO4%+;P6]>J[,AK;O#L#-O07P<&VW/WXXJ?O'9[J :$&R,(C),!3P:'$P
M(%1QBSA D!C%')%!.,!\% L=H3B*)1# ,8CC,Q,ZB*7.H1^&=B5C![U,R8 S
M>*W) 2"-<8"N@U/_(8AH.N:D U'S)H]!PM8/K0-^:+O:^@&?W*- UI\ZR./X
M!$/KBB<X9*(NNTP$90D.'JY-%<)4N-+''@(2R&I>0$/]D[> >KIOJ/?]2NW8
MVK7'-=2*  ";QG^,3@\91D!SO7L73/4C#D@K9G+D0>8*!H  .A':AF60XJD=
M!TN994!?30J*Q]1"MV /2_!Y1<+ 1@'!'731,A;,'F;I?*0%$U0)7(!P',>F
MJ11'RC7R#NOIVI(4&\2EYJ"0@:2!G3)@YB+(8XJY!Y9EE5CR%^CAV- JB8-O
M(XZ"D!Z@/V<O2 =OPS%&>^<8M2(=K/O%SC%UPSUVC\8[>PEXUD0P!#_5,J68
M=J@&QT%JCAY!%9NC$_Q%T)&(A9DAH]DV+?JJ!;+%J'.S-=$5:F^SVT.QH"Q7
M&?B(M@PL"*1B5@%+\K%&54#+9MC",_1!%($"QKD#^*K((,&\.X<(]LXA%IFB
M/Z%Q;L,IPH6'(;!L,8&-UEO8\H(_[9 >W.-V FT= #I":->.IH]D;I[68)<$
M1A?2'&N0\,=U*!G-JQOKT]Q9 O2Q^,4)WA.&V=YA>!'4'3HV48:G*P7YM2U;
MH?R"4(X$1@9!KA!+*VQARZB)U ;>XV$]C*4#&*@X!B0'3W0)P2D@R#Z2+A2'
M&I;;@R$\,TKSA5Z'3JN(Z@6UPO!LG8@SF[>L/8J<,B.QN.=Q<4KT2-[[:1.]
MT''>1G'<VC?'^<GBV)YPL[G/><LHBD%]%??+@(K(?0'9VB@#%JI1* 6,5'K!
M;^P+&#))A#&</Y.R1A(8%+8S ?K900[ .R!#:,Q \#\6)'.7YG_E M2W[ING
M@3U,.ORI'V*.Z_L'[0-ZN&_8;E9.?6O83@PD%TBW .SB,08>B02" ]@*<K(H
M1:><WB/;<*37\@U+U^VI^_PH\440+JI&=XRT)?12!ATU7T3>)^%>D'SH I@%
M+NXYRJ.![^@\ 32!F>QBBHRW]=#UIZ/R7D)WM(?0;30==(&WA I"FP= XC8:
M Q3MSRX%9CV7]D4ZD?&$8^Y/Z;CX]4@5 9PG62QG'%JGD711FZYY!"#XOT*,
M*CO_&%\\CZ0Q,FD?.1096^NN][ &H;F1\R[V/H][,P(_X JW+Z:9YNWYE[.5
M2Q+8_VP5U;@=D+.RF,[:(K4;8><MKAN=GE9.6@U[X\@H^&-S?8K;2!5W&ZEJ
MV&9CZZ32J->?;G^V\[.-C>/*T?')CIVK5G&G/)A$9S3]5&J4YCWF4,.]J&</
M"^@5>X&O=O2-QV:>(%$ REJ\<P,^HNHK$<7MI+\907[@/#L[X;KO[K@HJ"+
MM6R")[_1&3GR[&6X!;(+\[]9PUK1MC P5? _-_7'#TT(,/9S[?;+FK5_@.?_
M@TU?$0B*&&@#:P8;C6?B9+X/>^=Z6VY X1VO;B1X2+XL$LZ5*T.PZ>#:'3;"
MVV4[\J#.\CRR$#_<1%75AO[=+X\]?^,LD^ZV;MO]C#'AJU=8'UUN+6WO24>P
M@[GA9P5>:B^^!5M\N@NY]FKPQ=]02P,$%     @ 2X*F4*$(3$I!!@  C24
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M_-(X8S&F]8CH)017$TF0U,-6#9$2A(2IY23!I*KP5E?=) P!R5 :3(;8D2
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M9RJO55E5D)I@<CQ[S51T"+M2K%<,@P7KS>OBF]/US:<K6;?3U6+Y0DRIOBF
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MDZZC6?:B\R)X2&OMP5X;-0I,R5KKE%^)XYH (R*_4V[=R=J^IG4[L%MZ'\5
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M!<<Y6G[/VZV3*72BP?K(H1<PE.1BBN=?LC33Z,9@08^$JIT!#](9/+<L<I/
M?28+6QI-TZ$-!097L8KEI,?,I= Y4/A0O&:G5V=OS\E?!N/=W<'"Y!]S0TC1
M4_^\:S2LE%0D/PZ["[4YPK;_@6PQVT-J L9=D0:9?31U6!;BOY0L1U'.M,DX
MUDC<F-RB"]>'NU8'6;@=&8,[++5)[@A2;(#AWQL8OD'?+7%Y/J:V$>+R/-'
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M,<B)(&6T4PF.C>-L+:A\MY3FZ+LOI;FU5"N_"FFS/GB;78(I/DQ36!,%N%L
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M.M'"]B K,?JE72_FVES@*2[@#&-A^44U;@/T=8#LWI*"[(M-V&UK72Z'*W:
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M6&KN552T@@G*5:)S>0Z2,"8?D/T!LU%86Q5+C")$0-IR8*W>IDS&P$C+*H"
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M!9=M+D,1)F5AEV%!?+*UO5=N\(6ER2X! <B?^$$8>US^,B; .T.R+2NP^^X
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M[!9=^J.I81#)=]^_K2O*GF]*O;TYYANJ^?.HYF$Z[<&J*D*;@6T&]KUTVK\
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M@R*=P7_&]23[Y_\/4$L! A0#%     @ 2X*F4' OVZ#YI@( &-L9 !$
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M+FAT;5!+ 0(4 Q0    ( $N"IE"A"$Q*008  (TE   7              "
M 8A:! !A;&QO+3(P,C P,S,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    ( $N"IE!U
MCW2A4UT  (.Y @ 6              "  ?Y@! !A;&QO+3(P,C S,S%X97@Q
<,#$N:'1M4$L%!@     *  H G0(  (6^!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "allo-20200331.htm": {
   "axisCustom": 2,
   "axisStandard": 17,
   "contextCount": 183,
   "dts": {
    "calculationLink": {
     "local": [
      "allo-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "allo-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "allo-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "allo-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 406,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 28,
    "http://xbrl.sec.gov/dei/2019-01-31": 10,
    "total": 38
   },
   "keyCustom": 40,
   "keyStandard": 282,
   "memberCustom": 30,
   "memberStandard": 25,
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://allogene.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair Value Measurements",
     "role": "http://allogene.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Financial Instruments",
     "role": "http://allogene.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Balance Sheets Components",
     "role": "http://allogene.com/role/BalanceSheetsComponents",
     "shortName": "Balance Sheets Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - License Agreements",
     "role": "http://allogene.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119107 - Disclosure - Commitments and Contingencies",
     "role": "http://allogene.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Equity Method Investment",
     "role": "http://allogene.com/role/EquityMethodInvestment",
     "shortName": "Equity Method Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Stock-Based Compensation",
     "role": "http://allogene.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Related Party Transactions",
     "role": "http://allogene.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Income Taxes",
     "role": "http://allogene.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137112 - Disclosure - Net Loss Per Share",
     "role": "http://allogene.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://allogene.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140113 - Disclosure - Subsequent Events",
     "role": "http://allogene.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://allogene.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Financial Instruments (Tables)",
     "role": "http://allogene.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Balance Sheets Components (Tables)",
     "role": "http://allogene.com/role/BalanceSheetsComponentsTables",
     "shortName": "Balance Sheets Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://allogene.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338306 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://allogene.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i95e2b42df48e469fab49a7cae3c52280_I20191130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "allo:StockIssuanceMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://allogene.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i95e2b42df48e469fab49a7cae3c52280_I20191130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "allo:StockIssuanceMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://allogene.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i31a451c6e18e41cd9cdd174e7f67d1d4_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "iacebb076771044bc98c51c446b109263_I20200331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i31a451c6e18e41cd9cdd174e7f67d1d4_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)",
     "role": "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i1260b9ca85a04e0bae3d00635ba471c8_I20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)",
     "role": "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails",
     "shortName": "Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Financial Instruments - Additional Information (Details)",
     "role": "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Balance Sheets Components - Property and Equipment (Details)",
     "role": "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails",
     "shortName": "Balance Sheets Components - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - License Agreements (Details)",
     "role": "http://allogene.com/role/LicenseAgreementsDetails",
     "shortName": "License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i5c634926bf9d49b1a097075a247d38eb_D20200101-20200331",
      "decimals": "-5",
      "lang": null,
      "name": "allo:CollaborationArrangementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "allo:AllowanceForTenantImprovements",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LettersOfCreditOutstandingAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "allo:LiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "allo:LiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Commitments and Contingencies - Lease Costs (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails",
     "shortName": "Commitments and Contingencies - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Undiscounted Future Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "role": "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i42aa16303efb4bc6861242f37d3e85a3_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Equity Method Investment (Details)",
     "role": "http://allogene.com/role/EquityMethodInvestmentDetails",
     "shortName": "Equity Method Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "ib223d885c64d4b53a8881033526b8151_D20191101-20191101",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "ie582f6e76ada438881e8098bffd2c1d9_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "ie582f6e76ada438881e8098bffd2c1d9_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i15980bb5c1ce41e9b938ccd653a7a751_D20200101-20200331",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "idb31faa7f5644ea697201adc41fddd67_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "idb31faa7f5644ea697201adc41fddd67_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i8a437f63084d4bd18d9edeff003da5ff_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Related Party Transactions (Details)",
     "role": "http://allogene.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i8a437f63084d4bd18d9edeff003da5ff_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Net Loss Per Share (Details)",
     "role": "http://allogene.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i66ce85bfa375439480cf635174a723ff_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Statement of Stockholders' Equity (Deficit)",
     "role": "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit",
     "shortName": "Condensed Statement of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "i66ce85bfa375439480cf635174a723ff_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Statement of Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Statement of Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Statement of Cash Flows",
     "role": "http://allogene.com/role/CondensedStatementofCashFlows",
     "shortName": "Condensed Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://allogene.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://allogene.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20200331.htm",
      "contextRef": "if090a9e2d36944d8bb1ec95d9a857e64_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "allo_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents accrued and other current liabilities.",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AccruedAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Liabilities Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate potential milestone payable",
        "label": "Aggregate Potential Milestone Payable",
        "terseLabel": "Aggregate potential milestone payable"
       }
      }
     },
     "localname": "AggregatePotentialMilestonePayable",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate potential milestone payments.",
        "label": "Aggregate Potential Milestone Payments",
        "terseLabel": "Aggregate potential milestone payments"
       }
      }
     },
     "localname": "AggregatePotentialMilestonePayments",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate potential milestone receivable.",
        "label": "Aggregate Potential Milestone Receivable",
        "terseLabel": "Aggregate potential milestone receivable"
       }
      }
     },
     "localname": "AggregatePotentialMilestoneReceivable",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialRegulatoryAndDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate potential regulatory and development milestones.",
        "label": "Aggregate Potential Regulatory And Development Milestones",
        "terseLabel": "Aggregate potential regulatory and development milestones"
       }
      }
     },
     "localname": "AggregatePotentialRegulatoryAndDevelopmentMilestones",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AllowanceForTenantImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance for tenant improvements.",
        "label": "Allowance For Tenant Improvements",
        "negatedLabel": "Less: Tenant improvement allowance",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "localname": "AllowanceForTenantImprovements",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AreaOfNewOfficeBuilding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of new office building.",
        "label": "Area Of New Office Building",
        "terseLabel": "Area of office and laboratory"
       }
      }
     },
     "localname": "AreaOfNewOfficeBuilding",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AreaOfOffice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of office.",
        "label": "Area Of Office",
        "terseLabel": "Area of office space"
       }
      }
     },
     "localname": "AreaOfOffice",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AreaOfOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of operating lease.",
        "label": "Area Of Operating Lease",
        "terseLabel": "Area of operating lease"
       }
      }
     },
     "localname": "AreaOfOperatingLease",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AssetContributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset contribution agreement.",
        "label": "Asset Contribution Agreement [Member]",
        "verboseLabel": "Asset Contribution Agreement"
       }
      }
     },
     "localname": "AssetContributionAgreementMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_BellcoCapitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bellco Capital LLC.",
        "label": "Bellco Capital L L C [Member]",
        "terseLabel": "Bellco"
       }
      }
     },
     "localname": "BellcoCapitalLLCMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ByHeartIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ByHeart, Inc. [Member]",
        "label": "By Heart Inc [Member]",
        "terseLabel": "ByHeart"
       }
      }
     },
     "localname": "ByHeartIncMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CashEquivalentsAndShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments",
        "totalLabel": "Total cash equivalents and investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestments",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Received For Amounts Related To Tenant Improvement Allowances",
        "label": "Cash Received For Amounts Related To Tenant Improvement Allowances",
        "terseLabel": "Cash received for amounts related to tenant improvement allowances"
       }
      }
     },
     "localname": "CashReceivedForAmountsRelatedToTenantImprovementAllowances",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CellectisSAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cellectis S.A..",
        "label": "Cellectis S A [Member]",
        "terseLabel": "Cellectis"
       }
      }
     },
     "localname": "CellectisSAMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Changes in significant accounting policies.",
        "label": "Changes In Significant Accounting Policies Policy [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "ChangesInSignificantAccountingPoliciesPolicyTextBlock",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_ClinicalRegulatoryAndCommercialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical, Regulatory, and Commercial Milestone",
        "label": "Clinical, Regulatory, and Commercial Milestone [Member]",
        "terseLabel": "Clinical, Regulatory, and Commercial Milestone"
       }
      }
     },
     "localname": "ClinicalRegulatoryAndCommercialMilestoneMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Collaboration agreement, upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CollaborationArrangementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Arrangement, Expense",
        "label": "Collaboration Arrangement, Expense",
        "terseLabel": "Collaboration arrangement, expense"
       }
      }
     },
     "localname": "CollaborationArrangementExpense",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ComputerEquipmentAndPurchasedSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer equipment and purchased software.",
        "label": "Computer Equipment And Purchased Software [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "ComputerEquipmentAndPurchasedSoftwareMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consulting agreements.",
        "label": "Consulting Agreements [Member]",
        "terseLabel": "Consulting Agreements"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CostMethodInvestmentTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost Method Investment, Transaction Costs",
        "label": "Cost Method Investment, Transaction Costs",
        "terseLabel": "Transaction cost"
       }
      }
     },
     "localname": "CostMethodInvestmentTransactionCosts",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_DevelopmentAndSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Sales [Member]",
        "label": "Development And Sales [Member]",
        "terseLabel": "Development and Sales"
       }
      }
     },
     "localname": "DevelopmentAndSalesMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_EarlyExerciseOfStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early exercise of stock options.",
        "label": "Early Exercise Of Stock Options [Member]",
        "terseLabel": "Early exercised stock options subject to future vesting"
       }
      }
     },
     "localname": "EarlyExerciseOfStockOptionsMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_FounderSharesOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Founder shares of common stock.",
        "label": "Founder Shares Of Common Stock [Member]",
        "terseLabel": "Founder's shares of common stock subject to future vesting"
       }
      }
     },
     "localname": "FounderSharesOfCommonStockMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_IncomeLossFromCostMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) from Cost Method Investment",
        "label": "Income (Loss) from Cost Method Investment",
        "negatedTerseLabel": "Share of losses from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromCostMethodInvestment",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows",
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory equipment member.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LeaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease one.",
        "label": "Lease One [Member]",
        "terseLabel": "127 Months Lease Term"
       }
      }
     },
     "localname": "LeaseOneMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LeaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Two.",
        "label": "Lease Two [Member]",
        "terseLabel": "124 Months Lease Term"
       }
      }
     },
     "localname": "LeaseTwoMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liabilities, Lessee",
        "label": "Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Lease Liabilities"
       }
      }
     },
     "localname": "LiabilitiesLesseeTableTextBlock",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreements text block.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreement.",
        "label": "License And Collaboration Agreement [Member]",
        "verboseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum payments required per product against selected target.",
        "label": "Maximum Payments Required Per Product Against Selected Target",
        "terseLabel": "Maximum payments required per product against selected target"
       }
      }
     },
     "localname": "MaximumPaymentsRequiredPerProductAgainstSelectedTarget",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Aggregate potential milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_MilestoneTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Type [Axis]",
        "label": "Milestone Type [Axis]",
        "terseLabel": "Milestone Type [Axis]"
       }
      }
     },
     "localname": "MilestoneTypeAxis",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_MilestoneTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Milestone Type [Axis]",
        "label": "Milestone Type [Domain]",
        "terseLabel": "Milestone Type [Domain]"
       }
      }
     },
     "localname": "MilestoneTypeDomain",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NewarkMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Newark [Member]",
        "label": "Newark [Member]",
        "terseLabel": "Newark"
       }
      }
     },
     "localname": "NewarkMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NotchTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notch Therapeutics, Inc.",
        "label": "Notch Therapeutics, Inc. [Member]",
        "terseLabel": "Notch Therapeutics, Inc."
       }
      }
     },
     "localname": "NotchTherapeuticsIncMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NumberOfMembersAppointedToBoardOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of members appointed to board of directors.",
        "label": "Number Of Members Appointed To Board Of Directors",
        "terseLabel": "Number of members appointed to board of directors"
       }
      }
     },
     "localname": "NumberOfMembersAppointedToBoardOfDirectors",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "allo_NumberOfOptionsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options to extend lease.",
        "label": "Number Of Options To Extend Lease",
        "terseLabel": "Number of options to extend lease"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendLease",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares as percentage of common shares outstanding.",
        "label": "Number Of Shares As Percentage Of Common Shares Outstanding",
        "terseLabel": "Number of shares as percentage of common shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesAsPercentageOfCommonSharesOutstanding",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Option exercise price as percentage of fair value of common stock on grate date.",
        "label": "Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date",
        "terseLabel": "Option exercise price as percentage of fair value of common stock on grate date"
       }
      }
     },
     "localname": "OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PaymentTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Terms",
        "label": "Payment Terms [Axis]",
        "terseLabel": "Payment Terms [Axis]"
       }
      }
     },
     "localname": "PaymentTermsAxis",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_PaymentTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Terms",
        "label": "Payment Terms [Domain]",
        "terseLabel": "Payment Terms [Domain]"
       }
      }
     },
     "localname": "PaymentTermsDomain",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentsCommencingJanuary2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Commencing January 2019",
        "label": "Payments Commencing January 2019 [Member]",
        "terseLabel": "Payments Commencing January 2019"
       }
      }
     },
     "localname": "PaymentsCommencingJanuary2019Member",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentsCommencingJanuary2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Commencing January 2020",
        "label": "Payments Commencing January 2020 [Member]",
        "terseLabel": "Payments Commencing January 2020"
       }
      }
     },
     "localname": "PaymentsCommencingJanuary2020Member",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PercentageOfDevelopmentCostPayableByCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Of Development Cost Payable By Related Party",
        "label": "Percentage Of Development Cost Payable By Collaboration Partner",
        "terseLabel": "Percentage of development cost payable by collaboration partner"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostPayableByCollaborationPartner",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PercentageOfDevelopmentCostPayableByTheCompany": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Of Development Cost Payable By The Company",
        "label": "Percentage Of Development Cost Payable By The Company",
        "terseLabel": "Percentage of development costs payable by the Company"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostPayableByTheCompany",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PreClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-Clinical Development Milestone [Member]",
        "label": "Pre-Clinical Development Milestone [Member]",
        "terseLabel": "Pre-Clinical Development Milestone"
       }
      }
     },
     "localname": "PreClinicalDevelopmentMilestoneMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recent accounting pronouncements not yet adopted.",
        "label": "Recent Accounting Pronouncements Not Yet Adopted Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recently adopted accounting pronouncements.",
        "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_RecoveryOfResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recovery Of Research And Development Expense",
        "label": "Recovery Of Research And Development Expense",
        "terseLabel": "Recovery of research and development expense"
       }
      }
     },
     "localname": "RecoveryOfResearchAndDevelopmentExpense",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_RegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory milestone member.",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone"
       }
      }
     },
     "localname": "RegulatoryMilestoneMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RelatedPartyTransactionCompensationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related party transaction compensation percentage.",
        "label": "Related Party Transaction Compensation Percentage",
        "terseLabel": "Related party transaction compensation percentage"
       }
      }
     },
     "localname": "RelatedPartyTransactionCompensationPercentage",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_RelatedPartyTransactionMonthlyPaymentsInArrears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related party transaction monthly payments in arrears.",
        "label": "Related Party Transaction Monthly Payments In Arrears",
        "terseLabel": "Related party transaction monthly payment in arrears"
       }
      }
     },
     "localname": "RelatedPartyTransactionMonthlyPaymentsInArrears",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ResearchCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research collaboration and license agreement.",
        "label": "Research Collaboration And License Agreement [Member]",
        "terseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research Services",
        "label": "Research Services [Member]",
        "terseLabel": "Research Services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RoyaltyObligationPeriodFromDateOfFirstSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Obligation Period From Date Of First Sale",
        "label": "Royalty Obligation Period From Date Of First Sale",
        "terseLabel": "Royalty obligation period from date of first sale"
       }
      }
     },
     "localname": "RoyaltyObligationPeriodFromDateOfFirstSale",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales milestone member.",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ServierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Servier.",
        "label": "Servier [Member]",
        "verboseLabel": "Servier"
       }
      }
     },
     "localname": "ServierMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining vesting life, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Restricted stock units, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining vesting life, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issuance, Maximum Compensation Due To Third Party, Percent",
        "label": "Stock Issuance, Maximum Compensation Due To Third Party, Percent",
        "terseLabel": "Stock issuance, maximum compensation due to third party, percent"
       }
      }
     },
     "localname": "StockIssuanceMaximumCompensationDueToThirdPartyPercent",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_StockIssuanceMaximumValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issuance, Maximum Value",
        "label": "Stock Issuance, Maximum Value",
        "terseLabel": "Stock issuance, maximum value"
       }
      }
     },
     "localname": "StockIssuanceMaximumValue",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_StockOptionGrantedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock option granted period.",
        "label": "Stock Option Granted Period",
        "terseLabel": "Stock option grant period"
       }
      }
     },
     "localname": "StockOptionGrantedPeriod",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_SubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sublease Agreement [Member]",
        "label": "Sublease Agreement [Member]",
        "terseLabel": "Sublease Agreement"
       }
      }
     },
     "localname": "SubleaseAgreementMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TransitionServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transition services agreement.",
        "label": "Transition Services Agreement [Member]",
        "terseLabel": "Transition Services Agreement"
       }
      }
     },
     "localname": "TransitionServicesAgreementMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TwoRiverConsultingLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two River Consulting LLC [Member]",
        "label": "Two River Consulting L L C [Member]",
        "terseLabel": "Two River"
       }
      }
     },
     "localname": "TwoRiverConsultingLLCMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TwoThousandEighteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand eighteen plan.",
        "label": "Two Thousand Eighteen Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenPlanMember",
     "nsuri": "http://allogene.com/20200331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r93",
      "r127",
      "r128",
      "r263",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r25",
      "r74",
      "r208",
      "r209",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current",
        "terseLabel": "Payable to related party, current"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r11",
      "r17",
      "r239",
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r23",
      "r117"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r133",
      "r135",
      "r166",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r135",
      "r160",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r65",
      "r112",
      "r114"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of other intangible assets acquired"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r232",
      "r250"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r33"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized\u00a0Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized\u00a0Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r95",
      "r98"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r136",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r181",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r20",
      "r67"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r67",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash \u2014 end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash \u2014 beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r193"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r121",
      "r240",
      "r255"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Notes 6 and 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheetsParenthetical",
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 125,262,537 and 124,267,358 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Computers equipment and purchased software"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Maximum remaining contractual maturities of available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Other long term liabilities, related to shares held by employees and directors that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r65",
      "r72",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r65",
      "r115"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r126",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based compensation awards.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock based compensation expense, weighted average recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Expected shares to be purchased under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r190",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets And Liabilities Subject To Fair Value Measurements On Recurring Basis And Level Of Inputs Used In Such Measurements By Major Security Type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r188",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r184",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r185",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r185",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r185",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r185",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r183",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r183",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair value, measurements, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r46",
      "r76",
      "r231",
      "r242",
      "r257"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r72",
      "r90",
      "r172"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r111",
      "r113"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Net amortization/accretion on investment securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Equity method investment"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets",
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Non-cash rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r204",
      "r206"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Lease Payments Under Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020 (remaining 9 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, option to extend term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Sublease, term of contract"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r234",
      "r253"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r81",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r41",
      "r43",
      "r47",
      "r66",
      "r79",
      "r243",
      "r256"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit",
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r198",
      "r206"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, noncurrent",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r196",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r203",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r202",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Net unrealized gain on available-for-sale investments",
        "verboseLabel": "Net unrealized gain on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit",
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r51",
      "r258"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "negatedLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.",
        "label": "Payments for Leasing Costs, Commissions, and Tenant Improvements",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "PaymentsForLeasingCostsCommissionsAndTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to acquire interest in Notch"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares were issued and outstanding as of March 31, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r1",
      "r18",
      "r19"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of commissions and issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r59",
      "r163"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Proceeds from issuance of common stock and upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r41",
      "r43",
      "r61",
      "r91",
      "r92",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r23",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r22",
      "r116"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r4",
      "r5",
      "r118",
      "r254"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails",
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r4",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r4",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r8",
      "r233",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Non-cancellable purchase commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyCosts": {
     "auth_ref": [
      "r49",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.",
        "label": "Related Party Costs",
        "terseLabel": "Related party costs"
       }
      }
     },
     "localname": "RelatedPartyCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r131",
      "r208",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "verboseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r131",
      "r208",
      "r209",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "verboseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r169",
      "r266"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r3",
      "r6",
      "r71",
      "r264"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Unit",
        "verboseLabel": "Restricted stock units subject to vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r125",
      "r252"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets",
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r135",
      "r159",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r135",
      "r159",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity Under Plan"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r23",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponentsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r73",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r136",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r140",
      "r150",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule Stock Option Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedStatementofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Restricted stock units, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Restricted stock units, unvested, ending balance (in shares)",
        "periodStartLabel": "Restricted stock units, unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average fair value at date of grant per share, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Fair Value at Date of Grant per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining vesting life, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Restricted stock units, vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Expected risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Expected risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grants in period, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r142",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, ending balance (in shares)",
        "periodStartLabel": "Number of options, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r134",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average exercise price, options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value, unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r156",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Vesting of early exercised common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r7",
      "r235",
      "r236",
      "r238",
      "r249"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r32",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Other Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r9",
      "r10",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Issuance of common stock from public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit",
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r124",
      "r125",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options, options exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of RSU's (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r9",
      "r10",
      "r124",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r124",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from public offering, net of commissions and offering costs of $0.3 million",
        "verboseLabel": "Stock issues during period, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit",
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r124",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of RSU's"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r14",
      "r15",
      "r94"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets",
      "http://allogene.com/role/CondensedStatementofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r200",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheets Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetsComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Related party transaction, expenses from transactions with related party"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "verboseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r129",
      "r132",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r199",
      "r206"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888428&loc=SL77919359-209981"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "305",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r267": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r268": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r269": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r271": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r272": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617122528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s board of directors and consultants of the Company under terms and provisions established by the Company&#8217;s board of directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed 10 years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than 100% of the fair market value of the Company&#8217;s common stock on the grant date. Options granted typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5ZDkyMDRmYWVlMDQyNTliNDc5NDQ5NWUzZGZlYWNlL3NlYzozOWQ5MjA0ZmFlZTA0MjU5YjQ3OTQ0OTVlM2RmZWFjZV83MC9mcmFnOmY4ZmFjNWRjNjg5OTQwYWNiN2ZlZmQ0ZmEwYzMyNWY2L3RleHRyZWdpb246ZjhmYWM1ZGM2ODk5NDBhY2I3ZmVmZDRmYTBjMzI1ZjZfMTE4Mg_4fe0cc3d-a369-4851-b84c-7f351e9ac8c3">four</span>-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there were 12,448,841 shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes option activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:41.151%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.700%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Options</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,190,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.82</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,675,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(105,895)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(132,910)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,627,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.87</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,716,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.66&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.90</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,627,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.87</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic values of options exercised, outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on March 31, 2020. For the three months ended March 31, 2020, the estimated weighted-average grant-date fair value of employee options granted was $18.41 per share. As of March 31, 2020, there was $98.2&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of 3 years, 45 days.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:66.676%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.294%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.295%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term in years</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.07 - 6.09</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.99 - 6.25</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.42%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.84%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.80% - 1.65%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.45% - 2.62%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0%</span></td><td colspan="3" style="background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0%</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Unit Activity</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes restricted stock unit activity under the 2018 Plan:</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Restricted Stock Units</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Restricted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Stock Units</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Average Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Value at Date</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">of Grant per</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Share</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,941,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.98</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$50,431</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">885,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.44</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(270,751)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,534,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.17</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$49,274</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,534,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.17</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$49,274</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, there was $55.3&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 3 years, 133 days.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.076%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,732&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,867&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Early Exercised Options</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of March&#160;31, 2020 and 2019 there was $2.8 million and $5.3 million recorded in accrued and other liabilities and $3.2 million and $6.1 million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed financial statements since the exercise date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6653356736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheets Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheets Components</a></td>
<td class="text">Balance Sheets Components<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and Equipment consist of the following:</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.114%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,653&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,967&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers equipment and purchased software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,921&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,365)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,472)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,449&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797265488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Undiscounted Future Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (remaining 9 months)</a></td>
<td class="nump">$ 4,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">7,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">7,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">8,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">8,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2025 and thereafter</a></td>
<td class="nump">55,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">91,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(34,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Less: Tenant improvement allowance</a></td>
<td class="num">(3,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 53,343<span></span>
</td>
<td class="nump">$ 53,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6830161376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities (Detail) - Fair value, measurements, recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 539,288,000<span></span>
</td>
<td class="nump">$ 536,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">113,143,000<span></span>
</td>
<td class="nump">122,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">25,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">190,854,000<span></span>
</td>
<td class="nump">205,011,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">180,313,000<span></span>
</td>
<td class="nump">181,894,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">29,192,000<span></span>
</td>
<td class="nump">25,824,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">293,456,000<span></span>
</td>
<td class="nump">304,794,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">113,143,000<span></span>
</td>
<td class="nump">122,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">180,313,000<span></span>
</td>
<td class="nump">181,894,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">245,832,000<span></span>
</td>
<td class="nump">231,835,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">25,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">190,854,000<span></span>
</td>
<td class="nump">205,011,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">29,192,000<span></span>
</td>
<td class="nump">25,824,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831561856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 42,042,000<span></span>
</td>
<td class="nump">$ 23,403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,619,000<span></span>
</td>
<td class="nump">$ 23,829,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,829,000<span></span>
</td>
<td class="nump">4,892,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborationArrangementExpense', window );">Collaboration arrangement, expense</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RoyaltyObligationPeriodFromDateOfFirstSale', window );">Royalty obligation period from date of first sale</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">$ 325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones', window );">Aggregate potential regulatory and development milestones</a></td>
<td class="nump">840,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget', window );">Maximum payments required per product against selected target</a></td>
<td class="nump">185,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Research Services | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Pre-Clinical Development Milestone | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Development and Sales | Maximum | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostPayableByTheCompany', window );">Percentage of development costs payable by the Company</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner', window );">Percentage of development cost payable by collaboration partner</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RecoveryOfResearchAndDevelopmentExpense', window );">Recovery of research and development expense</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestoneReceivable', window );">Aggregate potential milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">137,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestoneReceivable', window );">Aggregate potential milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70.5<span></span>
</td>
<td class="nump">77,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">78,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Pre-Clinical Development Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Clinical, Regulatory, and Commercial Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">$ 283,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory and development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialRegulatoryAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum payments required per product against selected target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Cost Payable By Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostPayableByCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostPayableByTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Cost Payable By The Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostPayableByTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RecoveryOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RecoveryOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RoyaltyObligationPeriodFromDateOfFirstSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation Period From Date Of First Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RoyaltyObligationPeriodFromDateOfFirstSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812267136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheets Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and Equipment consist of the following:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.114%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,653&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,967&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers equipment and purchased software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,921&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,365)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,472)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,449&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617209696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsNone.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810441920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 17, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockIssuanceMaximumValue', window );">Stock issuance, maximum value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent', window );">Stock issuance, maximum compensation due to third party, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">570,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issues during period, value</a></td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="nump">$ 14,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450,602)<span></span>
</td>
<td class="num">$ (396,122)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance, Maximum Compensation Due To Third Party, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockIssuanceMaximumCompensationDueToThirdPartyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockIssuanceMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockIssuanceMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6829311344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 42,042<span></span>
</td>
<td class="nump">$ 23,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,641<span></span>
</td>
<td class="nump">13,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">57,683<span></span>
</td>
<td class="nump">36,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(57,683)<span></span>
</td>
<td class="num">(36,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">3,261<span></span>
</td>
<td class="nump">4,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">3,203<span></span>
</td>
<td class="nump">4,825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(54,480)<span></span>
</td>
<td class="num">(31,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,480)<span></span>
</td>
<td class="num">(31,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on available-for-sale investments</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (54,015)<span></span>
</td>
<td class="num">$ (30,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">108,963,522<span></span>
</td>
<td class="nump">97,315,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811636112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding', window );">Number of shares as percentage of common shares outstanding</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">12,448,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 18.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="nump">$ 98.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock based compensation expense, weighted average recognition period</a></td>
<td class="text">3 years 45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="nump">$ 55.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock based compensation expense, weighted average recognition period</a></td>
<td class="text">3 years 133 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockOptionGrantedPeriod', window );">Stock option grant period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate', window );">Option exercise price as percentage of fair value of common stock on grate date</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares as percentage of common shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise price as percentage of fair value of common stock on grate date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockOptionGrantedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option granted period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockOptionGrantedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6616775008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 14,215<span></span>
</td>
<td class="nump">$ 7,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">6,657<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 7,558<span></span>
</td>
<td class="nump">$ 5,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6616910192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offerings </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0&#160;million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. In January 2020, the Company sold an aggregate of 570,839 shares of common stock in ATM offerings resulting in net proceeds of $14.8&#160;million.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Need for Additional Capital</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of $553.0 million as of March&#160;31, 2020. Since inception through March&#160;31, 2020, the Company has incurred cumulative net losses of $450.6 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed financial statements are filed with the Securities and Exchange Commission (SEC). </span></div>In March 2020, the World Health Organization declared the global novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 outbreak on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
